<SEC-DOCUMENT>0001558370-22-012999.txt : 20220810
<SEC-HEADER>0001558370-22-012999.hdr.sgml : 20220810
<ACCEPTANCE-DATETIME>20220810112529
ACCESSION NUMBER:		0001558370-22-012999
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		62
CONFORMED PERIOD OF REPORT:	20220630
FILED AS OF DATE:		20220810
DATE AS OF CHANGE:		20220810

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			GENMAB A/S
		CENTRAL INDEX KEY:			0001434265
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38976
		FILM NUMBER:		221150872

	BUSINESS ADDRESS:	
		STREET 1:		TOLDBODGADE 33
		CITY:			1253 COPENHAGEN K
		STATE:			G7
		ZIP:			00000

	MAIL ADDRESS:	
		STREET 1:		TOLDBODGADE 33
		CITY:			1253 COPENHAGEN K
		STATE:			G7
		ZIP:			00000
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>gmab-20220630x6k.htm
<DESCRIPTION>6-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='UTF-8'?>

      <!-- iXBRL document created with: Toppan Merrill Bridge iXBRL 9.6.8167.22744 -->
      <!-- Based on: iXBRL 1.1 -->
      <!-- Created on: 8/10/2022 3:19:03 PM -->
      <!-- iXBRL Library version: 1.0.8167.22751 -->
      <!-- iXBRL Service Job ID: 5c239949-8d63-41aa-bbb1-15dea431259e -->

  <html xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns="http://www.w3.org/1999/xhtml" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:gmab="http://www.genmab.com/20220630" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:country="http://xbrl.sec.gov/country/2021" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2021" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ifrs-full="http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full" xmlns:xbrldi="http://xbrl.org/2006/xbrldi"><head><meta http-equiv="content-type" content="text/html" /><title></title></head><body><div style="margin-top:30pt;"></div><div style="display:none;"><ix:header><ix:hidden><ix:nonNumeric contextRef="Duration_1_1_2022_To_6_30_2022_dNPMG5n7t0WcNVF9KG4Bdw" name="dei:EntityCentralIndexKey" id="Tc_B7JyuSE95E6WpedpSxwepA_2_1">0001434265</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_6_30_2022_dNPMG5n7t0WcNVF9KG4Bdw" name="dei:CurrentFiscalYearEndDate" id="Tc_aI5C-STwiUauJH8AwHpRcg_3_1">--12-31</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_6_30_2022_dNPMG5n7t0WcNVF9KG4Bdw" name="dei:DocumentFiscalYearFocus" id="Tc_fgPHaeAwXUiwr-1K1wILTg_4_1">2022</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_6_30_2022_dNPMG5n7t0WcNVF9KG4Bdw" name="dei:DocumentFiscalPeriodFocus" id="Tc_9GvVmMoFbkSndCAEXAI8tA_5_1">Q2</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_6_30_2022_dNPMG5n7t0WcNVF9KG4Bdw" name="dei:AmendmentFlag" id="Tc_myxDIm84UkeCuBsGl6AyJg_6_1">false</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_6_30_2022_dNPMG5n7t0WcNVF9KG4Bdw" name="dei:EntityRegistrantName" id="Tc_pOCbcc1yy0KES6cRoghGTA_7_1">Genmab A/S</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_6_30_2022_dNPMG5n7t0WcNVF9KG4Bdw" name="dei:DocumentType" id="Tc_QFMVRxmoYE2lWu4Y6WVxIQ_8_1">6-K</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_6_30_2022_dNPMG5n7t0WcNVF9KG4Bdw" name="dei:DocumentPeriodEndDate" id="Tc_mFcLlEIyUUyenDkpUynyLw_9_1">2022-06-30</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:href="gmab-20220630.xsd" xlink:type="simple"></link:schemaRef></ix:references><ix:resources><xbrli:context id="Duration_1_1_2022_To_6_30_2022_dNPMG5n7t0WcNVF9KG4Bdw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434265</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2022_ifrs-full_ClassesOfAssetsAxis_gmab_PropertiesMember_fzUIN40VJUem2qiuz7q2TQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434265</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">gmab:PropertiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2022_ifrs-full_ClassesOfAssetsAxis_gmab_IfrsEquipmentMember_24WDaUkWB0CzmGMa-Eqrcg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434265</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">gmab:IfrsEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2021_ifrs-full_ClassesOfAssetsAxis_gmab_PropertiesMember_Dk9Hxplwdkeo6iuYxEh2kg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434265</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">gmab:PropertiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2021_ifrs-full_ClassesOfAssetsAxis_gmab_IfrsEquipmentMember_JPHlDxvGukWnsD4CjDhIbQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434265</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">gmab:IfrsEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_6_30_2022_gmab_IfrsRoyaltiesByProductAxis_gmab_TepezzaMember_gmab_TypesOfRevenuesAxis_gmab_RoyaltiesRevenueMember_2vu0gXPmvEOPW1nFEg8xWQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434265</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="gmab:IfrsRoyaltiesByProductAxis">gmab:TepezzaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="gmab:TypesOfRevenuesAxis">gmab:RoyaltiesRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_6_30_2022_gmab_IfrsRoyaltiesByProductAxis_gmab_OtherRoyaltyProductMember_gmab_TypesOfRevenuesAxis_gmab_RoyaltiesRevenueMember_E0nJo5T9H0y4j-kEZUvZ1g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434265</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="gmab:IfrsRoyaltiesByProductAxis">gmab:OtherRoyaltyProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="gmab:TypesOfRevenuesAxis">gmab:RoyaltiesRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_6_30_2022_gmab_IfrsRoyaltiesByProductAxis_gmab_KesimptaMember_gmab_TypesOfRevenuesAxis_gmab_RoyaltiesRevenueMember_HHevdLOZHkKv8JPTDpOBMA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434265</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="gmab:IfrsRoyaltiesByProductAxis">gmab:KesimptaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="gmab:TypesOfRevenuesAxis">gmab:RoyaltiesRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_6_30_2022_gmab_IfrsRoyaltiesByProductAxis_gmab_DarzalexMember_gmab_TypesOfRevenuesAxis_gmab_RoyaltiesRevenueMember_B_UEY1hASUOrDlLXGgV7LQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434265</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="gmab:IfrsRoyaltiesByProductAxis">gmab:DarzalexMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="gmab:TypesOfRevenuesAxis">gmab:RoyaltiesRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_6_30_2022_gmab_TypesOfRevenuesAxis_gmab_RoyaltiesRevenueMember_l90laluy2ECUtYZD9oF94A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434265</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="gmab:TypesOfRevenuesAxis">gmab:RoyaltiesRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_6_30_2022_gmab_TypesOfRevenuesAxis_gmab_ReimbursementIncomeMember_SqLe6wdBT06OGFsFXaHuhQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434265</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="gmab:TypesOfRevenuesAxis">gmab:ReimbursementIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_6_30_2022_gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_gmab_OtherCollaborationPartnersMember_AsIPBfv6PU6XdKxKRQhUDA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434265</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="gmab:IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis">gmab:OtherCollaborationPartnersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_6_30_2022_gmab_TypesOfRevenuesAxis_gmab_MilestonePaymentsRevenueMember_fqNpjY-zG02ssbNiOllMzA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434265</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="gmab:TypesOfRevenuesAxis">gmab:MilestonePaymentsRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_6_30_2022_gmab_TypesOfRevenuesAxis_gmab_CollaborationRevenueMember_ht1RNX53n0-X7tAGYv75YQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434265</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="gmab:TypesOfRevenuesAxis">gmab:CollaborationRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_6_30_2022_gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_gmab_AgreementsWithSeagenMember_pZplyqrryEKRXEj8O7llZQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434265</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="gmab:IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis">gmab:AgreementsWithSeagenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_6_30_2022_gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_gmab_AgreementsWithRocheMember_F60ez68CiEaIHbxeNRu9_Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434265</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="gmab:IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis">gmab:AgreementsWithRocheMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_6_30_2022_gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_gmab_AgreementsWithNovartisMember_2Lw8aj2ROUe2xOEG0T2NEA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434265</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="gmab:IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis">gmab:AgreementsWithNovartisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_6_30_2022_gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_gmab_AgreementsWithJanssenMember_dtnNRTQ9qUWE18D-r3fXbQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434265</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="gmab:IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis">gmab:AgreementsWithJanssenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_6_30_2022_gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_gmab_AgreementsWithBointechMember_-wOkAaAFTU-q5bYOFz9Nag"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434265</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="gmab:IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis">gmab:AgreementsWithBointechMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_6_30_2021_gmab_IfrsRoyaltiesByProductAxis_gmab_TepezzaMember_gmab_TypesOfRevenuesAxis_gmab_RoyaltiesRevenueMember_fs7jJ3nvNUyKr8Sk5fXrGg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434265</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="gmab:IfrsRoyaltiesByProductAxis">gmab:TepezzaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="gmab:TypesOfRevenuesAxis">gmab:RoyaltiesRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_6_30_2021_gmab_IfrsRoyaltiesByProductAxis_gmab_OtherRoyaltyProductMember_gmab_TypesOfRevenuesAxis_gmab_RoyaltiesRevenueMember_L_QgZHefbEqkV9UUM69KBg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434265</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="gmab:IfrsRoyaltiesByProductAxis">gmab:OtherRoyaltyProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="gmab:TypesOfRevenuesAxis">gmab:RoyaltiesRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_6_30_2021_gmab_IfrsRoyaltiesByProductAxis_gmab_KesimptaMember_gmab_TypesOfRevenuesAxis_gmab_RoyaltiesRevenueMember_FICwJ-6ee0Gxe75faT4PZQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434265</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="gmab:IfrsRoyaltiesByProductAxis">gmab:KesimptaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="gmab:TypesOfRevenuesAxis">gmab:RoyaltiesRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_6_30_2021_gmab_IfrsRoyaltiesByProductAxis_gmab_DarzalexMember_gmab_TypesOfRevenuesAxis_gmab_RoyaltiesRevenueMember_ygn3CpbP8kelusDjXKa8kw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434265</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="gmab:IfrsRoyaltiesByProductAxis">gmab:DarzalexMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="gmab:TypesOfRevenuesAxis">gmab:RoyaltiesRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_6_30_2021_gmab_TypesOfRevenuesAxis_gmab_RoyaltiesRevenueMember_C14oZ_22m06-TU9BB9BNhw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434265</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="gmab:TypesOfRevenuesAxis">gmab:RoyaltiesRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_6_30_2021_gmab_TypesOfRevenuesAxis_gmab_ReimbursementIncomeMember_omlBYt5DuUO9i8c4hNlRbg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434265</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="gmab:TypesOfRevenuesAxis">gmab:ReimbursementIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_6_30_2021_gmab_TypesOfRevenuesAxis_gmab_MilestonePaymentsRevenueMember_RLx1u9QEf0yprcS3a5mwXA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434265</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="gmab:TypesOfRevenuesAxis">gmab:MilestonePaymentsRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_6_30_2021_gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_gmab_AgreementsWithSeagenMember_eK57WUE_IE2_OzKv8nQlDQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434265</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="gmab:IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis">gmab:AgreementsWithSeagenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_6_30_2021_gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_gmab_AgreementsWithRocheMember_z9PLyE_EZEK_NCj-F9C2xA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434265</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="gmab:IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis">gmab:AgreementsWithRocheMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_6_30_2021_gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_gmab_AgreementsWithNovartisMember_Q_C1sF5FrU2rD44CqxQPtw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434265</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="gmab:IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis">gmab:AgreementsWithNovartisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_6_30_2021_gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_gmab_AgreementsWithJanssenMember_vuVrCms2xECcbUwIJRfXzw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434265</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="gmab:IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis">gmab:AgreementsWithJanssenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_6_30_2021_gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_gmab_AgreementsWithBointechMember__Roy-36-pUSfv1AGtbDu3Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434265</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="gmab:IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis">gmab:AgreementsWithBointechMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_6_30_2021_gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_gmab_AgreementsWithAbbvieMember_KrVymjM9ekWDbOoEhonp8Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434265</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="gmab:IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis">gmab:AgreementsWithAbbvieMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2022_gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_gmab_CurevacCollaborationMember_qc8QNPN5vUSdmz2Y_v8bjg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434265</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="gmab:IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis">gmab:CurevacCollaborationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2022_gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_gmab_BoltBiotherapeuticsIncMember_Cb3qRuFzkUCdz53av0zSRg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434265</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="gmab:IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis">gmab:BoltBiotherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_gmab_CurevacCollaborationMember_0V_v61kjsUagGH7vU0HsPA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434265</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="gmab:IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis">gmab:CurevacCollaborationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_gmab_BoltBiotherapeuticsIncMember_dAp_IxgOu0O5Vly-wxDrdA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434265</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="gmab:IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis">gmab:BoltBiotherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_6_30_2022_ifrs-full_ComponentsOfEquityAxis_ifrs-full_SharePremiumMember_SdwhengxmEaD2aINUnRJ-w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434265</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_6_30_2021_ifrs-full_ComponentsOfEquityAxis_ifrs-full_SharePremiumMember_XMRWtYbFi0-RVZrBJKYdMw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434265</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2022_ifrs-full_ClassesOfFinancialAssetsAxis_gmab_OtherInvestmentMember_ifrs-full_LevelsOfFairValueHierarchyAxis_ifrs-full_Level3OfFairValueHierarchyMember_ifrs-full_MeasurementAxis_ifrs-full_AtFairValueMember_hoHfcpf2WkG8ZksGtffiJg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434265</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">gmab:OtherInvestmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2022_ifrs-full_ClassesOfFinancialAssetsAxis_gmab_OtherInvestmentMember_ifrs-full_LevelsOfFairValueHierarchyAxis_ifrs-full_Level1OfFairValueHierarchyMember_ifrs-full_MeasurementAxis_ifrs-full_AtFairValueMember_A8Z5M0xP50-MphyTG1XuyQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434265</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">gmab:OtherInvestmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2022_ifrs-full_ClassesOfFinancialAssetsAxis_gmab_MarketableSecuritiesMember_ifrs-full_LevelsOfFairValueHierarchyAxis_ifrs-full_Level1OfFairValueHierarchyMember_ifrs-full_MeasurementAxis_ifrs-full_AtFairValueMember_ZqdE8gsn6ku4IF-3riiPzw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434265</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">gmab:MarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2022_ifrs-full_ClassesOfFinancialAssetsAxis_gmab_OtherInvestmentMember_ifrs-full_MeasurementAxis_ifrs-full_AtFairValueMember_DxVED2HGdUitGp0y05MVqQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434265</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">gmab:OtherInvestmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2022_ifrs-full_ClassesOfFinancialAssetsAxis_gmab_MarketableSecuritiesMember_ifrs-full_MeasurementAxis_ifrs-full_AtFairValueMember_gMTFg1fkaU-2kMTWZGvA2A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434265</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">gmab:MarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_ifrs-full_ClassesOfFinancialAssetsAxis_gmab_OtherInvestmentMember_ifrs-full_LevelsOfFairValueHierarchyAxis_ifrs-full_Level3OfFairValueHierarchyMember_ifrs-full_MeasurementAxis_ifrs-full_AtFairValueMember_aMyaV8Vr-EO7hwMWUT9G9g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434265</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">gmab:OtherInvestmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_ifrs-full_ClassesOfFinancialAssetsAxis_gmab_OtherInvestmentMember_ifrs-full_LevelsOfFairValueHierarchyAxis_ifrs-full_Level1OfFairValueHierarchyMember_ifrs-full_MeasurementAxis_ifrs-full_AtFairValueMember_Obo46paYeU6NBT9bV_1jig"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434265</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">gmab:OtherInvestmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_ifrs-full_ClassesOfFinancialAssetsAxis_gmab_MarketableSecuritiesMember_ifrs-full_LevelsOfFairValueHierarchyAxis_ifrs-full_Level1OfFairValueHierarchyMember_ifrs-full_MeasurementAxis_ifrs-full_AtFairValueMember_QdkiKQXr4UeiSvq7C18kVg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434265</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">gmab:MarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_ifrs-full_ClassesOfFinancialAssetsAxis_gmab_OtherInvestmentMember_ifrs-full_MeasurementAxis_ifrs-full_AtFairValueMember_QtPH5pFRWEevfw8ugwnNCA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434265</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">gmab:OtherInvestmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_ifrs-full_ClassesOfFinancialAssetsAxis_gmab_MarketableSecuritiesMember_ifrs-full_MeasurementAxis_ifrs-full_AtFairValueMember_OovtmPjP8kG5XP6UcVoSpw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434265</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">gmab:MarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2022_ifrs-full_ComponentsOfEquityAxis_ifrs-full_SharePremiumMember_c1xbYHnI60ydURKsrordAw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434265</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2022_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsMember_lUn1LjNR7EeooY5wvd9tfg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434265</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2022_ifrs-full_ComponentsOfEquityAxis_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_xwbw8UubEkGBVQFx7vgMbQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434265</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2022_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_yCKoTSQsEEOQZwa4oFi7oA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434265</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_ifrs-full_ComponentsOfEquityAxis_ifrs-full_SharePremiumMember_AoL9klgCl06NvjJ-Vt6Xlw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434265</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsMember_DT4Y_TJahk6Om4PoqoPzFg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434265</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_ifrs-full_ComponentsOfEquityAxis_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_yT7xpmSne0SrbvOgXluilQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434265</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_3hqv4rmeT0KprU066qSoRg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434265</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2021_ifrs-full_ComponentsOfEquityAxis_ifrs-full_SharePremiumMember_GV_3QWjql0Su3tgU-SgDXw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434265</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2021_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsMember_DjZRZNGrO0OpgJWJsdQZFQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434265</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2021_ifrs-full_ComponentsOfEquityAxis_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_4C8ErHNbuEyc6g9c8m0tEg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434265</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2021_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_pdtEW7BBIUqgf6EXtiJIaw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434265</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_ifrs-full_ComponentsOfEquityAxis_ifrs-full_SharePremiumMember_si1iRZkarUaeuSgvZfxZfw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434265</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsMember_MNr5zCVV90GEBvq8OjtfdQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434265</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_ifrs-full_ComponentsOfEquityAxis_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_1jjHlFLAike_v2Q-HdTGxw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434265</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_qxcDthXBpku77YP5whaVYg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434265</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_6_30_2022_ifrs-full_ClassesOfAssetsAxis_gmab_PropertiesMember_F5LrRJJceEih2g5m7wb9GA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434265</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">gmab:PropertiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_6_30_2022_ifrs-full_ClassesOfAssetsAxis_gmab_IfrsEquipmentMember_2Uc8kxVSSEeedQs5j0GsVg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434265</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">gmab:IfrsEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_6_30_2021_ifrs-full_ClassesOfAssetsAxis_gmab_PropertiesMember_G2NwEm7nQ0Kw6dT7ZkwBrQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434265</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">gmab:PropertiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_6_30_2021_ifrs-full_ClassesOfAssetsAxis_gmab_IfrsEquipmentMember_kM-fqB65HkSiWDPm7nBJiQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434265</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">gmab:IfrsEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_6_30_2022_ifrs-full_ComponentsOfEquityAxis_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_7kIYWvkWuEOdT0IirRs9kA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434265</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_6_30_2021_ifrs-full_ComponentsOfEquityAxis_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_ZmznApYSQ0yIovD2PRKBMA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434265</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2021_eEXLsHGqbE20an7xlGLjnw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434265</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2022_To_6_30_2022_voh1lJjNhUCZyLqqP0N5aw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434265</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2021_To_6_30_2021_20IW8JtRlk6Ow-5ZeByISg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434265</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_6_30_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_gmab_IfrsRestrictedStockUnitsRSUsMember_4-5BFoS8HkmkHqZSV1-skg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434265</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">gmab:IfrsRestrictedStockUnitsRSUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_6_30_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_gmab_IfrsRestrictedStockUnitsRSUsMember_XTrx_EPo2kixh36V-j_AVw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434265</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">gmab:IfrsRestrictedStockUnitsRSUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_6_30_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_gmab_RestrictedStockUnitsRSUsMember_9ULLlFPCsE2o9A92MVOndw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434265</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">gmab:RestrictedStockUnitsRSUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_6_30_2022_srt_StatementScenarioAxis_gmab_StockRepurchaseAuthorization2021Member_rWOMBYvakU6yGwmAnDi9_w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434265</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">gmab:StockRepurchaseAuthorization2021Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_6_30_2022_srt_StatementScenarioAxis_gmab_StockRepurchaseAuthorization2019Member_xfwDxjqmW02JCqvKbHtBaQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434265</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">gmab:StockRepurchaseAuthorization2019Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_6_30_2022_srt_StatementScenarioAxis_gmab_StockRepurchaseAuthorization2016Member_mmhw2ICcwkqWFdCPJ6rVhw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434265</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">gmab:StockRepurchaseAuthorization2016Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_3_29_2022_To_3_29_2022_ifrs-full_CategoriesOfRelatedPartiesAxis_gmab_DeirdreP.ConnellyChairPernilleErenbjergDeputyChairRolfHoffmannDr.PaoloPaolettiAndDr.AndersGerselPedersenMember_3rCJQ765kUqbhPx4A2vjig"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434265</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">gmab:DeirdreP.ConnellyChairPernilleErenbjergDeputyChairRolfHoffmannDr.PaoloPaolettiAndDr.AndersGerselPedersenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-03-29</xbrli:startDate><xbrli:endDate>2022-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_ccHyN2oOokuDhNdvPg9fRQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434265</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_6_30_2022_ifrs-full_TypesOfRisksAxis_ifrs-full_CurrencyRiskMember_srt_CurrencyAxis_currency_USD_5UvDDDnrAUyD1gvej8S37Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434265</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CurrencyRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_6_30_2022_ifrs-full_TypesOfRisksAxis_ifrs-full_CurrencyRiskMember_srt_CurrencyAxis_currency_GBP_DSPHKvhiT02Od8W80WG6KQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434265</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CurrencyRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:GBP</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_6_30_2022_ifrs-full_TypesOfRisksAxis_ifrs-full_CurrencyRiskMember_srt_CurrencyAxis_currency_EUR_SstAsF5VjkaHxTdVOHBYpg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434265</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CurrencyRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:EUR</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_6_30_2022_ifrs-full_TypesOfRisksAxis_ifrs-full_CurrencyRiskMember_srt_CurrencyAxis_currency_DKK_wEFDGqiOE0meYqnyprgzqw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434265</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CurrencyRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:DKK</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_6_30_2022_ifrs-full_TypesOfRisksAxis_ifrs-full_CurrencyRiskMember_ASM5neKz9keFOK65fKS2gQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434265</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CurrencyRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_ifrs-full_TypesOfRisksAxis_ifrs-full_CurrencyRiskMember_srt_CurrencyAxis_currency_USD_CHnFrAUKTEWMyHR2NduwAw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434265</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CurrencyRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_ifrs-full_TypesOfRisksAxis_ifrs-full_CurrencyRiskMember_srt_CurrencyAxis_currency_GBP_nnosnR0H8kS3TQbqxqHACA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434265</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CurrencyRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:GBP</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_ifrs-full_TypesOfRisksAxis_ifrs-full_CurrencyRiskMember_srt_CurrencyAxis_currency_EUR_9Wybode0pUWKJkinsc2Cxw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434265</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CurrencyRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:EUR</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_ifrs-full_TypesOfRisksAxis_ifrs-full_CurrencyRiskMember_srt_CurrencyAxis_currency_DKK_ayp_YF4WHEe51vXOnYlL2A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434265</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CurrencyRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:DKK</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_ifrs-full_TypesOfRisksAxis_ifrs-full_CurrencyRiskMember_xIqg6PH6QUGf8y8gkPOHag"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434265</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CurrencyRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2022_ifrs-full_ExternalCreditGradesAxis_gmab_TripleaRatingMember_ifrs-full_TypesOfRisksAxis_ifrs-full_CreditRiskMember_MchtLzCh3Uufn_bh-7kpNA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434265</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ExternalCreditGradesAxis">gmab:TripleaRatingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CreditRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_ifrs-full_ExternalCreditGradesAxis_gmab_TripleaRatingMember_ifrs-full_TypesOfRisksAxis_ifrs-full_CreditRiskMember_O0tp15gOUUSNGn0NNu-ntA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434265</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ExternalCreditGradesAxis">gmab:TripleaRatingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CreditRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_6_30_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_gmab_WarrantsMember_kH0r0sIdkU-S9yq6_erZfw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434265</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">gmab:WarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_6_30_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_gmab_WarrantsMember_sN8RX4-cR0-kSMFNCobg0Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434265</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">gmab:WarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2022_srt_StatementScenarioAxis_gmab_StockRepurchaseAuthorization2021Member_ll839TqkPUSnSuKvpYFvXQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434265</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">gmab:StockRepurchaseAuthorization2021Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2022_srt_StatementScenarioAxis_gmab_StockRepurchaseAuthorization2019Member_Ey8o8eyD7UaKwBJF-khG6w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434265</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">gmab:StockRepurchaseAuthorization2019Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2022_srt_StatementScenarioAxis_gmab_StockRepurchaseAuthorization2016Member_rs9bpzaf80uIoq7-Gcmw6w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434265</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">gmab:StockRepurchaseAuthorization2016Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_3_29_2022_To_3_29_2022_ifrs-full_CategoriesOfRelatedPartiesAxis_ifrs-full_KeyManagementPersonnelOfEntityOrParentMember_wG1K_J98VEKINTE73Xhmyg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434265</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ifrs-full:KeyManagementPersonnelOfEntityOrParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-03-29</xbrli:startDate><xbrli:endDate>2022-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_6_30_2022_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsMember_Obfciab50kOeB1cRJrxSkw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434265</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_6_30_2021_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsMember_3at9FYujHUm7dtmVg4zXig"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434265</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2022_kBUEJjmpl0mHNogMyIvzJg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434265</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2022_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_gmab_OfficeAndLaboratorySpaceMember_srt_StatementGeographicalAxis_country_DK_B5VFPCgUJ0SOaI0R2W2tew"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434265</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">gmab:OfficeAndLaboratorySpaceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:DK</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_3_29_2022_To_3_29_2022_ifrs-full_CategoriesOfRelatedPartiesAxis_gmab_MijkeZachariasseMartinSchultzAndTakahiroHamataniMember_eVcKyLWOlE-Ky0qUaYmu0Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434265</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">gmab:MijkeZachariasseMartinSchultzAndTakahiroHamataniMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-03-29</xbrli:startDate><xbrli:endDate>2022-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_3_29_2022_To_3_29_2022_ifrs-full_CategoriesOfRelatedPartiesAxis_gmab_ElizabethOfarrellMember_71bO48trL0yfIoKu2bbOIw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434265</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">gmab:ElizabethOfarrellMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-03-29</xbrli:startDate><xbrli:endDate>2022-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_yeBwiJf1M0aAa25fFQy9Bg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434265</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_6_30_2021_MRS0_D_onUCNBOxf7Qx_Cw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434265</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg"><xbrli:measure>iso4217:DKK</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_item_d-Yn30W8q0CdLFqZ4zWe8g"><xbrli:measure>gmab:item</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_director_1-CkTK7-YkaxWNG_tkhy7g"><xbrli:measure>gmab:director</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_shares_MrgY4vrrEUeN62nRwu-ZLA"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_pure_ydC7mNX6akalcP_kj1H8wg"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Divide_DKK_shares_uaEdw-3-XkitvcC2Swh0EQ"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:DKK</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="Unit_Standard_EquityInstruments_bRFAkAsdz0ugOZctjovS4A"><xbrli:measure>gmab:EquityInstruments</xbrli:measure></xbrli:unit></ix:resources></ix:header></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;min-height:11.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;padding-top:1pt;text-align:center;text-indent:0pt;border-bottom:1.0pt solid #000000;border-top:3.0pt solid #000000;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:1pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#x200B;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:6pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#x200B;</span></p><a id="_91d3d242_fc3b_49a7_8bb7_800afc120e81"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-size:18pt;font-weight:bold;">UNITED STATES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-size:18pt;font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">Washington,&#xA0;D.C. 20549</b></p><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-size:18pt;font-weight:bold;"><span style="display:inline-block;visibility:hidden;width:0pt;">&#x200B;</span><br /></b><b style="font-family:'Arial','Helvetica','sans-serif';font-size:18pt;font-weight:bold;">FORM&#xA0;6-K</b></p><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE&#xA0;13a-16 OR&#xA0;15d-16</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">OF THE SECURITIES EXCHANGE ACT OF 1934</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">FOR THE&#xA0;MONTH OF AUGUST 2022</b></p><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;white-space:pre-wrap;">COMMISSION FILE NUMBER 001-38976  </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-size:18pt;font-weight:bold;">Genmab A/S</b><b style="font-family:'Arial','Helvetica','sans-serif';font-size:18pt;font-weight:bold;"><br /></b><span style="color:#333333;font-family:'Arial','Helvetica','sans-serif';font-size:9.5pt;background:#ffffff;">(Exact name of Registrant as specified in its charter)</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">Kalvebod Brygge 43</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">1560 Copenhagen V</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">Denmark</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;">+45 70 20 27 28</b><b style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;"><br /></b><span style="color:#333333;font-family:'Arial','Helvetica','sans-serif';font-size:9.5pt;background:#ffffff;">(Address of principal executive offices)</span></p><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';">Indicate by check mark whether the registrant files or will file annual reports under cover Form&#xA0;20-F or&#xA0;Form&#xA0;40-F.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;">Form&#xA0;20-F&#xA0;</span><span style="font-family:'Times New Roman';">&#x2327;</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;white-space:pre-wrap;">      Form&#xA0;40-F&#xA0;</span><span style="font-family:'Times New Roman';font-size:10pt;">&#x25FB;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';">Indicate by check mark if the registrant is submitting the Form&#xA0;6-K in paper as permitted by Regulation&#xA0;S-T Rule&#xA0;101(b)(1)</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;">Yes&#xA0;</span><span style="font-family:'Times New Roman';font-size:10pt;">&#x25FB;</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;white-space:pre-wrap;">      No&#xA0;</span><span style="font-family:'Times New Roman';">&#x2327;</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;white-space:pre-wrap;">  </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';">Indicate by check mark if the registrant is submitting the Form&#xA0;6-K in paper as permitted by Regulation&#xA0;S-T Rule&#xA0;101(b)(7)</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;">Yes&#xA0;</span><span style="font-family:'Times New Roman';font-size:10pt;">&#x25FB;</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;white-space:pre-wrap;">      No&#xA0;</span><span style="font-family:'Times New Roman';">&#x2327;</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;white-space:pre-wrap;">  </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="background:#ffffff;">Exhibit 99.1 to this report on Form&#xA0;6-K&#xA0;shall be deemed to be&#xA0;</span>incorporated by reference<span style="background:#ffffff;">&#xA0;in Genmab A/S&#x2019;s registration statement on&#xA0;</span><span style="background:#ffffff;">Form&#xA0;S-8</span><span style="background:#ffffff;">&#xA0;(File&#xA0;No.&#xA0;333-232693)&#xA0;and in the outstanding prospectus contained in such registration statement. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:6pt;margin-bottom:12pt;visibility:hidden;">&#x200B;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;padding-top:1pt;text-align:center;text-indent:0pt;border-bottom:3.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#x200B;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:0pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><a id="_81614514_37b2_4457_a007_e8b41cb3324b"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';">SIGNATURE</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:50.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;width:3.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;width:45.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:50.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';visibility:hidden;">&#x200B;</span></p></td><td colspan="2" style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';">GENMAB A/S</span></p></td></tr><tr><td style="vertical-align:bottom;width:50.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:3.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:45.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:50.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:3.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';">BY:</span></p></td><td style="vertical-align:bottom;width:45.3%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';">/s/ Anthony Pagano</span></p></td></tr><tr><td style="vertical-align:bottom;width:50.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:3.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:45.3%;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';">Name: Anthony Pagano</span></p></td></tr><tr><td style="vertical-align:bottom;width:50.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:3.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:45.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';">Title: Executive Vice President &amp; Chief Financial Officer</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">DATE: August 10, 2022</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';visibility:hidden;">&#x200B;</span></p><a id="_731c59c9_0263_4345_8d3e_5a1e151a4bd3"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">EXHIBIT&#xA0;INDEX</b></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;table-layout:auto;width:96.42%;"><tr style="height:1pt;"><td style="vertical-align:top;width:10.98%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">A</b></p></div></div></td><td style="vertical-align:top;width:89.01%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:10.98%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exhibit</span></p></td><td style="vertical-align:top;width:89.01%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Description of Exhibit</span></p></td></tr><tr><td style="vertical-align:top;width:10.98%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:top;width:89.01%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:top;width:10.98%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';">99.1</span></p></td><td style="vertical-align:top;width:89.01%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';">Interim Report Dated August 10, 2022</span></p></td></tr><tr><td style="vertical-align:top;width:10.98%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';">101.INS</span></p></td><td style="vertical-align:top;width:89.01%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';">XBRL Instance Document</span></p></td></tr><tr><td style="vertical-align:top;width:10.98%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';">101.SCH</span></p></td><td style="vertical-align:top;width:89.01%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';">XBRL Taxonomy Extension Schema Document</span></p></td></tr><tr><td style="vertical-align:top;width:10.98%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';">101.CAL</span></p></td><td style="vertical-align:top;width:89.01%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';">XBRL Taxonomy Extension Calculation Linkbase Document</span></p></td></tr><tr><td style="vertical-align:top;width:10.98%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';">101.DEF</span></p></td><td style="vertical-align:top;width:89.01%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';">XBRL Taxonomy Extension Definition Linkbase Document</span></p></td></tr><tr><td style="vertical-align:top;width:10.98%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';">101.LAB</span></p></td><td style="vertical-align:top;width:89.01%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';">XBRL Taxonomy Extension Labels Linkbase Document</span></p></td></tr><tr><td style="vertical-align:top;width:10.98%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';">101.PRE</span></p></td><td style="vertical-align:top;width:89.01%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';">XBRL Taxonomy Extension Presentation Linkbase Document</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:1pt;visibility:hidden;">&#x200B;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';visibility:hidden;">&#x200B;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';visibility:hidden;">&#x200B;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:avoid;width:79.3%;border:0;"></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>gmab-20220630xex99d1.htm
<DESCRIPTION>EX-99.1
<TEXT>
<XBRL>
<?xml version='1.0' encoding='UTF-8'?>

      <!-- iXBRL document created with: Toppan Merrill Bridge iXBRL 9.6.8167.22744 -->
      <!-- Based on: iXBRL 1.1 -->
      <!-- Created on: 8/10/2022 3:19:13 PM -->
      <!-- iXBRL Library version: 1.0.8167.22751 -->
      <!-- iXBRL Service Job ID: 5c239949-8d63-41aa-bbb1-15dea431259e -->

  <html xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:country="http://xbrl.sec.gov/country/2021" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2021" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns="http://www.w3.org/1999/xhtml" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ifrs-full="http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:gmab="http://www.genmab.com/20220630" xmlns:xbrldi="http://xbrl.org/2006/xbrldi"><head><meta content="text/html" http-equiv="content-type" /><title>Interim Report for the 6 months ended June 30, 2011</title></head><body><div style="margin-top:30pt;"></div><div style="display:none;"><ix:header><ix:references><link:schemaRef xlink:type="simple" xlink:href="gmab-20220630.xsd"></link:schemaRef></ix:references><ix:resources></ix:resources></ix:header></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;min-height:36pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">Exhibit 99.1</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><img src="gmab-20220630xex99d1002.jpg" alt="Graphic" style="display:inline-block;height:44.99pt;left:0%;padding-bottom:0.05pt;position:relative;top:0pt;width:151.48pt;" /></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-size:13pt;font-weight:bold;">Genmab Announces Financial Results for the First Half of 2022</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></div><div style="clear:both;max-width:100%;position:relative;min-height:45.04pt;"><a id="_9ac88820_fa79_4979_9387_0782b246fa21"></a><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt;"><b style="color:#029c93;font-weight:bold;">August 10, 2022 Copenhagen, Denmark; </b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Interim Report for the First Six Months Ended June 30, 2022</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="color:#029c93;font-weight:bold;">Highlights</b></p><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#x25CF;</td><td style="padding:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:bold;">Genmab and AbbVie Inc. (AbbVie) announced topline results for epcoritamab from the Phase 1/2 trial in patients with relapsed/refractory large B-cell lymphoma (LBCL)</b></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#x25CF;</td><td style="padding:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:bold;">Genmab announced its intent to submit a biologics license application (BLA) to the U.S. Food and Drug Administration (U.S. FDA) for epcoritamab for the treatment of patients with relapsed/refractory LBCL, in the second half of 2022</b></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#x25CF;</td><td style="padding:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:bold;">DARZALEX</b><sup style="font-family:'Arial','Helvetica','sans-serif';font-size:7.5pt;font-style:normal;font-weight:bold;line-height:100%;top:0pt;vertical-align:top;">&#xAE;</sup><b style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:bold;"> net sales as reported by Johnson &amp; Johnson increased 37% compared to the first six months of 2021 to USD 3,842 million, resulting in royalty revenue to Genmab of DKK 4,024 million</b></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#x25CF;</td><td style="padding:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:bold;">Genmab announced the resolution of its arbitration with Janssen Biotech, Inc. (Janssen) under its daratumumab license agreement and subsequently </b><b style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:bold;">commenced a new arbitration under the daratumumab license agreement with Janssen</b></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#x25CF;</td><td style="padding:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:bold;">Genmab improves its 2022 financial guidance</b></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p><a id="_Hlk12956096"></a><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#x201C;Genmab&#x2019;s innovation was on display during the second quarter of 2022 with data presentations at multiple prestigious conferences and the publication by Genmab, and our partner, AbbVie, of topline results for epcoritamab from the Phase 1/2 trial in patients with relapsed/refractory LBCL. Based on this data, we intend to submit a BLA to the U.S. FDA for epcoritamab in the second half of this year,&#x201D; said Jan van de Winkel, Ph.D., Chief Executive Officer of Genmab. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p><p style="color:#029c93;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt;">Financial Performance First Half of 2022</p><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#x25CF;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Net sales of DARZALEX by Janssen were USD 3,842 million in the first six months of 2022 compared to USD 2,798 million in the first six months of 2021, an increase of USD 1,044 million, or 37%.</span></td></tr></table><a id="_Hlk109212521"></a><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#x25CF;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Royalty revenue was DKK 4,727 million in the first six months of 2022 compared to DKK 2,595 million in the first six months of 2021, an increase of DKK 2,132 million, or 82%. </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">The increase in royalties was driven by higher net sales of DARZALEX, TEPEZZA</span><sup style="font-family:'Arial','Helvetica','sans-serif';font-size:7.5pt;font-style:normal;font-weight:normal;line-height:100%;top:0pt;vertical-align:top;">&#xAE;</sup><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;"> and Kesimpta</span><sup style="font-family:'Arial','Helvetica','sans-serif';font-size:7.5pt;font-style:normal;font-weight:normal;line-height:100%;top:0pt;vertical-align:top;">&#xAE;</sup><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;"> and </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">higher average exchange rate between the USD and DKK</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">.</span></td></tr></table><a id="_Hlk527456255"></a><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#x25CF;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Revenue was DKK 5,281 million for the first six months of 2022 compared to DKK 3,553 million for the first six months of 2021. The increase of DKK 1,728 million, or 49%, was primarily driven by higher DARZALEX, TEPEZZA and Kesimpta royalties achieved under our collaborations with Janssen, Roche and Novartis Pharma AG (Novartis), respectively, partly offset by milestones achieved under our collaborations with Janssen and AbbVie in the first six months of 2021.</span></td></tr></table><a id="_Hlk527456303"></a><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#x25CF;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Operating expenses were DKK 3,520 million in the first six months of 2022 compared to DKK 2,234 million in the first six months of 2021. The increase of DKK 1,286 million, or 58%, was driven by the continued advancement of epcoritamab and multiple pipeline projects, an increase in </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">new employees to support Tivdak</span><sup style="font-family:'Arial','Helvetica','sans-serif';font-size:7.5pt;font-style:normal;font-weight:normal;line-height:100%;top:0pt;vertical-align:top;">&#xAE;</sup><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;"> post launch and </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">expansion of our product pipeline</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">, and the continued development of Genmab&#x2019;s commercialization and broader organizational capabilities and infrastructure.</span></td></tr></table><a id="OLE_LINK13"></a><a id="OLE_LINK14"></a><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#x25CF;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Operating profit was DKK 1,761 million in the first six months of 2022 compared to DKK 1,319 million in the first six months of 2021. </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;"> </span></td></tr></table></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><a id="_b84b4b89_0c22_4faa_8a56_a89aae161686"></a><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:24pt 0pt 0pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p><a id="_7bc3e293_4583_4831_90d1_eaed4ccac5d3"></a><a id="_b4466740_94f3_497c_857b_0ea9721f866b"></a><a id="_4b6f0550_7ce0_4f4d_89c2_7c8b17780aaf"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;table-layout:fixed;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td></tr><tr><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Genmab A/S</p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Tel: +45 7020 2728</p></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">Company Announcement no. 41</p></td></tr><tr><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Kalvebod Brygge 43</p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Fax: +45 7020 2729</p></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">Page 1/35</p></td></tr><tr><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">1560 Copenhagen V, Denmark</p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">www.genmab.com</p></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">CVR no. 2102 3884</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:76.47%;border:0;margin:30pt 11.76% 30pt 11.76%;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;min-height:36pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><img src="gmab-20220630xex99d1002.jpg" alt="Graphic" style="display:inline-block;height:44.99pt;left:0%;padding-bottom:0.05pt;position:relative;top:0pt;width:151.48pt;" /></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Arial Bold';font-size:9pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-size:13pt;font-weight:bold;">Genmab Announces Financial Results for the First Half of 2022</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></div><div style="clear:both;max-width:100%;position:relative;min-height:45.04pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="color:#029c93;font-weight:bold;visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="color:#029c93;font-weight:bold;">Outlook</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">As announced in Company Announcement No. 40, Genmab is raising its 2022 financial guidance published on May 11, 2022, driven primarily by increased royalty revenue due to higher net sales of DARZALEX and the foreign exchange impact of the strong US Dollar. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#x200B;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:54.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:17.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:17.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:54.78%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><span style="font-weight:bold;margin-left:0pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.86%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Revised</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.86%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Previous</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:54.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><b style="font-weight:bold;">(DKK million)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#xA0;&#xA0;&#xA0;&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Guidance</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#xA0;&#xA0;&#xA0;&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Guidance</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#xA0;&#xA0;&#xA0;&#xA0;</b></p></td></tr><tr><td style="vertical-align:bottom;width:54.78%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.86%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">12,000 - 13,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.86%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">11,000 - 12,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#xA0;</p></td></tr><tr><td style="vertical-align:bottom;width:54.78%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Operating expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.86%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">(7,600) - (8,200)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.86%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">(7,200) - (7,800)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#xA0;</p></td></tr><tr><td style="vertical-align:bottom;width:54.78%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Operating profit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.86%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">3,800 - 5,400</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.86%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">3,200 - 4,800</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#xA0;</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="color:#029c93;font-weight:bold;">Conference Call</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Genmab will hold a conference call in English to discuss the results for the first half of 2022 today, Wednesday, August 10, at 6:00 pm CEST, 5:00 pm BST or 12:00 pm EDT. To join the call dial </p><a id="OLE_LINK3"></a><a id="OLE_LINK4"></a><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">+1 631 913 1422 (U.S. participants) or +44 3333000804 (international participants) and provide conference code 29756170. A live and archived webcast of the call and relevant slides will be available at www.genmab.com/investors.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="color:#029c93;font-weight:bold;visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="color:#029c93;font-weight:bold;">Contact:</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Marisol Peron, Senior Vice President, Communications and Corporate Affairs</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">T: +1 609 524 0065; E: mmp@genmab.com</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="color:#029c93;font-weight:bold;visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Andrew Carlsen, Vice President, Head of Investor Relations</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">T: +45 3377 9558; E: acn@genmab.com</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p><p style="display:none;line-height:0pt;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:0pt;visibility:hidden;">&#x200B;</span></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><a id="_f92e69cb_f322_4f5c_ae91_7de4b6804228"></a><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:24pt 0pt 0pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p><a id="_af24834d_d781_4279_a0de_b23a4af70407"></a><a id="_f70fba65_3284_4a11_922f_803f87b1481f"></a><a id="_3a1e54e2_e9d6_40bd_9c37_b011b4208582"></a><a id="_1ee83899_a93d_462c_8b4d_278a091f13c8"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;table-layout:fixed;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td></tr><tr><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Genmab A/S</p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Tel: +45 7020 2728</p></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">Company Announcement no. 41</p></td></tr><tr><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Kalvebod Brygge 43</p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Fax: +45 7020 2729</p></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">Page 2/35</p></td></tr><tr><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">1560 Copenhagen V, Denmark</p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">www.genmab.com</p></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">CVR no. 2102 3884</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:76.47%;border:0;margin:30pt 11.76% 30pt 11.76%;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;min-height:36pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><img src="gmab-20220630xex99d1002.jpg" alt="Graphic" style="display:inline-block;height:44.99pt;left:0%;padding-bottom:0.05pt;position:relative;top:0pt;width:151.48pt;" /></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-size:13pt;font-weight:bold;">Interim Report for the First Half of 2022</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></div><div style="clear:both;max-width:100%;position:relative;min-height:45.04pt;"><a id="_934bfa7a_0926_457a_923d_5c756d55170c"></a><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="color:#029c93;font-weight:bold;">CONTENTS</b></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:96.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:top;width:3.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></div></div></td></tr><tr><td style="vertical-align:top;width:96.17%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 5pt 0pt;"><b style="color:#029c93;font-weight:bold;">MANAGEMENT&#x2019;S REVIEW</b></p></td><td style="vertical-align:top;width:3.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 5pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:top;width:96.17%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 5pt 0pt;"><a href="#CONSOLIDATEDKEYFIGURES_439617"><span style="font-style:normal;font-weight:normal;">CONSOLIDATED KEY FIGURES</span></a></p></td><td style="vertical-align:top;width:3.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 5pt 0pt;">4</p></td></tr><tr><td style="vertical-align:top;width:96.17%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 5pt 0pt;"><a href="#OUTLOOK_182548"><span style="font-style:normal;font-weight:normal;">OUTLOOK</span></a></p></td><td style="vertical-align:top;width:3.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 5pt 0pt;">5</p></td></tr><tr><td style="vertical-align:top;width:96.17%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 5pt 0pt;"><a href="#KEY2019PRIORITIES_328557"><span style="font-style:normal;font-weight:normal;">KEY 2022 PRIORITIES</span></a></p></td><td style="vertical-align:top;width:3.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 5pt 0pt;">6</p></td></tr><tr><td style="vertical-align:top;width:96.17%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 5pt 0pt;"><a href="#PRODUCTPIPELINE_603298"><span style="font-style:normal;font-weight:normal;">PRODUCT PIPELINE</span></a> <a href="#PRODUCTPIPELINE_603298"><span style="font-style:normal;font-weight:normal;">AND TECHNOLOGY PROGRESS FIRST HALF OF 2022 </span></a></p></td><td style="vertical-align:top;width:3.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 5pt 0pt;">6</p></td></tr><tr><td style="vertical-align:top;width:96.17%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 5pt 0pt;"><a href="#_SIGNIFICANT_RISKS_AND"><span style="font-style:normal;font-weight:normal;">SIGNIFICANT RISKS AND UNCERTAINTIES</span></a></p></td><td style="vertical-align:top;width:3.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 5pt 0pt;">14</p></td></tr><tr><td style="vertical-align:top;width:96.17%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 5pt 0pt;"><a href="#FINANCIALREVIEW_601130"><span style="font-style:normal;font-weight:normal;">FINANCIAL REVIEW</span></a></p></td><td style="vertical-align:top;width:3.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 5pt 0pt;">15</p></td></tr><tr><td style="vertical-align:top;width:96.17%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 5pt 0pt;"><b style="color:#029c93;font-weight:bold;">FINANCIAL STATEMENTS</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 5pt 0pt;"><a href="#STATEMENTSOFCOMPINCOMEQUARTER"><span style="font-style:normal;font-weight:normal;">STATEMENTS OF COMPREHENSIVE INCOME FOR THE 2ND QUARTER OF 2022</span></a></p></td><td style="vertical-align:bottom;width:3.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 5pt 0pt;">21</p></td></tr><tr><td style="vertical-align:top;width:96.17%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 5pt 0pt;"><a href="#STATEMENTSOFCOMPINCOMEYTD"><span style="font-style:normal;font-weight:normal;">STATEMENTS OF COMPREHENSIVE INCOME FOR THE FIRST HALF OF 2022</span></a></p></td><td style="vertical-align:top;width:3.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 5pt 0pt;">22</p></td></tr><tr><td style="vertical-align:top;width:96.17%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 5pt 0pt;"><a href="#BALANCESHEET_757698"><span style="font-style:normal;font-weight:normal;">BALANCE SHEETS AS OF JUNE 30, 2022</span></a></p></td><td style="vertical-align:top;width:3.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 5pt 0pt;">23</p></td></tr><tr><td style="vertical-align:top;width:96.17%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 5pt 0pt;"><a href="#STATEMENTOFCASHFLOWS_489627"><span style="font-style:normal;font-weight:normal;">STATEMENTS OF CASH FLOWS FOR THE FIRST HALF OF 2022</span></a></p></td><td style="vertical-align:top;width:3.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 5pt 0pt;">24</p></td></tr><tr><td style="vertical-align:top;width:96.17%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 5pt 0pt;"><a href="#STATEMENTOFCHANGESINEQUITY_43137"><span style="font-style:normal;font-weight:normal;">STATEMENTS OF CHANGES IN EQUITY FOR THE FIRST HALF OF 2022</span></a></p></td><td style="vertical-align:top;width:3.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 5pt 0pt;">25</p></td></tr><tr><td style="vertical-align:top;width:96.17%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 5pt 0pt;"><a href="#NOTESTOTHEFINANCIALSTATEMENTS_435403"><span style="font-style:normal;font-weight:normal;">NOTES&#xA0;TO THE FINANCIAL STATEMENTS</span></a></p></td><td style="vertical-align:top;width:3.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 5pt 0pt;">26</p></td></tr><tr><td style="vertical-align:top;width:96.17%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><a style="color:#029c93;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;" href="#ABOUTGENMAB_556806"><b style="color:#029c93;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:bold;">ABOUT GENMAB</b></a></p></td><td style="vertical-align:top;width:3.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 5pt 0pt;">34</p></td></tr><tr><td style="vertical-align:top;width:96.17%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><a style="color:#029c93;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;" href="#DIRECTORSANDMANAGEMENTSSTATEMENTONTHEINT"><b style="color:#029c93;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:bold;">DIRECTORS&#x2019; AND MANAGEMENT&#x2019;S STATEMENT ON THE INTERIM REPORT</b></a></p></td><td style="vertical-align:top;width:3.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 5pt 0pt;">35</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:24pt 0pt 0pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;table-layout:fixed;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td></tr><tr><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Genmab A/S</p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Tel: +45 7020 2728</p></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">Company Announcement no. 41</p></td></tr><tr><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Kalvebod Brygge 43</p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Fax: +45 7020 2729</p></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">Page 3/35</p></td></tr><tr><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">1560 Copenhagen V, Denmark</p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">www.genmab.com</p></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">CVR no. 2102 3884</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:76.47%;border:0;margin:30pt 11.76% 30pt 11.76%;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;min-height:36pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><img src="gmab-20220630xex99d1002.jpg" alt="Graphic" style="display:inline-block;height:44.99pt;left:0%;padding-bottom:0.05pt;position:relative;top:0pt;width:151.48pt;" /></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Arial Bold';font-size:9pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-size:13pt;font-weight:bold;">Interim Report for the First Half of 2022</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></div><div style="clear:both;max-width:100%;position:relative;min-height:45.04pt;"><a id="_56a5ce4a_87f7_43e2_8b6d_7431915684bb"></a><a id="_MON_1428392831"></a><a id="CONSOLIDATEDKEYFIGURES_439617"></a><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;font-weight:bold;padding-left:21.6pt;text-indent:-21.6pt;margin:0pt 0pt 3pt 0pt;"><b style="color:#029c93;font-weight:bold;">CONSOLIDATED KEY FIGURES</b><b style="color:#339966;font-weight:bold;white-space:pre-wrap;">   </b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:36.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:36.38%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt;">&#xA0;&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.91%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:center;margin:0pt;">2nd Quarter of</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt;">&#xA0;&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:center;margin:0pt;">2nd Quarter of</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:center;margin:0pt;">6 Months Ended</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;">&#xA0;&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:center;margin:0pt;">6 Months Ended</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.75%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:center;margin:0pt;">Full Year</p></td></tr><tr><td style="vertical-align:bottom;width:36.38%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.91%;background:#e6e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:center;margin:0pt;">2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#e6e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:center;margin:0pt;">2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;background:#e6e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:center;margin:0pt;">June 30,&#xA0;2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#e6e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:center;margin:0pt;">June 30,&#xA0;2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.75%;background:#e6e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:center;margin:0pt;">2021</p></td></tr><tr><td style="vertical-align:bottom;width:36.38%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt;">(DKK million)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.91%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.38%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:36.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt;"><b style="font-weight:bold;">Income Statement</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.91%;background:#e6e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt;">&#xA0;&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#e6e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt;">&#xA0;&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;background:#e6e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#e6e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.38%;background:#e6e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt;">&#xA0;&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#e6e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:36.38%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt;">Revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.91%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 3,162</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1,972</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 5,281</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 3,553</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.38%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 8,482</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:36.38%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt;">Research and development expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.91%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (1,282)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (921)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (2,435)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (1,769)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.38%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (4,181)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:36.38%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt;">Selling, general and administrative expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.91%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (633)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (264)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (1,085)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (465)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.38%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (1,283)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:36.38%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt;">Operating expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.91%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (1,915)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (1,185)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (3,520)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (2,234)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.38%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (5,464)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:36.38%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt;">Operating profit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.91%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1,247</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 787</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1,761</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1,319</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.38%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 3,018</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:36.38%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt;">Net financial items</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.91%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1,242</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (365)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1,340</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 527</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.38%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 965</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:36.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt;">Net profit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.91%;background:#e6e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1,891</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#e6e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 306</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;background:#e6e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 2,356</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#e6e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1,402</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.38%;background:#e6e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 3,008</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#e6e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:36.38%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.91%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.38%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:36.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt;"><b style="font-weight:bold;">Balance Sheet</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.91%;background:#e6e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#e6e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;background:#e6e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#e6e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.38%;background:#e6e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#e6e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:36.38%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt;">Marketable securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.91%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 11,799</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 8,398</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 11,799</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 8,398</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.38%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 10,381</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:36.38%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt;">Cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.91%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 9,816</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 9,477</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 9,816</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 9,477</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.38%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 8,957</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:36.38%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt;">Total non-current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.91%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1,985</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 2,179</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1,985</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 2,179</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.38%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1,891</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:36.38%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt;">Total assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.91%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 27,476</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 22,483</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 27,476</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 22,483</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.38%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 24,627</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:36.38%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt;">Shareholders' equity</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.91%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 24,482</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 20,252</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 24,482</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 20,252</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.38%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 22,196</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:36.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt;">Share capital</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.91%;background:#e6e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 66</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#e6e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 66</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;background:#e6e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 66</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#e6e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 66</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.38%;background:#e6e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 66</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#e6e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:36.38%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.91%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.38%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:36.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt;"><b style="font-weight:bold;">Cash Flow Statement</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.91%;background:#e6e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#e6e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;background:#e6e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#e6e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.38%;background:#e6e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#e6e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:36.38%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt;">Cash flow from operating activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.91%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 959</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 355</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1,546</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1,540</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.38%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 2,228</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:36.38%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt;">Cash flow from investing activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.91%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (576)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1,545</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (1,243)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 966</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.38%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (961)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:36.38%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt;">Cash flow from financing activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.91%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (214)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (240)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (278)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (460)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.38%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (420)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:36.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt;">Investment in tangible assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.91%;background:#e6e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (68)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#e6e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (79)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;background:#e6e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (125)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#e6e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (107)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.38%;background:#e6e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (252)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#e6e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:36.38%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.91%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.38%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:36.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt;"><b style="font-weight:bold;">Financial Ratios and Other Information</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.91%;background:#e6e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#e6e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;background:#e6e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#e6e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.38%;background:#e6e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#e6e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:36.38%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt;">Basic net profit per share</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.91%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 28.87</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 4.68</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 35.97</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 21.44</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.38%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 46.00</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:36.38%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt;">Diluted net profit per share</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.91%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 28.66</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 4.64</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 35.71</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 21.25</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.38%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 45.54</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:36.38%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt;">Period-end share market price</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.91%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 2,297</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 2,566</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 2,297</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 2,566</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.38%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 2,630</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:36.38%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt;">Price / book value</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.91%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 6.19</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 8.36</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 6.19</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 8.36</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.38%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 7.82</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:36.38%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt;">Shareholders' equity per share</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.91%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 370.94</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 306.85</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 370.94</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 306.85</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.38%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 336.30</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:36.38%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt;">Equity ratio</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.91%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 89</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 90</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 89</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 90</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.38%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 90</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:36.38%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt;">Shares outstanding</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.91%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 65,753,443</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 65,620,740</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 65,753,443</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 65,620,740</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.38%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 65,718,456</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:36.38%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt;">Average number of employees (FTE*)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.91%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1,406</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 969</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1,345</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 906</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.38%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1,022</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:36.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt;">Number of employees (FTE) at the end of the period </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.91%;background:#e6e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1,445</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#e6e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1,029</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;background:#e6e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1,445</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#e6e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1,029</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.38%;background:#e6e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1,212</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#e6e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#x200B;</span></p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt;"><span style="white-space:pre-wrap;">* Full-time equivalent or team members  </span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:24pt 0pt 0pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;table-layout:fixed;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td></tr><tr><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Genmab A/S</p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Tel: +45 7020 2728</p></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">Company Announcement no. 41</p></td></tr><tr><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Kalvebod Brygge 43</p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Fax: +45 7020 2729</p></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">Page 4/35</p></td></tr><tr><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">1560 Copenhagen V, Denmark</p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">www.genmab.com</p></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">CVR no. 2102 3884</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:76.47%;border:0;margin:30pt 11.76% 30pt 11.76%;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;min-height:36pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><img src="gmab-20220630xex99d1002.jpg" alt="Graphic" style="display:inline-block;height:44.99pt;left:0%;padding-bottom:0.05pt;position:relative;top:0pt;width:151.48pt;" /></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Arial Bold';font-size:9pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-size:13pt;font-weight:bold;">Interim Report for the First Half of 2022</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></div><div style="clear:both;max-width:100%;position:relative;min-height:45.04pt;"><a id="_898f92b5_02d3_41a8_a704_02bd71725584"></a><a id="_Toc16514641"></a><a id="OUTLOOK_182548"></a><a id="_Hlk22722517"></a><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">OUTLOOK</b><b style="font-size:11pt;font-weight:bold;"> </b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#x200B;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:54.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:17.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:17.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:54.78%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><span style="font-weight:bold;margin-left:0pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.86%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Revised</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.86%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Previous</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:54.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><b style="font-weight:bold;">(DKK million)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#xA0;&#xA0;&#xA0;&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Guidance</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#xA0;&#xA0;&#xA0;&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Guidance</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#xA0;&#xA0;&#xA0;&#xA0;</b></p></td></tr><tr><td style="vertical-align:bottom;width:54.78%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.86%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">12,000 - 13,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.86%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">11,000 - 12,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#xA0;</p></td></tr><tr><td style="vertical-align:bottom;width:54.78%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Operating expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.86%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">(7,600) - (8,200)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.86%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">(7,200) - (7,800)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#xA0;</p></td></tr><tr><td style="vertical-align:bottom;width:54.78%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Operating profit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.86%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">3,800 - 5,400</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.86%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">3,200 - 4,800</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#xA0;</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Genmab is raising its 2022 financial guidance published on May 11, 2022, driven primarily by increased royalty revenue due to higher net sales of DARZALEX and the foreign exchange impact of the strong US Dollar.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="color:#029c93;font-weight:bold;visibility:hidden;background:#ffff00;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="color:#029c93;font-weight:bold;">Revenue</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Genmab expects its 2022 revenue to be in the range of DKK 12,000 &#x2013; 13,000 million, an increase to the previous guidance of DKK 11,000 &#x2013; 12,000 million, driven primarily by the expected continued strong growth of DARZALEX net sales as well as the positive impact of the strong US Dollar. Genmab&#x2019;s projected revenue for 2022 primarily consists of DARZALEX royalties of DKK 8,800 &#x2013; 9,300 million compared to the previous guidance of DKK 8,000 &#x2013; 8,500 million. Such royalties are based on Genmab&#x2019;s revised estimate of DARZALEX 2022 net sales of USD 7.8 &#x2013; 8.2 billion compared to the previous guidance of USD 7.5 &#x2013; 8.0 billion. DARZALEX royalties are partly offset by Genmab&#x2019;s share of Janssen&#x2019;s royalty payments to Halozyme in connection with subcutaneous (SC) net sales. The remainder of Genmab&#x2019;s revenue primarily consists of royalties from TEPEZZA, Kesimpta and RYBREVANT<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#xAE;</sup>, reimbursement revenue, milestones for epcoritamab, teclistamab and other milestones as well as collaboration revenue with Seagen for Tivdak.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="color:#029c93;font-weight:bold;visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="color:#029c93;font-weight:bold;">Operating Expenses</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Genmab anticipates its 2022 operating expenses to be in the range of DKK 7,600 &#x2013; 8,200 million, an increase to the previous guidance of DKK 7,200 &#x2013; 7,800 million, driven by increased investment related to pipeline progression and epcoritamab launch readiness activities as well as the negative impact of the strong US Dollar. Operating expenses continue to be driven by the advancement of Genmab&#x2019;s clinical programs, continued investment in research and development, as well as building Genmab&#x2019;s commercial organization and broader organizational infrastructure. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="color:#029c93;font-weight:bold;">Operating Profit</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Genmab now expects its 2022 operating profit to be in the range of DKK 3,800 &#x2013; 5,400 million, an increase to the previous guidance of DKK 3,200 &#x2013; 4,800 million, driven primarily by the items described above.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="color:#029c93;font-weight:bold;">Outlook: Risks and Assumptions</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">In addition to factors already mentioned, the estimates above are subject to change due to numerous reasons, including but not limited to, the achievement of certain milestones associated with Genmab&#x2019;s collaboration agreements; the timing and variation of development activities (including activities carried out by Genmab&#x2019;s collaboration partners) and related income and costs; DARZALEX, Kesimpta, TEPEZZA and RYBREVANT net sales and royalties paid to Genmab; and currency exchange rates (the 2022 guidance assumes a USD / DKK exchange rate of 6.8 compared to 6.4 in the previous guidance). The financial guidance assumes that no significant new agreements are entered into during the remainder of 2022 that could materially affect the results. Refer to the section &#x201C;Significant Risks and Uncertainties&#x201D; in this interim report. Additionally, depending on trends related to the coronavirus and future variants, the </p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:24pt 0pt 0pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;table-layout:fixed;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td></tr><tr><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Genmab A/S</p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Tel: +45 7020 2728</p></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">Company Announcement no. 41</p></td></tr><tr><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Kalvebod Brygge 43</p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Fax: +45 7020 2729</p></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">Page 5/35</p></td></tr><tr><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">1560 Copenhagen V, Denmark</p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">www.genmab.com</p></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">CVR no. 2102 3884</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:76.47%;border:0;margin:30pt 11.76% 30pt 11.76%;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;min-height:36pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><img src="gmab-20220630xex99d1002.jpg" alt="Graphic" style="display:inline-block;height:44.99pt;left:0%;padding-bottom:0.05pt;position:relative;top:0pt;width:151.48pt;" /></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Arial Bold';font-size:9pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-size:13pt;font-weight:bold;">Interim Report for the First Half of 2022</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></div><div style="clear:both;max-width:100%;position:relative;min-height:45.04pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">COVID-19 pandemic could potentially have a material adverse impact on Genmab&#x2019;s business and financial performance, including clinical trials, projected regulatory approval timelines, supply chain and revenues, and cause Genmab&#x2019;s actual results to differ materially from 2022 Guidance and Key 2022 Priorities in this interim report. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Should the global outbreak of COVID-19 persist, it may have long-term impacts on the development, regulatory approval and commercialization of Genmab&#x2019;s investigational medicines and on net sales of approved medicines created by Genmab and developed and marketed by Genmab or Genmab&#x2019;s collaboration partners. As the pandemic continues, there may be an impact on Genmab&#x2019;s business. Genmab has an established COVID-19 response team, led by the CEO, that closely monitors the evolving situation, maintains precautionary measures to help limit the impact of COVID-19 at the workplace and on our communities, and ensures business continuity. The full extent and nature of the impact of the COVID-19 pandemic and related containment measures on Genmab&#x2019;s business and financial performance is uncertain as the situation continues. The factors discussed above, as well as other factors that are currently unforeseeable, may result in further and other unforeseen material adverse impacts on Genmab&#x2019;s business and financial performance, including on the sales of Tivdak and on net sales of DARZALEX, Kesimpta, TEPEZZA and RYBREVANT by Genmab&#x2019;s partners and on Genmab&#x2019;s royalty and milestone revenue therefrom.</p><a id="_c5403fb6_a6a4_4ecf_a69f_1d0421d75b7d"></a><a id="_Toc16514642"></a><a id="KEY2019PRIORITIES_328557"></a><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;font-weight:bold;padding-left:21.6pt;text-indent:-21.6pt;margin:12pt 0pt 3pt 0pt;"><b style="color:#029c93;font-weight:bold;">KEY 2022 PRIORITIES</b></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;width:99.89%;"><tr style="height:1pt;"><td style="vertical-align:top;width:29.83%;border-bottom:1px solid #b9fefa;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:top;width:4.81%;border-bottom:1px solid #b9fefa;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:top;width:65.34%;border-bottom:1px solid #b9fefa;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td></tr><tr><td style="vertical-align:top;width:29.83%;background:#029c93;border-bottom:1px solid #b9fefa;border-left:1px solid #b9fefa;border-right:1px solid #b9fefa;border-top:1px solid #b9fefa;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="color:#ffffff;font-weight:bold;">Priority</b></p></td><td style="vertical-align:top;width:4.81%;background:#029c93;border-bottom:1px solid #b9fefa;border-left:1px solid #b9fefa;border-right:1px solid #b9fefa;border-top:1px solid #b9fefa;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="color:#ffffff;font-family:'Times New Roman';font-weight:bold;">&#x2713;</b></p></td><td style="vertical-align:top;width:65.34%;background:#029c93;border-bottom:1px solid #b9fefa;border-left:1px solid #b9fefa;border-right:1px solid #b9fefa;border-top:1px solid #b9fefa;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="color:#ffffff;font-weight:bold;">Targeted Milestones</b></p></td></tr><tr style="height:52.6pt;"><td style="vertical-align:top;width:29.83%;border-left:1px solid #b9fefa;border-top:1px solid #b9fefa;margin:0pt;padding:0pt 5.4pt 0pt 5.15pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Broad and rapid development of late-stage clinical pipeline and further build US country organization</p></td><td style="vertical-align:top;width:4.81%;border-top:1px solid #b9fefa;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:top;width:65.34%;border-right:1px solid #b9fefa;border-top:1px solid #b9fefa;margin:0pt;padding:0pt 5.15pt 0pt 5.4pt;"><div style="border-collapse:collapse;display:table;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><div style="display:table-row;"><div style="color:#029c93;display:table-cell;font-family:'Wingdings';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#xD8;</div><div style="display:table-cell;padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Epcoritamab</span><sup style="font-family:'Arial','Helvetica','sans-serif';font-size:7.5pt;font-style:normal;font-weight:normal;line-height:100%;top:0pt;vertical-align:top;">1</sup><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">&#xA0;</span></div></div></div><div style="border-collapse:collapse;display:table;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><div style="display:table-row;"><div style="width:18pt;display:table-cell;"></div><div style="color:#029c93;display:table-cell;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#x25CF;</div><div style="display:table-cell;padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Expand clinical development program with multiple Phase 3 trials initiated and submission&#xA0;of first BLA (subject to supportive FDA feedback)</span></div></div></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><span style="font-size:3pt;margin-left:0pt;visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:top;width:29.83%;border-bottom:1px solid #b9fefa;border-left:1px solid #b9fefa;margin:0pt;padding:0pt 5.4pt 0pt 5.15pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:top;width:4.81%;border-bottom:1px solid #b9fefa;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:top;width:65.34%;border-bottom:1px solid #b9fefa;border-right:1px solid #b9fefa;margin:0pt;padding:0pt 5.15pt 0pt 5.4pt;"><div style="border-collapse:collapse;display:table;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><div style="display:table-row;"><div style="color:#029c93;display:table-cell;font-family:'Wingdings';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#xD8;</div><div style="display:table-cell;padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Tivdak</span><sup style="font-family:'Arial','Helvetica','sans-serif';font-size:7.5pt;font-style:normal;font-weight:normal;line-height:100%;top:0pt;vertical-align:top;">2</sup><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">&#xA0;</span></div></div></div><div style="border-collapse:collapse;display:table;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><div style="display:table-row;"><div style="width:18pt;display:table-cell;"></div><div style="color:#029c93;display:table-cell;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#x25CF;</div><div style="display:table-cell;padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Establish Tivdak as a clear choice for 2L+ r/m Cervical Cancer patients</span></div></div></div><div style="border-collapse:collapse;display:table;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><div style="display:table-row;"><div style="width:18pt;display:table-cell;"></div><div style="color:#029c93;display:table-cell;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#x25CF;</div><div style="display:table-cell;padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Broaden clinical development program including Phase 2 evaluation of combination therapy in&#xA0;earlier line treatment for cervical cancer and other solid tumors</span></div></div></div></td></tr><tr><td style="vertical-align:top;width:29.83%;border-left:1px solid #b9fefa;border-top:1px solid #b9fefa;margin:0pt;padding:0pt 5.4pt 0pt 5.15pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Growth and development of differentiated early-stage product candidates</p></td><td style="vertical-align:top;width:4.81%;border-top:1px solid #b9fefa;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:top;width:65.34%;border-right:1px solid #b9fefa;border-top:1px solid #b9fefa;margin:0pt;padding:0pt 5.15pt 0pt 5.4pt;"><div style="border-collapse:collapse;display:table;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><div style="display:table-row;"><div style="color:#029c93;display:table-cell;font-family:'Wingdings';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#xD8;</div><div style="display:table-cell;padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">DuoBody</span><sup style="font-family:'Arial','Helvetica','sans-serif';font-size:7.5pt;font-style:normal;font-weight:normal;line-height:100%;top:0pt;vertical-align:top;">&#xAE;</sup><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">-PD-L1x4-1BB</span><sup style="font-family:'Arial','Helvetica','sans-serif';font-size:7.5pt;font-style:normal;font-weight:normal;line-height:100%;top:0pt;vertical-align:top;">3</sup><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;"> &amp; DuoBody-CD40x4-1BB</span><sup style="font-family:'Arial','Helvetica','sans-serif';font-size:7.5pt;font-style:normal;font-weight:normal;line-height:100%;top:0pt;vertical-align:top;">3</sup><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">&#xA0;</span></div></div></div><div style="border-collapse:collapse;display:table;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><div style="display:table-row;"><div style="width:18pt;display:table-cell;"></div><div style="color:#029c93;display:table-cell;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#x25CF;</div><div style="display:table-cell;padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Data from clinical expansion cohorts to progress to next steps</span></div></div></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><span style="font-size:3pt;margin-left:0pt;visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><span style="font-size:3pt;margin-left:0pt;visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><span style="font-size:3pt;margin-left:0pt;visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:top;width:29.83%;border-bottom:1px solid #b9fefa;border-left:1px solid #b9fefa;margin:0pt;padding:0pt 5.4pt 0pt 5.15pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:top;width:4.81%;border-bottom:1px solid #b9fefa;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:top;width:65.34%;border-bottom:1px solid #b9fefa;border-right:1px solid #b9fefa;margin:0pt;padding:0pt 5.15pt 0pt 5.4pt;"><div style="border-collapse:collapse;display:table;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><div style="display:table-row;"><div style="color:#029c93;display:table-cell;font-family:'Wingdings';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#xD8;</div><div style="display:table-cell;padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Expand and advance proprietary clinical product portfolio</span></div></div></div></td></tr><tr><td style="vertical-align:top;width:29.83%;border-left:1px solid #b9fefa;border-top:1px solid #b9fefa;margin:0pt;padding:0pt 5.4pt 0pt 5.15pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Further scale organization aligned with growing product portfolio and brand needs</p></td><td style="vertical-align:top;width:4.81%;border-top:1px solid #b9fefa;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:top;width:65.34%;border-right:1px solid #b9fefa;border-top:1px solid #b9fefa;margin:0pt;padding:0pt 5.15pt 0pt 5.4pt;"><div style="border-collapse:collapse;display:table;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><div style="display:table-row;"><div style="color:#029c93;display:table-cell;font-family:'Wingdings';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#xD8;</div><div style="display:table-cell;padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Further scale organization aligned with differentiated antibody product portfolio growth and future launches</span></div></div></div><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><span style="font-size:3pt;margin-left:0pt;visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:top;width:29.83%;border-bottom:1px solid #b9fefa;border-left:1px solid #b9fefa;margin:0pt;padding:0pt 5.4pt 0pt 5.15pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:top;width:4.81%;border-bottom:1px solid #b9fefa;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:top;width:65.34%;border-bottom:1px solid #b9fefa;border-right:1px solid #b9fefa;margin:0pt;padding:0pt 5.15pt 0pt 5.4pt;"><div style="border-collapse:collapse;display:table;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><div style="display:table-row;"><div style="color:#029c93;display:table-cell;font-family:'Wingdings';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#xD8;</div><div style="display:table-cell;padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Use solid financial base to grow and broaden antibody product and technology portfolio</span></div></div></div></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">1.&#xA0;Co-development w/ AbbVie; 2. Co-development w/ Seagen Inc. (Seagen); 3. Co-development w/ BioNTech SE (BioNTech)</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p><a id="_31470f2e_6581_425b_898f_fe9c1f888fcb"></a><a id="PRODUCTPIPELINE_603298"></a><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="color:#029c93;font-weight:bold;">PRODUCT PIPELINE</b><b style="color:#029c93;font-weight:bold;"> AND TECHNOLOGY PROGRESS FIRST HALF OF 2022</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="color:#029c93;visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">At the end of the first six months of 2022, Genmab&#x2019;s proprietary pipeline of investigational medicines, where we are responsible for at least 50% of development, consisted of seven antibody products in </p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:24pt 0pt 0pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;table-layout:fixed;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td></tr><tr><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Genmab A/S</p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Tel: +45 7020 2728</p></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">Company Announcement no. 41</p></td></tr><tr><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Kalvebod Brygge 43</p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Fax: +45 7020 2729</p></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">Page 6/35</p></td></tr><tr><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">1560 Copenhagen V, Denmark</p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">www.genmab.com</p></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">CVR no. 2102 3884</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:76.47%;border:0;margin:30pt 11.76% 30pt 11.76%;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;min-height:36pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><img src="gmab-20220630xex99d1002.jpg" alt="Graphic" style="display:inline-block;height:44.99pt;left:0%;padding-bottom:0.05pt;position:relative;top:0pt;width:151.48pt;" /></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Arial Bold';font-size:9pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-size:13pt;font-weight:bold;">Interim Report for the First Half of 2022</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></div><div style="clear:both;max-width:100%;position:relative;min-height:256.5pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">clinical development. These include Genmab&#x2019;s first U.S. FDA approved medicine, Tivdak, which Genmab is co-developing and co-promoting in the U.S. with Seagen. In addition to our own pipeline, there are multiple investigational medicines in development by global pharmaceutical and biotechnology companies, including four approved medicines powered by Genmab&#x2019;s technology and innovations. Beyond the investigational medicines in clinical development, our pipeline also includes multiple preclinical programs. An overview of the development status of each of our investigational medicines is provided in the following sections, including updates for the second quarter of 2022. For events that occurred during the first quarter of 2022, please refer to Genmab&#x2019;s <a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1434265/000155837022008267/tmb-20220511xex99d1.htm"><span style="font-style:normal;font-weight:normal;">Q1 2022 report</span></a>. Detailed descriptions of dosing, efficacy and safety data from certain clinical trials have been disclosed in company announcements and media releases published via the Nasdaq Copenhagen stock exchange and may also be found in Genmab&#x2019;s filings with the U.S. Securities and Exchange Commission (SEC). Additional information is available on Genmab&#x2019;s website, www.genmab.com. The information accessible through our website is not part of this report and is not incorporated by reference herein.</p><a id="PRODUCTPIPELINEANDTECHNOLOGYPROGRESSFIRS"></a><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="color:#339966;font-weight:bold;visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="color:#029c93;font-size:11pt;font-weight:bold;">Genmab Proprietary Investigational Medicines</b><sup style="color:#029c93;font-size:8.25pt;font-weight:bold;line-height:100%;top:0pt;vertical-align:top;">1 </sup><b style="color:#029c93;font-size:11pt;font-weight:bold;">in Development</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><img src="gmab-20220630xex99d1005.jpg" alt="Graphic" style="display:inline-block;height:256.35pt;left:0%;padding-bottom:0.15pt;position:relative;top:0pt;width:468pt;" /></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;min-height:11.0pt;text-indent:0pt;margin:0pt 36pt 0pt 0pt;"><sup style="font-size:6pt;line-height:100%;top:0pt;vertical-align:top;">1</sup>Investigational medicines where Genmab has &#x2265;50% ownership. Certain investigational medicines in co-development, partners as indicated</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;min-height:11.0pt;text-indent:18pt;margin:0pt 36pt 0pt -18pt;"><sup style="font-size:6pt;line-height:100%;top:0pt;vertical-align:top;">2</sup>See U.S. prescribing information for precise indication and safety information</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;min-height:11.0pt;text-indent:0pt;margin:0pt 36pt 0pt 0pt;"><sup style="font-size:6pt;line-height:100%;top:0pt;vertical-align:top;">3</sup>AbbVie has decided to discontinue co-development of DuoHexaBody-CD37. Upon expiry of the notice period, Genmab will become solely responsible for the further development of DuoHexaBody-CD37 against low-single digit royalty payments to AbbVie, up to an agreed maximum total royalty amount, based on future potential sales of the product.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;min-height:11.0pt;text-indent:18pt;margin:0pt 36pt 0pt -18pt;"><sup style="font-size:6pt;line-height:100%;top:0pt;vertical-align:top;">4</sup>Genmab is developing HexaBody-CD38 in an exclusive worldwide license and option agreement with Janssen</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:11.0pt;text-indent:0pt;margin:0pt 36pt 0pt 0pt;"><span style="font-size:8pt;margin-bottom:11pt;margin-right:0pt;visibility:hidden;">&#x200B;</span></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:24pt 0pt 0pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;table-layout:fixed;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td></tr><tr><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Genmab A/S</p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Tel: +45 7020 2728</p></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">Company Announcement no. 41</p></td></tr><tr><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Kalvebod Brygge 43</p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Fax: +45 7020 2729</p></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">Page 7/35</p></td></tr><tr><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">1560 Copenhagen V, Denmark</p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">www.genmab.com</p></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">CVR no. 2102 3884</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:76.47%;border:0;margin:30pt 11.76% 30pt 11.76%;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;min-height:36pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><img src="gmab-20220630xex99d1002.jpg" alt="Graphic" style="display:inline-block;height:44.99pt;left:0%;padding-bottom:0.05pt;position:relative;top:0pt;width:151.48pt;" /></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Arial Bold';font-size:9pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-size:13pt;font-weight:bold;">Interim Report for the First Half of 2022</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></div><div style="clear:both;max-width:100%;position:relative;min-height:45.04pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="color:#029c93;font-weight:bold;">Tivdak (tisotumab vedotin-tftv) &#x2013; First and only U.S. FDA approved antibody-drug conjugate (ADC) for recurrent or metastatic cervical cancer</b></p><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#x25CF;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">An ADC directed to tissue factor (TF), a protein highly prevalent in solid tumors, including cervical cancer, which is associated with poor prognosis</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#x25CF;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Accelerated approval granted by the U.S. FDA for </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Tivdak</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">, the first and only approved ADC for the treatment of adult patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#x25CF;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">U.S. FDA approval was based on data from the innovaTV 204 (NCT03438396) Phase 2 single-arm clinical study evaluating tisotumab vedotin as monotherapy in patients with previously treated recurrent or metastatic cervical cancer </span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#x25CF;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">In addition to a Phase 3 study in recurrent or metastatic cervical cancer, multiple</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;"> Phase 2 clinical studies in other solid tumors are ongoing</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#x25CF;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Co-developed globally and co-promoted in the U.S. in collaboration with Seagen</span></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:11.0pt;text-indent:0pt;margin:0pt 4.5pt 11pt 0pt;">Tivdak is an ADC composed of Genmab&#x2019;s human monoclonal antibody directed to TF and Seagen&#x2019;s ADC technology that utilizes a protease-cleavable linker that covalently attaches the microtubule-disrupting agent monomethyl auristatin E to the antibody. Genmab used technology licensed from Medarex to generate the TF antibody forming part of Tivdak. Tivdak is the first and only U.S. FDA approved ADC for the treatment of adult patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy. Tivdak is being co-developed by Genmab and Seagen. Under a joint commercialization agreement, Genmab is co-promoting Tivdak in the U.S. and will lead commercial operational activities in Japan. Seagen is leading commercial operational activities in the U.S. and will lead commercial operational activities in Europe and China. In these four markets there will be a 50:50 cost and profit split. In any other markets, Seagen will commercialize Tivdak and Genmab will receive royalties based on a percentage of aggregate net sales ranging from the mid-teens to the mid-twenties. The companies have joint decision-making on the worldwide development and commercialization strategy for Tivdak. The companies have a broad clinical development program for Tivdak, including a confirmatory Phase 3 study in recurrent or metastatic cervical cancer.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:11.0pt;text-indent:0pt;margin:0pt 36pt 11pt 0pt;">Please consult the <span style="color:#029c93;">U.S. Prescribing Information</span> for Tivdak for the labeled indication and safety information, including the boxed warning.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Second Quarter 2022 Update</b></p><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#x25CF;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">June: Genmab and Seagen presented multiple tisotumab vedotin abstracts at</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;"> </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">the American Society of Clinical Oncology (ASCO) Annual Meeting, including interim data from the Phase 1b/2 innovaTV 205 (NCT03786081) study of tisotumab vedotin, which was presented during an oral session. The ongoing innovaTV 205 study is evaluating tisotumab vedotin as monotherapy and in combination with other agents in recurrent or metastatic cervical cancer.</span></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="color:#029c93;font-weight:bold;">Epcoritamab (DuoBody-CD3xCD20) &#x2013; Potential Best-in-class Investigational Medicine</b></p><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#x25CF;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Bispecific antibody-based investigational medicine created with Genmab&#x2019;s DuoBody technology platform</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#x25CF;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Multiple ongoing clinical studies across different settings and histologies, including a Phase 3 study in relapsed/refractory diffuse large B-cell lymphoma (DLBCL) with more studies in planning</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#x25CF;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">BLA submission to the U.S. FDA for SC epcoritamab for the treatment of patients with relapsed/refractory LBCL planned in second half of 2022</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#x25CF;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Co-developed in collaboration with AbbVie</span></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;background:#ffffff;">&#x200B;</span></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:24pt 0pt 0pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;table-layout:fixed;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td></tr><tr><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Genmab A/S</p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Tel: +45 7020 2728</p></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">Company Announcement no. 41</p></td></tr><tr><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Kalvebod Brygge 43</p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Fax: +45 7020 2729</p></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">Page 8/35</p></td></tr><tr><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">1560 Copenhagen V, Denmark</p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">www.genmab.com</p></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">CVR no. 2102 3884</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:76.47%;border:0;margin:30pt 11.76% 30pt 11.76%;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;min-height:36pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><img src="gmab-20220630xex99d1002.jpg" alt="Graphic" style="display:inline-block;height:44.99pt;left:0%;padding-bottom:0.05pt;position:relative;top:0pt;width:151.48pt;" /></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Arial Bold';font-size:9pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-size:13pt;font-weight:bold;">Interim Report for the First Half of 2022</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></div><div style="clear:both;max-width:100%;position:relative;min-height:45.04pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Epcoritamab is a proprietary bispecific antibody created using Genmab&#x2019;s DuoBody technology platform. Epcoritamab targets CD3, which is expressed on T-cells, and CD20, a clinically well-validated target on malignant B-cells. Genmab used technology licensed from Medarex to generate the CD20 antibody forming part of epcoritamab. Epcoritamab is being co-developed by Genmab and AbbVie. The first Phase 3 clinical study (NCT04628494) of epcoritamab in relapsed/refractory DLBCL is ongoing. In addition, Phase 1/2 clinical studies in B-cell non-Hodgkin lymphoma (B-NHL) including chronic lymphocytic leukemia (NCT04623541) and in combination with standard of care therapies for B-NHL (NCT04663347) are ongoing. Also currently recruiting are a Phase 2 study of epcoritamab in combination with anti-neoplastic patients in adults with NHL (NCT05283720), a Phase 1 study of epcoritamab in pediatric patients with relapsed/refractory aggressive mature B-cell neoplasms (NCT05206357) and a Phase 1 study of epcoritamab either as monotherapy or in combination with standard of care therapies in adult patients with B-NHL in China (NCT05201248). The combination of epcoritamab and DuoHexaBody<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#xAE;</sup>-CD37 (GEN3009) is also being explored in an arm of a Phase 1/2 clinical study (NCT04358458) of DuoHexaBody-CD37 in hematologic malignancies.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Second Quarter 2022 Updates</b></p><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#x25CF;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">June: Genmab announced its intent to submit a BLA to the U.S. FDA for SC epcoritamab for the treatment of patients with relapsed/refractory LBCL in the second half of 2022.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#x25CF;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">June: Genmab and AbbVie presented multiple epcoritamab abstracts at</span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;"> both </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">the ASCO Annual Meeting and the 27</span><sup style="font-family:'Arial','Helvetica','sans-serif';font-size:7.5pt;font-style:normal;font-weight:normal;line-height:100%;top:0pt;vertical-align:top;">th</sup><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;"> Annual Meeting of the European Hematology Association (EHA). Data from the first cohort of the Phase 1/2 EPCORE NHL-1 (NCT03625037) trial of epcoritamab in relapsed/refractory LBCL was presented as a late-breaking oral presentation during the Presidential Symposium at EHA.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#x25CF;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">April: Genmab and AbbVie announced topline results from the first cohort of the Phase 1/2 EPCORE NHL-1 trial of epcoritamab in relapsed/refractory LBCL. The study cohort included 157 patients with relapsed/refractory LBCL who received at least two prior lines of systemic therapy, including 38.9% who received prior treatment with chimeric antigen receptor (CAR) T-cell therapy. The topline results from this cohort demonstrated an overall response rate (ORR) of 63.1% as confirmed by an independent review committee (IRC), which exceeded the protocol prespecified threshold for efficacy. The observed median duration of response (DOR) was 12 months. The most common treatment-emergent adverse event was cytokine release syndrome (CRS) with 49.7%, including 2.5% grade 3. Based on the topline results, the companies will engage global regulatory authorities to determine next steps.</span></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="color:#029c93;font-weight:bold;">DuoBody-PD-L1x4-1BB (GEN1046) &#x2013; Bispecific Next Generation Checkpoint Immunotherapy</b></p><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#x25CF;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Bispecific antibody-based investigational medicine created with Genmab&#x2019;s DuoBody technology platform </span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#x25CF;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Clinical studies in solid tumors ongoing, including a Phase 2 study in non-small cell lung cancer (NSCLC)</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#x25CF;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Co-developed in collaboration with BioNTech</span></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">DuoBody-PD-L1x4-1BB (GEN1046) is a proprietary bispecific antibody, jointly owned by Genmab and BioNTech, created using Genmab&#x2019;s DuoBody technology platform. It is being co-developed by Genmab and BioNTech under an agreement in which the companies share all costs and future potential profits for DuoBody-PD-L1x4-1BB on a 50:50 basis. DuoBody-PD-L1x4-1BB is designed to induce an antitumor immune response by simultaneous and complementary PD-L1 blockade and conditional 4-1BB stimulation using an inert DuoBody format. Three clinical studies in solid tumors are ongoing including a </p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:24pt 0pt 0pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;table-layout:fixed;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td></tr><tr><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Genmab A/S</p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Tel: +45 7020 2728</p></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">Company Announcement no. 41</p></td></tr><tr><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Kalvebod Brygge 43</p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Fax: +45 7020 2729</p></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">Page 9/35</p></td></tr><tr><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">1560 Copenhagen V, Denmark</p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">www.genmab.com</p></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">CVR no. 2102 3884</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:76.47%;border:0;margin:30pt 11.76% 30pt 11.76%;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;min-height:36pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><img src="gmab-20220630xex99d1002.jpg" alt="Graphic" style="display:inline-block;height:44.99pt;left:0%;padding-bottom:0.05pt;position:relative;top:0pt;width:151.48pt;" /></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Arial Bold';font-size:9pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-size:13pt;font-weight:bold;">Interim Report for the First Half of 2022</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></div><div style="clear:both;max-width:100%;position:relative;min-height:45.04pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Phase 2 study of DuoBody-PD-L1x4-1BB as monotherapy or in combination with pembrolizumab in patients with recurrent metastatic NSCLC (NCT05117242).</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="color:#029c93;font-weight:bold;">DuoBody-CD40x4-1BB (GEN1042) &#x2013; Potential First-in-Class Bispecific Agonistic Antibody</b></p><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#x25CF;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Bispecific antibody-based investigational medicine created with Genmab&#x2019;s DuoBody technology platform</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#x25CF;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Phase 1/2 clinical study in solid tumors ongoing </span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#x25CF;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Co-developed in collaboration with BioNTech</span></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">DuoBody-CD40x4-1BB (GEN1042) is a proprietary bispecific antibody, jointly owned by Genmab and BioNTech, created using Genmab&#x2019;s DuoBody technology platform. It is being co-developed by Genmab and BioNTech under an agreement in which the companies share all costs and future potential profits for DuoBody-CD40x4-1BB on a 50:50 basis. CD40 and 4-1BB were selected as targets to enhance both dendritic cells and antigen-dependent T-cell activation, using an inert DuoBody format. A Phase 1/2 clinical study of DuoBody-CD40x4-1BB in solid tumors is ongoing (NCT04083599).</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="color:#029c93;font-weight:bold;">DuoHexaBody-CD37 (GEN3009) &#x2013; First DuoHexaBody Program in the Clinic</b></p><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#x25CF;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Antibody-based investigational medicine created with Genmab&#x2019;s DuoHexaBody technology platform</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#x25CF;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Phase 1/2 clinical study in hematologic malignancies ongoing </span></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">DuoHexaBody-CD37 (GEN3009) is a bispecific antibody that targets two non-overlapping CD37 epitopes, created using Genmab&#x2019;s DuoHexaBody technology platform. The DuoHexaBody technology platform combines the dual targeting of our DuoBody technology platform with the enhanced potency of our HexaBody technology platform, creating bispecific antibodies with target-mediated enhanced hexamerization. A Phase 1/2 clinical study (NCT04358458) in hematologic malignancies, including an arm in combination with epcoritamab, is ongoing. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Second Quarter 2022 Update</b></p><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#x25CF;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">June: AbbVie has decided to discontinue co-development of DuoHexaBody-CD37. Upon expiry of the notice period, Genmab will become solely responsible for the further development of DuoHexaBody-CD37 against low-single digit royalty payments to AbbVie, up to an agreed maximum total royalty amount, based on future potential sales of the product.</span></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="color:#029c93;font-weight:bold;">HexaBody-CD38 (GEN3014) &#x2013; HexaBody Molecule with Potential in Hematological Malignancies</b></p><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#x25CF;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Antibody-based investigational medicine created with Genmab&#x2019;s HexaBody technology platform</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#x25CF;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Phase 1/2 clinical study in hematological malignancies ongoing</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#x25CF;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Developed in an exclusive worldwide license and option agreement with Janssen</span></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">HexaBody-CD38 (GEN3014) is a human CD38 monoclonal antibody-based investigational medicine created using Genmab&#x2019;s HexaBody technology platform. In preclinical models of hematological malignancies HexaBody-CD38 demonstrated highly potent complement-dependent cytotoxicity and showed potent anti-tumor activity. In June 2019, Genmab entered into an exclusive worldwide license and option agreement with Janssen to develop and commercialize HexaBody-CD38. A Phase 1/2 clinical study (NCT04824794) in hematologic malignancies is ongoing. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:24pt 0pt 0pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;table-layout:fixed;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td></tr><tr><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Genmab A/S</p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Tel: +45 7020 2728</p></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">Company Announcement no. 41</p></td></tr><tr><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Kalvebod Brygge 43</p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Fax: +45 7020 2729</p></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">Page 10/35</p></td></tr><tr><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">1560 Copenhagen V, Denmark</p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">www.genmab.com</p></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">CVR no. 2102 3884</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:76.47%;border:0;margin:30pt 11.76% 30pt 11.76%;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;min-height:36pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><img src="gmab-20220630xex99d1002.jpg" alt="Graphic" style="display:inline-block;height:44.99pt;left:0%;padding-bottom:0.05pt;position:relative;top:0pt;width:151.48pt;" /></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Arial Bold';font-size:9pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-size:13pt;font-weight:bold;">Interim Report for the First Half of 2022</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></div><div style="clear:both;max-width:100%;position:relative;min-height:202.5pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="color:#029c93;font-weight:bold;">DuoBody-CD3xB7H4 (GEN1047) &#x2013; Most Recent Investigational Medicine in the Clinic</b></p><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#x25CF;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Bispecific antibody-based investigational medicine created with Genmab&#x2019;s DuoBody technology platform</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#x25CF;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Phase 1/2 clinical study in malignant solid tumors ongoing</span></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;background:#ffffff;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">DuoBody-CD3xB7H4 (GEN1047) is a bispecific antibody-based investigational medicine created using Genmab&#x2019;s DuoBody technology platform. B7H4 is an immune checkpoint protein expressed on malignant cells in various solid cancers including breast, ovarian and lung cancer. In preclinical studies, DuoBody-CD3xB7H4 induced T-cell mediated cytotoxicity of B7H4-positive tumor cells. DuoBody-CD3xB7H4 is being developed for the potential treatment of solid cancer indications known to express B7H4. A Phase 1/2 clinical study (NCT05180474) of DuoBody-CD3xB7H4 in malignant solid tumors is ongoing.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="color:#029c93;font-size:11pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="color:#029c93;font-size:11pt;font-weight:bold;">Products Powered by Genmab&#x2019;s Technology and Innovations</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="color:#029c93;font-weight:bold;visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><span style="font-size:10pt;">In addition to Genmab&#x2019;s own pipeline of investigational medicines, our innovations and proprietary technology platforms are applied in the pipelines of global pharmaceutical and biotechnology companies. These companies are running clinical development programs with antibodies created by Genmab or created using Genmab&#x2019;s proprietary DuoBody bispecific antibody technology platform. The programs run from Phase 1 development to approved medicines. The tables in this section include those therapies that have been approved in certain territories as well as clinical stage investigational medicines in Phase 2 development or later. Under the agreements for these products Genmab is entitled to certain potential milestones and royalties.</span> </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="color:#029c93;font-size:11pt;font-weight:bold;">Approved Medicines</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="color:#029c93;font-size:11pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><img src="gmab-20220630xex99d1006.jpg" alt="Graphic" style="display:inline-block;height:202.05pt;left:0%;padding-bottom:0.45pt;position:relative;top:0pt;width:468pt;" /></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><sup style="font-size:6pt;line-height:100%;top:0pt;vertical-align:top;">*</sup>See local country prescribing information for precise indications and safety information</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="color:#029c93;font-weight:bold;visibility:hidden;">&#x200B;</span></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:24pt 0pt 0pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;table-layout:fixed;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td></tr><tr><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Genmab A/S</p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Tel: +45 7020 2728</p></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">Company Announcement no. 41</p></td></tr><tr><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Kalvebod Brygge 43</p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Fax: +45 7020 2729</p></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">Page 11/35</p></td></tr><tr><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">1560 Copenhagen V, Denmark</p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">www.genmab.com</p></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">CVR no. 2102 3884</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:76.47%;border:0;margin:30pt 11.76% 30pt 11.76%;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;min-height:36pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><img src="gmab-20220630xex99d1002.jpg" alt="Graphic" style="display:inline-block;height:44.99pt;left:0%;padding-bottom:0.05pt;position:relative;top:0pt;width:151.48pt;" /></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Arial Bold';font-size:9pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-size:13pt;font-weight:bold;">Interim Report for the First Half of 2022</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></div><div style="clear:both;max-width:100%;position:relative;min-height:45.04pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="color:#029c93;font-weight:bold;">DARZALEX (daratumumab) &#x2013; Redefining the Treatment of Multiple Myeloma</b></p><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#x25CF;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">First-in-class human CD38 monoclonal antibody</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#x25CF;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Developed and commercialized by Janssen under an exclusive worldwide license from Genmab </span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#x25CF;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Intravenous (IV) formulation approved in combination with other therapies for frontline and for relapsed/refractory multiple myeloma in territories including the U.S., Europe and Japan and as monotherapy for heavily pretreated or double-refractory multiple myeloma in territories including the U.S. and Europe</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#x25CF;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">First and only SC CD38-directed antibody approved in territories including the U.S., Europe and Japan for the treatment of certain multiple myeloma indications, known as DARZALEX </span><i style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:italic;font-weight:normal;">FASPRO</i><sup style="font-family:'Arial','Helvetica','sans-serif';font-size:7.5pt;font-style:italic;font-weight:normal;line-height:100%;top:0pt;vertical-align:top;">&#xAE;</sup><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;"> (daratumumab and hyaluronidase-fihj) in the U.S., and DARZALEX SC in Europe</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#x25CF;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">SC daratumumab is the first and only approved therapy for light-chain (AL) amyloidosis in the U.S., Europe and Japan</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#x25CF;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Net sales of DARZALEX by Janssen were USD 3,842 million in the first six months of 2022</span></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">DARZALEX is a human monoclonal antibody that binds with high affinity to the CD38 molecule, which is highly expressed on the surface of multiple myeloma cells and is also expressed by AL amyloidosis plasma cells. Genmab used technology licensed from Medarex to generate the CD38 antibody forming part of daratumumab. Daratumumab is being developed by Janssen under an exclusive worldwide license from Genmab to develop, manufacture and commercialize daratumumab. Under the terms of the agreement, Genmab is entitled to double digit royalties between 12% and 20% with Janssen reducing its royalty payments for Genmab&#x2019;s share of Janssen&#x2019;s royalty payments made to Halozyme Therapeutics, Inc. (Halozyme). Daratumumab (marketed as DARZALEX for IV administration and as DARZALEX <i style="font-style:italic;">FASPRO </i>in the United States and as DARZALEX SC in Europe for SC administration) is approved in a large number of territories for the treatment of adult patients with certain multiple myeloma indications and is the only<i style="font-style:italic;"> </i>approved therapy in the U.S., Europe and Japan for the treatment of adult patients with AL amyloidosis.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Please consult the <span style="color:#029c93;">European Summary of Product Characteristics</span><span style="color:#029c93;"> </span>for DARZALEX and DARZALEX SC and the <span style="color:#029c93;">U.S. Prescribing Information</span> for DARZALEX and DARZALEX <i style="font-style:italic;">FASPRO</i><b style="color:#0070c0;font-size:13pt;font-weight:bold;"> </b>for the labeled indication and safety information.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="color:#029c93;font-weight:bold;">Kesimpta (ofatumumab) &#x2013; Approved in treatment of relapsing forms of multiple sclerosis (RMS)</b></p><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#x25CF;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Human CD20 monoclonal antibody developed and commercialized by Novartis under a license agreement with Genmab</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#x25CF;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Approved in territories including the U.S., EU and Japan for the treatment of RMS in adults</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#x25CF;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">First B-cell therapy that can be self-administered by patients at home using the Sensoready</span><sup style="font-family:'Arial','Helvetica','sans-serif';font-size:7.5pt;font-style:normal;font-weight:normal;line-height:100%;top:0pt;vertical-align:top;">&#xAE;</sup><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;"> autoinjector pen</span></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Kesimpta is a human monoclonal antibody that targets an epitope on the CD20 molecule encompassing parts of the small and large extracellular loops. Genmab used technology licensed from Medarex to generate the CD20 antibody forming part of Kesimpta. Kesimpta is approved in territories including the U.S., Europe and Japan for the treatment of certain adult patients with RMS. Kesimpta is the first B-cell therapy that can be self-administered by patients at home using the Sensoready autoinjector pen, once monthly after starting therapy. Kesimpta is being developed and marketed worldwide by Novartis under a license agreement between Genmab and Novartis. Under the terms of the agreement, Genmab is entitled to 10% royalties on net sales of Kesimpta.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:24pt 0pt 0pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;table-layout:fixed;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td></tr><tr><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Genmab A/S</p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Tel: +45 7020 2728</p></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">Company Announcement no. 41</p></td></tr><tr><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Kalvebod Brygge 43</p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Fax: +45 7020 2729</p></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">Page 12/35</p></td></tr><tr><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">1560 Copenhagen V, Denmark</p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">www.genmab.com</p></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">CVR no. 2102 3884</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:76.47%;border:0;margin:30pt 11.76% 30pt 11.76%;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;min-height:36pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><img src="gmab-20220630xex99d1002.jpg" alt="Graphic" style="display:inline-block;height:44.99pt;left:0%;padding-bottom:0.05pt;position:relative;top:0pt;width:151.48pt;" /></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Arial Bold';font-size:9pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-size:13pt;font-weight:bold;">Interim Report for the First Half of 2022</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></div><div style="clear:both;max-width:100%;position:relative;min-height:45.04pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Please consult the <span style="color:#029c93;">U.S. Prescribing Information</span> and the <span style="color:#029c93;">European Summary of Product Characteristics</span> for the labeled indication and safety information for Kesimpta. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="color:#029c93;font-weight:bold;visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="color:#029c93;font-weight:bold;">TEPEZZA (teprotumumab-trbw) &#x2013; First U.S. FDA-approved medicine for the treatment of thyroid eye disease (TED)</b></p><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#x25CF;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Developed and commercialized by Horizon Therapeutics, plc (Horizon) for the treatment of TED</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#x25CF;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">First and only U.S. FDA-approved medicine for the treatment of TED</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#x25CF;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Also being explored in a clinical trial for the treatment of diffuse cutaneous systemic sclerosis (dcSSC)</span></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">Teprotumumab, approved by the U.S. FDA under the trade name TEPEZZA, is a human monoclonal antibody that targets the Insulin-like Growth Factor 1 Receptor (IGF-1R), a well-validated target. Genmab used technology licensed from Medarex to generate the IGF-1R antibody forming part of teprotumumab.  The antibody was created by Genmab under a collaboration with Roche and development and commercialization of the product is now being conducted by Horizon under a sublicense from Roche. Under the terms of Genmab&#x2019;s agreement with Roche, Genmab will receive mid-single digit royalties on net sales of TEPEZZA. </span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Please consult the <span style="color:#029c93;">U.S. Prescribing Information</span> for the labeled indication and safety information for TEPEZZA.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="color:#029c93;font-weight:bold;">RYBREVANT (amivantamab-vmjw) &#x2013; First regulatory approvals for a DuoBody-based Medicine</b></p><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#x25CF;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Part of Genmab and Janssen DuoBody research and license agreement</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#x25CF;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">First approved medicine created using Genmab&#x2019;s proprietary DuoBody technology platform</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#x25CF;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Under the agreement with Janssen, Genmab will receive milestones and royalties on net sales of RYBREVANT</span></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:11.0pt;text-indent:0pt;margin:0pt 36pt 11pt 0pt;">In July 2012, Genmab entered into a collaboration with Janssen to create and develop bispecific antibodies using Genmab&#x2019;s DuoBody technology platform. The most advanced of these, Janssen&#x2019;s RYBREVANT, is a fully human bispecific antibody that targets epidermal growth factor receptor (EGFR) and Met, two validated cancer targets. The two antibody libraries used to produce amivantamab were both generated by Genmab. In collaboration with Janssen, the antibody pair used to create amivantamab was selected. Janssen is responsible for the development and commercialization of amivantamab. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:11.0pt;text-indent:0pt;margin:0pt 36pt 11pt 0pt;">In 2021, Janssen received approvals in the U.S., Europe and other markets for RYBREVANT for the treatment of certain adult patients with NSCLC with EGFR exon 20 insertion mutations. These are the first regulatory approvals for a therapy that was created using Genmab&#x2019;s proprietary DuoBody bispecific technology platform. Under our agreement with Janssen, Genmab will receive milestones and royalties between 8% and 10% on net sales of RYBREVANT.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:11.0pt;text-indent:0pt;margin:0pt 36pt 11pt 0pt;">Please consult the <span style="color:#029c93;">U.S. Prescribing Information</span> and the<span style="color:#029c93;"> European Summary of Product Characteristics</span> for RYBREVANT for the labeled indication and safety information.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:24pt 0pt 0pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;table-layout:fixed;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td></tr><tr><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Genmab A/S</p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Tel: +45 7020 2728</p></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">Company Announcement no. 41</p></td></tr><tr><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Kalvebod Brygge 43</p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Fax: +45 7020 2729</p></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">Page 13/35</p></td></tr><tr><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">1560 Copenhagen V, Denmark</p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">www.genmab.com</p></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">CVR no. 2102 3884</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:76.47%;border:0;margin:30pt 11.76% 30pt 11.76%;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;min-height:36pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><img src="gmab-20220630xex99d1002.jpg" alt="Graphic" style="display:inline-block;height:44.99pt;left:0%;padding-bottom:0.05pt;position:relative;top:0pt;width:151.48pt;" /></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Arial Bold';font-size:9pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-size:13pt;font-weight:bold;">Interim Report for the First Half of 2022</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></div><div style="clear:both;max-width:100%;position:relative;min-height:148.5pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="color:#029c93;font-weight:bold;">Clinical Stage Investigational Medicines, &gt;Phase 2 Development</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="color:#029c93;font-size:11pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-family:'Georgia';font-weight:bold;"><img src="gmab-20220630xex99d1007.jpg" alt="Graphic" style="display:inline-block;height:148.5pt;width:468pt;" /></b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;min-height:11.0pt;text-indent:0pt;margin:0pt 36pt 11pt 0pt;"><sup style="font-size:6pt;line-height:100%;top:0pt;vertical-align:top;">*</sup><span style="vertical-align:super;">UltiMAb</span><sup style="font-size:6pt;line-height:100%;top:0pt;vertical-align:top;"> </sup><span style="vertical-align:super;">transgenic mouse technology licensed from Medarex, Inc., a wholly owned subsidiary of Bristol Myers Squibb.</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="color:#029c93;font-size:11pt;font-weight:bold;">Preclinical Programs</b></p><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#x25CF;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Broad preclinical pipeline that includes both partnered products and in-house programs based on our proprietary technologies or antibodies</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#x25CF;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Multiple new Investigational New Drug (IND) applications expected to be submitted over coming years</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#x25CF;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Genmab has entered multiple strategic collaborations to support the expansion of our innovative pipeline</span></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Our preclinical pipeline includes immune effector function enhanced antibodies developed with our HexaBody technology platform and bispecific antibodies created with our DuoBody technology platform. We are also working with our partners to generate additional new antibody-based product concepts. A number of the preclinical programs are carried out in cooperation with our collaboration partners.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Second Quarter 2022 Update</b></p><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#x25CF;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">May: IND application and first Clinical Trial Application (CTA) submitted for HexaBody-CD27 (GEN1053/BNT313). GEN1053 is being co-developed in collaboration with BioNTech under an agreement in which the companies share all costs and future potential profits for GEN1053 on a 50:50 basis.</span><span style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"> </span></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p><a id="_SIGNIFICANT_RISKS_AND"></a><a id="SIGNIFICANTRISKSANDUNCERTAINTIES_402181"></a><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;text-indent:0pt;margin:12pt 0pt 3pt 0pt;"><b style="color:#029c93;font-weight:bold;">SIGNIFICANT RISKS AND UNCERTAINTIES</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">As a biotech company, Genmab faces a number of risks and uncertainties. These are common for the industry and relate to operations, intellectual property, research and development, commercialization and financial activities. For further information about risks and uncertainties which Genmab faces, refer to the 2021 Annual Report filed with NASDAQ Copenhagen and the Form 20-F filed with the U.S. SEC, both of which were filed in February 2022. At the date of this interim report, there have been no significant changes to Genmab&#x2019;s overall risk profile since the publication of these reports; however, the full extent and nature of the impact of the COVID-19 pandemic and related containment measures on our business and financial performance is uncertain. See Genmab&#x2019;s Form 20-F for a detailed summary of risks related to our collaborations as well as risks related to the COVID-19 pandemic. </p><a id="OLE_LINK15"></a><a id="OLE_LINK16"></a><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:24pt 0pt 0pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;table-layout:fixed;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td></tr><tr><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Genmab A/S</p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Tel: +45 7020 2728</p></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">Company Announcement no. 41</p></td></tr><tr><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Kalvebod Brygge 43</p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Fax: +45 7020 2729</p></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">Page 14/35</p></td></tr><tr><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">1560 Copenhagen V, Denmark</p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">www.genmab.com</p></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">CVR no. 2102 3884</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:76.47%;border:0;margin:30pt 11.76% 30pt 11.76%;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;min-height:36pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><img src="gmab-20220630xex99d1002.jpg" alt="Graphic" style="display:inline-block;height:44.99pt;left:0%;padding-bottom:0.05pt;position:relative;top:0pt;width:151.48pt;" /></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Arial Bold';font-size:9pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-size:13pt;font-weight:bold;">Interim Report for the First Half of 2022</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></div><div style="clear:both;max-width:100%;position:relative;min-height:45.04pt;"><a id="_60db4b2d_38b2_48ac_82a0_08e7825f7383"></a><a id="FINANCIALREVIEW_601130"></a><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;font-weight:bold;padding-left:21.6pt;text-indent:-21.6pt;margin:0pt 0pt 3pt 0pt;"><b style="color:#029c93;font-weight:bold;">FINANCIAL REVIEW</b></p><a id="OLE_LINK6"></a><a id="OLE_LINK7"></a><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">The interim report is prepared on a consolidated basis for the Genmab group. The financial statements are published in Danish Kroner (DKK).</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="color:#029c93;font-family:'Arial Bold';font-size:9pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="color:#029c93;font-weight:bold;">Revenue</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Genmab&#x2019;s revenue was DKK 5,281 million for the first six months of 2022 compared to DKK 3,553 million for the first six months of 2021. The increase of DKK 1,728 million, or 49%, was primarily driven by higher DARZALEX, TEPEZZA and Kesimpta royalties achieved under our collaborations with Janssen, Roche and Novartis, respectively, partly offset by milestones achieved under our collaborations with Janssen and AbbVie in the first six months of 2021.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> <span style="visibility:hidden;">&#x200B;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:55.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;width:18.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;width:18.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:55.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><b style="font-weight:bold;">(DKK million)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#xA0;&#xA0;&#xA0;&#xA0;</b></p></td><td style="vertical-align:bottom;width:18.99%;background:#e6e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">6 Months Ended June 30, 2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#xA0;&#xA0;&#xA0;&#xA0;</b></p></td><td style="vertical-align:bottom;width:18.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">6 Months Ended June 30, 2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:55.97%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Royalties</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.99%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 4,727</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.98%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 2,595</span></p></td></tr><tr><td style="vertical-align:bottom;width:55.97%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Reimbursement revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.99%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 287</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.98%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 227</span></p></td></tr><tr><td style="vertical-align:bottom;width:55.97%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Milestone revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.99%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 176</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.98%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 731</span></p></td></tr><tr><td style="vertical-align:bottom;width:55.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Collaboration revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.99%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 91</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#x2014;</span></p></td></tr><tr><td style="vertical-align:bottom;width:55.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><b style="font-weight:bold;">Total revenue</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.99%;background:#e6e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> 5,281</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> 3,553</b></p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Arial Bold';font-size:9pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Royalties</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Royalty revenue amounted to DKK 4,727 million in the first six months of 2022 compared to DKK 2,595 million in the first six months of 2021. The increase of DKK 2,132 million, or 82%, was primarily driven by higher DARZALEX, TEPEZZA and Kesimpta royalties achieved under our daratumumab collaboration with Janssen, teprotumumab collaboration with Roche and ofatumumab collaboration with Novartis, respectively. The table below summarizes Genmab&#x2019;s royalty revenue by product. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:55.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;width:18.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;width:18.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:55.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><b style="font-weight:bold;">(DKK million)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:18.99%;background:#e6e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">6 Months Ended June 30, 2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:18.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">6 Months Ended June 30, 2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:55.97%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">DARZALEX </p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.99%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 4,024</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.98%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 2,360</span></p></td></tr><tr><td style="vertical-align:bottom;width:55.97%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">TEPEZZA </p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.99%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 390</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.98%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 162</span></p></td></tr><tr><td style="vertical-align:bottom;width:55.97%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Kesimpta </p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.99%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 296</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.98%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 72</span></p></td></tr><tr><td style="vertical-align:bottom;width:55.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.99%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 17</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1</span></p></td></tr><tr><td style="vertical-align:bottom;width:55.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><b style="font-weight:bold;">Total royalties</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.99%;background:#e6e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> 4,727</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> 2,595</b></p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Net sales of DARZALEX by Janssen were USD 3,842 million in the first six months of 2022 compared to USD 2,798 million in the first six months of 2021. The increase of USD 1,044 million, or 37%, was driven by the continued strong uptake of DARZALEX. Royalty revenue on net sales of DARZALEX<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"> </sup>was DKK 4,024 million in the first six months of 2022 compared to DKK 2,360 million in the first six months of 2021, an increase of DKK 1,664 million. The percentage increase in royalties of 71% is higher than the percentage increase in the underlying net sales primarily due to the higher average exchange rate between the USD and DKK and a higher effective royalty rate for the first six months of 2022, partly offset by the increase in Genmab&#x2019;s share of Janssen&#x2019;s royalty payments to Halozyme in connection with SC net sales. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Net sales of TEPEZZA by Horizon were USD 981 million in the first six months of 2022 compared to USD 455 million in the first six months of 2021. TEPEZZA net sales in the first quarter of 2021 were negatively impacted by the U.S. government-mandated COVID-19 production interruption.&#xA0;Royalty revenue on net </p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:24pt 0pt 0pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;table-layout:fixed;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td></tr><tr><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Genmab A/S</p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Tel: +45 7020 2728</p></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">Company Announcement no. 41</p></td></tr><tr><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Kalvebod Brygge 43</p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Fax: +45 7020 2729</p></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">Page 15/35</p></td></tr><tr><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">1560 Copenhagen V, Denmark</p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">www.genmab.com</p></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">CVR no. 2102 3884</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:76.47%;border:0;margin:30pt 11.76% 30pt 11.76%;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;min-height:36pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><img src="gmab-20220630xex99d1002.jpg" alt="Graphic" style="display:inline-block;height:44.99pt;left:0%;padding-bottom:0.05pt;position:relative;top:0pt;width:151.48pt;" /></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Arial Bold';font-size:9pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-size:13pt;font-weight:bold;">Interim Report for the First Half of 2022</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></div><div style="clear:both;max-width:100%;position:relative;min-height:45.04pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">sales of TEPEZZA was DKK 390 million in the first six months of 2022 compared to DKK 162 million in the first six months of 2021, an increase of DKK 228 million.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Net sales of Kesimpta by Novartis were USD 434 million in the first six months of 2022 compared to USD 116 million in the first six months of 2021. The increase of USD 318 million was driven by US launch momentum due to strong access and increased demand. Royalty revenue on net sales of Kesimpta was DKK 296 million in the first six months of 2022 compared to DKK 72 million in the first six months of 2021, an increase of DKK 224 million.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p><a id="_Hlk109307172"></a><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Janssen was granted U.S. FDA approval for RYBREVANT during the second quarter of 2021, and Genmab subsequently started recognizing royalties on net sales of RYBREVANT. Royalties were not material for the first six months of 2022 or 2021.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p><a id="_Hlk109307336"></a><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Royalty revenue fluctuations from period to period are due primarily to the level of product net sales, foreign currency exchange rates and more specifically to DARZALEX, Genmab&#x2019;s share of Janssen&#x2019;s royalty payments to Halozyme in connection with SC sales.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Reimbursement Revenue</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Reimbursement revenue amounted to DKK 287 million in the first six months of 2022 compared to DKK 227 million in the first six months of 2021. The increase of DKK 60 million, or 26%, was primarily driven by higher activities under our collaboration agreement with BioNTech for DuoBody-CD40x4-1BB. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Arial Bold';font-size:9pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Milestone Revenue</b></p><a id="_Hlk14190762"></a><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Milestone revenue was DKK 176 million in the first six months of 2022 compared to DKK 731 million in the first six months of 2021, a decrease of DKK 555 million, or 76%, primarily driven by milestones achieved in the first six months of 2021 under our Janssen and AbbVie collaborations.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Milestone revenue may fluctuate significantly from period to period due to both the timing of achievements and the varying amount of each individual milestone under our license and collaboration agreements.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Collaboration Revenue</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">In September 2021, Genmab and Seagen announced U.S. FDA accelerated approval for Tivdak in previously treated recurrent or metastatic cervical cancer. Collaboration revenue was DKK 91 million for the first six months of 2022.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Arial Bold';font-size:9pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Refer to Financial Statement Note 2 in this interim report for further details about revenue.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="color:#029c93;font-weight:bold;visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="color:#029c93;font-weight:bold;">Research and Development Expenses</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Research and development expenses amounted to DKK 2,435 million in the first six months of 2022 compared to DKK 1,769 million in the first six months of 2021. The increase of DKK 666 million, or 38%, was driven by the continued advancement of epcoritamab under our collaboration with AbbVie, continued advancement of DuoBody-CD40x4-1BB under our collaboration with BioNTech, and the increase in new team members to support the expansion of our product pipeline. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Arial Bold';font-size:9pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Research and development expenses accounted for 69% of total operating expenses in the first six months of 2022 compared to 79% in the first six months of 2021. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Arial Bold';font-size:9pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="color:#029c93;font-weight:bold;visibility:hidden;">&#x200B;</span></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:24pt 0pt 0pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;table-layout:fixed;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td></tr><tr><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Genmab A/S</p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Tel: +45 7020 2728</p></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">Company Announcement no. 41</p></td></tr><tr><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Kalvebod Brygge 43</p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Fax: +45 7020 2729</p></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">Page 16/35</p></td></tr><tr><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">1560 Copenhagen V, Denmark</p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">www.genmab.com</p></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">CVR no. 2102 3884</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:76.47%;border:0;margin:30pt 11.76% 30pt 11.76%;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;min-height:36pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><img src="gmab-20220630xex99d1002.jpg" alt="Graphic" style="display:inline-block;height:44.99pt;left:0%;padding-bottom:0.05pt;position:relative;top:0pt;width:151.48pt;" /></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Arial Bold';font-size:9pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-size:13pt;font-weight:bold;">Interim Report for the First Half of 2022</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></div><div style="clear:both;max-width:100%;position:relative;min-height:45.04pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="color:#029c93;font-weight:bold;">Selling, General and Administrative Expenses</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Selling, general and administrative expenses were DKK 1,085 million in the first six months of 2022 compared to DKK 465 million in the first six months of 2021. The increase of DKK 620 million, or 133%, was driven by the increase in new team members to support Tivdak post launch, continued expansion of Genmab&#x2019;s commercialization capabilities in support of future launches, and investment in broader organizational infrastructure, including our technology portfolio.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Arial Bold';font-size:9pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Selling, general and administrative expenses accounted for 31% of total operating expenses in the first six months of 2022 compared to 21% in the first six months of 2021.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="color:#029c93;font-weight:bold;visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="color:#029c93;font-weight:bold;">Operating Profit </b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Operating profit was DKK 1,761 million in the first six months of 2022 compared to DKK 1,319 million in the first six months of 2021. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Arial Bold';font-size:9pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="color:#029c93;font-weight:bold;">Net Financial Items</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Net financial items were comprised of the following:</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:60.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:17.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:17.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:60.27%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#xA0;&#xA0;&#xA0;&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.1%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">6 Months Ended</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#xA0;&#xA0;&#xA0;&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">6 Months Ended</b></p></td></tr><tr><td style="vertical-align:bottom;width:60.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><b style="font-weight:bold;">(DKK million)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.1%;background:#e6e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June 30, 2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June 30, 2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:60.27%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Interest and other financial income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.1%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 87</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 127</span></p></td></tr><tr><td style="vertical-align:bottom;width:60.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Foreign exchange rate gain, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.1%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1,792</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 573</span></p></td></tr><tr><td style="vertical-align:bottom;width:60.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><b style="font-weight:bold;">Total financial income</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.1%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> 1,879</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> 700</b></p></td></tr><tr><td style="vertical-align:bottom;width:60.27%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.1%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:60.27%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Interest and other financial expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.1%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (10)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (6)</span></p></td></tr><tr><td style="vertical-align:bottom;width:60.27%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Loss on marketable securities, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.1%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (315)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.1%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (134)</span></p></td></tr><tr><td style="vertical-align:bottom;width:60.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Loss on other investments, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.1%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (214)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (33)</span></p></td></tr><tr><td style="vertical-align:bottom;width:60.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><b style="font-weight:bold;">Total financial expenses</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.1%;background:#e6e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> (539)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> (173)</b></p></td></tr><tr><td style="vertical-align:bottom;width:60.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><b style="font-weight:bold;">Net financial items</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.1%;background:#e6e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> 1,340</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> 527</b></p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Net financial items increased by DKK 813 million, which were primarily driven by: </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#x25CF;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Increase in foreign exchange rate gain, net due to the </span><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">USD strengthening against the DKK which was more favorable to our marketable securities, and cash and cash equivalents in the first six months of 2022,</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#x25CF;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Loss on marketable securities driven by increases in interest rates in the United States and Europe, and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#x25CF;</td><td style="padding:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">Loss on other investments due to the decrease in fair value of Genmab&#x2019;s investments in common shares of CureVac and Bolt.</span></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Refer to Financial Statement Note 4 in this interim report for further details about the net financial items.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="color:#029c93;font-family:'Arial Bold';font-size:9pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p><a id="_Hlk100929385"></a><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="color:#029c93;font-weight:bold;">Corporate Tax</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Corporate tax expense for the first six months of 2022 was DKK 745 million compared to DKK 444 million for the first six months of 2021. The increase in corporate tax expense is primarily the result of Genmab&#x2019;s higher net result before tax. The effective tax rate in the first six months of 2022 and 2021 was 24%. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:24pt 0pt 0pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;table-layout:fixed;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td></tr><tr><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Genmab A/S</p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Tel: +45 7020 2728</p></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">Company Announcement no. 41</p></td></tr><tr><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Kalvebod Brygge 43</p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Fax: +45 7020 2729</p></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">Page 17/35</p></td></tr><tr><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">1560 Copenhagen V, Denmark</p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">www.genmab.com</p></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">CVR no. 2102 3884</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:76.47%;border:0;margin:30pt 11.76% 30pt 11.76%;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;min-height:36pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><img src="gmab-20220630xex99d1002.jpg" alt="Graphic" style="display:inline-block;height:44.99pt;left:0%;padding-bottom:0.05pt;position:relative;top:0pt;width:151.48pt;" /></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Arial Bold';font-size:9pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-size:13pt;font-weight:bold;">Interim Report for the First Half of 2022</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></div><div style="clear:both;max-width:100%;position:relative;min-height:45.04pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="color:#029c93;font-weight:bold;">Net Profit </b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Net profit for the first six months of 2022 was DKK 2,356 million compared to DKK 1,402 million in the first six months of 2021. The increase was driven by the items described above. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="color:#029c93;font-weight:bold;">Liquidity and Capital Resources</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="color:#029c93;font-weight:bold;visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="color:#029c93;font-weight:bold;visibility:hidden;">&#x200B;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:57.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:18.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:19.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:57.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><b style="font-weight:bold;">(DKK million)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#xA0;&#xA0;&#xA0;&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.13%;background:#e6e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June 30, 2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;">&#xA0;&#xA0;&#xA0;&#xA0;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, 2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:57.61%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Marketable securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.13%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 11,799</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 10,381</span></p></td></tr><tr><td style="vertical-align:bottom;width:57.61%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.13%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 9,816</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.25%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 8,957</span></p></td></tr><tr><td style="vertical-align:bottom;width:57.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Shareholders' equity</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.13%;background:#e6e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 24,482</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 22,196</span></p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="color:#029c93;font-weight:bold;visibility:hidden;">&#x200B;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:59.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;width:16.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;width:18.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:59.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><b style="font-weight:bold;">Cash Flow (DKK million)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#xA0;&#xA0;&#xA0;&#xA0;</b></p></td><td style="vertical-align:bottom;width:16.74%;background:#e6e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">6 Months Ended June 30, 2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#xA0;&#xA0;&#xA0;&#xA0;</b></p></td><td style="vertical-align:bottom;width:18.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">6 Months Ended June 30, 2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:59.78%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Cash provided by operating activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.74%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1,546</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.02%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1,540</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.78%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Cash (used in) / provided by investing activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.74%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (1,243)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.02%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 966</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.78%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Cash (used in) financing activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.74%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (278)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.02%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (460)</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Exchange rate adjustments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.74%;background:#e6e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 834</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 171</span></p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="color:#029c93;font-weight:bold;visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Net cash provided by operating activities is primarily related to our operating profit, changes in operating assets and liabilities, reversal of net financial items, and adjustments related to non-cash transactions. Cash provided by operating activities was in line with the first six months of 2021 primarily driven by an increase in operating profit of DKK 442 million offset by the timing of corporate tax payments of DKK 455 million in Denmark in the first six months of 2022 that were not required in the first six months of 2021.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;background:#ffff00;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Net cash (used in) / provided by investing activities primarily reflects differences between the proceeds received from the sale and maturity of our investments and amounts invested, and the cash paid for investments in tangible assets. Purchases of marketable securities exceeded sales and maturities in the first six months of 2022, whereas sales and maturities of marketable securities exceeded purchases in the first six months of 2021. For the first six months of 2021, investing activities also include the proceeds from the sale of CureVac shares of DKK 438 million. There were no sales of other investments in the first six months of 2022.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Net cash (used in) financing activities is primarily related to the purchase of treasury shares, exercise of warrants, lease payments, and payment of withholding taxes on behalf of employees on net settled Restricted Stock Units (RSUs). The decrease in cash used in financing activities for the periods is primarily driven by cash payments for the purchase of treasury shares of DKK 437 million in the first six months of 2021 which were more significant than the cash payments for the purchase of treasury shares in the first six months of 2022 of DKK 211 million.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Exchange rate adjustments represent foreign currency gains or losses on Genmab&#x2019;s cash and cash equivalents, primarily driven by our cash and cash equivalents holdings denominated in USD. The increase in exchange rate adjustments results from the USD strengthening against the DKK to a much greater extent in the first six months of 2022 compared to the first six months of 2021.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:24pt 0pt 0pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;table-layout:fixed;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td></tr><tr><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Genmab A/S</p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Tel: +45 7020 2728</p></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">Company Announcement no. 41</p></td></tr><tr><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Kalvebod Brygge 43</p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Fax: +45 7020 2729</p></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">Page 18/35</p></td></tr><tr><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">1560 Copenhagen V, Denmark</p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">www.genmab.com</p></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">CVR no. 2102 3884</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:76.47%;border:0;margin:30pt 11.76% 30pt 11.76%;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;min-height:36pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><img src="gmab-20220630xex99d1002.jpg" alt="Graphic" style="display:inline-block;height:44.99pt;left:0%;padding-bottom:0.05pt;position:relative;top:0pt;width:151.48pt;" /></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Arial Bold';font-size:9pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-size:13pt;font-weight:bold;">Interim Report for the First Half of 2022</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></div><div style="clear:both;max-width:100%;position:relative;min-height:45.04pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Genmab&#x2019;s USD denominated cash and cash equivalents, and marketable securities represented 87% of Genmab&#x2019;s total cash and cash equivalents, and marketable securities as of June 30, 2022 compared to 86% as of December 31, 2021. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Cash and cash equivalents included short-term marketable securities of DKK 1,006 million as of June 30, 2022 compared to DKK 296 million as of December 31, 2021. In accordance with our accounting policy, securities purchased with a maturity of less than ninety days at the date of acquisition are classified as cash and cash equivalents. Refer to Financial Statement Note 3 in this interim report for further details about our marketable securities.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="color:#029c93;font-weight:bold;">Balance Sheet</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">As of June 30, 2022, total assets were DKK 27,476 million compared to DKK 24,627 million on December 31, 2021. As of June 30, 2022, assets were mainly comprised of marketable securities of DKK 11,799 million, cash and cash equivalents of DKK 9,816 million and current receivables of DKK 3,876 million. The current receivables consist primarily of amounts related to royalties from our collaboration agreements.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">As of June 30, 2022, total liabilities were DKK 2,994 million compared to DKK 2,431 million on December 31, 2021. The increase in total liabilities of DKK 563 million, or 23%, was <span style="background:#ffffff;">primarily driven by</span> the increase in corporate tax payable due to Genmab&#x2019;s net result before tax and timing of estimated tax payments, and lease liabilities related to the commencement of leases in the Netherlands with respect to office and laboratory space<span style="background:#ffffff;">.</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Shareholders&#x2019; equity as of June 30, 2022 was DKK 24,482 million compared to DKK 22,196 million on December 31, 2021. The increase of DKK 2,286 million, or 10%, was driven primarily by Genmab&#x2019;s net profit and share-based compensation expense related to the issuance of shares under Genmab&#x2019;s warrant and RSU programs, partly offset by the purchase of treasury shares during the period. Genmab&#x2019;s equity ratio was 89% as of June 30, 2022 compared to 90% as of December 31, 2021. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:126.1pt;"><b style="color:#029c93;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:bold;">Team Members</b></span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">As of June 30, 2022, the total number of team members was 1,445 compared to 1,029 as of June 30, 2021. The increase was primarily driven by the expansion and acceleration of our pipeline, as well as the investment in the expansion of Genmab&#x2019;s commercialization capabilities, including support for Tivdak post launch and future launches, and broader organizational infrastructure.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:51.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:21.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:20.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:51.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><b style="font-weight:bold;">Team Members</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#xA0;&#xA0;&#xA0;&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.72%;background:#e6e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June 30, 2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#xA0;&#xA0;&#xA0;&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June 30, 2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:51.8%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Research and development team members</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.72%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1,050</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 793</span></p></td></tr><tr><td style="vertical-align:bottom;width:51.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Selling, general and administrative team members</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.72%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 395</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 236</span></p></td></tr><tr><td style="vertical-align:bottom;width:51.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><b style="font-weight:bold;">Total team members</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.72%;background:#e6e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> 1,445</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> 1,029</b></p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="color:#029c93;font-weight:bold;">Legal Matters &#x2013; Janssen Binding Arbitrations </b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">In September 2020, Genmab commenced binding arbitration of two matters arising under its license agreement with Janssen relating to daratumumab. Under the license agreement, Genmab is, among other things, entitled to royalties from Janssen on net sales of daratumumab (marketed as DARZALEX for IV administration and as DARZALEX FASPRO in the United States and as DARZALEX SC in Europe for SC administration). In April 2022, the arbitral tribunal issued an award in the binding arbitration of the two matters. Genmab did not seek a review of the award, and the award is now final.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:24pt 0pt 0pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;table-layout:fixed;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td></tr><tr><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Genmab A/S</p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Tel: +45 7020 2728</p></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">Company Announcement no. 41</p></td></tr><tr><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Kalvebod Brygge 43</p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Fax: +45 7020 2729</p></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">Page 19/35</p></td></tr><tr><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">1560 Copenhagen V, Denmark</p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">www.genmab.com</p></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">CVR no. 2102 3884</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:76.47%;border:0;margin:30pt 11.76% 30pt 11.76%;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;min-height:36pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><img src="gmab-20220630xex99d1002.jpg" alt="Graphic" style="display:inline-block;height:44.99pt;left:0%;padding-bottom:0.05pt;position:relative;top:0pt;width:151.48pt;" /></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Arial Bold';font-size:9pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-size:13pt;font-weight:bold;">Interim Report for the First Half of 2022</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></div><div style="clear:both;max-width:100%;position:relative;min-height:45.04pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">The first matter concerned the question as to whether Janssen&#x2019;s obligation to pay royalties on net sales of licensed product extends, in each applicable country, until the expiration or invalidation of the last-to-expire relevant Genmab-owned patent or the last-to-expire relevant Janssen-owned patent covering the product, as further defined and described in the license agreement.  As to that matter, the tribunal determined by majority opinion that Janssen&#x2019;s obligation to pay royalties to Genmab on net sales of licensed product, in each applicable country, extends through the expiration or invalidation of the last-to-expire relevant Genmab-owned patent covering the product or use thereof, but not the relevant Janssen-owned patent. The relevant Genmab-owned issued U.S., European and Japanese patents will expire in the late 2020s and early 2030s. </span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">The second matter concerned the question as to whether Genmab is required to share in Janssen&#x2019;s royalty payments to Halozyme for the Halozyme enzyme technology used in the SC formulation of daratumumab (marketed as DARZALEX <i style="font-style:italic;">FASPRO</i> in the U.S.). The royalties Janssen pays to Halozyme represent a mid-single digit percentage rate of SC daratumumab net sales. As to that matter, the tribunal ruled by majority opinion that Janssen is permitted to continue reducing its royalty payments to Genmab as an offset against a share of Janssen&#x2019;s royalty payments made to Halozyme. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">On June 9, 2022, Genmab announced the commencement of a new arbitration under the daratumumab license agreement with Janssen. This new arbitration follows from the award in the prior arbitration, where the tribunal ruled in favor of Janssen on the question as to whether Genmab is required to share in Janssen&#x2019;s royalty payments to Halozyme for its technology used in the SC formulation of daratumumab. The tribunal based its ruling on the finding that DARZALEX <i style="font-style:italic;">FASPRO</i> constitutes a new licensed product under the license agreement.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">In this new arbitration, Genmab is consequently seeking an award of USD 405 million plus interest in accrued milestone payments for DARZALEX <i style="font-style:italic;">FASPRO</i> and a declaration that it is entitled to a new 13-year royalty term from the date of DARZALEX <i style="font-style:italic;">FASPRO</i>&#x2019;s first commercial sale. See Company Announcement no. 21.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:24pt 0pt 0pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;table-layout:fixed;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td></tr><tr><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Genmab A/S</p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Tel: +45 7020 2728</p></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">Company Announcement no. 41</p></td></tr><tr><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Kalvebod Brygge 43</p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Fax: +45 7020 2729</p></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">Page 20/35</p></td></tr><tr><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">1560 Copenhagen V, Denmark</p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">www.genmab.com</p></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">CVR no. 2102 3884</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:76.47%;border:0;margin:30pt 11.76% 30pt 11.76%;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;min-height:36pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><img src="gmab-20220630xex99d1002.jpg" alt="Graphic" style="display:inline-block;height:44.99pt;left:0%;padding-bottom:0.05pt;position:relative;top:0pt;width:151.48pt;" /></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Arial Bold';font-size:9pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-size:13pt;font-weight:bold;">Interim Report for the First Half of 2022</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></div><div style="clear:both;max-width:100%;position:relative;min-height:45.04pt;"><a id="_024cadda_22bb_4a31_8d24_5388ff96fd00"></a><a id="STATEMENTSOFCOMPINCOMEQUARTER"></a><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="color:#029c93;font-weight:bold;">STATEMENTS OF COMPREHENSIVE INCOME FOR THE 2ND QUARTER OF 2022</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="color:#029c93;font-weight:bold;visibility:hidden;">&#x200B;</span></p><a id="_08c2f9fb_363e_4fc8_893b_083c21569e9e"></a><a id="Tc_oY9O4V3mYUWmYXQSBuV0Mw_1_0"></a><a id="Tc_lTWuI1CZd06KSSeBV7g6gw_1_2"></a><a id="Tc_0vElfTXWkUGgz3acp7gJiA_1_4"></a><a id="Tc_OtJt163DdU67E2mNnugQtg_2_2"></a><a id="Tc_1kFA9fCsb0m_9upYsHdnbQ_2_4"></a><a id="Tc_Icqh9Fx_VkaxbMYhuPd36A_3_0"></a><a id="Tc_hItOeFa6CEqnQVoDNXW73g_5_0"></a><a id="Tc_cV6okHZth0azamkR7dMG2Q_7_0"></a><a id="Tc_MppQvQ3oVEm0dO5nVtX0ig_8_0"></a><a id="Tc_DNMgSeW9hkKv6xf97aAxgQ_9_0"></a><a id="Tc_qWt8I0q7MUuRF0tKN1Q0Yg_11_0"></a><a id="Tc_yYZoR0ijVEKGI7gaWie5BQ_13_0"></a><a id="Tc_lShKtINgckOtgMOtW_weQg_14_0"></a><a id="Tc_O0hmNfEtM0mbbyi2bR4xIw_16_0"></a><a id="Tc_Ki6cVpjhvUqnWYHWDJPiEw_18_0"></a><a id="Tc_CEYmBm0O7UmRGOEE0NO1Nw_20_0"></a><a id="Tc_2YfhzJhiKkmXegfIRaPw7Q_22_0"></a><a id="Tc_1ohsKTnjjEiuSx5jpCnghw_23_0"></a><a id="Tc_X8t6XmIWG0WpYMKrssQKgA_25_0"></a><a id="Tc_Ch1PRP4qc0ScCdXP8ARJ6Q_27_0"></a><a id="Tc_BrCtWOHOcUaw5cK1LkuyLw_29_0"></a><a id="Tc_453GdM4TLE2z-Lm-UrUdqw_31_0"></a><a id="Tc_x12BpqqSW0qyFjCpBUxBXg_32_0"></a><a id="Tc_RRxBhe9rB0a1cT1VcQKWMQ_34_0"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:63.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;width:3.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:63.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Income Statement</b></p></td><td style="vertical-align:bottom;width:3.07%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.55%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">2nd Quarter of</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#xA0;&#xA0;&#xA0;&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.52%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">2nd Quarter of</p></td></tr><tr><td style="vertical-align:bottom;width:63.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:3.07%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.55%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">2021</p></td></tr><tr><td style="vertical-align:bottom;width:63.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">(DKK million)</p></td><td style="vertical-align:bottom;width:3.07%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.55%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.52%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:63.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:3.07%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.55%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.52%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:63.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Revenue</b></p></td><td style="vertical-align:bottom;width:3.07%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.55%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg" contextRef="Duration_4_1_2022_To_6_30_2022_voh1lJjNhUCZyLqqP0N5aw" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:Revenue" scale="6" id="Tc_0v1fpp4G_kC3_h-_x4jrCQ_5_2">3,162</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg" contextRef="Duration_4_1_2021_To_6_30_2021_20IW8JtRlk6Ow-5ZeByISg" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:Revenue" scale="6" id="Tc_2rNPwEjMykGF052n9a3Ewg_5_4">1,972</ix:nonFraction></b></p></td></tr><tr><td style="vertical-align:bottom;width:63.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:3.07%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.55%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.52%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:63.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Research and development expenses</p></td><td style="vertical-align:bottom;width:3.07%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.55%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg" contextRef="Duration_4_1_2022_To_6_30_2022_voh1lJjNhUCZyLqqP0N5aw" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:ResearchAndDevelopmentExpense" scale="6" id="Tc_Qx23B6OsS0CK7__TmTDBPQ_7_2">1,282</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.52%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg" contextRef="Duration_4_1_2021_To_6_30_2021_20IW8JtRlk6Ow-5ZeByISg" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:ResearchAndDevelopmentExpense" scale="6" id="Tc_EOGRs-n1E0WEbhlx7B6o2Q_7_4">921</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:63.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Selling, general and administrative expenses</p></td><td style="vertical-align:bottom;width:3.07%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.55%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg" contextRef="Duration_4_1_2022_To_6_30_2022_voh1lJjNhUCZyLqqP0N5aw" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:SellingGeneralAndAdministrativeExpense" scale="6" id="Tc_2c04FZcXjkWAKX95cL5xeQ_8_2">633</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg" contextRef="Duration_4_1_2021_To_6_30_2021_20IW8JtRlk6Ow-5ZeByISg" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:SellingGeneralAndAdministrativeExpense" scale="6" id="Tc_NZk0ZRTvN0C0E5CZH7lBZQ_8_4">264</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:63.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Operating expenses</b></p></td><td style="vertical-align:bottom;width:3.07%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.55%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg" contextRef="Duration_4_1_2022_To_6_30_2022_voh1lJjNhUCZyLqqP0N5aw" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:OperatingExpense" scale="6" id="Tc_QqufzBDaCUSVMAcxxUyDWQ_9_2">1,915</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg" contextRef="Duration_4_1_2021_To_6_30_2021_20IW8JtRlk6Ow-5ZeByISg" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:OperatingExpense" scale="6" id="Tc_FC0vyLkQoU6reMCf7EjEiA_9_4">1,185</ix:nonFraction>)</b></p></td></tr><tr><td style="vertical-align:bottom;width:63.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:3.07%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.55%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.52%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:63.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Operating profit</b></p></td><td style="vertical-align:bottom;width:3.07%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.55%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg" contextRef="Duration_4_1_2022_To_6_30_2022_voh1lJjNhUCZyLqqP0N5aw" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:ProfitLossFromOperatingActivities" scale="6" id="Tc_4U1fHTAp0US-S7tYR1uePw_11_2">1,247</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.52%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg" contextRef="Duration_4_1_2021_To_6_30_2021_20IW8JtRlk6Ow-5ZeByISg" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:ProfitLossFromOperatingActivities" scale="6" id="Tc_pfB0I3LKr0uxUC2tOpIWqQ_11_4">787</ix:nonFraction></b></p></td></tr><tr><td style="vertical-align:bottom;width:63.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:3.07%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.55%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.52%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:63.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Financial income</p></td><td style="vertical-align:bottom;width:3.07%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.55%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg" contextRef="Duration_4_1_2022_To_6_30_2022_voh1lJjNhUCZyLqqP0N5aw" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:FinanceIncome" scale="6" id="Tc_kEcYZ6PXCkSz6yNE6Yxwgg_13_2">1,442</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.52%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg" contextRef="Duration_4_1_2021_To_6_30_2021_20IW8JtRlk6Ow-5ZeByISg" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:FinanceIncome" scale="6" id="Tc_BKJWCj6_9EyFhcVX4H4RKQ_13_4">65</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:63.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Financial expenses</p></td><td style="vertical-align:bottom;width:3.07%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.55%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg" contextRef="Duration_4_1_2022_To_6_30_2022_voh1lJjNhUCZyLqqP0N5aw" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:FinanceCosts" scale="6" id="Tc_bnUVCAu1Z0Of-9oP2NFKDA_14_2">200</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg" contextRef="Duration_4_1_2021_To_6_30_2021_20IW8JtRlk6Ow-5ZeByISg" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:FinanceCosts" scale="6" id="Tc_M9Ng8ECU4kWDvrHNphQBDg_14_4">430</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:63.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:3.07%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.55%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.52%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:63.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Net profit before tax</b></p></td><td style="vertical-align:bottom;width:3.07%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.55%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg" contextRef="Duration_4_1_2022_To_6_30_2022_voh1lJjNhUCZyLqqP0N5aw" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:ProfitLossBeforeTax" scale="6" id="Tc_W_rhsu6WAUuo4MA32wA28w_16_2">2,489</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.52%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg" contextRef="Duration_4_1_2021_To_6_30_2021_20IW8JtRlk6Ow-5ZeByISg" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:ProfitLossBeforeTax" scale="6" id="Tc_ImgJSI5Gkkyl4MnwIWbT0w_16_4">422</ix:nonFraction></b></p></td></tr><tr><td style="vertical-align:bottom;width:63.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:3.07%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.55%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.52%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:63.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Corporate tax</p></td><td style="vertical-align:bottom;width:3.07%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.55%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg" contextRef="Duration_4_1_2022_To_6_30_2022_voh1lJjNhUCZyLqqP0N5aw" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:IncomeTaxExpenseContinuingOperations" scale="6" id="Tc_axSnWTGds0GBgmTlaPWN0A_18_2">598</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg" contextRef="Duration_4_1_2021_To_6_30_2021_20IW8JtRlk6Ow-5ZeByISg" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:IncomeTaxExpenseContinuingOperations" scale="6" id="Tc_tmb3tpeoa0OWZpelFchESQ_18_4">116</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:63.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:3.07%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.55%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.52%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:63.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Net profit</b></p></td><td style="vertical-align:bottom;width:3.07%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.55%;background:#e6e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg" contextRef="Duration_4_1_2022_To_6_30_2022_voh1lJjNhUCZyLqqP0N5aw" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:ProfitLoss" scale="6" id="Tc_zfOPFR7Y-Ueb69suEJaQOQ_20_2">1,891</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg" contextRef="Duration_4_1_2021_To_6_30_2021_20IW8JtRlk6Ow-5ZeByISg" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:ProfitLoss" scale="6" id="Tc_vtgJ0n_PaE2n8iysHFedVA_20_4">306</ix:nonFraction></b></p></td></tr><tr><td style="vertical-align:bottom;width:63.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:3.07%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.55%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.52%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:63.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Basic net profit per share</p></td><td style="vertical-align:bottom;width:3.07%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.55%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_DKK_shares_uaEdw-3-XkitvcC2Swh0EQ" contextRef="Duration_4_1_2022_To_6_30_2022_voh1lJjNhUCZyLqqP0N5aw" decimals="2" format="ixt:numdotdecimal" name="ifrs-full:BasicEarningsLossPerShare" scale="0" id="Tc_Ioj9VuBj0Uimljv3jlZi0Q_22_2">28.87</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.52%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_DKK_shares_uaEdw-3-XkitvcC2Swh0EQ" contextRef="Duration_4_1_2021_To_6_30_2021_20IW8JtRlk6Ow-5ZeByISg" decimals="2" format="ixt:numdotdecimal" name="ifrs-full:BasicEarningsLossPerShare" scale="0" id="Tc_x6EnrD-3lEKMJaGCW5yDGA_22_4">4.68</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:63.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Diluted net profit per share</p></td><td style="vertical-align:bottom;width:3.07%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.55%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_DKK_shares_uaEdw-3-XkitvcC2Swh0EQ" contextRef="Duration_4_1_2022_To_6_30_2022_voh1lJjNhUCZyLqqP0N5aw" decimals="2" format="ixt:numdotdecimal" name="ifrs-full:DilutedEarningsLossPerShare" scale="0" id="Tc_U7Atevg3ekm0HPsIMuC64A_23_2">28.66</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.52%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_DKK_shares_uaEdw-3-XkitvcC2Swh0EQ" contextRef="Duration_4_1_2021_To_6_30_2021_20IW8JtRlk6Ow-5ZeByISg" decimals="2" format="ixt:numdotdecimal" name="ifrs-full:DilutedEarningsLossPerShare" scale="0" id="Tc_EyB8F7d3akmCUgG3u1LXmQ_23_4">4.64</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:63.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:3.07%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.55%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.52%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:63.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Statement of Comprehensive Income</b></p></td><td style="vertical-align:bottom;width:3.07%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.55%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#xA0;&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.52%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#xA0;&#xA0;</p></td></tr><tr><td style="vertical-align:bottom;width:63.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:3.07%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.55%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.52%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:63.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Net profit</b></p></td><td style="vertical-align:bottom;width:3.07%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.55%;background:#e6e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg" contextRef="Duration_4_1_2022_To_6_30_2022_voh1lJjNhUCZyLqqP0N5aw" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:ProfitLoss" scale="6" id="Tc_SEnaE6Sj00OdoKR43atstg_27_2">1,891</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg" contextRef="Duration_4_1_2021_To_6_30_2021_20IW8JtRlk6Ow-5ZeByISg" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:ProfitLoss" scale="6" id="Tc_87LWUtrVq0qabaZVt8qPVQ_27_4">306</ix:nonFraction></b></p></td></tr><tr><td style="vertical-align:bottom;width:63.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:3.07%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.55%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.52%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:63.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Other comprehensive income:</b></p></td><td style="vertical-align:bottom;width:3.07%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.55%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#xA0;&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.52%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">&#xA0;&#xA0;</b></p></td></tr><tr><td style="vertical-align:bottom;width:63.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:3.07%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.55%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.52%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:63.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Amounts which will be re-classified to the income statement:</b></p></td><td style="vertical-align:bottom;width:3.07%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.55%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#xA0;&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.52%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">&#xA0;&#xA0;</b></p></td></tr><tr><td style="vertical-align:bottom;width:63.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Adjustment of foreign currency fluctuations on subsidiaries</p></td><td style="vertical-align:bottom;width:3.07%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.55%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg" contextRef="Duration_4_1_2022_To_6_30_2022_voh1lJjNhUCZyLqqP0N5aw" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" scale="6" id="Tc_w3QHrQavGkKYU-tcsGndZQ_32_2">13</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg" contextRef="Duration_4_1_2021_To_6_30_2021_20IW8JtRlk6Ow-5ZeByISg" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" sign="-" scale="6" id="Tc_2EdIuZAM0Uqh99bFJb5vBw_32_4">13</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:63.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:3.07%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.55%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.52%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:63.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total comprehensive income</b></p></td><td style="vertical-align:bottom;width:3.07%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.55%;background:#e6e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg" contextRef="Duration_4_1_2022_To_6_30_2022_voh1lJjNhUCZyLqqP0N5aw" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:ComprehensiveIncome" scale="6" id="Tc_ZPLKGvLZ60S24S4BiTOECg_34_2">1,904</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.38%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg" contextRef="Duration_4_1_2021_To_6_30_2021_20IW8JtRlk6Ow-5ZeByISg" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:ComprehensiveIncome" scale="6" id="Tc_gdmz45TNEUygA9YPXd4Ghw_34_4">293</ix:nonFraction></b></p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="color:#029c93;font-size:1pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:24pt 0pt 0pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;table-layout:fixed;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td></tr><tr><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Genmab A/S</p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Tel: +45 7020 2728</p></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">Company Announcement no. 41</p></td></tr><tr><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Kalvebod Brygge 43</p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Fax: +45 7020 2729</p></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">Page 21/35</p></td></tr><tr><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">1560 Copenhagen V, Denmark</p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">www.genmab.com</p></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">CVR no. 2102 3884</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:76.47%;border:0;margin:30pt 11.76% 30pt 11.76%;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;min-height:36pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><img src="gmab-20220630xex99d1002.jpg" alt="Graphic" style="display:inline-block;height:44.99pt;left:0%;padding-bottom:0.05pt;position:relative;top:0pt;width:151.48pt;" /></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Arial Bold';font-size:9pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-size:13pt;font-weight:bold;">Interim Report for the First Half of 2022</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></div><div style="clear:both;max-width:100%;position:relative;min-height:45.04pt;"><a id="_3f1b076c_b9a7_4a6f_852a_b7d7612837f1"></a><a id="STATEMENTSOFCOMPINCOMEYTD"></a><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="color:#029c93;font-weight:bold;">STATEMENTS OF COMPREHENSIVE INCOME FOR THE FIRST HALF OF 2022</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="color:#029c93;font-weight:bold;visibility:hidden;">&#x200B;</span></p><a id="_8b9897d4_40ef_4c4e_87d1_85858de16a91"></a><a id="Tc_APvQcWprxkSQ8zche25ivw_1_0"></a><a id="Tc_oZ8cY4gx2Ua5GD2l46P2Kw_1_3"></a><a id="Tc_xvYwqqS33U2E-LbSr9X0ag_1_5"></a><a id="Tc_h4UQN8uM-kWExTblvn-UoQ_2_1"></a><a id="Tc_lPOFea5Ax0CPsYwWvXmCYw_2_3"></a><a id="Tc_ZBsTHfzC30O5xoyvkVejqg_2_5"></a><a id="Tc_J5gu3XUvd0OfjrT_uz1I8g_3_0"></a><a id="Tc_yTTenSf2j0WQU8zeAaLScg_5_0"></a><a id="Tc_6vynTBXgKE2vRh0H-3TiMA_5_1"></a><a id="Tc_-soKe37aU0eKg-8eA3IVrQ_7_0"></a><a id="Tc_bNCvXLaRdUKB5o30QXaHsg_8_0"></a><a id="Tc_2ZT6Tdc08Ui4Mudi0fWiDg_9_0"></a><a id="Tc_MQ22KZC9gESwku1uF-CMrA_11_0"></a><a id="Tc_rocWtKE930uW9fTG5PlfqQ_13_0"></a><a id="Tc_J7LhUfcS50Gw6iB2U4maRA_13_1"></a><a id="Tc_Xjsi9Rtnv0-rcyRoct6zpg_14_0"></a><a id="Tc_61bAiZU7i0mROA1LJoxOGA_14_1"></a><a id="Tc_D9QXm8n2_UmOqmdY3Ihwmg_16_0"></a><a id="Tc_uW87POgJPkybAqpGCwL-YA_18_0"></a><a id="Tc_4m5whmbD7EK2mWTaFi3iUQ_20_0"></a><a id="Tc_XNIj5cHY_ECYOPHhLToE2A_22_0"></a><a id="Tc_gUpzyxOYT0KyF-QuYh8nHw_23_0"></a><a id="Tc_T5V_zBepPEWo93J_pPn2gQ_25_0"></a><a id="Tc_pqF9PhIVTEmbFcyqRF82dg_27_0"></a><a id="Tc_KPeqDdjazkeWq3S4-Av4vg_29_0"></a><a id="Tc_FKraCKjwkkW3PjZVazEkDA_31_0"></a><a id="Tc_8WqIUxLcNEKvXzAO93MPwQ_32_0"></a><a id="Tc_5oFGK5fdZ0KL4NGatBNbeg_34_0"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:54.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:54.27%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Income Statement</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#xA0;&#xA0;&#xA0;&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.56%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">6 Months Ended</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.45%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#xA0;&#xA0;&#xA0;&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.56%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">6 Months Ended</p></td></tr><tr><td style="vertical-align:bottom;width:54.27%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Note</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.56%;background:#e6e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">June 30, 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.45%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">June 30, 2021</p></td></tr><tr><td style="vertical-align:bottom;width:54.27%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">(DKK million)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.56%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.45%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.56%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:54.27%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.56%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.45%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.56%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:54.27%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Revenue</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.56%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg" contextRef="Duration_1_1_2022_To_6_30_2022_dNPMG5n7t0WcNVF9KG4Bdw" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:Revenue" scale="6" id="Tc_7H0dOdM7M0-0k21UTF76Dg_5_3">5,281</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.45%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg" contextRef="Duration_1_1_2021_To_6_30_2021_MRS0_D_onUCNBOxf7Qx_Cw" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:Revenue" scale="6" id="Tc_AJyyYh4EVEqbWM39qoJrXw_5_5">3,553</ix:nonFraction></b></p></td></tr><tr><td style="vertical-align:bottom;width:54.27%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.56%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.45%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.56%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:54.27%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Research and development expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.56%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg" contextRef="Duration_1_1_2022_To_6_30_2022_dNPMG5n7t0WcNVF9KG4Bdw" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:ResearchAndDevelopmentExpense" scale="6" id="Tc_XZLspiZiKE2QllozNuGjEA_7_3">2,435</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.45%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.56%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg" contextRef="Duration_1_1_2021_To_6_30_2021_MRS0_D_onUCNBOxf7Qx_Cw" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:ResearchAndDevelopmentExpense" scale="6" id="Tc_GMEtpCEjwUyQi9XXmMhVYA_7_5">1,769</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:54.27%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Selling, general and administrative expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.56%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg" contextRef="Duration_1_1_2022_To_6_30_2022_dNPMG5n7t0WcNVF9KG4Bdw" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:SellingGeneralAndAdministrativeExpense" scale="6" id="Tc_erXfrjZh4kG12npXmmPg0w_8_3">1,085</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.45%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg" contextRef="Duration_1_1_2021_To_6_30_2021_MRS0_D_onUCNBOxf7Qx_Cw" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:SellingGeneralAndAdministrativeExpense" scale="6" id="Tc_E-FEL5OwsUWgTNArVg6GYQ_8_5">465</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:54.27%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Operating expenses</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.56%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg" contextRef="Duration_1_1_2022_To_6_30_2022_dNPMG5n7t0WcNVF9KG4Bdw" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:OperatingExpense" scale="6" id="Tc_yqlZ70PPI0uMdbc-RD5orw_9_3">3,520</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.45%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg" contextRef="Duration_1_1_2021_To_6_30_2021_MRS0_D_onUCNBOxf7Qx_Cw" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:OperatingExpense" scale="6" id="Tc_lis5_iJrpEezRyq7wbX3cg_9_5">2,234</ix:nonFraction>)</b></p></td></tr><tr><td style="vertical-align:bottom;width:54.27%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.56%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.45%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.56%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:54.27%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Operating profit</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.56%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg" contextRef="Duration_1_1_2022_To_6_30_2022_dNPMG5n7t0WcNVF9KG4Bdw" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:ProfitLossFromOperatingActivities" scale="6" id="Tc_TMQKido-TEG3XlbHIvKSlQ_11_3">1,761</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.45%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.56%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg" contextRef="Duration_1_1_2021_To_6_30_2021_MRS0_D_onUCNBOxf7Qx_Cw" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:ProfitLossFromOperatingActivities" scale="6" id="Tc_Z_4V1AYcu0yQ6-cVXss78g_11_5">1,319</ix:nonFraction></b></p></td></tr><tr><td style="vertical-align:bottom;width:54.27%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.56%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.45%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.56%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:54.27%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Financial income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">4</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.56%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg" contextRef="Duration_1_1_2022_To_6_30_2022_dNPMG5n7t0WcNVF9KG4Bdw" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:FinanceIncome" scale="6" id="Tc_pvzlD-rwRUOzHV0BJXnoZw_13_3">1,879</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.45%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.56%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg" contextRef="Duration_1_1_2021_To_6_30_2021_MRS0_D_onUCNBOxf7Qx_Cw" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:FinanceIncome" scale="6" id="Tc_pxhmcV3SH0aoCaWc0j1sxQ_13_5">700</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:54.27%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Financial expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">4</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.56%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg" contextRef="Duration_1_1_2022_To_6_30_2022_dNPMG5n7t0WcNVF9KG4Bdw" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:FinanceCosts" scale="6" id="Tc_Xx9d1umZ0UuUfdxtdIXQkQ_14_3">539</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.45%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg" contextRef="Duration_1_1_2021_To_6_30_2021_MRS0_D_onUCNBOxf7Qx_Cw" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:FinanceCosts" scale="6" id="Tc_nsXePR0_zkGp3jMcpgNafQ_14_5">173</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:54.27%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.56%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.45%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.56%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:54.27%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Net profit before tax</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.56%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg" contextRef="Duration_1_1_2022_To_6_30_2022_dNPMG5n7t0WcNVF9KG4Bdw" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:ProfitLossBeforeTax" scale="6" id="Tc_ZW-KVoHY20eoK_f5Wi4ygA_16_3">3,101</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.45%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.56%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg" contextRef="Duration_1_1_2021_To_6_30_2021_MRS0_D_onUCNBOxf7Qx_Cw" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:ProfitLossBeforeTax" scale="6" id="Tc_l9ol58SEmkKYuio9VRYrwg_16_5">1,846</ix:nonFraction></b></p></td></tr><tr><td style="vertical-align:bottom;width:54.27%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.56%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.45%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.56%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:54.27%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Corporate tax</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.56%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg" contextRef="Duration_1_1_2022_To_6_30_2022_dNPMG5n7t0WcNVF9KG4Bdw" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:IncomeTaxExpenseContinuingOperations" scale="6" id="Tc_H33A0pgCiEO05JDo1SVB_Q_18_3">745</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.45%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg" contextRef="Duration_1_1_2021_To_6_30_2021_MRS0_D_onUCNBOxf7Qx_Cw" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:IncomeTaxExpenseContinuingOperations" scale="6" id="Tc_YkOixXTlcUqSIg9vHjcp2A_18_5">444</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:54.27%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.56%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.45%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.56%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:54.27%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Net profit</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.56%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg" contextRef="Duration_1_1_2022_To_6_30_2022_dNPMG5n7t0WcNVF9KG4Bdw" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:ProfitLoss" scale="6" id="Tc_WQxVd5KteESBZn7rUwz0Vg_20_3">2,356</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.45%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg" contextRef="Duration_1_1_2021_To_6_30_2021_MRS0_D_onUCNBOxf7Qx_Cw" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:ProfitLoss" scale="6" id="Tc_mKrm8yPZ7EOtI26jr8RQJA_20_5">1,402</ix:nonFraction></b></p></td></tr><tr><td style="vertical-align:bottom;width:54.27%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.56%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.45%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.56%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:54.27%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Basic net profit per share</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.56%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_DKK_shares_uaEdw-3-XkitvcC2Swh0EQ" contextRef="Duration_1_1_2022_To_6_30_2022_dNPMG5n7t0WcNVF9KG4Bdw" decimals="2" format="ixt:numdotdecimal" name="ifrs-full:BasicEarningsLossPerShare" scale="0" id="Tc_GTddy9SGfUyMYOFwf-lO8Q_22_3">35.97</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.45%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.56%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_DKK_shares_uaEdw-3-XkitvcC2Swh0EQ" contextRef="Duration_1_1_2021_To_6_30_2021_MRS0_D_onUCNBOxf7Qx_Cw" decimals="2" format="ixt:numdotdecimal" name="ifrs-full:BasicEarningsLossPerShare" scale="0" id="Tc_xQf8ySVz60e0vBuM3LnJsQ_22_5">21.44</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:54.27%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Diluted net profit per share</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.56%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_DKK_shares_uaEdw-3-XkitvcC2Swh0EQ" contextRef="Duration_1_1_2022_To_6_30_2022_dNPMG5n7t0WcNVF9KG4Bdw" decimals="2" format="ixt:numdotdecimal" name="ifrs-full:DilutedEarningsLossPerShare" scale="0" id="Tc_Zw1Yqp2WdUO1r1ebfDvEjw_23_3">35.71</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.45%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.56%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_DKK_shares_uaEdw-3-XkitvcC2Swh0EQ" contextRef="Duration_1_1_2021_To_6_30_2021_MRS0_D_onUCNBOxf7Qx_Cw" decimals="2" format="ixt:numdotdecimal" name="ifrs-full:DilutedEarningsLossPerShare" scale="0" id="Tc_BzHlSiAYaU6-EOmpFGik6A_23_5">21.25</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:54.27%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.56%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.45%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.56%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:54.27%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Statement of Comprehensive Income</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.56%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#xA0;&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.45%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.56%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#xA0;&#xA0;</p></td></tr><tr><td style="vertical-align:bottom;width:54.27%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.56%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.45%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.56%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:54.27%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Net profit</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.56%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg" contextRef="Duration_1_1_2022_To_6_30_2022_dNPMG5n7t0WcNVF9KG4Bdw" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:ProfitLoss" scale="6" id="Tc_kZhZcSsaAUCVeAQIbp6BBg_27_3">2,356</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.45%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg" contextRef="Duration_1_1_2021_To_6_30_2021_MRS0_D_onUCNBOxf7Qx_Cw" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:ProfitLoss" scale="6" id="Tc_aYheMpMevkOsO24KnTfn-w_27_5">1,402</ix:nonFraction></b></p></td></tr><tr><td style="vertical-align:bottom;width:54.27%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.56%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.45%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.56%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:54.27%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Other comprehensive income:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#xA0;&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.56%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.45%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.56%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:54.27%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.56%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.45%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.56%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:54.27%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Amounts which will be re-classified to the income statement:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#xA0;&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.56%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.45%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.56%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:54.27%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Adjustment of foreign currency fluctuations on subsidiaries</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.56%;background:#e6e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg" contextRef="Duration_1_1_2022_To_6_30_2022_dNPMG5n7t0WcNVF9KG4Bdw" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" scale="6" id="Tc_YZ8QYrlTXUC1Scje2KIYHA_32_3">29</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.45%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg" contextRef="Duration_1_1_2021_To_6_30_2021_MRS0_D_onUCNBOxf7Qx_Cw" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" scale="6" id="Tc_h5MtroS63UiRjzxWGFh74A_32_5">28</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:54.27%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.56%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.45%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.56%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:54.27%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total comprehensive income</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.02%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.56%;background:#e6e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg" contextRef="Duration_1_1_2022_To_6_30_2022_dNPMG5n7t0WcNVF9KG4Bdw" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:ComprehensiveIncome" scale="6" id="Tc_o0U4GN3_iEi77lY0MWL3MA_34_3">2,385</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.45%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg" contextRef="Duration_1_1_2021_To_6_30_2021_MRS0_D_onUCNBOxf7Qx_Cw" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:ComprehensiveIncome" scale="6" id="Tc_CVKkrbCTAUKL_No7HDss7A_34_5">1,430</ix:nonFraction></b></p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="color:#029c93;font-size:1pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p><a id="_Toc16514648"></a><a id="_MON_1411968110"></a><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:24pt 0pt 0pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;table-layout:fixed;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td></tr><tr><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Genmab A/S</p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Tel: +45 7020 2728</p></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">Company Announcement no. 41</p></td></tr><tr><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Kalvebod Brygge 43</p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Fax: +45 7020 2729</p></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">Page 22/35</p></td></tr><tr><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">1560 Copenhagen V, Denmark</p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">www.genmab.com</p></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">CVR no. 2102 3884</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:76.47%;border:0;margin:30pt 11.76% 30pt 11.76%;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;min-height:36pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><img src="gmab-20220630xex99d1002.jpg" alt="Graphic" style="display:inline-block;height:44.99pt;left:0%;padding-bottom:0.05pt;position:relative;top:0pt;width:151.48pt;" /></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Arial Bold';font-size:9pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-size:13pt;font-weight:bold;">Interim Report for the First Half of 2022</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></div><div style="clear:both;max-width:100%;position:relative;min-height:45.04pt;"><a id="_86dcba01_c220_4767_a861_3ce954b53a8b"></a><a id="STATEMENTOFCOMPREHENSIVEINCOMEFORTHEFIRS"></a><a id="FIRSTNINEMONTHSOF2019_377366"></a><a id="BALANCESHEET_757698"></a><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="color:#029c93;font-weight:bold;">BALANCE SHEET</b><b style="color:#029c93;font-weight:bold;">S</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p><a id="_10d9d089_b9a2_4fdd_b939_6c1f8a667f4c"></a><a id="Tc_6P7nt-pu9Eyrvk914RTHsA_1_4"></a><a id="Tc_MLd3r0zKwU-6tLv__gK3EQ_1_6"></a><a id="Tc_ysBox-uXOEujmFfYTUExag_2_2"></a><a id="Tc_DuSlzEn0PUGSHytUxTQKTw_2_4"></a><a id="Tc_P1TJe7X-N0-JsnyT8n5N_Q_2_6"></a><a id="Tc_ghAwmGROWEyicM7BgIj7kA_3_0"></a><a id="Tc_5PQYg2rk-0msH5nvosdTzA_4_0"></a><a id="Tc_cKSLvP9TQEackIGSLVwymQ_6_0"></a><a id="Tc_RMkVfKnt9EGJaaVZQA6wFA_7_0"></a><a id="Tc_3Gk99LhLzka5ETFudV-XeQ_8_0"></a><a id="Tc_XU69b7boUkW77EkMc5GypQ_8_2"></a><a id="Tc_e4eEX6keQEigJt4VSb-iIA_9_0"></a><a id="Tc_eaWao127fEWdnEm6Q02FYw_10_0"></a><a id="Tc_mtMXjP0TCEidRJF0YJWTEw_11_0"></a><a id="Tc_9feaM5-3Oku-GyyqAD-V2A_11_2"></a><a id="Tc_MMakXmdGUUGuPe2JwqeZXQ_13_0"></a><a id="Tc_wfAMJMWCKkWK6JLozKoLUg_15_0"></a><a id="Tc_tsOfqbu6TUid00TCXJKlgA_15_4"></a><a id="Tc_I9ynfPet_k2yL-Y9L8jjrg_16_0"></a><a id="Tc_G6v1dcvLA0OxTh8j0SMr6w_17_0"></a><a id="Tc_qglOqYerCU2M5uXxJfdxAw_17_2"></a><a id="Tc_5Qc7sOrTLEaW73ttyQknXQ_18_0"></a><a id="Tc_I1TG44OGT06BMPF8Y0gGug_20_0"></a><a id="Tc_J11ru_oh0EavXfdL_Lzj_g_22_0"></a><a id="Tc_TJfoqxcUbUasAALN5icapQ_24_0"></a><a id="Tc_WbTd6F69c0OuXrRpOQ7spQ_26_0"></a><a id="Tc_NSzG6cU2AEeVNTHXzWcmEA_27_0"></a><a id="Tc_oLkuJ2jxt0OGp9f-X7nS1Q_28_0"></a><a id="Tc_YIkkS9z9wkis4mhgpst-zQ_29_0"></a><a id="Tc_XDReL7S8v0iOS_1wiZx1Fg_31_0"></a><a id="Tc_7AJD96AFGUerXyCLGThMfQ_33_0"></a><a id="Tc_MOmfE4THS0evcaX8ABprSA_34_0"></a><a id="Tc_TH9q2n0Xj0GX5BO8_AECLQ_34_2"></a><a id="Tc_HlIQtAezOEiFJeIXU2f3Vw_35_0"></a><a id="Tc__xbyRDS8NE2C_3DlP_1LRw_36_0"></a><a id="Tc_wIHMAG8KlEiQ8TamBcJ9Sg_36_6"></a><a id="Tc_pjOZIx-STUSKl0vw5AS01g_38_0"></a><a id="Tc_2TsozkevdkeLc6M_xkqU_A_40_0"></a><a id="Tc_-z_5jPb7HUWxSDJ_ldoGug_40_6"></a><a id="Tc_zSnOgfkjW02g_K2emgArGw_41_0"></a><a id="Tc_byrIIcs09UGHzE2PIMCfjA_41_6"></a><a id="Tc_L1jZLqaYjk6Fj-G-QnbzAw_42_0"></a><a id="Tc__NgFtf9D9k-rLFLIYb272g_42_2"></a><a id="Tc_GtA7SzsD4UC-nu03JnKXZg_43_0"></a><a id="Tc_k3isN8Z7mkW4p6sR_Ib8wQ_44_0"></a><a id="Tc_Bd4EpwSLW0aujiWII8DdVw_46_0"></a><a id="Tc_JQQMjya9gkO-UFiyDNLGWg_48_0"></a><a id="Tc_rPZGOiHp30ONpO6xLgb9Iw_50_0"></a><a id="Tc_QlbuaTD1eEmCPHFMha3fDA_52_0"></a><a id="Tc_3hdXK4VQUk6KMGnxzmJGEA_52_2"></a><a id="Tc_loabaoBOc0qQ9O1WK2wcIg_53_0"></a><a id="Tc_bYCnS7SaY0K8uShlhZiazA_53_2"></a><a id="Tc_yC_jLBpKmUq71lwBx85lnA_54_0"></a><a id="Tc_vP7pUdS11EmPwqHVudCcFA_54_2"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:52.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:52.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#xA0;&#xA0;&#xA0;&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#xA0;&#xA0;&#xA0;&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.74%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;">June&#xA0;30,&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#xA0;&#xA0;&#xA0;&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.74%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;">December&#xA0;31,&#xA0;</p></td></tr><tr><td style="vertical-align:bottom;width:52.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Note</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.74%;background:#e6e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;">2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;">2021</p></td></tr><tr><td style="vertical-align:bottom;width:52.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">(DKK million)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.74%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.74%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:52.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">ASSETS</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;">&#xA0;&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.74%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">&#xA0;&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.74%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">&#xA0;&#xA0;</p></td></tr><tr><td style="vertical-align:bottom;width:52.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.74%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.74%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:52.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Intangible assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;">&#xA0;&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.74%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg" contextRef="As_Of_6_30_2022_kBUEJjmpl0mHNogMyIvzJg" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" scale="6" id="Tc_2zlhBD73I0ubHQMMMn5P8A_6_4">216</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.74%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg" contextRef="As_Of_12_31_2021_yeBwiJf1M0aAa25fFQy9Bg" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" scale="6" id="Tc_hiNFqikDkEmg58UqwvCgAw_6_6">254</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:52.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Property and equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;">&#xA0;&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.74%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg" contextRef="As_Of_6_30_2022_kBUEJjmpl0mHNogMyIvzJg" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:PropertyPlantAndEquipment" scale="6" id="Tc_LU9ihB3hzEqF_pfEZ-hxig_7_4">684</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.74%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg" contextRef="As_Of_12_31_2021_yeBwiJf1M0aAa25fFQy9Bg" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:PropertyPlantAndEquipment" scale="6" id="Tc_-aWFAb9XwUCqLcLOBXfAtg_7_6">621</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:52.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Right-of-use assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;">7</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.74%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg" contextRef="As_Of_6_30_2022_kBUEJjmpl0mHNogMyIvzJg" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:RightofuseAssets" scale="6" id="Tc_sWbs_K-oRkeRFnQjRilz8w_8_4">554</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.74%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg" contextRef="As_Of_12_31_2021_yeBwiJf1M0aAa25fFQy9Bg" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:RightofuseAssets" scale="6" id="Tc_RYdvUmRJMkuvGSzDb2IKUQ_8_6">354</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:52.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Receivables</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;">&#xA0;&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.74%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg" contextRef="As_Of_6_30_2022_kBUEJjmpl0mHNogMyIvzJg" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:NoncurrentReceivables" scale="6" id="Tc_lhRxP054zk2BkLzvAOyTkg_9_4">66</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.74%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg" contextRef="As_Of_12_31_2021_yeBwiJf1M0aAa25fFQy9Bg" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:NoncurrentReceivables" scale="6" id="Tc_l9KL2K_vh0SGHuL3Z4RS4g_9_6">27</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:52.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Deferred tax assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;">&#xA0;&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.74%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg" contextRef="As_Of_6_30_2022_kBUEJjmpl0mHNogMyIvzJg" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:NetDeferredTaxAssets" scale="6" id="Tc_t23CrV_DfUSn7FragaePsw_10_4">264</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.74%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg" contextRef="As_Of_12_31_2021_yeBwiJf1M0aAa25fFQy9Bg" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:NetDeferredTaxAssets" scale="6" id="Tc_mSXvvYmOGkiFXaMySs6EUQ_10_6">264</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:52.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Other investments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;">3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.74%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg" contextRef="As_Of_6_30_2022_kBUEJjmpl0mHNogMyIvzJg" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:InvestmentAccountedForUsingEquityMethod" scale="6" id="Tc_VV3bksGzt0yJcGUVvyD1qA_11_4">201</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg" contextRef="As_Of_12_31_2021_yeBwiJf1M0aAa25fFQy9Bg" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:InvestmentAccountedForUsingEquityMethod" scale="6" id="Tc_rSBCkECkMEO9EYkhHkRjFQ_11_6">371</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:52.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.74%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.74%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:52.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Total non-current assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#xA0;&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.74%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg" contextRef="As_Of_6_30_2022_kBUEJjmpl0mHNogMyIvzJg" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:NoncurrentAssets" scale="6" id="Tc_2r0fG70ZkkGqVklVaGHIWA_13_4">1,985</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg" contextRef="As_Of_12_31_2021_yeBwiJf1M0aAa25fFQy9Bg" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:NoncurrentAssets" scale="6" id="Tc_U36ff-GT3kav7uITxoXuBA_13_6">1,891</ix:nonFraction></b></p></td></tr><tr><td style="vertical-align:bottom;width:52.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.74%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.74%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:52.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Corporate tax receivable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.74%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#x2014;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.74%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg" contextRef="As_Of_12_31_2021_yeBwiJf1M0aAa25fFQy9Bg" decimals="-6" format="ixt:numdotdecimal" name="gmab:CorporateTaxReceivable" scale="6" id="Tc_ZU2cUkzjYkCl_4T7_cw-Zw_15_6">31</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:52.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Receivables</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;">&#xA0;&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.74%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg" contextRef="As_Of_6_30_2022_kBUEJjmpl0mHNogMyIvzJg" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:TradeAndOtherCurrentReceivables" scale="6" id="Tc_206wA6QPBkKlLj1-PJwZXg_16_4">3,876</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.74%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg" contextRef="As_Of_12_31_2021_yeBwiJf1M0aAa25fFQy9Bg" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:TradeAndOtherCurrentReceivables" scale="6" id="Tc_-uTQHypiqkeIoH2jkMiQfg_16_6">3,367</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:52.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Marketable securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;">3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.74%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg" contextRef="As_Of_6_30_2022_kBUEJjmpl0mHNogMyIvzJg" decimals="-6" format="ixt:numdotdecimal" name="gmab:IfrsMarketableSecuritiesCurrent" scale="6" id="Tc_zlzSDxLOoUi3p-moi8b0_w_17_4">11,799</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.74%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg" contextRef="As_Of_12_31_2021_yeBwiJf1M0aAa25fFQy9Bg" decimals="-6" format="ixt:numdotdecimal" name="gmab:IfrsMarketableSecuritiesCurrent" scale="6" id="Tc_1oViucfx7kOeWrsLQBC41Q_17_6">10,381</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:52.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;">&#xA0;&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.74%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg" contextRef="As_Of_6_30_2022_kBUEJjmpl0mHNogMyIvzJg" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:CashAndCashEquivalents" scale="6" id="Tc_ZDpcJT6V5EWE_KN1RstJoQ_18_4">9,816</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg" contextRef="As_Of_12_31_2021_yeBwiJf1M0aAa25fFQy9Bg" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:CashAndCashEquivalents" scale="6" id="Tc_a5NQ8ZUGfUa0qhLDms_A1g_18_6">8,957</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:52.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.74%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.74%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:52.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Total current assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#xA0;&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.74%;background:#e6e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg" contextRef="As_Of_6_30_2022_kBUEJjmpl0mHNogMyIvzJg" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:CurrentAssets" scale="6" id="Tc_ZWU71fQYokmJ0H19I_ZzzA_20_4">25,491</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg" contextRef="As_Of_12_31_2021_yeBwiJf1M0aAa25fFQy9Bg" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:CurrentAssets" scale="6" id="Tc_S7HpeHyqPkepn-lgqe75ww_20_6">22,736</ix:nonFraction></b></p></td></tr><tr><td style="vertical-align:bottom;width:52.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.74%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.74%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:52.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Total assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#xA0;&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.74%;background:#e6e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg" contextRef="As_Of_6_30_2022_kBUEJjmpl0mHNogMyIvzJg" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:Assets" scale="6" id="Tc_96KxMKQqKkKfXxkgBhqHaw_22_4">27,476</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg" contextRef="As_Of_12_31_2021_yeBwiJf1M0aAa25fFQy9Bg" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:Assets" scale="6" id="Tc_H85v_KLzH0Kgtd0YuERN_A_22_6">24,627</ix:nonFraction></b></p></td></tr><tr><td style="vertical-align:bottom;width:52.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.74%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.74%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:52.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">SHAREHOLDERS&#x2019; EQUITY AND LIABILITIES</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;">&#xA0;&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.74%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">&#xA0;&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.74%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">&#xA0;&#xA0;</p></td></tr><tr><td style="vertical-align:bottom;width:52.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.74%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.74%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:52.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Share capital</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;">&#xA0;&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.74%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg" contextRef="As_Of_6_30_2022_kBUEJjmpl0mHNogMyIvzJg" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:IssuedCapital" scale="6" id="Tc_6ZVE06BWE0aeV5xpb2pIgA_26_4">66</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.74%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg" contextRef="As_Of_12_31_2021_yeBwiJf1M0aAa25fFQy9Bg" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:IssuedCapital" scale="6" id="Tc_bRSOeYSE8UuOIDCEGX13nw_26_6">66</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:52.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Share premium</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;">&#xA0;&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.74%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg" contextRef="As_Of_6_30_2022_kBUEJjmpl0mHNogMyIvzJg" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:SharePremium" scale="6" id="Tc_wOqziu5L1Ui7QXX-UDQkdA_27_4">12,063</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.74%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg" contextRef="As_Of_12_31_2021_yeBwiJf1M0aAa25fFQy9Bg" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:SharePremium" scale="6" id="Tc_Qn2HuCaDdkGboc3uUoYzow_27_6">12,029</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:52.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Other reserves</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;">&#xA0;&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.74%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg" contextRef="As_Of_6_30_2022_kBUEJjmpl0mHNogMyIvzJg" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:OtherReserves" scale="6" id="Tc_aCFOwRZr4kObTir0FVO-UA_28_4">110</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.74%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg" contextRef="As_Of_12_31_2021_yeBwiJf1M0aAa25fFQy9Bg" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:OtherReserves" scale="6" id="Tc_-kU2ns9FR0W6MIIkztv9Wg_28_6">81</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:52.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Retained earnings</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;">&#xA0;&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.74%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg" contextRef="As_Of_6_30_2022_kBUEJjmpl0mHNogMyIvzJg" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:RetainedEarnings" scale="6" id="Tc_pg1dU29twEWcXwkUAj5pZA_29_4">12,243</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg" contextRef="As_Of_12_31_2021_yeBwiJf1M0aAa25fFQy9Bg" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:RetainedEarnings" scale="6" id="Tc_LSPmNG1jaUK5aXQ-5VXwXQ_29_6">10,020</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:52.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.74%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.74%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:52.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Total shareholders' equity</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#xA0;&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.74%;background:#e6e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg" contextRef="As_Of_6_30_2022_kBUEJjmpl0mHNogMyIvzJg" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:Equity" scale="6" id="Tc_RKPDvWQwc0Kv-dK94JxHYQ_31_4">24,482</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg" contextRef="As_Of_12_31_2021_yeBwiJf1M0aAa25fFQy9Bg" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:Equity" scale="6" id="Tc_vYQ8s8xSm0yhSzsnPwUG9g_31_6">22,196</ix:nonFraction></b></p></td></tr><tr><td style="vertical-align:bottom;width:52.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.74%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.74%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:52.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Provisions</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;">&#xA0;&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.74%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg" contextRef="As_Of_6_30_2022_kBUEJjmpl0mHNogMyIvzJg" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:NoncurrentProvisions" scale="6" id="Tc_zmx1kJT270K0iBL0_ecvSA_33_4">7</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.74%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg" contextRef="As_Of_12_31_2021_yeBwiJf1M0aAa25fFQy9Bg" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:NoncurrentProvisions" scale="6" id="Tc_SQcK9RRjVUOOj8tejMPV2A_33_6">13</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:52.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;">7</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.74%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg" contextRef="As_Of_6_30_2022_kBUEJjmpl0mHNogMyIvzJg" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:NoncurrentLeaseLiabilities" scale="6" id="Tc_6EBUxCN2BUq-qsqpgJOHmg_34_4">554</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.74%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg" contextRef="As_Of_12_31_2021_yeBwiJf1M0aAa25fFQy9Bg" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:NoncurrentLeaseLiabilities" scale="6" id="Tc_8LPWd9X9RES0ky07517lBQ_34_6">363</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:52.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Deferred revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.74%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg" contextRef="As_Of_6_30_2022_kBUEJjmpl0mHNogMyIvzJg" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:RentDeferredIncomeClassifiedAsNoncurrent" scale="6" id="Tc_YkHK06Idu0iIZQ61ikj0Kg_35_4">487</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.74%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg" contextRef="As_Of_12_31_2021_yeBwiJf1M0aAa25fFQy9Bg" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:RentDeferredIncomeClassifiedAsNoncurrent" scale="6" id="Tc_wPGcCcVKj0K6ZLusQsxmbg_35_6">487</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:52.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Other payables</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;">&#xA0;&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.74%;background:#e6e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg" contextRef="As_Of_6_30_2022_kBUEJjmpl0mHNogMyIvzJg" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:OtherNoncurrentPayables" scale="6" id="Tc_gXaivJEHRUiezYQThNLoww_36_4">2</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;width:14.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#x2014;</p></td></tr><tr><td style="vertical-align:bottom;width:52.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.74%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.74%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:52.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Total non-current liabilities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#xA0;&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.74%;background:#e6e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg" contextRef="As_Of_6_30_2022_kBUEJjmpl0mHNogMyIvzJg" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:NoncurrentLiabilities" scale="6" id="Tc_IRewDkedpkeB7kudHQztUg_38_4">1,050</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg" contextRef="As_Of_12_31_2021_yeBwiJf1M0aAa25fFQy9Bg" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:NoncurrentLiabilities" scale="6" id="Tc_5FbLJv5NuUS2oB-p2EWiFQ_38_6">863</ix:nonFraction></b></p></td></tr><tr><td style="vertical-align:bottom;width:52.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.74%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.74%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:52.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Provisions</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;">&#xA0;&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.74%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg" contextRef="As_Of_6_30_2022_kBUEJjmpl0mHNogMyIvzJg" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:CurrentProvisions" scale="6" id="Tc_Sv6PrIC9A0aqSUnUigbEyg_40_4">6</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;width:14.74%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#x2014;</p></td></tr><tr><td style="vertical-align:bottom;width:52.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Corporate tax payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.74%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg" contextRef="As_Of_6_30_2022_kBUEJjmpl0mHNogMyIvzJg" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:CurrentTaxLiabilitiesCurrent" scale="6" id="Tc_r44WCbrqnEqYra3hWCz6nQ_41_4">257</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:14.74%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#x2014;</p></td></tr><tr><td style="vertical-align:bottom;width:52.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;">7</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.74%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg" contextRef="As_Of_6_30_2022_kBUEJjmpl0mHNogMyIvzJg" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:CurrentLeaseLiabilities" scale="6" id="Tc_1z4ZCjUGDkajFlMR4-vuqA_42_4">80</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.74%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg" contextRef="As_Of_12_31_2021_yeBwiJf1M0aAa25fFQy9Bg" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:CurrentLeaseLiabilities" scale="6" id="Tc_gtan8ENOLUGFsom7cZK1Vw_42_6">62</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:52.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Deferred revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.74%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg" contextRef="As_Of_6_30_2022_kBUEJjmpl0mHNogMyIvzJg" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:RentDeferredIncomeClassifiedAsCurrent" scale="6" id="Tc_x8hk8smZ1Um1Ta3kK_g1og_43_4">26</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.74%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg" contextRef="As_Of_12_31_2021_yeBwiJf1M0aAa25fFQy9Bg" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:RentDeferredIncomeClassifiedAsCurrent" scale="6" id="Tc_UIEQ1-t7y0OHjAdeYehpRQ_43_6">26</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:52.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Other payables</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;">&#xA0;&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.74%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg" contextRef="As_Of_6_30_2022_kBUEJjmpl0mHNogMyIvzJg" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:OtherCurrentPayables" scale="6" id="Tc_SIOL3Prwn02hxnoIf2qHGg_44_4">1,575</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg" contextRef="As_Of_12_31_2021_yeBwiJf1M0aAa25fFQy9Bg" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:OtherCurrentPayables" scale="6" id="Tc_FP8AEl2HZkyuvrRnsxKx3Q_44_6">1,480</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:52.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.74%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.74%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:52.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Total current liabilities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#xA0;&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.74%;background:#e6e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg" contextRef="As_Of_6_30_2022_kBUEJjmpl0mHNogMyIvzJg" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:CurrentLiabilities" scale="6" id="Tc_p-4S2Obe406h70KmpihHRg_46_4">1,944</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg" contextRef="As_Of_12_31_2021_yeBwiJf1M0aAa25fFQy9Bg" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:CurrentLiabilities" scale="6" id="Tc_2KIMC7WZj0KilhuYV4qfZg_46_6">1,568</ix:nonFraction></b></p></td></tr><tr><td style="vertical-align:bottom;width:52.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.74%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.74%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:52.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Total liabilities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#xA0;&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.74%;background:#e6e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg" contextRef="As_Of_6_30_2022_kBUEJjmpl0mHNogMyIvzJg" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:Liabilities" scale="6" id="Tc_wMm-AWNSP0WpkFrlZuwpTA_48_4">2,994</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg" contextRef="As_Of_12_31_2021_yeBwiJf1M0aAa25fFQy9Bg" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:Liabilities" scale="6" id="Tc_hrLJ9ejV8k28QaCF0AoLqQ_48_6">2,431</ix:nonFraction></b></p></td></tr><tr><td style="vertical-align:bottom;width:52.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.74%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.74%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:52.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Total shareholders' equity and liabilities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#xA0;&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.74%;background:#e6e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg" contextRef="As_Of_6_30_2022_kBUEJjmpl0mHNogMyIvzJg" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:EquityAndLiabilities" scale="6" id="Tc_9GRKHmTUl0W5hnOvsFISKg_50_4">27,476</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg" contextRef="As_Of_12_31_2021_yeBwiJf1M0aAa25fFQy9Bg" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:EquityAndLiabilities" scale="6" id="Tc_0tUy0vrJyEuqkVdcHRS_kQ_50_6">24,627</ix:nonFraction></b></p></td></tr><tr><td style="vertical-align:bottom;width:52.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.74%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.74%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:52.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Share-based instruments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;">5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.74%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">&#xA0;&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.74%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">&#xA0;&#xA0;</p></td></tr><tr><td style="vertical-align:bottom;width:52.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Related parties</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;">6</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.74%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">&#xA0;&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.74%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">&#xA0;&#xA0;</p></td></tr><tr><td style="vertical-align:bottom;width:52.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Subsequent events to the balance sheet date</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;">8</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.74%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">&#xA0;&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.74%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">&#xA0;&#xA0;</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p><a id="_MON_1411968448"></a><a id="_MON_1428926110"></a><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:24pt 0pt 0pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;table-layout:fixed;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td></tr><tr><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Genmab A/S</p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Tel: +45 7020 2728</p></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">Company Announcement no. 41</p></td></tr><tr><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Kalvebod Brygge 43</p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Fax: +45 7020 2729</p></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">Page 23/35</p></td></tr><tr><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">1560 Copenhagen V, Denmark</p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">www.genmab.com</p></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">CVR no. 2102 3884</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:76.47%;border:0;margin:30pt 11.76% 30pt 11.76%;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;min-height:36pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><img src="gmab-20220630xex99d1002.jpg" alt="Graphic" style="display:inline-block;height:44.99pt;left:0%;padding-bottom:0.05pt;position:relative;top:0pt;width:151.48pt;" /></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Arial Bold';font-size:9pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-size:13pt;font-weight:bold;">Interim Report for the First Half of 2022</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></div><div style="clear:both;max-width:100%;position:relative;min-height:45.04pt;"><a id="_12853050_4fe8_4098_8699_3e51900f7927"></a><a id="STATEMENTOFCASHFLOWS_489627"></a><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;font-weight:bold;text-indent:0pt;margin:0pt 0pt 3pt 0pt;"><b style="color:#029c93;font-weight:bold;">STATEMENTS OF CASH FLOWS</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p><a id="_5dd2a42f_bc1c_45e1_9113_28b5966d0299"></a><a id="Tc_PZ9K6iHmj02hA8IwiHNPaA_1_4"></a><a id="Tc_KyR96OoLE0uRnVzkIvR7Yg_1_6"></a><a id="Tc_3k7pDXU5KU-jEHYbBLOIQA_2_2"></a><a id="Tc_vKOJU7G_skmnPivscox7Uw_2_4"></a><a id="Tc_tieHuyW04E-BbqNKt_N17g_2_6"></a><a id="Tc_rQVGq_CPTkKzJeIndT0Qyg_3_0"></a><a id="Tc_Olr_9xcHLkGkVGBPqcx9LA_5_0"></a><a id="Tc_d7rl3fsBr0i_B9Q0AVQB3A_7_0"></a><a id="Tc_B7LhJBMln0mq2YVfNpuXoQ_8_0"></a><a id="Tc_Z_Z8D7t0sU28A0ZeOEoxjQ_9_0"></a><a id="Tc_afgMJeqj9k-okBiUyz057Q_11_0"></a><a id="Tc_cGQqjXKhfUO7VE_3r1WYPw_13_0"></a><a id="Tc__bippN9ST0mjnbR-yI01ag_14_0"></a><a id="Tc_dv4UrMHAXk6iSdUxNSOYUA_14_2"></a><a id="Tc_-DvOQS2nIEeoLlhN51dbvw_15_0"></a><a id="Tc_mW7tdIVb0UaRHoi_x2iWcQ_15_6"></a><a id="Tc_ptkNcxjbB0SXj_vpn1z7sQ_16_0"></a><a id="Tc_lsvoaPSzi0Srd4fbS3EWyg_18_0"></a><a id="Tc_Fzj4QTamw0e_7VGgNuo8Cg_20_0"></a><a id="Tc_S1vFU8-jGkOC3TdDhhfSzQ_21_0"></a><a id="Tc_YOrrdyyiOUWhhkY4g-HVrg_22_0"></a><a id="Tc_B9xqZ7bNxEqxyvz09RETrw_23_0"></a><a id="Tc_qJ7Aq-4h9Uef0ljmU8Tv1A_24_0"></a><a id="Tc__tADrwLOTEChrMx-v9oTyA_24_4"></a><a id="Tc_iIMgfokzMUuqqwwOg2cG5w_26_0"></a><a id="Tc_rYQqEPP8MUqm1zBLR0Y-Nw_28_0"></a><a id="Tc_GLgAJNWeI02_n0pmrq-7IQ_29_0"></a><a id="Tc_ykShNy3GF0K7nFM1ZR6-gw_30_0"></a><a id="Tc_FSty8EP-iEGqVI172v7EGg_31_0"></a><a id="Tc_XYNRb_BPBECZiIDSTEGSAQ_33_0"></a><a id="Tc_wV7K6zx-HEWNISy9ACj_iw_35_0"></a><a id="Tc_0SsKFfagXk-FtozEdG2tSw_37_0"></a><a id="Tc_OgfUljgM50OotyJ9EBMazw_38_0"></a><a id="Tc_rjx27h43SkmAl5cpDD2xRg_40_0"></a><a id="Tc_vefdvd09z02afYNdqjja4w_42_0"></a><a id="Tc_wwkVuQwaaEiIqbMUlYFfJw_43_0"></a><a id="Tc_QTYaP_zECU6nLZNkRyTV1A_44_0"></a><a id="Tc_tmaY0GCL-k6u-qxQzWvtRA_46_0"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:53.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;width:2.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;width:8.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;width:2.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;width:15.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;width:2.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;width:15.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:53.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:8.66%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:15.48%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:center;margin:0pt;">6 Months Ended</p></td><td style="vertical-align:bottom;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;">&#xA0;&#xA0;&#xA0;&#xA0;</b></p></td><td style="vertical-align:bottom;width:15.98%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:center;margin:0pt;">6 Months Ended</p></td></tr><tr><td style="vertical-align:bottom;width:53.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;">&#xA0;&#xA0;&#xA0;&#xA0;</b></p></td><td style="vertical-align:bottom;width:8.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Note</b></p></td><td style="vertical-align:bottom;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;">&#xA0;&#xA0;&#xA0;&#xA0;</b></p></td><td style="vertical-align:bottom;width:15.48%;background:#e6e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:center;margin:0pt;">June 30, 2022</p></td><td style="vertical-align:bottom;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;">&#xA0;&#xA0;&#xA0;&#xA0;</b></p></td><td style="vertical-align:bottom;width:15.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:center;margin:0pt;">June 30, 2021</p></td></tr><tr><td style="vertical-align:bottom;width:53.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt;">(DKK million)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.66%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:15.48%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:15.98%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:53.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.66%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:15.48%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:15.98%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:53.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">Net profit before tax</b></p></td><td style="vertical-align:bottom;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:8.66%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:15.48%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg" contextRef="Duration_1_1_2022_To_6_30_2022_dNPMG5n7t0WcNVF9KG4Bdw" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:ProfitLossBeforeTax" scale="6" id="Tc_T4POgn9W5E2MvnUDAlwfEA_5_4">3,101</ix:nonFraction></b></p></td><td style="vertical-align:bottom;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:15.98%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg" contextRef="Duration_1_1_2021_To_6_30_2021_MRS0_D_onUCNBOxf7Qx_Cw" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:ProfitLossBeforeTax" scale="6" id="Tc_n7rd5Sczgkqbhhvjqz0ufg_5_6">1,846</ix:nonFraction></b></p></td></tr><tr><td style="vertical-align:bottom;width:53.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:8.66%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:15.48%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:15.98%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:53.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt;">Reversal of financial items, net</p></td><td style="vertical-align:bottom;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:8.66%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:15.48%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg" contextRef="Duration_1_1_2022_To_6_30_2022_dNPMG5n7t0WcNVF9KG4Bdw" decimals="-6" format="ixt:numdotdecimal" name="gmab:ReversalOfFinancialItemsNet" scale="6" id="Tc_rD-1KQad0Emhub-m9JurzA_7_4">1,340</ix:nonFraction>)</p></td><td style="vertical-align:bottom;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:15.98%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg" contextRef="Duration_1_1_2021_To_6_30_2021_MRS0_D_onUCNBOxf7Qx_Cw" decimals="-6" format="ixt:numdotdecimal" name="gmab:ReversalOfFinancialItemsNet" scale="6" id="Tc_UeKJT6rdHku4barvLuNOOA_7_6">527</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:53.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt;">Adjustments for non-cash transactions</p></td><td style="vertical-align:bottom;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:8.66%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:15.48%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg" contextRef="Duration_1_1_2022_To_6_30_2022_dNPMG5n7t0WcNVF9KG4Bdw" decimals="-6" format="ixt:numdotdecimal" name="gmab:TotalAdjustmentsForNonCashTransactions" scale="6" id="Tc_Hq4H5jRkHUyurbT-GCTu3Q_8_4">347</ix:nonFraction></p></td><td style="vertical-align:bottom;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:15.98%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg" contextRef="Duration_1_1_2021_To_6_30_2021_MRS0_D_onUCNBOxf7Qx_Cw" decimals="-6" format="ixt:numdotdecimal" name="gmab:TotalAdjustmentsForNonCashTransactions" scale="6" id="Tc_8O2qwMT-NUuVmKnhT8dxZQ_8_6">227</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:53.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt;">Changes in operating assets and liabilities</p></td><td style="vertical-align:bottom;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:8.66%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:15.48%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg" contextRef="Duration_1_1_2022_To_6_30_2022_dNPMG5n7t0WcNVF9KG4Bdw" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:IncreaseDecreaseInWorkingCapital" scale="6" id="Tc_FcwTsHacnEGbnZr0qxnjWA_9_4">179</ix:nonFraction>)</p></td><td style="vertical-align:bottom;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:15.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg" contextRef="Duration_1_1_2021_To_6_30_2021_MRS0_D_onUCNBOxf7Qx_Cw" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:IncreaseDecreaseInWorkingCapital" scale="6" id="Tc_0_3XErtBqkyeLOiGNxMWUg_9_6">105</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:53.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:8.66%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:15.48%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:15.98%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:53.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">Cash flows from operating activities before financial items</b></p></td><td style="vertical-align:bottom;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:8.66%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:15.48%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg" contextRef="Duration_1_1_2022_To_6_30_2022_dNPMG5n7t0WcNVF9KG4Bdw" decimals="-6" format="ixt:numdotdecimal" name="gmab:CashFlowFromUsedInOperatingActivitiesBeforeFinancialItems" scale="6" id="Tc_qsCC0Mw0VkarksDAwiZNTQ_11_4">1,929</ix:nonFraction></b></p></td><td style="vertical-align:bottom;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:15.98%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg" contextRef="Duration_1_1_2021_To_6_30_2021_MRS0_D_onUCNBOxf7Qx_Cw" decimals="-6" format="ixt:numdotdecimal" name="gmab:CashFlowFromUsedInOperatingActivitiesBeforeFinancialItems" scale="6" id="Tc_I5J_trDL_EmpZY7nNUursA_11_6">1,441</ix:nonFraction></b></p></td></tr><tr><td style="vertical-align:bottom;width:53.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:8.66%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:15.48%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:15.98%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:53.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt;">Interest received</p></td><td style="vertical-align:bottom;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:8.66%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:15.48%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg" contextRef="Duration_1_1_2022_To_6_30_2022_dNPMG5n7t0WcNVF9KG4Bdw" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:InterestReceivedClassifiedAsOperatingActivities" scale="6" id="Tc_d9UD8CvkDESoS-gTXJE0WA_13_4">80</ix:nonFraction></p></td><td style="vertical-align:bottom;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:15.98%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg" contextRef="Duration_1_1_2021_To_6_30_2021_MRS0_D_onUCNBOxf7Qx_Cw" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:InterestReceivedClassifiedAsOperatingActivities" scale="6" id="Tc_fCzt3KmXQkqsdFGuwjhelA_13_6">107</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:53.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt;">Interest elements of lease payments</p></td><td style="vertical-align:bottom;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:8.66%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:center;margin:0pt;">7</p></td><td style="vertical-align:bottom;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:15.48%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg" contextRef="Duration_1_1_2022_To_6_30_2022_dNPMG5n7t0WcNVF9KG4Bdw" decimals="-6" format="ixt:numdotdecimal" name="gmab:AdjustmentsForInterestOnLeasePayments" sign="-" scale="6" id="Tc_F-72-NgwU0aTqdnS8eaF2A_14_4">7</ix:nonFraction>)</p></td><td style="vertical-align:bottom;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:15.98%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg" contextRef="Duration_1_1_2021_To_6_30_2021_MRS0_D_onUCNBOxf7Qx_Cw" decimals="-6" format="ixt:numdotdecimal" name="gmab:AdjustmentsForInterestOnLeasePayments" sign="-" scale="6" id="Tc_qGZAuj2eAUianU2nWrX4tA_14_6">6</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:53.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt;">Interest paid</p></td><td style="vertical-align:bottom;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:8.66%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:15.48%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg" contextRef="Duration_1_1_2022_To_6_30_2022_dNPMG5n7t0WcNVF9KG4Bdw" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:InterestPaidClassifiedAsOperatingActivities" scale="6" id="Tc_sY816rOv0ECkr3wCfRX7uQ_15_4">1</ix:nonFraction>)</p></td><td style="vertical-align:bottom;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.98%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#x2014;</p></td></tr><tr><td style="vertical-align:bottom;width:53.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt;">Corporate taxes paid</p></td><td style="vertical-align:bottom;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:8.66%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:15.48%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg" contextRef="Duration_1_1_2022_To_6_30_2022_dNPMG5n7t0WcNVF9KG4Bdw" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:AdjustmentsForIncomeTaxExpense" sign="-" scale="6" id="Tc_KE4zaQ7fLUCZSXrPbOw_1g_16_4">455</ix:nonFraction>)</p></td><td style="vertical-align:bottom;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:15.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg" contextRef="Duration_1_1_2021_To_6_30_2021_MRS0_D_onUCNBOxf7Qx_Cw" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:AdjustmentsForIncomeTaxExpense" sign="-" scale="6" id="Tc_RAWYDqRAm0-e2_N2nEjSrA_16_6">2</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:53.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:8.66%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:15.48%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:15.98%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:53.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">Net cash provided by operating activities</b></p></td><td style="vertical-align:bottom;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:8.66%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:15.48%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg" contextRef="Duration_1_1_2022_To_6_30_2022_dNPMG5n7t0WcNVF9KG4Bdw" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:CashFlowsFromUsedInOperatingActivities" scale="6" id="Tc_zUpMIL7tcE6gVURup4OO1Q_18_4">1,546</ix:nonFraction></b></p></td><td style="vertical-align:bottom;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:15.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg" contextRef="Duration_1_1_2021_To_6_30_2021_MRS0_D_onUCNBOxf7Qx_Cw" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:CashFlowsFromUsedInOperatingActivities" scale="6" id="Tc_mEk3icI__0OR4L0j-h9qwA_18_6">1,540</ix:nonFraction></b></p></td></tr><tr><td style="vertical-align:bottom;width:53.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:8.66%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:15.48%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:15.98%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:53.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt;">Investment in tangible assets</p></td><td style="vertical-align:bottom;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:8.66%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:15.48%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg" contextRef="Duration_1_1_2022_To_6_30_2022_dNPMG5n7t0WcNVF9KG4Bdw" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" scale="6" id="Tc_SFa5_-5hO0itQw83Kuuj8w_20_4">125</ix:nonFraction>)</p></td><td style="vertical-align:bottom;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:15.98%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg" contextRef="Duration_1_1_2021_To_6_30_2021_MRS0_D_onUCNBOxf7Qx_Cw" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" scale="6" id="Tc_FGKOOf5GM0O7-OK77xa89w_20_6">107</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:53.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt;">Marketable securities bought</p></td><td style="vertical-align:bottom;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:8.66%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:15.48%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg" contextRef="Duration_1_1_2022_To_6_30_2022_dNPMG5n7t0WcNVF9KG4Bdw" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:PurchaseOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod" scale="6" id="Tc_w_aClYSsNEuuyNyVIXrzrQ_21_4">4,061</ix:nonFraction>)</p></td><td style="vertical-align:bottom;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:15.98%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg" contextRef="Duration_1_1_2021_To_6_30_2021_MRS0_D_onUCNBOxf7Qx_Cw" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:PurchaseOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod" scale="6" id="Tc_Xd6JuEiEw0S-SrmZzFpYsw_21_6">7,410</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:53.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt;">Marketable securities sold</p></td><td style="vertical-align:bottom;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:8.66%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:15.48%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg" contextRef="Duration_1_1_2022_To_6_30_2022_dNPMG5n7t0WcNVF9KG4Bdw" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:ProceedsFromSalesOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod" scale="6" id="Tc_eq4T-RNUgE6YQIhzsHBQMw_22_4">2,965</ix:nonFraction></p></td><td style="vertical-align:bottom;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:15.98%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg" contextRef="Duration_1_1_2021_To_6_30_2021_MRS0_D_onUCNBOxf7Qx_Cw" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:ProceedsFromSalesOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod" scale="6" id="Tc_xTJz4qpAj0C9lhky1VOvow_22_6">8,137</ix:nonFraction></p></td></tr><tr><td style="vertical-align:middle;width:53.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt;">Other investments bought</p></td><td style="vertical-align:bottom;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:8.66%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:15.48%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg" contextRef="Duration_1_1_2022_To_6_30_2022_dNPMG5n7t0WcNVF9KG4Bdw" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:PurchaseOfInterestsInInvestmentsAccountedForUsingEquityMethod" scale="6" id="Tc_wFjhp7Tp3E-s8MDw4jdxRg_23_4">22</ix:nonFraction>)</p></td><td style="vertical-align:bottom;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:15.98%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg" contextRef="Duration_1_1_2021_To_6_30_2021_MRS0_D_onUCNBOxf7Qx_Cw" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:PurchaseOfInterestsInInvestmentsAccountedForUsingEquityMethod" scale="6" id="Tc_Otn6fV81GUWElrhU_IIElA_23_6">92</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:middle;width:53.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt;">Other investments sold</p></td><td style="vertical-align:bottom;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:8.66%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:15.48%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#x2014;</p></td><td style="vertical-align:bottom;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:15.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg" contextRef="Duration_1_1_2021_To_6_30_2021_MRS0_D_onUCNBOxf7Qx_Cw" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:ProceedsFromSalesOfInvestmentsAccountedForUsingEquityMethod" scale="6" id="Tc_b47bvPjxDUO8xucdTGmrkQ_24_6">438</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:53.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:8.66%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:15.48%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:15.98%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:53.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">Net cash (used in) / provided by investing activities</b></p></td><td style="vertical-align:bottom;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:8.66%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:15.48%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg" contextRef="Duration_1_1_2022_To_6_30_2022_dNPMG5n7t0WcNVF9KG4Bdw" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:CashFlowsFromUsedInInvestingActivities" sign="-" scale="6" id="Tc_UeAP5ax-XU2wmFxixbeZGg_26_4">1,243</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:15.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg" contextRef="Duration_1_1_2021_To_6_30_2021_MRS0_D_onUCNBOxf7Qx_Cw" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:CashFlowsFromUsedInInvestingActivities" scale="6" id="Tc_MYyo4qqRtUOHX69sCtCEmg_26_6">966</ix:nonFraction></b></p></td></tr><tr><td style="vertical-align:bottom;width:53.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:8.66%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:15.48%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:15.98%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:53.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt;">Warrants exercised</p></td><td style="vertical-align:bottom;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:8.66%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:15.48%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg" contextRef="Duration_1_1_2022_To_6_30_2022_dNPMG5n7t0WcNVF9KG4Bdw" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:ProceedsFromExerciseOfWarrants" scale="6" id="Tc_sZd4nSmUtkSUBYb010TaAg_28_4">34</ix:nonFraction></p></td><td style="vertical-align:bottom;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:15.98%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg" contextRef="Duration_1_1_2021_To_6_30_2021_MRS0_D_onUCNBOxf7Qx_Cw" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:ProceedsFromExerciseOfWarrants" scale="6" id="Tc_8lNJ8igefke-uRmfS9BFZA_28_6">46</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:53.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt;">Principal elements of lease payments</p></td><td style="vertical-align:bottom;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:8.66%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:15.48%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg" contextRef="Duration_1_1_2022_To_6_30_2022_dNPMG5n7t0WcNVF9KG4Bdw" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" scale="6" id="Tc_HiBE72L6E0CTMRe1rxVvnQ_29_4">30</ix:nonFraction>)</p></td><td style="vertical-align:bottom;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:15.98%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg" contextRef="Duration_1_1_2021_To_6_30_2021_MRS0_D_onUCNBOxf7Qx_Cw" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" scale="6" id="Tc_LXGVpVA_ZkKW9Ugef2K1bA_29_6">29</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:53.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt;">Purchase of treasury shares</p></td><td style="vertical-align:bottom;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:8.66%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:15.48%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg" contextRef="Duration_1_1_2022_To_6_30_2022_dNPMG5n7t0WcNVF9KG4Bdw" decimals="-6" format="ixt:numdotdecimal" name="gmab:PaymentsToAcquireTreasuryShares" scale="6" id="Tc_i3RDl-drtk6IGfJjHUdbQw_30_4">211</ix:nonFraction>)</p></td><td style="vertical-align:bottom;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:15.98%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg" contextRef="Duration_1_1_2021_To_6_30_2021_MRS0_D_onUCNBOxf7Qx_Cw" decimals="-6" format="ixt:numdotdecimal" name="gmab:PaymentsToAcquireTreasuryShares" scale="6" id="Tc_g76yUot8OEyAIZtLCsZbog_30_6">437</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:53.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt;">Payment of withholding taxes on behalf of employees on net settled RSUs</p></td><td style="vertical-align:bottom;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:8.66%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:15.48%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg" contextRef="Duration_1_1_2022_To_6_30_2022_dNPMG5n7t0WcNVF9KG4Bdw" decimals="-6" format="ixt:numdotdecimal" name="gmab:PaymentOfWithholdingTaxesOnBehalfOfEmployeesOnNetSettledRSUs" scale="6" id="Tc_rq-So9QbC0yt7nKMb9fZzw_31_4">71</ix:nonFraction>)</p></td><td style="vertical-align:bottom;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:15.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg" contextRef="Duration_1_1_2021_To_6_30_2021_MRS0_D_onUCNBOxf7Qx_Cw" decimals="-6" format="ixt:numdotdecimal" name="gmab:PaymentOfWithholdingTaxesOnBehalfOfEmployeesOnNetSettledRSUs" scale="6" id="Tc_oUTcDeYqf0a1uiY3x1yoeA_31_6">40</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:53.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:8.66%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:15.48%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:15.98%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:53.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">Net cash (used in) financing activities</b></p></td><td style="vertical-align:bottom;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:8.66%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:15.48%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg" contextRef="Duration_1_1_2022_To_6_30_2022_dNPMG5n7t0WcNVF9KG4Bdw" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:CashFlowsFromUsedInFinancingActivities" sign="-" scale="6" id="Tc_cT3CferTsU-Rkvk7XZY1tA_33_4">278</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:15.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg" contextRef="Duration_1_1_2021_To_6_30_2021_MRS0_D_onUCNBOxf7Qx_Cw" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:CashFlowsFromUsedInFinancingActivities" sign="-" scale="6" id="Tc_uVoNyXDLB0ytmRp1uYUiAQ_33_6">460</ix:nonFraction>)</b></p></td></tr><tr><td style="vertical-align:bottom;width:53.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:8.66%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:15.48%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:15.98%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:53.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">Change in cash and cash equivalents</b></p></td><td style="vertical-align:bottom;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:8.66%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:15.48%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg" contextRef="Duration_1_1_2022_To_6_30_2022_dNPMG5n7t0WcNVF9KG4Bdw" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" scale="6" id="Tc_QrbemPzlQk-TtyPWxiIn0g_35_4">25</ix:nonFraction></b></p></td><td style="vertical-align:bottom;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:15.98%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg" contextRef="Duration_1_1_2021_To_6_30_2021_MRS0_D_onUCNBOxf7Qx_Cw" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" scale="6" id="Tc_pu6urxudukWVCah4wZG-lQ_35_6">2,046</ix:nonFraction></b></p></td></tr><tr><td style="vertical-align:bottom;width:53.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:8.66%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:15.48%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:15.98%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:53.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt;">Cash and cash equivalents at the beginning of the period</p></td><td style="vertical-align:bottom;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:8.66%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:15.48%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg" contextRef="As_Of_12_31_2021_yeBwiJf1M0aAa25fFQy9Bg" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:CashAndCashEquivalents" scale="6" id="Tc_fXYVvTtfSEKF0UJL8tGD4g_37_4">8,957</ix:nonFraction></p></td><td style="vertical-align:bottom;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:15.98%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg" contextRef="As_Of_12_31_2020_ccHyN2oOokuDhNdvPg9fRQ" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:CashAndCashEquivalents" scale="6" id="Tc_4iLXJM0C2Eeln0OwvX7Hsg_37_6">7,260</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:53.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt;">Exchange rate adjustments</p></td><td style="vertical-align:bottom;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:8.66%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:15.48%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg" contextRef="Duration_1_1_2022_To_6_30_2022_dNPMG5n7t0WcNVF9KG4Bdw" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents" scale="6" id="Tc_QM2FDDMftU2LeAVnggoPMQ_38_4">834</ix:nonFraction></p></td><td style="vertical-align:bottom;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:15.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg" contextRef="Duration_1_1_2021_To_6_30_2021_MRS0_D_onUCNBOxf7Qx_Cw" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents" scale="6" id="Tc_18uxgs5IMUGaUCUjBPO0Gw_38_6">171</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:53.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:8.66%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:15.48%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:15.98%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:53.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">Cash and cash equivalents at the end of the period</b></p></td><td style="vertical-align:bottom;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:8.66%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:15.48%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg" contextRef="As_Of_6_30_2022_kBUEJjmpl0mHNogMyIvzJg" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:CashAndCashEquivalents" scale="6" id="Tc_GwLHwD3btk-LxtZNMIIArA_40_4">9,816</ix:nonFraction></b></p></td><td style="vertical-align:bottom;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:15.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg" contextRef="As_Of_6_30_2021_eEXLsHGqbE20an7xlGLjnw" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:CashAndCashEquivalents" scale="6" id="Tc_IVSC4JjhQ0KMuE_aJK1xQQ_40_6">9,477</ix:nonFraction></b></p></td></tr><tr><td style="vertical-align:bottom;width:53.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:8.66%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:15.48%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:15.98%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:53.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">Cash and cash equivalents include:</b></p></td><td style="vertical-align:bottom;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:8.66%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:15.48%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:15.98%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:53.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt;">Bank deposits</p></td><td style="vertical-align:bottom;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:8.66%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:15.48%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg" contextRef="As_Of_6_30_2022_kBUEJjmpl0mHNogMyIvzJg" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:Cash" scale="6" id="Tc_wl7T4-KFzUqjdBHlQO0g9w_43_4">8,810</ix:nonFraction></p></td><td style="vertical-align:bottom;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:15.98%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg" contextRef="As_Of_6_30_2021_eEXLsHGqbE20an7xlGLjnw" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:Cash" scale="6" id="Tc__Agr9ne3HUuf_JSkignRew_43_6">6,908</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:53.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt;">Short-term marketable securities</p></td><td style="vertical-align:bottom;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:8.66%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:15.48%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg" contextRef="As_Of_6_30_2022_kBUEJjmpl0mHNogMyIvzJg" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:ShorttermInvestmentsClassifiedAsCashEquivalents" scale="6" id="Tc_EwlyW3aRM0Sywg1nfmc4TA_44_4">1,006</ix:nonFraction></p></td><td style="vertical-align:bottom;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:15.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg" contextRef="As_Of_6_30_2021_eEXLsHGqbE20an7xlGLjnw" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:ShorttermInvestmentsClassifiedAsCashEquivalents" scale="6" id="Tc_s6jmOpvF2kSVPsWTDVcyHA_44_6">2,569</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:53.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:8.66%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:15.48%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:15.98%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:53.46%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">Cash and cash equivalents at the end of the period</b></p></td><td style="vertical-align:bottom;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:8.66%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:15.48%;background:#e6e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg" contextRef="As_Of_6_30_2022_kBUEJjmpl0mHNogMyIvzJg" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:CashAndCashEquivalents" scale="6" id="Tc_YuI1Jj-BmU2_XB05Wi3aaQ_46_4">9,816</ix:nonFraction></b></p></td><td style="vertical-align:bottom;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:15.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg" contextRef="As_Of_6_30_2021_eEXLsHGqbE20an7xlGLjnw" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:CashAndCashEquivalents" scale="6" id="Tc_9YPXtOYBSUWyAEMH_H7fow_46_6">9,477</ix:nonFraction></b></p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:24pt 0pt 0pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;table-layout:fixed;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td></tr><tr><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Genmab A/S</p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Tel: +45 7020 2728</p></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">Company Announcement no. 41</p></td></tr><tr><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Kalvebod Brygge 43</p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Fax: +45 7020 2729</p></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">Page 24/35</p></td></tr><tr><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">1560 Copenhagen V, Denmark</p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">www.genmab.com</p></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">CVR no. 2102 3884</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:76.47%;border:0;margin:30pt 11.76% 30pt 11.76%;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;min-height:36pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><img src="gmab-20220630xex99d1002.jpg" alt="Graphic" style="display:inline-block;height:44.99pt;left:0%;padding-bottom:0.05pt;position:relative;top:0pt;width:151.48pt;" /></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Arial Bold';font-size:9pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-size:13pt;font-weight:bold;">Interim Report for the First Half of 2022</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></div><div style="clear:both;max-width:100%;position:relative;min-height:45.04pt;"><a id="_6cb53d1d_24b3_4ea9_ae12_9d0e861034d0"></a><a id="STATEMENTOFCHANGESINEQUITY_43137"></a><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;font-weight:bold;padding-left:21.6pt;text-indent:-21.6pt;margin:0pt;"><b style="color:#029c93;font-weight:bold;">STATEMENTS OF CHANGES IN EQUITY</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p><a id="_ddd00744_b1e3_483b_bbb1_15d28758f0a8"></a><a id="Tc_1vTc1j2oYU2zM60uxjv1tw_1_2"></a><a id="Tc_qAuxaYEd0kmGia0IpfVIqQ_1_4"></a><a id="Tc_8xqffg9a_UCfHbmoiV4yPw_1_6"></a><a id="Tc_c42o0Nc3lEeTbeZbtXZxxw_1_8"></a><a id="Tc_Aw_C8UcL_UiP2X4YjTpexA_1_10"></a><a id="Tc_6GzSWRliF0S8zmAFnuVoEw_2_2"></a><a id="Tc_dRlnKe3XzkmofgLSY4fITQ_2_4"></a><a id="Tc_TBJw9qOMR0GcL5XrZFucxg_2_6"></a><a id="Tc_m6xretmOtkmK3y0hTZTK1A_2_8"></a><a id="Tc_iDcpEzbKcUCQw49WcWvrVg_2_10"></a><a id="Tc_X3yraZqwA02cNpuBQJoNNw_3_0"></a><a id="Tc_EsY6PzaHmUCHN_MZbbWpeQ_5_0"></a><a id="Tc_UdyvCQpQkkqMMoSAb_gGtw_7_0"></a><a id="Tc_768_gN-K-ECvha41wvH9sg_7_2"></a><a id="Tc_ZRByT_6Ys0y51-23FQKwnQ_7_4"></a><a id="Tc_di4unM8mQUSXo0CJtSoeqg_7_6"></a><a id="Tc_OWffoIA2cUa19pEzU6mLjA_8_0"></a><a id="Tc_etqaze2Ty06qviokpO0epw_8_2"></a><a id="Tc_wusnLUznfkKU8m4gggIGzw_8_4"></a><a id="Tc_fAMVt1hti0-E8laWKjL-tw_8_8"></a><a id="Tc_JUYon6V4F0eQoNNk-rjelg_9_0"></a><a id="Tc_R82fGNiV40K0xIPMhXQMHA_9_2"></a><a id="Tc_iMebqrLfGU67t8lfiQwaEg_9_4"></a><a id="Tc_B-Qbt9MPx0aj3FbMH7Bjow_11_0"></a><a id="Tc_VG5Ni-i2DEOF4cEejxPUXw_12_0"></a><a id="Tc_D52LtAvTGUCy7jrRghoBYw_12_2"></a><a id="Tc_jtcpZkx3NkeGPJJrfMPczQ_12_6"></a><a id="Tc_SfCKFehJmkCF1pXmw5n3XQ_12_8"></a><a id="Tc_tBC8gKHfwk-7J6lXyMgqYw_13_0"></a><a id="Tc_mLJoTAZ8L0i-rS7aUXBzYw_13_2"></a><a id="Tc_YosykaDu9EOsv0td0Whk6Q_13_4"></a><a id="Tc_GWNc5JIzXkigz3d9P_xDRg_13_6"></a><a id="Tc_gB-1Dv1t5UWTGHVKuZQBDQ_14_0"></a><a id="Tc_317qPbIAjE2iA1MxQXl_Vg_14_2"></a><a id="Tc_v4qFQOhI-U-iwVNkdyeBHQ_14_4"></a><a id="Tc_Pyg7Qe2cE0SLQfHlI5cEng_14_6"></a><a id="Tc_esvZ6fhUgE-Ufl9Zyve24w_15_0"></a><a id="Tc_RqZFA1J4g0SWyjrVJ99H2g_15_2"></a><a id="Tc_kRkUHxvYEEmcty4gdUqSZw_15_4"></a><a id="Tc_dwkyMWcKmkGc2yN5ym-Log_15_6"></a><a id="Tc_aS71WlLKk0awfvRrsKx1Kw_17_0"></a><a id="Tc_nM4tAtueEUmzisuQKo8LZw_19_0"></a><a id="Tc_MD_KqKxQLEqKFy_icgh13g_21_0"></a><a id="Tc_uRSd6uGUpkKx0LgslmjGNw_21_2"></a><a id="Tc_LXXCnPzSTUWd7LFVCVGVDw_21_4"></a><a id="Tc_Yxi1apjlTECgMeX0bUb5dQ_21_6"></a><a id="Tc_GnceZV3qpEGdXwTEp3EaTg_22_0"></a><a id="Tc_oWUU_96CPUe6lzdsKLrxpg_22_2"></a><a id="Tc_3klGJ88-okSJu_BE8LdqJg_22_4"></a><a id="Tc_daxPtHU4YEGkv8hGY-vl0A_22_8"></a><a id="Tc_9sfe2OF-d0GQFJ0i59uSOA_23_0"></a><a id="Tc_kAQIBl4yfUG5FXVquGoqRg_23_2"></a><a id="Tc__ocHqmMcFEqkfPI3D8UCUg_23_4"></a><a id="Tc_9MdregTZm0iBPeiA2bsQZg_25_0"></a><a id="Tc_dw_zj54YCEG5fPDrjF_zHQ_26_0"></a><a id="Tc_0dAYTnjhbE2x7yIShh11dQ_26_2"></a><a id="Tc_fFYkmFbouEOj8VYc8wLNBg_26_6"></a><a id="Tc_a497s6LEJEeS9J-t7YWB0g_26_8"></a><a id="Tc_ja-VTCy2MEu1cjVSiZSsvw_27_0"></a><a id="Tc_PpzPKLynfkyszksAm4lH5w_27_2"></a><a id="Tc_CgFfsRp3IEyJU2ZKS2taUw_27_4"></a><a id="Tc_x1D22mBF3UqFrYN6Q60TJg_27_6"></a><a id="Tc_mTDAh6NiD0OSq3fIrw7QZQ_28_0"></a><a id="Tc_sPtwgUtUFEWUbaT-2P5u5Q_28_2"></a><a id="Tc_4VlbdYbTg0qXBYZf1mxl1g_28_4"></a><a id="Tc_5iwA024rWkeQx74O5dBKSQ_28_6"></a><a id="Tc_NmNTR02zw0KSu-jNYvycig_29_0"></a><a id="Tc_NL1bFO-2AkaThSWptg2T2Q_29_2"></a><a id="Tc_EQMVjNY1zU-MChFw1ucBLw_29_4"></a><a id="Tc_a6mANOLLTEewQAzuhT-W9g_29_6"></a><a id="Tc_NB7Dqu67_kWUWUtbRW7idQ_31_0"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:31.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:31.85%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;">&#xA0;&#xA0;&#xA0;&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;">Share</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;">&#xA0;&#xA0;&#xA0;&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;">Share</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;">&#xA0;&#xA0;&#xA0;&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;">Translation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;">&#xA0;&#xA0;&#xA0;&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.38%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;">Retained</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;">&#xA0;&#xA0;&#xA0;&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.38%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;">Shareholders'</p></td></tr><tr><td style="vertical-align:bottom;width:31.85%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;">capital</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;">premium</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;">reserves</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;">earnings</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;">equity</p></td></tr><tr><td style="vertical-align:bottom;width:31.85%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">(DKK million)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.38%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.38%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:31.85%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.38%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.38%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:31.85%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Balance at December 31, 2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg" contextRef="As_Of_12_31_2020_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_qxcDthXBpku77YP5whaVYg" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:Equity" scale="6" id="Tc_N_GrIbU_KkKluAbD1Kay9g_5_2">66</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg" contextRef="As_Of_12_31_2020_ifrs-full_ComponentsOfEquityAxis_ifrs-full_SharePremiumMember_si1iRZkarUaeuSgvZfxZfw" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:Equity" scale="6" id="Tc_aDLqEw2UlkK-URF9KpmnVg_5_4">11,894</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg" contextRef="As_Of_12_31_2020_ifrs-full_ComponentsOfEquityAxis_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_1jjHlFLAike_v2Q-HdTGxw" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:Equity" scale="6" id="Tc_PKiod5YebUqHQM0nYQD1ew_5_6">54</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg" contextRef="As_Of_12_31_2020_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsMember_MNr5zCVV90GEBvq8OjtfdQ" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:Equity" scale="6" id="Tc_5_L5_tomxE6ZZK6D9hDcYA_5_8">7,107</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg" contextRef="As_Of_12_31_2020_ccHyN2oOokuDhNdvPg9fRQ" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:Equity" scale="6" id="Tc_axvs1ohquEqVPQMhhrZfdQ_5_10">19,121</ix:nonFraction></b></p></td></tr><tr><td style="vertical-align:bottom;width:31.85%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.38%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.38%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:31.85%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Net profit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#x2014;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#x2014;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#x2014;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.38%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg" contextRef="Duration_1_1_2021_To_6_30_2021_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsMember_3at9FYujHUm7dtmVg4zXig" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:ProfitLoss" scale="6" id="Tc_5yzUtvk0hEGRaE-dtc-sRw_7_8">1,402</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.38%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg" contextRef="Duration_1_1_2021_To_6_30_2021_MRS0_D_onUCNBOxf7Qx_Cw" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:ProfitLoss" scale="6" id="Tc_eb6Y6KUWK0W6Mvyv6ehjKQ_7_10">1,402</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:31.85%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Other comprehensive income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#x2014;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#x2014;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg" contextRef="Duration_1_1_2021_To_6_30_2021_ifrs-full_ComponentsOfEquityAxis_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_ZmznApYSQ0yIovD2PRKBMA" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:OtherComprehensiveIncome" scale="6" id="Tc_jGbCcyQCCUK6Kt9_IwVbUQ_8_6">28</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#x2014;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg" contextRef="Duration_1_1_2021_To_6_30_2021_MRS0_D_onUCNBOxf7Qx_Cw" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:OtherComprehensiveIncome" scale="6" id="Tc_6Pm7lMkRB0SttoNK9kiAkg_8_10">28</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:31.85%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Total comprehensive income</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#x2014;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#x2014;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg" contextRef="Duration_1_1_2021_To_6_30_2021_ifrs-full_ComponentsOfEquityAxis_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_ZmznApYSQ0yIovD2PRKBMA" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:ComprehensiveIncome" scale="6" id="Tc_LmQJTnEW-0WW7KLZ41K_sw_9_6">28</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.38%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg" contextRef="Duration_1_1_2021_To_6_30_2021_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsMember_3at9FYujHUm7dtmVg4zXig" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:ComprehensiveIncome" scale="6" id="Tc_9DyE7iYiZky3MCGC9oNS2g_9_8">1,402</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.38%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg" contextRef="Duration_1_1_2021_To_6_30_2021_MRS0_D_onUCNBOxf7Qx_Cw" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:ComprehensiveIncome" scale="6" id="Tc_EKz4po-aU0KnyEV_QkPjfw_9_10">1,430</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:31.85%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.38%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.38%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:31.85%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Transactions with owners:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">&#xA0;&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">&#xA0;&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">&#xA0;&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.38%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">&#xA0;&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.38%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">&#xA0;&#xA0;</p></td></tr><tr><td style="vertical-align:bottom;width:31.85%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Exercise of warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#x2014;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg" contextRef="Duration_1_1_2021_To_6_30_2021_ifrs-full_ComponentsOfEquityAxis_ifrs-full_SharePremiumMember_XMRWtYbFi0-RVZrBJKYdMw" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity" scale="6" id="Tc_tNK1bYif-0e4RZ_AnOE2jA_12_4">46</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#x2014;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.38%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#x2014;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.38%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg" contextRef="Duration_1_1_2021_To_6_30_2021_MRS0_D_onUCNBOxf7Qx_Cw" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity" scale="6" id="Tc_eDWIfNZa_k-04uq5PIulQw_12_10">46</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:31.85%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Purchase of treasury shares</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#x2014;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#x2014;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#x2014;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.38%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg" contextRef="Duration_1_1_2021_To_6_30_2021_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsMember_3at9FYujHUm7dtmVg4zXig" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:PurchaseOfTreasuryShares" scale="6" id="Tc_eCnSitHlb0aOoE9BAauwqA_13_8">447</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.38%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg" contextRef="Duration_1_1_2021_To_6_30_2021_MRS0_D_onUCNBOxf7Qx_Cw" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:PurchaseOfTreasuryShares" scale="6" id="Tc_DFfeTnD_xUGqDCxe2yqkGw_13_10">447</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:31.85%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Share-based compensation expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#x2014;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#x2014;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#x2014;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.38%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg" contextRef="Duration_1_1_2021_To_6_30_2021_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsMember_3at9FYujHUm7dtmVg4zXig" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" scale="6" id="Tc_FmuHoGKbukqtUyuNZsqaaA_14_8">142</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.38%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg" contextRef="Duration_1_1_2021_To_6_30_2021_MRS0_D_onUCNBOxf7Qx_Cw" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" scale="6" id="Tc_LDpmTBXAjkevstN0ctiSwQ_14_10">142</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:31.85%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Net settlement of RSUs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#x2014;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#x2014;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#x2014;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg" contextRef="Duration_1_1_2021_To_6_30_2021_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsMember_3at9FYujHUm7dtmVg4zXig" decimals="-6" format="ixt:numdotdecimal" name="gmab:IncreaseDecreaseThroughNetSettlementOfRestrictedStockUnitsEquity" sign="-" scale="6" id="Tc_lVDD6OOsQUGenRiGC4aAEg_15_8">40</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg" contextRef="Duration_1_1_2021_To_6_30_2021_MRS0_D_onUCNBOxf7Qx_Cw" decimals="-6" format="ixt:numdotdecimal" name="gmab:IncreaseDecreaseThroughNetSettlementOfRestrictedStockUnitsEquity" sign="-" scale="6" id="Tc_a0eFkqSNt0K2jzsNPhkZcw_15_10">40</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:31.85%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.38%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.38%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:31.85%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Balance at June 30, 2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg" contextRef="As_Of_6_30_2021_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_pdtEW7BBIUqgf6EXtiJIaw" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:Equity" scale="6" id="Tc_zHYRJrL6-k6iMrfP28ZkYw_17_2">66</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg" contextRef="As_Of_6_30_2021_ifrs-full_ComponentsOfEquityAxis_ifrs-full_SharePremiumMember_GV_3QWjql0Su3tgU-SgDXw" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:Equity" scale="6" id="Tc_UZVH-1oLnk-kz7ksTq4UjA_17_4">11,940</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg" contextRef="As_Of_6_30_2021_ifrs-full_ComponentsOfEquityAxis_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_4C8ErHNbuEyc6g9c8m0tEg" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:Equity" scale="6" id="Tc_1w0kbnC5TUWryHDpekrQNQ_17_6">82</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg" contextRef="As_Of_6_30_2021_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsMember_DjZRZNGrO0OpgJWJsdQZFQ" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:Equity" scale="6" id="Tc_2MspzCwWjUuQWKAtSilKDg_17_8">8,164</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg" contextRef="As_Of_6_30_2021_eEXLsHGqbE20an7xlGLjnw" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:Equity" scale="6" id="Tc_lMIdzHhEq0GqJR4EzHijQQ_17_10">20,252</ix:nonFraction></b></p></td></tr><tr><td style="vertical-align:bottom;width:31.85%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.38%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.38%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:31.85%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Balance at December 31, 2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg" contextRef="As_Of_12_31_2021_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_3hqv4rmeT0KprU066qSoRg" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:Equity" scale="6" id="Tc_Md_aEe3tbEO0gAvrgxipmw_19_2">66</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg" contextRef="As_Of_12_31_2021_ifrs-full_ComponentsOfEquityAxis_ifrs-full_SharePremiumMember_AoL9klgCl06NvjJ-Vt6Xlw" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:Equity" scale="6" id="Tc_DuKowYPjY06bG6zHsBYxQQ_19_4">12,029</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg" contextRef="As_Of_12_31_2021_ifrs-full_ComponentsOfEquityAxis_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_yT7xpmSne0SrbvOgXluilQ" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:Equity" scale="6" id="Tc_gxjzYILoBEexauLytLN8Dw_19_6">81</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg" contextRef="As_Of_12_31_2021_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsMember_DT4Y_TJahk6Om4PoqoPzFg" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:Equity" scale="6" id="Tc_ZM2SjUnQCUKSsTtzP__q9Q_19_8">10,020</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg" contextRef="As_Of_12_31_2021_yeBwiJf1M0aAa25fFQy9Bg" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:Equity" scale="6" id="Tc_fvly8IJgJUmpxoEzRwA0-Q_19_10">22,196</ix:nonFraction></b></p></td></tr><tr><td style="vertical-align:bottom;width:31.85%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.38%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.38%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:31.85%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Net profit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#x2014;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#x2014;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#x2014;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.38%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg" contextRef="Duration_1_1_2022_To_6_30_2022_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsMember_Obfciab50kOeB1cRJrxSkw" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:ProfitLoss" scale="6" id="Tc_-rwcUsXtTkCsIXt6F6Hl0Q_21_8">2,356</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.38%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg" contextRef="Duration_1_1_2022_To_6_30_2022_dNPMG5n7t0WcNVF9KG4Bdw" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:ProfitLoss" scale="6" id="Tc_QAhxsSLvOEWEoSZKIKVrhQ_21_10">2,356</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:31.85%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Other comprehensive income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#x2014;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#x2014;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg" contextRef="Duration_1_1_2022_To_6_30_2022_ifrs-full_ComponentsOfEquityAxis_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_7kIYWvkWuEOdT0IirRs9kA" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:OtherComprehensiveIncome" scale="6" id="Tc_sdECepUK3kSMmhj_-mXNjg_22_6">29</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#x2014;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg" contextRef="Duration_1_1_2022_To_6_30_2022_dNPMG5n7t0WcNVF9KG4Bdw" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:OtherComprehensiveIncome" scale="6" id="Tc_RuMG45RVm0aaijx_FmaicQ_22_10">29</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:31.85%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Total comprehensive income</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#x2014;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#x2014;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg" contextRef="Duration_1_1_2022_To_6_30_2022_ifrs-full_ComponentsOfEquityAxis_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_7kIYWvkWuEOdT0IirRs9kA" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:ComprehensiveIncome" scale="6" id="Tc_m-74vIdfQ0C9W0rioFflZQ_23_6">29</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.38%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg" contextRef="Duration_1_1_2022_To_6_30_2022_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsMember_Obfciab50kOeB1cRJrxSkw" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:ComprehensiveIncome" scale="6" id="Tc_qYg_T3YBuEeeIdAuq-ea4w_23_8">2,356</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.38%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg" contextRef="Duration_1_1_2022_To_6_30_2022_dNPMG5n7t0WcNVF9KG4Bdw" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:ComprehensiveIncome" scale="6" id="Tc_t0yt_DvX4U-WLWkAHZcvrg_23_10">2,385</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:31.85%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.38%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.38%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:31.85%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Transactions with owners:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">&#xA0;&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">&#xA0;&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">&#xA0;&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.38%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">&#xA0;&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.38%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">&#xA0;&#xA0;</p></td></tr><tr><td style="vertical-align:bottom;width:31.85%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Exercise of warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#x2014;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg" contextRef="Duration_1_1_2022_To_6_30_2022_ifrs-full_ComponentsOfEquityAxis_ifrs-full_SharePremiumMember_SdwhengxmEaD2aINUnRJ-w" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity" scale="6" id="Tc_F__ymwA5ck-ZBG6494tJRQ_26_4">34</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#x2014;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.38%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#x2014;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.38%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg" contextRef="Duration_1_1_2022_To_6_30_2022_dNPMG5n7t0WcNVF9KG4Bdw" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity" scale="6" id="Tc_7O2lrPU5IkSy1utB07idIw_26_10">34</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:31.85%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Purchase of treasury shares</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#x2014;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#x2014;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#x2014;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.38%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg" contextRef="Duration_1_1_2022_To_6_30_2022_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsMember_Obfciab50kOeB1cRJrxSkw" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:PurchaseOfTreasuryShares" scale="6" id="Tc_mClL9ihzr0CJinhuY0CdUw_27_8">270</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.38%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg" contextRef="Duration_1_1_2022_To_6_30_2022_dNPMG5n7t0WcNVF9KG4Bdw" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:PurchaseOfTreasuryShares" scale="6" id="Tc_ZFsdov3lBEGKVyafINEftg_27_10">270</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:31.85%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Share-based compensation expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#x2014;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#x2014;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#x2014;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.38%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg" contextRef="Duration_1_1_2022_To_6_30_2022_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsMember_Obfciab50kOeB1cRJrxSkw" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" scale="6" id="Tc_LtGbSw2q6UuhYSws2rEg7Q_28_8">208</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.38%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg" contextRef="Duration_1_1_2022_To_6_30_2022_dNPMG5n7t0WcNVF9KG4Bdw" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" scale="6" id="Tc_tbTp1fNU2UyjKNcaTjZFRQ_28_10">208</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:31.85%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Net settlement of RSUs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#x2014;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#x2014;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#x2014;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg" contextRef="Duration_1_1_2022_To_6_30_2022_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsMember_Obfciab50kOeB1cRJrxSkw" decimals="-6" format="ixt:numdotdecimal" name="gmab:IncreaseDecreaseThroughNetSettlementOfRestrictedStockUnitsEquity" sign="-" scale="6" id="Tc_R94rRjrM8U-q4vVbMWwIkw_29_8">71</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg" contextRef="Duration_1_1_2022_To_6_30_2022_dNPMG5n7t0WcNVF9KG4Bdw" decimals="-6" format="ixt:numdotdecimal" name="gmab:IncreaseDecreaseThroughNetSettlementOfRestrictedStockUnitsEquity" sign="-" scale="6" id="Tc_u4iH4EWQZEW1kQxfLRxiZQ_29_10">71</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:31.85%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.38%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.38%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:31.85%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Balance at June 30, 2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg" contextRef="As_Of_6_30_2022_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_yCKoTSQsEEOQZwa4oFi7oA" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:Equity" scale="6" id="Tc_xe_8SSfq1E6yRmhrdSdy7w_31_2">66</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg" contextRef="As_Of_6_30_2022_ifrs-full_ComponentsOfEquityAxis_ifrs-full_SharePremiumMember_c1xbYHnI60ydURKsrordAw" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:Equity" scale="6" id="Tc_R9vavWv3ckiFNFLpjHqJjA_31_4">12,063</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg" contextRef="As_Of_6_30_2022_ifrs-full_ComponentsOfEquityAxis_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_xwbw8UubEkGBVQFx7vgMbQ" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:Equity" scale="6" id="Tc_cYvF0RgBdE6BU2G6odEM4Q_31_6">110</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg" contextRef="As_Of_6_30_2022_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsMember_lUn1LjNR7EeooY5wvd9tfg" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:Equity" scale="6" id="Tc_UAuxumeZ102jJDpPurSJRg_31_8">12,243</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg" contextRef="As_Of_6_30_2022_kBUEJjmpl0mHNogMyIvzJg" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:Equity" scale="6" id="Tc_dnYSmE1SFkGWbEM8OdEVxw_31_10">24,482</ix:nonFraction></b></p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:24pt 0pt 0pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;table-layout:fixed;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td></tr><tr><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Genmab A/S</p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Tel: +45 7020 2728</p></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">Company Announcement no. 41</p></td></tr><tr><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Kalvebod Brygge 43</p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Fax: +45 7020 2729</p></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">Page 25/35</p></td></tr><tr><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">1560 Copenhagen V, Denmark</p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">www.genmab.com</p></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">CVR no. 2102 3884</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:76.47%;border:0;margin:30pt 11.76% 30pt 11.76%;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;min-height:36pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><img src="gmab-20220630xex99d1002.jpg" alt="Graphic" style="display:inline-block;height:44.99pt;left:0%;padding-bottom:0.05pt;position:relative;top:0pt;width:151.48pt;" /></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Arial Bold';font-size:9pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-size:13pt;font-weight:bold;">Interim Report for the First Half of 2022</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></div><div style="clear:both;max-width:100%;position:relative;min-height:45.04pt;"><a id="_8a7e53f9_b866_4907_8a70_cef4d28b8569"></a><a id="NOTESTOTHEFINANCIALSTATEMENTS_435403"></a><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;font-weight:bold;padding-left:21.6pt;text-indent:-21.6pt;margin:0pt;"><b style="color:#029c93;font-weight:bold;">NOTES TO THE FINANCIAL STATEMENTS</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="color:#029c93;font-weight:bold;visibility:hidden;">&#x200B;</span></p><ix:nonNumeric contextRef="Duration_1_1_2022_To_6_30_2022_dNPMG5n7t0WcNVF9KG4Bdw" name="ifrs-full:DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory" id="Tb_xMKEEjNrXkyIrZf7mcrlcg" escape="true"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="color:#029c93;font-weight:bold;">Note 1 &#x2013; Basis of Presentation</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p><ix:nonNumeric contextRef="Duration_1_1_2022_To_6_30_2022_dNPMG5n7t0WcNVF9KG4Bdw" name="gmab:DescriptionOfAccountingPolicyForBasisOfPresentationPolicyTextBlock" id="Tb_gLydBW7Cg0aWWe1EKsIqbg" escape="true"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Accounting Policies</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">These interim statements of the Genmab group (Genmab or the Company) have been prepared in accordance with IAS 34 as issued by the International Accounting Standards Board (IASB) and in accordance with IAS 34 as endorsed by the EU and additional Danish disclosure requirements for interim reports of listed companies. The interim report has not been reviewed or audited by Genmab&#x2019;s external auditors. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">The interim report has been prepared using the same accounting policies as outlined in Section 1 &#x2013; Basis of Presentation in the financial statements in the Genmab 2021 Annual Report (Annual Report). A number of new or amended standards became applicable for the current reporting period. Genmab was not required to change its accounting policies as a result of adopting these standards. These interim financial statements should be read in conjunction with the Annual Report. </p></ix:nonNumeric><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p><ix:nonNumeric contextRef="Duration_1_1_2022_To_6_30_2022_dNPMG5n7t0WcNVF9KG4Bdw" name="gmab:DescriptionOfAccountingPolicyForJudgmentsAndEstimatesPolicyTextBlock" id="Tb_PFYQVNsFVka_BihArFEhKA" escape="true"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Management Judgements and Estimates under IFRS</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">In preparing interim reports, certain provisions under IFRS require management to make judgements (various accounting estimates and assumptions), which may significantly impact the group&#x2019;s financial statements. For a description of significant judgements and estimates, refer to Note 1.3 in the Annual Report.</p></ix:nonNumeric><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p><ix:nonNumeric contextRef="Duration_1_1_2022_To_6_30_2022_dNPMG5n7t0WcNVF9KG4Bdw" name="ifrs-full:DescriptionOfAccountingPolicyForSegmentReportingExplanatory" id="Tb_Q9XNieVELEWFsrtgdtzQiw" escape="true"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Information about Geographical Areas</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Genmab is managed and operated as <ix:nonFraction unitRef="Unit_Standard_item_d-Yn30W8q0CdLFqZ4zWe8g" contextRef="As_Of_6_30_2022_kBUEJjmpl0mHNogMyIvzJg" decimals="INF" format="ixt-sec:numwordsen" name="gmab:IfrsNumberOfReportingUnits" scale="0" id="Narr_4e_DvdC5-0ujcF1JortDgA">one</ix:nonFraction> business unit, which is reflected in the organizational structure and internal reporting. No separate lines of business or separate business entities have been identified with respect to any licensed products, product candidates or geographical markets and no segment information is currently prepared for internal reporting. Refer to Note 2.2 in the Annual Report for further details.</p></ix:nonNumeric></ix:nonNumeric></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:24pt 0pt 0pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;table-layout:fixed;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td></tr><tr><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Genmab A/S</p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Tel: +45 7020 2728</p></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">Company Announcement no. 41</p></td></tr><tr><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Kalvebod Brygge 43</p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Fax: +45 7020 2729</p></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">Page 26/35</p></td></tr><tr><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">1560 Copenhagen V, Denmark</p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">www.genmab.com</p></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">CVR no. 2102 3884</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:76.47%;border:0;margin:30pt 11.76% 30pt 11.76%;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;min-height:36pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><img src="gmab-20220630xex99d1002.jpg" alt="Graphic" style="display:inline-block;height:44.99pt;left:0%;padding-bottom:0.05pt;position:relative;top:0pt;width:151.48pt;" /></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Arial Bold';font-size:9pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-size:13pt;font-weight:bold;">Interim Report for the First Half of 2022</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></div><div style="clear:both;max-width:100%;position:relative;min-height:45.04pt;"><a id="_MON_1428926213"></a><a id="_MON_1428393242"></a><a id="Tc_qFWrLtoZck-OZ1MgAzOPAA_1_2"></a><a id="Tc_s20R6XX7wkemX9Z5RcwNlw_1_4"></a><a id="Tc_RR7HkG1_kkKRpz3MqlvT1A_2_2"></a><a id="Tc_DU1JvPK-10qiIjW61htNUg_2_4"></a><a id="Tc_YBhJNucEO0S99cg2TdNVPg_3_0"></a><a id="Tc_GryLP27_mEyCavtrOv7IiA_4_0"></a><a id="Tc_-WxthFFz-0y3b7Z89mca-A_5_0"></a><a id="Tc_iXQwSOc9ZEWb7F_ZebL85g_6_0"></a><a id="Tc_NsqWhcsYM0-rHA8HVFJfCw_7_0"></a><a id="Tc_55UKhCwhcUG_SNs4ayZLOg_8_0"></a><a id="Tc_PLZkY7ORWkGSc_0uqOR3eg_8_4"></a><a id="Tc_CuZiW2TbKU2wSa2p1-KS8w_9_0"></a><a id="Tc_vs2-S9t8HEWCp2E1xgwP0g_11_0"></a><a id="Tc_xTk2cSt-nE-zGQOGL48i2w_12_0"></a><a id="Tc_qnOxt3JOrkKkKTa7woy3CA_13_0"></a><a id="Tc_KTtehfX39kiiu10ouxAwMA_13_2"></a><a id="Tc_b2Bepu0rakWVgogtbADFqg_14_0"></a><a id="Tc_OYzndszF30mudHnnNvNK7Q_15_0"></a><a id="Tc_m07Iyt_qdUyFo5Cwzv8OJQ_16_0"></a><a id="Tc_d5DbufaR5UqgS9ip7P5gfw_17_0"></a><a id="Tc_Z0KP-CBm6kGRxFcmelPHkA_18_0"></a><a id="Tc__IGdwhD070uHKpWBivGk2w_18_4"></a><a id="Tc_NkN0QOcHvkSCbuFrtIYcCg_19_0"></a><a id="Tc_zF6J3j6UCEqdKrrZmLmGxg_21_0"></a><a id="Tc_ZKFMgM0gYUeOxCHfkZVkTg_22_0"></a><a id="Tc__AlGbAhDoU-zEUX9ccE6NA_23_0"></a><a id="Tc_TUaxQ0z2X0eC4MDcre5ekw_24_0"></a><a id="Tc_td6hOszti06mP3WhA6GqCQ_25_0"></a><a id="Tc_-cfAgiTjW0OELkOb-UQYvA_26_0"></a><ix:nonNumeric contextRef="Duration_1_1_2022_To_6_30_2022_dNPMG5n7t0WcNVF9KG4Bdw" name="ifrs-full:DisclosureOfRevenueFromContractsWithCustomersExplanatory" id="Tb_kqsmCdaxH0uSbUtRnQcEqA" continuedAt="Tb_kqsmCdaxH0uSbUtRnQcEqA_cont1" escape="true"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="color:#029c93;font-weight:bold;">Note 2 &#x2013; Revenue </b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">The table below summarizes Genmab&#x2019;s revenue by type and collaboration partner, and royalties by product, under Genmab&#x2019;s agreements.</p><ix:nonNumeric contextRef="Duration_1_1_2022_To_6_30_2022_dNPMG5n7t0WcNVF9KG4Bdw" name="ifrs-full:DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory" id="Tb_utMh08Y4PE-GAsML70b8PA" escape="true"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:55.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:19.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:19.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:55.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#xA0;&#xA0;&#xA0;&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.51%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;">6 Months Ended</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#xA0;&#xA0;&#xA0;&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.24%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;">6 Months Ended</p></td></tr><tr><td style="vertical-align:bottom;width:55.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.51%;background:#e6e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;">June 30, 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;">June 30, 2021</p></td></tr><tr><td style="vertical-align:bottom;width:55.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">(DKK million)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.51%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.24%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:55.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Revenue by type:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.51%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.24%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">&#xA0;&#xA0;</p></td></tr><tr><td style="vertical-align:bottom;width:55.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Royalties</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.51%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg" contextRef="Duration_1_1_2022_To_6_30_2022_gmab_TypesOfRevenuesAxis_gmab_RoyaltiesRevenueMember_l90laluy2ECUtYZD9oF94A" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:RevenueFromContractsWithCustomers" scale="6" id="Tc_FtKZ8XD7Dkq0ET9dqNUx1w_5_2">4,727</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.24%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg" contextRef="Duration_1_1_2021_To_6_30_2021_gmab_TypesOfRevenuesAxis_gmab_RoyaltiesRevenueMember_C14oZ_22m06-TU9BB9BNhw" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:RevenueFromContractsWithCustomers" scale="6" id="Tc_rxwPUQRFl0OW3k4dW8Yk8g_5_4">2,595</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:55.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Reimbursement revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.51%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg" contextRef="Duration_1_1_2022_To_6_30_2022_gmab_TypesOfRevenuesAxis_gmab_ReimbursementIncomeMember_SqLe6wdBT06OGFsFXaHuhQ" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:RevenueFromContractsWithCustomers" scale="6" id="Tc_k9OBL8I_QU2qFy002zATvQ_6_2">287</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.24%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg" contextRef="Duration_1_1_2021_To_6_30_2021_gmab_TypesOfRevenuesAxis_gmab_ReimbursementIncomeMember_omlBYt5DuUO9i8c4hNlRbg" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:RevenueFromContractsWithCustomers" scale="6" id="Tc_65-kUxz-0k6cmflPiTDEQw_6_4">227</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:55.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Milestone revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.51%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg" contextRef="Duration_1_1_2022_To_6_30_2022_gmab_TypesOfRevenuesAxis_gmab_MilestonePaymentsRevenueMember_fqNpjY-zG02ssbNiOllMzA" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:RevenueFromContractsWithCustomers" scale="6" id="Tc_zGfi-Sce6U-B-YXLn4r-cg_7_2">176</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.24%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg" contextRef="Duration_1_1_2021_To_6_30_2021_gmab_TypesOfRevenuesAxis_gmab_MilestonePaymentsRevenueMember_RLx1u9QEf0yprcS3a5mwXA" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:RevenueFromContractsWithCustomers" scale="6" id="Tc_64ZgU1lXqkqfNqBQFYQhJw_7_4">731</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:55.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Collaboration revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.51%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg" contextRef="Duration_1_1_2022_To_6_30_2022_gmab_TypesOfRevenuesAxis_gmab_CollaborationRevenueMember_ht1RNX53n0-X7tAGYv75YQ" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:RevenueFromContractsWithCustomers" scale="6" id="Tc_hBgs_uE9uUiQG7vzxE2-sw_8_2">91</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#x2014;</p></td></tr><tr><td style="vertical-align:bottom;width:55.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.51%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg" contextRef="Duration_1_1_2022_To_6_30_2022_dNPMG5n7t0WcNVF9KG4Bdw" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:RevenueFromContractsWithCustomers" scale="6" id="Tc_2Y7aR3A-OkmguvDAK2IdZg_9_2">5,281</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg" contextRef="Duration_1_1_2021_To_6_30_2021_MRS0_D_onUCNBOxf7Qx_Cw" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:RevenueFromContractsWithCustomers" scale="6" id="Tc_iWxh9sY2xkuS7fFCic-xPA_9_4">3,553</ix:nonFraction></b></p></td></tr><tr><td style="vertical-align:bottom;width:55.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.51%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.24%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:55.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Revenue by collaboration partner:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.51%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.24%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:55.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Janssen</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.51%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg" contextRef="Duration_1_1_2022_To_6_30_2022_gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_gmab_AgreementsWithJanssenMember_dtnNRTQ9qUWE18D-r3fXbQ" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:RevenueFromContractsWithCustomers" scale="6" id="Tc_3Ucl492jLEWoHj_ZVCocAg_12_2">4,206</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.24%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg" contextRef="Duration_1_1_2021_To_6_30_2021_gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_gmab_AgreementsWithJanssenMember_vuVrCms2xECcbUwIJRfXzw" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:RevenueFromContractsWithCustomers" scale="6" id="Tc_wkOHgjwkOEqB9bN7aHpPIQ_12_4">2,846</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:55.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">AbbVie</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.51%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#x2014;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.24%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg" contextRef="Duration_1_1_2021_To_6_30_2021_gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_gmab_AgreementsWithAbbvieMember_KrVymjM9ekWDbOoEhonp8Q" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:RevenueFromContractsWithCustomers" scale="6" id="Tc_8goY_2yOYkGbNKxSKsYJyQ_13_4">245</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:55.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Roche</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.51%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg" contextRef="Duration_1_1_2022_To_6_30_2022_gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_gmab_AgreementsWithRocheMember_F60ez68CiEaIHbxeNRu9_Q" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:RevenueFromContractsWithCustomers" scale="6" id="Tc_slFrypWBlEGeuPqwgtk45Q_14_2">390</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.24%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg" contextRef="Duration_1_1_2021_To_6_30_2021_gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_gmab_AgreementsWithRocheMember_z9PLyE_EZEK_NCj-F9C2xA" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:RevenueFromContractsWithCustomers" scale="6" id="Tc_CuSPBksEBUWwZFDN8TOM_Q_14_4">162</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:55.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Novartis</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.51%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg" contextRef="Duration_1_1_2022_To_6_30_2022_gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_gmab_AgreementsWithNovartisMember_2Lw8aj2ROUe2xOEG0T2NEA" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:RevenueFromContractsWithCustomers" scale="6" id="Tc_gyYFa4NQzUOmHoCVuq1MNg_15_2">305</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.24%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg" contextRef="Duration_1_1_2021_To_6_30_2021_gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_gmab_AgreementsWithNovartisMember_Q_C1sF5FrU2rD44CqxQPtw" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:RevenueFromContractsWithCustomers" scale="6" id="Tc_xV4uXnjaJkG5UFiXs7Jzww_15_4">73</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:55.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">BioNTech</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.51%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg" contextRef="Duration_1_1_2022_To_6_30_2022_gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_gmab_AgreementsWithBointechMember_-wOkAaAFTU-q5bYOFz9Nag" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:RevenueFromContractsWithCustomers" scale="6" id="Tc_ITNohEayQk-V88lnIa1-Vw_16_2">231</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.24%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg" contextRef="Duration_1_1_2021_To_6_30_2021_gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_gmab_AgreementsWithBointechMember__Roy-36-pUSfv1AGtbDu3Q" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:RevenueFromContractsWithCustomers" scale="6" id="Tc_faaFtXDl2UGLmmlWSB7i0w_16_4">171</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:55.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Seagen</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.51%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg" contextRef="Duration_1_1_2022_To_6_30_2022_gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_gmab_AgreementsWithSeagenMember_pZplyqrryEKRXEj8O7llZQ" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:RevenueFromContractsWithCustomers" scale="6" id="Tc_q9Ei4W0XsUuGNAnZ70JtrQ_17_2">138</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.24%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg" contextRef="Duration_1_1_2021_To_6_30_2021_gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_gmab_AgreementsWithSeagenMember_eK57WUE_IE2_OzKv8nQlDQ" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:RevenueFromContractsWithCustomers" scale="6" id="Tc_86gw4zxdaEaJKr3Z2aqcUg_17_4">56</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:55.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.51%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg" contextRef="Duration_1_1_2022_To_6_30_2022_gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_gmab_OtherCollaborationPartnersMember_AsIPBfv6PU6XdKxKRQhUDA" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:RevenueFromContractsWithCustomers" scale="6" id="Tc_yT1rA4DkwUWu9NarluGXwQ_18_2">11</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#x2014;</p></td></tr><tr><td style="vertical-align:bottom;width:55.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.51%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg" contextRef="Duration_1_1_2022_To_6_30_2022_dNPMG5n7t0WcNVF9KG4Bdw" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:RevenueFromContractsWithCustomers" scale="6" id="Tc_ngsABpEkrkmecjITLpQLXQ_19_2">5,281</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg" contextRef="Duration_1_1_2021_To_6_30_2021_MRS0_D_onUCNBOxf7Qx_Cw" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:RevenueFromContractsWithCustomers" scale="6" id="Tc_EYRujR8lNES66MXwsYsYxA_19_4">3,553</ix:nonFraction></b></p></td></tr><tr><td style="vertical-align:bottom;width:55.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.51%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.24%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:55.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Royalties by product:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.51%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.24%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:55.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">DARZALEX </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.51%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg" contextRef="Duration_1_1_2022_To_6_30_2022_gmab_IfrsRoyaltiesByProductAxis_gmab_DarzalexMember_gmab_TypesOfRevenuesAxis_gmab_RoyaltiesRevenueMember_B_UEY1hASUOrDlLXGgV7LQ" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:RevenueFromContractsWithCustomers" scale="6" id="Tc_353p1M6QrUKJuQT-VPpkuQ_22_2">4,024</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.24%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg" contextRef="Duration_1_1_2021_To_6_30_2021_gmab_IfrsRoyaltiesByProductAxis_gmab_DarzalexMember_gmab_TypesOfRevenuesAxis_gmab_RoyaltiesRevenueMember_ygn3CpbP8kelusDjXKa8kw" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:RevenueFromContractsWithCustomers" scale="6" id="Tc_VFidr4Nt_0emNOJ3qiA1eg_22_4">2,360</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:55.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">TEPEZZA </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.51%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg" contextRef="Duration_1_1_2022_To_6_30_2022_gmab_IfrsRoyaltiesByProductAxis_gmab_TepezzaMember_gmab_TypesOfRevenuesAxis_gmab_RoyaltiesRevenueMember_2vu0gXPmvEOPW1nFEg8xWQ" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:RevenueFromContractsWithCustomers" scale="6" id="Tc_7KTPAM8DhUyoNhk72qYtyw_23_2">390</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.24%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg" contextRef="Duration_1_1_2021_To_6_30_2021_gmab_IfrsRoyaltiesByProductAxis_gmab_TepezzaMember_gmab_TypesOfRevenuesAxis_gmab_RoyaltiesRevenueMember_fs7jJ3nvNUyKr8Sk5fXrGg" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:RevenueFromContractsWithCustomers" scale="6" id="Tc_bSagtqOGBEq65tnFb5RsqQ_23_4">162</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:55.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Kesimpta </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.51%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg" contextRef="Duration_1_1_2022_To_6_30_2022_gmab_IfrsRoyaltiesByProductAxis_gmab_KesimptaMember_gmab_TypesOfRevenuesAxis_gmab_RoyaltiesRevenueMember_HHevdLOZHkKv8JPTDpOBMA" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:RevenueFromContractsWithCustomers" scale="6" id="Tc_CcC9mb_BwkCx2VbfMMtaiw_24_2">296</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.24%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg" contextRef="Duration_1_1_2021_To_6_30_2021_gmab_IfrsRoyaltiesByProductAxis_gmab_KesimptaMember_gmab_TypesOfRevenuesAxis_gmab_RoyaltiesRevenueMember_FICwJ-6ee0Gxe75faT4PZQ" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:RevenueFromContractsWithCustomers" scale="6" id="Tc_4MoCsxa9J063RfS5s7CCRg_24_4">72</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:55.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.51%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg" contextRef="Duration_1_1_2022_To_6_30_2022_gmab_IfrsRoyaltiesByProductAxis_gmab_OtherRoyaltyProductMember_gmab_TypesOfRevenuesAxis_gmab_RoyaltiesRevenueMember_E0nJo5T9H0y4j-kEZUvZ1g" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:RevenueFromContractsWithCustomers" scale="6" id="Tc_LCRwhmjbfku-mq0d5Z669Q_25_2">17</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg" contextRef="Duration_1_1_2021_To_6_30_2021_gmab_IfrsRoyaltiesByProductAxis_gmab_OtherRoyaltyProductMember_gmab_TypesOfRevenuesAxis_gmab_RoyaltiesRevenueMember_L_QgZHefbEqkV9UUM69KBg" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:RevenueFromContractsWithCustomers" scale="6" id="Tc_zD90qj2Ge0u-ZYtGh2pONg_25_4">1</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:55.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.51%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg" contextRef="Duration_1_1_2022_To_6_30_2022_gmab_TypesOfRevenuesAxis_gmab_RoyaltiesRevenueMember_l90laluy2ECUtYZD9oF94A" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:RevenueFromContractsWithCustomers" scale="6" id="Tc_Fw9wUAkiuEeN3z6ZeywO-Q_26_2">4,727</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg" contextRef="Duration_1_1_2021_To_6_30_2021_gmab_TypesOfRevenuesAxis_gmab_RoyaltiesRevenueMember_C14oZ_22m06-TU9BB9BNhw" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:RevenueFromContractsWithCustomers" scale="6" id="Tc_B2cp3vnNhkag09pU6Clw-g_26_4">2,595</ix:nonFraction></b></p></td></tr><tr><td style="vertical-align:bottom;width:55.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.51%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.24%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td></tr></table></ix:nonNumeric><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">In September 2020, Genmab commenced binding arbitration of two matters arising under its license agreement with Janssen relating to daratumumab. Under the license agreement, Genmab is, among other things, entitled to royalties from Janssen on net sales of daratumumab (marketed as DARZALEX for IV administration and as DARZALEX <i style="font-style:italic;">FASPRO</i> in the United States and as DARZALEX SC in Europe for SC administration). In April 2022, the arbitral tribunal issued an award in the binding arbitration of the two matters. Genmab did not seek a review of the award, and the award is now final.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">The first matter concerned the question as to whether Janssen&#x2019;s obligation to pay royalties on net sales of licensed product extends, in each applicable country, until the expiration or invalidation of the last-to-expire relevant Genmab-owned patent or the last-to-expire relevant Janssen-owned patent covering the product, as further defined and described in the license agreement.  As to that matter, the tribunal determined by majority opinion that Janssen&#x2019;s obligation to pay royalties to Genmab on net sales of licensed product, in each applicable country, extends through the expiration or invalidation of the last-to-expire relevant Genmab-owned patent covering the product or use thereof, but not the relevant Janssen-owned patent. The relevant Genmab-owned issued U.S., European and Japanese patents will expire in the late 2020s and early 2030s. </span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></ix:nonNumeric></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:24pt 0pt 0pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;table-layout:fixed;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td></tr><tr><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Genmab A/S</p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Tel: +45 7020 2728</p></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">Company Announcement no. 41</p></td></tr><tr><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Kalvebod Brygge 43</p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Fax: +45 7020 2729</p></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">Page 27/35</p></td></tr><tr><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">1560 Copenhagen V, Denmark</p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">www.genmab.com</p></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">CVR no. 2102 3884</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:76.47%;border:0;margin:30pt 11.76% 30pt 11.76%;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;min-height:36pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><img src="gmab-20220630xex99d1002.jpg" alt="Graphic" style="display:inline-block;height:44.99pt;left:0%;padding-bottom:0.05pt;position:relative;top:0pt;width:151.48pt;" /></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Arial Bold';font-size:9pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-size:13pt;font-weight:bold;">Interim Report for the First Half of 2022</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></div><div style="clear:both;max-width:100%;position:relative;min-height:45.04pt;"><ix:continuation id="Tb_kqsmCdaxH0uSbUtRnQcEqA_cont1"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">The second matter concerned the question as to whether Genmab is required to share in Janssen&#x2019;s royalty payments to Halozyme for the Halozyme enzyme technology used in the SC formulation of daratumumab (marketed as DARZALEX <i style="font-style:italic;">FASPRO</i> in the U.S.). The royalties Janssen pays to Halozyme represent a mid-single digit percentage rate of SC daratumumab net sales. As to that matter, the tribunal ruled by majority opinion that Janssen is permitted to continue reducing its royalty payments to Genmab as an offset against a share of Janssen&#x2019;s royalty payments made to Halozyme. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Refer to Note 2.1 in the Annual Report for further details regarding revenue.</p></ix:continuation><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p><a id="_Hlk100827949"></a><a id="_Hlk100828495"></a><a id="Tc_ak23JQ_gyE-X9pxTLCqOQQ_1_2"></a><a id="Tc_9DpfvLVzwkSiJV4jkjQFOw_1_5"></a><a id="Tc_w_mrFbeMLkmzCVCTjbBDlQ_2_2"></a><a id="Tc_Np_4v7jLEUmRkVcCshD_Ow_2_5"></a><a id="Tc_mBXUkXxo4UmTqk4fis4TJw_3_0"></a><a id="Tc_lHpxvff37Ue_EkSIvouaoA_5_0"></a><a id="Tc_f_Vbp460oUCuhTD1XvaTKw_5_3"></a><a id="Tc_PhMl8kMaCkejPY7AXj2e8A_5_6"></a><a id="Tc_8lnJ2vx3EU2ZPoCx64c7lA_6_0"></a><a id="Tc_Vt1bm1wd9kew_OX1oTkZSA_6_3"></a><a id="Tc_A4zHPNqAcUCkSRyv0ZrBDA_6_6"></a><a id="Tc_WDbnnsX7UEiNEmtXj9-kKA_7_0"></a><a id="Tc_doDw2OuozEmgspu5eGvCVg_7_3"></a><a id="Tc_VYM_D6nZOEOm9p7Z8B1hIA_7_6"></a><a id="Tc_xtBXOr4CKUuRAC1-FWvIGA_8_0"></a><a id="Tc_am8E5sGh4Uagtx_pXCVyPQ_8_3"></a><a id="Tc_YPp5Vh2qDEa7j3tohVgM4A_8_6"></a><a id="Tc_2GI08TzGtEeqdszV8010jA_9_0"></a><a id="Tc__EkNc4-iZU-J5bf8p4N6CQ_9_3"></a><a id="Tc_RFji3O8yM0i2uV1bx9tA3w_9_6"></a><a id="Tc_6bi0vwVBykeKTOI1DyupYQ_1_0"></a><a id="Tc_UWSqhOdFr0uUfaJ4Z_E_GQ_1_2"></a><a id="Tc_hfMMWoRWGEeH8PZwB8eB-A_1_10"></a><a id="Tc_t9GTNMMqC0ClvG8ZopWp1Q_2_0"></a><a id="Tc_MuBjy3bD9UyKH0WXEt0TVg_2_2"></a><a id="Tc_n15ISnWyMUuFxTZxZBoasg_2_4"></a><a id="Tc_YN0wNzM9uE6OuTsyh6infA_2_6"></a><a id="Tc_uomdxQCX_kWz0fhyQo_8fg_2_8"></a><a id="Tc_nsTkyaQYDUGVcIOOfAiWXg_2_10"></a><a id="Tc_qO7iFe3HokyGBo7vSMrUfA_2_12"></a><a id="Tc_6M4O0QG71kunhqpwXyj2sg_2_14"></a><a id="Tc_UeJ6ROAQd0yTqPBojK87PA_2_16"></a><a id="Tc_gNqWBVqGmEuWyoqN0xCFJQ_4_0"></a><a id="Tc_mJG8xAPUNEm6dRFZ-IbyrA_4_4"></a><a id="Tc_6Za3JdEKU0iFR4iDZ0W_1A_4_6"></a><a id="Tc_Oxllhejhbk604Yirbv31kQ_4_12"></a><a id="Tc_aXAkJviC_kyIANscjUkBUg_4_14"></a><a id="Tc_6-JRl0pHLUSznkF7Jxkp1g_5_0"></a><a id="Tc_IBIbD_yb70S3C2ncjWRvhw_5_4"></a><a id="Tc_hKHN6OlSWU2C__fFB4x0rQ_5_12"></a><ix:nonNumeric contextRef="Duration_1_1_2022_To_6_30_2022_dNPMG5n7t0WcNVF9KG4Bdw" name="ifrs-full:DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory" id="Tb_fDkc_ZjDBUK1nxt1b9NPxg" continuedAt="Tb_fDkc_ZjDBUK1nxt1b9NPxg_cont1" escape="true"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="color:#029c93;font-weight:bold;">Note 3 &#x2013; Financial Instruments</b> </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:50.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:20.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:20.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Genmab&#x2019;s portfolio is spread over a number of different securities with a focus on liquidity and the preservation of capital. Genmab&#x2019;s marketable securities in USD, DKK, EUR, and GBP as a percentage of total marketable securities was as follows: </p><ix:nonNumeric contextRef="Duration_1_1_2022_To_6_30_2022_dNPMG5n7t0WcNVF9KG4Bdw" name="gmab:DisclosureOfMarketableSecuritiesByCurrencyTableTextBlock" id="Tb_i4NebAuDckO0oTB0wAEexg" escape="true"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:33.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:28.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:28.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:33.48%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#xA0;&#xA0;&#xA0;&#xA0;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:31.28%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">June 30,</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:31.26%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">December&#xA0;31,&#xA0;</p></td></tr><tr><td style="vertical-align:bottom;width:33.48%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:31.28%;background:#e6e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:31.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">2021</p></td></tr><tr><td style="vertical-align:bottom;width:33.48%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Percent</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:28.02%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:28.02%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.23%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:33.48%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:28.02%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:28.02%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.23%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:33.48%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">USD</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:28.02%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_ydC7mNX6akalcP_kj1H8wg" contextRef="Duration_1_1_2022_To_6_30_2022_ifrs-full_TypesOfRisksAxis_ifrs-full_CurrencyRiskMember_srt_CurrencyAxis_currency_USD_5UvDDDnrAUyD1gvej8S37Q" decimals="4" format="ixt:numdotdecimal" name="gmab:PercentageOfMarketableSecuritiesInvested" scale="-2" id="Tc_-mdeghWIuk2v49MUd-dENg_5_2">79</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:28.02%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_ydC7mNX6akalcP_kj1H8wg" contextRef="Duration_1_1_2021_To_12_31_2021_ifrs-full_TypesOfRisksAxis_ifrs-full_CurrencyRiskMember_srt_CurrencyAxis_currency_USD_CHnFrAUKTEWMyHR2NduwAw" decimals="4" format="ixt:numdotdecimal" name="gmab:PercentageOfMarketableSecuritiesInvested" scale="-2" id="Tc_8pXVizxzMEOMpBCjJfxffg_5_5">75</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.23%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:33.48%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">DKK</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:28.02%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_ydC7mNX6akalcP_kj1H8wg" contextRef="Duration_1_1_2022_To_6_30_2022_ifrs-full_TypesOfRisksAxis_ifrs-full_CurrencyRiskMember_srt_CurrencyAxis_currency_DKK_wEFDGqiOE0meYqnyprgzqw" decimals="4" format="ixt:numdotdecimal" name="gmab:PercentageOfMarketableSecuritiesInvested" scale="-2" id="Tc_xjw2Z7-kRk-kTHT-3f2cgw_6_2">13</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:28.02%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_ydC7mNX6akalcP_kj1H8wg" contextRef="Duration_1_1_2021_To_12_31_2021_ifrs-full_TypesOfRisksAxis_ifrs-full_CurrencyRiskMember_srt_CurrencyAxis_currency_DKK_ayp_YF4WHEe51vXOnYlL2A" decimals="4" format="ixt:numdotdecimal" name="gmab:PercentageOfMarketableSecuritiesInvested" scale="-2" id="Tc_cHnWNvY2RkySdIRd6Lu5tw_6_5">16</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.23%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:33.48%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">EUR</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:28.02%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_ydC7mNX6akalcP_kj1H8wg" contextRef="Duration_1_1_2022_To_6_30_2022_ifrs-full_TypesOfRisksAxis_ifrs-full_CurrencyRiskMember_srt_CurrencyAxis_currency_EUR_SstAsF5VjkaHxTdVOHBYpg" decimals="4" format="ixt:numdotdecimal" name="gmab:PercentageOfMarketableSecuritiesInvested" scale="-2" id="Tc__RNqHgfyYUmz6m5gAylJiw_7_2">7</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:28.02%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_ydC7mNX6akalcP_kj1H8wg" contextRef="Duration_1_1_2021_To_12_31_2021_ifrs-full_TypesOfRisksAxis_ifrs-full_CurrencyRiskMember_srt_CurrencyAxis_currency_EUR_9Wybode0pUWKJkinsc2Cxw" decimals="4" format="ixt:numdotdecimal" name="gmab:PercentageOfMarketableSecuritiesInvested" scale="-2" id="Tc_vVUEysNNoEyxnu2se3HGmA_7_5">8</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.23%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:33.48%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">GBP</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:28.02%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_ydC7mNX6akalcP_kj1H8wg" contextRef="Duration_1_1_2022_To_6_30_2022_ifrs-full_TypesOfRisksAxis_ifrs-full_CurrencyRiskMember_srt_CurrencyAxis_currency_GBP_DSPHKvhiT02Od8W80WG6KQ" decimals="4" format="ixt:numdotdecimal" name="gmab:PercentageOfMarketableSecuritiesInvested" scale="-2" id="Tc_Elmqc1sIuEyDdFaIb4bfBA_8_2">1</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;background:#e6e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:28.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_ydC7mNX6akalcP_kj1H8wg" contextRef="Duration_1_1_2021_To_12_31_2021_ifrs-full_TypesOfRisksAxis_ifrs-full_CurrencyRiskMember_srt_CurrencyAxis_currency_GBP_nnosnR0H8kS3TQbqxqHACA" decimals="4" format="ixt:numdotdecimal" name="gmab:PercentageOfMarketableSecuritiesInvested" scale="-2" id="Tc__HlKwEpoaU2mtpgEr_UiIg_8_5">1</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:33.48%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:28.02%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_pure_ydC7mNX6akalcP_kj1H8wg" contextRef="Duration_1_1_2022_To_6_30_2022_ifrs-full_TypesOfRisksAxis_ifrs-full_CurrencyRiskMember_ASM5neKz9keFOK65fKS2gQ" decimals="4" format="ixt:numdotdecimal" name="gmab:PercentageOfMarketableSecuritiesInvested" scale="-2" id="Tc_eVTFTb6vpkGW4tlhYMCIGA_9_2">100</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;background:#e6e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:28.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_pure_ydC7mNX6akalcP_kj1H8wg" contextRef="Duration_1_1_2021_To_12_31_2021_ifrs-full_TypesOfRisksAxis_ifrs-full_CurrencyRiskMember_xIqg6PH6QUGf8y8gkPOHag" decimals="4" format="ixt:numdotdecimal" name="gmab:PercentageOfMarketableSecuritiesInvested" scale="-2" id="Tc_J1uxK3G9NkyHbyhb10EtbQ_9_5">100</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">%</p></td></tr></table></ix:nonNumeric><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">As of June 30, 2022, <ix:nonFraction unitRef="Unit_Standard_pure_ydC7mNX6akalcP_kj1H8wg" contextRef="As_Of_6_30_2022_ifrs-full_ExternalCreditGradesAxis_gmab_TripleaRatingMember_ifrs-full_TypesOfRisksAxis_ifrs-full_CreditRiskMember_MchtLzCh3Uufn_bh-7kpNA" decimals="4" format="ixt:numdotdecimal" name="gmab:PercentageOfMarketableSecurities" scale="-2" id="Narr_aCJ0_lk5UkGXd6p-T8I8FA">71</ix:nonFraction>% of Genmab&#x2019;s marketable securities were long-term A rated or higher, or short-term A-1 / P-1 rated by S&amp;P, Moody&#x2019;s or Fitch compared to <ix:nonFraction unitRef="Unit_Standard_pure_ydC7mNX6akalcP_kj1H8wg" contextRef="As_Of_12_31_2021_ifrs-full_ExternalCreditGradesAxis_gmab_TripleaRatingMember_ifrs-full_TypesOfRisksAxis_ifrs-full_CreditRiskMember_O0tp15gOUUSNGn0NNu-ntA" decimals="4" format="ixt:numdotdecimal" name="gmab:PercentageOfMarketableSecurities" scale="-2" id="Narr_0Ppjc64mrUehxgJjBJhxhQ">68</ix:nonFraction>% as of December 31, 2021. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">The table below shows the fair value measurements by level for Genmab&#x2019;s financial assets measured at fair value through profit or loss:</p><ix:nonNumeric contextRef="Duration_1_1_2022_To_6_30_2022_dNPMG5n7t0WcNVF9KG4Bdw" name="ifrs-full:DisclosureOfOffsettingOfFinancialAssetsAndFinancialLiabilitiesExplanatory" id="Tb_yv9G2nx9AkCN1yipez55jw" escape="true"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:26.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:10.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:10.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:6.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:6.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:5.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:6.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:6.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:6.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td></tr><tr><td style="vertical-align:middle;width:26.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">(DKK million)</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td colspan="7" style="vertical-align:middle;white-space:nowrap;width:39.58%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June 30, 2022</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td colspan="7" style="vertical-align:middle;white-space:nowrap;width:30.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#xA0;31,&#xA0;2021</b></p></td></tr><tr><td style="vertical-align:middle;width:26.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Assets Measured at Fair Value</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#xA0;&#xA0;&#xA0;&#xA0;</p></td><td style="vertical-align:middle;white-space:nowrap;width:10.8%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level&#xA0;1</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.9%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#xA0;&#xA0;&#xA0;&#xA0;</p></td><td style="vertical-align:middle;white-space:nowrap;width:10.8%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level&#xA0;2</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.9%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#xA0;&#xA0;&#xA0;&#xA0;</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:6.03%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level&#xA0;3</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.9%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#xA0;&#xA0;&#xA0;&#xA0;</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:6.23%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#xA0;&#xA0;&#xA0;&#xA0;</p></td><td style="vertical-align:middle;white-space:nowrap;width:5.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level&#xA0;1</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;">&#xA0;&#xA0;&#xA0;&#xA0;</p></td><td style="vertical-align:middle;white-space:nowrap;width:6.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level&#xA0;2</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#xA0;&#xA0;&#xA0;&#xA0;</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:6.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level&#xA0;3</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#xA0;&#xA0;&#xA0;&#xA0;</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:6.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:middle;width:26.28%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:10.8%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.9%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:10.8%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.9%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">&#xA0;&#xA0;&#xA0;&#xA0;</p></td><td style="vertical-align:middle;white-space:nowrap;width:6.03%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.9%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">&#xA0;&#xA0;&#xA0;&#xA0;</p></td><td style="vertical-align:middle;white-space:nowrap;width:6.23%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:5.85%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:6.03%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">&#xA0;&#xA0;&#xA0;&#xA0;</p></td><td style="vertical-align:middle;white-space:nowrap;width:6.03%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">&#xA0;&#xA0;&#xA0;&#xA0;</p></td><td style="vertical-align:middle;white-space:nowrap;width:6.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:26.28%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Marketable securities</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:10.8%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg" contextRef="As_Of_6_30_2022_ifrs-full_ClassesOfFinancialAssetsAxis_gmab_MarketableSecuritiesMember_ifrs-full_LevelsOfFairValueHierarchyAxis_ifrs-full_Level1OfFairValueHierarchyMember_ifrs-full_MeasurementAxis_ifrs-full_AtFairValueMember_ZqdE8gsn6ku4IF-3riiPzw" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:FinancialAssets" scale="6" id="Tc_BvAtnXhDxEGiwipyAPOvTA_4_2">11,799</ix:nonFraction></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.9%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.8%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> &#x2014;</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.9%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.03%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> &#x2014;</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.9%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:6.23%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg" contextRef="As_Of_6_30_2022_ifrs-full_ClassesOfFinancialAssetsAxis_gmab_MarketableSecuritiesMember_ifrs-full_MeasurementAxis_ifrs-full_AtFairValueMember_gMTFg1fkaU-2kMTWZGvA2A" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:FinancialAssets" scale="6" id="Tc_yGvVjYTJJ0qJcnnk6gZd1g_4_8">11,799</ix:nonFraction></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:5.85%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg" contextRef="As_Of_12_31_2021_ifrs-full_ClassesOfFinancialAssetsAxis_gmab_MarketableSecuritiesMember_ifrs-full_LevelsOfFairValueHierarchyAxis_ifrs-full_Level1OfFairValueHierarchyMember_ifrs-full_MeasurementAxis_ifrs-full_AtFairValueMember_QdkiKQXr4UeiSvq7C18kVg" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:FinancialAssets" scale="6" id="Tc_zK2hDj3HX0SRQcwY6ozn0g_4_10">10,381</ix:nonFraction></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.03%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> &#x2014;</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.03%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> &#x2014;</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:6.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg" contextRef="As_Of_12_31_2021_ifrs-full_ClassesOfFinancialAssetsAxis_gmab_MarketableSecuritiesMember_ifrs-full_MeasurementAxis_ifrs-full_AtFairValueMember_OovtmPjP8kG5XP6UcVoSpw" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:FinancialAssets" scale="6" id="Tc_-6fsE6a8Nk-xg9GcdiJleA_4_16">10,381</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:26.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Other investments</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:10.8%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg" contextRef="As_Of_6_30_2022_ifrs-full_ClassesOfFinancialAssetsAxis_gmab_OtherInvestmentMember_ifrs-full_LevelsOfFairValueHierarchyAxis_ifrs-full_Level1OfFairValueHierarchyMember_ifrs-full_MeasurementAxis_ifrs-full_AtFairValueMember_A8Z5M0xP50-MphyTG1XuyQ" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:FinancialAssets" scale="6" id="Tc_CgmrykCxvESyhKsCGe6KgA_5_2">150</ix:nonFraction></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.9%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.8%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> &#x2014;</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.9%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:6.03%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg" contextRef="As_Of_6_30_2022_ifrs-full_ClassesOfFinancialAssetsAxis_gmab_OtherInvestmentMember_ifrs-full_LevelsOfFairValueHierarchyAxis_ifrs-full_Level3OfFairValueHierarchyMember_ifrs-full_MeasurementAxis_ifrs-full_AtFairValueMember_hoHfcpf2WkG8ZksGtffiJg" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:FinancialAssets" scale="6" id="Tc_H2ymA3nj4kWJzbypPhEUkg_5_6">51</ix:nonFraction></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.9%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:6.23%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg" contextRef="As_Of_6_30_2022_ifrs-full_ClassesOfFinancialAssetsAxis_gmab_OtherInvestmentMember_ifrs-full_MeasurementAxis_ifrs-full_AtFairValueMember_DxVED2HGdUitGp0y05MVqQ" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:FinancialAssets" scale="6" id="Tc_wyXFwalKKE6AIrz-spQwUQ_5_8">201</ix:nonFraction></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:5.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg" contextRef="As_Of_12_31_2021_ifrs-full_ClassesOfFinancialAssetsAxis_gmab_OtherInvestmentMember_ifrs-full_LevelsOfFairValueHierarchyAxis_ifrs-full_Level1OfFairValueHierarchyMember_ifrs-full_MeasurementAxis_ifrs-full_AtFairValueMember_Obo46paYeU6NBT9bV_1jig" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:FinancialAssets" scale="6" id="Tc_zRYmCpsI4EeQMIOfrdnwEg_5_10">344</ix:nonFraction></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> &#x2014;</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:6.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg" contextRef="As_Of_12_31_2021_ifrs-full_ClassesOfFinancialAssetsAxis_gmab_OtherInvestmentMember_ifrs-full_LevelsOfFairValueHierarchyAxis_ifrs-full_Level3OfFairValueHierarchyMember_ifrs-full_MeasurementAxis_ifrs-full_AtFairValueMember_aMyaV8Vr-EO7hwMWUT9G9g" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:FinancialAssets" scale="6" id="Tc_2rcuUxeIfUOxTGsoVt3RRw_5_14">27</ix:nonFraction></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:6.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg" contextRef="As_Of_12_31_2021_ifrs-full_ClassesOfFinancialAssetsAxis_gmab_OtherInvestmentMember_ifrs-full_MeasurementAxis_ifrs-full_AtFairValueMember_QtPH5pFRWEevfw8ugwnNCA" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:FinancialAssets" scale="6" id="Tc_6qRWG91dYkSDmO_746M9sg_5_16">371</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Marketable Securities</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">All fair values are determined by reference to external sources using unadjusted quoted prices in established markets for Genmab&#x2019;s marketable securities (Level 1). </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Other Investments </b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Other investments as of June 30, 2022 consist primarily of a DKK <ix:nonFraction unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg" contextRef="As_Of_6_30_2022_gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_gmab_CurevacCollaborationMember_qc8QNPN5vUSdmz2Y_v8bjg" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:InvestmentAccountedForUsingEquityMethod" scale="6" id="Narr_uli7Qf9dJEqf9CMjFvGFbQ">138</ix:nonFraction> million investment in common shares of CureVac, compared to DKK <ix:nonFraction unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg" contextRef="As_Of_12_31_2021_gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_gmab_CurevacCollaborationMember_0V_v61kjsUagGH7vU0HsPA" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:InvestmentAccountedForUsingEquityMethod" scale="6" id="Narr_WWWCs-km50CdQ3uberwnKQ">318</ix:nonFraction> million as of December 31, 2021. During the second quarter of 2021, Genmab made an investment in common shares of Bolt. As of June 30, 2022, the investment in Bolt was valued at DKK <ix:nonFraction unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg" contextRef="As_Of_6_30_2022_gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_gmab_BoltBiotherapeuticsIncMember_Cb3qRuFzkUCdz53av0zSRg" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:InvestmentAccountedForUsingEquityMethod" scale="6" id="Narr_fXHhSLdXPkuGAwcIB7sgLw">12</ix:nonFraction> million, compared to DKK <ix:nonFraction unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg" contextRef="As_Of_12_31_2021_gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_gmab_BoltBiotherapeuticsIncMember_dAp_IxgOu0O5Vly-wxDrdA" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:InvestmentAccountedForUsingEquityMethod" scale="6" id="Narr_fOFeEGFzZUu7fYFgQjsxvA">26</ix:nonFraction> million as of December 31, 2021.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></ix:nonNumeric></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:24pt 0pt 0pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;table-layout:fixed;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td></tr><tr><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Genmab A/S</p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Tel: +45 7020 2728</p></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">Company Announcement no. 41</p></td></tr><tr><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Kalvebod Brygge 43</p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Fax: +45 7020 2729</p></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">Page 28/35</p></td></tr><tr><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">1560 Copenhagen V, Denmark</p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">www.genmab.com</p></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">CVR no. 2102 3884</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:76.47%;border:0;margin:30pt 11.76% 30pt 11.76%;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;min-height:36pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><img src="gmab-20220630xex99d1002.jpg" alt="Graphic" style="display:inline-block;height:44.99pt;left:0%;padding-bottom:0.05pt;position:relative;top:0pt;width:151.48pt;" /></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Arial Bold';font-size:9pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-size:13pt;font-weight:bold;">Interim Report for the First Half of 2022</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></div><div style="clear:both;max-width:100%;position:relative;min-height:45.04pt;"><ix:continuation id="Tb_fDkc_ZjDBUK1nxt1b9NPxg_cont1"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">The investments in CureVac and Bolt are recorded at fair value through profit or loss. The fair value of Genmab&#x2019;s investments in CureVac and Bolt are determined using unadjusted quoted prices in established markets (Level 1).</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Refer to Note 4.3 and Note 4.4 in the Annual Report for further details regarding Genmab&#x2019;s marketable securities and other investments.</p></ix:continuation><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p><a id="Tc_8u2W-hUWkECJczen4wMVmg_1_2"></a><a id="Tc_2gbnZWXHn0mB2Z2F-JnPdQ_1_4"></a><a id="Tc_x-T0e1Uha0qKEanHZuBuuQ_2_2"></a><a id="Tc_Nt2XSwmKJUiiSW_uGZd3Uw_2_4"></a><a id="Tc_k-nNVNQC1Ea_r5SfBCynJA_3_0"></a><a id="Tc_WYBOmK1u4kGizZLh4dhYsw_5_0"></a><a id="Tc_hPC94MfLTUugrIkOkvD7FA_6_0"></a><a id="Tc_B7WF70G1k0W0aVShGtBVtA_7_0"></a><a id="Tc_qf5yMl6XYE2VyRiqRkj6CA_9_0"></a><a id="Tc_8nOeLGYIMEG4rzOaFKuZBQ_11_0"></a><a id="Tc_dN1FAPCMzEqIbNrJKKC2TQ_12_0"></a><a id="Tc_bnOBod3nEkuMG-F2NeygsA_13_0"></a><a id="Tc_-6seedZQWkGhxNeFnQ8okg_14_0"></a><a id="Tc_dykpIWrPDkyj2nLEfrtt0w_16_0"></a><a id="Tc_W8hqXLlGHkCT_Y8rOhPY3w_18_0"></a><ix:nonNumeric contextRef="Duration_1_1_2022_To_6_30_2022_dNPMG5n7t0WcNVF9KG4Bdw" name="ifrs-full:DisclosureOfFinanceIncomeExpenseExplanatory" id="Tb_eoSkG1XwFE-x3mB6MwxTzA" escape="true"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="color:#029c93;font-weight:bold;">Note 4 &#x2013; Financial Income and Expenses</b></p><ix:nonNumeric contextRef="Duration_1_1_2022_To_6_30_2022_dNPMG5n7t0WcNVF9KG4Bdw" name="gmab:DisclosureOfFinanceIncomeExpensesTableTextBlock" id="Tb_chB1aFF23Ui5BE3G3VKAGQ" escape="true"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:57.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:18.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:18.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:57.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#xA0;&#xA0;&#xA0;&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.69%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">6 Months Ended</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#xA0;&#xA0;&#xA0;&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.66%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">6 Months Ended</p></td></tr><tr><td style="vertical-align:bottom;width:57.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.69%;background:#e6e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">June 30, 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">June 30, 2021</p></td></tr><tr><td style="vertical-align:bottom;width:57.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">(DKK million)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.69%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.66%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:57.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.69%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.66%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:57.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Financial income:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.69%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.66%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:57.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Interest and other financial income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.69%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg" contextRef="Duration_1_1_2022_To_6_30_2022_dNPMG5n7t0WcNVF9KG4Bdw" decimals="-6" format="ixt:numdotdecimal" name="gmab:InterestAndOtherFinancialIncome" scale="6" id="Tc_UQ4UgRpSTUybjIJMGgj-jg_6_2">87</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.66%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg" contextRef="Duration_1_1_2021_To_6_30_2021_MRS0_D_onUCNBOxf7Qx_Cw" decimals="-6" format="ixt:numdotdecimal" name="gmab:InterestAndOtherFinancialIncome" scale="6" id="Tc_EEMWg_qX4k-JXujVj2qACQ_6_4">127</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:57.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Foreign exchange rate gain, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.69%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg" contextRef="Duration_1_1_2022_To_6_30_2022_dNPMG5n7t0WcNVF9KG4Bdw" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:NetForeignExchangeGain" scale="6" id="Tc_vKnD3EdTMU2sZN85qQqhlg_7_2">1,792</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg" contextRef="Duration_1_1_2021_To_6_30_2021_MRS0_D_onUCNBOxf7Qx_Cw" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:NetForeignExchangeGain" scale="6" id="Tc_GIIJITqw10aXHH5sIqQnow_7_4">573</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:57.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.69%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> </b><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.66%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> </b><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:57.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total financial income</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.69%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg" contextRef="Duration_1_1_2022_To_6_30_2022_dNPMG5n7t0WcNVF9KG4Bdw" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:FinanceIncome" scale="6" id="Tc_uH7VtLD3dECv4AnVM_Z30w_9_2">1,879</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg" contextRef="Duration_1_1_2021_To_6_30_2021_MRS0_D_onUCNBOxf7Qx_Cw" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:FinanceIncome" scale="6" id="Tc_5-f5HmHzskOvY4sBc1Hwzg_9_4">700</ix:nonFraction></b></p></td></tr><tr><td style="vertical-align:bottom;width:57.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.69%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.66%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:57.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Financial expenses:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.69%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.66%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:57.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Interest and other financial expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.69%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg" contextRef="Duration_1_1_2022_To_6_30_2022_dNPMG5n7t0WcNVF9KG4Bdw" decimals="-6" format="ixt:numdotdecimal" name="gmab:InterestAndOtherFinancialExpenses" scale="6" id="Tc_aocd7lOMmkKxaDWDdRwRzw_12_2">10</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.66%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg" contextRef="Duration_1_1_2021_To_6_30_2021_MRS0_D_onUCNBOxf7Qx_Cw" decimals="-6" format="ixt:numdotdecimal" name="gmab:InterestAndOtherFinancialExpenses" scale="6" id="Tc_86BSbl45gUe7ydA2BOqhJw_12_4">6</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:57.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Loss on marketable securities, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.69%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg" contextRef="Duration_1_1_2022_To_6_30_2022_dNPMG5n7t0WcNVF9KG4Bdw" decimals="-6" format="ixt:numdotdecimal" name="gmab:LossesOnMarketableSecurities" scale="6" id="Tc_Gho02hPpO0GVWyHI_70-vg_13_2">315</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.66%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg" contextRef="Duration_1_1_2021_To_6_30_2021_MRS0_D_onUCNBOxf7Qx_Cw" decimals="-6" format="ixt:numdotdecimal" name="gmab:LossesOnMarketableSecurities" scale="6" id="Tc_euYOdXooQUyG6z6x1QQTZA_13_4">134</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:57.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Loss on other investments, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.69%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg" contextRef="Duration_1_1_2022_To_6_30_2022_dNPMG5n7t0WcNVF9KG4Bdw" decimals="-6" format="ixt:numdotdecimal" name="gmab:LossesOnOtherInvestmentsNet" scale="6" id="Tc_lm6on6VfRkO5PkxSW9K5wQ_14_2">214</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg" contextRef="Duration_1_1_2021_To_6_30_2021_MRS0_D_onUCNBOxf7Qx_Cw" decimals="-6" format="ixt:numdotdecimal" name="gmab:LossesOnOtherInvestmentsNet" scale="6" id="Tc_6bbsrPplV0SzsJoEpm7q-Q_14_4">33</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:57.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.69%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.66%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:57.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total financial expenses</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.69%;background:#e6e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg" contextRef="Duration_1_1_2022_To_6_30_2022_dNPMG5n7t0WcNVF9KG4Bdw" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:FinanceCosts" scale="6" id="Tc_56wJCp_vsk-J4BRWBykKbw_16_2">539</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg" contextRef="Duration_1_1_2021_To_6_30_2021_MRS0_D_onUCNBOxf7Qx_Cw" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:FinanceCosts" scale="6" id="Tc_ar8pilXT90Oq7GJidihDIg_16_4">173</ix:nonFraction>)</b></p></td></tr><tr><td style="vertical-align:bottom;width:57.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.69%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.66%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:57.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Net financial items</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.69%;background:#e6e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg" contextRef="Duration_1_1_2022_To_6_30_2022_dNPMG5n7t0WcNVF9KG4Bdw" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:FinanceIncomeCost" scale="6" id="Tc_FDjGwcKupk6OoCy-r6S06w_18_2">1,340</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg" contextRef="Duration_1_1_2021_To_6_30_2021_MRS0_D_onUCNBOxf7Qx_Cw" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:FinanceIncomeCost" scale="6" id="Tc_k9PLJ3l8b0qGVBr0twW7SA_18_4">527</ix:nonFraction></b></p></td></tr></table></ix:nonNumeric><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Foreign exchange rate gain, net was DKK <ix:nonFraction unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg" contextRef="Duration_1_1_2022_To_6_30_2022_dNPMG5n7t0WcNVF9KG4Bdw" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:NetForeignExchangeGain" scale="6" id="Narr_-yBjmymaok6ynfdktj2HEQ">1,792</ix:nonFraction> million in the first six months of 2022 compared to DKK <ix:nonFraction unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg" contextRef="Duration_1_1_2021_To_6_30_2021_MRS0_D_onUCNBOxf7Qx_Cw" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:NetForeignExchangeGain" scale="6" id="Narr_bi3mP7ptfkOIXzvc8TqI2Q">573</ix:nonFraction> million in the first six months of 2021. The USD strengthened against the DKK in each period which positively impacted our USD denominated marketable securities and cash holdings, but to a greater extent in 2022. Refer to Note 4.2 in the Annual Report for further details regarding foreign currency risk. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Loss on marketable securities, net was DKK <ix:nonFraction unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg" contextRef="Duration_1_1_2022_To_6_30_2022_dNPMG5n7t0WcNVF9KG4Bdw" decimals="-6" format="ixt:numdotdecimal" name="gmab:LossesOnMarketableSecurities" scale="6" id="Narr_-F6sJSQwKkeRW8Eo4piyYQ">315</ix:nonFraction> million in the first six months of 2022 compared to DKK <ix:nonFraction unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg" contextRef="Duration_1_1_2021_To_6_30_2021_MRS0_D_onUCNBOxf7Qx_Cw" decimals="-6" format="ixt:numdotdecimal" name="gmab:LossesOnMarketableSecurities" scale="6" id="Narr_Xjz56Rj7UUqVtQqdNl_bSg">134</ix:nonFraction> million in the first six months of 2021. The increase in fair value losses on marketable securities was primarily driven by increases in interest rates in the United States and Europe.<span style="white-space:pre-wrap;">  </span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="background:#ffffff;">Loss on other investments, net was DKK </span><span style="background:#ffffff;"><ix:nonFraction unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg" contextRef="Duration_1_1_2022_To_6_30_2022_dNPMG5n7t0WcNVF9KG4Bdw" decimals="-6" format="ixt:numdotdecimal" name="gmab:LossesOnOtherInvestmentsNet" scale="6" id="Narr_9okgvapJgkO7KL7jbHDEfA">214</ix:nonFraction></span><span style="background:#ffffff;"> million in the first six months of 2022 compared to DKK </span><span style="background:#ffffff;"><ix:nonFraction unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg" contextRef="Duration_1_1_2021_To_6_30_2021_MRS0_D_onUCNBOxf7Qx_Cw" decimals="-6" format="ixt:numdotdecimal" name="gmab:LossesOnOtherInvestmentsNet" scale="6" id="Narr_HaPoKeOxjkGW5f6Aaq8BGQ">33</ix:nonFraction></span><span style="background:#ffffff;"> million in the first six months of 2021. The change was driven&#xA0;by the decrease in fair value of Genmab&#x2019;s investment in common shares of CureVac and Bolt.&#xA0;</span></p></ix:nonNumeric><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="color:#029c93;font-weight:bold;visibility:hidden;">&#x200B;</span></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:24pt 0pt 0pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;table-layout:fixed;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td></tr><tr><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Genmab A/S</p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Tel: +45 7020 2728</p></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">Company Announcement no. 41</p></td></tr><tr><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Kalvebod Brygge 43</p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Fax: +45 7020 2729</p></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">Page 29/35</p></td></tr><tr><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">1560 Copenhagen V, Denmark</p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">www.genmab.com</p></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">CVR no. 2102 3884</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:76.47%;border:0;margin:30pt 11.76% 30pt 11.76%;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;min-height:36pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><img src="gmab-20220630xex99d1002.jpg" alt="Graphic" style="display:inline-block;height:44.99pt;left:0%;padding-bottom:0.05pt;position:relative;top:0pt;width:151.48pt;" /></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Arial Bold';font-size:9pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-size:13pt;font-weight:bold;">Interim Report for the First Half of 2022</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></div><div style="clear:both;max-width:100%;position:relative;min-height:45.04pt;"><a id="Tc_Sx7gkMbK4kWJ5_u508KWKA_1_2"></a><a id="Tc_6ie7IYnLA0ymFA8FZ4RdmA_1_4"></a><a id="Tc_sl-fBxSPXUacghXbgkZq3w_2_2"></a><a id="Tc_IKwYbxjgKE6W5kxf0hMVKQ_2_4"></a><a id="Tc_qLQgDXDEJEmK7l0UEVhZ7Q_3_0"></a><a id="Tc_E67V3__eaES2k16wMokQOg_4_0"></a><a id="Tc_vgap64eQSkimCo4NhvOhRQ_6_0"></a><a id="Tc_sEyB4DY_EkqBlHUqujpmug_1_2"></a><a id="Tc_zG1NMiqqjU6mMwDPDar-lQ_1_4"></a><a id="Tc_pum5-ERBH0i1uJMKRzndJA_2_2"></a><a id="Tc_oNsFWTSl_k-4IKAr3w8Bow_2_4"></a><a id="Tc_6ouJhWoiJEahfVMuNb9GBg_3_0"></a><a id="Tc_D78Ipwr1k0STVuOfIjmZ1w_4_0"></a><a id="Tc_pliZoPechk-XW6Ou5zXFgA_5_0"></a><a id="Tc_gswuz1A7u0uLGt_OitWEPQ_7_0"></a><a id="Tc_oV2Iv8a5YUirxjLB5mD5Ww_8_0"></a><a id="Tc_4L9KfG58M0ymDyzY_dGkuQ_9_0"></a><a id="Tc_cw5zO9x3BU2oVe199XeqFg_1_2"></a><a id="Tc_DY1sOJdZRUuZ8dMuOk1dOA_1_4"></a><a id="Tc_0QsO8Zx68UyhSvFOC3MlqA_1_6"></a><a id="Tc_atzFUxkDb06ixyaBrxDviw_2_0"></a><a id="Tc_Kw1UllZ86EunVRYki9mA3g_3_0"></a><a id="Tc_dsgtZ3vr-0uKF-PDe-qN7Q_3_2"></a><a id="Tc_O5tESR_hSUWad1jPMCx-0g_4_0"></a><a id="Tc_U3iHdGBYuk6bjSz3jSXDUw_4_6"></a><ix:nonNumeric contextRef="Duration_1_1_2022_To_6_30_2022_dNPMG5n7t0WcNVF9KG4Bdw" name="ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory" id="Tb_8wFGEOrLlkS6G4ICEnJvZA" continuedAt="Tb_8wFGEOrLlkS6G4ICEnJvZA_cont1" escape="true"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="color:#029c93;font-weight:bold;">Note 5 &#x2013; Share-Based Instruments</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="color:#029c93;font-weight:bold;visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Restricted Stock Unit Program</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Genmab A/S established RSU programs as an incentive for all Genmab employees, members of the registered Executive Management, and members of the Board of Directors. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p><ix:nonNumeric contextRef="Duration_1_1_2022_To_6_30_2022_dNPMG5n7t0WcNVF9KG4Bdw" name="ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory" id="Tb_NEmt93u8N0GI9XqxiKs17A" escape="true"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:57.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:18.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:19.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:57.58%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.21%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><span style="font-size:8.5pt;">6 Months Ended</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.54%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><span style="font-size:8.5pt;">6 Months Ended</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:57.58%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8.5pt;">&#xA0;&#xA0;&#xA0;&#xA0;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.21%;background:#e6e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><span style="font-size:8.5pt;">June 30, 2022</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8.5pt;">&#xA0;&#xA0;&#xA0;&#xA0;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><span style="font-size:8.5pt;">June 30, 2021</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:57.58%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">RSUs granted</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.21%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:8.5pt;"> <ix:nonFraction unitRef="Unit_Standard_EquityInstruments_bRFAkAsdz0ugOZctjovS4A" contextRef="Duration_1_1_2022_To_6_30_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_gmab_IfrsRestrictedStockUnitsRSUsMember_4-5BFoS8HkmkHqZSV1-skg" decimals="INF" format="ixt:numdotdecimal" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" scale="0" id="Tc_3wCY4gYu5kq2yRWtzwct4Q_3_2">240,741</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.54%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:8.5pt;"> <ix:nonFraction unitRef="Unit_Standard_EquityInstruments_bRFAkAsdz0ugOZctjovS4A" contextRef="Duration_1_1_2021_To_6_30_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_gmab_IfrsRestrictedStockUnitsRSUsMember_XTrx_EPo2kixh36V-j_AVw" decimals="INF" format="ixt:numdotdecimal" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" scale="0" id="Tc_Vet3RymnW02KqmU9Yn7jgg_3_4">159,567</ix:nonFraction></span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:57.58%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><i style="font-size:8.5pt;font-style:italic;">Weighted average fair value per RSU granted (DKK) </i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.21%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><i style="font-size:8.5pt;font-style:italic;"> <ix:nonFraction unitRef="Unit_Divide_DKK_shares_uaEdw-3-XkitvcC2Swh0EQ" contextRef="Duration_1_1_2022_To_6_30_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_gmab_IfrsRestrictedStockUnitsRSUsMember_4-5BFoS8HkmkHqZSV1-skg" decimals="2" format="ixt:numdotdecimal" name="gmab:Weightedaveragefairvalueofotherequityinstrumentsgrantedinsharebasedpaymentarrangement" scale="0" id="Tc_4VDE6ePlo0m_SKaaNlmZEg_4_2">2,178.22</ix:nonFraction></i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;font-style:italic;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.54%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><i style="font-size:8.5pt;font-style:italic;"> <ix:nonFraction unitRef="Unit_Divide_DKK_shares_uaEdw-3-XkitvcC2Swh0EQ" contextRef="Duration_1_1_2021_To_6_30_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_gmab_IfrsRestrictedStockUnitsRSUsMember_XTrx_EPo2kixh36V-j_AVw" decimals="2" format="ixt:numdotdecimal" name="gmab:Weightedaveragefairvalueofotherequityinstrumentsgrantedinsharebasedpaymentarrangement" scale="0" id="Tc_zZpJbWn3CkuVrWJHnDU4pg_4_4">2,149.55</ix:nonFraction></i></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:57.58%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.21%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.54%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:57.58%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">RSUs vested</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.21%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:8.5pt;"> <ix:nonFraction unitRef="Unit_Standard_EquityInstruments_bRFAkAsdz0ugOZctjovS4A" contextRef="Duration_1_1_2022_To_6_30_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_gmab_IfrsRestrictedStockUnitsRSUsMember_4-5BFoS8HkmkHqZSV1-skg" decimals="INF" format="ixt:numdotdecimal" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" scale="0" id="Tc_O81ExK3GT0aYnl63-l67jA_6_2">82,001</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:8.5pt;"> <ix:nonFraction unitRef="Unit_Standard_EquityInstruments_bRFAkAsdz0ugOZctjovS4A" contextRef="Duration_1_1_2021_To_6_30_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_gmab_IfrsRestrictedStockUnitsRSUsMember_XTrx_EPo2kixh36V-j_AVw" decimals="INF" format="ixt:numdotdecimal" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" scale="0" id="Tc_v690y_2Ei0CwtCNozZe4kQ_6_4">49,012</ix:nonFraction></span></p></td></tr></table></ix:nonNumeric><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Refer to Note 4.6 in the Annual Report for details on the RSU programs.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Warrant Program</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Genmab A/S established warrant programs as an incentive for all Genmab employees, and members of the registered Executive Management.</p><ix:nonNumeric contextRef="Duration_1_1_2022_To_6_30_2022_dNPMG5n7t0WcNVF9KG4Bdw" name="gmab:DisclosureOfWarrantsActivityTableTextBlock" id="Tb_jLUoFwcip0WRTM-0aqIUjw" escape="true"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:63.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:63.09%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.61%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><span style="font-size:8.5pt;">6 Months Ended</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.99%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><span style="font-size:8.5pt;">6 Months Ended</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:63.09%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8.5pt;">&#xA0;&#xA0;&#xA0;&#xA0;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.61%;background:#e6e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><span style="font-size:8.5pt;">June 30, 2022</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8.5pt;">&#xA0;&#xA0;&#xA0;&#xA0;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><span style="font-size:8.5pt;">June 30, 2021</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:63.09%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">Warrants granted</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.61%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:8.5pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_MrgY4vrrEUeN62nRwu-ZLA" contextRef="Duration_1_1_2022_To_6_30_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_gmab_WarrantsMember_kH0r0sIdkU-S9yq6_erZfw" decimals="INF" format="ixt:numdotdecimal" name="gmab:NumberOfWarrantsGrantedDuringPeriod" scale="0" id="Tc_BP6V1d2eF0Os2a4GxVnixA_3_2">230,112</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.99%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:8.5pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_MrgY4vrrEUeN62nRwu-ZLA" contextRef="Duration_1_1_2021_To_6_30_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_gmab_WarrantsMember_sN8RX4-cR0-kSMFNCobg0Q" decimals="INF" format="ixt:numdotdecimal" name="gmab:NumberOfWarrantsGrantedDuringPeriod" scale="0" id="Tc_m9w_9HTojE67Rm-RzdV0KQ_3_4">147,568</ix:nonFraction></span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:63.09%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><i style="font-size:8.5pt;font-style:italic;">Weighted average exercise price per warrant granted (DKK) </i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;font-style:italic;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.61%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><i style="font-size:8.5pt;font-style:italic;"> <ix:nonFraction unitRef="Unit_Divide_DKK_shares_uaEdw-3-XkitvcC2Swh0EQ" contextRef="Duration_1_1_2022_To_6_30_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_gmab_WarrantsMember_kH0r0sIdkU-S9yq6_erZfw" decimals="2" format="ixt:numdotdecimal" name="gmab:WeightedAverageExercisePriceOfWarrantsGranted" scale="0" id="Tc_w_XZ0TbsaUOe3VTG_nWagg_4_2">2,178.40</ix:nonFraction></i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;font-style:italic;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.99%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><i style="font-size:8.5pt;font-style:italic;"> <ix:nonFraction unitRef="Unit_Divide_DKK_shares_uaEdw-3-XkitvcC2Swh0EQ" contextRef="Duration_1_1_2021_To_6_30_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_gmab_WarrantsMember_sN8RX4-cR0-kSMFNCobg0Q" decimals="2" format="ixt:numdotdecimal" name="gmab:WeightedAverageExercisePriceOfWarrantsGranted" scale="0" id="Tc_oxr4f8uqh0ysclOLbDDvOA_4_4">2,189.21</ix:nonFraction></i></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:63.09%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><i style="font-size:8.5pt;font-style:italic;">Weighted average Black-Scholes fair value per warrant granted (DKK) </i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;font-style:italic;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.61%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><i style="font-size:8.5pt;font-style:italic;"> <ix:nonFraction unitRef="Unit_Divide_DKK_shares_uaEdw-3-XkitvcC2Swh0EQ" contextRef="Duration_1_1_2022_To_6_30_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_gmab_WarrantsMember_kH0r0sIdkU-S9yq6_erZfw" decimals="2" format="ixt:numdotdecimal" name="gmab:WeightedAverageExercisePriceOfFairValueOfWarrants" scale="0" id="Tc_u5i_vX8UYUSh7eCfjyMqrg_5_2">629.05</ix:nonFraction></i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;font-style:italic;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.99%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><i style="font-size:8.5pt;font-style:italic;"> <ix:nonFraction unitRef="Unit_Divide_DKK_shares_uaEdw-3-XkitvcC2Swh0EQ" contextRef="Duration_1_1_2021_To_6_30_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_gmab_WarrantsMember_sN8RX4-cR0-kSMFNCobg0Q" decimals="2" format="ixt:numdotdecimal" name="gmab:WeightedAverageExercisePriceOfFairValueOfWarrants" scale="0" id="Tc_5f8uC3r3BUmicAHiaXo5vA_5_4">683.79</ix:nonFraction></i></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:63.09%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;font-style:italic;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;font-style:italic;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.61%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8.5pt;font-style:italic;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;font-style:italic;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.99%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8.5pt;font-style:italic;visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:63.09%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">Warrants exercised</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.61%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:8.5pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_MrgY4vrrEUeN62nRwu-ZLA" contextRef="Duration_1_1_2022_To_6_30_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_gmab_WarrantsMember_kH0r0sIdkU-S9yq6_erZfw" decimals="INF" format="ixt:numdotdecimal" name="gmab:NumberOfWarrantsExercisedDuringPeriod" scale="0" id="Tc_nplCpQSFZUGuQB9Buq-S1A_7_2">34,987</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.99%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:8.5pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_MrgY4vrrEUeN62nRwu-ZLA" contextRef="Duration_1_1_2021_To_6_30_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_gmab_WarrantsMember_sN8RX4-cR0-kSMFNCobg0Q" decimals="INF" format="ixt:numdotdecimal" name="gmab:NumberOfWarrantsExercisedDuringPeriod" scale="0" id="Tc_nA6qNWoNHEqVvZPNCvi0sg_7_4">74,992</ix:nonFraction></span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:63.09%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><i style="font-size:8.5pt;font-style:italic;">Weighted average exercise price on date of grant per warrant exercised (DKK)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;font-style:italic;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.61%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><i style="font-size:8.5pt;font-style:italic;"> <ix:nonFraction unitRef="Unit_Divide_DKK_shares_uaEdw-3-XkitvcC2Swh0EQ" contextRef="Duration_1_1_2022_To_6_30_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_gmab_WarrantsMember_kH0r0sIdkU-S9yq6_erZfw" decimals="2" format="ixt:numdotdecimal" name="gmab:WeightedAverageExercisePriceOfWarrantsExercised" scale="0" id="Tc_2NE3av02bkKIigCzSjWR-A_8_2">983.98</ix:nonFraction></i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;font-style:italic;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.99%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><i style="font-size:8.5pt;font-style:italic;"> <ix:nonFraction unitRef="Unit_Divide_DKK_shares_uaEdw-3-XkitvcC2Swh0EQ" contextRef="Duration_1_1_2021_To_6_30_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_gmab_WarrantsMember_sN8RX4-cR0-kSMFNCobg0Q" decimals="2" format="ixt:numdotdecimal" name="gmab:WeightedAverageExercisePriceOfWarrantsExercised" scale="0" id="Tc_TRQX923kZ0mkSFSOsFCxFg_8_4">606.22</ix:nonFraction></i></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:63.09%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><i style="font-size:8.5pt;font-style:italic;">% change in share capital - warrants exercised</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;font-style:italic;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.61%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><i style="font-size:8.5pt;font-style:italic;"><ix:nonFraction unitRef="Unit_Standard_pure_ydC7mNX6akalcP_kj1H8wg" contextRef="Duration_1_1_2022_To_6_30_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_gmab_WarrantsMember_kH0r0sIdkU-S9yq6_erZfw" decimals="4" format="ixt:numdotdecimal" name="gmab:PercentageOfShareCapitalAttributedToExerciseOfWarrants" scale="-2" id="Tc_s0_xESGFG0ejeTl7h30RRg_9_2">0.05</ix:nonFraction>%</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;font-style:italic;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><i style="font-size:8.5pt;font-style:italic;"><ix:nonFraction unitRef="Unit_Standard_pure_ydC7mNX6akalcP_kj1H8wg" contextRef="Duration_1_1_2021_To_6_30_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_gmab_WarrantsMember_sN8RX4-cR0-kSMFNCobg0Q" decimals="4" format="ixt:numdotdecimal" name="gmab:PercentageOfShareCapitalAttributedToExerciseOfWarrants" scale="-2" id="Tc_UHwWc4PCMU6oXiEkoK1Mkg_9_4">0.11</ix:nonFraction>%</i></p></td></tr></table></ix:nonNumeric><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Refer to Note 4.6 in the Annual Report for details on the warrant programs.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Share-based compensation expense</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:11.0pt;text-indent:0pt;margin:0pt 36pt 11pt 0pt;">Share-based compensation expenses related to Genmab RSU and warrant programs for the first six months of 2022 was DKK <ix:nonFraction unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg" contextRef="Duration_1_1_2022_To_6_30_2022_dNPMG5n7t0WcNVF9KG4Bdw" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" scale="6" id="Narr_0_C6Dtxxy0CGfuY4mariDg">208</ix:nonFraction> million compared to DKK <ix:nonFraction unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg" contextRef="Duration_1_1_2021_To_6_30_2021_MRS0_D_onUCNBOxf7Qx_Cw" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" scale="6" id="Narr_NTYDFcd1o0iJeEXEd5xGKQ">142</ix:nonFraction> million for the first six months of 2021. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Share repurchases</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">In general, Genmab intends to purchase its own shares in order to cover a portion of obligations in relation to RSUs. As of June 30, 2022, Genmab has <ix:nonFraction unitRef="Unit_Standard_item_d-Yn30W8q0CdLFqZ4zWe8g" contextRef="Duration_1_1_2022_To_6_30_2022_dNPMG5n7t0WcNVF9KG4Bdw" decimals="INF" format="ixt-sec:numwordsen" name="gmab:ShareBasedArrangementNumberOfAuthorization" scale="0" id="Narr_iWk-gF53FEiJu3fu7UAtJg">two</ix:nonFraction> authorizations to repurchase shares: the 2021 and 2019 authorizations. The 2016 authorization expired in March 2021. </p><ix:nonNumeric contextRef="Duration_1_1_2022_To_6_30_2022_dNPMG5n7t0WcNVF9KG4Bdw" name="gmab:ScheduleOfShareRepurchasesTableTextBlock" id="Tb_4LmmJNnYlEGkjGXRi42bNw" escape="true"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:49.62%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:14.63%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:15.73%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:15.68%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:49.62%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:14.63%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">2021 <br />Authorization</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:15.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">2019 <br />Authorization</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:15.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">2016 <br />Authorization</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:49.62%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Number of shares authorized for repurchase</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.63%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_MrgY4vrrEUeN62nRwu-ZLA" contextRef="As_Of_6_30_2022_srt_StatementScenarioAxis_gmab_StockRepurchaseAuthorization2021Member_ll839TqkPUSnSuKvpYFvXQ" decimals="INF" format="ixt:numdotdecimal" name="gmab:NumberOfSharesAuthorizedToBeRepurchased" scale="0" id="Tc_lk5283eMY0SV7nznOKH-Eg_2_2">500,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.73%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_MrgY4vrrEUeN62nRwu-ZLA" contextRef="As_Of_6_30_2022_srt_StatementScenarioAxis_gmab_StockRepurchaseAuthorization2019Member_Ey8o8eyD7UaKwBJF-khG6w" decimals="INF" format="ixt:numdotdecimal" name="gmab:NumberOfSharesAuthorizedToBeRepurchased" scale="0" id="Tc_NwwmoudN0Eq2HCXW0yvYtQ_2_4">500,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.68%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_MrgY4vrrEUeN62nRwu-ZLA" contextRef="As_Of_6_30_2022_srt_StatementScenarioAxis_gmab_StockRepurchaseAuthorization2016Member_rs9bpzaf80uIoq7-Gcmw6w" decimals="INF" format="ixt:numdotdecimal" name="gmab:NumberOfSharesAuthorizedToBeRepurchased" scale="0" id="Tc_V8vufYQbD0OJaJTFYNlkIA_2_6">500,000</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:49.62%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Actual shares repurchased under authorization</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.63%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#x2014;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.73%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_MrgY4vrrEUeN62nRwu-ZLA" contextRef="Duration_1_1_2022_To_6_30_2022_srt_StatementScenarioAxis_gmab_StockRepurchaseAuthorization2019Member_xfwDxjqmW02JCqvKbHtBaQ" decimals="INF" format="ixt:numdotdecimal" name="gmab:ShareRepurchasedDuringPeriodShares" scale="0" id="Tc_HW2HqBYZskeKQXoc16JlGg_3_4">294,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.68%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_MrgY4vrrEUeN62nRwu-ZLA" contextRef="Duration_1_1_2022_To_6_30_2022_srt_StatementScenarioAxis_gmab_StockRepurchaseAuthorization2016Member_mmhw2ICcwkqWFdCPJ6rVhw" decimals="INF" format="ixt:numdotdecimal" name="gmab:ShareRepurchasedDuringPeriodShares" scale="0" id="Tc_t97WbSmo60qeTd1KZwp28w_3_6">255,000</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:49.62%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Shares available for repurchase as of June 30, 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.63%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_MrgY4vrrEUeN62nRwu-ZLA" contextRef="Duration_1_1_2022_To_6_30_2022_srt_StatementScenarioAxis_gmab_StockRepurchaseAuthorization2021Member_rWOMBYvakU6yGwmAnDi9_w" decimals="INF" format="ixt:numdotdecimal" name="gmab:SharesAvailableForRepurchase" scale="0" id="Tc_4qyHxVRPzUq9xItN0cuQKQ_4_2">500,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_MrgY4vrrEUeN62nRwu-ZLA" contextRef="Duration_1_1_2022_To_6_30_2022_srt_StatementScenarioAxis_gmab_StockRepurchaseAuthorization2019Member_xfwDxjqmW02JCqvKbHtBaQ" decimals="INF" format="ixt:numdotdecimal" name="gmab:SharesAvailableForRepurchase" scale="0" id="Tc_ep-LdCpiRkSwtgNSluQipA_4_4">206,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#x2014;</p></td></tr></table></ix:nonNumeric><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></ix:nonNumeric></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:24pt 0pt 0pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;table-layout:fixed;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td></tr><tr><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Genmab A/S</p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Tel: +45 7020 2728</p></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">Company Announcement no. 41</p></td></tr><tr><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Kalvebod Brygge 43</p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Fax: +45 7020 2729</p></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">Page 30/35</p></td></tr><tr><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">1560 Copenhagen V, Denmark</p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">www.genmab.com</p></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">CVR no. 2102 3884</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:76.47%;border:0;margin:30pt 11.76% 30pt 11.76%;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;min-height:36pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><img src="gmab-20220630xex99d1002.jpg" alt="Graphic" style="display:inline-block;height:44.99pt;left:0%;padding-bottom:0.05pt;position:relative;top:0pt;width:151.48pt;" /></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Arial Bold';font-size:9pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-size:13pt;font-weight:bold;">Interim Report for the First Half of 2022</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></div><div style="clear:both;max-width:100%;position:relative;min-height:45.04pt;"><ix:continuation id="Tb_8wFGEOrLlkS6G4ICEnJvZA_cont1"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">As announced on June 17, 2022, Genmab initiated a share buy-back program. During the first six months of 2022, Genmab acquired <ix:nonFraction unitRef="Unit_Standard_shares_MrgY4vrrEUeN62nRwu-ZLA" contextRef="Duration_1_1_2022_To_6_30_2022_dNPMG5n7t0WcNVF9KG4Bdw" decimals="INF" format="ixt:numdotdecimal" name="gmab:TreasurySharesAcquired" scale="0" id="Narr_oIFJ60l7hUGwz1hVXPwkgQ">124,000</ix:nonFraction> of its own shares, representing approximately <ix:nonFraction unitRef="Unit_Standard_pure_ydC7mNX6akalcP_kj1H8wg" contextRef="As_Of_12_31_2021_yeBwiJf1M0aAa25fFQy9Bg" decimals="3" format="ixt:numdotdecimal" name="gmab:PercentageOfShareCapitalRepurchased" scale="-2" id="Narr_GDsfVP5DbUaOn53aL1VpnQ">0.2</ix:nonFraction>% of share capital as of December 31, 2021. The total amount paid to acquire the shares, including directly attributable costs, was DKK <ix:nonFraction unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg" contextRef="Duration_1_1_2022_To_6_30_2022_dNPMG5n7t0WcNVF9KG4Bdw" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:PurchaseOfTreasuryShares" scale="6" id="Narr_Ap97m7GHZE6gnRKPjOfAAQ">270</ix:nonFraction> million and was recognized as a deduction to shareholders&#x2019; equity. During the first six months of 2021, Genmab acquired <ix:nonFraction unitRef="Unit_Standard_shares_MrgY4vrrEUeN62nRwu-ZLA" contextRef="Duration_1_1_2021_To_6_30_2021_MRS0_D_onUCNBOxf7Qx_Cw" decimals="INF" format="ixt:numdotdecimal" name="gmab:TreasurySharesAcquired" scale="0" id="Narr_jwfdPKDKx0iG21yrvStogg">200,000</ix:nonFraction> of its own shares, representing approximately <ix:nonFraction unitRef="Unit_Standard_pure_ydC7mNX6akalcP_kj1H8wg" contextRef="As_Of_12_31_2020_ccHyN2oOokuDhNdvPg9fRQ" decimals="3" format="ixt:numdotdecimal" name="gmab:PercentageOfShareCapitalRepurchased" scale="-2" id="Narr_1ZBNS4gNzkS0gLGQjGFnwA">0.3</ix:nonFraction>% of share capital as of December 31, 2020. The total amount paid to acquire the shares, including directly attributable costs, was DKK <ix:nonFraction unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg" contextRef="Duration_1_1_2021_To_6_30_2021_MRS0_D_onUCNBOxf7Qx_Cw" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:PurchaseOfTreasuryShares" scale="6" id="Narr_gkYP3vElV06OtxXwyONakQ">447</ix:nonFraction> million and was recognized as a deduction to shareholders&#x2019; equity. These shares are classified as treasury shares and are presented within retained earnings on the balance sheet as of June 30, 2022.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;">As of June 30, 2022, <ix:nonFraction unitRef="Unit_Standard_shares_MrgY4vrrEUeN62nRwu-ZLA" contextRef="Duration_1_1_2022_To_6_30_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_gmab_RestrictedStockUnitsRSUsMember_9ULLlFPCsE2o9A92MVOndw" decimals="INF" format="ixt:numdotdecimal" name="gmab:TreasurySharesAcquired" scale="0" id="Narr_hxrBqrbIKkqGdPhjByPrJw">357,885</ix:nonFraction> treasury shares were held by Genmab to cover obligations in relation to the RSU programs and to mitigate the dilutive effect of share capital increases resulting from future exercises of warrants.</p></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2022_To_6_30_2022_dNPMG5n7t0WcNVF9KG4Bdw" name="ifrs-full:DisclosureOfRelatedPartyExplanatory" id="Tb_vAX7-KJ6yU-rd5j2l8DjWw" escape="true"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="color:#029c93;font-weight:bold;">Note 6 &#x2013; Related Parties</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Genmab&#x2019;s related parties are Genmab A/S&#x2019; (parent company) subsidiaries, Board of Directors, the registered Executive Management, and close members of the family of these persons. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Genmab has not granted any loans, guarantees or other commitments to or on behalf of any of the members of the Board of Directors or members of the registered Executive Management.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Other than the remuneration and other transactions relating to the Board of Directors and the registered Executive Management described in Note&#xA0;5.1 in the Annual Report, there were no material related party transactions during the first six months of 2022.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Changes to the Executive Management Team and the Board of Directors</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">During the first six months of 2022, there were <ix:nonFraction unitRef="Unit_Standard_item_d-Yn30W8q0CdLFqZ4zWe8g" contextRef="Duration_1_1_2022_To_6_30_2022_dNPMG5n7t0WcNVF9KG4Bdw" decimals="INF" format="ixt-sec:numwordsen" name="gmab:NumberOfChangesToExecutiveManagementTeam" scale="0" id="Narr_Mxlu5INlf0GxEepzCe-o1g">two</ix:nonFraction> changes to the Executive Management Team. Effective March 1, 2022, Chris Cozic was appointed Executive Vice President and Chief People Officer, and Birgitte Stephensen was appointed Executive Vice President and Chief Legal Officer. They join the existing Executive Management Team of Jan van de Winkel, President and Chief Executive Officer, Judith Klimovsky, Executive Vice President and Chief Development Officer, Anthony Pagano, Executive Vice President and Chief Financial Officer, Anthony Mancini, Executive Vice President and Chief Operating Officer, and Tahamtan Ahmadi, Executive Vice President and Chief Medical Officer. Chris Cozic and Birgitte Stephensen are not regarded as executive managers pursuant to the Danish Companies Act and will therefore not be registered with the Danish Business Authority.&#xA0;</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Following Genmab A/S&#x2019; Annual General Meeting on March 29, 2022, the Board of Directors is comprised of <ix:nonFraction unitRef="Unit_Standard_director_1-CkTK7-YkaxWNG_tkhy7g" contextRef="Duration_3_29_2022_To_3_29_2022_ifrs-full_CategoriesOfRelatedPartiesAxis_ifrs-full_KeyManagementPersonnelOfEntityOrParentMember_wG1K_J98VEKINTE73Xhmyg" decimals="INF" format="ixt-sec:numwordsen" name="gmab:NumberOfIndependentBoardMembers" scale="0" id="Narr_C9kK-L_B2UK2gafoxTSMgw">five</ix:nonFraction> independent board members, <ix:nonFraction unitRef="Unit_Standard_director_1-CkTK7-YkaxWNG_tkhy7g" contextRef="Duration_3_29_2022_To_3_29_2022_ifrs-full_CategoriesOfRelatedPartiesAxis_ifrs-full_KeyManagementPersonnelOfEntityOrParentMember_wG1K_J98VEKINTE73Xhmyg" decimals="INF" format="ixt-sec:numwordsen" name="gmab:NumberOfNonIndependentBoardMembers" scale="0" id="Narr_sxpAjemCaEKZLRJd7zio7Q">one</ix:nonFraction> non-independent board member, and <ix:nonFraction unitRef="Unit_Standard_director_1-CkTK7-YkaxWNG_tkhy7g" contextRef="Duration_3_29_2022_To_3_29_2022_ifrs-full_CategoriesOfRelatedPartiesAxis_ifrs-full_KeyManagementPersonnelOfEntityOrParentMember_wG1K_J98VEKINTE73Xhmyg" decimals="INF" format="ixt-sec:numwordsen" name="gmab:NumberOfEmployeeElectedBoardMembers" scale="0" id="Narr_w3bD0LbdD0aJGkZzcNFhFw">three</ix:nonFraction> employee-elected board members. Deirdre P. Connelly (Chair), Pernille Erenbjerg (Deputy Chair), Rolf Hoffmann, Dr. Paolo Paoletti, and Dr. Anders Gersel Pedersen were re-elected to the Board of Directors for a <ix:nonNumeric contextRef="Duration_3_29_2022_To_3_29_2022_ifrs-full_CategoriesOfRelatedPartiesAxis_gmab_DeirdreP.ConnellyChairPernilleErenbjergDeputyChairRolfHoffmannDr.PaoloPaolettiAndDr.AndersGerselPedersenMember_3rCJQ765kUqbhPx4A2vjig" format="ixt-sec:durwordsen" name="gmab:ReElectionToBoardOfDirectorsTerm" id="Narr_eCyUHvBn00isy4hWLFntWA">one-year</ix:nonNumeric> period. Elizabeth O&#x2019;Farrell was newly elected for a <ix:nonNumeric contextRef="Duration_3_29_2022_To_3_29_2022_ifrs-full_CategoriesOfRelatedPartiesAxis_gmab_ElizabethOfarrellMember_71bO48trL0yfIoKu2bbOIw" format="ixt-sec:durwordsen" name="gmab:ElectionToBoardOfDirectorsTerm" id="Narr_Tya1cfS47kWSG6odXUMb3g">one-year</ix:nonNumeric> period. Mijke Zachariasse, Martin Schultz and Takahiro Hamatani were elected to the Board of Directors by the employees for a <ix:nonNumeric contextRef="Duration_3_29_2022_To_3_29_2022_ifrs-full_CategoriesOfRelatedPartiesAxis_gmab_MijkeZachariasseMartinSchultzAndTakahiroHamataniMember_eVcKyLWOlE-Ky0qUaYmu0Q" format="ixt-sec:durwordsen" name="gmab:ElectionToBoardOfDirectorsTerm" id="Narr_G9ZRKHb3PUmFS4w8t4w0bQ">three-year</ix:nonNumeric> period. Peter Storm Kristensen and Rima Bawarshi Nassar stepped down from the Board of Directors.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;white-space:pre-wrap;">  </i><span style="visibility:hidden;">&#x200B;</span></p></ix:nonNumeric><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:24pt 0pt 0pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;table-layout:fixed;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td></tr><tr><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Genmab A/S</p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Tel: +45 7020 2728</p></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">Company Announcement no. 41</p></td></tr><tr><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Kalvebod Brygge 43</p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Fax: +45 7020 2729</p></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">Page 31/35</p></td></tr><tr><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">1560 Copenhagen V, Denmark</p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">www.genmab.com</p></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">CVR no. 2102 3884</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:76.47%;border:0;margin:30pt 11.76% 30pt 11.76%;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;min-height:36pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><img src="gmab-20220630xex99d1002.jpg" alt="Graphic" style="display:inline-block;height:44.99pt;left:0%;padding-bottom:0.05pt;position:relative;top:0pt;width:151.48pt;" /></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Arial Bold';font-size:9pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-size:13pt;font-weight:bold;">Interim Report for the First Half of 2022</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></div><div style="clear:both;max-width:100%;position:relative;min-height:45.04pt;"><a id="_eea88b16_539f_473f_aaaa_65c5d1a58344"></a><a id="Tc_icdloPszxkGXbofqqpaJnQ_1_2"></a><a id="Tc_tEJoDjIthUKXZFW0lgvgzg_1_4"></a><a id="Tc_k6qgpDLmGUWIq_lcqZU3Fw_2_2"></a><a id="Tc_pelGIY-5ZkOq0jLP9h2nwg_2_4"></a><a id="Tc_YDgRjCzdmkmRFDVZF0T_Uw_3_0"></a><a id="Tc_wbBNzAYYo0iHkceiqt6ucA_4_0"></a><a id="Tc_lacu0O3UfkyAdM3hGSNXKw_5_0"></a><a id="Tc_F69pphjNdk-2gijTvh25ng_6_0"></a><a id="Tc_-27uiu7IWU2_XDH1JDpb6w_8_0"></a><a id="Tc_h1p23OpkaE2K9mptYlN1Gg_10_0"></a><a id="Tc_5bdpPamCRk2RNRQUJHY1Eg_11_0"></a><a id="Tc_FoLNSE7uiUO2hem-KyoDbg_12_0"></a><a id="Tc_tFxB0mwssEa8BTy_rfM7HQ_14_0"></a><a id="_5ba61620_18d0_4dbe_8987_589f9385ba49"></a><a id="Tc_Nk88TkUYXUGK9rbBcShf7A_1_2"></a><a id="Tc_sSLyL34aB0ubkLDAvfP2rQ_1_4"></a><a id="Tc_uijd0ZJjj0SVlJMyeiB0NA_2_2"></a><a id="Tc_rYnWIV8qjE-TBYw26fuytA_2_4"></a><a id="Tc_8a-t6JQh10Gil46e9FrXKA_3_0"></a><a id="Tc_Undzy3I4fUm5FjW6lAN1IQ_4_0"></a><a id="Tc_Hn2NmWEdGUWStKNtktE5CQ_5_0"></a><a id="Tc_DBA326C5-02owmXOIFNdhA_6_0"></a><a id="Tc_pvPbmMCYJUa4jxJMST6EPg_8_0"></a><a id="Tc_pBYQaE1Enk6umWPiSKK-Cw_10_0"></a><a id="Tc_7yf-WWyYRE6Q-i0Cy-lh-w_11_0"></a><a id="Tc_haxizmuNw0-HoyvybnZYHw_11_2"></a><ix:nonNumeric contextRef="Duration_1_1_2022_To_6_30_2022_dNPMG5n7t0WcNVF9KG4Bdw" name="ifrs-full:DisclosureOfLeasesExplanatory" id="Tb_xHNOF0510Eevvp8NFxSHmQ" continuedAt="Tb_xHNOF0510Eevvp8NFxSHmQ_cont1" escape="true"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="color:#029c93;font-weight:bold;">Note 7 &#x2013; Leases</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Amounts recognized in the balance sheet</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p><ix:nonNumeric contextRef="Duration_1_1_2022_To_6_30_2022_dNPMG5n7t0WcNVF9KG4Bdw" name="gmab:DisclosureOfBalanceSheetInformationRelatingToLeasesTableTextBlock" id="Tb_bBA3B06pPUeV7V4al21XaA" escape="true"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">The balance sheet shows the following amounts relating to leases:</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="color:#029c93;font-weight:bold;visibility:hidden;">&#x200B;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:57.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:17.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:17.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:57.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#xA0;&#xA0;&#xA0;&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.5%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">June 30,</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#xA0;&#xA0;&#xA0;&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.47%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">December&#xA0;31,&#xA0;</p></td></tr><tr><td style="vertical-align:bottom;width:57.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.5%;background:#e6e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">2021</p></td></tr><tr><td style="vertical-align:bottom;width:57.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">(DKK million)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.5%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.47%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:57.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Right-of-use assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.5%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#xA0;&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.47%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#xA0;&#xA0;</p></td></tr><tr><td style="vertical-align:bottom;width:57.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Properties</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.5%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg" contextRef="As_Of_6_30_2022_ifrs-full_ClassesOfAssetsAxis_gmab_PropertiesMember_fzUIN40VJUem2qiuz7q2TQ" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:RightofuseAssets" scale="6" id="Tc_IMvhQTyRrUKp-pIoUisq_A_5_2">553</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.47%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg" contextRef="As_Of_6_30_2021_ifrs-full_ClassesOfAssetsAxis_gmab_PropertiesMember_Dk9Hxplwdkeo6iuYxEh2kg" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:RightofuseAssets" scale="6" id="Tc_ckAqwMJB4EWoVE3dhNBo0A_5_4">352</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:57.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.5%;background:#e6e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg" contextRef="As_Of_6_30_2022_ifrs-full_ClassesOfAssetsAxis_gmab_IfrsEquipmentMember_24WDaUkWB0CzmGMa-Eqrcg" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:RightofuseAssets" scale="6" id="Tc_3AHmAaDnRUmKLsgcQrnOkg_6_2">1</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg" contextRef="As_Of_6_30_2021_ifrs-full_ClassesOfAssetsAxis_gmab_IfrsEquipmentMember_JPHlDxvGukWnsD4CjDhIbQ" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:RightofuseAssets" scale="6" id="Tc_g3LmZwvDdUuZHN5kDg2mxw_6_4">2</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:57.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.5%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.47%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:57.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total right-of-use assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.5%;background:#e6e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg" contextRef="As_Of_6_30_2022_kBUEJjmpl0mHNogMyIvzJg" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:RightofuseAssets" scale="6" id="Tc_6l2PBYe7nUC32P6pmDb8Vg_8_2">554</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg" contextRef="As_Of_6_30_2021_eEXLsHGqbE20an7xlGLjnw" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:RightofuseAssets" scale="6" id="Tc_pku0n_yZeEKVqtWbyRNvyg_8_4">354</ix:nonFraction></b></p></td></tr><tr><td style="vertical-align:bottom;width:57.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.5%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.47%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:57.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Lease liabilities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.5%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.47%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:57.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Current</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.5%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg" contextRef="As_Of_6_30_2022_kBUEJjmpl0mHNogMyIvzJg" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:CurrentLeaseLiabilities" scale="6" id="Tc_Bfrxn_mSdkKV2aNEen5HMA_11_2">80</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.47%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg" contextRef="As_Of_6_30_2021_eEXLsHGqbE20an7xlGLjnw" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:CurrentLeaseLiabilities" scale="6" id="Tc_W3h9nUX9wkC6ZMAqhTrGOg_11_4">62</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:57.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Non-current</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.5%;background:#e6e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg" contextRef="As_Of_6_30_2022_kBUEJjmpl0mHNogMyIvzJg" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:NoncurrentLeaseLiabilities" scale="6" id="Tc_bNkm3wEO70qtbPDjTOxIEg_12_2">554</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg" contextRef="As_Of_6_30_2021_eEXLsHGqbE20an7xlGLjnw" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:NoncurrentLeaseLiabilities" scale="6" id="Tc_eLscrGqOP0-r83q-J_XfbA_12_4">363</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:57.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.5%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.47%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:57.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total lease liabilities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.5%;background:#e6e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg" contextRef="As_Of_6_30_2022_kBUEJjmpl0mHNogMyIvzJg" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:LeaseLiabilities" scale="6" id="Tc_RBwatGppJUWisNElSxzTgA_14_2">634</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg" contextRef="As_Of_6_30_2021_eEXLsHGqbE20an7xlGLjnw" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:LeaseLiabilities" scale="6" id="Tc_pid4gnMfKk-j1ZXTPFSkXg_14_4">425</ix:nonFraction></b></p></td></tr></table></ix:nonNumeric><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">During the first six months of 2022, there were additions to Genmab&#x2019;s right-of-use assets and lease liabilities related to the commencement of leases in the Netherlands with respect to office and laboratory space. During the first six months of 2021, there were additions to Genmab&#x2019;s right-of-use assets and lease liabilities related to the commencement of a lease in Japan with respect to office space.<span style="font-family:'Times New Roman','Times','serif';font-size:12pt;"> </span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> <span style="visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Significant leases not yet commenced</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">During 2020, Genmab entered into a lease agreement with respect to the new headquarters in Denmark with a commencement date in March 2023 and is non-cancellable until March 2038. The total future minimum payments over the term of the lease are approximately DKK <ix:nonFraction unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg" contextRef="As_Of_6_30_2022_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_gmab_OfficeAndLaboratorySpaceMember_srt_StatementGeographicalAxis_country_DK_B5VFPCgUJ0SOaI0R2W2tew" decimals="-6" format="ixt:numdotdecimal" name="gmab:FutureMinimumOperatingLeasePayments" scale="6" id="Narr_8XlJfrRKQkiPtpLRZvj1hg">339</ix:nonFraction> million and estimated capital expenditures to fit out the space are approximately DKK <ix:nonFraction unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg" contextRef="As_Of_6_30_2022_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_gmab_OfficeAndLaboratorySpaceMember_srt_StatementGeographicalAxis_country_DK_B5VFPCgUJ0SOaI0R2W2tew" decimals="-6" format="ixt:numdotdecimal" name="gmab:EstimatedCapitalExpenditureForLease" scale="6" id="Narr_C4sZdSx_GkKBt1VDSnDwxw">40</ix:nonFraction> million.<span style="font-family:'Times New Roman','Times','serif';font-size:12pt;"> </span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Amounts recognized in the statement of comprehensive income</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p><ix:nonNumeric contextRef="Duration_1_1_2022_To_6_30_2022_dNPMG5n7t0WcNVF9KG4Bdw" name="gmab:DisclosureOfComprehensiveInformationRelatingToLeasesTableTextBlock" id="Tb_RxIr6qVlo0SU7FoD7tpk3A" continuedAt="Tb_RxIr6qVlo0SU7FoD7tpk3A_cont1" escape="true"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">The statement of comprehensive income shows the following amounts relating to leases:</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:51.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:20.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:21.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.07%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.41%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">6 Months Ended</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.07%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.92%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">6 Months Ended</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.07%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';">&#xA0;&#xA0;&#xA0;&#xA0;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.41%;background:#e6e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">June 30, 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.07%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';">&#xA0;&#xA0;&#xA0;&#xA0;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">June 30, 2021</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">(DKK million)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.07%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.41%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.07%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.92%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Depreciation charge of right-of-use assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.07%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.41%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.07%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.92%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Properties</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.07%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.41%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg" contextRef="Duration_1_1_2022_To_6_30_2022_ifrs-full_ClassesOfAssetsAxis_gmab_PropertiesMember_F5LrRJJceEih2g5m7wb9GA" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:DepreciationRightofuseAssets" scale="6" id="Tc_l3ECn8HpeUeuR8IYqP-1Og_5_2">30</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.07%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.92%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg" contextRef="Duration_1_1_2021_To_6_30_2021_ifrs-full_ClassesOfAssetsAxis_gmab_PropertiesMember_G2NwEm7nQ0Kw6dT7ZkwBrQ" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:DepreciationRightofuseAssets" scale="6" id="Tc_trp1hg-NakOeT_J2UtxZeg_5_4">25</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.07%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.41%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg" contextRef="Duration_1_1_2022_To_6_30_2022_ifrs-full_ClassesOfAssetsAxis_gmab_IfrsEquipmentMember_2Uc8kxVSSEeedQs5j0GsVg" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:DepreciationRightofuseAssets" scale="6" id="Tc_8-fqDRt6Uk-SUzhut2V6Pg_6_2">1</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.07%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg" contextRef="Duration_1_1_2021_To_6_30_2021_ifrs-full_ClassesOfAssetsAxis_gmab_IfrsEquipmentMember_kM-fqB65HkSiWDPm7nBJiQ" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:DepreciationRightofuseAssets" scale="6" id="Tc_-s3gjfG6g0KU1ifMZI8_KQ_6_4">1</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.07%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.41%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.07%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.92%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total depreciation charge of right-of-use assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.07%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.41%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg" contextRef="Duration_1_1_2022_To_6_30_2022_dNPMG5n7t0WcNVF9KG4Bdw" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:DepreciationRightofuseAssets" scale="6" id="Tc_8DHvSUZgjkyjoSgleVG7eQ_8_2">31</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.07%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg" contextRef="Duration_1_1_2021_To_6_30_2021_MRS0_D_onUCNBOxf7Qx_Cw" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:DepreciationRightofuseAssets" scale="6" id="Tc_Pd2BPJEX9U28wZNiE1guHQ_8_4">26</ix:nonFraction></b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.07%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.41%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.07%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.92%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Interest expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.07%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.41%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg" contextRef="Duration_1_1_2022_To_6_30_2022_dNPMG5n7t0WcNVF9KG4Bdw" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:InterestExpenseOnLeaseLiabilities" scale="6" id="Tc_l_-wofoBcUuQO9ko1RObLw_10_2">7</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.07%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.92%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg" contextRef="Duration_1_1_2021_To_6_30_2021_MRS0_D_onUCNBOxf7Qx_Cw" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:InterestExpenseOnLeaseLiabilities" scale="6" id="Tc_QvE5tELjEkC5-VMjt9p1Sw_10_4">6</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Expense relating to short-term leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.07%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.41%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#x2014;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.07%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.92%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg" contextRef="Duration_1_1_2021_To_6_30_2021_MRS0_D_onUCNBOxf7Qx_Cw" decimals="-6" format="ixt:numdotdecimal" name="ifrs-full:ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed" scale="6" id="Tc_mV3bSlNbsUCFHLSkK4TnAg_11_4">1</ix:nonFraction></p></td></tr></table></ix:nonNumeric></ix:nonNumeric></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:24pt 0pt 0pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;table-layout:fixed;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td></tr><tr><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Genmab A/S</p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Tel: +45 7020 2728</p></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">Company Announcement no. 41</p></td></tr><tr><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Kalvebod Brygge 43</p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Fax: +45 7020 2729</p></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">Page 32/35</p></td></tr><tr><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">1560 Copenhagen V, Denmark</p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">www.genmab.com</p></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">CVR no. 2102 3884</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:76.47%;border:0;margin:30pt 11.76% 30pt 11.76%;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;min-height:36pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><img src="gmab-20220630xex99d1002.jpg" alt="Graphic" style="display:inline-block;height:44.99pt;left:0%;padding-bottom:0.05pt;position:relative;top:0pt;width:151.48pt;" /></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Arial Bold';font-size:9pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-size:13pt;font-weight:bold;">Interim Report for the First Half of 2022</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></div><div style="clear:both;max-width:100%;position:relative;min-height:45.04pt;"><ix:continuation id="Tb_xHNOF0510Eevvp8NFxSHmQ_cont1"><ix:continuation id="Tb_RxIr6qVlo0SU7FoD7tpk3A_cont1"></ix:continuation><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Interest expense is included in net financial items and expenses relating to short-term leases are included in operating expenses in the statement of comprehensive income.</p></ix:continuation><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p><ix:nonNumeric contextRef="Duration_1_1_2022_To_6_30_2022_dNPMG5n7t0WcNVF9KG4Bdw" name="ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory" id="Tb_I7iVrujR0ESFxtvYGdwfjw" escape="true"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="color:#029c93;font-weight:bold;">Note 8 - Subsequent Events to the Balance Sheet Date</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">No events have occurred subsequent to the balance sheet date that could significantly affect the financial statements as of June 30, 2022.</p></ix:nonNumeric><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:24pt 0pt 0pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;table-layout:fixed;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td></tr><tr><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Genmab A/S</p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Tel: +45 7020 2728</p></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">Company Announcement no. 41</p></td></tr><tr><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Kalvebod Brygge 43</p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Fax: +45 7020 2729</p></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">Page 33/35</p></td></tr><tr><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">1560 Copenhagen V, Denmark</p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">www.genmab.com</p></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">CVR no. 2102 3884</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:76.47%;border:0;margin:30pt 11.76% 30pt 11.76%;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;min-height:36pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><img src="gmab-20220630xex99d1002.jpg" alt="Graphic" style="display:inline-block;height:44.99pt;left:0%;padding-bottom:0.05pt;position:relative;top:0pt;width:151.48pt;" /></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Arial Bold';font-size:9pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-size:13pt;font-weight:bold;">Interim Report for the First Half of 2022</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></div><div style="clear:both;max-width:100%;position:relative;min-height:45.04pt;"><a id="_e1a00437_b5b9_4945_8b08_bff649e44f80"></a><a id="_Toc16514653"></a><a id="ABOUTGENMAB_556806"></a><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;font-weight:bold;padding-left:21.6pt;text-indent:-21.6pt;margin:0pt 0pt 3pt 0pt;"><b style="color:#029c93;font-weight:bold;">ABOUT GENMAB</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt;"><i style="font-size:7.5pt;font-style:italic;">Genmab is an international biotechnology company with a core purpose to improve the lives of people with cancer. For more than 20 years, Genmab&#x2019;s vision to transform cancer treatment has driven its passionate, innovative and collaborative teams to invent next-generation antibody technology platforms and leverage translational research and data sciences, fueling multiple differentiated cancer treatments that make an impact on people&#x2019;s lives. To develop and deliver novel therapies to patients, Genmab has formed 20+ strategic partnerships with biotechnology and pharmaceutical companies. Genmab&#x2019;s proprietary pipeline includes bispecific T-cell engagers, next-generation immune checkpoint modulators, effector function enhanced antibodies and antibody-drug conjugates.</i></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt;"><i style="font-size:7.5pt;font-style:italic;"> </i><span style="font-size:7.5pt;font-style:italic;visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt;"><i style="font-size:7.5pt;font-style:italic;">Genmab is headquartered in Copenhagen, Denmark with locations in Utrecht, the Netherlands, Princeton, New Jersey, U.S. and Tokyo, Japan. For more information, please visit </i><i style="color:#029c93;font-size:7.5pt;font-style:italic;">Genmab.com</i><i style="font-size:7.5pt;font-style:italic;"> and follow us on </i><i style="color:#029c93;font-size:7.5pt;font-style:italic;">Twitter.com/Genmab</i><i style="font-size:7.5pt;font-style:italic;">.</i></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;font-style:italic;visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt;"><i style="font-size:7.5pt;font-style:italic;">This Interim Report contains forward looking statements. The words &#x201C;believe&#x201D;, &#x201C;expect&#x201D;, &#x201C;anticipate&#x201D;, &#x201C;intend&#x201D; and &#x201C;plan&#x201D; and similar expressions identify forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with pre-clinical and clinical development of products, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products or technologies obsolete, and other factors. For a further discussion of these risks, please refer to the risk management sections in Genmab&#x2019;s most recent financial reports, which are available on </i><i style="color:#029c93;font-size:7.5pt;font-style:italic;">www.genmab.com</i><i style="font-size:7.5pt;font-style:italic;"> and the risk factors included in Genmab&#x2019;s most recent Annual Report on Form 20-F and other filings with the U.S. Securities and Exchange Commission (SEC), which are available at </i><i style="color:#029c93;font-size:7.5pt;font-style:italic;">www.sec.gov</i><i style="font-size:7.5pt;font-style:italic;">. Genmab does not undertake any obligation to update or revise forward looking statements in this Interim Report nor to confirm such statements to reflect subsequent events or circumstances after the date made or in relation to actual results, unless required by law. </i></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;font-style:italic;visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7pt;margin:0pt;"><i style="font-size:8pt;font-style:italic;">Genmab A/S and/or its subsidiaries own the following trademarks: Genmab</i><sup style="font-size:6pt;font-style:italic;line-height:100%;top:0pt;vertical-align:top;">&#xAE;</sup><i style="font-size:8pt;font-style:italic;">; the Y-shaped Genmab logo</i><sup style="font-size:6pt;font-style:italic;line-height:100%;top:0pt;vertical-align:top;">&#xAE;</sup><i style="font-size:8pt;font-style:italic;">; Genmab in combination with the </i><i style="font-size:7.5pt;font-style:italic;">Y-shaped Genmab logo</i><sup style="font-size:5.62pt;font-style:italic;line-height:100%;top:0pt;vertical-align:top;">&#xAE;</sup><i style="font-size:7.5pt;font-style:italic;">; HuMax&#xAE;; DuoBody</i><sup style="font-size:5.62pt;font-style:italic;line-height:100%;top:0pt;vertical-align:top;">&#xAE;</sup><i style="font-size:7.5pt;font-style:italic;">; DuoBody in combination with the DuoBody logo</i><sup style="font-size:5.62pt;font-style:italic;line-height:100%;top:0pt;vertical-align:top;">&#xAE;</sup><i style="font-size:7.5pt;font-style:italic;">; HexaBody</i><sup style="font-size:5.62pt;font-style:italic;line-height:100%;top:0pt;vertical-align:top;">&#xAE;</sup><i style="font-size:7.5pt;font-style:italic;">; HexaBody in combination with the HexaBody logo</i><sup style="font-size:5.62pt;font-style:italic;line-height:100%;top:0pt;vertical-align:top;">&#xAE;</sup><i style="font-size:7.5pt;font-style:italic;">; DuoHexaBody</i><sup style="font-size:5.62pt;font-style:italic;line-height:100%;top:0pt;vertical-align:top;">&#xAE;</sup><i style="font-size:7.5pt;font-style:italic;">; and HexElect</i><sup style="font-size:5.62pt;font-style:italic;line-height:100%;top:0pt;vertical-align:top;">&#xAE;</sup><i style="font-size:7.5pt;font-style:italic;">. </i><i style="font-size:8pt;font-style:italic;">Tivdak</i><sup style="font-size:6pt;font-style:italic;line-height:100%;top:0pt;vertical-align:top;">&#xAE;</sup><i style="font-size:8pt;font-style:italic;"> is a trademark of Seagen Inc.;</i><span style="font-size:10pt;"> </span><i style="font-size:8pt;font-style:italic;">EPCORE&#x2122; is a trademark of AbbVie Biotechnology Ltd.; </i><i style="font-size:7.5pt;font-style:italic;">Kesimpta</i><sup style="font-size:5.62pt;font-style:italic;line-height:100%;top:0pt;vertical-align:top;">&#xAE;</sup><i style="font-size:7.5pt;font-style:italic;"> and Sensoready</i><sup style="font-size:5.62pt;font-style:italic;line-height:100%;top:0pt;vertical-align:top;">&#xAE;</sup><i style="font-size:7.5pt;font-style:italic;"> are trademarks of Novartis AG or its affiliates; DARZALEX</i><sup style="font-size:5.62pt;font-style:italic;line-height:100%;top:0pt;vertical-align:top;">&#xAE;</sup><i style="font-size:7.5pt;font-style:italic;">, DARZALEX FASPRO</i><sup style="font-size:5.62pt;font-style:italic;line-height:100%;top:0pt;vertical-align:top;">&#xAE;</sup><i style="font-size:7.5pt;font-style:italic;"> and RYBREVANT</i><sup style="font-size:5.62pt;font-style:italic;line-height:100%;top:0pt;vertical-align:top;">&#xAE;</sup><i style="font-size:7.5pt;font-style:italic;"> are trademarks of Johnson &amp; Johnson; TEPEZZA</i><sup style="font-size:5.62pt;font-style:italic;line-height:100%;top:0pt;vertical-align:top;">&#xAE;</sup><i style="font-size:7.5pt;font-style:italic;"> is a trademark of Horizon Therapeutics Ireland DAC. </i></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;font-style:italic;visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;font-style:italic;visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:7.5pt;font-style:italic;visibility:hidden;">&#x200B;</span></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:24pt 0pt 0pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;table-layout:fixed;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td></tr><tr><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Genmab A/S</p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Tel: +45 7020 2728</p></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">Company Announcement no. 41</p></td></tr><tr><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Kalvebod Brygge 43</p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Fax: +45 7020 2729</p></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">Page 34/35</p></td></tr><tr><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">1560 Copenhagen V, Denmark</p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">www.genmab.com</p></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">CVR no. 2102 3884</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:76.47%;border:0;margin:30pt 11.76% 30pt 11.76%;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;min-height:36pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><img src="gmab-20220630xex99d1002.jpg" alt="Graphic" style="display:inline-block;height:44.99pt;left:0%;padding-bottom:0.05pt;position:relative;top:0pt;width:151.48pt;" /></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Arial Bold';font-size:9pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-size:13pt;font-weight:bold;">Interim Report for the First Half of 2022</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#x200B;</span></p></div><div style="clear:both;max-width:100%;position:relative;min-height:45.04pt;"><a id="_7e633bb9_4fe4_4663_afa6_fa51378402f5"></a><a id="_Toc16514654"></a><a id="DIRECTORSANDMANAGEMENTSSTATEMENTONTHEINT"></a><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;font-weight:bold;text-indent:0pt;margin:0pt 0pt 3pt 0pt;"><b style="color:#029c93;font-weight:bold;">DIRECTORS&#x2019; AND MANAGEMENT&#x2019;S STATEMENT ON THE INTERIM REPORT</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:11.0pt;text-indent:0pt;margin:0pt 36pt 11pt 0pt;">The Board of Directors and the registered members of Executive Management have today considered and adopted the unaudited interim report of the Genmab group for the six months ended June 30, 2022.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:11.0pt;text-indent:0pt;margin:0pt 36pt 11pt 0pt;">The interim report is prepared in accordance with IAS 34, &#x201C;Interim Financial Reporting,&#x201D; as issued by the IASB and in accordance with IAS 34 as endorsed by the EU, and additional Danish disclosure requirements for interim reports of listed companies.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:11.0pt;text-indent:0pt;margin:0pt 36pt 11pt 0pt;">We consider the applied accounting policies to be appropriate and, in our opinion, the interim report gives a true and fair view of the assets and liabilities, financial position, results of operation and cash flows of the group.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:11.0pt;text-indent:0pt;margin:0pt 36pt 11pt 0pt;">Furthermore, we consider the Management&#x2019;s Review to give a true and fair account of the development in the group&#x2019;s activities and financial affairs, results of operations and the group&#x2019;s financial position as a whole as well as a description of the significant risks and uncertainties which the group faces, as further described in our 2021 Annual Report and the Form 20-F filed with the U.S. Securities and Exchange Commission in February 2022.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Copenhagen, August 10, 2022</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;font-style:italic;font-weight:bold;text-indent:0pt;margin:12pt 0pt 3pt 0pt;"><b style="color:#029c93;font-style:normal;font-weight:bold;">Registered Members of Executive Management</b></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1.25pt;"><td style="vertical-align:bottom;width:19.4%;margin:0pt;padding:0pt;"><div style="height:1.25pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td colspan="2" style="vertical-align:bottom;width:18.49%;margin:0pt;padding:0pt;"><div style="height:1.25pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td colspan="2" style="vertical-align:bottom;width:17.58%;margin:0pt;padding:0pt;"><div style="height:1.25pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td colspan="2" style="vertical-align:top;width:19.45%;margin:0pt;padding:0pt;"><div style="height:1.25pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td colspan="2" style="vertical-align:bottom;width:25.06%;margin:0pt;padding:0pt;"><div style="height:1.25pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td></tr><tr style="height:14.7pt;"><td colspan="2" style="vertical-align:bottom;width:20%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><img src="gmab-20220630xex99d1008.jpg" alt="Graphic" style="display:inline-block;height:30.25pt;width:60.6pt;" /></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td colspan="2" style="vertical-align:bottom;width:20%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><img src="gmab-20220630xex99d1009.jpg" alt="Graphic" style="display:inline-block;height:31.41pt;left:0%;padding-bottom:0.1pt;position:relative;top:0pt;width:82.2pt;" /></p></td><td colspan="2" style="vertical-align:bottom;width:20%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><img src="gmab-20220630xex99d1010.jpg" alt="Graphic" style="display:inline-block;height:29.05pt;width:49.8pt;" /></p></td><td colspan="2" style="vertical-align:bottom;width:20%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><img src="gmab-20220630xex99d1011.jpg" alt="Graphic" style="display:inline-block;height:32.31pt;left:0%;padding-bottom:0.7pt;position:relative;top:0pt;width:76.2pt;" /></p></td><td style="vertical-align:bottom;width:20%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><img src="gmab-20220630xex99d1012.jpg" alt="Graphic" style="display:inline-block;height:27.02pt;width:69.6pt;" /></p></td></tr><tr style="height:14.7pt;"><td colspan="2" style="vertical-align:bottom;width:20%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Jan van de Winkel</p></td><td colspan="2" style="vertical-align:bottom;width:20%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Anthony Pagano</p></td><td colspan="2" style="vertical-align:bottom;width:20%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Judith Klimovsky</p></td><td colspan="2" style="vertical-align:bottom;width:20%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Anthony Mancini</p></td><td style="vertical-align:bottom;width:20%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Tahamtan Ahmadi</p></td></tr><tr style="height:13.95pt;"><td colspan="2" style="vertical-align:top;width:20%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">(President &amp; CEO)</p></td><td colspan="2" style="vertical-align:bottom;width:20%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">(Executive Vice President &amp; CFO)</p></td><td colspan="2" style="vertical-align:bottom;width:20%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">(Executive Vice President &amp; CDO)</p></td><td colspan="2" style="vertical-align:bottom;width:20%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">(Executive Vice President &amp; COO)</p></td><td style="vertical-align:top;width:20%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">(Executive Vice President &amp; CMO)</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;font-style:italic;font-weight:bold;padding-left:28.8pt;text-indent:-28.8pt;margin:12pt 0pt 3pt 0pt;"><b style="color:#029c93;font-style:normal;font-weight:bold;">Board of Directors</b></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:3.4pt;"><td style="vertical-align:bottom;width:33.32%;margin:0pt;padding:0pt;"><div style="height:3.4pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;width:33.32%;margin:0pt;padding:0pt;"><div style="height:3.4pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;width:33.35%;margin:0pt;padding:0pt;"><div style="height:3.4pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:33.32%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:33.32%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:33.35%;margin:0pt;padding:0pt;"></td></tr><tr style="height:27.4pt;"><td style="vertical-align:bottom;width:33.32%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><img src="gmab-20220630xex99d1013.jpg" alt="Graphic" style="display:inline-block;height:27.65pt;left:0%;padding-bottom:0pt;position:relative;top:0pt;width:49.2pt;" /></p></td><td style="vertical-align:bottom;width:33.32%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><img src="gmab-20220630xex99d1014.jpg" alt="Graphic" style="display:inline-block;height:20pt;width:69pt;" /></p></td><td style="vertical-align:bottom;width:33.35%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><img src="gmab-20220630xex99d1015.jpg" alt="Graphic" style="display:inline-block;height:21pt;width:102pt;" /></p></td></tr><tr><td style="vertical-align:bottom;width:33.32%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Deirdre P. Connelly</p></td><td style="vertical-align:bottom;width:33.32%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Pernille Erenbjerg </p></td><td style="vertical-align:bottom;width:33.35%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Anders Gersel Pedersen</p></td></tr><tr><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">(Chair)</p></td><td style="vertical-align:bottom;width:33.32%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">(Deputy Chair)</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:33.35%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:33.32%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><img src="gmab-20220630xex99d1016.jpg" alt="Graphic" style="display:inline-block;height:28.03pt;left:0%;padding-bottom:0.5pt;position:relative;top:0pt;width:97.2pt;" /></p></td><td style="vertical-align:bottom;width:33.32%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><img src="gmab-20220630xex99d1017.jpg" alt="Graphic" style="display:inline-block;height:28pt;left:0%;padding-bottom:0.5pt;position:relative;top:0pt;width:58pt;" /></p></td><td style="vertical-align:bottom;width:33.35%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><img src="gmab-20220630xex99d1018.jpg" alt="Graphic" style="display:inline-block;height:27.79pt;left:0%;padding-bottom:0.75pt;position:relative;top:0pt;width:102pt;" /></p></td></tr><tr><td style="vertical-align:bottom;width:33.32%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:33.32%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:33.35%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:33.32%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Rolf Hoffmann</p></td><td style="vertical-align:bottom;width:33.32%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Paolo Paoletti</p></td><td style="vertical-align:bottom;width:33.35%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Elizabeth O&#x2019;Farrell</p></td></tr><tr style="height:29.2pt;"><td style="vertical-align:bottom;width:33.32%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><img src="gmab-20220630xex99d1019.jpg" alt="Graphic" style="display:inline-block;height:33pt;width:71pt;" /></p></td><td style="vertical-align:bottom;width:33.32%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><img src="gmab-20220630xex99d1020.jpg" alt="Graphic" style="display:inline-block;height:25.41pt;left:0%;padding-bottom:0.1pt;position:relative;top:0pt;width:104.4pt;" /></p></td><td style="vertical-align:bottom;width:33.35%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><img src="gmab-20220630xex99d1021.jpg" alt="Graphic" style="display:inline-block;height:25.8pt;left:0%;padding-bottom:0pt;position:relative;top:0pt;width:46.18pt;" /></p></td></tr><tr><td style="vertical-align:bottom;width:33.32%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:33.32%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:33.35%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:33.32%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Mijke Zachariasse</p></td><td style="vertical-align:bottom;width:33.32%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Takahiro Hamatani</p></td><td style="vertical-align:bottom;width:33.35%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Martin Schultz</p></td></tr><tr><td style="vertical-align:bottom;width:33.32%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">(Employee elected)</p></td><td style="vertical-align:bottom;width:33.32%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">(Employee elected)</p></td><td style="vertical-align:bottom;width:33.35%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">(Employee elected)</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:24pt 0pt 0pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;table-layout:fixed;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td></tr><tr><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Genmab A/S</p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Tel: +45 7020 2728</p></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">Company Announcement no. 41</p></td></tr><tr><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Kalvebod Brygge 43</p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Fax: +45 7020 2729</p></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">Page 35/35</p></td></tr><tr><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">1560 Copenhagen V, Denmark</p></td><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">www.genmab.com</p></td><td style="vertical-align:top;width:33.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">CVR no. 2102 3884</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:avoid;width:76.47%;border:0;"></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>gmab-20220630xex99d1016.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gmab-20220630xex99d1016.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1"  Y ,,# 2(  A$! Q$!_\0
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MC;Y\J$8!/5CW)]R>:T,C'6L';H M%)2T %%%% !1110 4444 %%%% !1110
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M6NDGU.]1;;P]IUP]WJJQ*+S4),$6JD??;L7/.U?QZ"O/KNZNO$_QAM[:T/\
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J24>P#@,"@4"EK- %%%%, HHHH **** "BBB@ HHHH **** "BBB@#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>gmab-20220630xex99d1014.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gmab-20220630xex99d1014.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1"  H (H# 2(  A$! Q$!_\0
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M/:SH$T5S<S-EHK2ZA*RQRD'EX6P&&>2K$<,#CG8/B)H'B'4+?[3X/:;Q5-&
M&CDBA@N"1C,=P[KO! &%(W@$ J*[-?AE<0:]9ZO%XGU22YA_=2B[2"5;FW)Y
MADPBDJ#D@YRI)(/)!U=6^&/A'7MW]H>&=)O"S&0M+91D[CQNSC.<=^M6I4XZ
M,EQDSDI?AIJ>N:4VG-'#X7TZ8.LL=K?W%W.%8$$ L5C!.3U5P..#BKNHZ;J?
MPSTS3I]-URZU#2X;BTL7TW5=DA,<DL<.4FPK*5#[OF+ [<<9S4L7P;M-)O!<
MZ%KNN:,0P(@6^>XA [J$E+  \<#@8X KK6T".^T)M+U=O[9ADB,<[7**/.'J
M0H ';H!R,]:F4]E?0:B^QJ \5S^F^-='UCQ7J?A^TG\W4=-BCFN!M^0!BRX#
M="RE?F ^[N4'!-9L/PU:",6__"4>(9-/' M'O5/R?W?,V>:1VSOS[U#XE^'X
MMM+TVX\*10:9K&AJYTZ,#;#*C8,EO(.Z2X&6ZA@K9)&#FE'9LIN6]CN\T=:Q
M/"?B:U\7Z!::I:J\<<P(>&08>&125DC<=F5@RGW!K;'%0U;1EIW%HHHH&%%%
M% !1110 4444 %%%% "4M%% !1110 4TKFBB@#SJRDC\'?%V72XRZ67B>VDU
E&.()\D=Y"568@XP#)&\;$>L1/5C7HIHHK2?1D1ZCJ***S+/_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>gmab-20220630xex99d1006.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gmab-20220630xex99d1006.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" &5 Z@# 2(  A$! Q$!_\0
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M#>"KN2PC80P1,T+PHB?:C(2JL6<^6P<A0., 'Z"R:A;0W45M)<1)<2@F.)G
M=P.N!U./:JM_XDTG2KE+>]U.SM+AP"L4]PB.V3@8!()K\Z_@M\2-4^)O[37P
M,U?7OB3!XUUZZT74[B^TA+*VMVT.9@H:V(A56^4@C$F6^4G."*E_;<CT*X_:
MHN;?7+_X8V$<W@N".*7XF6\TT*L;BX^:V\L@B0<'//;B@#]( P(R.:.M?FOX
M4_:$^(7PA^ OPNN-#341I'B;PQ+X>T.ROK=+AXM>2X6.WN/,* F&6-RZ*W&V
M+[O7/Z*>%;74+'PWI=OJU\VIZG%;1I=7KQK&9Y0HWN54!1DY.  * -6BBB@
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M(.&4D'!!'X5^:WP_^(?B#QSXC^"7B+QCX[U&%K/7=;T>.Z\R-DN=L.;>*1S
MGF-(#LWE$+JV<#-:<OQN\2:)X(\$VNO^/;[X5^&9]+U6\MM7T;3H$%_JD=[*
M(K5OW#*@V@'8 #)SR>: /T@W#UI=PSC-?FSXI^.'QJUW3=<O=0\5:SX.U/1?
MAM;^*3IVGVD,:2WPF*@R*\;,%==K,BD=<<"M$?M+^.;?XY>$_P"TO%VI:C#J
M:Z5M\.Z))';SQ">!6EWV$]I_I,1<D^?%,-@X'2@#]%0<TM-4Y'I3J "BBB@
MHHHH *S=9\2Z3X=^S?VKJ=GIOVF00P?:[A(O-<]%7<1N/L.:TJ^-/^"C7@^7
MQS9_#?3+="UV-1N[NV95)*SPV_FQD8YSE,#ZT ?6\'BC1[G6I]'AU6REU:!!
M)+8)<H9XU/0M&#N ]R*TMX]:_)#X=^,O'MGXL\5_&+2M.N+3Q?XE\*RWR1F(
MW4EG EV(2XC*_,R1JS;<'.,G.*]23]H#QK_PA_Q#B\*?%>]\1>#=/33)+3QQ
MK%J08[B8_P"EV9NH;9A$!VE:(B(G!/2@#]&Y+B*+9OD5-[;5W,!D^@]35;5]
M:T_0-/EOM3O;?3K*+!DN;N98HTR<#+,0!S[U^:B?$B_^(4'P*\1^(/&7BG2=
M-TSQI<Z=-K-W>6MU;M^[/E/'=QVZ+<*Q/E"1D!(8CKS7N?[=%WJ7Q)U#P5\'
MM$\.:EXT35V?6-;TO2[R&SFDL(054>=,Z1KND8'!;/R< T ?8$-S%<PI-%(D
ML4@#)(C JP/0@CK4&F:O8ZS:"ZL+RWOK8DJ)K:59$)!P1E21P1BOSA\-?'CQ
MAH7@CX=^"O%GB?6/A78^'-5O= \3:I:Q1W$\,\"*UE"\^V5#O4@G;D.00#53
MP!\5/B%\%?V?O &M^'+B[U32O$4>I^'H;);5%\O5YKIC:7;+LRI.Y\K]WY!D
M>H!^F>\>M&\'O7YT_$/X^>./!7QJ\.>'8/'OB ZCH^J:/I.JVNJS6L$-TDVP
M3RI:K;%ID8MDSO+&$/"@YKIX?B1\4],\0>&?%$/C75M7_M#QOK7A]/#$\,"6
M,EM%]H\A&(0/NWQ+B3<, XZ#D ^\-P/>C<,9R,5^</AG]I+QR_PL\7:_X?\
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M "D* ]LTZB@!NP9Z4I44M% #=H[C- 0 YQSZTZB@ HHHH **** "BBB@ I"
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MM%OHC+:*.K2KNR@]VQ7A&J?L\:Q%XR@O])TK2K.P6+1%=872++6ID\WY57G
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M2*OE\SD]O+_GW+\/\ST"BO/_ /A'/B)_T.FC_P#A/M_\D4?\(Y\1?^ATT?\
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M_0Z:/_X3[?\ R11_PC?Q%_Z'31__  GV_P#DBGR^:(]O+_GW+\/\ST"BO/\
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MB_\ 0Z:/_P"$^W_R11R^8>WE_P ^Y?A_F>@45Y__ ,(Y\1?^ATT?_P )]O\
MY(H_X1SXB?\ 0Z:/_P""!O\ Y(HY?,/;R_Y]R_#_ #/0**\__P"$;^(O_0Z:
M/_X3[?\ R11_PC?Q%_Z'31__  GV_P#DBCE\T'MY?\^Y?A_F>@45Y_\ \(W\
M1?\ H=-'_P#"?;_Y(H_X1OXB_P#0Z:/_ .$^W_R11R^:#V\O^?<OP_S/0**\
M_P#^$<^(O_0Z:/\ ^$^W_P D4?\ "-_$7_H=-'_\)]O_ )(HY?-![>7_ #[E
M^'^9Z!17G_\ PC?Q%_Z'31__  GV_P#DBC_A&_B+_P!#IH__ (3[?_)%'+YA
M[>7_ #[E^'^9Z!17G_\ PCGQ$_Z'31__  GV_P#DBC_A&_B+_P!#IH__ (3[
M?_)%'+YA[>7_ #[E^'^9WY.*,UP'_".?$7_H=-'_ /"?;_Y(K7\,Z3XKL+^2
M37/$%AJUJ8]J0VNEFU97R/F+&5\C&1C'?KQ2<;=2HUG)I<C7W?YG4TF:6F2!
MBC!3AB#@D9YJ3I' TM>?_P#"-_$3_H=-'_\ "?;_ .2*/^$<^(O_ $.FC_\
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MW?\ !/::0FO%_P"V/B#_ -#1I/\ X(S_ /'ZZ'3](^(FH6<=P/&6CH'&<?V
M3C_R8HY+=4=.'S6EBI.-*$FUY+_,]'(W#%-\L8Q@8],5P7_".?$7_H=-'_\
M"?;_ .2*/^$;^(O_ $.FC_\ A/M_\D4N7S1W^WE_S[E^'^9Z!17G_P#PC?Q%
M_P"ATT?_ ,)]O_DBC_A&_B+_ -#IH_\ X3[?_)%'+YA[>7_/N7X?YGH%%>?_
M /"-_$7_ *'31_\ PGV_^2*/^$;^(O\ T.FC_P#A/M_\D4<OF'MY?\^Y?A_F
M>@45P,?AWXAK(A?QEI#H&!91H# D9Y&?M'%%+E\RE6;^PU]W^9X;KO[:GB70
M;SQ]K!^$]SJ'PZ\$:]<:)K/B*RUN%KF$0F/S)ULV4,ZJLJL0&SC/I75_&7]L
M70OA'\4? GA+^R+C6[77TAN=2UBUDQ!HUK/.EO;3S?*<K)+)M&2N,>XK@M<_
M94^*NK6OQ6\&VWB[PII7P\^(7B*[UB_N5L+F?6(8+GREE@C)=85)2+;N(;&X
MGGC$'C?_ ()\Q?%74/B7J/B7QAJEC-KT46FZ-I^AWLL5C:Z?;0JMG%<Q$?OB
MLJF5AG&XDCK4G2=-\6/VPO$?@+XB>._#VB?#FU\1Z=X,L;6_U34+GQ/;Z:_E
MS0O+^[BE7YR%C?H>P]:H?%']M/Q/X&\!^%_'.E?"Y-;\)>)+&PN-.EN/$<-K
M?SW%TH9+6.T\MVDD&X?=)R 3T%8NI?L"R?$N'QIJ7Q'OM&U3QCK&CZ-;:9XB
ML[9GN=-O[*!TDN$>1<[)9/+=D'W@"#V(DU#]GG]H'4_B?X8\<:CKWPWU^_\
M#VDQV6FV.JVM[]DLKHJ!/>11Q;!YLFW@G[@.% P#0!V_QG_;'@^!MU\/++Q#
MX2NO[0U^&.[UV&"Z61?#ML7BCDFE<*1(J2S*F1@,0>>E>E:-\88-9^..O?#B
M/3F672M%M=9.I"<,DJS2R1A F,C'EYSGG->$>*OV&]4^-?C#QEXI^)GC.[MM
M4UG2;;1;6T\'WDUK9PVJ1[I8Y4<$RHUP6D"DXP!WIOA/]GWX]?#SQC8>)]$\
M1^ M4U<^%+'PWJ,NNPWTGGFUDD*SKY94Y973=N)Y#4 :_B_]L3Q-I_QF\;^
MO#/P\TK6CX6DM(Y[[5/%]MI1F,\ E79'*F6QD@X)Z#UJ]\3?VR;CX1>*YO"W
MB+P%>CQ%J%I:S>%[2QN_/CUR>5ECEMED"!8WBD?G.04^?OBN%\1?L??$"_\
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M>"=.U+PRL%^M[INL7-_8O<Q1S&:VNK4(7MVMA&9?,^8Y7:" I)&.:]&B\?\
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MBT4451\^%%%% !1110 5ZKH/_(HZ+_USE_\ 1K5Y57JN@_\ (HZ+_P!<Y?\
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M>S@KM+$8 "D<$&@#4OOVAXK+PWI.K?V%*ZZA/J\(B^T@&/["+DDD[>?,^S'
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MLS;460H0OFC(.* /N':N*C22*1W575F0X8!@2I]#Z5\,^(_CWXZA\/036_Q
MCDTS3M3U&WBU&WN-/L[_ %BU@$)2Y3[3%]GN50O(KI&T9?9D'@U%>?&+Q&$\
M57NC>(;'0FO->L_-D5;+1[^^1M+CFVK+/')"DVX@E9CDJ"BOG% 'VY#X@TJ?
M6YM'BO[=]4@C662S$@\U$.<,5ZX.#6EY8KSKX(WFG>-?!.B>-1;FYUG4K(0S
MZO>6$5M>7"([##^62NW*Y&TE#]Y>"*](H ;Y:^E&P4ZB@!NP4>6OI3J* &[!
M1L%.HH ;Y8HV#TIU% #=@]*^!?\ @I N/&OA'_KPD_\ 0S7WY7P)_P %(?\
MD=O"/_7A)_Z&:N&Y\YQ#_P B^?R_,^/*,"BBMS\=# ]*,444 &*,444"#%>X
M^"!CX-:3_P!A>\_]!CKPZO<?!/\ R1O2?^PO>?\ H,=4MS'$_P"Z5O3]4.Q1
M116A\ %%%% !1BBB@ Q7LGAP ?##PS_UWO\ _P!'+7C=>R>'/^28>&?^N]__
M .CEH1UTOX%?_"O_ $N(M%%%4?/A1110 4444 %>J:" ?".B_P#7.7_T:U>5
MUZKH/_(HZ+_USE_]&M4RV/K.'OXM7_#_ .W(L8'I1@4M%9'UPF!Z48'I2T4
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M[4F=&'B.^55/*B&##<DX/R>X'_ 1[TJ^'M1$P<^([YE'_+,PPX/W?]C/8_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M]#-7#<^<XA_Y%\_E^9\>4445T'XZ%%%% !1110 5[CX)_P"2-Z3_ -A>\_\
M08Z\.KW'P3_R1O2?^PO>?^@QTUN88G_=*W^']4.HHHK0^ "BBB@ HHHH *]D
M\.?\DP\,_P#7>_\ _1RUXW7LGAS_ ))AX9_Z[W__ *.6FCKI?P*_^%?^EQ%H
MHHJCY\**** "BBB@ KU70?\ D4=%_P"N<O\ Z-:O*J]5T'_D4=%_ZYR_^C6J
M9;'UG#W\6K_A_P#;D6:***Q/K@KU?X7?\BY)_P!=V_D*\HKU?X7?\BY)_P!=
MV_D*SGL?7<,?[\_\+_0[&BBBL#]8"BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** //3\>/!JD@WU^"./^0->_P#QFD_X7UX,/_+_ '__ ()K
MW_XS747/C+P_9Z=J6H3ZYI\-AILI@O;J2\C6*UD&,I*Y;",-R\,0?F'J*U+6
MY@O;:*XMYEG@E021RQN&5U(R&!'!!'.15WAV_'_@''R8K^>/_@+_ /DC@_\
MA?7@S_G^O_\ P37O_P 9H_X7UX,_Y_K_ /\ !->__&:[J]O;;3;.>[N[B.UM
M8$:66>:0(D:*,EF8G   ))--L-0M-5L;>]LKJ*\L[B-98;BWE$D<J,,JRL"0
M01R".#3O#M^/_ %R8K^>/_@+_P#DCA_^%]>#/^?Z_P#_  37O_QFC_A?7@S_
M )_K_P#\$U[_ /&:] X]3^=(SHH!+8!.!EL9/I1>';\?^ ')BOYX_P#@+_\
MDS@/^%]>#/\ G^O_ /P37O\ \9H_X7UX,_Y_K_\ \$U[_P#&:]! ![G\Z-ON
M?SHO#M^/_ #DQ7\\?_ 7_P#)GGW_  OKP9_S_7__ ()KW_XS1_POKP9_S_7_
M /X)KW_XS7H.WW/YT;?<_G1>';\?^ ')BOYX_P#@+_\ DSS[_A?7@S_G^O\
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MW/YT7AV_'_@!R8K^>/\ X"__ )(\^_X7UX,_Y_K_ /\ !->__&:/^%]>#/\
MG^O_ /P37O\ \9KT';[G\Z"N.Y_.B\.WX_\  #DQ7\\?_ 7_ /)'GW_"^O!G
M_/\ 7_\ X)KW_P",T?\ "^O!G_/]?_\ @FO?_C-=_N7=MW?-UQGFG;?<_G1>
M';\?^ ')BOYX_P#@+_\ DSS[_A?7@S_G^O\ _P $U[_\9H_X7UX,_P"?Z_\
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M"3]HGQ7XE^).BIXEU*UAT77;AK:Q@TFUM[NR=_LRRB$S)-]H@G4D[A+&4(P
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MW5]#NVGTZ73H+66VM8[596FD\LW<UPOE2(!O6/;C&?NG[=S[49]J /DCX/\
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MV,_95O\ GZ_N1R/_  L36O\ HGWB/_ONS_\ C]'_  L36O\ HGWB/_ONS_\
MC]=SN'I^E&X>GYBCFCV#V5;_ )^O[D<-_P +$UK_ *)]XC_[[L__ (_1_P +
M$UK_ *)]XC_[[L__ (_53Q[^T#X%^&.LPZ7XEU2[T^]F*K$J:3>3I(S#*JKQ
M1,K,<'Y0<\=*Z#PK\1O#WC6YN+?1[XW-S;1133P26\L,D22KNC+)(JE<CG!&
M?6CFCV#V5;_GZ_N1E?\ "Q-:_P"B?>(_^^[/_P"/T?\ "Q-:_P"B?>(_^^[/
M_P"/UW.X>E)O'H?RHYH]@]E6_P"?K^Y'#_\ "Q-:_P"B?>(_^^[/_P"/T?\
M"Q-:_P"B?>(_^^[/_P"/UW.X9Z'\J-PST_2CFCV#V5;_ )^O[D<-_P +$UK_
M *)]XC_[[L__ (_1_P +$UK_ *)]XC_[[L__ (_77ZIJMGHNGW%]?SQVEG A
M>6>4[411W)[4RPUJSU22Y2UD,K6Y59#Y; 990PP2,,,$<C-'-'L'LJW_ #]?
MW(Y/_A8FM?\ 1/O$?_?=G_\ 'Z/^%B:U_P!$^\1_]]V?_P ?KN-P]/TI2P'8
M_E1S1[![*M_S]?W(X;_A8FM?]$^\1_\ ?=G_ /'Z/^%B:U_T3[Q'_P!]V?\
M\?K>T[QOH>K>)]7\.VFH1SZUI*0O?6:AM\"RKNC)XQ\P&>#6S+-'#$\DC+'&
M@+,SG  '4DGI1S1[![*M_P _7]R.(_X6)K7_ $3[Q'_WW9__ !^C_A8FM?\
M1/O$?_?=G_\ 'ZT?"WQ.\,>-+TV>C:I'>W0LH=1\H(ZG[-*SK%+\P'RN8WQZ
M@9Z$5I>&?%FD>,M*&I:+>1ZC8F:6W\Z(''F1NT<B\C/#*P_"CFCV#V5;_GZ_
MN1SG_"Q-:_Z)]XC_ .^[/_X_1_PL36O^B?>(_P#ONS_^/UUVJ:M:Z+9-=W;/
M' K(A9(FD.68*O"@GJP^G4\"K0<'L?RHYH]@]E6_Y^O[D</_ ,+$UK_HGWB/
M_ONS_P#C]'_"Q-:_Z)]XC_[[L_\ X_7<[AZ'\J48(Z4<T>P>RK?\_7]R.%_X
M6)K7_1/O$?\ WW9__'Z/^%B:U_T3[Q'_ -]V?_Q^NZQ1BCFCV#V5;_GZ_N1P
MO_"Q-:_Z)]XC_P"^[/\ ^/UJ^&_%6H:Y?207?A?5M$C5-XGOV@*,<@;1Y<C'
M/.>F..M=+BC%)M=$7&G43NZE_DA:8Y*HQ +$#.!U-/IKNL:,S$!0,DGL*@Z3
MA1\1-:'7X?>(_P#OY9__ !^E_P"%B:U_T3[Q'_WW9_\ Q^JMC^T3\+M3U&&P
MM/B%X9N;Z9Q%';1:K"TCN3@*%#9))XKNM+U6RUO3K:_T^Z@OK&YC$L-S;R!X
MY$(R&5AP0?45IS1[')[*K_S\?W+_ "./_P"%B:U_T3[Q'_WW9_\ Q^C_ (6)
MK7_1/O$?_?=G_P#'Z[K('I5>^O[73+.>[NYXK:U@0R2S2L%1% R6)/0 =Z.:
M/87LJW_/U_<CC?\ A8FM?]$^\1_]]V?_ ,?H_P"%B:U_T3[Q'_WW9_\ Q^NH
M?Q+I,>CP:JVHVBZ9<+&\5X9E$4BOC85;."&W#'KD5I<#THYH]@]E6_Y^O[D<
M+_PL36O^B?>(_P#ONS_^/T?\+$UK_HGWB/\ [[L__C]=UQ[4<9QQFCFCV#V5
M;_GZ_N1PO_"Q-:_Z)]XC_P"^[/\ ^/T?\+$UK_HGWB/_ +[L_P#X_77:QK-A
MX?TZ?4-3O+?3[&W7?-<W,@CCC7U9CP!3=+US3M:2=K"]M[U8)3!*T$@<1R
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M>?\ 75 1771#_B6V'_7'^IJ9278]?+X3?/:?1=%W.9_X2S5/^A.UO_ONU_\
MCU'_  EFJ?\ 0G:W_P!_+7_X]738HQ4<R['H^SJ?S_@CF?\ A+-4_P"A.UO_
M +^6O_QZC_A+-4_Z$[6_^_EK_P#'JZ;%&*.9=A\E3^?\$<S_ ,)9JG_0G:W_
M -_+7_X]1_PEFJ?]"=K?_?RU_P#CU=-BC%',NP>SJ?S_ ((YG_A+-4_Z$[6_
M^_EK_P#'J[?1/'^LP:7;H/ /B&0!?O+)9X/_ )'K.Q7I'AL#^Q;7_=J92C;8
M^CR.G4=:=JG3LNYR_P#PL36O^B?>(_\ ONS_ /C]'_"Q-:_Z)]XC_P"^[/\
M^/UW0'%&*CFCV/L_95O^?K^Y'"_\+$UK_HGWB/\ [[L__C]'_"Q-:_Z)]XC_
M .^[/_X_7=8HQ1S1[![*M_S]?W(X7_A8FM?]$^\1_P#?=G_\?H_X6)K7_1/O
M$?\ WW9__'Z[K%&*.:/8/95O^?K^Y'#Q_$+67D53X \1(&(!9GL\+SU/[^BN
MXP/2BE>/8M4ZBWJ?@CPJ3PSK!_;?C\0C3;K^P1\.S8'4O+/D?:?[363RM_3?
ML^;'IS7RY\#;+QE\/?BEXGL]3C^-6BVM[\0M0OXM/T+P];RZ#=6\MX"DLLTD
M9D"..7*L,+R,5]6^(/VEK#P_KKP/I-Q=:4_BRU\&PWENLC,]Z\>^=RHC/[N,
ME4R#EF60<;<GIHOV@OA_+=ZA!_PDD$?V&*\GEFDBE2!TM/\ CZ,4K($F\KG>
M(V8K@Y'!J#I/EOX$_LI>+?%[ZU-XU\4:UHOA*P^(NI>(;/P<-*A@%S+'>^;!
M<&Y8&5HF(# +@$=#7)_ AO&7PY\:ZC::K%\<+"-O&6HWPTC2/#=O)H5Q#)>.
MZLTSQF38ZD%B&&,G&*^OQ^U'\+_^$>O=<;Q9!%IEG':SRS2VTZ$Q7+^7;RHC
M1AI(Y'^570%2> :OI^T-\/WUBRTP>(D%Y=_9@BM;3JD;W S;QRN8]L,D@QMC
MD*N<CCD9 /DWX8_%+Q!K_P 9=7^)?Q&^$_Q-N?$JF73_  MHZ>&W:PT.R/\
M%YI8#SYL#?)C@?*"1T/@O\3?$">*/%OQ+\;_  J^)5Y\4M4L[F/3[>3P[+_9
MNCV4:L\-C;R$YW2%5+OM!=V P!G/U?\ #+X[^'OB7;$PM+IMZU_J=E#97<<B
M22K93^5+* R+\O*-[;\'D,!6U?\ :<^&.@BW:_\ %]I;QSV=OJ E,4S1QVT[
M%89I'"%8T=@5#.5&>.M 'QS^SI\'OC=\#?BM\/\ QUXF\+Z/<V7B8W%EXFF\
M.FYEU$M>R&Y2>^C90J^3+M0E,A5&/>OT9!R*X;PO\;/!?C'4!8:5KL<^H>9+
M$;.2&6&='CC61PT<B*RX21&&X#(8$9K*U?\ :7^&F@" WWBRTA66U6^W".5U
MCMVD,8FD*H1''O4KO?"@]3R* /3Z*\R3]I'X=R6QE3Q")91=?8A9QV5RUVTO
ME>;A;<1^:P\OY]P4C;SG%84O[5W@BW\36]M+J<)T&[T;^V+;5X4FE5T$IC?<
MBQDQJA'S.^ IX.* /:J*\]^,?QGTOX.^!(_%-W:W&JV4MS;6T:V*F3?YTBHK
M J#\OS9SW[9)%</XS_;#\$^'M0L;72[P:RPUJWTC4S'#<+]A,A )_P!4=[C(
M_=K\W(Z4 >]45YW!^T'\/9]'N=3'BBSCM+:TN+Z<S!XWAA@<),SHRAE*,RAE
M(W#<,CFH=:^.6AV5_I TZXM]7L+BYM+>^FMI"7LUNU/V61EQ@JY ZD8!S0!Z
M512 Y%+0 4444 >1_M3^'-3\5_!G5],T>"[GOYY;<1BQ0/,N)E)9001D#GD$
M<5XS\9?A+\0-(\?V%_H>O>,O&4P\/W\*W<WV5)+9F*_)%)##$%=EW ;LGTP:
M^J/%OC#1O VD-JFNZA%IM@LB1&>;.T,[!5' /4D"N3\1?M _#_PKJTVE:EXC
MABU.*\6P:RB@FFF-PR&18E1$8LQ4$X - 'S7;^ ;OQCJ$.G>&=(\=Z1\.KK5
M=,2[MM2EO[*X,B[OM+H9'$R1XP)&X5CR":N?%[0I[*RNO"\WA3Q3=0W6NSI9
M:U966H7R:38!$!=!"2SNP!" Y&<L>E>Y^*?VGOA]X=\(+KL7B"WODN+.>[M8
MH8YG,BQ9#%PJ%HE##:6<* >#5^R_:!\&@:/;ZEJ\5AJ5_;VLSP".62*V:=0T
M:23JGEH6S\N]EW=J /G76/#]U_:,T-CHWQ%GUG%@O@N]"WR16T";?,\\L0D+
M?>,HN,%\\9&*W/AS\-?$VD^(/"?B2YM?$4>NOXJOX]0EEN[DQFP;.P-$SE1#
MD KQQ7T-X0^+WA'Q]J.L66@:S'J4VDN8[UHXI!'"ZG#*9&4(2".0"2.^*R[3
M]H7X?7L<\D?B*-8851_.EMIXXY$:7RE>-VC E4O\NY"PSWH R?C_ *#JFN3_
M  X.F65S>"S\5V=U<_9T+>5$J2!G;'11D<^]>/?&;X4ZUJ'C[XJ^+M,TK7'U
MRW316T*ZL99U#,AC$QC1&"R$*7#9!XSFO;/B#^T!X>\!ZK8V<DZ71.J1Z9?B
M(2-):/)&70!$1FD8@<*H-9'B#]I71X0MQHEQI=YI4FF?V@NJ7]U+;P(PN!"8
MY L3NA!/0KD' ('4 '@6F>'?B#/\1]4GU(^)D\3F]OI7EAT>]:*6Q,+B&,W?
MVD6OE'Y-L:1>8K#IG)J#Q1\.-9\.> _!FD1^&O$US-?Z5<7E_?W4FJZHYU$H
M0L1@@G1DFX!621UB3L,YKZJ;X^> K?Q VAW/B2TM]2C)CDWK((%E5/,:/SR@
MCWA<L4W;L G%5H?VC?AU-I.H:DWB6*WLK%(Y9Y+JVG@/ER-MCD57C!=&;@.H
M*D\ T ?)<KZUK.IWMG<V/CR\\?1Z)H_]BM!]K\FRN\*7,NTE(7P#O:;AEXR:
MZ*P\(_$*\^+-^FHS>((/$\NIW;&YM]+O3;26#0NL2&\-T+18,[,(L?F*P!QG
M<:^A+;XX?"RV-WXBM]2A6^O+C^S[@PZ;<&^EDB3=L>$1><=B<\K@ @YQ6I>_
MM"?#W3S8F7Q+;LEY;Q7:2PQ2RQQPRMMCDE=$*PJS< R%<F@#Y/DT/QAXZ\#:
M5X:O/#/BZZ.C>";S3=72_M;J*.>_66-E1&?'VA\*2KH6!Z!CTKN?$&C:F+2S
MEO\ 1/%DWP[35+-[S3=/AN_M'V8:=&J P(?.:-9@0Z(,[L$C@U[-\:?C3)\,
MY_"]GIUE;W]WK=YY?G7K7$=K!;JI>25I(89>0HX4XSU) YIMG^U)\,K[0[;5
M;?Q,MU9W!D\E[:RNI3*(U#22(HBW-&H(S(!M&>30!\X^(=#U^+Q-X2U#3?#W
MCA@%LDT_1M<BU"66*%+AB6CO[>7;;R;&!DCNT(*C:6.>/1?VD[K2Y/C!X(LO
M$=AXGU;1YM"U-FTWPV+N60W&^!8W>.V.XD;B%<\*3DXX(]5UO]I+X9^'G1;[
MQ=8QJT$-T98Q)+$D,W^JD=T4JBN>%9B 3P.>*O:+XT\&^.K>^\6Z(+?5=1T.
M.XLVGDMGAN;8[0[PD2(KH&VH<$<_*>>* /D/3_ _Q&LM3U;4/$FB>*);"X7P
MU_PD;6ZR27=[:16<HN$5H#NE99?)\P1\D!A@\@^YZE8R#]E#Q[!X>TCQ/I%J
M^GZF=/L]9G<W_D$.1Y:RDR1*5SY<;_,H*@@=*Q_ '[5_B;Q!9^!-7U?PSX8C
MT3Q=<0VUO!H_B5KK4[9I49U,ELUNF0H7YPKDKUY ->M:5^T'\.]:O[NSM?%-
MD[V]O<732R!XX)(8#B>2.5U"2K&?O%&8#O0!Y3H'PXU3Q=\:;S6M#\0^(?"7
MAN3P=HT-KJ&B);&&[*R71,9::&5245E.%Q]_G.17DND^"-8\->%H-/\ &V@_
M$/5=.6SU2/1AH23B7^U&U&Z<32K;;3',Z&W:.9PL2C=TR:]QN_VIOAYX+'@W
M2O#1AGT>^U1=+GA@M[B&6PC>UEGAD2V,7F2+(8PJ;5P=W!.,5W=Q^T3\/(="
MT[6!XCCN+*_CGE@-K;3SR;(#MG9XDC+HL;<.750IX.#0!X%H'PL\:31^.O$/
MB"WU^X\9QW>@VEE*M[<"$Q^3IQO&AB5_+/[Q9M[@?POSC.<:ZTR]\2>._B!K
M7AGPUXU\*^(X[+4+#PU;#3]1@BN[AD/FWTMQ)^X5Y""MNK$*F0Q&Y\+]KZ=J
M-KJUA;WME<1W5I<1K+#/"P9)$(R&4C@@@YS7G4G[27PX2\UVT_X2:*2XT2]&
MFWT<=M.Y2Z,GEBW7$9\R4OQY:;F[XQS0!\R:OX/U/7Y+:S\!:%\0-*\%S:OX
M<BU*#5&O[:5YUO7%[(@F<3*!;[!-*IV/\I!)#&O<_@O+_P *HU+Q%X8U./5[
M33=2\9W5EX;AO!/<1K ;-+C"2,6*0[DN,$G;NRH["N^T#XU>"?$\\,.G^(+>
M2:6WNKH1RK)"R1VT@CN-X=5*&-F4,K889Y&*R%_:$^&M_JFEPQ^(+>[GN7M$
MM[F.UFDAC>[16MT:<1E(GE5T*J[*6#KQ\PR >H45\_>'/VLK'6[ "YTL:5?R
M6&O7ZR7+S&RB33;V2VS-,D+; XC+DX)7IAB5W>BS_&_P99^+(O#-SKD,>M-/
M!:/&L4K0QW,R;XH'GV>6DKJ05C9@S!EP/F&0#O**XGP?\9O!_CW6I=*T'6%O
M[Q8I9T MYD2>.*7R9)(9'0),BR84M&6 )'/-=J.: %HHHH \>:S;_AH'QK*+
M=O*;P=8(LGEG:6%Q>Y ..3R./<5X%\,_ GC'2OA=X$TS0/&/BJVOM>\ W%QY
M5Y>-Y%E>P?9GMO+0*/)"[FC*+C>A.[+?-7V[CWK/U[1(/$6C7FF74EQ';7<3
M0R-:7#P2A2,';(A#*?<$$4 ?)OA_Q+XO^/EMX4\0#7_$WAC0O%GB!X8['3+@
MVLD%I:Z?.'0NJYCWWB29;/(CCP>:YV;QWXD N%MO%WBR[\?DZS'XE\/3+*]K
MIUHD-P;=TB,82(!DM?+E0YE,G.[<<?:7AWPYIOA+0K#1=(M([#2["%;>VMHL
M[8XU& .>3]3DGJ3FM';SU- 'Y^WOB76_$.DV%GXU\1>)+/71!X;DT#1;<2^1
MJ5L8;=[F66$)L<^<91([<QA5/R]_9/VM?%OB?P_XJ\(6L.JOH'@VXM[QKS41
MJEUIJ_;!L^SQM<6T,KC*F5@A 5V4 D\*?I_;[FC;[F@#XUB\4?$[3[OP=X<G
M\1:C>7_Q!TZVCAU&&*6$V#V\A:YE5)E#1-):G?RBY>/.%R!4?P:\;>.]7^.%
MG::KXFN(]6_M._36?#\]Q?7'EVBEQ"/LQME@ME $++.LAWY(RQ8@?5LG@'1I
M_&T/BR:WEGUN"U:S@EEN)'C@C8Y?RXRVQ&; !8#<0 "<5T.WF@#XK_;$UF6\
MNO'FC:[XB\0Z4&T2W'AK1[ RQV>J2LS_ &@,$0B=AB,%'/RJV1C)(S/&OC3Q
M1I7A_49[GQ7?Z/:6_B;4(8[.>ZO-+2Z1;:'R8X[Z"&3RV5B2D;J4D.0:^Y]O
MN:3;[T ?!NK?$SXCZCXPTPW&O:MX6U*:TTR30M.U6:\$URK*#,7L[:U:*[D9
MLAPS+L&#A,YJ63XI>,;KXW6::1KWB"%)=<OM.U&VN[V>\DMH!"XC9[!+=8($
M#!3&0S2/QR<U]V[?<T;?<T ?GQI_Q2\=V_@?6;;2O$>L:Y''<6 U;Q#'JM[+
M:V\!DVW#L9+7[183$$EXD$@C )&W%?1?P#U[Q!J?PE\47D^N'7;>.6Y_LB\B
MFNKIU01Y"K<7$4;W #?=DVG/3)Q7OFWW/YT%010!\O/:+=_LA>%3;QRW4TLE
MI-,6A_>-*;C,I8 ==V[-4?VBO%[>!_CII=V/B)8_#:*?0'B%Y?>'6U5+DB=3
ML4!E"$=>O-?3/AKPIIGA&QEL]*M_LEI)/)<>2K$JKN=S;03\H)R<#C)/K6OM
MH ^2[#XU^"_#/Q.T_6?%/BJVU?3M8\*);P:LND3)%J+BX^8+"J/MS_</ZU6\
M$Z)>^&O"GPH\O3)M(N;GQ;<FPTZ\+1RQZ9,7+H8B00NS!V$?*".!7UX5SW/Y
MUEW/A?3KSQ#9:W/"9=0LHWBMY'8D1!_O%5Z D<9ZXXH T;:VAM($B@B2&)1A
M4C4*H'L!4M)2T %? G_!2'_D=O"/_7A)_P"AFOONO@3_ (*0_P#([>$?^O"3
M_P!#-7#<^<XA_P"1?/Y?F?'E%%%=!^.A1110 4444 %>X^"?^2-Z3_V%[S_T
M&.O#J]Q\$_\ )&])_P"PO>?^@QTUN88G_=*W^']4.HHHK0^ "BBB@ HHHH *
M]D\.?\DP\,_]=[__ -'+7C=>R>'/^28>&?\ KO?_ /HY::.NG_ K_P"%?^EQ
M%HHHJCY\**** "BBB@ KU70?^11T7_KG+_Z-:O*J]5T'_D4=%_ZYR_\ HUJF
M6Q]9P]_%J_X?_;D6:***Q/K@HHHH&%%%% !76P_\@VP_ZX_U-<E76P_\@VP_
MZX_U-3(]?+O^7GHOS"BBBLSTPHHHH ****  =:](\.?\@2V_W:\W'6O2/#G_
M "!+;_=J9'TV1?QI^GZFD.E+2#I034'VHM%)FN6^('Q)T7X;:2+W5IFWRL(K
M:S@&^>YD/1(T[D_D*:3D[(RJ5848.I4=DNIU5%9'A;5=0UG0[:]U/2CHUW*-
MS63S"5HQV#,!C..H[>M:U)Z:%QDII2746BBB@H^;Q\(/$VK1:CH$!AT^7P]\
M0E\7:;=WL,K6VH6DTC7#1^8#Q(KS7"'&=OEQDC#@UYYJG[(&O>"_!.M6]M)8
MZW8Z#H>MQZ)Y1OKK4[M[BTN(HT\F25H(7"S%2T2DRGL@8BOM+'-!&: /E31?
MV<_''CS0O#VI^+-6TC3=4LK+P_;6]I86<J;8;*^M[V4S;R&65S"$$8^6/!.3
MGCH_%W[.7B77]7\7Z-;ZUI4?@/Q=K=MKVIF6&4:G;R1+;*\,)4B-E<6D>';Y
MDW-P_&/H@#%+0!\X6OP&^(7AK5;34M"UOPV]U::OKLT:7]O<>6UGJ5P+@EMK
M9\V)\C ^5P!RA/":1^RKJ=AX;U33)]?LKB2]\.Z'HC2?96"[[&29Y'*EC\LG
MG<+VP<DU](44 ?.NJ?L\^+])^+/B#Q[X9UG17O=4U?[7]BU6&81I;OI\-HXW
M1G/F!H0XXP1E3C.X5(/V4=63P?JVD3>([.>[OO"\&@-=BS91YD<\LK2E=W"M
MYOW<\8ZFOI6B@#YJ^(/[-/B_6_B7K/BG0_$UI%9ZG=027&D3375F)42VDA&Z
MXMG$GRL^\("%;&&]:R]!_9:\=>"?#=KI&A>(O#L\<N@S:!>S7UE< HDEU)-Y
MT6'))59"/+8_,0"7&.?JFB@#P/Q=^RG8W?PO'AOP_K.I0ZA!!I\4$VKZC=75
MJ?LC1-&# 9-D>[R5!,:J1DX]*R)/V:/%5GX9B&G:YHW]OP^-#XP0W-O,;4DA
M,P':P;JI&_T(XKZ3HH ^8]8_9+U;QA;V-UKNO:>FJ7VMS:AXB@M+1FM+NSEC
M1'LHU<YVXBC.\XR03M'2HX/V>]6\(?#RT\$M/)XBNM:\1P37.I00M#'9Z? R
MM&A.3L\N*,(O8L?>OJ"DV\YH 11@4ZBB@ HHHH \^^.OPTN?BQ\.K[0+*^CT
MZ]>2*XMYYD+Q^9&X=0X'.TD8)'->4^%?V:/%_P#PM2#QYXDU[1OMS:X-7FL-
M*MYO*5!;&$1*[MECDYW$#/H*](_:.\;^(/A[\+-0UKPREJVJQ30(AO'VHJO*
MJL?N-S@^E<ZO[1>IQZHL\_@[R_"2:PFA3ZTNIJTJW!P#(MOY8+0AR%W[@QZ[
M,4 <FO[,7B[PQ+=77AOQ!H;7FI:?>:1??VK:2M&EO-.TRR1A6Y=2V"K<'U%4
M+S]C[55\0.UKJFE7NDZB;*6_;4'OMT4L"(K>5;Q3+!(K; 1Y@^3_ &J] ^*V
MJZ]XK^)>G^ ]-\37W@[2VTB;5;_4=(CC.H3*KA%BMVD215P>20A;L,5PMA^T
MA!\+=*BT2Y\3S>.M3GU4V-G-XFLYM%GM8A'O/VR0V^7( R'CA^;/3O0![-\)
M_AE+\.?".HZ/-=P7<EW?W5YYL<.% F8D J2<D=_6O$+;]DOQ<EEX@L(]?TC1
M=.N%$EK8:8;PV5Q<K.)DFDM9)"EL>-I6WQG).>U;$/[7^IZU;V[:%X >]E72
M+S5[W[=J9LXH4MI"CK$S0$S;@"4;:H/?%12?MC:I?1:C?Z)\/_[5T>QDTZ%Y
MI-92"=VO(P\>V(Q$87(#9;IDC/2@"]%\!_B'_:MUXJEUWPX_BF?68-7^Q?99
MS8H(X#%Y(?/F<YSYF,C^Z:RKK]D76M1\-:I;S^)+ :MJ\<LMY)':OY*7,MZE
MR_E@MGRQLV@$Y[^U:/B#]KB]\-V$XU#PQI&G:I:75Y:75MJ'B5(HGDMP"5MR
ML#2S,P/'[I0/XB*Q=)_:<\4/XN\5Z_;^'9-7\!VUAI-ZT<E_'#/8K<1CS/*C
M\L^<06W'<Z<=.>* -V3]F[Q<=&\1>"HO$>DP^!-:NKN^FN#:22:FKW"G=$"6
M\L*&.0X^; VX[UA:'^R)KQMY_P"UM0T.&[BALK.UN+5K^ZD>&"X69F=KF9RF
M_:/W:?*IYR:]G^('Q8F\,:AX5TC1-(37-=\2/)]B@N;O[) L<:!Y)))-CD !
ME  4DD^U>61?MAZAK-O*V@^ S?S6&EWFIZLMUK"VZ6OV65XYHHV$3F5OW;%3
MA0>Y6@"3X@?LOZUXAUWQ3K%E=Z)J$VK:O%J<%OJ0NK:2VVVR0YBN[:1989 5
M+!DR"#@C@$<]J/['OBFXU-+J7Q)IWB";4].L['6+K6I+X.#  N]4AF5;C<HQ
MMG/!Y);I7K7COX]-X;\ ^#/$>BZ VN2^*=0M+"TLY[P6@C,Z,X=W*-PH0Y &
M?3TK@M4_;).DM:Z5=>&K*P\4/>ZA9SVM]K)CLH_LCA'9;E;=F?>Q 4>4.Y.,
M<@'I_P 2?A3/XWL-"M;6_ALETU)T.^(L'$ELT(P >,%@?PKSNW_9V\6^"QX&
MU;PGK6C3^(] \.MX;N%UB&86DT18,)D\L[PRMGY2<,#C*]:T_A'\<->^*'Q6
MF@6P33_"LOAFSU2&VN25NHIY)9%<,IC!(^3'WL8 ('S8#==_:6U2QU*.2T\'
M+<^&)O$P\+1ZNVJJD_VC+*\OV?RC^[#HRCY]QQG !H R-,_9*N-%\$W?AZU\
M06\BRVNCVR7,UJV[_0ITE<D!NC%3@=L]Z])\+?"J[\/ZK\2+N348IU\57:W,
M*K&0;<"TC@VMS\W*9XQP<5XM\,_VI/$S_#2RD?0_^$PU;1O#2>(?$%]<:@ED
MPA9I"!"HB822;(G;!*+P!NR>-O0OVD-=TW6=<U:_T9M2\!S>(++3K75&O5CG
MMUNHXA$$MQ'\Z"2158EP<N2 0M $WA3]D*T\ :!\/;GPU+I&C>,O#]O'I^K:
MM:Z>(EUJT*[9XY=N'W'ATD)+*P]&-9\W[*_BSQ'X?T_PGKOB71H_#>@:3?:7
MH]UI]@YO)O/B$227 D8JOEJ.50D2'DXZ5D?$#]LJZ_LGQ7HEE8V&DZPVB:W-
MIUYINM1ZA/9W-G"6 N$2+RD8CY@%EDP1M:O6/&_QJN_AG\+_  KK]SIO]JMJ
M/V>*[OKF5X+2R#0EVN+F2.*5HX\J%R$(RPS@<T 8=O\ !?Q]XE\:>"O$?BW7
MO#\9\,:BMQ%8:-92!98EM+B#<97._>QG#;#E5"X&22:XW7?V/]=BUFWUW1M:
MTV\U7&IVT\&H37UK;^1=7\MW&X-K*CL\9E*LC':_&"F,G6\<?MF+X+\(Z5KT
MF@:/-%=:)_;;P_\ "46[O,@8AH[/R8Y#.0!NWL(X_F4;LE@K]6_:;N/ NM:O
M9WT<.HW.H>(I++34U&[^R6MG;I903.994BD; ,F!A&)9QT'( /5/A7X;UGP)
M!'X2:TL$\*Z+I=C:Z==6L31-)*JL)E*%VP@Q&5QTW$9.,UYW>_LW:W;Z*\VE
MZ[8G7[+QY>^-M-%U#(+5C.UP/LTVT[@/+N7&]>C ':1E3D7_ .VB8+'PO=+X
M/.GP:S;>9YVOZE_9L+3BZ-N]M;SO"8I9 5,B^8\0=&C*GYOE]2\$>)M2B^*W
MC3PGJ-RUW;P16FM:=)+)ND2WN?,1HC@8PDL$FWD_*X':@#P/XD_L[Z_-8:59
M"2>Y\<>+O%=S?ZMJ6C6,IT^QT^YMUMK^'S6YC7[+'&%9F5GE52H'('5?$#]F
M'Q9XR\6W+QZ]I_\ PC@U?2M3L8[F>]#6,5G);O\ 98[2*1;8Y\AOW[JS_O,$
M?*I'TYM%+0!\U1_LO^([#P[_ &-::_ICP7>F^*=,O99K>4,JZI>-=0O$ V,Q
ML55PWWAD@@@"F:C^RKJTWQ-O-4AOM)N/#^HZ]9^(KDWTM\UQ!- ;=FBC@686
M[[FM@5E==T6X85]BD?3%% '@?P:^ GB;X;?$:]U:;5M,LM >&Z1M,T)KN.WU
M":6576XDM)9&@M9$"L#]G #ER3M4!*][%+10 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !7P)_P4A_Y';PC_UX2?\ H9K[
M[KX$_P""D/\ R.WA'_KPD_\ 0S5PW/G.(?\ D7S^7YGQY11170?CH4444 %%
M%% !7N/@G_DC>D_]A>\_]!CKPZO<?!/_ "1O2?\ L+WG_H,=-;F&)_W2M_A_
M5#J***T/@ HHHH **** "O9/#G_),/#/_7>__P#1RUXW7LGAS_DF'AG_ *[W
M_P#Z.6FCKI?P*_\ A7_I<1:***H^?"BBB@ HHHH *]5T'_D4=%_ZYR_^C6KR
MJO5=!_Y%'1?^N<O_ *-:IEL?6</?Q:O^'_VY%FBBBL3ZX****!A1110 5UL/
M_(-L/^N/]37)5UL/_(-L/^N/]34R/7R[_EYZ+\PHHHK,],**** "BBB@ '6O
M2/#G_($MO]VO-QUKTCPY_P @2V_W:F1]-D7\:?I^II#I2,<4HZ4'TJ#[4\1D
M_:O\*VNI>*["_M;_ $NYT%&<QWL8C:ZP<809R"3CKVYK)^!?@[4_B+KC_%+Q
MG$6O;G(T:PDSLL;?LP7IN/K5_P"+/[,.G_%+XDZ3XCGNUL[.% M_ B9>Z*G*
M#/0#L3Z5[=9VT=G:Q6\*".&)0B(HP  , 5URG3C#]WN]_(^4P^%QV)Q3>86=
M.FWR6^U?9M?W5HO/4FVTHZ4M%<A]6%%%% !129%&X>M "T4FX>M&X>M "T4F
MX>M&X>M "T4FX>M&X>M "T4FX>M&X>M "T4FX>M&X>M "T4FX>M&X>M "T4F
MX>M&X>M "T4FX>M&X>M '/\ CSP/I?Q&\+7_ (?UA)FL+Q0KFWE,4B$'(97'
M*L" 0:XC3_V:_"FG^*+?6A<ZW.(KA;YM,GU65K&6]4 "[>'.UIN 2>A/.W->
MK[AZT;AZT <1\1?A%H?Q*:RN;Z2_TO6+#>++6M&O'M+VU###!)5_A(ZJP*GT
MKES^R[X0&AFT2[\01ZN;H7Q\2C69SJWVC;MW_:"2?N\;,;,?PUZ_N'K1N'K0
M!YOIGP \)Z9#M$>H74K:5/H\MS>:A+/--!,2TI=W))<DD[NW;%0:3^SAX(T3
M2[S3[6QN5MKN6SFE5KMR2UJH6'G/& !GU[UZ?N'K1N'K0!Y'XB_9A\'^(-;O
M=76?6](U#4'G-_/I&JRVK7<<O+Q.5.=F><*01ZUGO^R)X#:\@E5]<BM1#;6]
MUI\>L3"UOX[< 0K<1Y_>!< ]B2.<U[9N'K1N'K0!Q7Q$^$VC?$BRT^.\EU#2
MKW39#+8:GHUVUI=VC$;6V2+V(X*D$'CC@5CZ)^SKX)\/:?-9V.GW"1SZ5-H\
M[O=R/)-#,S-*SL22TC,[$N>>:]-W#UHW#UH XN^^$7AS4?#WAC19K:8V'ANZ
M@O-/03L&22%62,L>K !CP>M<[KW[-?A/69Y+RVN-:T'5FOKF^&JZ+JDMK=*U
MPP:= ZG[CE1E<8&,C!YKU;</6C</6@#A_#OP>T#PKXGM->TPZA!>V^EIHY62
M_EECF@1BR>8')+NI9L.3GYCDFO)?$?[,NL>)OBK!J\DUCIWAZ'Q FOD6.J7J
MF:158 -8MFW$C,WS2AN<9"!B37TEN'K1N'K0!XO=_LE>!9['3[*V;6]*M+>R
M73+F+3=7F@&HV:EBMO<[3F1 7;T.&(S@XK1F_9E\&3^*AK)75%A-W%?RZ.NH
MRC3IKB)52&5[?.TE B[1TR 2"0"/5]P]:-P]: /$$_8^\![?)N)=?OK**UO;
M&RL;K69GM[&WNHS'-%#'G"@J< G+#CYN*[KQ=\*-+\6^%M.T7[=J^BC32C65
M]HVH26MU;E4* AU^]E200P8'/3(!':[AZT;AZT >(W7['W@"XMWMHSK=G:7.
MFG2M2M[75YHUU2#=(X%R0=SG?-*V01DN<Y'%;_B+]G?PMX@M9-DNK:3J1O?[
M0AU?2M1DM[RWG,*P,T<@Z!HT"E2"IZXR 1Z?N'K1N'K0!Y#K/[,'A/6=*L--
M;4/$MO80VQL[RWAUZYVZI 7=VCN]S-YNYI');AOG(W8XKI?!GP^GT#QOXL\2
M7ERLDNJFVM;2VB8^7:V5O&1&G(^\7>5SCCYP.V3W.X>M&X>M "T4FX>M&X>M
M "T4FX>M&X>M "T4FX>M&X>M "T4FX>M&X>M "T4FX>M&X>M "T4FX>M&X>M
M "T4FX>M&X>M "T4FX>M&X>M "T4FX>M&X>M "T4FX>M&X>M "T4FX>M&X>M
M "T4FX>M&X>M "T4FX>M&X>M "T4FX>M&X>M "U\"?\ !2'_ )';PC_UX2?^
MAFOOK</6O@7_ (*0G_BM?"/_ %X2?^AFKAN?-\0?\B^?R_,^/****Z#\>"BB
MB@04444 %>X^"?\ DC>D_P#87O/_ $&.O#J]Q\$_\D;TG_L+WG_H,=-;F.)_
MW2MZ?JAU%%%:GP 4444@"BBB@ KV3PY_R3#PS_UWO_\ T<M>-U[)X<_Y)AX9
M_P"N]_\ ^CEIHZZ?\"O_ (5_Z7$6BBBJ/GPHHHH **** "O5=!_Y%'1?^N<O
M_HUJ\JKU303_ ,4CHO\ USE_]&M4RV/K.'OXM7_#_P"W(M44E%8GUPM%%% !
M124M !76P_\ (-L/^N/]37)5UL)_XEMA_P!<?ZFI9[&7?\O/1?F@HHS1FH/3
M"BC-&: "BC-&:  =:](\.?\ ($MO]VO-\UZ/X<(_L6UY_AJ)'TV1?QI^GZFF
M.E+2;AZT;AZU!]J&*,4;AZT;AZT +12;AZT;AZT +12;AZT4 < ?AQXA))_X
M63XC'MY%C_\ (]'_  K?Q#_T4KQ'_P" ]C_\CU\A>/?VZOB-X4\8?$46.H?#
M*]MO"OB:;1;3P-.UVOB;6(D,8#6ZQR."6\PX;RBN8VS@ X]&^)/[6'CWX8>.
MO$/P^O/"]EJ7C;77MI/APD$$R6^IQRD)*EV=[!'M6W/(0RAD ("Y%:<\OZ2.
M+ZG2\_\ P*7^9[O_ ,*W\0_]%*\1_P#@/8__ "/1_P *W\0_]%*\1_\ @/8_
M_(]?&_Q7_;V^('PM^*7CWPU<Z[\-=_A*2RBCT/4+*_AU'77DM(I95MG25TC)
MD=E3>IQE=Q.":W_BW^VK\0/"OQ@\3>&]/U?X9>#K#1M%L-6CL?&[W/VV^DGB
M+O;0-!+\[J1M^6-CR.#FCGE_20?4Z7G_ .!2_P SZI_X5OXA_P"BE>(__ >Q
M_P#D>C_A6_B'_HI7B/\ \!['_P"1Z^/?B3^WUX[T'QQX1T@WG@+X76NL>"K+
MQ+./'UG?SR)<S2R(UNIMW4\! PW*#C.<'@>J^'_VL=?\+:YK5IX^E\/7^FKX
M%3QGI.K^'()X;>^1 WVE%\Z1F(P8F7A2%8YS1SR_I(/J=+S_ / I?YGMO_"M
M_$/_ $4KQ'_X#V/_ ,CT?\*W\0_]%*\1_P#@/8__ "/7SG\3/VO?B3\-_@K\
M,-5'AC2=9^(OB2SDUW4]'@AF2"UTR&(W$[ >865UC:)<LQR[?=[5T7Q7_;53
MX<_$_P"%$<%E;W_PV\7Z4^I7VM!'\ZPC=H5@G)#;1'NG4/D$C/48HYY?TD'U
M.EY_^!2_S/:O^%;^(?\ HI7B/_P'L?\ Y'H_X5OXA_Z*5XC_ / >Q_\ D>OF
M3Q_^U-\9[/X*ZW\1?"\7@5;'0]?U'2+VUU6SNY'F2*]6"W>(QS 9VDER3@G&
MT"OJ[X8?\)I_PB5L?'T^A7'B,LS2OX<AFBM-A^YM69F?..N31SR_I(/J=+S_
M / I?YF9_P *W\0_]%*\1_\ @/8__(]'_"M_$/\ T4KQ'_X#V/\ \CUZ!11S
MR_I(/J=+S_\  I?YGG__  K?Q#_T4KQ'_P" ]C_\CT?\*W\0_P#12O$?_@/8
M_P#R/7H%%'/+^D@^ITO/_P "E_F>?_\ "M_$/_12O$?_ (#V/_R/1_PK?Q#_
M -%*\1_^ ]C_ /(]>@44<\OZ2#ZG2\__  *7^9Y__P *W\0_]%*\1_\ @/8_
M_(]'_"M_$/\ T4KQ'_X#V/\ \CUZ!11SR_I(/J=+S_\  I?YGG__  K?Q#_T
M4KQ'_P" ]C_\CT?\*W\0_P#12O$?_@/8_P#R/7?GI7A>B?M)FW'B)-:T>_U"
MXLM<O=/M8/#^G23M]FMT1FDE);:I 8\EAGH!FCGE_20?4Z7G_P"!2_S.U_X5
MOXA_Z*5XC_\  >Q_^1Z/^%;^(?\ HI7B/_P'L?\ Y'KEY?VM/ ICBGLQK.IV
M1LX-0FO++29I(;:WE;:CRM@;?FX(&6'ICFM6W_:.\*76K:M;0QZK+8:6\T5W
MK$>GN]E%)$F]T:09*D \;@ >@)HYY?TD'U.EY_\ @4O\S3_X5OXA_P"BE>(_
M_ >Q_P#D>C_A6_B'_HI7B/\ \!['_P"1ZQ+?]I;PS-X?.JOIGB&!))((K*!]
M)D,FHF89B^S[25DR.N&^7^+%4[G]JWP?"+&"&Q\07NK7+W43:1:Z3(]W;O;@
M&=94R-A4$'DX.1@G-'/+^D@^ITO/_P "E_F=/_PK?Q#_ -%*\1_^ ]C_ /(]
M'_"M_$/_ $4KQ'_X#V/_ ,CTFM_&71K7X.7'Q#TQVU#239?:K;Y&4REB%12,
M9'SD*>..:\!\;?M.^,_#OQ$U#PY=^.OACX'-AIEE>"'Q39W+2WTLT>]TB*W2
M' /RC".V>QZ4<\OZ2#ZG2\__  *7^9[_ /\ "M_$/_12O$?_ (#V/_R/1_PK
M?Q#_ -%*\1_^ ]C_ /(]<-H?[5VEP^$]*O/$NA:Q8ZR^FIJ>J6>G:?+<IIMN
MS%1-*< JC8W $;]O)7BNO_X:$\&- TL=]<2[=3&E>6EI(7:4QF0,%QDQ[!NW
M@8QBCGE_20?4Z7G_ .!2_P RU_PK?Q#_ -%*\1_^ ]C_ /(]'_"M_$/_ $4K
MQ'_X#V/_ ,CUR&N?M-Z>VEZG'I>FZGIVMP6UO?6T.OZ;);QW-M)<K"95Y!QR
MW#;3T.,5A:3^U2M_XKCL=56/PG90:QJ>GR_VCI\TOVN*TC#M(DRN%AVC);>K
M#L.>:.>7])!]3I>?_@4O\STS_A6_B'_HI7B/_P !['_Y'H_X5OXA_P"BE>(_
M_ >Q_P#D>N;7]JOP5%IUS=WRZMI)2WBN[:WU'3G@EOH99!'') K'Y@7('.",
MC< #71W/Q<BD^&'B+Q;::+JL4ND6US*VF:E:-;3L\*,VW!X*G'#J2"#D$T<\
MOZ2#ZG2\_P#P*7^8O_"M_$/_ $4KQ'_X#V/_ ,CT?\*W\0_]%*\1_P#@/8__
M "/7&Z7^UCX:_L'3[[5M/U>Q?[#:WNK/%822V^D"< Q_:9!PF<@\9PI#-@'-
M=%\7_BGJ7A5O"NB>%K:ROO$OBJ[:UTZ746<6<")$9))Y-GS.%7&$4@L6'S 9
M-'/+^D@^ITO/_P "E_F:'_"M_$/_ $4KQ'_X#V/_ ,CT?\*W\0_]%*\1_P#@
M/8__ "/7%>'?CCJ7A"U\0GX@ZYX3UR#37@2#4/!KLTL\TLAC6U:Q,LLB2[\
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M\OZ2#ZG2\_\ P*7^9Y__ ,*W\0_]%*\1_P#@/8__ "/1_P *W\0_]%*\1_\
M@/8__(]>@44<\OZ2#ZG2\_\ P*7^9Y__ ,*W\0_]%*\1_P#@/8__ "/1_P *
MW\0_]%*\1_\ @/8__(]>@44<\OZ2#ZG2\_\ P*7^9Y__ ,*W\0_]%*\1_P#@
M/8__ "/1_P *W\0_]%*\1_\ @/8__(]>@44<\OZ2#ZG2\_\ P*7^9Y__ ,*W
M\0_]%*\1_P#@/8__ "/1_P *W\0_]%*\1_\ @/8__(]>@44<\OZ2#ZG2\_\
MP*7^9Y__ ,*W\0_]%*\1_P#@/8__ "/1_P *W\0_]%*\1_\ @/8__(]>@44<
M\OZ2#ZG2\_\ P*7^9Y__ ,*W\0_]%*\1_P#@/8__ "/1_P *W\0_]%*\1_\
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M9_Z[W_\ Z.6A29U4U^XK_P"%?^EQ,G^Q+W_H/ZA_WQ#_ /$4O]B7G_0?O_\
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M\&^'_$FEZ4\FKP:%XBM&TFXNK<6:7DDT1MY")/\ 2"A0-N(5&R08^ :V;?\
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M(\ZYG64*5SAC\@!;/.<U])01^3"B9SM4#/T%?%6L?M%>/_%>G:QH<GV&VU*
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M%SX+\=6#+#H-_P")'T>TBB,FV^TZ4"-9F7>5+"4%@V.%7'<T ?1E%(IR*6@
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MY,9N0/:4Q1E_[Q4$\U9_X0_5OL%O!_PF.KF6.(1M<^5;;Y&V.N\CRL9RRMP
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MCF.WRO!''[O'<'\!2OX4U-HE7_A+-55@V[>([?)&2<?ZOI@@>O HLNXN>?\
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MQF)4MM.32M-L(+=8HK&W!W,%QU+''I@#%=Q110 4444 %%%% !1110 4444
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MC#;WR01K+IUQ9S3SV]S%ZNLLRL >,QCU-4/&'[&FG>(].TC38->":99>'O[
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MK6UI/[(GBQM:_M+6?%6EZE=Q6%]8+<7L%U?_ &L3G(>6*>8QQ@#@QQ*!W!%
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M ,D;TG_L+WG_ *#'7AU>X^"?^2-Z3_V%[S_T&.FMS#$_[I6_P_JAU%%%:'P
M4444 %%%% !7LGAS_DF'AG_KO?\ _HY:\;KV3PY_R3#PS_UWO_\ T<M-'72_
M@5_\*_\ 2XBT4451\^%%%% !1110 5ZKH/\ R*.B_P#7.7_T:U>55ZKH/_(H
MZ+_USE_]&M4RV/K.'OXM7_#_ .W(LT445B?7!7J_PN_Y%R3_ *[M_(5Y17J_
MPN_Y%R3_ *[M_(5G/8^NX8_WY_X7^AV-%%%8'ZP%%%% !1110 4444 %%%%
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M&_!/I7>U@^!_"%IX#\+:?H5C)++:62%(WG(+D%BW)  ZDUO4 %%%% !1110
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M@]?^?"?_ .2*/^%Z>-.>=!_\ )__ )(HHH]G#L'UW$_\_']X'XZ>-.>=!_\
M "?_ .2*#\=/&G/.@_\ @!/_ /)%%%'LX=@^NXG_ )^/[P_X7IXT]=!Z?\^$
M_P#\D4?\+T\:>N@]/^?"?_Y(HHH]G#L'UW$_\_']X?\ "]/&GKH/3_GPG_\
MDBO:? FLWGB#PO8:A?\ D?:YE)?[-&R)U(X#,Q'YFBBN>M&,4K(]G*L16JUF
MJDFU;_(I?$WQ+J/A7PRU]IGV7[4)40?:XFD3!//"NIS^->1_\+S\:#_H _\
M@OG_ /DBBBJHPC*-VB<SQ-:E7Y83:5D'_"]/&GKH/7_GPG_^2*/^%Z>-/70>
MO_/A/_\ )%%%;>SAV/(^NXG_ )^/[P/QT\:>N@_^ $__ ,D4?\+T\:>N@]?^
M?"?_ .2***/9P[!]=Q/_ #\?W@?CIXT]=!_\ )__ )(H/QT\:<\Z#_X 3_\
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M_P#)%%%'LX=@^NXG_GX_O#_A>GC3(YT'_P  )_\ Y(H_X7IXTXYT'_P G_\
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M_ "?_P"2*/\ A>GC3UT'K_SX3_\ R1111[.'8/KN)_Y^/[P_X7IXT]=!Z_\
M/A/_ /)%!^.GC3UT'_P G_\ DBBBCV<.P?7<3_S\?W@?CIXTYYT'_P  )_\
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1%%%%1*G#L=E#%XB2=YL__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>gmab-20220630xex99d1011.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gmab-20220630xex99d1011.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1"  X (4# 2(  A$! Q$!_\0
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7 4444 %%%% !1110 QDW'K1110!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>gmab-20220630xex99d1007.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gmab-20220630xex99d1007.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" $I Z@# 2(  A$! Q$!_\0
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MGCN^O-%\1:GI>H>+_#5YXEB\*3-:W6M:=#HD,-V+-ED1RHNU7<J.K%5.#P:
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MPJ%#1%%AMU=3&P<XR:^Y: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M;1Z"@J#V%+10 FT'L*,#T%+10 FT>@HVCT%+10 @ '08I:** "BBB@ HHHH
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M7V@+XRTZW\:6%S:6\%V;@1WMA 7(+6\*S6A4)M W.<=<>K:U\=OB/HWC.W\
MM-X2D\23>)++23K(MIQ:);W6FWMXI^S>=O\ .1K(KM\S#JZGY,G !]/45\D-
M^U;XZ.G7>JKI.B/IWAK1=;U77T@AGEEOGTZ^N+,I9#>/+68PB0,^_8,KAL[A
MLWW[0WCGP%KS:=XI7PUJEO;V6F>(;[4]%@GCMK72KB[:UN-Q>1OFA)29920K
MQ1S$HI49 /IZDS7QYKG[7'C^ZN(U\.^'[*=9-'NO%5MNL);A;K3?M<T-E&S+
M.@MS+'!YK7+;E02H/+X8UT7B/XL>./%7BG1KFUN-*T'PK;>-M*T*;3XYI#J<
MKM%%/+NE1_+9"90GD[3NC4R;SD+0!]144@Z"B@"(W4/_ #U3_OL4?:H?^>L?
M_?8KD6^#?@8 L?">D>I/V1?\*\=\+_%O]F#QIXDL- T/6_!.IZS?S"WMK&W"
MM++(>BJ,=:OW?,Y+XGM'[W_D?2'VJ'_GK'_WV*/M4/\ SUC_ .^Q7(#X-^!&
MZ>%-(/\ VZ+65K?@7X7^&[G2+?4]#T&RFU>\%A81S6RJ;FX,;R"-..6V1NV/
M131:/F%\3VC][_R/1/M4/_/6/_OL4?:H?^>L?_?8KSCPGX(^%OCGP]9:[H.A
MZ#JFD7J>9;WEO;*T<JY(R#CID$?A5JS^&_PTU&_O[*TT'P_<WFGNL5Y!##&[
MV[L@=5D4<J2K*P!YP0>AHM'S"^)[1^]_Y'>_:H?^>L?_ 'V*/M4/_/6/_OL5
MR'_"F_ N/^13TC_P$7_"C_A37@7_ *%/2/\ P$6BT?,+XGM'[W_D=?\ :H?^
M>L?_ 'V*/M4/_/6/_OL5YIK/A+X3^'_$6@Z#J.D^'K/6-=:9-,LIK=!+=F)/
M,E$:XYVI\Q]!6Z/@SX%(_P"13TC_ ,!%HM'S"^)[1^]_Y'7?:H?^>L?_ 'V*
M/M4/_/6/_OL5R/\ PIGP-_T*>D?^ BT?\*9\#?\ 0IZ1_P" BT6CYA?$]H_>
M_P#(Z[[5#_SUC_[[%'VJ'_GK'_WV*Y'_ (4SX&_Z%/2/_ 1:/^%,^!O^A3TC
M_P !%HM'S"^)[1^]_P"1UWVJ'_GK'_WV*0W</_/5/^^Q7)?\*9\#?]"GI'_@
M(M'_  IGP-_T*>D?^ BT>[YA?$]H_>_\CL58.H*G(]0:?5/2M(L]#T^&QL+6
M*SLX%VQ00KM1!UP .G6KE0=2O;4C>>-#AG53Z%@*;]JA_P">J?\ ?8K"U[X=
M^&?%%^+W5M"L-1NP@C\ZY@5VVC.!D]N3^=9W_"F? W_0IZ1_X"+5>[U.>3KW
M]U*WJ_\ (Z[[5#_SUC_[[%'VJ'_GK'_WV*Y'_A3/@;_H4](_\!%H_P"%,^!O
M^A3TC_P$6G:/F3?$]H_>_P#(Z[[5#_SUC_[[%'VJ'_GK'_WV*Y'_ (4SX&_Z
M%/2/_ 1:\XUCQ)^S]X?\8R>%M3F\)V&O1W,=F]G<1*A2:159(RQ&T,P92 3S
MN'K1:/F%\3VC][_R/=?M4/\ SUC_ .^Q1]JA_P">L?\ WV*Y ?!KP*1_R*>D
M?^ B_P"%9OB;X?\ PQ\':!J.MZUH.A:;I.GP-<W5Y<6RK'#&HRS,<= *+1\P
MOB>T?O?^1Z#]JA_YZQ_]]BC[5#_SUC_[[%>._#Y?@C\5)+Z/PI;>&=;FL=GV
MJ&V@7S(0^=A9" P!P<'&#@^E=F?@WX%QD>$](_\  1:+1\POB>T?O?\ D=?]
MJA_YZQ_]]BC[5#_SUC_[[%<#H/PX^&GBC2+?5-*\/Z'?Z?<*6AN8+9&20 D$
M@XYY!'X5H?\ "F? O_0IZ1_X"+1:/F%\3VC][_R.N^U0_P#/6/\ [[%'VJ'_
M )ZQ_P#?8KD?^%,^!O\ H4](_P# 1:/^%,^!O^A3TC_P$6BT?,+XGM'[W_D=
M=]JA_P">L?\ WV*/M4/_ #UC_P"^Q7(_\*9\#?\ 0IZ1_P" BT?\*9\#?]"G
MI'_@(M%H^87Q/:/WO_(Z[[5#_P ]8_\ OL4?:H?^>L?_ 'V*Y$_!GP*!G_A$
M](_\!%K)T+P)\+_$LVKPZ9H>@WTNDWK:=?)#;*QM[@(DAB?CA@DL;8]&%%H^
M87Q/:/WO_(]$^U0_\]8_^^Q1]JA_YZQ_]]BN1_X4UX%'_,IZ1_X"+_A2?\*:
M\"Y_Y%32/_ 1:+1\POB>T?O?^1U_VJ'_ )ZQ_P#?8H^U0_\ /6/_ +[%<A_P
MIOP+C/\ PB>D8_Z]%_PH/P:\"C_F4](_\!%_PHM'S"^)[1^]_P"1U_VJ'_GK
M'_WV*/M4/_/6/_OL5R/_  IGP-_T*>D?^ BT?\*9\#?]"GI'_@(M%H^87Q/:
M/WO_ ".N^U0_\]8_^^Q1]JA_YZQ_]]BN1_X4SX&_Z%/2/_ 1:/\ A3/@;_H4
M](_\!%HM'S"^)[1^]_Y'7?:H?^>L?_?8H^UP_P#/6/\ [[%<C_PIGP-_T*>D
M?^ BT?\ "F? W_0IZ1_X"+1:/F%\3VC][_R.M%S$Q $B$GL&%3#I7(VOPC\&
M6-U#<V_A?2H;B%Q)'*EJH9&!R"#V(-==4NW0VI^TM^\2^0C'%1_:H<X\V,?\
M"%2E0>M<:_P;\#NS,WA32"S$DDVB\DT*W453VG_+M+Y_\,=;]JA_YZQ_]]BC
M[5#_ ,]8_P#OL5Y-I]C\$-6U]=#LG\%7FM-(\(TZWN+9[@NF=Z^6&W97:V1C
M(P<]*Z2]^$_P]TVSGN[OPUH=M:V\;2S3S6Z(D:*,LS,>   22>E5:/F97Q/:
M/WO_ ".U^U0_\]8_^^Q1]JA_YZQ_]]BN/C^#O@.5%=/"VC.C %66U0@@]"*=
M_P *:\"_]"IH_P#X")1:/F%\3VC][_R.N^U0_P#/6/\ [[%'VJ'_ )ZQ_P#?
M8KD?^%->!<?\BIH__@(E5=4^%_PXT2PFO=0\/Z#8V<*[I+BYACCC09QDLV !
MR.M%H^87Q/:/WO\ R.X^U0_\]8_^^Q1]JA_YZQ_]]BN1_P"%->!1_P RII'_
M ("+1_PIKP+_ -"II'_@(M%H^87Q/:/WO_(Z[[5#_P ]8_\ OL4?:H?^>L?_
M 'V*Y'_A37@7_H5-(_\  1:S=6^'WPOT"6QBU/1_#>GRW\XM;1+I(HC<2D9$
M<88C<Q /RC)XHM'S"^)[1^]_Y'H'VJ'_ )ZQ_P#?8H^U0_\ /6/_ +[%<A_P
MIKP)_P!"IH__ ("I0?@WX$49/A31P!US:I1:/F%\3VC][_R.O^U0_P#/6/\
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MZTS[)#_SS7]:=;B_"T9<KI2V3W757(P_AYF>(@YJM!:M?:Z-KMY'ZB_:HO\
MGJG_ 'U5;48;#5]/NK&]2"[LKJ)H9[>8!DEC8896!X(()!!]:_,/[)#_ ,\Q
M^M'V2'_GF/UK'_7/"?\ /J7WHZO^(:YI_P _Z?\ Y-_D?H]K?P]\'^);'4K+
M5M#TO4[/4IHI[RWNX%DCGDB55B9E/!*B- #VVCTJUX1\(^&O .G2:?X<TNPT
M2RDE,[V]C&L2-(0 6('?"@9]A7YK_9(?^>8_6C[)#_SS6C_7/"_\^I?>@_XA
MKFG_ #_I_P#DW^1^HOVJ+_GJG_?5'VJ+_GHG_?0K\NOLD/\ SS6C[)#_ ,\E
M_6C_ %SPO_/J7WH/^(:YI_S_ *?_ )-_D?J(;J+/^L3_ +Z%+]JB_P">B?\
M?0KX(^%GAS2]1\)Z]+=:?;W$L5]:HCR)N908YB0#Z' _*NC_ .$0T7_H%6G_
M 'Z%>S3XAP]2G&HH/57Z=[?H?-5N$,PHUIT74A[KM]KLGV\S[4^U1?\ /1/^
M^A1]JB_YZ)_WT*^*_P#A$-%_Z!5I_P!^A1_PB&B_] JT_P"_0J_[?H?R/\#/
M_5/,/^?D/Q_R/I_5?A!\/M<\3OXCO_"FAW>O/)'*^I2VL;7#/& (V+]25  '
MIBNT%S$/^6B?]]"OBS_A$-%_Z!5I_P!^A1_PB&B_] JT_P"_0H_M^A_(_P
M_P!4\P_Y^0_'_(^U/M47_/1/^^A1]JBZ^8G_ 'T*^*_^$0T7_H%6G_?H4G_"
M(:)_T"K3_OT*/[?H?R/\ _U3S#_GY#\?\C[4^U1?\]$_[Z%+]JA_YZI_WV*^
M3?!W@?P]<C5?.T2QEV6ZLN^$'!\Q1D?A6L/ 'AK_ * .G_\ ?@5V0S:C."GR
MO7T/-GD&.A4E3YH:>O:_8^G/M4/_ #U3_OL4?:H?^>J?]]BOF/\ X0#PU_T
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M#SK#]E5ED9R5(WY9FK[<VCTHP!0 V(DHI/7'-/I,8I: "BBB@ HHHH ****
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MQGXB(/((EMN?_(-%H]P]K6_Y]_BCLLT9KCO^$ O/^AR\1_\ ?RW_ /C-'_"
M7G_0Y>(_^_EO_P#&:+1[A[6M_P ^_P 4=CFC-<=_P@%Y_P!#EXC_ ._EO_\
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MZBD $A<IL,GIO*?(7QN*_+G'% '7#H**!TI: $I&[?6G4UN@^HI ?AU\9O\
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MR-EC_P #_P#0&KV.OJ,K_@OU_P CX3//]Y7HOS8E%+17L'SHE%+10 E%+10
ME%+10 E%+10 E%+10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M/X#_ ,<__2Y!1117 >J%%%% !1110!ZU\'_^1.\1?]A"S_\ 1<]=37+?!_\
MY$[Q%_V$+/\ ]%SUU-?<8;_=J7I^K/RS&_[]B/\ %_[;$****Z#E"BBB@ HH
MHH$=-X(_YC'_ %[)_P"C5K:'2L7P1_S&/^O9/_1JUM#I7MT?X,/G^9\QB/\
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M ./T<J[A]8E_S[E^'^9U]%<>-(\:-T\3:5_X*&_^/TO]C>-?^AFTO_P4/_\
M'Z.5=P^L2_Y]R_#_ #.OHKD/[&\:_P#0S:7_ ."A_P#X_1_8OC7_ *&;2_\
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M *&;2_\ P4/_ /'Z.5=P^L2_Y]R_#_,Z^D;M]17(_P!B^-?^AFTO_P %#_\
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M$=U]S_S)].U*UU:RBN[.XBNK64;HYH7#(P]01P:M5%!;16L2Q0QI%&O 1%
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M<"UTXP.0%E$<>TYZ8.,<T>[YA_M'=?<_\RC_ ,+0\(?]#/I'_@;'_P#%4?\
M"T/"'_0S:1_X&Q_XU'X3U'PKXT\.6FN:7:VDNG7*&2.22U6,[0Q7)5@".5/6
MML>'M*/_ ##+/_OPG^%'N^8?[1W7W/\ S,C_ (6AX0_Z&;2/_ V/_&C_ (6A
MX0_Z&;2/_ V/_&M?_A'=+_Z!EG_WX3_"C_A'=+_Z!EG_ -^$_P */=\P_P!H
M[K[G_F9'_"T/"'_0S:1_X&Q_XT?\+0\(?]#-I'_@;'_C6O\ \([I?_0,L_\
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M\P_VCNON?^9D?\+0\(?]#-I'_@;'_C1_PM#PA_T,VD?^!L?^-:__  CNE_\
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MX&Q_XU?L].T'4;2WNK6SL+BVN$$L4L<*,LB$9# @<@@@YJ8:%I)./[-L\_\
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M,IHP@H<ST]#S9Y_C9U)5.6.OKVMW/G?_ (2W0_\ H,Z?_P"!2?XT?\);H?\
MT&=/_P# I/\ &OHC_A'M,_Z!UI_WX3_"C_A'M,_Z!UI_WX3_  JO[*H_S/\
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M^-TDP0%R>V^#OCJ?XC_#G2-=O+7[%J$OFVU[;@$+'=03/!.%SSM\V)]I/;%
M':4444 %%%% !1110 4444 %%%% "'H:^9_&.C>.FL/C3X,TKP'J&H'QC<W)
MT_77O;6'3T2XT^WMMTA,OFC8R.2!&2=HQG-?3-)B@#Y/M?AMXY\,>)#X/LO#
M>H:CHZ>)]"U>'Q2UW"MN+*UL+.UD+(9/,\X26I8QA<%7W;CR*\_7]GOQO=>
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M\0Z/;&XCCOIHI-,*6ZW,@D\Q;6* YD5H@DDFY6=BH.5XWX:6'B[QE\/M+O\
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MQGC-3CX7Z0?^7O6?_!O<_P#Q=%H]_P  Y\1_S[7_ (%_]J=?N'K1N'K7(_\
M"K])_P"?O6?_  ;W/_Q='_"K])_Y^]9_\&]S_P#%T6CW_ .?$_\ /M?^!?\
MVIUVX>M&X>M<C_PJ_2?^?O6?_!O<_P#Q='_"K])_Y^]9_P#!O<__ !=%H]_P
M#GQ/_/M?^!?_ &IUV<]*6J>F:9%I-C#:0O,\40PK3RM*Y^K,23^)JW4'6KVU
M L!2;A6%K?@JPU^]^U7,^HQR; FVUOYH4P,_PHP&>>M9_P#PJ_2?^?O6?_!O
M<_\ Q=6E'JSFE.NFU&":]?\ @'7;AZT;AZUR/_"K])_Y^]9_\&]S_P#%T?\
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M'K7(_P#"K])_Y^]9_P#!O<__ !='_"K])_Y^]9_\&]S_ /%T6CW_  #GQ/\
MS[7_ (%_]J==N'K1N'K7(_\ "K])_P"?O6?_  ;W/_Q='_"K])_Y^]9_\&]S
M_P#%T6CW_ .?$_\ /M?^!?\ VIUVX>M&X>M<@?A?I _Y>]9_\&]S_P#%U3E\
M#^&H;.:[DU;4DMH6*23-KEP$0@[2"?,P"#Q]:+1[_@'/B?\ GVO_  +_ .U.
M[W#UHW#UK@]-\%>&=8A::PU?4;R)3AG@URX< ^Y$E1Z5X1\*ZZ\ZZ=K=_?-
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M . __;'L_6,S_P"@>/\ X,_^T&9HS3_,/HO_ 'R*/,/HO_?(H]GA?^?C_P#
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MQFG_ $#1_P#!C_\ D"?-&14'V&/^]+_W\:C[%'_>E_[^-1[/"_\ /Q_^ _\
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MGQ/_ #[7_@7_ -J==N'K1N'K7(_\*OTG_G[UG_P;W/\ \71_PJ_2?^?O6?\
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M)!1116)U!1110 4J_>'UI*5?O#ZT >^^*O\ D4?AE_V*5K_Z/N:YFNF\5?\
M(H_#+_L4K7_T?<US-?/YC_O4_7]#ZW)?^1?2]'^;"BBBO-/;"BBB@ HHHH ]
M>T/_ ))?X7_Z^M1_]#BJ.I-#_P"27^%_^OK4?_0XJCK3&_Q5_AC_ .DHRRS^
M _\ '/\ ]+D%%%%<!ZH4444 %%%% 'K7P?\ ^1.\1?\ 80L__1<]=37+?!__
M )$[Q%_V$+/_ -%SUU-?<8;_ ':EZ?JS\LQO^_8C_%_[;$****Z#D/1?@5_R
M.<O_ %Z/_P"A+7OU> _ K_D<Y?\ KT?_ -"6O?J_0\E_W->K/Q[B7_D8R]%^
M04445[I\L%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 (PR
M/QKX@?\ 8@\=6,>ERZ?KVBB?0?%VMZYIT<5S<6@N;74HW5UF=(V,<L98!=H9
M2I89&:^WG.%]Z^4?'7[1>HZ=\$9O$4WB)?#&H^+O%MQH&B74D",-)MHKN2!Y
M]N&WE8;6:<[@1ND53@= #B=>_8-\4P1>$4\):IHOA^\TC1-/TM]4BO;LLK0S
MM+*CV\J2QW4 #L(E?8RY&6P*[*#]CK7#\8=.\67>IZ/<Z7;_ !$U7QE):2([
M.UO=:?!:QQ8*;?,5X2Q[8Q@YXJWX+^+NL_'O2OA&=+\77OAQM5L=7&MR:-'
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MP8EQU->CCI0 M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MQ/P-@U^U^"O@&'Q7]H_X2B+0+!-6-VVZ;[8+=!/O/=MX;)[G-=O110 4444
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MSO\ A3G@7_H3]#_\ (_\*T7)UN<DGB>9\JC;U?\ D=#_ ,)%I?\ T$;7_O\
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M7_H3M#_\ (__ (FCW/,.;%=H_>_\CH?^$BTO_H(VO_?Y?\:/^$BTO_H(VO\
MW^7_ !KCO$/P[^&OA30=1UK5O#/A^QTO3[=[JZN9;&,)%$BEF8G;T !-<WX'
M/P3^)%[/9>'=-\,ZC?01">2T6QC698\[=^QE!VYXW8QFCW/,+XOM'[W_ )'J
MO_"1:7_T$;7_ +_+_C1_PD6E_P#01M?^_P O^-<Z/@_X#/\ S*&A?^ $7^%+
M_P *=\"?]"?H?_@!%_\ $T>YYA?%]H_>_P#(Z'_A(M+_ .@C:_\ ?Y?\:/\
MA(M+_P"@C:_]_E_QKG?^%/> \9_X1#0L>OV"+_"L36?"GPG\/W$]O?:%X:@N
M8(HKB6W-G$94CDE\J-R@&=K2?*#C&0?0T>YYA?%]H_>_\CO?^$BTO_H(VO\
MW^7_ !H_X2+2_P#H(VO_ '^7_&N=_P"%/> R<?\ "(:%G_KPB_PI1\'? AZ>
M#]#_ / "+_XFCW/,+XOM'[W_ )'0_P#"1:7_ -!&U_[_ "_XT?\ "1:7_P!!
M&U_[_+_C7CUEK/P&U#Q?)X7AMO"IUQ+Q].^RO9QJ6N4)#0J2N&<%6^4'/!]*
MZ_0OAY\-O$NEPZCIWA?0;FSF+*DJZ?& 2K%&ZKV92/PHM#S"^+[1^]_Y'9?\
M)%I?_01M?^_R_P"-'_"1:7_T$;7_ +_+_C7/?\*<\"_]"?H?_@!'_P#$T?\
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MUSW_  ISP+_T)VA_^ $?_P 31_PISP+_ -"=H?\ X 1__$T>YYA?%=H_>_\
M(Z'_ (2+2_\ H(VO_?Y?\:/^$BTO_H(VO_?Y?\:Y[_A3G@7_ *$[0_\ P C_
M /B:/^%.>!?^A.T/_P  (_\ XFCW/,+XOM'[W_D=#_PD6E_]!&U_[_+_ (TA
M\0Z6<8U&UZ_\]E_QKG_^%.>!?^A/T/\ \ (_\*#\'? HQ_Q1^A]?^?"+_"CW
M/,+XKM'[W_D?C9\8XWE^+GCAT1G1M=OR&49!'VA^17(?9Y?^>3_]\FNS^+5]
M<V'Q4\9VUK<2V]M!K=[%%#$Y5(T6=PJJ!T    KE/[:U#_G^N?\ OZW^-?E-
M98;VDKN6[Z+_ #/WS"RS/V%.T(;+[4NW^$K_ &>7_GD__?)H^SR_\\G_ .^3
M5C^VM0_Y_P"Y_P"_K?XT?VUJ'_/_ '/_ '];_&LK8;O+[E_F=7-F?\D/_ I?
M_(E?[/+_ ,\G_P"^31]GE_YY/_WR:L?VUJ'_ #_W/_?UO\:/[:U#_G_N?^_K
M?XT6PW>7W+_,.;,_Y*?_ (%+_P"1*_V>7_GD_P#WR:%MY=P_=OU_NFK']M:A
M_P _]S_W];_&E76M0W#_ $ZYZ_\ /4T6PW>7W+_,.;,_Y*?_ (%+_P"1/<?%
M)W>$_AH!R5\)VJL/0^?<\&N:VGT/Y5TGB51#X6^'4L:B.2X\+VT\[J,&60SW
M +L>[$*!D\\"N=\Z3_GHWYUX&81POUJ?,Y7OV7^9]3D\\U^HTN6%.VOVI=W_
M '1NP^A_*C8?0_E3O/D_YZ-^='GR?WV_.O/Y<)WE]R_S/:Y\X_Y]T_\ P*7_
M ,@-V'T/Y4;#Z'\J=Y\G_/1OSH\^3_GHWYT<N$[R^Y?YASYQ_P ^Z?\ X%+_
M .0&[#Z'\J-I]*=Y\G_/1OSH\^3^^WYT<N$[R^Y?YBY\X_Y]T_\ P*7_ ,@>
MLZ)(B_#+PPI90PN=0RN>1\\51^:G]X?G2:/I]K)\./#EP]M$UQ)<WX>4H"SA
M7BV@GJ<9./3)J,6%M_S[1?\ ? J\8L(ZJO*6T>B_E7F99=/-_8OEA3^*?VI?
MSR_NDOFI_>'YT>:G]X?G4?V"V_Y]HO\ O@4?8+;_ )]HO^^!7%RX/^:7W+_,
M]/GSC^2E_P"!2_\ D23S4_O#\Z/-3^\/SJ/[!;?\^T7_ 'P*/L%M_P ^T7_?
M HY<'_-+[E_F'/G'\E+_ ,"E_P#(DGFI_>'YT>:G]X?G47V"V_Y]HO\ O@4&
MPMO^?>+_ +X%+EP?\TON7^8<^<_R4O\ P*7_ ,@>N?"*[@B\'^(0\T:$ZA:$
M!F )Q'-73?VA:_\ /Q%_WV*XWX5^'-)U#PIKTMSI=G<2QWUJJ/+ K%08YB0"
M1P#@?D*Z3_A$="_Z UA_X#I_A7VN&6&^K4K.6W9=WYGYEC)YI]=KWA3OS?S2
M_EC_ '2]_:%K_P _$7_?8H_M"U_Y^(O^^Q5'_A$="_Z UA_X#I_A1_PB.A?]
M :P_\!T_PK>V'[R^Y?YG+S9G_)3_ / I?_(GJ'P/U:R@\83/)=P(OV1^6D '
MWE]Z]X_X2+2_^@C:_P#?Y?\ &OG+X-?#_P ,:KXLFAO/#NEW47V5VV2VB,,[
MEYP17MG_  ISP+_T)VA_^ $?_P 37WV3JE]47*WN_P"MS\FXBEC?K\N>,;V6
MS?;T.A_X2+2_^@C:_P#?Y?\ &C_A(M+_ .@C:_\ ?Y?\:Y[_ (4YX%_Z$[0_
M_ "/_P")H_X4YX%_Z$[0_P#P C_^)KV_<\SYF^*[1^]_Y'0_\)%I?_01M?\
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M\)%I?_01M?\ O\O^-<]_PISP+_T)VA_^ $?_ ,31_P *<\"_]"=H?_@!'_\
M$T>YYA?%=H_>_P#(Z'_A(M+_ .@C:_\ ?Y?\:/\ A(M+_P"@C:_]_E_QKGO^
M%.>!?^A.T/\ \ (__B:/^%.>!?\ H3M#_P# "/\ ^)H]SS"^+[1^]_Y'0_\
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MTO1_FPHHHKS3VPHHHH **** /7M#_P"28>%_^OK4?_0XJCQ4FA_\DO\ "_\
MU]:C_P"AQ5'6F-_BK_#'_P!)1EEG\!_XY_\ I<@Q1BBBN ]4,48HHH ,48HH
MH ]:^#__ ")WB+_L(6?_ *+GKJ:Y;X/_ /(G>(O^PA9_^BYZZFON,-_NU+T_
M5GY9C?\ ?L1_B_\ ;8A11170<AZ+\"O^1SF_Z]'_ /0EKWW%>!? K_D<Y?\
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M."*[L<"I:2V9T4YSFGSQY?N_0"<4;AZTC#/?%>?O\*]0=V8>/_%"@DG:)+;
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M ,"A_P#)$=%2>:/^>:?K_C1YH_YYI^O^-'L*'_/Y?=+_ "%]=QW_ $"2_P#
MH?\ R1'14GFC_GFGZ_XT>:/^>:?K_C3]A0_Y_+[I?Y!]=QW_ $!R_P# H?\
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MO\'O UWJ7BB:)/%FNV3?97;S+=X0Q^9>.8CQ7LW_  JC4?\ HH/BG_OY;?\
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M,?4X$2**]:SC,T:(<HJOMW *0" #QVH ^*O#W[1'B[X1_!#2]0T[4=+\<?\
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MX7_Z^M1_]#BJ.M,;_%7^&/\ Z2C++/X#_P <_P#TN04445P'JA1110 4444
M>M?!_P#Y$[Q%_P!A"S_]%SUU-<M\'_\ D3O$7_80L_\ T7/74U]QAO\ =J7I
M^K/RS&_[]B/\7_ML0HHHKH.0]%^!7_(Y3?\ 7H__ *$M>_5X#\"O^1SE_P"O
M1_\ T):]^K]#R7_<UZL_'N)?^1C+T7Y!1117NGRP4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110!A?\ "=>'LX_MJPS_ -?"?XT?\)SX>_Z#
M5A_X$I_C7R _WC3:[UAD^I\:\^FO^7:^\^P?^$Y\/?\ 0:L/_ E/\:/^$Y\/
M?]!JP_\  E/\:^/J*?U5=Q?V_4_Y]K[S[!_X3GP]_P!!JP_\"4_QH_X3GP]_
MT&K#_P "4_QKX^HH^JKN']OU/^?:^\^P?^$Y\/?]!JP_\"4_QH_X3GP]_P!!
MJP_\"4_QKX^HH^JKN']OU/\ GVOO/L'_ (3GP]_T&K#_ ,"4_P :/^$Y\/?]
M!JP_\"4_QKX^HH^JKN']OU/^?:^\^P?^$Y\/?]!JP_\  E/\:/\ A.?#W_0:
ML/\ P)3_ !KX^HH^JKN']OU/^?:^\^P?^$Y\/?\ 0:L/_ E/\:/^$Z\/?]!J
MP_\  E/\:^/J*/JJ[A_;]3_GVOO/L'_A.?#W_0:L/_ E/\:/^$Z\/?\ 0:L/
M_ E/\:^/J#TH^JKN']OU/^?:^\^U[.]@U"WCN+:5)X)!E)(V#*P]B*FSQ7(_
M"7_DG6B?]<?_ &8UUPZ5P25FT?6T9^TIQF^J3,S4?$^DZ3<""]U&UM9MH;RY
MIE5L'H<$^QJM_P )SX>_Z#5A_P"!*?XUX3^T%_R/J?\ 7E%_Z$]>:5V0PZE%
M.Y\WB<YG0K2IJ"=GW/L'_A.?#W_0:L/_  )3_&C_ (3GP]_T&K#_ ,"4_P :
M^/J*OZJNYS?V_4_Y]K[S[!_X3GP]_P!!JP_\"4_QH_X3GP]_T&K#_P "4_QK
MX^HH^JKN']OU/^?:^\^P?^$Y\/?]!JP_\"4_QH_X3GP]_P!!JP_\"4_QKX^H
MH^JKN']OU/\ GVOO/L'_ (3GP]_T&K#_ ,"4_P :/^$Y\/?]!JP_\"4_QKX^
MHH^JKN']OU/^?:^\^P?^$Y\/?]!JP_\  E/\:/\ A.?#W_0:L/\ P)3_ !KX
M^HH^JKN']OU/^?:^\^P?^$Y\/?\ 0:L/_ E/\:/^$Y\/?]!JP_\  E/\:^/J
M*/JJ[A_;]3_GVOO/L'_A.?#W_0:L/_ E/\:/^$Y\/?\ 0:L/_ E/\:^/J*/J
MJ[A_;]3_ )]K[S[!_P"$Y\/?]!JP_P# E/\ &C_A.?#W_0:L/_ E/\:^/J*/
MJJ[A_;]3_GVOO/L'_A.?#W_0:L/_  )3_&C_ (3GP]_T&K#_ ,"4_P :^/J*
M/JJ[A_;]3_GVOO/L'_A.?#W_ $&K#_P)3_&C_A.?#W_0:L/_  )3_&OCZBCZ
MJNX?V_4_Y]K[S[!_X3GP]_T&K#_P)3_&C_A.?#W_ $&K#_P)3_&OCZBCZJNX
M?V_4_P"?:^\^P?\ A.?#W_0:L/\ P)3_ !H_X3GP]_T&K#_P)3_&OCZBCZJN
MX?V_4_Y]K[S[!_X3GP]_T&K#_P "4_QH_P"$Y\/?]!JP_P# E/\ &OCZBCZJ
MNX?V_4_Y]K[S[$A\::#<3)%%J]E)([!51;A26)Z #-;(.17QUX/_ .1LT;_K
M\A_]#%?8HZ5RU:?LVE<]W+\;+&QE*4;6 G%89\<^'@2#K5@"#@C[0G^-;3U\
M4WG_ !^W'_75_P#T(TZ5+VE]3/,L?+ J#C&]SZ\_X3GP]_T&K#_P)3_&C_A.
M?#W_ $&K#_P)3_&OCZBNGZJNYXW]OU/^?:^\^P?^$Y\/?]!JP_\  E/\:/\
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MO^@U8?\ @2G^-?'U%'U5=P_M^I_S[7WGV#_PG/A[_H-6'_@2G^-'_"<^'O\
MH-6'_@2G^-?'U%'U5=P_M^I_S[7WGV#_ ,)SX>_Z#5A_X$I_C1_PG/A[_H-6
M'_@2G^-?'U%'U5=P_M^I_P ^U]Y]@_\ "<^'O^@U8?\ @2G^-'_"<^'O^@U8
M?^!*?XU\?44?55W#^WZG_/M?>?8/_"<^'O\ H-6'_@2G^-'_  G/A[_H-6'_
M ($I_C7Q]11]57</[?J?\^U]Y]A)XWT"1U1=9L6=B%51<)DD]!UHKY)T;_D,
76'_7S%_Z&M%9RH*/4[</F\ZR;<$C_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>gmab-20220630xex99d1009.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gmab-20220630xex99d1009.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" !! *H# 2(  A$! Q$!_\0
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ME$3312,9+E0Q( S!#,"6XP3FM&*\^,WBFT6STW0_#OPXL%7R5N-2NCJETB]
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&%%% '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>gmab-20220630xex99d1021.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gmab-20220630xex99d1021.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1"  U %\# 2(  A$! Q$!_\0
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B=JNT %%%% !1110 4444 %%%% !1110 4444 %%%% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>gmab-20220630xex99d1013.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gmab-20220630xex99d1013.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1"  X &,# 2(  A$! Q$!_\0
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M*TX]5UD.BR:&,%<L\5XC 'T&0":W,"C%)RON@.??Q%JJ,0/#5XX!ZBXAY_\
M'Z6#Q!JDT^QO#EU"N,^8]Q#CZ<-FM_%&*5UV Y_^TO$-QQ'HUK; @_-<WN<'
M/'"(<\<]:C_X1B[U9HSKFHB[B5@_V.UB\F D<C=DEGP?4@>U=)C%%/F:V 3:
M1TQBBG45%D V169&"MM8C@XSBJ%OH=M#<BY=6N+D=)ISN8?3LOX 444P-&BB
8B@ HHHH **** "BBB@ HHHH **** /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>gmab-20220630xex99d1005.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gmab-20220630xex99d1005.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" (! Z@# 2(  A$! Q$!_\0
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MXGO;:/S9K?3+Y)I$3.-Q4'.,\9]Z^=] \#^)8O\ @F;JWAF71-63Q/)X5U2
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M6?&&DSE@>^: /TPW#'6JEYK5AIT]M!=7D%M/=,4@BED"O*P4L0JDY8A02<=
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M75U,EO;0H9))9#A44#))/H!5BN:^)-I-?^ ?$5O;1//<2Z?.D<<:[F9C&P
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M $4+6_\ P$L?_C%'_"">(O\ HH6M_P#@)8__ !BCEC_-^8O;U?\ GT_OC_\
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M3^^/_P D=ONHW5Q'_"">(O\ HH6M_P#@)8__ !BC_A!/$7_10M;_ / 2Q_\
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M@.<!\]6[$Y_,8?\ !17XVD#_ (G]I_X+H/\ XBC_ (>*_&W_ *#]I_X+H/\
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M>M4_\!+/_P",T?V?5[H/]><N_P"?<_NC_P#)'OFZC.:\#^V^,/\ H>M4_P#
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M_P" EC_\8HY8_P WYA[>K_SZ?WQ_^2.V!HKC;?P3K\-Q&[^/=9G16!,;VMF
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M",_3_P!A;PCI_CZ;Q4GB7Q$\[WFL7L=HYM"B-J43QW0,OV?SI!B3*>9(Q7:
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M+XT_9LT#Q-=W5QI.HW_@HWVE2:)?KX=2WA6YLV<MLPT3>6RLS[73##S&ZY&
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MHVLHRC;LKN;G._/?_IK)_P!]?2EC\&Z/$&"6**&8L?F;DEBWKZDG\:^%+_\
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M7]KGQ]H7P:\/MINB6'BZ?PK\/--\7^*]3\1:T]O=7<<T;MLM_D??+MB=B\A
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M1]4>\CFNEMK&.R2Z(N659 <0SCG:7!/'S8K[3Q1B@ 48%+110 4444 %%%%
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MLR!0I5LX.3R_@[]DF_\ "O@C4?#[^)8+LW/A[3=$$YM&4;K6XN96D*[NC"X
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MZUW%<+\-&"I?9..5Z_C7<>8O]]?SKYC%_P :1_1W"\E_9%#7H_S8ZBF^8O\
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M]@"D%2<XS?L=9^#,^N>((I?"NFMH]E;:5/I]]80S7<NIM?>=Y:101J79OW7
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M:.>7</JU#^1?<CE/A1J7PU\:SZC'K_@G3- FS>S6%HUA>K++:V<@BN)W\V)
M/G9<*N3S@\@XZ'3=2^ &L:GIME9Z3:3-J$=K)#<C2[H6R_:8_,MTDFV;(W=,
M$([!N1P"1G0\1?LY:V;C3+WP[XJLM/U*WM]7L)I=0TQKF,VU_<^>Y5%E3$B$
M* 22IYR.>,.W_9$O+37/"4\'B>SMK31K&PL9[ZRT^2UU*YBMHA&T+S13JDD,
MHW96:-R@9MIY!!SR[A]6H?R+[D;_ (,T[X'^/M9;2]&T*UFN6BDGMWGTVXMX
MKR)'V/);R2*J3JK$ M&6 R.Q!KNO^%!?#W_H4M-_[]G_ !KA/@M^S./A1XDL
M;VXN]"OK;2+.2PTZ6UT8P7I1MHW33/*_S!%VD1*@;J1T ]ZW#&<\>M'-+N'U
M:A_(ON1P'_"@OA[_ -"EIO\ W[/^->??M _!OP5X?^"'CK4]-\-V-G?V>CW4
MT%Q$A#1NL;$,.>H-?0&X'H:\R_:9_P"3>_B-_P!@*\_]%-51G+F6IA7PU#V4
M_<6SZ(_$P>+]9P/^)E/T]1_A1_PEVM?]!*X_,?X5CCH/I2U[5V?DGLX?RK[C
M7_X2[6O^@E<?F/\ "C_A+M:_Z"5Q^8_PK(HHNP]G#^5?<:__  EVM?\ 02N/
MS'^%'_"7:U_T$KC\Q_A6111=A[.'\J^XU_\ A+M:_P"@E<?F/\*U/"OB;5;O
MQ/I$$U_-)%)=Q(Z,1A@7 (Z5RE;'@W_D;]$_Z_8?_0Q2;=C2G3@YQ]U;]CV3
MXH7$FE_$KQ79VCF"UM]4N8HHD^ZB"0@ >P%<Q_:UY_S\R?G71_%__DK'C/\
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M/_\ A07P]_Z%+3?^_9_QH_X4%\/?^A2TW_OV?\:] HHYI=P^K4/Y%]R//_\
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M?X=06?C/6]0FN(]D]X]C;VZP)OE:20Q,V>44!4.2XR0 2."UG]MZUTKX@_\
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M'0&N'^'WQ1\>^/9-!^'UWXGU70=1FU?4K:^U6[L[:/7+>TMX4DA@E788%NI
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MQ'%KW@NU\0RK=VEO"+:Z9H@ZQ>5&F$(E^ZVXC8.>37T-L7.=HSZXI0H'8#%
M'Q)I'Q*\2?!Y?'WB+34-WHDWCW5=.N=/2V#LUU-:6HLI-V-P'GA(R,@?O<G[
MM:6F^,?BI>>,M<TK4/B+?VTNC^*-&\..EGIMEY4B7%I ]S)\T!._S)7*G.%P
M!M(S7U%XH^'>E^,-;T+4M2>\D&CW'VN"RCNGCM9)A@H\L0.V0H0&7=G:1FNF
M"+Z#\J /@G_AH?QG'XA\6Z3JGQ.GTB7P]I=^^E0FQLS/J]W#?R0PB13#F5B@
M1#'$%+\$8.:UO"GBCQAX-U[Q?XGTW5+R*?4/B)9Z?>>&#! ;25KBPLEE!8QF
M57#. "'P-@R.37U[%\/-$A\>W/C%;4_V]<6*:<\YD)7R4D,B@)T!W,3GK71[
M%_NC\J /B6'X\>.3H=M/HOCT^(-5O_#5W?ZS!+I]L5\-Z@CQK''Y:1JR .SP
M^7,69]FX'@FMO_A8OC_P_P"//%T5SXZU74-+\,^*].TA+5M-M'-W;7%O%)+Y
MFR%69PTAV;"N, ?-7UZL$:LS!%#-RQ Z_6G;%]!^5 'RO^S#\:-?\>?$J33-
M0\42:YI=WX>758H;J>REFCF\V,'(M8E6'Y9"# TDK+@9(/+>N?M,_P#)O7Q&
M_P"P%>?^BFKTI((XL[(T3)S\HQSW->:_M,_\F]?$;_L!7G_HIJJ/Q(Y\1_"G
MZ,_#4'@?2BD'0?2EKVS\?"BBB@ S1110 9K8\&_\C?HG_7[#_P"ABL>MCP;_
M ,C?HG_7[#_Z&*3V-:7QQ]3V'XO_ /)6/&?_ &&+O_T:U<A77?%__DK'C/\
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MKXYTAG*![K<!G_CRG],_W**5F/VU/^9'04444C4**** "BBB@ HHHH ****
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M/SHQ_G-+10 F*,?YS2T4 -HQ]:=10 W'UHIU% !1110 4444 %%%% !1110
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M-/OK]G'V72-%TNSDU"]NFC0N[*HR6(4,[.Q'<DY/(!X#\)OC3K6HZ7X8@O\
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M@5_R1KP3_P!@>U_]%BN[KY>7Q,_I'#?P(>B_(****DZ0HHHH **** "BBB@
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MOY"B;P%X<G55ET2PD"XP&MU..G^ _(4:!>KV7W_\ VOM40&?,3_OH4?:8O\
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M_M164>L:9/J6A2Z9X+U?6+K0M.\22WL3+)<P>:&:2$?-%$S6\ZJY8_<!95#
MUF_%']IP/I&O6OPRMHO&6H67AZ?6Y=1T^]B,5K&&:.,H"")I"Z2'8,#]V<D$
MJ"<\NX?5:/\ *>D?\*EM_P#H9_%?_@ZEH_X5);_]#/XK_P#!U+7E&G_MC:4O
MC*U\,-91ZA-!=V.D7UPFH1)<F\GAC<M':8W/"AFCW/D8W-A2$)JYK?[9.B:)
MX8CUB30+_,>GFXO[9I8U-C=&]6QCM97^X&:?S06SA5A=CD4<\NX?5:/\IZ7_
M ,*EM_\ H9_%?_@ZEH_X5);_ /0S^*__  =2UXE+^UZ=1UWP[?11FST*SN]6
MAUR&Q9+Z*[2VTUKN-[6<*OF+]WD!3N5E(XKHM>_:HU?PK:QP:M\.+^SUV];3
M3IFG'4X"MVMY<I;J#-C;')&\B"13D#>"&;FCGEW#ZK1_E/2_^%26_P#T,_BO
M_P '4M'_  J2W_Z&?Q7_ .#J6O--3_:LU&QU.WT*/X?WLWB87&HV]Y9MJ420
M6YLX(;AG$Y7YU>*>,H0@.3M8+@D4K[]L^UT?2K2]U;PG-H_]K6FG7NC"]U.!
M4N(;QF"M.XR+?8%W-]_@C&3D YY=P^JT?Y3UC_A4EO\ ]#/XK_\ !U+2?\*E
MM^G_  D_BO\ \'4M>8:=^UU-XGM]-C\->"+K6]2N(-3GGC_M&*&WB%BT*R%)
MV7$JR>?&8V48.?FVX.-SX)?&O6OBI\4?'%A+8P6OABPTS1;_ $MMP^T$7D$D
MK>8!WX QGC;WW<'/+N'U6C_*>G^&?!T?AAYVCU35]1\T $:G?/<!,?W=W2O,
M_C-\0?#7A?XG>!/#.OZMXAT>;Q/]HM[2\TV_:WM(Y4V;5FP>"[2*BMC&2 2,
MBO;:\?\ BY\#Q\5_'V@W>HK;S>&H-&U33+^!I&6=FN?(\MH\#C:8B=V05.TC
MV5W>YK[*'+R6T.>T;7O!=[8Z]>ZKXY\1>&;/2=;FT)[C6?$GV=)IXT1SL9FP
M00_ Z_*>*W;RW\":?J-EI]U\5+ZVO[T1M:VLOBP++.)/]644OE@W\..O;->3
M^ ?V9_B1\.]9M/$=Y=Z%XXUBTU'6=T5[<O;"[M[R*VCBN6?RF"7"BVVNH0@B
M60AN<%1^R)XFB^&WC+01+H+ZGJVA:1IMI,K.L<,EM-/+*@/E[DB4RH(P,G"#
M(&!3YY=S+ZK1_E/:?$GA+PWX-TXZAK_C_7-$L P0W.H^(V@CW'H-SD#)]*R;
MO_A7]A+8Q7/Q8O+>2^B2:U27Q:JFXC?[CIE_F5L'!'![52^,/P/UGQ+8P3Z3
MJ6I:Y?1:N-3A%]KKV$VG?NY4S9310L$_UF"DJ.K)N4X)!KSJ?]E3QIK7AW6H
MM9F\.7NK:CH>B::90@CCWVE]/<3 JD"J%V21@%44.RD[$R!1SR[A]5H_RGID
M]Y\.+;2(=5E^+UQ'I<TS6\5Z_B]1"\B_>17WX+#/('([URVK^-O#&E^.K/PP
MNM>-KN:ZU.PTR*\M]<+0,UW#-+'(#NY0+"<D?WAC-4O'_P"SWXWU#QUXBU30
MO[*32]7N;IU6VO187<8EM;6++3_996$9,#[XXBA;]V=QQMK+\(_LK^-=(U+P
M%=WMUHQ.AW7A^:[$5U*VX65G<03;"8QDEI4*YQD9SC')SR[A]5H_RGKWB/0?
M"?@^2SCU_P"(^KZ))>$K;)J/B8P&8C&0@=ANQD=/45G:XG@W1+G5; _$36;G
M6].MGNIM&A\3YO BIO/[K=N^[SR.A!Z5'\3/A?XGO_B%?>(M$TSP_P");75?
M#S:!/I_B.9D@MOWN_P S8L;^;&X)$B94G8G/IY3H_P"R-XPT;Q!>0-?PZAI7
M]KZAK-M=2ZS-'#&UQ%(JHED(3M93)Y>YIF7RU'!/R@YY=P^JT?Y3T;X:WVB?
M$ZPO;NQUKQM:I:V-E?LMQK3Y*7-L)T P3R%.#[]*N>!G\+^-O ECXI_X3/Q)
MI-G<V4=_)%J'B(QO;1.6"M+\V%!*-@G@X//!JQ\"O@YKGPTT?5;759K&62ZT
MG2[%#:RLX$EM9""0G*C@N.#W'7'2O*+W]F?XD67PSN/"&G1^&KHZMX6LM"O+
MVYU":,6DMO-.Y=5$!\U&6<XY4@J.,'(.>7</JM'^4]CM],\%W?B%M!@^)NIS
M:XI8'38_%.ZY!498&,-NR!R1C@4>'M,\%^+M1N=/T/XG:EK-_; F>UT_Q3Y\
ML0!VDLJ,2,'CD=>*X;7OV<=;GBMIT;3(WA\;W?B:>6'>TIMI+62%=H"9:4;A
M\N>G&ZN1_98CO]8^+.BS+I&F0Z9X8\#GPY+J6F6US"7F%Q!L29)X(FBD*Q,Y
MA^<H2^6Y!8YY=P^JT?Y3VI]%\(1^(9- ;XDZJNN1QF5]-/B?_240+N+&/=N
M"\YQTYZ52TU_A]K&F7FHV/Q9N[S3[-U2YNX/%JO%"S?=#N'PI.#C)YQQ7,WO
MP9\;V[^*=*T[1O!-S;:AJU[K-IK^K*\]PCS6_EJK0&/'F _(9-Y7RN-AZ'!\
M)?LV>,)-=^V^(X].N+.0Z'YEO>ZG]M;_ $&Z\U@%6UBB5-I^1%0 $<XSP<\N
MX?5:/\IZ-,/ %MH-IK<OQ7O8M&NY3!;ZB_BP"WFD&<HDA;:S#!R <C!]*L/I
M?@N+7K71'^)NIIK-U&)H-.;Q3BXE0@D,L>[<P(!(('(!QTKB[KX$>*_#WCUO
M%6CZ;X>UL&[U<?V1?7#6\7E7J6^)MPA<>8&@967'*2O\V>#QVC_LD^+M&\9M
M,7TV72+K5M.UEDL-5FL[&R:WBA0PQV(A8N$,/[HF8##X90%(8YY=P^JT?Y3V
M[PYX9\+>,?M9T'XB:SK8M)/*N#IWB4W'DO\ W7V,=IX/!K:_X5);_P#0S^*_
M_!U+5/\ 9]^&]U\*/A5HOAS44LAJ5J)C<26 S&[//)(#G:I/#CDCKFO2*.>7
M</JM'^4X/_A4EO\ ]#/XK_\ !U+7GO[0?PWAT?X'>.[U=?\ $5TUOHUU((;O
M59)87Q&QPZ'AE/<'K7OIKS+]IG_DWKXC?]@*\_\ 13549RYEJ85\-15*7N]&
M?B4/$+X'^@Z?_P" JT?\)"__ #XZ?_X"K62.@^E+7LW/R7V<>QJ_\)"__/CI
M_P#X"K1_PD3_ //CI_\ X"K6511<7LX]C5_X2%_^?'3_ /P%6C_A(7_Y\=/_
M / 5:RJ*+A[./8U?^$A?_GQT_P#\!5K4\*ZX]QXGTB(V=B@>[B7<ELJL,N.0
M>QKEJV/!O_(WZ)_U^P_^ABDWH:4Z<'-:=3V3XHS&Q^)?BNW54F$.JW,8DG7?
M(V)&&68\D^I-<Q_:#?\ /&W_ ._0KH_B_P#\E8\9_P#88N__ $:U<C79%WBC
MY+$1BJTU;JRW_:#?\\;?_OT*/[0;_GA;_P#?H54HJC#E78](TW]HWXEZ/I]M
M8V/C35K2SMHUBA@BGPD: 8"@=@!5G_AI_P"*W_0^:U_X$5Y=14<D>QVK&8E*
MRJ2^]_YGJ/\ PT_\5O\ H?-:_P# BD_X:?\ BMC_ )'S6O\ P(_^M7E]!Z4O
M9P[#6,Q/_/V7_@3_ ,S]#]#OM>O_  UH-[+XN\2&>[TVWN9B-4< NZ L0.W-
M7/-UK_H;?$G_ (-9*I^%O^1*\*_]@:T_]%BM&O8HT*3IQ;BON/RS.,[S.CF%
M>G3Q,U%2=DI/_,B\W6O^AM\2_P#@UDH\W6O^AM\2?^#62I:*W^KT?Y%]R/&_
MM_-O^@JI_P"!R_S(O-UO_H;?$G_@UDI/-UO_ *&WQ)_X-9*FHI?5Z/\ (ON0
M?V_FW_054_\  Y?YD7FZW_T-OB3_ ,&LE)YNM_\ 0V^)/_!I)4U%'U>C_(ON
M0_[?S;_H*J?^!2_S-W3M)U"ZTFVG?Q7XF\UV<$C5I.V*F_L._P#^AL\3?^#:
M2KVB_P#(!L_]^3^8JU7E.G"[]U;OH?J"S'&>SIOVTM8Q?Q/^5>9C_P!AW_\
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MC0I1VB?.!_9'^#NE:[K.I7E]JC6,6JGQ)JFB7OBBY.DK=N_FK<3VAD$7WE#
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MF+_,P&6"H#G:,;^M_"SP]K_B3PAKES9LM]X4FGGTH02&*.%I86A?*+A6&QV
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MC^&@"IH_[.7@[1[N"\6&_NM23[<TM_=7TDDUS)=HB3R2MGYF*11J#CY0BA0
M*;JO[-W@W5+'2;?RM0LY=(L;.PT^\M-0DCGM4M6S R.#]]>06.=P)#9!(KU.
MB@#SOP]\"?#'AVZ@NX_[1O+^.WO;=KR^U"6>687;QO.SECR288\8P%"X4 5:
M\#?!OPY\.M=NM5T.&YM9[O3K/3)XWNGDCDBM4*0,5;/SJK%=PZ@\YKNJ* "O
M/O'GCV_T7QMX7\,Z7"K7.II=7US<2PLZ16EN@+X(( 9GDB09[,Q[5Z#7GOCG
MP1J.J_$+PAXETZ0LM@EWIU];&8(KVERB[G (Y9)(HF [@-WQ0!X3\.OVP_$O
MBSP;X#_M/1=-T[QCJFM:;::E9(DA@DL+PN8;JV)?(#!"OS%MKHX(Z5L^$_VC
M?$TWC:'3/$&H:%87_FW9OO"%]I5UINH6\$?FF*2UN)7,=Z2L:LP10"K%@5"\
M]?+^R5X/GL_A@C37PO? #Q_8+]'59;F)1S#/@89"0K< $%001S3]&_9F@T_4
M-#M]0\9:]KGA/P_<_:]'\.WZVY2TD =5#7"QB>5$$C!5=SP%!+8H K?#OQQ\
M5/&GA;PIXZ"^&I_#VO1)?R:(D$T5S8V4J%XG%R92)954H73RU!RP4\ E=#_:
M!U)OV7;/XF:EIMK<ZU/9F1-/M2T4$MPTS11("2Q52VP$DG&2:M:'^S5%I$^C
M:?-XTU_4/!>AS)<:3X9F\A8;5T),*M.D8FECB)&R-V(&U,[@H%5_"7[,C>'O
M!DW@G4?'&L^(/ \EG-9#1+JTLXMB2$G(GBB67<I8D'=UQ0!NV:?%[39+A-1O
M_"NK6\VFRR+=6=C/:&RO@ 43RVED\^%OF&<HPVCKN^7K_AGXR_X6#X#T/Q";
M5K&34+5)I;5SDPR=)$SWVN&&?:N!T_X,:YX<O)?$-WXQUSQ]KNF6%Q::)::Q
M);VL$7F*!F0P1*))#M ,K@D M@#)SW7PL\'2?#_X?:#X?GNOMUU86B1SW(&!
M++]Z1P,# +EB!Z$4 =7129HS0 M%)FC/M0 M(!BC/M1GVH 6BDS[49]J %HI
M,^U&: %HI,T9H #7F7[3/_)O7Q&_[ 5Y_P"BFKTW->9?M-<?L]?$;_L!7?\
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M%%% !6QX-_Y&_1/^OV'_ -#%8];'@W_D;]$_Z_8?_0Q2>QI2^./JCV#XO_\
M)6/&?_88N_\ T:U<C77?%_\ Y*QXS_[#%W_Z-:N1KLA\*/D,1_&GZL****LY
MPHHHH *#THH/2D-;GZ'^%O\ D2O"O_8&M/\ T6*T:SO"W_(E>%?^P-:?^BQ6
MC7N4/X4?0_'L]_Y&>(_Q,*#THH/2MSPCW?X0_P#(F0_]=G_I7;UQ'PA_Y$R'
M_KL_]*[>OSS%_P"\3]6?WCPQ_P B3!_]>X_D@HHHKE/IPHHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *2N/\
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MR^:#ZP_Y)?=_P3L<T9KCOLGCW_H)>'/_  7W'_Q^C[+X]_Z"7AS_ ,%]Q_\
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MC_X_1]E\>_\ 02\.?^"^X_\ C]'+YH/K#_DE]W_!.QS1FN.^R^/?^@EX<_\
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MV7QZ?^8EX<_\%]Q_\?HY?-!]8?\ )+[O^"=CFC-<=]D\>_\ 02\.?^"^X_\
MC]'V3Q[_ -!+PY_X+[C_ ./T<OF@^L/^27W?\$['-&:X[[)X]_Z"7AS_ ,%]
MQ_\ 'Z/LGCW_ *"7AS_P7W'_ ,?HY?-!]8?\DON_X)V.:,UQWV3Q[_T$O#G_
M (+[C_X_1]D\>_\ 02\.?^"^X_\ C]'+YH/K#_DE]W_!.QS1FN.^R>/?^@EX
M<_\ !?<?_'Z/LGCW_H)>'/\ P7W'_P ?HY?-!]8?\DON_P""=CFC-<=]D\>_
M]!+PY_X+[C_X_1]D\>_]!+PY_P""^X_^/T<OF@^L/^27W?\ !.QKS+]IHX_9
MZ^(W_8"O/_135N?9/'O_ $$O#G_@ON/_ (_7GG[0]MXQ3X%^/6U"_P!$EL1H
MMT9H[6RF25D\MLA6:4@'W(/TJHQ]Y:F->NW2E[DMGT_X)^+8Z#Z4M:(DT?:/
M]'ONG_/9/_B:7S-'_P">%_\ ]_D_^)KV3\FY_)F;16EYFC_\\+__ +_)_P#$
MT>9H_P#SPO\ _O\ )_\ $T!S^3,VBM+S-'_YX7__ '^3_P")H\S1_P#GA?\
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MS,$^XQ]*O^5KW_/SIG_@/+_\<KVJ#_=1]#\DSN/-F5=W2]YFO0>161Y6O?\
M/SIG_@/+_P#'*/)U[_GYTW_P'E_^.5O<\3V:_F1]'?"$_P#%&1?]=G_I7;9K
MR'X76WC-O"D9M+_04A\U\":QG9L\=Q,*ZW[)X]_Z"7AS_P %]Q_\?KX#%1O7
MGKU9_<7#5?ER7"+D;_=QZ>2\SL<T9KCOLGCW_H)>'/\ P7W'_P ?H^R>/?\
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MAS_P7W'_ ,?H^R>/?^@EX<_\%]Q_\?HY?-!]8?\ )+[O^"=CFC-<=]D\>_\
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M#\^2#_A)K+S8_$2^$V3Y\C52NX6GW?OXY]/>OG-/V(O&%]H/C3P'JGCW1_\
MA6'B_P 53^)-6LK/194U259)HY3:K<M<%$0F*,%A'NQNP><5LWO['7B>;XC7
M=_!XWTY?!\_Q"A^(+:9+I$AO?/$?ER6_V@3!0F.5/EY!ZDU)TGI\7[5OPTUG
M4=>T;P_XKT[6O$6EVE[=#3HG=?M!M@?-6*0KLDVD8;86QR>QKR;X!?MT7?Q:
M\9^#="U7PSH%E'XJTN75+:?P]XJBU673ECA69EOX!&C6V0P7)SA_E/-'@?\
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M% !1110 4444 %%%% !1110 AKS+]IG_ )-Z^(W_ & KO_T4U>FFO,OVF?\
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MB>3P!H?C#X?^'[_XC:=J1F\/W=MI^MZSYDAMI==ALYGM-1\^2=!<"0IMD8;
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M^1*\*_\ 8&M/_18K1K.\+?\ (E>%?^P-:?\ HL5HU[E#^%'T/Q[/?^1GB/\
M$PH/2B@]*W/"/=_A#_R)D/\ UV?^E=O7$?"'_D3(?^NS_P!*[>OSS%_[Q/U9
M_>/#'_(DP?\ U[C^2"BBBN4^G"BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HKD/^%N^"AU\4Z6/^WE?\:/\
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M_,!W,/,GB(C<,@7../I?]G'1]=\.>!M0TC7(;^!+#7-2MM,349&ED&GK<O\
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MO_0/G_[XK6\)Z#J-OXIT>62QFCC2\A9F9>  XR:3O8TIS@IQ]Y;]SU#XO_\
M)6/&?_88N_\ T:U<C79?%2%[_P")WBVYMT,]O-JMS)')'RKJ9&((/H:Y;^SK
MK_GWD_*NR*]U'R.(E%UIV?5E:BK/]G77_/O)^5']G77_ #[R?E5&',NY6HK3
M3PSJ\B*RZ5?.K#(9;9R"/KBG?\(KK7_0(O\ _P !G_PI7+Y7V,J@]*U?^$5U
MK_H$7_\ X#/_ (4?\(KK6#_Q*+__ ,!G_P *!J+['WUX6_Y$KPK_ -@:T_\
M18K1KG?#GB32[?PCX:@EOX(YH=)M8I(V;#(XC *D=B#VJ]_PE&D_]!&V_P"^
MZ]JA)*E%-]#\DSO#UIYE7E&#:YGT9J4'I67_ ,)1I/\ T$;;_ONC_A)])/\
MS$;;_ONM^:/<\3ZKB/\ GV_N9]%_"'_D3(?^NS_TKMZ\B^%_Q-\)Z9X4C@N_
M$6G6TPE<F.2X"G''8UUW_"WO!7_0TZ5_X%+7P.*C)UYM+JS^X>&Z]&GDV$A.
M:35..C:['7T5R'_"WO!7_0TZ5_X%+1_PM[P5_P!#3I7_ (%+7+R2['T?UJA_
MS\7WHZ^BN0_X6]X*_P"AITK_ ,"EH_X6]X*_Z&G2O_ I:.278/K5#_GXOO1U
M]%<A_P +>\%?]#3I7_@4M'_"WO!7_0TZ5_X%+1R2[!]:H?\ /Q?>CKZ*Y#_A
M;W@K_H:=*_\  I:/^%O>"O\ H:=*_P# I:.278/K5#_GXOO1U]%<A_PM[P5_
MT-.E?^!2T?\ "WO!7_0TZ5_X%+1R2[!]:H?\_%]Z.OHKD/\ A;W@K_H:=*_\
M"EH_X6]X*_Z&G2O_  *6CDEV#ZU0_P"?B^]'7T5R'_"WO!7_ $-.E?\ @4M'
M_"WO!7_0TZ5_X%+1R2[!]:H?\_%]Z.OHKD/^%O>"O^AITK_P*6C_ (6]X*_Z
M&G2O_ I:.278/K5#_GXOO1U]%<A_PM[P5_T-.E?^!2T?\+>\%?\ 0TZ5_P"!
M2T<DNP?6J'_/Q?>CKZ*Y#_A;W@K_ *&G2O\ P*6C_A;W@K_H:=*_\"EHY)=@
M^M4/^?B^]'7T5R'_  M[P5_T-.E?^!2T?\+>\%?]#3I7_@4M')+L'UJA_P _
M%]Z.OHKD/^%O>"O^AITK_P "EH_X6]X*_P"AITK_ ,"EHY)=@^M4/^?B^]'7
MT5R'_"WO!7_0TZ5_X%+1_P +>\%?]#3I7_@4M')+L'UJA_S\7WHZ^BN3A^*_
M@ZZF2*'Q-IDDKG:J+<J2Q]!12<9+H6J]*7PS3^9HV7BC0=1U-]-M-5TZYU&/
M=OM(;F-Y5Q][* DC'?BM<1(?X5_(5^14D7@.\\"_&"PT*WL)/VD9/B?>/X0_
ML^$C6U/VRW*.CJ,K"%6<L7.P*'SS7T?>?M8>+;#XG7W@>7Q*J>)8_C%!HL6C
MO8QK-_PCLD(9!S'Q&[' F)W'/#5)KRKL?<DHA@B>20HB("S,V % Y))[5236
M=*?[!MOK-O[0&ZTQ*A^T#;NS'S\_'/RYXYK\^OAW^T9\1O'VIV>GZKXPDU_4
MM;TOQ&/&7@3^QH85\'+!#.+;]ZD8D7+K'&/-9O,W[AZCE?"EI\2_#\O[&NJ:
MIJFB^(+*/0+ZX\/:5IVDR6UQ 5T+='%/*96$K'$:DJJ9()[\.X^5=C]/O)3^
MZOY"CR4_NC\A7YN_#C]JSXCZW\+?'.JZG\4K43V?A:RU1;N*QM[N[TW77F"C
M3A!':I'MF.8O(D9IT*Y!YW5M7W[5WC5_@WHLVN^-M0\+?$+5_%&HZ=J=HFGV
M=A::!-!"SIILD]Q%*$4KY3))LEDF+%5(&<%PLNQ]XZOXIT#0+J.VU/5]-T^X
ME4,D5W<Q1.PSC(#$$C.16N(D(SM7\A7Y+^//'5G\5O%?PX\4>/\ Q+\/-.U'
M5OA/;O<W_C_0Q?6D]W]ON%E6%$9/)F#*V2H)&" M=GX7^.WBSP#\&_A7H4GC
MG5/A!X;M_ ,^HZ?J^I:<FHSZ[JT-W)$MG_I$1.PQJDJ0HJR%)T4$[ :+ARKL
M?I;J-Y9:39R7=[/!:6T8R\T[K&BC..6. .2*ED\F*%I7*)&HW%VP !ZYK\M?
MVN_C9X\\8?#'QOH'CWQ)+X'O)/"'AZ^T_P #+I$8&N3SK'+J!WR(TH\B563:
MCKL\OYL\Y]]U+XA?$?Q-\?;SX"2ZM<16][?MX@.M?V? RCPNUEC[*>,%OMG[
M@L1O*Y.:+A9=CZP\+>.O#7C8W(T'6+#5C;-MF%I*KE/0X]#@X/0X.#6A=ZWI
M.GZA:6%S?6=O?7F?LUM+,B2S8Z[%)RV/8&OG'PY\*?'W[/FC7>M>&/"UE\0]
M;WM;QZ-;ZNM@9$E96EG:XFC 1 8DV6X#;-[?O'XQX!K<WPHL_'?QD/[17AI]
M2^)%_P"(+>?P]IMG!/+JLNF-% +*+2Y$*DE)!*KF%E^8.6ZBBXN5=C]!E\4:
M"^L'25U;3FU0-M-D+F,S XSC9G=G'/2KKZAI\>H1V#7-NM])&9DMF=1(R @%
M@O4@$@$XQS7Y:?$V/X5W/C3]JNS\1VFGS_%"YOX%\%PF!Y-9:]^PH(1:F,&3
M<)C'G!QG);C)KT3XD3^'-,^/GP@EN+5KWXUVFKZ$/%.G0P3#5M09K!4\VSN6
M8HME%F1IXXU$<A#!F5E))<?*NQ]_6?B+1=1NA:VNIV%S<G)$,,\;N<=?E!SQ
M6GY*?W1^0KY%_9K^"'P_?]I/XF>.O#'@_3?#UGX5N?\ A$M+_L^V,*RW C66
M_N7S]YRTJP@C@+&W7?Q]?47"R[#/)3^Z/R%'DI_='Y"GT47"R[$?DJ#D  ^P
MIY&:6BD"26Q'Y"?W1^0I?)3^Z/R%/HH"R[#/)3^Z/R%'DI_='Y"GT4[A9=AG
MDI_='Y"D,2 9VC\A4E>2_M56FNWWP&\4P^'TNI;QHHO/BL=QGDM!,ANEC"_,
M6, E "_,2>.<47"R['?VWBG0+RTOKJ#5M.FMK%VCNIH[F-DMV'42,#A"/0XJ
M;1M<TCQ%:M<Z5?V6I6ZL4::SF29%;K@E21GD<5\4_M!7_P $KWX0?$-?AG8Z
M7-JK^!;V:XO/"L2II\5FQCV)>"+">:Q&8U=2XVR_=&[/17-Q\(;[XBI<?#FS
MTR?PM;^'-4C\:OX'M66V:S,<9BB?[*%!N"YW(!F38)<8S1<.5=CZO?Q/H,>G
M+J#:KIRV+2&);HW,8B+@D%0V<9!!&,YX-7=-OK#6+5;FQN+>\MV) EMW61"?
MJN17Q/I,W@SPWX8^..I0:1X0\=>';5-/U'1X=)TU'T*.Y>&2&WMU@(D47 )C
M,LR$EEF3(3: ?JKX(_"K3?@U\-])\,:=%$AMT,MW-#&L8N+J0[YY=J@!=TA8
MA0  ,    47#E78[CR4_NC\A1Y*?W1^0I]%%PLNPSR4_NC\A1Y*?W1^0I]%%
MPLNQ&84'\(_(5GS:WI,&L0:3)?V<>J3H98K%YD$\B#.65,[B!@\@=JT9,[#C
MK7Q=H%U\+-,T/Q%;?$S3(-2^+'_"5W1DM[:$CQ#<2O>.VG-9N-LI46X@V-$P
MC4(P)&'HN%EV/M#R4_NC\A4=PT%K"\LICBB0%F=\*J@=22>@KY-TKXV>,Y/'
M6B)8^(CX@\37OBC4=*U7X?,MO$FFV$(G\J8,(_-3Y8[=_.=F1_M& .5 J_M"
M_$SQ3=VGB/1/%NI#X7:<W@Z[O+.T@E@OQJMZ7:)H"[19EVH8SY,05V\_.?E&
M"X678^OHUBE1638RL,AEP01ZT[R4_NC\A7Q/H_QG^("?%2VT!=;M-%M+/5=*
MTJQT*>\MU:\L)+>W+3"U^S/<2L^^;$R2JB&'D *Y-OQ/\=?BM9>#_&#6UWY>
MH^!4BTC6;V2Q2-9[F:^0?;1E&5%CL0)R0I13/E@X0BBX678^QY9[6">&"26%
M)IR1%&S*&? R<#J<#GBIA$A_A'Y"O@O_ (69XUU37?#VL+>VWBG5]"U#7TT2
M:W==2,NW0VD6-Y8(88[AA*Q&8EZ'83N4UI^*_C]X@T;1(GT/XP2ZOH=Q_P (
M]_:/BE]/L_\ B537=\D5PBGR?*&Z%G;R75GB\L%C\PHN%EV/N'R4_NC\A1Y*
M?W1^0KXS3XI^/=?\06>AZ3\0KZ;P\MSK_P!F\06^G6OGZG;VEK;/"1(8C&P2
M>2>,R1H XC(ZY-9?B'XU?$[PQX<\-SGQ;-?KXBT?0M4U"]NX[2RCTK[2["<Q
M2^0RPQMF--TJR!/O9Y)HN%EV/N#R4_NC\A2>4F<;1_WR*^.O!WQ(^)?Q &CZ
M9)XY;2[<V&OW0U+18+>YDNQ:36J6Q::2V6.3:9959HD"2;1@]372_LL:WJ6O
M_&CXAZGK&J7$M_JOAWPSJ/V.4(D9,EK*9'B3:"%#Y'!(!<@]L%Q<J['U$(U7
MH /H,5X/\;?C3J?PP^-OPYTE+74]3T#6+'59+VPT;1VU"ZDDA6$Q,%12ZJI=
MLD<<C->]UR6N?#32=?\ B#X=\8W)N?[6T*VN[6T$<N(BEP$$F]<<G]VN#D8Y
MZTAV6Q\V^'?VV;+1;'4_^$EB)U._\2ZE::18ZP8-$,%E:QV[,)FN"@5P9@ K
M9=BZ\8!([*Y_;$TV>R_M/1O VNZYHL-CIVH7EW;R6B- EX\B1((VDS(X:-MP
M7C R&/ /67?[+_A=M2FU;3]0UK1=<DU*\U)=5L;F/SXVNDC2XB7?&Z>4PAC.
MTJ2"@(((K0@_9V\+P66J6OGZK*NI6VG6MQ)/>F65ELF=XFWL"2Q,C%F).[VI
MW#E78X7Q!^UU9>&M!U&]U'PE-I]UI%]/8ZI%J&K6-M#;/%'%*529Y )F:.>,
MJB DG<#C&:ATG]JBYU'6KZ2#PA>:CH]]!H[^'DMFA2XNGOHC(BS!I,1 #DLW
M"A&ZY%=-K7[)WA'5_%^K>)DOM;T_5M5>Y^V36EV@\R*>.!)8EW1MY:D6T1#(
M5<'.'&<4Y_V4?":6]K#9ZEK^G)9V&G6=G]DOPIMGL>+:Y0E#^^5<J2<JRDAE
M-%Q<J['":S^U5-I_CK2I+O2[_1M(T[2]<?7]">VBFNOM=H;,QB*13AP5N<J5
M(#;QG!&!V4W[15Y:74VAW7P[UF#QI]IMX+?0OM%JZSK,DSI+]H#^6J*MO-OS
MRI7 #97-E_V2_ UTC&_.K:G/-;:C;WES=7Y,MZ;TP^?+(R@?/BWB"E-H0( !
M6-XV_9NNX=$>\\/:EJ/B#Q>U]:W3:SKNNR6MZJ6Z.D:PSPPE(R!+)PT+*_F/
MO!W9"#E78R+?]K+39=1.IW6F:]I\=KINIB;PV+6TF9[JVO[>T($J.3O,DP50
M#L(<LQ&!7KV@^/[RY\+:UJFO>$]0\-W6D[S-9W#Q3"953?OAE0E74@XSQA@0
M1W/F'@/]C_1K;PD;;Q;<7=_J]U!J4-R]M?NRQB\O([IBLI57:1'AB(E.TY!.
MT9 'J7ASX46.A>'M;TRXU;6-<EUDL;W4-5NQ+<29C$8"[55$ 4<!$ SDD$DD
MNX<J['D7_#81M]*.J7WPTUVQTQ=(M_$3W#W=FX339>DN%D.9!D'RAR0>N<@5
M/B3^UW;:+?>(O"]IIATGQ%_9VI2Z3-)>6=S*);6"24O/:H[/"A$9*F0?-P"!
MFO2]2_9O\)ZKX6FT"9]2%A+X>@\,L4N0'^R1?<(.W[_'+?I7.C]CCP1A(6O=
M=:P@?47M++[:@BMC?)*ER5Q&&<D3R8,C.5SP0.*+ARKL9/A?]H>XCLK2R-A?
M^+O%>IS6UO:Z7&EI9IO_ +-BNYV60L!Y:JS,2WS;F"@$8JQ>_M9V\6D-J-KX
M U^XBM=+FUC4HY'M8GL;>&X>"52#)\\H,;$(I(8#[PJ;Q[^SE)9:-9OX(28Z
MO!>Q7*W,VM/87$ 2S%IF&98)5^:-5#H\;!@6P5."+WP]_9CT[0_AK)H&OWEQ
M>:A?Z+-HVHS6MT[*8I9Y9FV/("[,#,1YC<MC) SBBX<J[%;Q+^U;H/A3XBZ1
MX9O]'D2'5;N&QM+H7UH;B665%='%H'\[R?F"F0@8.>".:SM'_;!TJ\TB+5-1
M\%ZWI=E?Z1<:SI(W6]Q-?Q0RI$Z!(W/EN6ECVAC@@Y)&,5T#?LF>#FUQM0-Y
MK0A.L0^(/L"W:"#[=&D:"4XCWL-L2_(SE!R0H/-6IOV6/!-SH.B:/.NI36.D
M:-=:';J;PJWV>=XW=BR@'>&B0JPQC%%PY5V.=\2_M"2>$M6TJX\6:'KG@Z."
M+4;B[TTP6MW%=106IG\Q9T8G  .-G.\$-Q@G%TW]N7PGJ7AK6M272U-QIHM)
M'2'5+.:U2*Y=DC>:[1S%!M*GS YRF1U!S7>/^S#X8U.9)_$&IZ]XHN=ES'-/
MJ]^':9)[?[.Z,$1 H"9P$"_,2QR3FK&G?L[V.FZ;<0)XP\827KBV2'4I-5'G
M6\<&=D:J(Q$RG)#^9&YDS\Y; P7#E78[7P%XGC\<^%-/UL6/V!;M"PA-Q!<C
M@D966%WC=3C(96Y!&0#D#H/)3^Z/R%<S\-OAQI/PL\+1:%H_GM:K--<O+<N&
MDEEED:21VVA5!9F)PH '8"NJHN.R[$?DI_='Y"O,_P!IF)1^SW\1B% (T*[Z
M#_IDU>GFO,OVF?\ DWKXC?\ 8"O/_134XOWD<^(2]E/3HS\-03@<GIZT9/J:
M0=!]*6O;/R ,GU-&3ZFBB@ R?4T9/J:** #)]36QX-)/B[1.3_Q^P_\ H8K'
MK8\&_P#(WZ)_U^P_^ABD]C2G\<?4]@^+_'Q8\9_]ABZ_]&M7(_B?SKKOB_\
M\E8\9_\ 88N__1K5R-=D/A1\AB/XT_5A^)H-%!Z59@C]D/@7$K?!KP3D _\
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MV0^%'R&(_C3]6%!Z44'I5&"W/V3^!7_)&O!/_8'M?_18KNZX3X%?\D:\$_\
M8'M?_18KNZ^7E\3/Z1PW\"'HOR"BBBI.D**** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@!,8-+29HS0 M%)FC- "T4F:,T % &*,T9H 6BDS1F@!:*3-&: %HI,T9H
M 6BDS1F@!:*3-&: %HI,BC- "T4F11F@!:*3-&: %HI,T9H 6BDS1F@!:*3-
M&: %HI,T9H 6BDS1F@ )P,U\K6O[65O/^U+/X1/BK0SX?>]D\,Q:*LD8OTU%
M(!<?:F!(?RF;=;!<8W@$=<U]3R*)$*YQD=0>:\Z7X!>$5^'UOX/%K,NGP7:Z
M@ET)L78NQ<_:?M'FXR9/.^<GH3QC'% 'B]E^U)XKL?AO<MKWA^73]:U#2M9N
MO#^K+)#(+Z>S$S[6M@!Y>8TWIDD,$.=I(!W_ !'^T-XGTPPR:GX?E\'W?A^^
MTZ^U_39IH;[[1H]VTD'G))&,HT4@+NH&1Y) +!MU=99_LI^";:*_@FEUG4+.
MXL[RQM[6\U.22/3TNRQNFMAUC>3>WS9)4'"[02#N>'?@-X<T'1O$>GW%QJGB
M ^(+?[%?W>N7SW<\EL%94@#-]V- [X ')9F8LQ)H \PU7X_:K9_$D7UQJ,EO
MX)_X2&?0;>WM;2)_M'V/3;JYO)G=AOQYJ",!#G=;D<;CE/#W[3$'QHT'4;"V
MTS6M"FDL8-4LKGP_.=0D:!Y454G^SQEX)/G0R1J"P0N5?*DCTZW_ &?/!UOX
M<\':']DN)=.\+/+)91SW+2&1I8)H)3,QYD+K<2EL]2V:M?#/X+Z3\+97;3M7
MU_48EMULK2VU?59;J&QME(VPPH<* , ;F#/A0"Q Q0!I_">XUFZ^'/AZ3Q"+
MD:T;-/M1NTV2LXX)9< @G ." >>><UUU)D49H 6BDS1F@!:*3-&: %HI,T;A
M0 M%)FC- "T4F:,T +129HS0 M%)FC- "T4F:,T +129HS0 M%)FC- "T4F:
M,T +129HS0 &O,OVF?\ DWKXC?\ 8"O/_135Z:37F7[3/_)O7Q&_[ 5W_P"B
MFJH_$CGQ'\*?H_R/PT'0?2EI!T'TI:]L_'PHHHH **** "MCP;_R-^B?]?L/
M_H8K'K8\&_\ (W:)_P!?L/\ Z&*3V-*?QQ]4>P?%_P#Y*QXS_P"PQ=_^C6KD
M:Z[XO_\ )6/&?_88N_\ T:U<C79#X4?(8C^-/U84'I10>AJC!'[)_ K_ )(U
MX)_[ ]K_ .BQ7=UPGP*/_%F?!/\ V![7_P!%BNZR*^7E\3/Z1PW\"'HOR%HI
M,T9J3I%HI,T9H 6BDS1F@!:*3-&: %HI,T9H 6BDS1F@!:*3-&: %HI,T9H
M6BDS1F@!:*3-&: %HI,T9H 6BDS1F@!:*3-&: %HI,T9H 6BDS1F@!:*3-&:
M %HI,T9H 6BDR** .%_X1?QN?^9WM_\ P21__'*7_A%O&_\ T.]O_P""./\
M^.5\H^)?^"DEAX:\#_$I;B7P[%\1?#_BV30](\-R239OK1;N"+SV YW;))FX
M(&8QQUKZ)@_:G\ 3_$&X\&Q7NHRZI%=SZ8EPFEW'V*XOX8_-ELHKG9Y4EPJ
MDQJV<@@9/%:<[\ON1Q?4Z?>7_@<O\SI?^$6\;_\ 0[V__@CC_P#CE'_"+>-_
M^AWM_P#P1Q__ !RN0\,_M?\ PS\9Z7K>H:!J>HZS;:'IZ7^I_8='NY7L]TC1
MK;R(L>Y;C<K?N,;P 6( YKS;XQ?MNVNE?#W0/$'@:XTK37N_%_\ PB>J2^/;
M2[L8M*F%G+<MYR*!(#A8L8R#Y@_ YWY?<A?4Z?>7_@<O\SW?_A%O&_\ T.]O
M_P""./\ ^.4O_"+>-_\ H=[?_P $<?\ \<KQ;X1_MLZ9KOPPU/Q1XTCLH_LW
MB(^&]-N/"(N-2A\03[%=38P^6)G)RP*[3C8QW$ X[&\_;)^&B>&]"U2RO]4U
M2XUN>\M+32K#1;NXU!9K0#[4DMJD?FQ&'<N_<HQN7U%'._+[D/ZG3[R_\#E_
MF=Q_PBWC?_H=[?\ \$<?_P <H_X1;QO_ -#O;_\ @CC_ /CE>,_!+]N#PQXP
M^#%AXJ\;W,'AS7$\-/XJU&SM;:9H([);J6WWPDAC(=\84H"6#,!W%1^#_P!H
M;Q5K/Q@FL[D6Z^'Y[B."&QDM_*DA5D#RALCS%E@4J9"^(^'V\8*G._+[D+ZG
M3[R_\#E_F>U?\(MXW_Z'>W_\$<?_ ,<H_P"$6\;_ /0[V_\ X(X__CE>:_$W
MX[>,K_XN6?PP^$VG^&]1\1_V&WB*_P!5\274WV&VMO.\B.-5@!:221PPSN 0
M+D[NE<CX@_:#^-UU\3?!7@+1?!/A/0?%.J>&;C7]2T[Q%J,TR0/#<^28H[BV
MR"&!5@Q4D;N0",4<[\ON0?4Z?>7_ ('+_,]X_P"$6\;_ /0[V_\ X(X__CE)
M_P (MXW_ .AWM_\ P1Q__'*^<O$_[;GBN+X&V/Q'TCP?HEI:Z?->6?B.WU?5
MG)AU"WN! -.M?*C+22S'+)*RB-5QNZ\:OBC]LO7O#_[26B?#=O"NGV\%]+I4
M(L[V\D74[E;U&:2X@VH8?+MBCK(K,"^UMIX 8YWY?<A_4Z?>7_@<O\SWG_A%
MO&__ $.]O_X(X_\ XY2?\(MXW_Z'>W_\$<?_ ,<KN5.1FG4<[\ON0OJ=/O+_
M ,#E_F<+_P (MXW_ .AWM_\ P1Q__'*/^$6\;_\ 0[V__@CC_P#CE=U11SOR
M^Y!]3I]Y?^!R_P SA?\ A%O&_P#T.]O_ ."./_XY1_PBWC?_ *'>W_\ !''_
M /'*[JBCG?E]R#ZG3[R_\#E_F<GH>@^*+'4DFU/Q/#J=F 0ULFEI 6..#O#G
M&/I74FGT5#=]3IITU27+&_S;?YW.+O?#?C&>\GDMO&%O;6[.3'"='1S&N>%W
M&09QZU!_PBWC?_H=[?\ \$<?_P <KNZ*KG?E]R.=X2FW>\O_  *7^9PO_"+>
M-_\ H=[?_P $<?\ \<H_X1;QO_T.]O\ ^"./_P".5W5%/G?E]R%]3I]Y?^!R
M_P SA?\ A%O&_P#T.]O_ ."./_XY1_PBWC?_ *'>W_\ !''_ /'*[JN*^,GQ
M*@^$?PZU;Q1-9OJ+V@CC@LT?8;B>618H8]^#M#22("V#@$GM1SOR^Y!]3I]Y
M?^!R_P R+_A%O&__ $.]O_X(X_\ XY1_PBWC?_H=[?\ \$<?_P <KRWXA?%7
MXP_![X=^./$OB;0_"6JV^F:1<ZEI]YHTUPD4$L>W9;7,4K;Y-P9B)8RH^0@H
MF03K6OQ0^)?A#Q%:^'/%VB>&];U;6-.O+G1)_#UU-:17%W;H'^R2I<;BFY"6
M$H8@;&RHXRN=^7W(/J=/O+_P.7^9WG_"+>-_^AWM_P#P1Q__ !RC_A%O&_\
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MK2YWY?<@^IT^\O\ P.7^9];#POXW(_Y'>W_\$<?_ ,<H_P"$6\;_ /0[V_\
MX(X__CE4OV?+/6=.^%NEVNN:(- O(I+A4LP\A_<^<YB?9)+*T6Y"&\HNVS.T
M' P/2*.=^7W(7U.GWE_X'+_,X3_A%O&__0[V_P#X)(__ (Y7GO[0GA[Q;:?
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ME)\"O^2->"?^P/:_^BQ7=U\S*;YGM]R/Z(P^$INC!WELOM2[>IPO_"+>-_\
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MWY?<@^IT^\O_  .7^9P\'AKQG%<1O-XSMYHE8%HQHR*6'IGS.**[BBDY-_\
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M $:U<C77?%__ )*QXS_[#%W_ .C6KD:[(?"CY#$?QI^K"@]**#TJC!;G[)_
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MR;E.] 68A6R 2<=:RO\ A6&D_P#/[KO_ (.[O_XY0/ACI!Z7VN'_ +CEW_\
M'*+0[_A_P1<^)_Y]K_P)_P#R)8NOACX.OO#EMX>N?"NB7&@VTAEATN73H6M8
MG.[++$5V@_.W(&?F/J:W)]*L;D6@FM+>46D@EM_,B5O)<*5#)D?*0&(R.Q([
MUSG_  K#2?\ G]UW_P '=W_\<I/^%8Z3_P _NN?^#N[_ /CE%H=_P_X(<^)_
MY]K_ ,"?_P B=!>:1;75PEV(84U"&*2&"\,2M+"KXW!6(R 2J$CH=HSTK-\
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MNS1FN1_X5CI/_/[KG_@[N_\ XY0?ACI(ZWNN?^#N[_\ CE%H=_P_X(^?$_\
M/M?^!/\ ^1.NS1FN1_X5CI'_ #_:Y_X/+O\ ^.4?\*QTG_G^US_P=W?_ ,<H
MM#O^'_!#GQ/_ #[7_@3_ /D3KLT9KD?^%8Z3_P _NN?^#N[_ /CE+_PK#2?^
M?W7?_!W=_P#QRBT._P"'_!%SXG_GVO\ P)__ ")UN:,UR/\ PK#2?^?W7?\
MP=W?_P <I?\ A6&D_P#/[KO_ (.[O_XY1:'?\/\ @ASXG_GVO_ G_P#(G6YH
MS7)?\*PTG_G]UW_P=W?_ ,<I/^%8Z2/^7[7/_!W=_P#QRBT._P"'_!#GQ/\
MS[7_ ($__D3KLT9KDO\ A6&D_P#/[KO_ (.[O_XY1_PK#2?^?W7?_!W=_P#Q
MRBT._P"'_!#GQ/\ S[7_ ($__D3K<T9KDO\ A6&D_P#/[KO_ (.[O_XY2?\
M"L-)_P"?W7?_  =W?_QRBT._X?\ !#GQ/_/M?^!/_P"1.NS1FN2_X5AI/_/[
MKO\ X.[O_P".4?\ "L-)_P"?W7?_  =W?_QRBT._X?\ !#GQ/_/M?^!/_P"1
M.MS1FN2_X5AI/_/[KO\ X.[O_P".4?\ "L-)_P"?W7?_  =W?_QRBT._X?\
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M=5.)>&&1D'!&>E%H=_P_X(<^)_Y]K_P)_P#R)Z5FC-<E_P *PTG_ )_==_\
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M_P#CE'_"L-)_Y_==_P#!W=__ !RBT._X?\$.?$_\^U_X$_\ Y$ZVO,OVF?\
MDWKXC?\ 8"O/_135O_\ "L-)_P"?W7?_  =W?_QRO._VB/ &G:5\"O'MY#=:
MN\L&BW4BK<:M<RQDB-C\R-(58>Q!%5%1YEJ8UYXCV4KP6S^UY?X3\60>!]*,
MUIC7[K _=VG3_GTC_P */[>NO^>=I_X"1_X5[.A^3WGV_'_@&9FC-:?]O77_
M #SM/_ 2/_"C^WKK_GG:?^ D?^%&@7GV_'_@&9FC-:?]O77_ #SM/_ 2/_"C
M^WKK_GG:?^ D?^%&@7GV_'_@&9FMGP:?^*OT3_K]A_\ 0Q4/]O77_/.T_P#
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MFT._X?\ !.CGQ/\ S[7_ ($__D3K<T9KD?\ A6&D_P#/[KO_ (.[O_XY2_\
M"L-)_P"?W7?_  =W?_QRBT._X?\ !#GQ/_/M?^!/_P"1.MS1FN1_X5AI/_/[
MKO\ X.[O_P".4O\ PK#2?^?W7?\ P=W?_P <HM#O^'_!'SXG_GVO_ G_ /(G
M6YHS7)?\*PTG_G]UW_P=W?\ \<H_X5AI/_/[KO\ X.[O_P".46AW_#_@BY\3
M_P ^U_X$_P#Y$ZW-&:Y+_A6&D_\ /[KO_@[N_P#XY1_PK#2?^?W7?_!W=_\
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MO_"L-)_Y_==_\'=W_P#'*+0[_A_P0Y\3_P ^U_X$_P#Y$ZW-&:Y'_A6&D_\
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MU3?]F#X&^%=>USQ!J5Q(+;3]4/B34]/U;Q+<-I5K>RMYBW4UJ\OD*QP""Z]
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MR/XFT'X?:IX?U&YT*^N+KPOI>AK("YC:6VN;J64D-'D(PG3'4Y!R!@$[-[\
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M\519]@]K3_F7WF_16!_PGWAG_H8=*_\  Z+_ .*H_P"$^\,_]##I7_@=%_\
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M.NY4N;A(V(]0&(XI697/&W-?0U**P/\ A/O#/_0PZ5_X'1?_ !5'_"?>&?\
MH8=*_P# Z+_XJG9]B?:T_P"9?>;]%8'_  GWAG_H8=*_\#HO_BJ/^$^\,_\
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M@K8\&_\ (W:)_P!?L/\ Z&*SOL5Q_P \7_[Y-:OA&UEC\6:,SQNJ+>PDL5P
M-XI/8TIM<ZUZGKGQ?_Y*QXS_ .PQ=_\ HUJY&NM^++I<?%+QA+$ZR1OJ]TRN
MC!@P,K8(([5R>#79#X4?(XC^-/U?YB4'I2X-&.*LP6Y^R7P*_P"2,^"?^P/:
M_P#HL5W=>5?!+QKX?L_A!X,AGUW3(9H](ME>-[R-64B,9!!;@UVW_"?>&?\
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M7_Q5%GV#VM/^9?>;]%8'_"?>&?\ H8=*_P# Z+_XJC_A/O#/_0PZ5_X'1?\
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@:E'2BB@#0\._\A_3_P#KLO\ .BBBN:IN>S@?@?J?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>gmab-20220630xex99d1020.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gmab-20220630xex99d1020.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1"  U -@# 2(  A$! Q$!_\0
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M#H:S/%.M'0-'FNDB\^X)$<,).-\C'"C/89_2N(TOX@:SX2N?L/CZVBM4D?\
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M%%^.=WY4 >E0A8HU1!A5&T =@.E2;AWI$ Q2%\ ^F.] CS+QVW_"1_%CP5H
M.^WL_.UN[3MB(!(<_P#;1P1_N^U>E@X(&.*\C\%^*M'O_B5KVM7FI6T,NIW"
MZ)H\,L@#7"6X+2E!W!D=O^^:]0NM4L[*[M+>XNHH;BZ8I!%(X#2L 20H[D $
M_A3*+A<!^,9-*&Z5P5F_ACQ1\1KJ[TC62/$>BH+;4;>VE)5XFY"2H>#SR".0
M>_:N@L_'.BWOBRZ\,1W9_MNU@%S+:M"ZXC)P&#$;2,^AI$FZX8J<<MVKR/QQ
MX2DTZWM=>U'5M1N->.HPI;?9[N2."'<^!&L:D @KG)8$FO7S@$'->6_$+Q;I
M=GXXT:/4YWAL-+/VJ010R2O).PQ$@1%))QEN* /3@P Q7$:-CQCXUN=7;$FF
M:3NL[+."'F_Y:R#Z<*#[&N>\;_'3P[%H36VEZC,-6O6%M;HUE<)(A;@OL* G
M:,G@=<5DWWQ<_P"$.TV#0_#N@W+&RM1-/J6M VEK:Q=YI0?WAW'.%"@L>E,9
MZ%XS^%/A[X@7$$NMP7=P81A8XK^>&/&<\HCA6_$&JMA\#/ .F$&'PEI;'^]-
M )3^)?-9/B?XZ:7X2O="TJ2*;6-;U6#S(K?3XRN6*@H"K<KO)XST )/%97@K
MXVZGXW\4:*J:3%I^B7B7%O+YKF2;[7%M+A&'RF-<E=W<BD&IZ/:^ O#-@X:V
M\/:5;L.C16,2D?B%K6&G6L2_);0IZ8C48_2O)]7^,%Y/\9M$\(Z(EK/8R,ZW
MUQ)\Y)6/S"$P>-H*#/J_M73^+/&D]W'J&D>&66ZU:")_M%X!N@T_"DY<]&D_
MNQCGNV!0(P/@I8Q:SJ_CKQ7)$K-JFM2VMNS*.+:U_<H!QT++(>/6O0KB311J
M<&G3_8OM\R--%;2!/,=5QN8+U(&1S7FO@OXC>$/AK\)_#ZZAK-O&\6EI=2P0
MMY\[$IYDC;$RW5B22 .:\G^%7C.#4?C?X@\7>+'6TU.#38XK73=_VBZWW+EE
MACB3)!2*-%*@'!=BQ!S@&?6D<44/"QHF/[J@5(,9QS^=>':QXTU2/XIZ-/JG
MVBU2/3Y[BR\-6C!KB>1V6.,2@'!<@NV/N(!R>IK>\)_$"^TJ_P#%1\:ZK9VA
MMKN!+:UB Q$'A5_*3^*5LG&0#D@X % CN/%7B>+PM;6<\UO//#<745J6AY\L
MNVT,WMDBK]KI5K9S7$\%ND<UPV^:11\TA P-QZFN"\#^.(_B0]ZVHVD%MIDU
MTT>E6=VA6XF$!_>2LIZ8?&!U&WFO20P'XT#&KP<44X<\T4"'5RMIX_L[SX@Z
MCX32"5;RQM(KMYV(\M@Y("CG.1CTQS74UYC\0OAO-/XFA\7:$)8=;BB\J5[5
M@)70=,!OE?T*-@'L0>: .W\7:H-$\,:K?[@AM[6212>FX*<?KBL#1;NQ^'7P
MPM;S4I/LUKI]B)9B3DYVY('J23@#N37%:QJGC;XBP6_A^#1K:&T+I+?ZE>PW
M%M&%1@WE^4RY8L0,[6( SS74:E\(+7Q9I\D7BC4KO5[A]IC:%S;1VA4@@P(I
MPIX'S'<WO0,\W^'GQ*DM_&NO:GXHD5-3N+))VLPQ:2R5I"+:QB3HTA'S/CG<
MX!QBN5URW\6ZEJ'C;QNNL76G2Z#J]@D]I8/L62"(HT\!;G<(TD9?0D,3VQ]*
MZ5X \/:(-/-KI%JLM@K+;7#QAYH]QRY#G+98\DYR34.E^!-.T[2];TZ53>6N
ML7-S<W:3#A_.)WKQVP<4PN0>/O$MQH/AZ/\ LQXCJFI3I8V#2\QB23/SGU5%
M#.?4)7C_ ,.?%.IWD?BO2-.UBXU6'4M7DM-(NYY?.F$,2*MY>%\_ZO?NV 87
M=@#K7K'_  JO2-3\.Z5HVO)_PD-GI<BO:"\7:5"J50/M(#X0[3NX/<5J^'?
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M>Q112$*1\E,5LX7M110 ]AW]!4>[ Z FBBF@0$EL&I.U%%#&QQZXIK+112$
A7'>D*\XR:** '*H4<4I.*** $W<BE-%% "9R:*** /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>gmab-20220630xex99d1012.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gmab-20220630xex99d1012.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1"  W (X# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#]4Z*** "B
MJ]Y?6]A"9;B:.",<;I& %9CZW>7C!=-TYIDS@W%VQ@C_  R"S?@N/>@#:R!0
M6 K .B:I?#-[K4L(/6+3HEA7_OIMS?B"*:_@+2)R&N%N[I\8WSWTS''_ 'W0
M!T(8&EK#709-+E@DTVYFCB5U$MK-*TD;IT.-Q)5AU&#@XY'IMCI0 M%-9@HR
M2 />L2?QA8+.(+4RZG<'_EE8H9<=OF8?*OXD4 ;M)N%8QEUJ^4>7';Z6AZF8
M^=)C_=4A0?Q-,E\*0WVXZC>7>H @9CDF,<?_ 'PFT'\<T 6+SQ3I-A<"WFOX
M!<GI C;Y#_P!<G]*KRZ_=SQEM/T>ZN#C*M<D6R'_ +Z^8?\ ?--EN]%\*1>7
M;6J1R.<"WT^WWR.?]U!G\34%[KE\+-[B?[+X>M1R9]2D5G4=_E#;0?JQ]Q0!
M)<C7[FWWR76GZ.N"7*JUP5'LS;%_,5S<LJ:S*UO;7FN^)GP5=X)%M;,'H094
M" _12QJ!/B%X!?6[#2[OQ39ZYJ]S*$MXGF$^YVX^5$&P?E^->EJ@ &!C'0>E
M 'F;?!'2==0C6[&Q6WD!$MC9Q;ED']V2:0&1ACCY=@/I7H>EZ7:Z)IUKI]A;
MQVEE:Q+#!;Q+M2-%&%51V   JW10 5RVM>,(;/Q$-",JZ=/);B=+V[7$+Y8K
MLC)(#.,9(R,97KFNIJ"]L;?4;=[>Z@CN8'&&BE4,K#W!XH HV.@6L$XNI"][
M=]1<7#;V'^[V7_@(%:@&*Y./PI/X9/F^'IY$@4#.DW$A>!P.T9;)C/T.WU'>
MMC2O$=EJND+J*R>1#R)%G^1HF'#*X/0@\&@#5I"0*X#5_C!ID#>3IB/J=PQ*
MKL5@I/L "S=>-H(]ZRY-$\:>.4_TVZ.@V#ELH!B1E/3Y%.0?]YOPIV [+Q#X
M_P!!\+1LVH:C%$P./*0[W)]-HR:Y!/B3XG\91@>#_"[1P.2HU37G\B!<?Q!%
MRS@^V/?%=#H7PMT#1I1.]J+^\'S&>[ <YQC(7[H_+/O6EXF\:Z'X.MEFU;4(
M;,,=L<;',DC=E1!EF/L :0'-^'OAUK,MTM[XQ\3R^(I@/ET^"!;:PB.<YV#+
M.1V+L?I7;O+9Z19Y9H;.UB'?"(H_D*X63Q/XR\7!T\/:&N@V1'RZIXA4J[<\
ME+93OZ<_.4^E9\WPST?3D&I^./$M[XDF7/\ R$IA#:@DYPD$>%]AG<: +^H?
M'#P]]M-AI4KZO>YV[+6-Y!GZ(K,?J%Q[BJ:W_C?7IKATTDVUL6VJ=4N%LX0O
M3<$C\R5_^!E/H*W](FD^Q-'X8T"'2K1F!%Q=0?9HV&/O")1O;M]X+GUJY'X*
M%\1)KE]/K#_\\&_=6PYSQ$IY_P"!%J //1#>W[26D7B>]U$(,'3?!EDEM$&Q
MP'N7+8/U=?I6A:?!:#5+K[5J%I:VV[AFN';4KQQC&3-/N6,GOL4^S5ZG;VL-
MC;I!;PI##&,)%&H55'H .!61KVL7.EVT16)Y;B9_+BM[6+S9';!/4D   9);
M % #]!\(Z/X6C==-LHK9G)9Y ,NY(&26//8>U;(Z"O.KKP7XJ\6/G5/$M[X?
MM P9+71I$\XCT>5H\#Z*/Q->B1KL15R3@ 98\F@!U%%% !37D6,$L0H'<FLC
MQ%XLT[PQ K7DW[V0@16\8W2R$GHJCDUP$/@C5?B XNO%LEU<6;/\FDQR/9VJ
M1Y/WU5M\K8Q]["^W>@!/&?QP%G=Q6?@_39/&%['+LO([%6:.W0@_.9 "N5.,
MKUP3Z5A6N@S>-_$EA_PD6L#.I!YAI^DG<D1101YC= =IQG&3CK7L^C:'I_AW
M38;#3+.&PLH5"QP6Z!$4?05S7B?XDZ-X:U(Z=;PSZOKTD1E33-,A,L[@$<MC
MA1SU8@4[@;/A[P=H_A2,KIMC%;NWWYL;I7_WG.2?SJOK7CO2]&N!9JTFH:DW
MW;"PC,TQ]RJ_='NV![UB7OA3Q!XY0#7M1ET/32P8:;H\Y29L8.);@8/7^%,?
M[QKI/"G@_1_!6E+I^C62V=L"6;YF=Y&/5G=B6<^[$FD!@_8_%_BB7-U<1^%=
M-)'[BUVSWKKSD-(<QQ_\!#GW%6;;1/"_@1A>-'$E_+\OVRZ8S7<QQT#MES]!
M^56[VZUC5[J:TT^/^S;>-S&]_<)EFXY\I._;YFX] :B\)?#O2O",CW$+7E_J
M$@VO?ZE=/<SD>@9C\H]E 'M0 P7NO^)%/V*W_L"S;@7%['NN&]UBSA?^!G/^
MS6AI'A"QTF47#>9?W_4WMZWF2_@>BCV4 5MXQ2T )BEHHH *3&32T4 %%%%
M!1110!1_L6Q_M4ZG]DA.H&(0_:B@,FP$D+NZ@9)XJZ!@444 <WK.@ZIX@NI8
M9=4;3M)*X\NP^6XESUS(?N#V49]Q5_P]X6TOPK9&UTNSCM8BVYRO+R-_>=CR
FS>Y)-%% &M1110 4444 %%%% !1110 4444 %%%% !1110!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>gmab-20220630xex99d1010.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gmab-20220630xex99d1010.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1"  [ &0# 2(  A$! Q$!_\0
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-* "DI:* "BBB@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>gmab-20220630xex99d1019.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gmab-20220630xex99d1019.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" !" (X# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#]4C67KNMQ
MZ);(?)DNKF9Q%;VL."\SG/ R0   22<  $FM0US/AW_B>ZC<:](P>!BUOIXZ
MA80<-(/=V!.?[JK[TTEJV(;_ &'KFKQL^H:U+IA8Y6WTE5 C&>\DBL7/N H]
MJ=I>HZCI&K1Z1K$R7@N S66H*@0R[1EHY%' <#)!'# $X!!!Z7BN<\>2FR\-
MW&HJBF33F6\7=T 1@6YR,97<,^YK2,N9\K Z6BF1N'16!!4@$$>E/K(84444
M %%%% !1110 4444 %%%% !1110!@^,[B:/0Y+>U?R[J]=+.%O[I<[2W_ 5+
M-^%4[^>9)K7PWH;"U>.!3-<A-PM( "J[0>"[8(4'@ $D$  IXFO((?$_AV.X
MD"1Q_:KP[ER,)%M)]L"0FK'@JVE.DG4;E-E[J<AO)<CE0P C7_@*!1CU!/>M
ME[L4V(S-*UL^&FUJQO+R?419W,26HD.^XD\U%98R3C<V[?@]AC/0FK5SJG_"
M4^"];41+;7"Q7-I+"Q$@CD564@G R.AZ=#6;X;1M=^(/B6]D5#9Z9<I:VQ7^
M*8P(9&/NH8*/3<WK63JVIIX?^'/BF[L QNM0O[R&W$I*!IWD:($'K@$9R.PX
MK=P3DDM]/Q%<[3P=K,&IZ+9P"ZCGOH+6#[4B,"49D!Y';/-=!7!>$/#</ASQ
M3'8V;,EKI^B6UJR')RWF2$,6/!8X))ZDG)ZUWM<U1)2T&@I".U!.*Y6WU6?4
MO&VRVNI3I]O!-;RP%0$,JM&2P.,DC>%Z@#YNO:(KF!NQU=%%%(84444 %%4[
MJ]^RSV\;0R,DS%?-7&V,]MW.1GH, \^E6P<T +15%]7LXY+N-KF)7M$$DX+
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MG[W8<YY4LI(ZCD<9%/\ &NM>*)M'OO#.D:1IUWJ5Q;^4GV&Z+)9(< F96"X
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MQ[D]2>YJS7.,****8!1110 4444 %%%% !1110 4444 %%%% !1110 4444
'%%%% '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>gmab-20220630xex99d1015.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gmab-20220630xex99d1015.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1"  J ,P# 2(  A$! Q$!_\0
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MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#]4Z**0G%
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M ,O)?B3%2LTM"#P9X\N/$6M7NC3Z<4NM,MH'O;R$_P"C+<2#<85R=VY1@D$
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J@HHHH 3 I:** $P*6BB@!*6BB@ HHHH **** "BBB@ HHHH **** /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>gmab-20220630xex99d1017.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gmab-20220630xex99d1017.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1"  X '0# 2(  A$! Q$!_\0
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M<TY)RO$WBFEJ>,^&I-0U4^%O!UW:SK?^'+SS=1N3;LL(@MPRVS*Y&UC+F)@
M20!)G!%>R@ BC;S2YXJ93YM@C&PM%%%26%%%% !1110 4444 -/2O+O@MX7G
ML]+U^XUG3O)O9O$NH74"7,)W1()3'$R%L\%%!##C#8'%%%:)M0:1FU>2/4Z*
:**S- HHHH **** "BBB@ HHHH **** /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>gmab-20220630xex99d1002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gmab-20220630xex99d1002.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1"  \ ,H# 2(  A$! Q$!_\0
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M;')RHZ9S\[_L\ZYXCL?C+X7CT*[NS<7=]''<PK(S)- 3F7S!T(";CD]" >M
M'IO[0/[5_BN]\::KH7A347T'1M-N'M3<6RKY]S(A*NQ<@[5W @ 8X&2><#T;
M]C+XT>*_B#?:]H7B.\DUB*QMX[F"_F4"5-S%3&S #=GJ">>#U[:GQ%_8C\/^
M-O%]]KMCKUYH0OY6N+FTC@29#(QRS(205R<G!R,DX]*];^$_P@\/?!SP^^EZ
M%#(6F8275Y<,&FN7 P"Q  P!P   /Q.0#MZ*** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** /)O&W[+GPY\>ZU)JVH:(UO?S/OGEL+A[<
M3-W+JIP2>YQD^M> ?M&_%W4/@[K%E\-_ATR^%=)TNV2:XDM$!EDDDRP7<V3C
M&&)ZL6Y/'/VQ7R5^U?\ LU>)/'/C&+Q9X3M4U.2X@2"]LC,L<BLG"R+N(!!7
M (SD;0><G !<^"ESI7[6WP_N=/\ B'8)J>M>'KA8TU* F"9HY%RK93&"=C!A
MT.T'&:]M^&WP/\&?"<RR>'=(6WO)EV27L[M-.R_W=[$D#V&!7&_LJ_!+4/@Y
MX/OSK;1C7-6F6:X@A<.L"("$CW#@GEB2./FP,XR?;J "BO.?CA\<] ^!7A==
M5U@M<W=P3'9:="P$MRX&3@G[JC(W,>!D=20#X;I?CW]IWXFVJ:SH7A[1/"^D
M3C?;17ZJ))$/(/[PECD=]J@]JZZ>&G4CSMI+NW8\?$YI0P]7V"C*<]VHJ[2\
M^B^;/KBBOFSX<?&WXLZ5\0M)\&_$GP"V_4W9+?6='7,(VC<S.=S(5 Y.&4C^
MZ:^DZRJTI4G:5M>SN=6$QE/&0<J::L[----/T84445B=P4444 %%%% !1110
M 4444 %%%% !17D/[6=WJ.F_ +Q1J&DZG>:1?V:0S1W-C.T4F/.0,NY2#@JQ
M%2?LHZQ>:]^SYX-O;^YEN[M[>5'GG<N[[9Y%!+'DG"CK71[%^Q]M?K;\+GF_
M75]>^I<NO)SW^=K'K5%%%<YZ04444 %?$O[97QJ\2V?Q#_X1'1M5N]&T[3[>
M*6<V4S1/<2R#<-S*0=JKMP,]22<\8^VJ^9/VGOV6]5^*/B2W\3^%Y[1=2:%;
M:\M+QS&LH7.R16 /(!P01R .>.0#3_8R^+&M?$7P=J^G:_=2:C?:+/&B7LQS
M)+#(I*AS_$RE&&3R1C/K7T17D?[-OP/?X)>#[JVO;J*\UO4IA/>2P9\I,#"1
MIGDA1GD@9+'BO7* /AC7E'QT_;P@TC41]IT/PZYC%M(-R;;=-[ CH0TY /J,
M"ON>OASX#D67[>'CV&XXEEDU/R]W?,R./_':^J?C+H/C3Q%X--MX!UV#P]X@
M6XCD6ZN5#1M&,AT.4?&0<].H%>MC5>=.G>R45Z>I\;D<W&AB<4XN4W4E=+=V
MV2OVZ'=5A>./&VD?#KPKJ/B+7+G[+IEC'YDC@99CG"JH[LQ( '<D5\4_%GQ9
M^T!\#;[PU_PD?Q M+V'5[HQ1KI\$38",F[=N@7&0XZ>]=I_P4=UJYMO!/A'2
M8Y"EO>7\T\H!X8Q1@+G\9"?PJ88%NI3BY)J5]5Y;FM;/U'"XFK&E*,Z26DK;
MRVV;+FD?'+X]?%RTDU_P!X&TBP\,;V%J^K2@RW(4D'!,B \@C(&,Y&XXKN/@
M'^TS<?$;Q-J'@GQAHG_"+>.; ,SV8)\J<+C=L#<JP!!VY.5.X$C..&\&?MD:
M#X3\(:)HMM\._&'V?3[*&U0Q6"[2$0+D?-SG&<^]>:O\0)?B3^V#X'\8Z+X7
MUW1+9Y;:RNC?V;(Q)\R-F)7(V['49)[5V/#\ZG&5-123L^NG?76YXT<R^KRH
MU:6*=64I)3BUI9[M:*UNFI]!_M0?M ZY\"+OPDUAIMA=Z;JMPT=U/=%R\2HT
M98*%('*,V"<X(Z&N4U3]I3XH?$:>XG^$7P\.I>'8&94UK6%*+=X/)B5GC&/Q
M8^H!XK"_X*)HLFF_#Q& 96U&<$'H1MCXKZ^M;6&QMHK>VACM[>) D<42A410
M,  #@ #L*Y+TJ5"G4<$Y.^^VC/72Q>,S#$X=5W"G#DV2OK'HVG9=]+^9X-^S
M=^TQ=_%W6-8\+>)]%7P_XPTE6>:WCW!)%5@C_*WS(RL0"I)Z@@]<+^U%^T%K
MOP'O/"+Z?IVGW>F:K.Z7<UUO,D:QM&6"!2!DHQP3G!'2O+_A, O[?WCX 8_T
M:Y/'TMZM_P#!0Y%EMOALCJ'1M2G5E(R""(LBMU0I?6X1Y?=DKV^1Y\L?BUDU
M>I[3]Y3DXJ75VDEK\F:.N?M,?%?Q]Y^H?"CX=27GAB!FV:KJ<)+W@4G)B3>G
M!]!N/T/%,\,_MZV6I>!_]*\-7-U\06NOL4'A[3U<K<N1Q(I()5<Y!7YF!&!G
MJ/J^VMH;.WBM[>)(((E"1Q1J%5% P  .  .U?%_[%>EV=S\=OBQ>S6L,MW:7
M,BV\[H"\(>YF#[3VR% ./2HINA5I3DZ=E&UM=7ZLZ,3',,+BZ%.&);=7F3NE
M965[Q73RNWYEKQ#^U+\:OA9?:?K'C[X?V-CX7O9A'Y=OD2IWVB02L ^T$A74
M9P>G;ZS3Q39W'A%?$=HL]_I\ED+^);6,O+-&4WJ$3J6(Q@>IKP;]OT _ )LC
MIJMKC_Q^O4?@&ZI\#/ ;NP55T.T)9C@ >2M8UE"="%912=VM#LP,L10S"M@I
MU7.*BI)RM=-NSV2T/$+/]I7XN_%MWG^&'PTCCT3)$>J:Z^U9,=QET7/LI?%2
M^#?VH/'GA+XI:5X'^+GABSTB7572.TU'3R0FYVVH3\[JZEL*2""I/(KJ-:_;
M#\-QZW-H'@7PYK7Q!O[;Y7&@VV;=,<</W'N%V^A-?/7[0?Q%U[XC?%3X7'7/
M NI>!YK74$6%-1D#M<AKB#)7"C&W:,_[U=M*BJKY)4E&+3Z^]MZW_ \/%XUX
M6"KTL9*I44DFK>X[M)K2-E_X%?YGU3^UO_R;GXX_Z]$_]'1U\Z_!+X^^-K7X
M1^'/!OPP\$2^)M6TR&7^T=1NU(M;=WFD=4'S*"=K Y+#V!KZ*_:W_P"3<_''
M_7HG_HZ.JG[&UM#;_LW^#VBB2,RI<22%% +M]HD&X^IP ,^PKFI3C#!WE&_O
M?H>IBZ-7$9TH4JCA^ZU:2O;GV5]O6S/,O"'[8'BSPGXZLO"_QA\)1^&3>L%B
MU*W1HT3)P&8,S*R9X+JWR]Q7UKUKY=_X*&:):WOP;TO49(U-W9:M&D4N.0DD
M;AU^API_X"*[CX6_%:ZG^&7A&2XB\^X?1[-I)6R2[&%,D_4U%:E&K2C6IQM>
MZ:Z&^"Q57"8NK@<54<U%*49/>SZ.V^O4]KHHHKRSZP**** "BBB@#XH_:3T/
M4_@-^T1H/QCTVRDN]"NY4345A'W)-GE2(3T'F1\J3QN!]J^J? OQ:\(_$C2H
MK_P_KUE?1NH9HA*%FB/]UXS\RD>XKHM7TBQU_3+G3M2M(;^PN4,<UM<1AXY%
M/9E/!KYR\7?L'_#"_NGO;-=8T7>W^HL+Q3&OT$B.1],UZL)4\7&-.I=2BK76
MNGF?'UZ>(R:K4Q&&Y94ZCNXMM-2>[32>CZW1P?[?OB'2]3UCX<65GJ5I=7EK
M>SO/;P3*[Q*S0!2P!RN<'&?0UW/[?GP^N_%GPDM-:L8FGET"Z-Q.B#)%NZ[)
M&Q_LG83[ GM72> ?V+?A?X(O8-0&E7&N7D962-]8G\Y48<@^6H5"?JIKW66)
M)XGBE19(W4JR.,A@>H([BJGB(T)4HT[ODOOUN9T,NJYA3Q53$VC[=1LE=VY5
M9/5*^MF>6?L^_&;P]\4/AUHDMIJ5NNK6UI%!?6$DH$T,JJ%8E2<E21D-T(/K
MD#K_ /A9OA0^,;;PHNOV,GB*YC>6/3XY0\A5!ELXX!QS@X) ) X->.>+_P!A
M;X7^(=4?4+>WU+06D;+0:5=*D()Z[5='V_1<#VKN/A3^S1X!^#ER;W0=),NJ
MD%?[2OY//N #U"DX"9[[0,]ZRJTZ'*ZL6]=E9?G?]#JP>*S!U(X2I&%XVYI7
M>J7966K];'A__!1'_CP^'7_82G_]!CK["K@?BO\ !'PQ\9XM)C\2Q74BZ9*T
MUO\ 9K@Q89@,YQU^Z*[ZL:M12H4X+=7_ !9WX7#3I8_%5VU:?);OHFG<^,OA
M/_R?]X^_Z]KC^5O5W_@H5_JOAI_V$YOY15[_ *'\"_"WA[XHZI\0+.*[7Q%J
M*.D[O<%HB&V9PG0?<6G_ !5^"7ACXRKHX\2174@TJ9I[;[-<&+#-MSG'7[HK
ML6(A]8IU+:))?@>'/+:SRS$X>ZO.;:WM9R3UT.^KXT_8D_Y+1\8O^OH_^E4]
M?9=>??#KX&^%OA;XAU_6M"BNH[[6W\R\,]P9%)WL_P H/3EVKCHU%"E4B^MO
MS/;QN&G6QF%JQ:M!R;^<;:'E_P"WY_R0%_\ L*VO_L]5O&5WJ-C^P1;RZ8SK
M<?\ ",V*.T9.X0L(EE_\AE\^V:]L^*'PMT+XO^%SH'B*.>33C.EQMMIC$V]<
MXY';DUJ:'X0TO0/"%EX8@M_.T:ULUL%@N?WF^$)LVOG[V5X.>M:PKQA1@K7M
M*YRULOJ5L;7FI64Z?*NZ>NIX=^P<FB)\![4Z;Y']I->3_P!I[,>8)=Y";^_^
MKV8]OQKR']K3X@>'_$'[1GPUL;+4H+H:'>0#4)8G#1P,]S&VTMTR%3)],C/.
M0/4M6_88^'?]N-/IU[XAT."Z8[[33M0"Q!<_=&Y&;;[%C71>)_V0OAK>_#JV
M\,PZ3+IUM:7*W27MI+B[>0X5R\C!MVX<$$8'&,8%=ZE2AB/;MM\U^VE_F?.3
MIXRMEW]GQC%>Q2N[O7E:>BY5:]M7KZ&M^UTP3]G+QN3_ ,^L8_.:,5Q_[%OQ
M2\+:A\&-!\-)K-K#KNEB6*YL+B01R_-,[AE!^\I##D9]#BO8O&7POT+QQX!?
MP;J$=Q'H+1PPF&VG9'V1E2B[^3C*+]<5YOXI_8Q^&'B7P]I>FOI=S82:7;_9
MX+^RGV7+("3B1B"'.2>6!/I@5QT94IT/8SOK*]UZ'NXRGBZ6/^O45%J-.S3;
MU]Z^C2_3Y'DO[=GQ*L/&-KX<^''AFYBUK6[G4DGG@LG$FQ]I2*(D<;F:0G'4
M!><9%?3W@CX<:?X7\%Z!HTT*33:=I]O:/(.CM'&J$_B17&?!_P#96\ _"#4%
MU?2;*YO]7"D1WVIRB62$$8/E@*JJ2.,@9QQG!KV2HQ-6,8QH4[VCU[MFV686
4I5JU,PQ5N:I9)+5**\W:[?4__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>gmab-20220630xex99d1008.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gmab-20220630xex99d1008.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1"  ^ 'P# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#]4Z*** "B
MBB@ HHIKYVG!P>QH 5CM%8'A;Q1'XI^W30I&MM#<&*%A*&>5!QYC+_"K$,5Y
M.Y<-QNP.1UWXG?\ "->&9+/Q +FQUX*+3S8K.1XYI6(C66(J"K!BP8)NSGY>
MHKI? >BMI.D^;):_9)K@@B$\O%"JA(49CRS+&JY+$G<6YQBBW<1U-%)2%L T
MKC'45SFJZ_>2:W%HNE1QB],(NI[FY1C#!$6*KP"-[LRD!01@ DGH&IV>E^*=
M&\V;^VXM>S@BUNK5+;CG[LB=#_O C@=.M,#KZ*P-.\8V=Y,+:X672[XD#[)?
MKY3DDD?*<E7Y'5"PZ>HK=5@R@T .HHHH **9)((UR6 ]R:S(_$5K='%HS7I]
M;=2Z]%(^;H.&!Z\\XZ4 :U-+ '%5(IKN8*3$D'S#(9MQQDYZ<=,$<]Z(H9 B
M&:X:1UVEB@V*2,\XYZYZ9[4@++S)&I+$* "22<8 [U =4M?M!MQ,K3^5Y_EJ
M<L8\XW8],U7NH]-L(3=W!AB2*-U,\[#Y4)RPW-VX_2LFY\<Z59VT4PN(8K:0
M[(9[B00PN<$_*6QN X&5!Z^QIB&:_P")(!'HLD0FE^T7!D%F+0O-.B(Q.%;!
M4JQC;<>FWWK6U?7H-#T62_G4JJ)N$3NL;$]E^8@9R0,9JIKFKZ+ID=EJFIS1
M1A Q@F)+#YEP<8[$4UY=#UNWM=?%I%J1LPS6UPEL998LXW>6 "P)XZ<T 9D'
MCN?Q!:6B:)9(]_=1&=5NIT\N&,'&Z0QEB,ME  "<@\?*<4-(\?>*;F:2TU#P
M+?6=X%(3R[E)8"V,\RX"A<=^?3&>*W?#>IZ//?W@T[2+JPN+EO/N)9=*EMA,
M^,;F9D4,WXYJ?6_$-QI,X2'0M1U$'_EI:(A'ZL*?E8"DEIXHMQYD1TF2XF >
MX9VF WXQA1@_*  .V>3@$FG1#QEYY\P:)Y7^R\V[_P!!K8T?4YM2M1+)I]U8
M,?\ EE=*H8?D3574-8U>VE"V^A2W:8^^MS$H_)F%&H$6K:;JNIZ4;>6VTFZ9
MN7BN0[1$@@@XQU&,_7%'A3PY=^'FG$EYOLY$B\JP0,8[5P")/+=B6*L2N%.
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M:VNE8NA#[=?7VJ!D>*;;# RCDQIGG/<%F<CV^M;=4 4F :6BD 4444 %%%%
M!1110 4444 5=3C:;3[F-&=&:-E#1_>!P>GO4.E:M!JUA#=V[9CD7.">5/=3
MZ$'@_2KY&:YO4_!&FZG=23*;FRED?S)6L[AHO,;&,L!Q2$;T][#:QM)+(L4:
MC)9S@"L&[N9?%0:ULC)!IY;;/><J9%S\R1]^<8+=L\<U)IW@S3;)4$B2WS)G
M:U[*TQ'S*W?C@J"#C(K> "\8Z4P&6MK%901P0(L4,2!$11@*H& ![ "IJ0=*
56@84444 %%%% !1110 4444 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>gmab-20220630xex99d1018.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gmab-20220630xex99d1018.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1"  Z -0# 2(  A$! Q$!_\0
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M&97[07Q(O/B-X]MO@SX+MUOYD19M858V$ 48VP2NI&R(##/W( 4=:^@/AIX
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1HHH **** "BBB@ HHHH _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>21
<FILENAME>gmab-20220630.xsd
<DESCRIPTION>EX-101.SCH
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  9.6.8167.22744 -->
<!--Based on XBRL 2.1-->
<!--Created on: 8/10/2022 3:19:08 PM-->
<!--Modified on: 8/10/2022 3:19:08 PM-->
<xsd:schema xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:country="http://xbrl.sec.gov/country/2021" xmlns:attributeFormDefault="unqualified" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" targetNamespace="http://www.genmab.com/20220630" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:srt-types="http://fasb.org/srt-types/2021-01-31" xmlns:gmab="http://www.genmab.com/20220630" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:deprecated="http://www.xbrl.org/2009/role/deprecated" xmlns:currency="http://xbrl.sec.gov/currency/2021" xmlns:fact-explanatoryFact="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:ifrs-full="http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full" xmlns:srt-roles="http://fasb.org/srt-roles/2021-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2021" xmlns:stpr="http://xbrl.sec.gov/stpr/2021" xmlns:net="http://www.xbrl.org/2009/role/net" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:naics="http://xbrl.sec.gov/naics/2021" xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns:exch="http://xbrl.sec.gov/exch/2021">
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType roleURI="http://www.genmab.com/role/DisclosureStandardAndCustomAxisDomainDefaults" id="DisclosureStandardAndCustomAxisDomainDefaults">
        <link:definition>99900 - Disclosure - Standard And Custom Axis Domain Defaults</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.genmab.com/role/StatementStatementsOfComprehensiveIncome" id="StatementStatementsOfComprehensiveIncome">
        <link:definition>00100 - Statement - STATEMENTS OF COMPREHENSIVE INCOME</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.genmab.com/role/StatementBalanceSheets" id="StatementBalanceSheets">
        <link:definition>00200 - Statement - BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.genmab.com/role/StatementStatementsOfCashFlows" id="StatementStatementsOfCashFlows">
        <link:definition>00300 - Statement - STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.genmab.com/role/DisclosureResultsForYearStaffCostsDetailsCalc2" id="DisclosureResultsForYearStaffCostsDetailsCalc2">
        <link:definition>40203 - Disclosure - RESULTS FOR THE YEAR - Staff Costs (Details) Calc 2</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.genmab.com/role/DisclosureFinancialIncomeAndExpensesDetails" id="DisclosureFinancialIncomeAndExpensesDetails">
        <link:definition>40401 - Disclosure - Financial Income and Expenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.genmab.com/role/DisclosureLeasesDetails" id="DisclosureLeasesDetails">
        <link:definition>40701 - Disclosure - Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.genmab.com/role/DocumentDocumentAndEntityInformation" id="DocumentDocumentAndEntityInformation">
        <link:definition>00090 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.genmab.com/role/StatementStatementsOfChangesInEquity" id="StatementStatementsOfChangesInEquity">
        <link:definition>00400 - Statement - STATEMENTS OF CHANGES IN EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.genmab.com/role/DisclosureRevenueDetails" id="DisclosureRevenueDetails">
        <link:definition>40201 - Disclosure - Revenue (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.genmab.com/role/DisclosureFinancialInstrumentsFinancialRiskDetails" id="DisclosureFinancialInstrumentsFinancialRiskDetails">
        <link:definition>40301 - Disclosure - Financial Instruments - Financial Risk (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.genmab.com/role/DisclosureFinancialInstrumentsFairValueMeasurementDetails" id="DisclosureFinancialInstrumentsFairValueMeasurementDetails">
        <link:definition>40302 - Disclosure - Financial Instruments - Fair Value Measurement (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.genmab.com/role/DisclosureFinancialInstrumentsOtherInvestmentsDetails" id="DisclosureFinancialInstrumentsOtherInvestmentsDetails">
        <link:definition>40303 - Disclosure - Financial Instruments - Other Investments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.genmab.com/role/DisclosureShareBasedInstrumentsRestrictedStockUnitProgramDetails" id="DisclosureShareBasedInstrumentsRestrictedStockUnitProgramDetails">
        <link:definition>40501 - Disclosure - Share-Based Instruments - Restricted Stock Unit Program (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.genmab.com/role/DisclosureShareBasedInstrumentsWarrantProgramDetails" id="DisclosureShareBasedInstrumentsWarrantProgramDetails">
        <link:definition>40502 - Disclosure - Share-Based Instruments - Warrant Program (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.genmab.com/role/DisclosureShareBasedInstrumentsShareRepurchasesDetails" id="DisclosureShareBasedInstrumentsShareRepurchasesDetails">
        <link:definition>40503 - Disclosure - Share-Based Instruments - Share repurchases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.genmab.com/role/DisclosureRelatedPartiesDetails" id="DisclosureRelatedPartiesDetails">
        <link:definition>40601 - Disclosure - Related Parties (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.genmab.com/role/DisclosureBasisOfPresentation" id="DisclosureBasisOfPresentation">
        <link:definition>10101 - Disclosure - Basis of Presentation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.genmab.com/role/DisclosureRevenue" id="DisclosureRevenue">
        <link:definition>10201 - Disclosure - Revenue</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.genmab.com/role/DisclosureFinancialInstruments" id="DisclosureFinancialInstruments">
        <link:definition>10301 - Disclosure - Financial Instruments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.genmab.com/role/DisclosureFinancialIncomeAndExpenses" id="DisclosureFinancialIncomeAndExpenses">
        <link:definition>10401 - Disclosure - Financial Income and Expenses</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.genmab.com/role/DisclosureShareBasedInstruments" id="DisclosureShareBasedInstruments">
        <link:definition>10501 - Disclosure - Share-Based Instruments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.genmab.com/role/DisclosureRelatedParties" id="DisclosureRelatedParties">
        <link:definition>10601 - Disclosure - Related Parties</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.genmab.com/role/DisclosureLeases" id="DisclosureLeases">
        <link:definition>10701 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.genmab.com/role/DisclosureSubsequentEventsToBalanceSheetDate" id="DisclosureSubsequentEventsToBalanceSheetDate">
        <link:definition>10801 - Disclosure - Subsequent Events to the Balance Sheet Date</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.genmab.com/role/DisclosureBasisOfPresentationPolicies" id="DisclosureBasisOfPresentationPolicies">
        <link:definition>20102 - Disclosure - Basis of Presentation (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.genmab.com/role/DisclosureRevenueTables" id="DisclosureRevenueTables">
        <link:definition>30203 - Disclosure - Revenue (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.genmab.com/role/DisclosureFinancialInstrumentsTables" id="DisclosureFinancialInstrumentsTables">
        <link:definition>30303 - Disclosure - Financial Instruments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.genmab.com/role/DisclosureFinancialIncomeAndExpensesTables" id="DisclosureFinancialIncomeAndExpensesTables">
        <link:definition>30403 - Disclosure - Financial Income and Expenses (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.genmab.com/role/DisclosureShareBasedInstrumentsTables" id="DisclosureShareBasedInstrumentsTables">
        <link:definition>30503 - Disclosure - Share-Based Instruments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.genmab.com/role/DisclosureLeasesTables" id="DisclosureLeasesTables">
        <link:definition>30703 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.genmab.com/role/DisclosureBasisOfPresentationDetails" id="DisclosureBasisOfPresentationDetails">
        <link:definition>40101 - Disclosure - Basis of Presentation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:type="simple" xlink:href="gmab-20220630_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="gmab-20220630_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="gmab-20220630_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="gmab-20220630_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Calculation Links, all" />
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:import namespace="http://xbrl.sec.gov/dei/2021q4" schemaLocation="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xsd:import namespace="http://fasb.org/srt/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/country/2021" schemaLocation="https://xbrl.sec.gov/country/2021/country-2021.xsd" />
  <xsd:import namespace="http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full" schemaLocation="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/currency/2021" schemaLocation="https://xbrl.sec.gov/currency/2021/currency-2021.xsd" />
  <xsd:element name="DocumentAndEntityInformationAbstract" id="gmab_DocumentAndEntityInformationAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element id="gmab_IfrsMarketableSecuritiesCurrent" name="IfrsMarketableSecuritiesCurrent" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <xsd:element id="gmab_ReversalOfFinancialItemsNet" name="ReversalOfFinancialItemsNet" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <xsd:element id="gmab_CashFlowFromUsedInOperatingActivitiesBeforeFinancialItems" name="CashFlowFromUsedInOperatingActivitiesBeforeFinancialItems" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="gmab_AdjustmentsForInterestOnLeasePayments" name="AdjustmentsForInterestOnLeasePayments" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <xsd:element id="gmab_PaymentsToAcquireTreasuryShares" name="PaymentsToAcquireTreasuryShares" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <xsd:element id="gmab_PaymentOfWithholdingTaxesOnBehalfOfEmployeesOnNetSettledRSUs" name="PaymentOfWithholdingTaxesOnBehalfOfEmployeesOnNetSettledRSUs" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <xsd:element id="gmab_IncreaseDecreaseThroughNetSettlementOfRestrictedStockUnitsEquity" name="IncreaseDecreaseThroughNetSettlementOfRestrictedStockUnitsEquity" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <xsd:element id="gmab_IncreaseDecreaseThroughTaxOnItemsRecognizedDirectlyInEquity" name="IncreaseDecreaseThroughTaxOnItemsRecognizedDirectlyInEquity" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <xsd:element id="gmab_TransactionsWithOwners" name="TransactionsWithOwners" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="gmab_ExerciseOfWarrants" name="ExerciseOfWarrants" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="gmab_BasisOfPresentationAbstract" name="BasisOfPresentationAbstract" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="gmab_DescriptionOfAccountingPolicyForBasisOfPresentationPolicyTextBlock" name="DescriptionOfAccountingPolicyForBasisOfPresentationPolicyTextBlock" nillable="true" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="gmab_DescriptionOfAccountingPolicyForRecentAccountingStandardsAdoptedPolicyTextBlock" name="DescriptionOfAccountingPolicyForRecentAccountingStandardsAdoptedPolicyTextBlock" nillable="true" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="gmab_TypesOfRevenuesAxis" name="TypesOfRevenuesAxis" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrldt:dimensionItem" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="gmab_TypesOfRevenuesMember" name="TypesOfRevenuesMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="gmab_RoyaltiesRevenueMember" name="RoyaltiesRevenueMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="gmab_MilestonePaymentsRevenueMember" name="MilestonePaymentsRevenueMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="gmab_LicenseFeesMember" name="LicenseFeesMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="gmab_ReimbursementIncomeMember" name="ReimbursementIncomeMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis" name="IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrldt:dimensionItem" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeDomain" name="IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeDomain" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="gmab_AgreementsWithJanssenMember" name="AgreementsWithJanssenMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="gmab_AgreementsWithNovartisMember" name="AgreementsWithNovartisMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="gmab_OtherCollaborationPartnersMember" name="OtherCollaborationPartnersMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="gmab_DisclosureOfBalanceSheetInformationRelatingToLeasesTableTextBlock" name="DisclosureOfBalanceSheetInformationRelatingToLeasesTableTextBlock" nillable="true" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="gmab_DisclosureOfComprehensiveInformationRelatingToLeasesTableTextBlock" name="DisclosureOfComprehensiveInformationRelatingToLeasesTableTextBlock" nillable="true" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="gmab_PropertiesMember" name="PropertiesMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="gmab_IfrsEquipmentMember" name="IfrsEquipmentMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="gmab_DisclosureOfFinanceIncomeExpensesAbstract" name="DisclosureOfFinanceIncomeExpensesAbstract" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="gmab_DisclosureOfFinanceIncomeExpensesTableTextBlock" name="DisclosureOfFinanceIncomeExpensesTableTextBlock" nillable="true" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="gmab_FinanceIncomeAbstract" name="FinanceIncomeAbstract" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="gmab_GainsOnHedgingInstruments" name="GainsOnHedgingInstruments" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <xsd:element id="gmab_InterestAndOtherFinancialIncome" name="InterestAndOtherFinancialIncome" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <xsd:element id="gmab_FinanceExpensesAbstract" name="FinanceExpensesAbstract" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="gmab_InterestAndOtherFinancialExpenses" name="InterestAndOtherFinancialExpenses" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <xsd:element id="gmab_LossesOnMarketableSecurities" name="LossesOnMarketableSecurities" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <xsd:element id="gmab_IfrsRestrictedStockUnitsRSUsMember" name="IfrsRestrictedStockUnitsRSUsMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="gmab_NumberOfWarrantsGrantedDuringPeriod" name="NumberOfWarrantsGrantedDuringPeriod" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="gmab_NumberOfWarrantsExercisedDuringPeriod" name="NumberOfWarrantsExercisedDuringPeriod" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="gmab_MarketableSecuritiesMember" name="MarketableSecuritiesMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="gmab_TripleaRatingMember" name="TripleaRatingMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="gmab_PercentageOfMarketableSecurities" name="PercentageOfMarketableSecurities" nillable="true" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" />
  <xsd:element id="gmab_DisclosureOfWarrantsActivityTableTextBlock" name="DisclosureOfWarrantsActivityTableTextBlock" nillable="true" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="gmab_RestrictedStockUnitsRSUsMember" name="RestrictedStockUnitsRSUsMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="gmab_StockRepurchaseFirstAuthorizationMember" name="StockRepurchaseFirstAuthorizationMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="gmab_StockRepurchaseSecondAuthorizationMember" name="StockRepurchaseSecondAuthorizationMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="gmab_IfrsShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod" name="IfrsShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod" nillable="true" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="gmab_ShareBasedArrangementPeriodFromVestingDateHolderReceivesShares" name="ShareBasedArrangementPeriodFromVestingDateHolderReceivesShares" nillable="true" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="gmab_ShareBasedArrangementNumberOfSharesPerRsu" name="ShareBasedArrangementNumberOfSharesPerRsu" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="gmab_ShareBasedArrangementNumberOfAuthorization" name="ShareBasedArrangementNumberOfAuthorization" nillable="true" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="gmab_NumberOfSharesAuthorizedToBeRepurchased" name="NumberOfSharesAuthorizedToBeRepurchased" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" />
  <xsd:element id="gmab_SharesRepurchasedNominalValue" name="SharesRepurchasedNominalValue" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" />
  <xsd:element id="gmab_ShareRepurchasedDuringPeriodShares" name="ShareRepurchasedDuringPeriodShares" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="gmab_ShareRepurchasedDuringPeriodValue" name="ShareRepurchasedDuringPeriodValue" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <xsd:element id="gmab_SharesAvailableForRepurchase" name="SharesAvailableForRepurchase" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="gmab_SharesAvailableForRepurchaseAmount" name="SharesAvailableForRepurchaseAmount" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <xsd:element id="gmab_TreasurySharesAcquired" name="TreasurySharesAcquired" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="gmab_PercentageOfShareCapitalRepurchased" name="PercentageOfShareCapitalRepurchased" nillable="true" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" />
  <xsd:element id="gmab_Weightedaveragefairvalueofotherequityinstrumentsgrantedinsharebasedpaymentarrangement" name="Weightedaveragefairvalueofotherequityinstrumentsgrantedinsharebasedpaymentarrangement" nillable="true" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="gmab_WarrantsGrantedFromAugust2004UntilApril2012Member" name="WarrantsGrantedFromAugust2004UntilApril2012Member" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="gmab_WarrantsGrantedFromApril2012UntilMarch2017Member" name="WarrantsGrantedFromApril2012UntilMarch2017Member" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="gmab_WarrantsGrantedFromMarch2017Member" name="WarrantsGrantedFromMarch2017Member" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="gmab_WarrantVestingPeriod" name="WarrantVestingPeriod" nillable="true" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="gmab_NumberOfWarrantsOutstanding" name="NumberOfWarrantsOutstanding" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" />
  <xsd:element id="gmab_NumberOfWarrantsExpiredOrLapsedOrCancelledDuringPeriod" name="NumberOfWarrantsExpiredOrLapsedOrCancelledDuringPeriod" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="gmab_WeightedAverageExercisePriceOfWarrantsGranted" name="WeightedAverageExercisePriceOfWarrantsGranted" nillable="true" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="gmab_WeightedAverageExercisePriceOfWarrantsExercised" name="WeightedAverageExercisePriceOfWarrantsExercised" nillable="true" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="gmab_PercentageOfShareCapitalAttributedToExerciseOfWarrants" name="PercentageOfShareCapitalAttributedToExerciseOfWarrants" nillable="true" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="gmab_IfrsCumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption" name="IfrsCumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <xsd:element id="gmab_EquityAdjustedForCumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption" name="EquityAdjustedForCumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" />
  <xsd:element id="gmab_WeightedAverageExercisePriceOfFairValueOfWarrants" name="WeightedAverageExercisePriceOfFairValueOfWarrants" nillable="true" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="gmab_DescriptionOfAccountingPolicyForJudgmentsAndEstimatesPolicyTextBlock" name="DescriptionOfAccountingPolicyForJudgmentsAndEstimatesPolicyTextBlock" nillable="true" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="gmab_StockRepurchaseThresholdPriceDeviationPercentage" name="StockRepurchaseThresholdPriceDeviationPercentage" nillable="true" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="gmab_FutureMinimumOperatingLeasePayments" name="FutureMinimumOperatingLeasePayments" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" />
  <xsd:element id="gmab_EstimatedCapitalExpenditureForLease" name="EstimatedCapitalExpenditureForLease" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" />
  <xsd:element id="gmab_AmericanDepositorySharesMember" name="AmericanDepositorySharesMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="gmab_IfrsSubsidiarySaleOfStockAxis" name="IfrsSubsidiarySaleOfStockAxis" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrldt:dimensionItem" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="gmab_IfrsSaleOfStockNameOfTransactionDomain" name="IfrsSaleOfStockNameOfTransactionDomain" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="gmab_DisclosureOfNewAccountingPoliciesAndDisclosuresPolicyTextBlock" name="DisclosureOfNewAccountingPoliciesAndDisclosuresPolicyTextBlock" nillable="true" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeTable" name="IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeTable" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="gmab_CollaborativeArrangementAndArrangementOtherThanCollaborativeLineItems" name="CollaborativeArrangementAndArrangementOtherThanCollaborativeLineItems" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="gmab_CurevacCollaborationMember" name="CurevacCollaborationMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="gmab_IfrsNumberOfReportingUnits" name="IfrsNumberOfReportingUnits" nillable="true" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" />
  <xsd:element id="gmab_ScheduleOfSegmentDisclosuresInFinancialStatementsTableTextBlock" name="ScheduleOfSegmentDisclosuresInFinancialStatementsTableTextBlock" nillable="true" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="gmab_DisclosureOfStaffCostTableTextBlock" name="DisclosureOfStaffCostTableTextBlock" nillable="true" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="gmab_StaffCostsIncludedInResearchAndDevelopmentExpense" name="StaffCostsIncludedInResearchAndDevelopmentExpense" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <xsd:element id="gmab_StaffCostsIncludedInGeneralAndAdministrativeExpenses" name="StaffCostsIncludedInGeneralAndAdministrativeExpenses" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <xsd:element id="gmab_StaffCostsIncludedInGovernmentGrantsRelatedToResearchAndDevelopmentExpenses" name="StaffCostsIncludedInGovernmentGrantsRelatedToResearchAndDevelopmentExpenses" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <xsd:element id="gmab_ValuationAssumptionsForWarrantsGrantedTableTextBlock" name="ValuationAssumptionsForWarrantsGrantedTableTextBlock" nillable="true" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="gmab_DisclosureOfCorporateAndDeferredTaxTableTextBlock" name="DisclosureOfCorporateAndDeferredTaxTableTextBlock" nillable="true" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="gmab_OfficeAndLaboratorySpaceMember" name="OfficeAndLaboratorySpaceMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="gmab_DisclosureOfNetResultTableTextBlock" name="DisclosureOfNetResultTableTextBlock" nillable="true" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="gmab_DisclosureOfImpactOfExchangeRateOnNetResultBeforeTaxTableTextBlock" name="DisclosureOfImpactOfExchangeRateOnNetResultBeforeTaxTableTextBlock" nillable="true" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="gmab_DisclosureOfMaturityProfileOfOurMarketableSecuritiesTableTextBlock" name="DisclosureOfMaturityProfileOfOurMarketableSecuritiesTableTextBlock" nillable="true" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="gmab_ScheduleOfPortfolioOfMarketableSecurities" name="ScheduleOfPortfolioOfMarketableSecurities" nillable="true" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="gmab_MarketableSecuritiesIncludingInterestReceivables" name="MarketableSecuritiesIncludingInterestReceivables" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <xsd:element id="gmab_BankDepositsIncludingShortTermMarketableSecurities" name="BankDepositsIncludingShortTermMarketableSecurities" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <xsd:element id="gmab_PercentageOfRevenue" name="PercentageOfRevenue" nillable="true" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="gmab_PercentageOfMarketableSecuritiesInvested" name="PercentageOfMarketableSecuritiesInvested" nillable="true" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="gmab_PercentageOfPossibleIncreaseDecreaseInExchangeRate" name="PercentageOfPossibleIncreaseDecreaseInExchangeRate" nillable="true" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="gmab_IfrsSaleOfStockAxis" name="IfrsSaleOfStockAxis" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrldt:dimensionItem" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="gmab_IfrsSaleOfStockDomain" name="IfrsSaleOfStockDomain" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="gmab_TotalAdjustmentsForNonCashTransactions" name="TotalAdjustmentsForNonCashTransactions" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <xsd:element id="gmab_DisclosureOfNumberAndWeightedAverageExercisePricesOfWarrantsTableTextBlock" name="DisclosureOfNumberAndWeightedAverageExercisePricesOfWarrantsTableTextBlock" nillable="true" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="gmab_ExpensesRelatedToCapitalIncreaseDecrease" name="ExpensesRelatedToCapitalIncreaseDecrease" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <xsd:element id="gmab_AgreementsWithSeatleGeneticsMember" name="AgreementsWithSeatleGeneticsMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="gmab_AgreementsWithBointechMember" name="AgreementsWithBointechMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="gmab_NumberOfTreasurySharesOutstanding" name="NumberOfTreasurySharesOutstanding" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" />
  <xsd:element id="gmab_AgreementsWithAbbvieMember" name="AgreementsWithAbbvieMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="gmab_WarrantsMember" name="WarrantsMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="gmab_AgreementsWithSeagenMember" name="AgreementsWithSeagenMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="gmab_CorporateTaxReceivable" name="CorporateTaxReceivable" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <xsd:element id="gmab_AgreementsWithRocheMember" name="AgreementsWithRocheMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="gmab_DisclosureOfFairValueMeasurementOfAssetsLevel3ReconciliationTableTextBlock" name="DisclosureOfFairValueMeasurementOfAssetsLevel3ReconciliationTableTextBlock" nillable="true" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="gmab_GainOnOtherInvestments" name="GainOnOtherInvestments" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <xsd:element id="gmab_LossesOnOtherInvestmentsNet" name="LossesOnOtherInvestmentsNet" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <xsd:element id="gmab_PercentageOfInvestmentInCommonShares" name="PercentageOfInvestmentInCommonShares" nillable="true" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="gmab_BoltBiotherapeuticsIncMember" name="BoltBiotherapeuticsIncMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="gmab_NumberOfIndependentBoardMembers" name="NumberOfIndependentBoardMembers" nillable="true" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="gmab_NumberOfNonIndependentBoardMembers" name="NumberOfNonIndependentBoardMembers" nillable="true" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="gmab_NumberOfEmployeeElectedBoardMembers" name="NumberOfEmployeeElectedBoardMembers" nillable="true" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="gmab_StaffCostsIncludedInSellingGeneralAndAdministrativeExpenses" name="StaffCostsIncludedInSellingGeneralAndAdministrativeExpenses" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <xsd:element id="gmab_OtherInvestmentMember" name="OtherInvestmentMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="gmab_CollaborationRevenueMember" name="CollaborationRevenueMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="gmab_DisclosureOfMarketableSecuritiesByCurrencyTableTextBlock" name="DisclosureOfMarketableSecuritiesByCurrencyTableTextBlock" nillable="true" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="gmab_NumberOfApprovedProductsCommercializedByThirdParties" name="NumberOfApprovedProductsCommercializedByThirdParties" nillable="true" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="gmab_NumberOfApprovedProductsJointlyCommercializedWithCollaboration" name="NumberOfApprovedProductsJointlyCommercializedWithCollaboration" nillable="true" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="gmab_CollaborativeAgreementProfitSharingPercentage" name="CollaborativeAgreementProfitSharingPercentage" nillable="true" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element name="TaxOnItemsRecognizedDirectlyInEquity" id="gmab_TaxOnItemsRecognizedDirectlyInEquity" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="IfrsRoyaltiesByProductAxis" id="gmab_IfrsRoyaltiesByProductAxis" type="xbrli:stringItemType" substitutionGroup="xbrldt:dimensionItem" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="IfrsRoyaltiesByProductDomain" id="gmab_IfrsRoyaltiesByProductDomain" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="DarzalexMember" id="gmab_DarzalexMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="TepezzaMember" id="gmab_TepezzaMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="KesimptaMember" id="gmab_KesimptaMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="OtherRoyaltyProductMember" id="gmab_OtherRoyaltyProductMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="ScheduleOfShareRepurchasesTableTextBlock" id="gmab_ScheduleOfShareRepurchasesTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="ThirdAuthorizationMember" id="gmab_ThirdAuthorizationMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="DeirdreP.ConnellyChairPernilleErenbjergDeputyChairRolfHoffmannDr.PaoloPaolettiAndDr.AndersGerselPedersenMember" id="gmab_DeirdreP.ConnellyChairPernilleErenbjergDeputyChairRolfHoffmannDr.PaoloPaolettiAndDr.AndersGerselPedersenMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="ElizabethOfarrellMember" id="gmab_ElizabethOfarrellMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="MijkeZachariasseMartinSchultzAndTakahiroHamataniMember" id="gmab_MijkeZachariasseMartinSchultzAndTakahiroHamataniMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="ReElectionToBoardOfDirectorsTerm" id="gmab_ReElectionToBoardOfDirectorsTerm" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="StockRepurchaseAuthorization2021Member" id="gmab_StockRepurchaseAuthorization2021Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="StockRepurchaseAuthorization2019Member" id="gmab_StockRepurchaseAuthorization2019Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="StockRepurchaseAuthorization2016Member" id="gmab_StockRepurchaseAuthorization2016Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="ElectionToBoardOfDirectorsTerm" id="gmab_ElectionToBoardOfDirectorsTerm" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="NumberOfChangesToExecutiveManagementTeam" id="gmab_NumberOfChangesToExecutiveManagementTeam" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>22
<FILENAME>gmab-20220630_cal.xml
<DESCRIPTION>EX-101.CAL
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  9.6.8167.22744 -->
<!--Based on XBRL 2.1-->
<!--Created on: 8/10/2022 3:19:08 PM-->
<!--Modified on: 8/10/2022 3:19:08 PM-->
<link:linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <roleRef xlink:type="simple" xlink:href="gmab-20220630.xsd#StatementStatementsOfComprehensiveIncome" roleURI="http://www.genmab.com/role/StatementStatementsOfComprehensiveIncome" />
  <roleRef xlink:type="simple" xlink:href="gmab-20220630.xsd#StatementBalanceSheets" roleURI="http://www.genmab.com/role/StatementBalanceSheets" />
  <roleRef xlink:type="simple" xlink:href="gmab-20220630.xsd#StatementStatementsOfCashFlows" roleURI="http://www.genmab.com/role/StatementStatementsOfCashFlows" />
  <roleRef xlink:type="simple" xlink:href="gmab-20220630.xsd#DisclosureResultsForYearStaffCostsDetailsCalc2" roleURI="http://www.genmab.com/role/DisclosureResultsForYearStaffCostsDetailsCalc2" />
  <roleRef xlink:type="simple" xlink:href="gmab-20220630.xsd#DisclosureFinancialIncomeAndExpensesDetails" roleURI="http://www.genmab.com/role/DisclosureFinancialIncomeAndExpensesDetails" />
  <roleRef xlink:type="simple" xlink:href="gmab-20220630.xsd#DisclosureLeasesDetails" roleURI="http://www.genmab.com/role/DisclosureLeasesDetails" />
  <calculationLink xlink:role="http://www.genmab.com/role/StatementStatementsOfComprehensiveIncome" xlink:type="extended" xlink:title="00100 - Statement - STATEMENTS OF COMPREHENSIVE INCOME">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ComprehensiveIncome" xlink:label="ifrs-full_ComprehensiveIncome" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" xlink:label="ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation_637957415459845413" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ComprehensiveIncome" xlink:to="ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation_637957415459845413" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxChangeInFairValueOfFinancialLiabilityAttributableToChangeInCreditRiskOfLiability" xlink:label="ifrs-full_OtherComprehensiveIncomeNetOfTaxChangeInFairValueOfFinancialLiabilityAttributableToChangeInCreditRiskOfLiability_637957415459855411" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ComprehensiveIncome" xlink:to="ifrs-full_OtherComprehensiveIncomeNetOfTaxChangeInFairValueOfFinancialLiabilityAttributableToChangeInCreditRiskOfLiability_637957415459855411" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ReclassificationAdjustmentsOnCashFlowHedgesNetOfTax" xlink:label="ifrs-full_ReclassificationAdjustmentsOnCashFlowHedgesNetOfTax_637957415459855411" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ComprehensiveIncome" xlink:to="ifrs-full_ReclassificationAdjustmentsOnCashFlowHedgesNetOfTax_637957415459855411" order="3" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProfitLoss" xlink:label="ifrs-full_ProfitLoss_637957415459855411" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ComprehensiveIncome" xlink:to="ifrs-full_ProfitLoss_637957415459855411" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:label="ifrs-full_IncomeTaxExpenseContinuingOperations_637957415459855411" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ProfitLoss_637957415459855411" xlink:to="ifrs-full_IncomeTaxExpenseContinuingOperations_637957415459855411" order="1" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProfitLossBeforeTax" xlink:label="ifrs-full_ProfitLossBeforeTax_637957415459855411" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ProfitLoss_637957415459855411" xlink:to="ifrs-full_ProfitLossBeforeTax_637957415459855411" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_FinanceIncome" xlink:label="ifrs-full_FinanceIncome_637957415459855411" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ProfitLossBeforeTax_637957415459855411" xlink:to="ifrs-full_FinanceIncome_637957415459855411" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_FinanceCosts" xlink:label="ifrs-full_FinanceCosts_637957415459855411" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ProfitLossBeforeTax_637957415459855411" xlink:to="ifrs-full_FinanceCosts_637957415459855411" order="2" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProfitLossFromOperatingActivities" xlink:label="ifrs-full_ProfitLossFromOperatingActivities_637957415459855411" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ProfitLossBeforeTax_637957415459855411" xlink:to="ifrs-full_ProfitLossFromOperatingActivities_637957415459855411" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OperatingExpense" xlink:label="ifrs-full_OperatingExpense_637957415459855411" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ProfitLossFromOperatingActivities_637957415459855411" xlink:to="ifrs-full_OperatingExpense_637957415459855411" order="1" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_SellingGeneralAndAdministrativeExpense" xlink:label="ifrs-full_SellingGeneralAndAdministrativeExpense_637957415459865413" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_OperatingExpense_637957415459855411" xlink:to="ifrs-full_SellingGeneralAndAdministrativeExpense_637957415459865413" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_GeneralAndAdministrativeExpense" xlink:label="ifrs-full_GeneralAndAdministrativeExpense_637957415459865413" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_OperatingExpense_637957415459855411" xlink:to="ifrs-full_GeneralAndAdministrativeExpense_637957415459865413" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ResearchAndDevelopmentExpense" xlink:label="ifrs-full_ResearchAndDevelopmentExpense_637957415459865413" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_OperatingExpense_637957415459855411" xlink:to="ifrs-full_ResearchAndDevelopmentExpense_637957415459865413" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_Revenue" xlink:label="ifrs-full_Revenue_637957415459865413" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ProfitLossFromOperatingActivities_637957415459855411" xlink:to="ifrs-full_Revenue_637957415459865413" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IncomeTaxRelatingToExchangeDifferencesOnTranslationOfOtherComprehensiveIncome" xlink:label="ifrs-full_IncomeTaxRelatingToExchangeDifferencesOnTranslationOfOtherComprehensiveIncome_637957415459865413" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ComprehensiveIncome" xlink:to="ifrs-full_IncomeTaxRelatingToExchangeDifferencesOnTranslationOfOtherComprehensiveIncome_637957415459865413" order="5" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OtherComprehensiveIncomeBeforeTaxExchangeDifferencesOnTranslation" xlink:label="ifrs-full_OtherComprehensiveIncomeBeforeTaxExchangeDifferencesOnTranslation_637957415459865413" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ComprehensiveIncome" xlink:to="ifrs-full_OtherComprehensiveIncomeBeforeTaxExchangeDifferencesOnTranslation_637957415459865413" order="6" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.genmab.com/role/StatementBalanceSheets" xlink:type="extended" xlink:title="00200 - Statement - BALANCE SHEETS">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_Assets" xlink:label="ifrs-full_Assets" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CurrentAssets" xlink:label="ifrs-full_CurrentAssets_637957415459865413" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_Assets" xlink:to="ifrs-full_CurrentAssets_637957415459865413" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CashAndCashEquivalents" xlink:label="ifrs-full_CashAndCashEquivalents_637957415459875413" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CurrentAssets_637957415459865413" xlink:to="ifrs-full_CashAndCashEquivalents_637957415459875413" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_IfrsMarketableSecuritiesCurrent" xlink:label="gmab_IfrsMarketableSecuritiesCurrent_637957415459875413" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CurrentAssets_637957415459865413" xlink:to="gmab_IfrsMarketableSecuritiesCurrent_637957415459875413" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TradeAndOtherCurrentReceivables" xlink:label="ifrs-full_TradeAndOtherCurrentReceivables_637957415459875413" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CurrentAssets_637957415459865413" xlink:to="ifrs-full_TradeAndOtherCurrentReceivables_637957415459875413" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_CorporateTaxReceivable" xlink:label="gmab_CorporateTaxReceivable_637957415459875413" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CurrentAssets_637957415459865413" xlink:to="gmab_CorporateTaxReceivable_637957415459875413" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NoncurrentAssets" xlink:label="ifrs-full_NoncurrentAssets_637957415459875413" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_Assets" xlink:to="ifrs-full_NoncurrentAssets_637957415459875413" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_InvestmentAccountedForUsingEquityMethod" xlink:label="ifrs-full_InvestmentAccountedForUsingEquityMethod_637957415459875413" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_NoncurrentAssets_637957415459875413" xlink:to="ifrs-full_InvestmentAccountedForUsingEquityMethod_637957415459875413" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwill" xlink:label="ifrs-full_IntangibleAssetsOtherThanGoodwill_637957415459875413" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_NoncurrentAssets_637957415459875413" xlink:to="ifrs-full_IntangibleAssetsOtherThanGoodwill_637957415459875413" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_PropertyPlantAndEquipment" xlink:label="ifrs-full_PropertyPlantAndEquipment_637957415459875413" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_NoncurrentAssets_637957415459875413" xlink:to="ifrs-full_PropertyPlantAndEquipment_637957415459875413" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RightofuseAssets" xlink:label="ifrs-full_RightofuseAssets_637957415459975419" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_NoncurrentAssets_637957415459875413" xlink:to="ifrs-full_RightofuseAssets_637957415459975419" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NoncurrentReceivables" xlink:label="ifrs-full_NoncurrentReceivables_637957415459975419" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_NoncurrentAssets_637957415459875413" xlink:to="ifrs-full_NoncurrentReceivables_637957415459975419" order="5" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NetDeferredTaxAssets" xlink:label="ifrs-full_NetDeferredTaxAssets_637957415459975419" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_NoncurrentAssets_637957415459875413" xlink:to="ifrs-full_NetDeferredTaxAssets_637957415459975419" order="6" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_EquityAndLiabilities" xlink:label="ifrs-full_EquityAndLiabilities" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_Equity" xlink:label="ifrs-full_Equity_637957415459975419" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_EquityAndLiabilities" xlink:to="ifrs-full_Equity_637957415459975419" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IssuedCapital" xlink:label="ifrs-full_IssuedCapital_637957415459985418" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_Equity_637957415459975419" xlink:to="ifrs-full_IssuedCapital_637957415459985418" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OtherReserves" xlink:label="ifrs-full_OtherReserves_637957415459985418" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_Equity_637957415459975419" xlink:to="ifrs-full_OtherReserves_637957415459985418" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RetainedEarnings" xlink:label="ifrs-full_RetainedEarnings_637957415459985418" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_Equity_637957415459975419" xlink:to="ifrs-full_RetainedEarnings_637957415459985418" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_SharePremium" xlink:label="ifrs-full_SharePremium_637957415459985418" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_Equity_637957415459975419" xlink:to="ifrs-full_SharePremium_637957415459985418" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_Liabilities" xlink:label="ifrs-full_Liabilities_637957415459985418" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_EquityAndLiabilities" xlink:to="ifrs-full_Liabilities_637957415459985418" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CurrentLiabilities" xlink:label="ifrs-full_CurrentLiabilities_637957415459985418" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_Liabilities_637957415459985418" xlink:to="ifrs-full_CurrentLiabilities_637957415459985418" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CurrentProvisions" xlink:label="ifrs-full_CurrentProvisions_637957415459985418" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CurrentLiabilities_637957415459985418" xlink:to="ifrs-full_CurrentProvisions_637957415459985418" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CurrentLeaseLiabilities" xlink:label="ifrs-full_CurrentLeaseLiabilities_637957415459985418" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CurrentLiabilities_637957415459985418" xlink:to="ifrs-full_CurrentLeaseLiabilities_637957415459985418" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RentDeferredIncomeClassifiedAsCurrent" xlink:label="ifrs-full_RentDeferredIncomeClassifiedAsCurrent_637957415459995417" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CurrentLiabilities_637957415459985418" xlink:to="ifrs-full_RentDeferredIncomeClassifiedAsCurrent_637957415459995417" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OtherCurrentPayables" xlink:label="ifrs-full_OtherCurrentPayables_637957415459995417" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CurrentLiabilities_637957415459985418" xlink:to="ifrs-full_OtherCurrentPayables_637957415459995417" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CurrentTaxLiabilitiesCurrent" xlink:label="ifrs-full_CurrentTaxLiabilitiesCurrent_637957415459995417" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CurrentLiabilities_637957415459985418" xlink:to="ifrs-full_CurrentTaxLiabilitiesCurrent_637957415459995417" order="5" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OtherCurrentLiabilities" xlink:label="ifrs-full_OtherCurrentLiabilities_637957415459995417" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CurrentLiabilities_637957415459985418" xlink:to="ifrs-full_OtherCurrentLiabilities_637957415459995417" order="6" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NoncurrentLiabilities" xlink:label="ifrs-full_NoncurrentLiabilities_637957415459995417" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_Liabilities_637957415459985418" xlink:to="ifrs-full_NoncurrentLiabilities_637957415459995417" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NoncurrentLeaseLiabilities" xlink:label="ifrs-full_NoncurrentLeaseLiabilities_637957415459995417" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_NoncurrentLiabilities_637957415459995417" xlink:to="ifrs-full_NoncurrentLeaseLiabilities_637957415459995417" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RentDeferredIncomeClassifiedAsNoncurrent" xlink:label="ifrs-full_RentDeferredIncomeClassifiedAsNoncurrent_637957415459995417" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_NoncurrentLiabilities_637957415459995417" xlink:to="ifrs-full_RentDeferredIncomeClassifiedAsNoncurrent_637957415459995417" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NoncurrentProvisions" xlink:label="ifrs-full_NoncurrentProvisions_637957415460005420" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_NoncurrentLiabilities_637957415459995417" xlink:to="ifrs-full_NoncurrentProvisions_637957415460005420" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OtherNoncurrentPayables" xlink:label="ifrs-full_OtherNoncurrentPayables_637957415460005420" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_NoncurrentLiabilities_637957415459995417" xlink:to="ifrs-full_OtherNoncurrentPayables_637957415460005420" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OtherNoncurrentLiabilities" xlink:label="ifrs-full_OtherNoncurrentLiabilities_637957415460005420" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_NoncurrentLiabilities_637957415459995417" xlink:to="ifrs-full_OtherNoncurrentLiabilities_637957415460005420" order="5" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.genmab.com/role/StatementStatementsOfCashFlows" xlink:type="extended" xlink:title="00300 - Statement - STATEMENTS OF CASH FLOWS">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" xlink:label="ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivities_637957415460005420" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" xlink:to="ifrs-full_CashFlowsFromUsedInOperatingActivities_637957415460005420" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_InterestPaidClassifiedAsOperatingActivities" xlink:label="ifrs-full_InterestPaidClassifiedAsOperatingActivities_637957415460005420" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivities_637957415460005420" xlink:to="ifrs-full_InterestPaidClassifiedAsOperatingActivities_637957415460005420" order="1" use="optional" weight="-1" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_InterestReceivedClassifiedAsOperatingActivities" xlink:label="ifrs-full_InterestReceivedClassifiedAsOperatingActivities_637957415460005420" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivities_637957415460005420" xlink:to="ifrs-full_InterestReceivedClassifiedAsOperatingActivities_637957415460005420" order="2" use="optional" weight="1" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AdjustmentsForIncomeTaxExpense" xlink:label="ifrs-full_AdjustmentsForIncomeTaxExpense_637957415460015417" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivities_637957415460005420" xlink:to="ifrs-full_AdjustmentsForIncomeTaxExpense_637957415460015417" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_AdjustmentsForInterestOnLeasePayments" xlink:label="gmab_AdjustmentsForInterestOnLeasePayments_637957415460015417" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivities_637957415460005420" xlink:to="gmab_AdjustmentsForInterestOnLeasePayments_637957415460015417" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_CashFlowFromUsedInOperatingActivitiesBeforeFinancialItems" xlink:label="gmab_CashFlowFromUsedInOperatingActivitiesBeforeFinancialItems_637957415460015417" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivities_637957415460005420" xlink:to="gmab_CashFlowFromUsedInOperatingActivitiesBeforeFinancialItems_637957415460015417" order="5" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProfitLossBeforeTax" xlink:label="ifrs-full_ProfitLossBeforeTax_637957415460015417" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="gmab_CashFlowFromUsedInOperatingActivitiesBeforeFinancialItems_637957415460015417" xlink:to="ifrs-full_ProfitLossBeforeTax_637957415460015417" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_TotalAdjustmentsForNonCashTransactions" xlink:label="gmab_TotalAdjustmentsForNonCashTransactions_637957415460015417" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="gmab_CashFlowFromUsedInOperatingActivitiesBeforeFinancialItems_637957415460015417" xlink:to="gmab_TotalAdjustmentsForNonCashTransactions_637957415460015417" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_ReversalOfFinancialItemsNet" xlink:label="gmab_ReversalOfFinancialItemsNet_637957415460015417" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="gmab_CashFlowFromUsedInOperatingActivitiesBeforeFinancialItems_637957415460015417" xlink:to="gmab_ReversalOfFinancialItemsNet_637957415460015417" order="3" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IncreaseDecreaseInWorkingCapital" xlink:label="ifrs-full_IncreaseDecreaseInWorkingCapital_637957415460015417" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="gmab_CashFlowFromUsedInOperatingActivitiesBeforeFinancialItems_637957415460015417" xlink:to="ifrs-full_IncreaseDecreaseInWorkingCapital_637957415460015417" order="4" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:label="ifrs-full_CashFlowsFromUsedInFinancingActivities_637957415460015417" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" xlink:to="ifrs-full_CashFlowsFromUsedInFinancingActivities_637957415460015417" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_PaymentOfWithholdingTaxesOnBehalfOfEmployeesOnNetSettledRSUs" xlink:label="gmab_PaymentOfWithholdingTaxesOnBehalfOfEmployeesOnNetSettledRSUs_637957415460015417" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivities_637957415460015417" xlink:to="gmab_PaymentOfWithholdingTaxesOnBehalfOfEmployeesOnNetSettledRSUs_637957415460015417" order="1" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" xlink:label="ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities_637957415460015417" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivities_637957415460015417" xlink:to="ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities_637957415460015417" order="2" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_PaymentsToAcquireTreasuryShares" xlink:label="gmab_PaymentsToAcquireTreasuryShares_637957415460025418" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivities_637957415460015417" xlink:to="gmab_PaymentsToAcquireTreasuryShares_637957415460025418" order="3" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProceedsFromExerciseOfWarrants" xlink:label="ifrs-full_ProceedsFromExerciseOfWarrants_637957415460025418" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivities_637957415460015417" xlink:to="ifrs-full_ProceedsFromExerciseOfWarrants_637957415460025418" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProceedsFromIssuingShares" xlink:label="ifrs-full_ProceedsFromIssuingShares_637957415460025418" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivities_637957415460015417" xlink:to="ifrs-full_ProceedsFromIssuingShares_637957415460025418" order="5" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_PaymentsForShareIssueCosts" xlink:label="ifrs-full_PaymentsForShareIssueCosts_637957415460025418" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivities_637957415460015417" xlink:to="ifrs-full_PaymentsForShareIssueCosts_637957415460025418" order="6" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:label="ifrs-full_CashFlowsFromUsedInInvestingActivities_637957415460025418" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" xlink:to="ifrs-full_CashFlowsFromUsedInInvestingActivities_637957415460025418" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" xlink:label="ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities_637957415460025418" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivities_637957415460025418" xlink:to="ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities_637957415460025418" order="1" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProceedsFromSalesOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod" xlink:label="ifrs-full_ProceedsFromSalesOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod_637957415460025418" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivities_637957415460025418" xlink:to="ifrs-full_ProceedsFromSalesOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod_637957415460025418" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:label="ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_637957415460025418" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivities_637957415460025418" xlink:to="ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_637957415460025418" order="3" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_PurchaseOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod" xlink:label="ifrs-full_PurchaseOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod_637957415460035417" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivities_637957415460025418" xlink:to="ifrs-full_PurchaseOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod_637957415460035417" order="4" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_PurchaseOfInterestsInInvestmentsAccountedForUsingEquityMethod" xlink:label="ifrs-full_PurchaseOfInterestsInInvestmentsAccountedForUsingEquityMethod_637957415460035417" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivities_637957415460025418" xlink:to="ifrs-full_PurchaseOfInterestsInInvestmentsAccountedForUsingEquityMethod_637957415460035417" order="5" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProceedsFromSalesOfInvestmentsAccountedForUsingEquityMethod" xlink:label="ifrs-full_ProceedsFromSalesOfInvestmentsAccountedForUsingEquityMethod_637957415460035417" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivities_637957415460025418" xlink:to="ifrs-full_ProceedsFromSalesOfInvestmentsAccountedForUsingEquityMethod_637957415460035417" order="6" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities" xlink:label="ifrs-full_CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities_637957415460035417" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivities_637957415460025418" xlink:to="ifrs-full_CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities_637957415460035417" order="7" use="optional" weight="-1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.genmab.com/role/DisclosureResultsForYearStaffCostsDetailsCalc2" xlink:type="extended" xlink:title="40203 - Disclosure - RESULTS FOR THE YEAR - Staff Costs (Details) Calc 2">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_EmployeeBenefitsExpense" xlink:label="ifrs-full_EmployeeBenefitsExpense" />
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_StaffCostsIncludedInResearchAndDevelopmentExpense" xlink:label="gmab_StaffCostsIncludedInResearchAndDevelopmentExpense_637957415460035417" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_EmployeeBenefitsExpense" xlink:to="gmab_StaffCostsIncludedInResearchAndDevelopmentExpense_637957415460035417" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_StaffCostsIncludedInGeneralAndAdministrativeExpenses" xlink:label="gmab_StaffCostsIncludedInGeneralAndAdministrativeExpenses_637957415460035417" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_EmployeeBenefitsExpense" xlink:to="gmab_StaffCostsIncludedInGeneralAndAdministrativeExpenses_637957415460035417" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_StaffCostsIncludedInSellingGeneralAndAdministrativeExpenses" xlink:label="gmab_StaffCostsIncludedInSellingGeneralAndAdministrativeExpenses_637957415460045418" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_EmployeeBenefitsExpense" xlink:to="gmab_StaffCostsIncludedInSellingGeneralAndAdministrativeExpenses_637957415460045418" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_StaffCostsIncludedInGovernmentGrantsRelatedToResearchAndDevelopmentExpenses" xlink:label="gmab_StaffCostsIncludedInGovernmentGrantsRelatedToResearchAndDevelopmentExpenses_637957415460045418" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_EmployeeBenefitsExpense" xlink:to="gmab_StaffCostsIncludedInGovernmentGrantsRelatedToResearchAndDevelopmentExpenses_637957415460045418" order="4" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.genmab.com/role/DisclosureFinancialIncomeAndExpensesDetails" xlink:type="extended" xlink:title="40401 - Disclosure - Financial Income and Expenses (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_FinanceIncomeCost" xlink:label="ifrs-full_FinanceIncomeCost" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_FinanceCosts" xlink:label="ifrs-full_FinanceCosts_637957415460045418" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_FinanceIncomeCost" xlink:to="ifrs-full_FinanceCosts_637957415460045418" order="1" use="optional" weight="-1" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NetForeignExchangeLoss" xlink:label="ifrs-full_NetForeignExchangeLoss_637957415460045418" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_FinanceCosts_637957415460045418" xlink:to="ifrs-full_NetForeignExchangeLoss_637957415460045418" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_LossesOnMarketableSecurities" xlink:label="gmab_LossesOnMarketableSecurities_637957415460045418" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_FinanceCosts_637957415460045418" xlink:to="gmab_LossesOnMarketableSecurities_637957415460045418" order="2" use="optional" weight="1" priority="3" />
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_InterestAndOtherFinancialExpenses" xlink:label="gmab_InterestAndOtherFinancialExpenses_637957415460045418" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_FinanceCosts_637957415460045418" xlink:to="gmab_InterestAndOtherFinancialExpenses_637957415460045418" order="3" use="optional" weight="1" priority="3" />
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_LossesOnOtherInvestmentsNet" xlink:label="gmab_LossesOnOtherInvestmentsNet_637957415460045418" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_FinanceCosts_637957415460045418" xlink:to="gmab_LossesOnOtherInvestmentsNet_637957415460045418" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_FinanceIncome" xlink:label="ifrs-full_FinanceIncome_637957415460045418" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_FinanceIncomeCost" xlink:to="ifrs-full_FinanceIncome_637957415460045418" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NetForeignExchangeGain" xlink:label="ifrs-full_NetForeignExchangeGain_637957415460045418" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_FinanceIncome_637957415460045418" xlink:to="ifrs-full_NetForeignExchangeGain_637957415460045418" order="1" use="optional" weight="1" priority="3" />
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_GainsOnHedgingInstruments" xlink:label="gmab_GainsOnHedgingInstruments_637957415460055419" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_FinanceIncome_637957415460045418" xlink:to="gmab_GainsOnHedgingInstruments_637957415460055419" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_GainOnOtherInvestments" xlink:label="gmab_GainOnOtherInvestments_637957415460055419" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_FinanceIncome_637957415460045418" xlink:to="gmab_GainOnOtherInvestments_637957415460055419" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_InterestAndOtherFinancialIncome" xlink:label="gmab_InterestAndOtherFinancialIncome_637957415460055419" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_FinanceIncome_637957415460045418" xlink:to="gmab_InterestAndOtherFinancialIncome_637957415460055419" order="4" use="optional" weight="1" priority="3" />
  </calculationLink>
  <calculationLink xlink:role="http://www.genmab.com/role/DisclosureLeasesDetails" xlink:type="extended" xlink:title="40701 - Disclosure - Leases (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_LeaseLiabilities" xlink:label="ifrs-full_LeaseLiabilities_637637461730083168" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NoncurrentLeaseLiabilities" xlink:label="ifrs-full_NoncurrentLeaseLiabilities_637957415460055419" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_LeaseLiabilities_637637461730083168" xlink:to="ifrs-full_NoncurrentLeaseLiabilities_637957415460055419" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CurrentLeaseLiabilities" xlink:label="ifrs-full_CurrentLeaseLiabilities_637957415460055419" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_LeaseLiabilities_637637461730083168" xlink:to="ifrs-full_CurrentLeaseLiabilities_637957415460055419" order="2" use="optional" weight="1" priority="2" />
  </calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>23
<FILENAME>gmab-20220630_def.xml
<DESCRIPTION>EX-101.DEF
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  9.6.8167.22744 -->
<!--Based on XBRL 2.1-->
<!--Created on: 8/10/2022 3:19:08 PM-->
<!--Modified on: 8/10/2022 3:19:08 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="gmab-20220630.xsd#DocumentDocumentAndEntityInformation" roleURI="http://www.genmab.com/role/DocumentDocumentAndEntityInformation" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="gmab-20220630.xsd#StatementStatementsOfChangesInEquity" roleURI="http://www.genmab.com/role/StatementStatementsOfChangesInEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="gmab-20220630.xsd#DisclosureRevenueDetails" roleURI="http://www.genmab.com/role/DisclosureRevenueDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="gmab-20220630.xsd#DisclosureFinancialInstrumentsFinancialRiskDetails" roleURI="http://www.genmab.com/role/DisclosureFinancialInstrumentsFinancialRiskDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="gmab-20220630.xsd#DisclosureFinancialInstrumentsFairValueMeasurementDetails" roleURI="http://www.genmab.com/role/DisclosureFinancialInstrumentsFairValueMeasurementDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="gmab-20220630.xsd#DisclosureFinancialInstrumentsOtherInvestmentsDetails" roleURI="http://www.genmab.com/role/DisclosureFinancialInstrumentsOtherInvestmentsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="gmab-20220630.xsd#DisclosureShareBasedInstrumentsRestrictedStockUnitProgramDetails" roleURI="http://www.genmab.com/role/DisclosureShareBasedInstrumentsRestrictedStockUnitProgramDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="gmab-20220630.xsd#DisclosureShareBasedInstrumentsWarrantProgramDetails" roleURI="http://www.genmab.com/role/DisclosureShareBasedInstrumentsWarrantProgramDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="gmab-20220630.xsd#DisclosureShareBasedInstrumentsShareRepurchasesDetails" roleURI="http://www.genmab.com/role/DisclosureShareBasedInstrumentsShareRepurchasesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="gmab-20220630.xsd#DisclosureRelatedPartiesDetails" roleURI="http://www.genmab.com/role/DisclosureRelatedPartiesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="gmab-20220630.xsd#DisclosureLeasesDetails" roleURI="http://www.genmab.com/role/DisclosureLeasesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <link:arcroleRef arcroleURI="http://www.esma.europa.eu/xbrl/esef/arcrole/wider-narrower" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd#wider-narrower" />
  <link:roleRef roleURI="http://www.genmab.com/role/DisclosureStandardAndCustomAxisDomainDefaults" xlink:href="gmab-20220630.xsd#DisclosureStandardAndCustomAxisDomainDefaults" xlink:type="simple" />
  <roleRef xmlns="http://www.xbrl.org/2003/linkbase" xlink:type="simple" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd#eedm" roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" />
  <definitionLink xmlns="http://www.xbrl.org/2003/linkbase" xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="extended" xlink:title="Extensible Enumeration Domain Members" />
  <link:definitionLink xlink:role="http://www.genmab.com/role/DisclosureStandardAndCustomAxisDomainDefaults" xlink:type="extended" xlink:title="99900 - Disclosure - Standard And Custom Axis Domain Defaults">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ClassesOfShareCapitalAxis" xlink:label="ifrs-full_ClassesOfShareCapitalAxis_1" xlink:title="ifrs-full_ClassesOfShareCapitalAxis_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ClassesOfShareCapitalMember" xlink:label="ifrs-full_ClassesOfShareCapitalMember_1" xlink:title="ifrs-full_ClassesOfShareCapitalMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="ifrs-full_ClassesOfShareCapitalAxis_1" xlink:to="ifrs-full_ClassesOfShareCapitalMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:ifrs-full_ClassesOfShareCapitalAxis_1 To ifrs-full_ClassesOfShareCapitalMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ComponentsOfEquityAxis" xlink:label="ifrs-full_ComponentsOfEquityAxis_1" xlink:title="ifrs-full_ComponentsOfEquityAxis_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_EquityMember" xlink:label="ifrs-full_EquityMember_1" xlink:title="ifrs-full_EquityMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="ifrs-full_ComponentsOfEquityAxis_1" xlink:to="ifrs-full_EquityMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:ifrs-full_ComponentsOfEquityAxis_1 To ifrs-full_EquityMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:label="ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis_1" xlink:title="ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RestatedMember" xlink:label="ifrs-full_RestatedMember_1" xlink:title="ifrs-full_RestatedMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis_1" xlink:to="ifrs-full_RestatedMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis_1 To ifrs-full_RestatedMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:label="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_1" xlink:title="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_PropertyPlantAndEquipmentMember" xlink:label="ifrs-full_PropertyPlantAndEquipmentMember_1" xlink:title="ifrs-full_PropertyPlantAndEquipmentMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_1" xlink:to="ifrs-full_PropertyPlantAndEquipmentMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_1 To ifrs-full_PropertyPlantAndEquipmentMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_TypesOfRevenuesAxis" xlink:label="gmab_TypesOfRevenuesAxis_1" xlink:title="gmab_TypesOfRevenuesAxis_1" />
    <link:loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_TypesOfRevenuesMember" xlink:label="gmab_TypesOfRevenuesMember_1" xlink:title="gmab_TypesOfRevenuesMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="gmab_TypesOfRevenuesAxis_1" xlink:to="gmab_TypesOfRevenuesMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:gmab_TypesOfRevenuesAxis_1 To gmab_TypesOfRevenuesMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis" xlink:label="gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_1" xlink:title="gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeDomain" xlink:label="gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeDomain_1" xlink:title="gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_1" xlink:to="gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_1 To gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RangeAxis" xlink:label="ifrs-full_RangeAxis_1" xlink:title="ifrs-full_RangeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RangesMember" xlink:label="ifrs-full_RangesMember_1" xlink:title="ifrs-full_RangesMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="ifrs-full_RangeAxis_1" xlink:to="ifrs-full_RangesMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:ifrs-full_RangeAxis_1 To ifrs-full_RangesMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_PerformanceObligationsAxis" xlink:label="ifrs-full_PerformanceObligationsAxis_1" xlink:title="ifrs-full_PerformanceObligationsAxis_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_PerformanceObligationsMember" xlink:label="ifrs-full_PerformanceObligationsMember_1" xlink:title="ifrs-full_PerformanceObligationsMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="ifrs-full_PerformanceObligationsAxis_1" xlink:to="ifrs-full_PerformanceObligationsMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:ifrs-full_PerformanceObligationsAxis_1 To ifrs-full_PerformanceObligationsMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_GeographicalAreasAxis" xlink:label="ifrs-full_GeographicalAreasAxis_1" xlink:title="ifrs-full_GeographicalAreasAxis_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_GeographicalAreasMember" xlink:label="ifrs-full_GeographicalAreasMember_1" xlink:title="ifrs-full_GeographicalAreasMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="ifrs-full_GeographicalAreasAxis_1" xlink:to="ifrs-full_GeographicalAreasMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:ifrs-full_GeographicalAreasAxis_1 To ifrs-full_GeographicalAreasMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:label="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_1" xlink:title="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_SharebasedPaymentArrangementsMember" xlink:label="ifrs-full_SharebasedPaymentArrangementsMember_1" xlink:title="ifrs-full_SharebasedPaymentArrangementsMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_1" xlink:to="ifrs-full_SharebasedPaymentArrangementsMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_1 To ifrs-full_SharebasedPaymentArrangementsMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" xlink:label="ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_1" xlink:title="ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember" xlink:label="ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_1" xlink:title="ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_1" xlink:to="ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_1 To ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis" xlink:label="ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_1" xlink:title="ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwillMember" xlink:label="ifrs-full_IntangibleAssetsOtherThanGoodwillMember_1" xlink:title="ifrs-full_IntangibleAssetsOtherThanGoodwillMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_1" xlink:to="ifrs-full_IntangibleAssetsOtherThanGoodwillMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_1 To ifrs-full_IntangibleAssetsOtherThanGoodwillMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:label="ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_1" xlink:title="ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CarryingAmountMember" xlink:label="ifrs-full_CarryingAmountMember_1" xlink:title="ifrs-full_CarryingAmountMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_1" xlink:to="ifrs-full_CarryingAmountMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_1 To ifrs-full_CarryingAmountMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ClassesOfAssetsAxis" xlink:label="ifrs-full_ClassesOfAssetsAxis_1" xlink:title="ifrs-full_ClassesOfAssetsAxis_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ClassesOfAssetsMember" xlink:label="ifrs-full_ClassesOfAssetsMember_1" xlink:title="ifrs-full_ClassesOfAssetsMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="ifrs-full_ClassesOfAssetsAxis_1" xlink:to="ifrs-full_ClassesOfAssetsMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:ifrs-full_ClassesOfAssetsAxis_1 To ifrs-full_ClassesOfAssetsMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_MaturityAxis" xlink:label="ifrs-full_MaturityAxis_1" xlink:title="ifrs-full_MaturityAxis_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AggregatedTimeBandsMember" xlink:label="ifrs-full_AggregatedTimeBandsMember_1" xlink:title="ifrs-full_AggregatedTimeBandsMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="ifrs-full_MaturityAxis_1" xlink:to="ifrs-full_AggregatedTimeBandsMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:ifrs-full_MaturityAxis_1 To ifrs-full_AggregatedTimeBandsMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis_1" xlink:title="srt_StatementGeographicalAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain_1" xlink:title="srt_SegmentGeographicalDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_StatementGeographicalAxis_1" xlink:to="srt_SegmentGeographicalDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_StatementGeographicalAxis_1 To srt_SegmentGeographicalDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TypesOfRisksAxis" xlink:label="ifrs-full_TypesOfRisksAxis_1" xlink:title="ifrs-full_TypesOfRisksAxis_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TypesOfRisksMember" xlink:label="ifrs-full_TypesOfRisksMember_1" xlink:title="ifrs-full_TypesOfRisksMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="ifrs-full_TypesOfRisksAxis_1" xlink:to="ifrs-full_TypesOfRisksMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:ifrs-full_TypesOfRisksAxis_1 To ifrs-full_TypesOfRisksMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ExternalCreditGradesAxis" xlink:label="ifrs-full_ExternalCreditGradesAxis_1" xlink:title="ifrs-full_ExternalCreditGradesAxis_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_EntitysTotalForExternalCreditGradesMember" xlink:label="ifrs-full_EntitysTotalForExternalCreditGradesMember_1" xlink:title="ifrs-full_EntitysTotalForExternalCreditGradesMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="ifrs-full_ExternalCreditGradesAxis_1" xlink:to="ifrs-full_EntitysTotalForExternalCreditGradesMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:ifrs-full_ExternalCreditGradesAxis_1 To ifrs-full_EntitysTotalForExternalCreditGradesMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CurrencyAxis" xlink:label="srt_CurrencyAxis_1" xlink:title="srt_CurrencyAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2021/currency-2021.xsd#currency_AllCurrenciesDomain" xlink:label="currency_AllCurrenciesDomain_1" xlink:title="currency_AllCurrenciesDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_CurrencyAxis_1" xlink:to="currency_AllCurrenciesDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_CurrencyAxis_1 To currency_AllCurrenciesDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CategoriesOfFinancialAssetsAxis" xlink:label="ifrs-full_CategoriesOfFinancialAssetsAxis_1" xlink:title="ifrs-full_CategoriesOfFinancialAssetsAxis_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_FinancialAssetsCategoryMember" xlink:label="ifrs-full_FinancialAssetsCategoryMember_1" xlink:title="ifrs-full_FinancialAssetsCategoryMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="ifrs-full_CategoriesOfFinancialAssetsAxis_1" xlink:to="ifrs-full_FinancialAssetsCategoryMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:ifrs-full_CategoriesOfFinancialAssetsAxis_1 To ifrs-full_FinancialAssetsCategoryMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ClassesOfFinancialAssetsAxis" xlink:label="ifrs-full_ClassesOfFinancialAssetsAxis_1" xlink:title="ifrs-full_ClassesOfFinancialAssetsAxis_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_FinancialAssetsMember" xlink:label="ifrs-full_FinancialAssetsMember_1" xlink:title="ifrs-full_FinancialAssetsMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="ifrs-full_ClassesOfFinancialAssetsAxis_1" xlink:to="ifrs-full_FinancialAssetsMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:ifrs-full_ClassesOfFinancialAssetsAxis_1 To ifrs-full_FinancialAssetsMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CategoriesOfFinancialLiabilitiesAxis" xlink:label="ifrs-full_CategoriesOfFinancialLiabilitiesAxis_1" xlink:title="ifrs-full_CategoriesOfFinancialLiabilitiesAxis_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_FinancialLiabilitiesCategoryMember" xlink:label="ifrs-full_FinancialLiabilitiesCategoryMember_1" xlink:title="ifrs-full_FinancialLiabilitiesCategoryMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="ifrs-full_CategoriesOfFinancialLiabilitiesAxis_1" xlink:to="ifrs-full_FinancialLiabilitiesCategoryMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:ifrs-full_CategoriesOfFinancialLiabilitiesAxis_1 To ifrs-full_FinancialLiabilitiesCategoryMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ClassesOfFinancialLiabilitiesAxis" xlink:label="ifrs-full_ClassesOfFinancialLiabilitiesAxis_1" xlink:title="ifrs-full_ClassesOfFinancialLiabilitiesAxis_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_FinancialLiabilitiesMember" xlink:label="ifrs-full_FinancialLiabilitiesMember_1" xlink:title="ifrs-full_FinancialLiabilitiesMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="ifrs-full_ClassesOfFinancialLiabilitiesAxis_1" xlink:to="ifrs-full_FinancialLiabilitiesMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:ifrs-full_ClassesOfFinancialLiabilitiesAxis_1 To ifrs-full_FinancialLiabilitiesMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_MeasurementAxis" xlink:label="ifrs-full_MeasurementAxis_1" xlink:title="ifrs-full_MeasurementAxis_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AggregatedMeasurementMember" xlink:label="ifrs-full_AggregatedMeasurementMember_1" xlink:title="ifrs-full_AggregatedMeasurementMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="ifrs-full_MeasurementAxis_1" xlink:to="ifrs-full_AggregatedMeasurementMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:ifrs-full_MeasurementAxis_1 To ifrs-full_AggregatedMeasurementMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_LevelsOfFairValueHierarchyAxis" xlink:label="ifrs-full_LevelsOfFairValueHierarchyAxis_1" xlink:title="ifrs-full_LevelsOfFairValueHierarchyAxis_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AllLevelsOfFairValueHierarchyMember" xlink:label="ifrs-full_AllLevelsOfFairValueHierarchyMember_1" xlink:title="ifrs-full_AllLevelsOfFairValueHierarchyMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="ifrs-full_LevelsOfFairValueHierarchyAxis_1" xlink:to="ifrs-full_AllLevelsOfFairValueHierarchyMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:ifrs-full_LevelsOfFairValueHierarchyAxis_1 To ifrs-full_AllLevelsOfFairValueHierarchyMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis_1" xlink:title="srt_StatementScenarioAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain_1" xlink:title="srt_ScenarioUnspecifiedDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_StatementScenarioAxis_1" xlink:to="srt_ScenarioUnspecifiedDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_StatementScenarioAxis_1 To srt_ScenarioUnspecifiedDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_1" xlink:title="srt_RangeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember_1" xlink:title="srt_RangeMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_RangeAxis_1" xlink:to="srt_RangeMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_RangeAxis_1 To srt_RangeMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis_1" xlink:title="ifrs-full_CategoriesOfRelatedPartiesAxis_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="ifrs-full_EntitysTotalForRelatedPartiesMember_1" xlink:title="ifrs-full_EntitysTotalForRelatedPartiesMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis_1" xlink:to="ifrs-full_EntitysTotalForRelatedPartiesMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:ifrs-full_CategoriesOfRelatedPartiesAxis_1 To ifrs-full_EntitysTotalForRelatedPartiesMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_IfrsSaleOfStockAxis" xlink:label="gmab_IfrsSaleOfStockAxis_1" xlink:title="gmab_IfrsSaleOfStockAxis_1" />
    <link:loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_IfrsSaleOfStockDomain" xlink:label="gmab_IfrsSaleOfStockDomain_1" xlink:title="gmab_IfrsSaleOfStockDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="gmab_IfrsSaleOfStockAxis_1" xlink:to="gmab_IfrsSaleOfStockDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:gmab_IfrsSaleOfStockAxis_1 To gmab_IfrsSaleOfStockDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis_1" xlink:title="dei_LegalEntityAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain_1" xlink:title="dei_EntityDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="dei_LegalEntityAxis_1" xlink:to="dei_EntityDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:dei_LegalEntityAxis_1 To dei_EntityDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_SignificantInvestmentsInSubsidiariesAxis" xlink:label="ifrs-full_SignificantInvestmentsInSubsidiariesAxis_1" xlink:title="ifrs-full_SignificantInvestmentsInSubsidiariesAxis_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_EntitysTotalForSubsidiariesMember" xlink:label="ifrs-full_EntitysTotalForSubsidiariesMember_1" xlink:title="ifrs-full_EntitysTotalForSubsidiariesMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="ifrs-full_SignificantInvestmentsInSubsidiariesAxis_1" xlink:to="ifrs-full_EntitysTotalForSubsidiariesMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:ifrs-full_SignificantInvestmentsInSubsidiariesAxis_1 To ifrs-full_EntitysTotalForSubsidiariesMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:label="ifrs-full_ClassesOfFinancialInstrumentsAxis_1" xlink:title="ifrs-full_ClassesOfFinancialInstrumentsAxis_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ClassesOfFinancialInstrumentsMember" xlink:label="ifrs-full_ClassesOfFinancialInstrumentsMember_1" xlink:title="ifrs-full_ClassesOfFinancialInstrumentsMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsAxis_1" xlink:to="ifrs-full_ClassesOfFinancialInstrumentsMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:ifrs-full_ClassesOfFinancialInstrumentsAxis_1 To ifrs-full_ClassesOfFinancialInstrumentsMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CounterpartiesAxis" xlink:label="ifrs-full_CounterpartiesAxis_1" xlink:title="ifrs-full_CounterpartiesAxis_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CounterpartiesMember" xlink:label="ifrs-full_CounterpartiesMember_1" xlink:title="ifrs-full_CounterpartiesMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="ifrs-full_CounterpartiesAxis_1" xlink:to="ifrs-full_CounterpartiesMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:ifrs-full_CounterpartiesAxis_1 To ifrs-full_CounterpartiesMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_SignificantInvestmentsInAssociatesAxis" xlink:label="ifrs-full_SignificantInvestmentsInAssociatesAxis_1" xlink:title="ifrs-full_SignificantInvestmentsInAssociatesAxis_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_EntitysTotalForAssociatesMember" xlink:label="ifrs-full_EntitysTotalForAssociatesMember_1" xlink:title="ifrs-full_EntitysTotalForAssociatesMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="ifrs-full_SignificantInvestmentsInAssociatesAxis_1" xlink:to="ifrs-full_EntitysTotalForAssociatesMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:ifrs-full_SignificantInvestmentsInAssociatesAxis_1 To ifrs-full_EntitysTotalForAssociatesMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_InitiallyAppliedIFRSsAxis" xlink:label="ifrs-full_InitiallyAppliedIFRSsAxis_1" xlink:title="ifrs-full_InitiallyAppliedIFRSsAxis_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_InitiallyAppliedIFRSsMember" xlink:label="ifrs-full_InitiallyAppliedIFRSsMember_1" xlink:title="ifrs-full_InitiallyAppliedIFRSsMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="ifrs-full_InitiallyAppliedIFRSsAxis_1" xlink:to="ifrs-full_InitiallyAppliedIFRSsMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:ifrs-full_InitiallyAppliedIFRSsAxis_1 To ifrs-full_InitiallyAppliedIFRSsMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_IfrsSubsidiarySaleOfStockAxis" xlink:label="gmab_IfrsSubsidiarySaleOfStockAxis_1" xlink:title="gmab_IfrsSubsidiarySaleOfStockAxis_1" />
    <link:loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_IfrsSaleOfStockNameOfTransactionDomain" xlink:label="gmab_IfrsSaleOfStockNameOfTransactionDomain_1" xlink:title="gmab_IfrsSaleOfStockNameOfTransactionDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="gmab_IfrsSubsidiarySaleOfStockAxis_1" xlink:to="gmab_IfrsSaleOfStockNameOfTransactionDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:gmab_IfrsSubsidiarySaleOfStockAxis_1 To gmab_IfrsSaleOfStockNameOfTransactionDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:label="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_1" xlink:title="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NonadjustingEventsMember" xlink:label="ifrs-full_NonadjustingEventsMember_1" xlink:title="ifrs-full_NonadjustingEventsMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_1" xlink:to="ifrs-full_NonadjustingEventsMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_1 To ifrs-full_NonadjustingEventsMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_IfrsRoyaltiesByProductAxis" xlink:label="gmab_IfrsRoyaltiesByProductAxis_1" xlink:title="gmab_IfrsRoyaltiesByProductAxis_1" />
    <link:loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_IfrsRoyaltiesByProductDomain" xlink:label="gmab_IfrsRoyaltiesByProductDomain_1" xlink:title="gmab_IfrsRoyaltiesByProductDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="gmab_IfrsRoyaltiesByProductAxis_1" xlink:to="gmab_IfrsRoyaltiesByProductDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:gmab_IfrsRoyaltiesByProductAxis_1 To gmab_IfrsRoyaltiesByProductDomain_1" order="1" />
  </link:definitionLink>
  <definitionLink xlink:role="http://www.genmab.com/role/DocumentDocumentAndEntityInformation" xlink:type="extended" xlink:title="00090 - Document - Document and Entity Information" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ClassesOfShareCapitalAxis" xlink:label="ifrs-full_ClassesOfShareCapitalAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="dei_DocumentInformationTable" xlink:to="ifrs-full_ClassesOfShareCapitalAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ClassesOfShareCapitalMember" xlink:label="ifrs-full_ClassesOfShareCapitalMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_ClassesOfShareCapitalAxis" xlink:to="ifrs-full_ClassesOfShareCapitalMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OrdinarySharesMember" xlink:label="ifrs-full_OrdinarySharesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_ClassesOfShareCapitalMember" xlink:to="ifrs-full_OrdinarySharesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_AmericanDepositorySharesMember" xlink:label="gmab_AmericanDepositorySharesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_ClassesOfShareCapitalMember" xlink:to="gmab_AmericanDepositorySharesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentRegistrationStatement" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentAnnualReport" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCommonStockSharesOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityWellKnownSeasonedIssuer" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityVoluntaryFilers" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCurrentReportingStatus" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityInteractiveDataCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFilerCategory" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityExTransitionPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityShellCompany" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="16" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentShellCompanyReport" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="17" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentTransitionReport" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="18" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="19" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CurrentFiscalYearEndDate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="20" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalYearFocus" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="21" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalPeriodFocus" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="22" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.genmab.com/role/StatementStatementsOfChangesInEquity" xlink:type="extended" xlink:title="00400 - Statement - STATEMENTS OF CHANGES IN EQUITY" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_StatementOfChangesInEquityTable" xlink:label="ifrs-full_StatementOfChangesInEquityTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ComponentsOfEquityAxis" xlink:label="ifrs-full_ComponentsOfEquityAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="ifrs-full_StatementOfChangesInEquityTable" xlink:to="ifrs-full_ComponentsOfEquityAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_EquityMember" xlink:label="ifrs-full_EquityMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_ComponentsOfEquityAxis" xlink:to="ifrs-full_EquityMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IssuedCapitalMember" xlink:label="ifrs-full_IssuedCapitalMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_EquityMember" xlink:to="ifrs-full_IssuedCapitalMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_SharePremiumMember" xlink:label="ifrs-full_SharePremiumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_EquityMember" xlink:to="ifrs-full_SharePremiumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember" xlink:label="ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="ifrs-full_EquityMember" xlink:to="ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CashFlowHedgesMember" xlink:label="ifrs-full_CashFlowHedgesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="ifrs-full_EquityMember" xlink:to="ifrs-full_CashFlowHedgesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RetainedEarningsMember" xlink:label="ifrs-full_RetainedEarningsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="ifrs-full_EquityMember" xlink:to="ifrs-full_RetainedEarningsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:label="ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="ifrs-full_StatementOfChangesInEquityTable" xlink:to="ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RestatedMember" xlink:label="ifrs-full_RestatedMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:to="ifrs-full_RestatedMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IncreaseDecreaseDueToApplicationOfIFRS15Member" xlink:label="ifrs-full_IncreaseDecreaseDueToApplicationOfIFRS15Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_RestatedMember" xlink:to="ifrs-full_IncreaseDecreaseDueToApplicationOfIFRS15Member" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_StatementOfChangesInEquityLineItems" xlink:label="ifrs-full_StatementOfChangesInEquityLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_StatementOfChangesInEquityTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_Equity" xlink:label="ifrs-full_Equity" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_Equity" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NumberOfSharesOutstanding" xlink:label="ifrs-full_NumberOfSharesOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_NumberOfSharesOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_IfrsCumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption" xlink:label="gmab_IfrsCumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="gmab_IfrsCumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_EquityAdjustedForCumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption" xlink:label="gmab_EquityAdjustedForCumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="gmab_EquityAdjustedForCumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProfitLoss" xlink:label="ifrs-full_ProfitLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_ProfitLoss" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OtherComprehensiveIncome" xlink:label="ifrs-full_OtherComprehensiveIncome" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_OtherComprehensiveIncome" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ComprehensiveIncome" xlink:label="ifrs-full_ComprehensiveIncome" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_ComprehensiveIncome" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_TransactionsWithOwners" xlink:label="gmab_TransactionsWithOwners" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="gmab_TransactionsWithOwners" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity" xlink:label="ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="gmab_TransactionsWithOwners" xlink:to="ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_ExerciseOfWarrants" xlink:label="gmab_ExerciseOfWarrants" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="gmab_TransactionsWithOwners" xlink:to="gmab_ExerciseOfWarrants" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IssueOfEquity" xlink:label="ifrs-full_IssueOfEquity" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="gmab_TransactionsWithOwners" xlink:to="ifrs-full_IssueOfEquity" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_ExpensesRelatedToCapitalIncreaseDecrease" xlink:label="gmab_ExpensesRelatedToCapitalIncreaseDecrease" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="gmab_TransactionsWithOwners" xlink:to="gmab_ExpensesRelatedToCapitalIncreaseDecrease" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ChangesInEquity" xlink:label="ifrs-full_ChangesInEquity" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="gmab_TransactionsWithOwners" xlink:to="ifrs-full_ChangesInEquity" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_PurchaseOfTreasuryShares" xlink:label="ifrs-full_PurchaseOfTreasuryShares" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="gmab_TransactionsWithOwners" xlink:to="ifrs-full_PurchaseOfTreasuryShares" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions" xlink:label="ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="gmab_TransactionsWithOwners" xlink:to="ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_IncreaseDecreaseThroughNetSettlementOfRestrictedStockUnitsEquity" xlink:label="gmab_IncreaseDecreaseThroughNetSettlementOfRestrictedStockUnitsEquity" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="gmab_TransactionsWithOwners" xlink:to="gmab_IncreaseDecreaseThroughNetSettlementOfRestrictedStockUnitsEquity" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_TaxOnItemsRecognizedDirectlyInEquity" xlink:label="gmab_TaxOnItemsRecognizedDirectlyInEquity" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="gmab_TransactionsWithOwners" xlink:to="gmab_TaxOnItemsRecognizedDirectlyInEquity" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_IncreaseDecreaseThroughTaxOnItemsRecognizedDirectlyInEquity" xlink:label="gmab_IncreaseDecreaseThroughTaxOnItemsRecognizedDirectlyInEquity" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="gmab_TransactionsWithOwners" xlink:to="gmab_IncreaseDecreaseThroughTaxOnItemsRecognizedDirectlyInEquity" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.genmab.com/role/DisclosureRevenueDetails" xlink:type="extended" xlink:title="40201 - Disclosure - Revenue (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" xlink:label="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" />
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_TypesOfRevenuesAxis" xlink:label="gmab_TypesOfRevenuesAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" xlink:to="gmab_TypesOfRevenuesAxis" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_TypesOfRevenuesMember" xlink:label="gmab_TypesOfRevenuesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="gmab_TypesOfRevenuesAxis" xlink:to="gmab_TypesOfRevenuesMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_RoyaltiesRevenueMember" xlink:label="gmab_RoyaltiesRevenueMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="gmab_TypesOfRevenuesMember" xlink:to="gmab_RoyaltiesRevenueMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_ReimbursementIncomeMember" xlink:label="gmab_ReimbursementIncomeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="gmab_TypesOfRevenuesMember" xlink:to="gmab_ReimbursementIncomeMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_MilestonePaymentsRevenueMember" xlink:label="gmab_MilestonePaymentsRevenueMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="gmab_TypesOfRevenuesMember" xlink:to="gmab_MilestonePaymentsRevenueMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_LicenseFeesMember" xlink:label="gmab_LicenseFeesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="gmab_TypesOfRevenuesMember" xlink:to="gmab_LicenseFeesMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_CollaborationRevenueMember" xlink:label="gmab_CollaborationRevenueMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="gmab_TypesOfRevenuesMember" xlink:to="gmab_CollaborationRevenueMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis" xlink:label="gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" xlink:to="gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeDomain" xlink:label="gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis" xlink:to="gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeDomain" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_AgreementsWithJanssenMember" xlink:label="gmab_AgreementsWithJanssenMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeDomain" xlink:to="gmab_AgreementsWithJanssenMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_AgreementsWithAbbvieMember" xlink:label="gmab_AgreementsWithAbbvieMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeDomain" xlink:to="gmab_AgreementsWithAbbvieMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_AgreementsWithRocheMember" xlink:label="gmab_AgreementsWithRocheMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeDomain" xlink:to="gmab_AgreementsWithRocheMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_AgreementsWithSeagenMember" xlink:label="gmab_AgreementsWithSeagenMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeDomain" xlink:to="gmab_AgreementsWithSeagenMember" use="optional" />
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_AgreementsWithBointechMember" xlink:label="gmab_AgreementsWithBointechMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeDomain" xlink:to="gmab_AgreementsWithBointechMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_AgreementsWithNovartisMember" xlink:label="gmab_AgreementsWithNovartisMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeDomain" xlink:to="gmab_AgreementsWithNovartisMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_OtherCollaborationPartnersMember" xlink:label="gmab_OtherCollaborationPartnersMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeDomain" xlink:to="gmab_OtherCollaborationPartnersMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_AgreementsWithSeatleGeneticsMember" xlink:label="gmab_AgreementsWithSeatleGeneticsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeDomain" xlink:to="gmab_AgreementsWithSeatleGeneticsMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_IfrsRoyaltiesByProductAxis" xlink:label="gmab_IfrsRoyaltiesByProductAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" xlink:to="gmab_IfrsRoyaltiesByProductAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_IfrsRoyaltiesByProductDomain" xlink:label="gmab_IfrsRoyaltiesByProductDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="gmab_IfrsRoyaltiesByProductAxis" xlink:to="gmab_IfrsRoyaltiesByProductDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_DarzalexMember" xlink:label="gmab_DarzalexMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="gmab_IfrsRoyaltiesByProductDomain" xlink:to="gmab_DarzalexMember" use="optional" />
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_TepezzaMember" xlink:label="gmab_TepezzaMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="gmab_IfrsRoyaltiesByProductDomain" xlink:to="gmab_TepezzaMember" use="optional" />
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_KesimptaMember" xlink:label="gmab_KesimptaMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="gmab_IfrsRoyaltiesByProductDomain" xlink:to="gmab_KesimptaMember" use="optional" />
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_OtherRoyaltyProductMember" xlink:label="gmab_OtherRoyaltyProductMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="gmab_IfrsRoyaltiesByProductDomain" xlink:to="gmab_OtherRoyaltyProductMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:label="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:to="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RevenueFromContractsWithCustomers" xlink:label="ifrs-full_RevenueFromContractsWithCustomers" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:to="ifrs-full_RevenueFromContractsWithCustomers" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.genmab.com/role/DisclosureFinancialInstrumentsFinancialRiskDetails" xlink:type="extended" xlink:title="40301 - Disclosure - Financial Instruments - Financial Risk (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfCreditRiskExposureTable" xlink:label="ifrs-full_DisclosureOfCreditRiskExposureTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TypesOfRisksAxis" xlink:label="ifrs-full_TypesOfRisksAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="ifrs-full_DisclosureOfCreditRiskExposureTable" xlink:to="ifrs-full_TypesOfRisksAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TypesOfRisksMember" xlink:label="ifrs-full_TypesOfRisksMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_TypesOfRisksAxis" xlink:to="ifrs-full_TypesOfRisksMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CreditRiskMember" xlink:label="ifrs-full_CreditRiskMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_TypesOfRisksMember" xlink:to="ifrs-full_CreditRiskMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CurrencyRiskMember" xlink:label="ifrs-full_CurrencyRiskMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_TypesOfRisksMember" xlink:to="ifrs-full_CurrencyRiskMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ExternalCreditGradesAxis" xlink:label="ifrs-full_ExternalCreditGradesAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="ifrs-full_DisclosureOfCreditRiskExposureTable" xlink:to="ifrs-full_ExternalCreditGradesAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_EntitysTotalForExternalCreditGradesMember" xlink:label="ifrs-full_EntitysTotalForExternalCreditGradesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_ExternalCreditGradesAxis" xlink:to="ifrs-full_EntitysTotalForExternalCreditGradesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_TripleaRatingMember" xlink:label="gmab_TripleaRatingMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_EntitysTotalForExternalCreditGradesMember" xlink:to="gmab_TripleaRatingMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CurrencyAxis" xlink:label="srt_CurrencyAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="ifrs-full_DisclosureOfCreditRiskExposureTable" xlink:to="srt_CurrencyAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2021/currency-2021.xsd#currency_AllCurrenciesDomain" xlink:label="currency_AllCurrenciesDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_CurrencyAxis" xlink:to="currency_AllCurrenciesDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2021/currency-2021.xsd#currency_USD" xlink:label="currency_USD" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="currency_AllCurrenciesDomain" xlink:to="currency_USD" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2021/currency-2021.xsd#currency_DKK" xlink:label="currency_DKK" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="currency_AllCurrenciesDomain" xlink:to="currency_DKK" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2021/currency-2021.xsd#currency_EUR" xlink:label="currency_EUR" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="currency_AllCurrenciesDomain" xlink:to="currency_EUR" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2021/currency-2021.xsd#currency_GBP" xlink:label="currency_GBP" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="currency_AllCurrenciesDomain" xlink:to="currency_GBP" use="optional" />
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis" xlink:label="gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="ifrs-full_DisclosureOfCreditRiskExposureTable" xlink:to="gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeDomain" xlink:label="gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis" xlink:to="gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_AgreementsWithAbbvieMember" xlink:label="gmab_AgreementsWithAbbvieMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeDomain" xlink:to="gmab_AgreementsWithAbbvieMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfCreditRiskExposureLineItems" xlink:label="ifrs-full_DisclosureOfCreditRiskExposureLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="ifrs-full_DisclosureOfCreditRiskExposureLineItems" xlink:to="ifrs-full_DisclosureOfCreditRiskExposureTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_MaximumExposureToCreditRisk" xlink:label="ifrs-full_MaximumExposureToCreditRisk" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_DisclosureOfCreditRiskExposureLineItems" xlink:to="ifrs-full_MaximumExposureToCreditRisk" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_MaximumExposureToCreditRiskOfLoansOrReceivables" xlink:label="ifrs-full_MaximumExposureToCreditRiskOfLoansOrReceivables" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="ifrs-full_DisclosureOfCreditRiskExposureLineItems" xlink:to="ifrs-full_MaximumExposureToCreditRiskOfLoansOrReceivables" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_PercentageOfMarketableSecurities" xlink:label="gmab_PercentageOfMarketableSecurities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="ifrs-full_DisclosureOfCreditRiskExposureLineItems" xlink:to="gmab_PercentageOfMarketableSecurities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_MarketableSecuritiesIncludingInterestReceivables" xlink:label="gmab_MarketableSecuritiesIncludingInterestReceivables" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="ifrs-full_DisclosureOfCreditRiskExposureLineItems" xlink:to="gmab_MarketableSecuritiesIncludingInterestReceivables" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_BankDepositsIncludingShortTermMarketableSecurities" xlink:label="gmab_BankDepositsIncludingShortTermMarketableSecurities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="ifrs-full_DisclosureOfCreditRiskExposureLineItems" xlink:to="gmab_BankDepositsIncludingShortTermMarketableSecurities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_PercentageOfRevenue" xlink:label="gmab_PercentageOfRevenue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="ifrs-full_DisclosureOfCreditRiskExposureLineItems" xlink:to="gmab_PercentageOfRevenue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_PercentageOfMarketableSecuritiesInvested" xlink:label="gmab_PercentageOfMarketableSecuritiesInvested" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="ifrs-full_DisclosureOfCreditRiskExposureLineItems" xlink:to="gmab_PercentageOfMarketableSecuritiesInvested" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_PercentageOfPossibleIncreaseDecreaseInExchangeRate" xlink:label="gmab_PercentageOfPossibleIncreaseDecreaseInExchangeRate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="ifrs-full_DisclosureOfCreditRiskExposureLineItems" xlink:to="gmab_PercentageOfPossibleIncreaseDecreaseInExchangeRate" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.genmab.com/role/DisclosureFinancialInstrumentsFairValueMeasurementDetails" xlink:type="extended" xlink:title="40302 - Disclosure - Financial Instruments  - Fair Value Measurement (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfFairValueMeasurementOfAssetsTable" xlink:label="ifrs-full_DisclosureOfFairValueMeasurementOfAssetsTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_MeasurementAxis" xlink:label="ifrs-full_MeasurementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="ifrs-full_DisclosureOfFairValueMeasurementOfAssetsTable" xlink:to="ifrs-full_MeasurementAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AggregatedMeasurementMember" xlink:label="ifrs-full_AggregatedMeasurementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_MeasurementAxis" xlink:to="ifrs-full_AggregatedMeasurementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AtFairValueMember" xlink:label="ifrs-full_AtFairValueMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_AggregatedMeasurementMember" xlink:to="ifrs-full_AtFairValueMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ClassesOfFinancialAssetsAxis" xlink:label="ifrs-full_ClassesOfFinancialAssetsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="ifrs-full_DisclosureOfFairValueMeasurementOfAssetsTable" xlink:to="ifrs-full_ClassesOfFinancialAssetsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_FinancialAssetsMember" xlink:label="ifrs-full_FinancialAssetsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_ClassesOfFinancialAssetsAxis" xlink:to="ifrs-full_FinancialAssetsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_MarketableSecuritiesMember" xlink:label="gmab_MarketableSecuritiesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_FinancialAssetsMember" xlink:to="gmab_MarketableSecuritiesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_OtherInvestmentMember" xlink:label="gmab_OtherInvestmentMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_FinancialAssetsMember" xlink:to="gmab_OtherInvestmentMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_LevelsOfFairValueHierarchyAxis" xlink:label="ifrs-full_LevelsOfFairValueHierarchyAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="ifrs-full_DisclosureOfFairValueMeasurementOfAssetsTable" xlink:to="ifrs-full_LevelsOfFairValueHierarchyAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AllLevelsOfFairValueHierarchyMember" xlink:label="ifrs-full_AllLevelsOfFairValueHierarchyMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_LevelsOfFairValueHierarchyAxis" xlink:to="ifrs-full_AllLevelsOfFairValueHierarchyMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_Level1OfFairValueHierarchyMember" xlink:label="ifrs-full_Level1OfFairValueHierarchyMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_AllLevelsOfFairValueHierarchyMember" xlink:to="ifrs-full_Level1OfFairValueHierarchyMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_Level2OfFairValueHierarchyMember" xlink:label="ifrs-full_Level2OfFairValueHierarchyMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_AllLevelsOfFairValueHierarchyMember" xlink:to="ifrs-full_Level2OfFairValueHierarchyMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_Level3OfFairValueHierarchyMember" xlink:label="ifrs-full_Level3OfFairValueHierarchyMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="ifrs-full_AllLevelsOfFairValueHierarchyMember" xlink:to="ifrs-full_Level3OfFairValueHierarchyMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfFairValueMeasurementOfAssetsLineItems" xlink:label="ifrs-full_DisclosureOfFairValueMeasurementOfAssetsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="ifrs-full_DisclosureOfFairValueMeasurementOfAssetsLineItems" xlink:to="ifrs-full_DisclosureOfFairValueMeasurementOfAssetsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ReconciliationOfChangesInFairValueMeasurementAssetsAbstract" xlink:label="ifrs-full_ReconciliationOfChangesInFairValueMeasurementAssetsAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_DisclosureOfFairValueMeasurementOfAssetsLineItems" xlink:to="ifrs-full_ReconciliationOfChangesInFairValueMeasurementAssetsAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_FinancialAssets" xlink:label="ifrs-full_FinancialAssets" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_ReconciliationOfChangesInFairValueMeasurementAssetsAbstract" xlink:to="ifrs-full_FinancialAssets" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.genmab.com/role/DisclosureFinancialInstrumentsOtherInvestmentsDetails" xlink:type="extended" xlink:title="40303 - Disclosure - Financial Instruments - Other Investments (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeTable" xlink:label="gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeTable" />
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis" xlink:label="gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeTable" xlink:to="gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeDomain" xlink:label="gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis" xlink:to="gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_CurevacCollaborationMember" xlink:label="gmab_CurevacCollaborationMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeDomain" xlink:to="gmab_CurevacCollaborationMember" use="optional" />
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_BoltBiotherapeuticsIncMember" xlink:label="gmab_BoltBiotherapeuticsIncMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeDomain" xlink:to="gmab_BoltBiotherapeuticsIncMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_CollaborativeArrangementAndArrangementOtherThanCollaborativeLineItems" xlink:label="gmab_CollaborativeArrangementAndArrangementOtherThanCollaborativeLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="gmab_CollaborativeArrangementAndArrangementOtherThanCollaborativeLineItems" xlink:to="gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_InvestmentAccountedForUsingEquityMethod" xlink:label="ifrs-full_InvestmentAccountedForUsingEquityMethod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="gmab_CollaborativeArrangementAndArrangementOtherThanCollaborativeLineItems" xlink:to="ifrs-full_InvestmentAccountedForUsingEquityMethod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_PercentageOfInvestmentInCommonShares" xlink:label="gmab_PercentageOfInvestmentInCommonShares" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="gmab_CollaborativeArrangementAndArrangementOtherThanCollaborativeLineItems" xlink:to="gmab_PercentageOfInvestmentInCommonShares" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProceedsFromIssueOfOrdinaryShares" xlink:label="ifrs-full_ProceedsFromIssueOfOrdinaryShares" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="gmab_CollaborativeArrangementAndArrangementOtherThanCollaborativeLineItems" xlink:to="ifrs-full_ProceedsFromIssueOfOrdinaryShares" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.genmab.com/role/DisclosureShareBasedInstrumentsRestrictedStockUnitProgramDetails" xlink:type="extended" xlink:title="40501 - Disclosure - Share-Based Instruments - Restricted Stock Unit Program (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:to="ifrs-full_CategoriesOfRelatedPartiesAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="ifrs-full_EntitysTotalForRelatedPartiesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_EntitysTotalForRelatedPartiesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:label="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:to="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_SharebasedPaymentArrangementsMember" xlink:label="ifrs-full_SharebasedPaymentArrangementsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:to="ifrs-full_SharebasedPaymentArrangementsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_IfrsRestrictedStockUnitsRSUsMember" xlink:label="gmab_IfrsRestrictedStockUnitsRSUsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_SharebasedPaymentArrangementsMember" xlink:to="gmab_IfrsRestrictedStockUnitsRSUsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" xlink:label="ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted" xlink:label="ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_Weightedaveragefairvalueofotherequityinstrumentsgrantedinsharebasedpaymentarrangement" xlink:label="gmab_Weightedaveragefairvalueofotherequityinstrumentsgrantedinsharebasedpaymentarrangement" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="gmab_Weightedaveragefairvalueofotherequityinstrumentsgrantedinsharebasedpaymentarrangement" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" xlink:label="ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" xlink:label="ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_SaleOrIssueOfTreasuryShares" xlink:label="ifrs-full_SaleOrIssueOfTreasuryShares" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_SaleOrIssueOfTreasuryShares" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TreasuryShares" xlink:label="ifrs-full_TreasuryShares" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_TreasuryShares" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.genmab.com/role/DisclosureShareBasedInstrumentsWarrantProgramDetails" xlink:type="extended" xlink:title="40502 - Disclosure - Share-Based Instruments - Warrant Program (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:label="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:to="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_SharebasedPaymentArrangementsMember" xlink:label="ifrs-full_SharebasedPaymentArrangementsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:to="ifrs-full_SharebasedPaymentArrangementsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_WarrantsGrantedFromAugust2004UntilApril2012Member" xlink:label="gmab_WarrantsGrantedFromAugust2004UntilApril2012Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_SharebasedPaymentArrangementsMember" xlink:to="gmab_WarrantsGrantedFromAugust2004UntilApril2012Member" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_WarrantsGrantedFromApril2012UntilMarch2017Member" xlink:label="gmab_WarrantsGrantedFromApril2012UntilMarch2017Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_SharebasedPaymentArrangementsMember" xlink:to="gmab_WarrantsGrantedFromApril2012UntilMarch2017Member" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_WarrantsGrantedFromMarch2017Member" xlink:label="gmab_WarrantsGrantedFromMarch2017Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="ifrs-full_SharebasedPaymentArrangementsMember" xlink:to="gmab_WarrantsGrantedFromMarch2017Member" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_WarrantsMember" xlink:label="gmab_WarrantsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="ifrs-full_SharebasedPaymentArrangementsMember" xlink:to="gmab_WarrantsMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_WarrantVestingPeriod" xlink:label="gmab_WarrantVestingPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="gmab_WarrantVestingPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_NumberOfWarrantsOutstanding" xlink:label="gmab_NumberOfWarrantsOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="gmab_NumberOfWarrantsOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_NumberOfWarrantsGrantedDuringPeriod" xlink:label="gmab_NumberOfWarrantsGrantedDuringPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="gmab_NumberOfWarrantsGrantedDuringPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_NumberOfWarrantsExercisedDuringPeriod" xlink:label="gmab_NumberOfWarrantsExercisedDuringPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="gmab_NumberOfWarrantsExercisedDuringPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_NumberOfWarrantsExpiredOrLapsedOrCancelledDuringPeriod" xlink:label="gmab_NumberOfWarrantsExpiredOrLapsedOrCancelledDuringPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="gmab_NumberOfWarrantsExpiredOrLapsedOrCancelledDuringPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_WeightedAverageExercisePriceOfWarrantsGranted" xlink:label="gmab_WeightedAverageExercisePriceOfWarrantsGranted" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="gmab_WeightedAverageExercisePriceOfWarrantsGranted" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_WeightedAverageExercisePriceOfFairValueOfWarrants" xlink:label="gmab_WeightedAverageExercisePriceOfFairValueOfWarrants" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="gmab_WeightedAverageExercisePriceOfFairValueOfWarrants" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_WeightedAverageExercisePriceOfWarrantsExercised" xlink:label="gmab_WeightedAverageExercisePriceOfWarrantsExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="gmab_WeightedAverageExercisePriceOfWarrantsExercised" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProceedsFromExerciseOfWarrants" xlink:label="ifrs-full_ProceedsFromExerciseOfWarrants" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_ProceedsFromExerciseOfWarrants" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_PercentageOfShareCapitalAttributedToExerciseOfWarrants" xlink:label="gmab_PercentageOfShareCapitalAttributedToExerciseOfWarrants" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="gmab_PercentageOfShareCapitalAttributedToExerciseOfWarrants" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" xlink:label="ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_NumberOfTreasurySharesOutstanding" xlink:label="gmab_NumberOfTreasurySharesOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="gmab_NumberOfTreasurySharesOutstanding" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.genmab.com/role/DisclosureShareBasedInstrumentsShareRepurchasesDetails" xlink:type="extended" xlink:title="40503 - Disclosure - Share-Based Instruments - Share repurchases (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:to="srt_StatementScenarioAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_StockRepurchaseFirstAuthorizationMember" xlink:label="gmab_StockRepurchaseFirstAuthorizationMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="gmab_StockRepurchaseFirstAuthorizationMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_StockRepurchaseSecondAuthorizationMember" xlink:label="gmab_StockRepurchaseSecondAuthorizationMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="gmab_StockRepurchaseSecondAuthorizationMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_ThirdAuthorizationMember" xlink:label="gmab_ThirdAuthorizationMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="gmab_ThirdAuthorizationMember" use="optional" />
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_StockRepurchaseAuthorization2021Member" xlink:label="gmab_StockRepurchaseAuthorization2021Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="gmab_StockRepurchaseAuthorization2021Member" use="optional" />
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_StockRepurchaseAuthorization2019Member" xlink:label="gmab_StockRepurchaseAuthorization2019Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="gmab_StockRepurchaseAuthorization2019Member" use="optional" />
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_StockRepurchaseAuthorization2016Member" xlink:label="gmab_StockRepurchaseAuthorization2016Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="gmab_StockRepurchaseAuthorization2016Member" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:label="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:to="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_SharebasedPaymentArrangementsMember" xlink:label="ifrs-full_SharebasedPaymentArrangementsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:to="ifrs-full_SharebasedPaymentArrangementsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_RestrictedStockUnitsRSUsMember" xlink:label="gmab_RestrictedStockUnitsRSUsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_SharebasedPaymentArrangementsMember" xlink:to="gmab_RestrictedStockUnitsRSUsMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_NumberOfSharesAuthorizedToBeRepurchased" xlink:label="gmab_NumberOfSharesAuthorizedToBeRepurchased" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="gmab_NumberOfSharesAuthorizedToBeRepurchased" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_ShareRepurchasedDuringPeriodShares" xlink:label="gmab_ShareRepurchasedDuringPeriodShares" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="gmab_ShareRepurchasedDuringPeriodShares" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_SharesAvailableForRepurchase" xlink:label="gmab_SharesAvailableForRepurchase" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="gmab_SharesAvailableForRepurchase" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_IfrsShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod" xlink:label="gmab_IfrsShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="gmab_IfrsShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_ShareBasedArrangementPeriodFromVestingDateHolderReceivesShares" xlink:label="gmab_ShareBasedArrangementPeriodFromVestingDateHolderReceivesShares" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="gmab_ShareBasedArrangementPeriodFromVestingDateHolderReceivesShares" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_ShareBasedArrangementNumberOfSharesPerRsu" xlink:label="gmab_ShareBasedArrangementNumberOfSharesPerRsu" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="gmab_ShareBasedArrangementNumberOfSharesPerRsu" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_ShareBasedArrangementNumberOfAuthorization" xlink:label="gmab_ShareBasedArrangementNumberOfAuthorization" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="gmab_ShareBasedArrangementNumberOfAuthorization" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_SharesRepurchasedNominalValue" xlink:label="gmab_SharesRepurchasedNominalValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="gmab_SharesRepurchasedNominalValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_StockRepurchaseThresholdPriceDeviationPercentage" xlink:label="gmab_StockRepurchaseThresholdPriceDeviationPercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="gmab_StockRepurchaseThresholdPriceDeviationPercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_ShareRepurchasedDuringPeriodValue" xlink:label="gmab_ShareRepurchasedDuringPeriodValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="gmab_ShareRepurchasedDuringPeriodValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_SharesAvailableForRepurchaseAmount" xlink:label="gmab_SharesAvailableForRepurchaseAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="gmab_SharesAvailableForRepurchaseAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_TreasurySharesAcquired" xlink:label="gmab_TreasurySharesAcquired" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="gmab_TreasurySharesAcquired" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_PercentageOfShareCapitalRepurchased" xlink:label="gmab_PercentageOfShareCapitalRepurchased" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="gmab_PercentageOfShareCapitalRepurchased" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_PurchaseOfTreasuryShares" xlink:label="ifrs-full_PurchaseOfTreasuryShares" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_PurchaseOfTreasuryShares" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.genmab.com/role/DisclosureRelatedPartiesDetails" xlink:type="extended" xlink:title="40601 - Disclosure - Related Parties (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:label="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:to="ifrs-full_CategoriesOfRelatedPartiesAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="ifrs-full_EntitysTotalForRelatedPartiesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_EntitysTotalForRelatedPartiesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_KeyManagementPersonnelOfEntityOrParentMember" xlink:label="ifrs-full_KeyManagementPersonnelOfEntityOrParentMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="ifrs-full_KeyManagementPersonnelOfEntityOrParentMember" use="optional" />
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_DeirdreP.ConnellyChairPernilleErenbjergDeputyChairRolfHoffmannDr.PaoloPaolettiAndDr.AndersGerselPedersenMember" xlink:label="gmab_DeirdreP.ConnellyChairPernilleErenbjergDeputyChairRolfHoffmannDr.PaoloPaolettiAndDr.AndersGerselPedersenMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="gmab_DeirdreP.ConnellyChairPernilleErenbjergDeputyChairRolfHoffmannDr.PaoloPaolettiAndDr.AndersGerselPedersenMember" use="optional" />
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_ElizabethOfarrellMember" xlink:label="gmab_ElizabethOfarrellMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="gmab_ElizabethOfarrellMember" use="optional" />
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_MijkeZachariasseMartinSchultzAndTakahiroHamataniMember" xlink:label="gmab_MijkeZachariasseMartinSchultzAndTakahiroHamataniMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="gmab_MijkeZachariasseMartinSchultzAndTakahiroHamataniMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:label="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_NumberOfChangesToExecutiveManagementTeam" xlink:label="gmab_NumberOfChangesToExecutiveManagementTeam" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="gmab_NumberOfChangesToExecutiveManagementTeam" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_NumberOfIndependentBoardMembers" xlink:label="gmab_NumberOfIndependentBoardMembers" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="gmab_NumberOfIndependentBoardMembers" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_NumberOfNonIndependentBoardMembers" xlink:label="gmab_NumberOfNonIndependentBoardMembers" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="gmab_NumberOfNonIndependentBoardMembers" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_NumberOfEmployeeElectedBoardMembers" xlink:label="gmab_NumberOfEmployeeElectedBoardMembers" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="gmab_NumberOfEmployeeElectedBoardMembers" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_ReElectionToBoardOfDirectorsTerm" xlink:label="gmab_ReElectionToBoardOfDirectorsTerm" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="gmab_ReElectionToBoardOfDirectorsTerm" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_ElectionToBoardOfDirectorsTerm" xlink:label="gmab_ElectionToBoardOfDirectorsTerm" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="gmab_ElectionToBoardOfDirectorsTerm" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.genmab.com/role/DisclosureLeasesDetails" xlink:type="extended" xlink:title="40701 - Disclosure - Leases (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable" xlink:label="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ClassesOfAssetsAxis" xlink:label="ifrs-full_ClassesOfAssetsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable" xlink:to="ifrs-full_ClassesOfAssetsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ClassesOfAssetsMember" xlink:label="ifrs-full_ClassesOfAssetsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_ClassesOfAssetsAxis" xlink:to="ifrs-full_ClassesOfAssetsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_PropertiesMember" xlink:label="gmab_PropertiesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_ClassesOfAssetsMember" xlink:to="gmab_PropertiesMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_IfrsEquipmentMember" xlink:label="gmab_IfrsEquipmentMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_ClassesOfAssetsMember" xlink:to="gmab_IfrsEquipmentMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:label="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable" xlink:to="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_PropertyPlantAndEquipmentMember" xlink:label="ifrs-full_PropertyPlantAndEquipmentMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:to="ifrs-full_PropertyPlantAndEquipmentMember" use="optional" />
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_OfficeAndLaboratorySpaceMember" xlink:label="gmab_OfficeAndLaboratorySpaceMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_PropertyPlantAndEquipmentMember" xlink:to="gmab_OfficeAndLaboratorySpaceMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable" xlink:to="srt_StatementGeographicalAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_DK" xlink:label="country_DK" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_DK" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:label="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:to="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RightofuseAssets" xlink:label="ifrs-full_RightofuseAssets" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:to="ifrs-full_RightofuseAssets" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_LeaseLiabilitiesAbstract" xlink:label="ifrs-full_LeaseLiabilitiesAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:to="ifrs-full_LeaseLiabilitiesAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CurrentLeaseLiabilities" xlink:label="ifrs-full_CurrentLeaseLiabilities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_LeaseLiabilitiesAbstract" xlink:to="ifrs-full_CurrentLeaseLiabilities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NoncurrentLeaseLiabilities" xlink:label="ifrs-full_NoncurrentLeaseLiabilities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_LeaseLiabilitiesAbstract" xlink:to="ifrs-full_NoncurrentLeaseLiabilities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_LeaseLiabilities" xlink:label="ifrs-full_LeaseLiabilities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="ifrs-full_LeaseLiabilitiesAbstract" xlink:to="ifrs-full_LeaseLiabilities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AdditionsToRightofuseAssets" xlink:label="ifrs-full_AdditionsToRightofuseAssets" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="ifrs-full_LeaseLiabilitiesAbstract" xlink:to="ifrs-full_AdditionsToRightofuseAssets" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DepreciationRightofuseAssets" xlink:label="ifrs-full_DepreciationRightofuseAssets" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="ifrs-full_LeaseLiabilitiesAbstract" xlink:to="ifrs-full_DepreciationRightofuseAssets" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_InterestExpenseOnLeaseLiabilities" xlink:label="ifrs-full_InterestExpenseOnLeaseLiabilities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="ifrs-full_LeaseLiabilitiesAbstract" xlink:to="ifrs-full_InterestExpenseOnLeaseLiabilities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed" xlink:label="ifrs-full_ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="ifrs-full_LeaseLiabilitiesAbstract" xlink:to="ifrs-full_ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_FutureMinimumOperatingLeasePayments" xlink:label="gmab_FutureMinimumOperatingLeasePayments" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="ifrs-full_LeaseLiabilitiesAbstract" xlink:to="gmab_FutureMinimumOperatingLeasePayments" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_EstimatedCapitalExpenditureForLease" xlink:label="gmab_EstimatedCapitalExpenditureForLease" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="ifrs-full_LeaseLiabilitiesAbstract" xlink:to="gmab_EstimatedCapitalExpenditureForLease" priority="1" use="optional" />
  </definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>24
<FILENAME>gmab-20220630_lab.xml
<DESCRIPTION>EX-101.LAB
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  9.6.8167.22744 -->
<!--Based on XBRL 2.1-->
<!--Created on: 8/10/2022 3:19:08 PM-->
<!--Modified on: 8/10/2022 3:19:08 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xmlns="http://www.xbrl.org/2003/linkbase" />
  <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_DocumentAndEntityInformationAbstract" xlink:label="gmab_DocumentAndEntityInformationAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmab_DocumentAndEntityInformationAbstract" xlink:to="gmab_DocumentAndEntityInformationAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gmab_DocumentAndEntityInformationAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document and Entity Information [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentInformationTable" xlink:to="dei_DocumentInformationTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentInformationTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Information [Table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ClassesOfShareCapitalAxis" xlink:label="ifrs-full_ClassesOfShareCapitalAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ClassesOfShareCapitalAxis" xlink:to="ifrs-full_ClassesOfShareCapitalAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ClassesOfShareCapitalAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Classes of share capital [axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ClassesOfShareCapitalMember" xlink:label="ifrs-full_ClassesOfShareCapitalMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ClassesOfShareCapitalMember" xlink:to="ifrs-full_ClassesOfShareCapitalMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ClassesOfShareCapitalMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share capital [member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OrdinarySharesMember" xlink:label="ifrs-full_OrdinarySharesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OrdinarySharesMember" xlink:to="ifrs-full_OrdinarySharesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OrdinarySharesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ordinary shares [member]</label>
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_AmericanDepositorySharesMember" xlink:label="gmab_AmericanDepositorySharesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmab_AmericanDepositorySharesMember" xlink:to="gmab_AmericanDepositorySharesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gmab_AmericanDepositorySharesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for American Depository Shares.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gmab_AmericanDepositorySharesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">ADS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentInformationLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Information [Line Items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Type</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Registration Statement</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Period End Date</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Registrant Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Annual Report</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Common Stock, Shares Outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Well-known Seasoned Issuer</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Voluntary Filers</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Current Reporting Status</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Interactive Data Current</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Filer Category</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Emerging Growth Company</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Ex Transition Period</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Shell Company</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Shell Company Report</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Transition Report</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Central Index Key</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current Fiscal Year End Date</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Fiscal Year Focus</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Fiscal Period Focus</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amendment Flag</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_StatementOfProfitOrLossAndOtherComprehensiveIncomeAbstract" xlink:label="ifrs-full_StatementOfProfitOrLossAndOtherComprehensiveIncomeAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_StatementOfProfitOrLossAndOtherComprehensiveIncomeAbstract" xlink:to="ifrs-full_StatementOfProfitOrLossAndOtherComprehensiveIncomeAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_StatementOfProfitOrLossAndOtherComprehensiveIncomeAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">STATEMENTS OF COMPREHENSIVE INCOME</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IncomeStatementAbstract" xlink:label="ifrs-full_IncomeStatementAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_IncomeStatementAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IncomeStatementAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Profit or loss [abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_IncomeStatementAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Statement</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_Revenue" xlink:label="ifrs-full_Revenue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Revenue" xlink:to="ifrs-full_Revenue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_Revenue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_Revenue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ResearchAndDevelopmentExpense" xlink:label="ifrs-full_ResearchAndDevelopmentExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ResearchAndDevelopmentExpense" xlink:to="ifrs-full_ResearchAndDevelopmentExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and development expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and development expenses</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_GeneralAndAdministrativeExpense" xlink:label="ifrs-full_GeneralAndAdministrativeExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_GeneralAndAdministrativeExpense" xlink:to="ifrs-full_GeneralAndAdministrativeExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">General and administrative expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">General and administrative expenses</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_SellingGeneralAndAdministrativeExpense" xlink:label="ifrs-full_SellingGeneralAndAdministrativeExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_SellingGeneralAndAdministrativeExpense" xlink:to="ifrs-full_SellingGeneralAndAdministrativeExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_SellingGeneralAndAdministrativeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Selling, general and administrative expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_SellingGeneralAndAdministrativeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Selling, general and administrative expenses</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OperatingExpense" xlink:label="ifrs-full_OperatingExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OperatingExpense" xlink:to="ifrs-full_OperatingExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OperatingExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="ifrs-full_OperatingExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating expenses</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProfitLossFromOperatingActivities" xlink:label="ifrs-full_ProfitLossFromOperatingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProfitLossFromOperatingActivities" xlink:to="ifrs-full_ProfitLossFromOperatingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ProfitLossFromOperatingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Profit (loss) from operating activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_ProfitLossFromOperatingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating profit</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_FinanceIncome" xlink:label="ifrs-full_FinanceIncome" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FinanceIncome" xlink:to="ifrs-full_FinanceIncome_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_FinanceIncome_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Financial income</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_FinanceIncome_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total financial income</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_FinanceCosts" xlink:label="ifrs-full_FinanceCosts" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FinanceCosts" xlink:to="ifrs-full_FinanceCosts_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_FinanceCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finance costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_FinanceCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Financial expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="ifrs-full_FinanceCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total financial expenses</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProfitLossBeforeTax" xlink:label="ifrs-full_ProfitLossBeforeTax" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProfitLossBeforeTax" xlink:to="ifrs-full_ProfitLossBeforeTax_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ProfitLossBeforeTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Profit (loss) before tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_ProfitLossBeforeTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net profit before tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_ProfitLossBeforeTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net profit before tax</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:label="ifrs-full_IncomeTaxExpenseContinuingOperations" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:to="ifrs-full_IncomeTaxExpenseContinuingOperations_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IncomeTaxExpenseContinuingOperations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tax expense (income), continuing operations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_IncomeTaxExpenseContinuingOperations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Corporate tax</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProfitLoss" xlink:label="ifrs-full_ProfitLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProfitLoss" xlink:to="ifrs-full_ProfitLoss_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ProfitLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Profit (loss)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ProfitLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net profit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_ProfitLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net profit</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_BasicEarningsLossPerShare" xlink:label="ifrs-full_BasicEarningsLossPerShare" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_BasicEarningsLossPerShare" xlink:to="ifrs-full_BasicEarningsLossPerShare_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_BasicEarningsLossPerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Basic earnings (loss) per share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_BasicEarningsLossPerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Basic net profit per share</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DilutedEarningsLossPerShare" xlink:label="ifrs-full_DilutedEarningsLossPerShare" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DilutedEarningsLossPerShare" xlink:to="ifrs-full_DilutedEarningsLossPerShare_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DilutedEarningsLossPerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Diluted earnings (loss) per share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DilutedEarningsLossPerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Diluted net profit per share</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_StatementOfComprehensiveIncomeAbstract" xlink:label="ifrs-full_StatementOfComprehensiveIncomeAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_StatementOfComprehensiveIncomeAbstract" xlink:to="ifrs-full_StatementOfComprehensiveIncomeAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_StatementOfComprehensiveIncomeAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statement of comprehensive income [abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_StatementOfComprehensiveIncomeAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statement of Comprehensive Income</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OtherComprehensiveIncomeAbstract" xlink:label="ifrs-full_OtherComprehensiveIncomeAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherComprehensiveIncomeAbstract" xlink:to="ifrs-full_OtherComprehensiveIncomeAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherComprehensiveIncomeAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other comprehensive income [abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_OtherComprehensiveIncomeAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other comprehensive income:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract" xlink:label="ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract" xlink:to="ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Components of other comprehensive income that will be reclassified to profit or loss, net of tax [abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amounts which will be re-classified to the income statement:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" xlink:label="ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" xlink:to="ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other comprehensive income, net of tax, exchange differences on translation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustment of foreign currency fluctuations on subsidiaries</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OtherComprehensiveIncomeBeforeTaxExchangeDifferencesOnTranslation" xlink:label="ifrs-full_OtherComprehensiveIncomeBeforeTaxExchangeDifferencesOnTranslation" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherComprehensiveIncomeBeforeTaxExchangeDifferencesOnTranslation" xlink:to="ifrs-full_OtherComprehensiveIncomeBeforeTaxExchangeDifferencesOnTranslation_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherComprehensiveIncomeBeforeTaxExchangeDifferencesOnTranslation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other comprehensive income, before tax, exchange differences on translation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_OtherComprehensiveIncomeBeforeTaxExchangeDifferencesOnTranslation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustment of foreign currency fluctuations on subsidiaries</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IncomeTaxRelatingToExchangeDifferencesOnTranslationOfOtherComprehensiveIncome" xlink:label="ifrs-full_IncomeTaxRelatingToExchangeDifferencesOnTranslationOfOtherComprehensiveIncome" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncomeTaxRelatingToExchangeDifferencesOnTranslationOfOtherComprehensiveIncome" xlink:to="ifrs-full_IncomeTaxRelatingToExchangeDifferencesOnTranslationOfOtherComprehensiveIncome_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IncomeTaxRelatingToExchangeDifferencesOnTranslationOfOtherComprehensiveIncome_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income tax relating to exchange differences on translation of other comprehensive income</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_IncomeTaxRelatingToExchangeDifferencesOnTranslationOfOtherComprehensiveIncome_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Excess tax benefits</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CashFlowHedgesAbstract" xlink:label="ifrs-full_CashFlowHedgesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowHedgesAbstract" xlink:to="ifrs-full_CashFlowHedgesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CashFlowHedgesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash flow hedges [abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CashFlowHedgesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair value adjustments of cash flow hedges:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxChangeInFairValueOfFinancialLiabilityAttributableToChangeInCreditRiskOfLiability" xlink:label="ifrs-full_OtherComprehensiveIncomeNetOfTaxChangeInFairValueOfFinancialLiabilityAttributableToChangeInCreditRiskOfLiability" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherComprehensiveIncomeNetOfTaxChangeInFairValueOfFinancialLiabilityAttributableToChangeInCreditRiskOfLiability" xlink:to="ifrs-full_OtherComprehensiveIncomeNetOfTaxChangeInFairValueOfFinancialLiabilityAttributableToChangeInCreditRiskOfLiability_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherComprehensiveIncomeNetOfTaxChangeInFairValueOfFinancialLiabilityAttributableToChangeInCreditRiskOfLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other comprehensive income, net of tax, change in fair value of financial liability attributable to change in credit risk of liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_OtherComprehensiveIncomeNetOfTaxChangeInFairValueOfFinancialLiabilityAttributableToChangeInCreditRiskOfLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair value adjustments during the period</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ReclassificationAdjustmentsOnCashFlowHedgesNetOfTax" xlink:label="ifrs-full_ReclassificationAdjustmentsOnCashFlowHedgesNetOfTax" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ReclassificationAdjustmentsOnCashFlowHedgesNetOfTax" xlink:to="ifrs-full_ReclassificationAdjustmentsOnCashFlowHedgesNetOfTax_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ReclassificationAdjustmentsOnCashFlowHedgesNetOfTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Reclassification adjustments on cash flow hedges, net of tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_ReclassificationAdjustmentsOnCashFlowHedgesNetOfTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair value adjustments reclassified to the income statement to financial income</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ComprehensiveIncome" xlink:label="ifrs-full_ComprehensiveIncome" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ComprehensiveIncome" xlink:to="ifrs-full_ComprehensiveIncome_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ComprehensiveIncome_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Comprehensive income</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ComprehensiveIncome_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total comprehensive income</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_ComprehensiveIncome_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total comprehensive income</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_StatementOfFinancialPositionAbstract" xlink:label="ifrs-full_StatementOfFinancialPositionAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_StatementOfFinancialPositionAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">BALANCE SHEETS</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AssetsAbstract" xlink:label="ifrs-full_AssetsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AssetsAbstract" xlink:to="ifrs-full_AssetsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AssetsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets [abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_AssetsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">ASSETS</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwill" xlink:label="ifrs-full_IntangibleAssetsOtherThanGoodwill" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IntangibleAssetsOtherThanGoodwill" xlink:to="ifrs-full_IntangibleAssetsOtherThanGoodwill_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IntangibleAssetsOtherThanGoodwill_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Intangible assets other than goodwill</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_IntangibleAssetsOtherThanGoodwill_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Intangible assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_PropertyPlantAndEquipment" xlink:label="ifrs-full_PropertyPlantAndEquipment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PropertyPlantAndEquipment" xlink:to="ifrs-full_PropertyPlantAndEquipment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_PropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, plant and equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_PropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property and equipment</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RightofuseAssets" xlink:label="ifrs-full_RightofuseAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RightofuseAssets" xlink:to="ifrs-full_RightofuseAssets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_RightofuseAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Right-of-use assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_RightofuseAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Right-of-use assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NoncurrentReceivables" xlink:label="ifrs-full_NoncurrentReceivables" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncurrentReceivables" xlink:to="ifrs-full_NoncurrentReceivables_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NoncurrentReceivables_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Trade and other non-current receivables</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_NoncurrentReceivables_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Receivables</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NetDeferredTaxAssets" xlink:label="ifrs-full_NetDeferredTaxAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NetDeferredTaxAssets" xlink:to="ifrs-full_NetDeferredTaxAssets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NetDeferredTaxAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net deferred tax assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_NetDeferredTaxAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred tax assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_InvestmentAccountedForUsingEquityMethod" xlink:label="ifrs-full_InvestmentAccountedForUsingEquityMethod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_InvestmentAccountedForUsingEquityMethod" xlink:to="ifrs-full_InvestmentAccountedForUsingEquityMethod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_InvestmentAccountedForUsingEquityMethod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Investments accounted for using equity method</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_InvestmentAccountedForUsingEquityMethod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other investments</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NoncurrentAssets" xlink:label="ifrs-full_NoncurrentAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncurrentAssets" xlink:to="ifrs-full_NoncurrentAssets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NoncurrentAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non-current assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_NoncurrentAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total non-current assets</label>
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_CorporateTaxReceivable" xlink:label="gmab_CorporateTaxReceivable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmab_CorporateTaxReceivable" xlink:to="gmab_CorporateTaxReceivable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gmab_CorporateTaxReceivable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Corporate Tax Receivable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gmab_CorporateTaxReceivable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Corporate Tax Receivable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="gmab_CorporateTaxReceivable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Corporate tax receivable</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TradeAndOtherCurrentReceivables" xlink:label="ifrs-full_TradeAndOtherCurrentReceivables" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TradeAndOtherCurrentReceivables" xlink:to="ifrs-full_TradeAndOtherCurrentReceivables_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TradeAndOtherCurrentReceivables_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Trade and other current receivables</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_TradeAndOtherCurrentReceivables_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Receivables</label>
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_IfrsMarketableSecuritiesCurrent" xlink:label="gmab_IfrsMarketableSecuritiesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmab_IfrsMarketableSecuritiesCurrent" xlink:to="gmab_IfrsMarketableSecuritiesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gmab_IfrsMarketableSecuritiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of investments in debt and equity securities which have original maturities over to 90 days, including, but not limited to, held-to-maturity, trading and available-for-sale expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gmab_IfrsMarketableSecuritiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ifrs Marketable Securities Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="gmab_IfrsMarketableSecuritiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Marketable securities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CashAndCashEquivalents" xlink:label="ifrs-full_CashAndCashEquivalents" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashAndCashEquivalents" xlink:to="ifrs-full_CashAndCashEquivalents_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CashAndCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and cash equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="ifrs-full_CashAndCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and cash equivalents at the end of the period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="ifrs-full_CashAndCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and cash equivalents at the beginning of the period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CashAndCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and cash equivalents</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CurrentAssets" xlink:label="ifrs-full_CurrentAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentAssets" xlink:to="ifrs-full_CurrentAssets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrentAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_CurrentAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total current assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_Assets" xlink:label="ifrs-full_Assets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Assets" xlink:to="ifrs-full_Assets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_Assets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_Assets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_EquityAndLiabilitiesAbstract" xlink:label="ifrs-full_EquityAndLiabilitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EquityAndLiabilitiesAbstract" xlink:to="ifrs-full_EquityAndLiabilitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_EquityAndLiabilitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity and liabilities [abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_EquityAndLiabilitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">SHAREHOLDERS' EQUITY AND LIABILITIES</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IssuedCapital" xlink:label="ifrs-full_IssuedCapital" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IssuedCapital" xlink:to="ifrs-full_IssuedCapital_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IssuedCapital_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issued capital</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_IssuedCapital_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share capital</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_SharePremium" xlink:label="ifrs-full_SharePremium" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_SharePremium" xlink:to="ifrs-full_SharePremium_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_SharePremium_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share premium</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_SharePremium_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share premium</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OtherReserves" xlink:label="ifrs-full_OtherReserves" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherReserves" xlink:to="ifrs-full_OtherReserves_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherReserves_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other reserves</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_OtherReserves_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other reserves</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RetainedEarnings" xlink:label="ifrs-full_RetainedEarnings" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RetainedEarnings" xlink:to="ifrs-full_RetainedEarnings_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_RetainedEarnings_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Retained earnings</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_RetainedEarnings_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Retained earnings</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_Equity" xlink:label="ifrs-full_Equity" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Equity" xlink:to="ifrs-full_Equity_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_Equity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="ifrs-full_Equity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance at end of period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="ifrs-full_Equity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance at beginning of period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_Equity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total shareholders' equity</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NoncurrentProvisions" xlink:label="ifrs-full_NoncurrentProvisions" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncurrentProvisions" xlink:to="ifrs-full_NoncurrentProvisions_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NoncurrentProvisions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non-current provisions</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_NoncurrentProvisions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Provisions</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NoncurrentLeaseLiabilities" xlink:label="ifrs-full_NoncurrentLeaseLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncurrentLeaseLiabilities" xlink:to="ifrs-full_NoncurrentLeaseLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NoncurrentLeaseLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non-current lease liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_NoncurrentLeaseLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lease liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_NoncurrentLeaseLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non-current</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RentDeferredIncomeClassifiedAsNoncurrent" xlink:label="ifrs-full_RentDeferredIncomeClassifiedAsNoncurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RentDeferredIncomeClassifiedAsNoncurrent" xlink:to="ifrs-full_RentDeferredIncomeClassifiedAsNoncurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_RentDeferredIncomeClassifiedAsNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Rent deferred income classified as non-current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_RentDeferredIncomeClassifiedAsNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred revenue</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OtherNoncurrentPayables" xlink:label="ifrs-full_OtherNoncurrentPayables" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherNoncurrentPayables" xlink:to="ifrs-full_OtherNoncurrentPayables_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherNoncurrentPayables_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other non-current payables</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_OtherNoncurrentPayables_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other payables</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NoncurrentLiabilities" xlink:label="ifrs-full_NoncurrentLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncurrentLiabilities" xlink:to="ifrs-full_NoncurrentLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NoncurrentLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non-current liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_NoncurrentLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total non-current liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CurrentProvisions" xlink:label="ifrs-full_CurrentProvisions" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentProvisions" xlink:to="ifrs-full_CurrentProvisions_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrentProvisions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current provisions</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CurrentProvisions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Provisions</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CurrentTaxLiabilitiesCurrent" xlink:label="ifrs-full_CurrentTaxLiabilitiesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentTaxLiabilitiesCurrent" xlink:to="ifrs-full_CurrentTaxLiabilitiesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrentTaxLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current tax liabilities, current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CurrentTaxLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Corporate tax payable</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CurrentLeaseLiabilities" xlink:label="ifrs-full_CurrentLeaseLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentLeaseLiabilities" xlink:to="ifrs-full_CurrentLeaseLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrentLeaseLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current lease liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CurrentLeaseLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lease liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_CurrentLeaseLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RentDeferredIncomeClassifiedAsCurrent" xlink:label="ifrs-full_RentDeferredIncomeClassifiedAsCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RentDeferredIncomeClassifiedAsCurrent" xlink:to="ifrs-full_RentDeferredIncomeClassifiedAsCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_RentDeferredIncomeClassifiedAsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Rent deferred income classified as current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_RentDeferredIncomeClassifiedAsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred revenue</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OtherCurrentPayables" xlink:label="ifrs-full_OtherCurrentPayables" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherCurrentPayables" xlink:to="ifrs-full_OtherCurrentPayables_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherCurrentPayables_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other current payables</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_OtherCurrentPayables_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other payables</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CurrentLiabilities" xlink:label="ifrs-full_CurrentLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentLiabilities" xlink:to="ifrs-full_CurrentLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrentLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_CurrentLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total current liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_Liabilities" xlink:label="ifrs-full_Liabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Liabilities" xlink:to="ifrs-full_Liabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_Liabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_Liabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_EquityAndLiabilities" xlink:label="ifrs-full_EquityAndLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EquityAndLiabilities" xlink:to="ifrs-full_EquityAndLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_EquityAndLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity and liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_EquityAndLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total shareholders' equity and liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_StatementOfCashFlowsAbstract" xlink:label="ifrs-full_StatementOfCashFlowsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_StatementOfCashFlowsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">STATEMENTS OF CASH FLOWS</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash flows from (used in) operating activities [abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash flows from operating activities:</label>
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_ReversalOfFinancialItemsNet" xlink:label="gmab_ReversalOfFinancialItemsNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmab_ReversalOfFinancialItemsNet" xlink:to="gmab_ReversalOfFinancialItemsNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gmab_ReversalOfFinancialItemsNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The reversal of financial items to the cash flow under operating activities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gmab_ReversalOfFinancialItemsNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Reversal Of Financial Items, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="gmab_ReversalOfFinancialItemsNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Reversal of financial items, net</label>
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_TotalAdjustmentsForNonCashTransactions" xlink:label="gmab_TotalAdjustmentsForNonCashTransactions" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmab_TotalAdjustmentsForNonCashTransactions" xlink:to="gmab_TotalAdjustmentsForNonCashTransactions_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gmab_TotalAdjustmentsForNonCashTransactions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments for total non-cash items to reconcile profit (loss) to net cash flow from (used in) operating activities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gmab_TotalAdjustmentsForNonCashTransactions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total Adjustments For Non Cash Transactions</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="gmab_TotalAdjustmentsForNonCashTransactions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments for non-cash transactions</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IncreaseDecreaseInWorkingCapital" xlink:label="ifrs-full_IncreaseDecreaseInWorkingCapital" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncreaseDecreaseInWorkingCapital" xlink:to="ifrs-full_IncreaseDecreaseInWorkingCapital_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IncreaseDecreaseInWorkingCapital_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (decrease) in working capital</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="ifrs-full_IncreaseDecreaseInWorkingCapital_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Changes in operating assets and liabilities</label>
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_CashFlowFromUsedInOperatingActivitiesBeforeFinancialItems" xlink:label="gmab_CashFlowFromUsedInOperatingActivitiesBeforeFinancialItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmab_CashFlowFromUsedInOperatingActivitiesBeforeFinancialItems" xlink:to="gmab_CashFlowFromUsedInOperatingActivitiesBeforeFinancialItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gmab_CashFlowFromUsedInOperatingActivitiesBeforeFinancialItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The cash flows from (used in) operating activities, which are the principal revenue-producing activities of the entity and other activities before reconciling the financial items.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gmab_CashFlowFromUsedInOperatingActivitiesBeforeFinancialItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash Flow From (Used In) Operating Activities Before Financial Items</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="gmab_CashFlowFromUsedInOperatingActivitiesBeforeFinancialItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash flows from operating activities before financial items</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_InterestReceivedClassifiedAsOperatingActivities" xlink:label="ifrs-full_InterestReceivedClassifiedAsOperatingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_InterestReceivedClassifiedAsOperatingActivities" xlink:to="ifrs-full_InterestReceivedClassifiedAsOperatingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_InterestReceivedClassifiedAsOperatingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest received, classified as operating activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_InterestReceivedClassifiedAsOperatingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest received</label>
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_AdjustmentsForInterestOnLeasePayments" xlink:label="gmab_AdjustmentsForInterestOnLeasePayments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmab_AdjustmentsForInterestOnLeasePayments" xlink:to="gmab_AdjustmentsForInterestOnLeasePayments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gmab_AdjustmentsForInterestOnLeasePayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments for interest on lease payments to reconcile profit (loss) to net cash flow from (used in) operating activities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gmab_AdjustmentsForInterestOnLeasePayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments For Interest On Lease Payments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="gmab_AdjustmentsForInterestOnLeasePayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest elements of lease payments</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_InterestPaidClassifiedAsOperatingActivities" xlink:label="ifrs-full_InterestPaidClassifiedAsOperatingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_InterestPaidClassifiedAsOperatingActivities" xlink:to="ifrs-full_InterestPaidClassifiedAsOperatingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_InterestPaidClassifiedAsOperatingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest paid, classified as operating activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="ifrs-full_InterestPaidClassifiedAsOperatingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest paid</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AdjustmentsForIncomeTaxExpense" xlink:label="ifrs-full_AdjustmentsForIncomeTaxExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForIncomeTaxExpense" xlink:to="ifrs-full_AdjustmentsForIncomeTaxExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdjustmentsForIncomeTaxExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments for income tax expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_AdjustmentsForIncomeTaxExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Corporate taxes paid</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:to="ifrs-full_CashFlowsFromUsedInOperatingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash flows from (used in) operating activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net cash provided by operating activities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:label="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash flows from (used in) investing activities [abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash flows from investing activities:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" xlink:label="ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" xlink:to="ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Purchase of intangible assets, classified as investing activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Investment in intangible assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:label="ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:to="ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Purchase of property, plant and equipment, classified as investing activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Investment in tangible assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities" xlink:label="ifrs-full_CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities" xlink:to="ifrs-full_CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash flows used in obtaining control of subsidiaries or other businesses, classified as investing activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Transactions with subsidiaries</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_PurchaseOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod" xlink:label="ifrs-full_PurchaseOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PurchaseOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod" xlink:to="ifrs-full_PurchaseOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_PurchaseOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Purchase of investments other than investments accounted for using equity method</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_PurchaseOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Marketable securities bought</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProceedsFromSalesOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod" xlink:label="ifrs-full_ProceedsFromSalesOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProceedsFromSalesOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod" xlink:to="ifrs-full_ProceedsFromSalesOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ProceedsFromSalesOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from sales of investments other than investments accounted for using equity method</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ProceedsFromSalesOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Marketable securities sold</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_PurchaseOfInterestsInInvestmentsAccountedForUsingEquityMethod" xlink:label="ifrs-full_PurchaseOfInterestsInInvestmentsAccountedForUsingEquityMethod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PurchaseOfInterestsInInvestmentsAccountedForUsingEquityMethod" xlink:to="ifrs-full_PurchaseOfInterestsInInvestmentsAccountedForUsingEquityMethod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_PurchaseOfInterestsInInvestmentsAccountedForUsingEquityMethod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Purchase of interests in investments accounted for using equity method</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_PurchaseOfInterestsInInvestmentsAccountedForUsingEquityMethod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other investments bought</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProceedsFromSalesOfInvestmentsAccountedForUsingEquityMethod" xlink:label="ifrs-full_ProceedsFromSalesOfInvestmentsAccountedForUsingEquityMethod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProceedsFromSalesOfInvestmentsAccountedForUsingEquityMethod" xlink:to="ifrs-full_ProceedsFromSalesOfInvestmentsAccountedForUsingEquityMethod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ProceedsFromSalesOfInvestmentsAccountedForUsingEquityMethod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from sales of investments accounted for using equity method</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ProceedsFromSalesOfInvestmentsAccountedForUsingEquityMethod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other investments sold</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:label="ifrs-full_CashFlowsFromUsedInInvestingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:to="ifrs-full_CashFlowsFromUsedInInvestingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CashFlowsFromUsedInInvestingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash flows from (used in) investing activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_CashFlowsFromUsedInInvestingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net cash (used in) / provided by investing activities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:label="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash flows from (used in) financing activities [abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash flows from financing activities:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProceedsFromExerciseOfWarrants" xlink:label="ifrs-full_ProceedsFromExerciseOfWarrants" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProceedsFromExerciseOfWarrants" xlink:to="ifrs-full_ProceedsFromExerciseOfWarrants_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ProceedsFromExerciseOfWarrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds From Exercise Of Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ProceedsFromExerciseOfWarrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_ProceedsFromExerciseOfWarrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise of warrants</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProceedsFromIssuingShares" xlink:label="ifrs-full_ProceedsFromIssuingShares" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProceedsFromIssuingShares" xlink:to="ifrs-full_ProceedsFromIssuingShares_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ProceedsFromIssuingShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from issuing shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ProceedsFromIssuingShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares issued for cash</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_PaymentsForShareIssueCosts" xlink:label="ifrs-full_PaymentsForShareIssueCosts" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PaymentsForShareIssueCosts" xlink:to="ifrs-full_PaymentsForShareIssueCosts_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_PaymentsForShareIssueCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments for share issue costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_PaymentsForShareIssueCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Costs related to issuance of shares</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" xlink:label="ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" xlink:to="ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments of lease liabilities, classified as financing activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Principal elements of lease payments</label>
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_PaymentsToAcquireTreasuryShares" xlink:label="gmab_PaymentsToAcquireTreasuryShares" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmab_PaymentsToAcquireTreasuryShares" xlink:to="gmab_PaymentsToAcquireTreasuryShares_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gmab_PaymentsToAcquireTreasuryShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The cash outflow to acquire treasury shares.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gmab_PaymentsToAcquireTreasuryShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments To Acquire Treasury Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="gmab_PaymentsToAcquireTreasuryShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Purchase of treasury shares</label>
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_PaymentOfWithholdingTaxesOnBehalfOfEmployeesOnNetSettledRSUs" xlink:label="gmab_PaymentOfWithholdingTaxesOnBehalfOfEmployeesOnNetSettledRSUs" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmab_PaymentOfWithholdingTaxesOnBehalfOfEmployeesOnNetSettledRSUs" xlink:to="gmab_PaymentOfWithholdingTaxesOnBehalfOfEmployeesOnNetSettledRSUs_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gmab_PaymentOfWithholdingTaxesOnBehalfOfEmployeesOnNetSettledRSUs_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The cash outflow for withholding taxes on behalf of employees on net settled restricted stock units (RSUs).</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gmab_PaymentOfWithholdingTaxesOnBehalfOfEmployeesOnNetSettledRSUs_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payment Of Withholding Taxes On Behalf Of Employees On Net Settled R S Us</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="gmab_PaymentOfWithholdingTaxesOnBehalfOfEmployeesOnNetSettledRSUs_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payment of withholding taxes on behalf of employees on net settled RSUs</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:label="ifrs-full_CashFlowsFromUsedInFinancingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:to="ifrs-full_CashFlowsFromUsedInFinancingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CashFlowsFromUsedInFinancingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash flows from (used in) financing activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_CashFlowsFromUsedInFinancingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net cash (used in) financing activities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" xlink:label="ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" xlink:to="ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (decrease) in cash and cash equivalents before effect of exchange rate changes</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Change in cash and cash equivalents</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents" xlink:label="ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents" xlink:to="ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effect of exchange rate changes on cash and cash equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exchange rate adjustments</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CashAndCashEquivalentsAbstract" xlink:label="ifrs-full_CashAndCashEquivalentsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashAndCashEquivalentsAbstract" xlink:to="ifrs-full_CashAndCashEquivalentsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CashAndCashEquivalentsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and cash equivalents [abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CashAndCashEquivalentsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and cash equivalents include:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_Cash" xlink:label="ifrs-full_Cash" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Cash" xlink:to="ifrs-full_Cash_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_Cash_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_Cash_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Bank deposits</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ShorttermInvestmentsClassifiedAsCashEquivalents" xlink:label="ifrs-full_ShorttermInvestmentsClassifiedAsCashEquivalents" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ShorttermInvestmentsClassifiedAsCashEquivalents" xlink:to="ifrs-full_ShorttermInvestmentsClassifiedAsCashEquivalents_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ShorttermInvestmentsClassifiedAsCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Short-term investments, classified as cash equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ShorttermInvestmentsClassifiedAsCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Short-term marketable securities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_StatementOfChangesInEquityAbstract" xlink:label="ifrs-full_StatementOfChangesInEquityAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_StatementOfChangesInEquityAbstract" xlink:to="ifrs-full_StatementOfChangesInEquityAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_StatementOfChangesInEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">STATEMENTS OF CHANGES IN EQUITY</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_StatementOfChangesInEquityTable" xlink:label="ifrs-full_StatementOfChangesInEquityTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_StatementOfChangesInEquityTable" xlink:to="ifrs-full_StatementOfChangesInEquityTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_StatementOfChangesInEquityTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statement of changes in equity [table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ComponentsOfEquityAxis" xlink:label="ifrs-full_ComponentsOfEquityAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ComponentsOfEquityAxis" xlink:to="ifrs-full_ComponentsOfEquityAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ComponentsOfEquityAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Components of equity [axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_EquityMember" xlink:label="ifrs-full_EquityMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EquityMember" xlink:to="ifrs-full_EquityMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_EquityMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity [member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IssuedCapitalMember" xlink:label="ifrs-full_IssuedCapitalMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IssuedCapitalMember" xlink:to="ifrs-full_IssuedCapitalMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IssuedCapitalMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issued capital [member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_SharePremiumMember" xlink:label="ifrs-full_SharePremiumMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_SharePremiumMember" xlink:to="ifrs-full_SharePremiumMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_SharePremiumMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share premium [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember" xlink:label="ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember" xlink:to="ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Translation reserves</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CashFlowHedgesMember" xlink:label="ifrs-full_CashFlowHedgesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowHedgesMember" xlink:to="ifrs-full_CashFlowHedgesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CashFlowHedgesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash flow hedges [member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RetainedEarningsMember" xlink:label="ifrs-full_RetainedEarningsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RetainedEarningsMember" xlink:to="ifrs-full_RetainedEarningsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_RetainedEarningsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Retained Earnings [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:label="ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:to="ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Retrospective application and retrospective restatement [axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RestatedMember" xlink:label="ifrs-full_RestatedMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RestatedMember" xlink:to="ifrs-full_RestatedMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_RestatedMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Currently stated [member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IncreaseDecreaseDueToApplicationOfIFRS15Member" xlink:label="ifrs-full_IncreaseDecreaseDueToApplicationOfIFRS15Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncreaseDecreaseDueToApplicationOfIFRS15Member" xlink:to="ifrs-full_IncreaseDecreaseDueToApplicationOfIFRS15Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IncreaseDecreaseDueToApplicationOfIFRS15Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (decrease) due to application of IFRS 15 [member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_StatementOfChangesInEquityLineItems" xlink:label="ifrs-full_StatementOfChangesInEquityLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_StatementOfChangesInEquityLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_StatementOfChangesInEquityLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statement of changes in equity [line items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_StatementOfChangesInEquityLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">STATEMENT OF CHANGES IN EQUITY</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NumberOfSharesOutstanding" xlink:label="ifrs-full_NumberOfSharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfSharesOutstanding" xlink:to="ifrs-full_NumberOfSharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NumberOfSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of shares outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="ifrs-full_NumberOfSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of shares, at end of period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="ifrs-full_NumberOfSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of shares, at beginning of period</label>
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_IfrsCumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption" xlink:label="gmab_IfrsCumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmab_IfrsCumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption" xlink:to="gmab_IfrsCumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gmab_IfrsCumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount after tax of increase (decrease) to equity or (increase) decrease to net assets, resulting from the cumulative effect adjustment of a new accounting principle applied in the period of adoption.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gmab_IfrsCumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ifrs Cumulative Effect of New Accounting Principle in Period of Adoption</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="gmab_IfrsCumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Change in accounting policy: Adoption of IFRS 15</label>
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_EquityAdjustedForCumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption" xlink:label="gmab_EquityAdjustedForCumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmab_EquityAdjustedForCumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption" xlink:to="gmab_EquityAdjustedForCumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gmab_EquityAdjustedForCumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of stockholder's equity, after the cumulative effect adjustment of a new accounting principle applied in the period of adoption.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gmab_EquityAdjustedForCumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity Adjusted For Cumulative Effect Of New Accounting Principle In Period Of Adoption</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="gmab_EquityAdjustedForCumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjusted total equity at January 1, 2018</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OtherComprehensiveIncome" xlink:label="ifrs-full_OtherComprehensiveIncome" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherComprehensiveIncome" xlink:to="ifrs-full_OtherComprehensiveIncome_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherComprehensiveIncome_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other comprehensive income</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_OtherComprehensiveIncome_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other comprehensive income</label>
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_TransactionsWithOwners" xlink:label="gmab_TransactionsWithOwners" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmab_TransactionsWithOwners" xlink:to="gmab_TransactionsWithOwners_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gmab_TransactionsWithOwners_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">n/a</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gmab_TransactionsWithOwners_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Transactions With Owners</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="gmab_TransactionsWithOwners_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Transactions with owners:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity" xlink:label="ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity" xlink:to="ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (decrease) through exercise of warrants, equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise of warrants</label>
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_ExerciseOfWarrants" xlink:label="gmab_ExerciseOfWarrants" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmab_ExerciseOfWarrants" xlink:to="gmab_ExerciseOfWarrants_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gmab_ExerciseOfWarrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of shares of warrants exercised.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gmab_ExerciseOfWarrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise of Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="gmab_ExerciseOfWarrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise of warrants (in shares)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IssueOfEquity" xlink:label="ifrs-full_IssueOfEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IssueOfEquity" xlink:to="ifrs-full_IssueOfEquity_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IssueOfEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issue of equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_IssueOfEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares issued for cash</label>
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_ExpensesRelatedToCapitalIncreaseDecrease" xlink:label="gmab_ExpensesRelatedToCapitalIncreaseDecrease" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmab_ExpensesRelatedToCapitalIncreaseDecrease" xlink:to="gmab_ExpensesRelatedToCapitalIncreaseDecrease_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gmab_ExpensesRelatedToCapitalIncreaseDecrease_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expenses Related To Capital Increase Decrease</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gmab_ExpensesRelatedToCapitalIncreaseDecrease_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expenses Related To Capital Increase Decrease</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="gmab_ExpensesRelatedToCapitalIncreaseDecrease_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expenses related to capital increases</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ChangesInEquity" xlink:label="ifrs-full_ChangesInEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ChangesInEquity" xlink:to="ifrs-full_ChangesInEquity_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ChangesInEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (decrease) in equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_ChangesInEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expenses related to capital increases</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_PurchaseOfTreasuryShares" xlink:label="ifrs-full_PurchaseOfTreasuryShares" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PurchaseOfTreasuryShares" xlink:to="ifrs-full_PurchaseOfTreasuryShares_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_PurchaseOfTreasuryShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Purchase of treasury shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_PurchaseOfTreasuryShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Purchase of treasury shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_PurchaseOfTreasuryShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Acquisition of treasury shares</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions" xlink:label="ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions" xlink:to="ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (decrease) through share-based payment transactions, equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based compensation expenses</label>
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_IncreaseDecreaseThroughNetSettlementOfRestrictedStockUnitsEquity" xlink:label="gmab_IncreaseDecreaseThroughNetSettlementOfRestrictedStockUnitsEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmab_IncreaseDecreaseThroughNetSettlementOfRestrictedStockUnitsEquity" xlink:to="gmab_IncreaseDecreaseThroughNetSettlementOfRestrictedStockUnitsEquity_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gmab_IncreaseDecreaseThroughNetSettlementOfRestrictedStockUnitsEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The increase (decrease) in equity resulting from net settlement of restricted stock units.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gmab_IncreaseDecreaseThroughNetSettlementOfRestrictedStockUnitsEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase Decrease Through Net Settlement Of Restricted Stock Units, Equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="gmab_IncreaseDecreaseThroughNetSettlementOfRestrictedStockUnitsEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net settlement of RSUs</label>
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_TaxOnItemsRecognizedDirectlyInEquity" xlink:label="gmab_TaxOnItemsRecognizedDirectlyInEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmab_TaxOnItemsRecognizedDirectlyInEquity" xlink:to="gmab_TaxOnItemsRecognizedDirectlyInEquity_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gmab_TaxOnItemsRecognizedDirectlyInEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tax on items recognized directly in equity.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gmab_TaxOnItemsRecognizedDirectlyInEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tax On Items Recognized Directly In Equity</label>
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_IncreaseDecreaseThroughTaxOnItemsRecognizedDirectlyInEquity" xlink:label="gmab_IncreaseDecreaseThroughTaxOnItemsRecognizedDirectlyInEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmab_IncreaseDecreaseThroughTaxOnItemsRecognizedDirectlyInEquity" xlink:to="gmab_IncreaseDecreaseThroughTaxOnItemsRecognizedDirectlyInEquity_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gmab_IncreaseDecreaseThroughTaxOnItemsRecognizedDirectlyInEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The increase (decrease) in equity resulting from tax on items recognized directly in equity.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gmab_IncreaseDecreaseThroughTaxOnItemsRecognizedDirectlyInEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase Decrease Through Tax On Items Recognized Directly In Equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="gmab_IncreaseDecreaseThroughTaxOnItemsRecognizedDirectlyInEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tax on items recognized directly in equity</label>
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_BasisOfPresentationAbstract" xlink:label="gmab_BasisOfPresentationAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmab_BasisOfPresentationAbstract" xlink:to="gmab_BasisOfPresentationAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gmab_BasisOfPresentationAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">No definition available.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gmab_BasisOfPresentationAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Basis of Presentation</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory" xlink:label="ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory" xlink:to="ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of basis of preparation of financial statements [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Basis of Presentation</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RevenueAbstract" xlink:label="ifrs-full_RevenueAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RevenueAbstract" xlink:to="ifrs-full_RevenueAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_RevenueAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfRevenueFromContractsWithCustomersExplanatory" xlink:label="ifrs-full_DisclosureOfRevenueFromContractsWithCustomersExplanatory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfRevenueFromContractsWithCustomersExplanatory" xlink:to="ifrs-full_DisclosureOfRevenueFromContractsWithCustomersExplanatory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfRevenueFromContractsWithCustomersExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of revenue from contracts with customers [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfRevenueFromContractsWithCustomersExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfFinancialInstrumentsAbstract" xlink:label="ifrs-full_DisclosureOfFinancialInstrumentsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsAbstract" xlink:to="ifrs-full_DisclosureOfFinancialInstrumentsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfFinancialInstrumentsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Financial Instruments</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory" xlink:label="ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory" xlink:to="ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of detailed information about financial instruments [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Financial Instruments</label>
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_DisclosureOfFinanceIncomeExpensesAbstract" xlink:label="gmab_DisclosureOfFinanceIncomeExpensesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmab_DisclosureOfFinanceIncomeExpensesAbstract" xlink:to="gmab_DisclosureOfFinanceIncomeExpensesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gmab_DisclosureOfFinanceIncomeExpensesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">NA</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gmab_DisclosureOfFinanceIncomeExpensesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Financial Income and Expenses</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory" xlink:label="ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory" xlink:to="ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of finance income (cost) [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Financial Income and Expenses</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:to="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Instruments</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory" xlink:label="ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory" xlink:to="ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of share-based payment arrangements [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Instruments</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract" xlink:label="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract" xlink:to="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related Parties</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfRelatedPartyExplanatory" xlink:label="ifrs-full_DisclosureOfRelatedPartyExplanatory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfRelatedPartyExplanatory" xlink:to="ifrs-full_DisclosureOfRelatedPartyExplanatory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfRelatedPartyExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of related party [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfRelatedPartyExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related Parties</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_PresentationOfLeasesForLesseeAbstract" xlink:label="ifrs-full_PresentationOfLeasesForLesseeAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PresentationOfLeasesForLesseeAbstract" xlink:to="ifrs-full_PresentationOfLeasesForLesseeAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_PresentationOfLeasesForLesseeAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Leases</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfLeasesExplanatory" xlink:label="ifrs-full_DisclosureOfLeasesExplanatory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfLeasesExplanatory" xlink:to="ifrs-full_DisclosureOfLeasesExplanatory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfLeasesExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of leases [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfLeasesExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Leases</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract" xlink:label="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract" xlink:to="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Events to the Balance Sheet Date</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory" xlink:label="ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory" xlink:to="ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of events after reporting period [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Events to the Balance Sheet Date</label>
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_DescriptionOfAccountingPolicyForBasisOfPresentationPolicyTextBlock" xlink:label="gmab_DescriptionOfAccountingPolicyForBasisOfPresentationPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmab_DescriptionOfAccountingPolicyForBasisOfPresentationPolicyTextBlock" xlink:to="gmab_DescriptionOfAccountingPolicyForBasisOfPresentationPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gmab_DescriptionOfAccountingPolicyForBasisOfPresentationPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The description of the entity's accounting policy for Basis of presentation.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gmab_DescriptionOfAccountingPolicyForBasisOfPresentationPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Description Of Accounting Policy For Basis Of Presentation Policy [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="gmab_DescriptionOfAccountingPolicyForBasisOfPresentationPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounting Policies</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory" xlink:label="ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory" xlink:to="ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of significant accounting policies [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Nature of Business and Accounting Policies</label>
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_DescriptionOfAccountingPolicyForRecentAccountingStandardsAdoptedPolicyTextBlock" xlink:label="gmab_DescriptionOfAccountingPolicyForRecentAccountingStandardsAdoptedPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmab_DescriptionOfAccountingPolicyForRecentAccountingStandardsAdoptedPolicyTextBlock" xlink:to="gmab_DescriptionOfAccountingPolicyForRecentAccountingStandardsAdoptedPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gmab_DescriptionOfAccountingPolicyForRecentAccountingStandardsAdoptedPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The description of the entity's accounting policy for recently adopted new accounting standards.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gmab_DescriptionOfAccountingPolicyForRecentAccountingStandardsAdoptedPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">New Accounting Standards - Recently Adopted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="gmab_DescriptionOfAccountingPolicyForRecentAccountingStandardsAdoptedPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">New Accounting Policies and Disclosures</label>
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_DisclosureOfNewAccountingPoliciesAndDisclosuresPolicyTextBlock" xlink:label="gmab_DisclosureOfNewAccountingPoliciesAndDisclosuresPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmab_DisclosureOfNewAccountingPoliciesAndDisclosuresPolicyTextBlock" xlink:to="gmab_DisclosureOfNewAccountingPoliciesAndDisclosuresPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gmab_DisclosureOfNewAccountingPoliciesAndDisclosuresPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of accounting policy for new accounting policy and disclosures.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gmab_DisclosureOfNewAccountingPoliciesAndDisclosuresPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure Of New Accounting policies And Disclosures [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="gmab_DisclosureOfNewAccountingPoliciesAndDisclosuresPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">New Accounting Policies and Disclosures</label>
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_DescriptionOfAccountingPolicyForJudgmentsAndEstimatesPolicyTextBlock" xlink:label="gmab_DescriptionOfAccountingPolicyForJudgmentsAndEstimatesPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmab_DescriptionOfAccountingPolicyForJudgmentsAndEstimatesPolicyTextBlock" xlink:to="gmab_DescriptionOfAccountingPolicyForJudgmentsAndEstimatesPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gmab_DescriptionOfAccountingPolicyForJudgmentsAndEstimatesPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The description of the entity's accounting policy for Basis of presentation.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gmab_DescriptionOfAccountingPolicyForJudgmentsAndEstimatesPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Description Of Accounting Policy For Judgments And Estimates [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="gmab_DescriptionOfAccountingPolicyForJudgmentsAndEstimatesPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Management Judgments and Estimates under IFRS</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForSegmentReportingExplanatory" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForSegmentReportingExplanatory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForSegmentReportingExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForSegmentReportingExplanatory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForSegmentReportingExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Description of accounting policy for segment reporting [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForSegmentReportingExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Information about Geographical Areas</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Description of accounting policy for fair value measurement [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Measurement</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Description of accounting policy for financial instruments [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Marketable Securities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForInvestmentInAssociates" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForInvestmentInAssociates" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForInvestmentInAssociates" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForInvestmentInAssociates_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForInvestmentInAssociates_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Description of accounting policy for investment in associates [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForInvestmentInAssociates_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Investments</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory" xlink:label="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory" xlink:to="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of disaggregation of revenue from contracts with customers [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of revenue by type and collaboration partner under agreements</label>
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_ScheduleOfSegmentDisclosuresInFinancialStatementsTableTextBlock" xlink:label="gmab_ScheduleOfSegmentDisclosuresInFinancialStatementsTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmab_ScheduleOfSegmentDisclosuresInFinancialStatementsTableTextBlock" xlink:to="gmab_ScheduleOfSegmentDisclosuresInFinancialStatementsTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gmab_ScheduleOfSegmentDisclosuresInFinancialStatementsTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tabular disclosure for segment disclosures in the financial statements as the group's business activities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gmab_ScheduleOfSegmentDisclosuresInFinancialStatementsTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule Of Segment Disclosures In Financial Statements [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="gmab_ScheduleOfSegmentDisclosuresInFinancialStatementsTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of segment disclosures in the financial statements as the group's business activities.</label>
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_DisclosureOfStaffCostTableTextBlock" xlink:label="gmab_DisclosureOfStaffCostTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmab_DisclosureOfStaffCostTableTextBlock" xlink:to="gmab_DisclosureOfStaffCostTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gmab_DisclosureOfStaffCostTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of staff cost.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gmab_DisclosureOfStaffCostTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure Of Staff Cost [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="gmab_DisclosureOfStaffCostTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of staff cost</label>
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_ValuationAssumptionsForWarrantsGrantedTableTextBlock" xlink:label="gmab_ValuationAssumptionsForWarrantsGrantedTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmab_ValuationAssumptionsForWarrantsGrantedTableTextBlock" xlink:to="gmab_ValuationAssumptionsForWarrantsGrantedTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gmab_ValuationAssumptionsForWarrantsGrantedTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tabular disclosure of fair value of each warrant granted.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gmab_ValuationAssumptionsForWarrantsGrantedTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Valuation Assumptions for Warrants Granted [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="gmab_ValuationAssumptionsForWarrantsGrantedTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair value of each warrant granted</label>
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_DisclosureOfCorporateAndDeferredTaxTableTextBlock" xlink:label="gmab_DisclosureOfCorporateAndDeferredTaxTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmab_DisclosureOfCorporateAndDeferredTaxTableTextBlock" xlink:to="gmab_DisclosureOfCorporateAndDeferredTaxTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gmab_DisclosureOfCorporateAndDeferredTaxTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tabular disclosure for corporate and deferred Tax.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gmab_DisclosureOfCorporateAndDeferredTaxTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure Of Corporate And Deferred Tax [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="gmab_DisclosureOfCorporateAndDeferredTaxTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of corporate and deferred Tax</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfDeferredTaxesExplanatory" xlink:label="ifrs-full_DisclosureOfDeferredTaxesExplanatory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfDeferredTaxesExplanatory" xlink:to="ifrs-full_DisclosureOfDeferredTaxesExplanatory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfDeferredTaxesExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of deferred taxes [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_DisclosureOfDeferredTaxesExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of components of the deferred tax asset</label>
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_DisclosureOfNetResultTableTextBlock" xlink:label="gmab_DisclosureOfNetResultTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmab_DisclosureOfNetResultTableTextBlock" xlink:to="gmab_DisclosureOfNetResultTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gmab_DisclosureOfNetResultTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tabular disclosure of net result for the year.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gmab_DisclosureOfNetResultTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure Of Net Result [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="gmab_DisclosureOfNetResultTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of net result</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfEarningsPerShareExplanatory" xlink:label="ifrs-full_DisclosureOfEarningsPerShareExplanatory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfEarningsPerShareExplanatory" xlink:to="ifrs-full_DisclosureOfEarningsPerShareExplanatory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfEarningsPerShareExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of earnings per share [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfEarningsPerShareExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Result Per Share</label>
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_DisclosureOfMarketableSecuritiesByCurrencyTableTextBlock" xlink:label="gmab_DisclosureOfMarketableSecuritiesByCurrencyTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmab_DisclosureOfMarketableSecuritiesByCurrencyTableTextBlock" xlink:to="gmab_DisclosureOfMarketableSecuritiesByCurrencyTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gmab_DisclosureOfMarketableSecuritiesByCurrencyTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tabular disclosure of marketable securities in foreign currency.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gmab_DisclosureOfMarketableSecuritiesByCurrencyTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure Of Marketable Securities By Currency [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="gmab_DisclosureOfMarketableSecuritiesByCurrencyTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of total marketable securities by currency</label>
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_DisclosureOfImpactOfExchangeRateOnNetResultBeforeTaxTableTextBlock" xlink:label="gmab_DisclosureOfImpactOfExchangeRateOnNetResultBeforeTaxTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmab_DisclosureOfImpactOfExchangeRateOnNetResultBeforeTaxTableTextBlock" xlink:to="gmab_DisclosureOfImpactOfExchangeRateOnNetResultBeforeTaxTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gmab_DisclosureOfImpactOfExchangeRateOnNetResultBeforeTaxTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tabular disclosure of impact of exchange rate on our net result before tax.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gmab_DisclosureOfImpactOfExchangeRateOnNetResultBeforeTaxTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure Of Impact Of Exchange Rate On Net Result Before Tax [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="gmab_DisclosureOfImpactOfExchangeRateOnNetResultBeforeTaxTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of impact of exchange rate on our net result before tax</label>
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_DisclosureOfMaturityProfileOfOurMarketableSecuritiesTableTextBlock" xlink:label="gmab_DisclosureOfMaturityProfileOfOurMarketableSecuritiesTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmab_DisclosureOfMaturityProfileOfOurMarketableSecuritiesTableTextBlock" xlink:to="gmab_DisclosureOfMaturityProfileOfOurMarketableSecuritiesTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gmab_DisclosureOfMaturityProfileOfOurMarketableSecuritiesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tabular disclosure of maturity profile of our marketable securities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gmab_DisclosureOfMaturityProfileOfOurMarketableSecuritiesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure Of Maturity Profile Of Our Marketable Securities [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="gmab_DisclosureOfMaturityProfileOfOurMarketableSecuritiesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of maturity profile of our marketable securities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfOffsettingOfFinancialAssetsAndFinancialLiabilitiesExplanatory" xlink:label="ifrs-full_DisclosureOfOffsettingOfFinancialAssetsAndFinancialLiabilitiesExplanatory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfOffsettingOfFinancialAssetsAndFinancialLiabilitiesExplanatory" xlink:to="ifrs-full_DisclosureOfOffsettingOfFinancialAssetsAndFinancialLiabilitiesExplanatory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfOffsettingOfFinancialAssetsAndFinancialLiabilitiesExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of offsetting of financial assets and financial liabilities [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfOffsettingOfFinancialAssetsAndFinancialLiabilitiesExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Financial Assets</label>
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_DisclosureOfFairValueMeasurementOfAssetsLevel3ReconciliationTableTextBlock" xlink:label="gmab_DisclosureOfFairValueMeasurementOfAssetsLevel3ReconciliationTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmab_DisclosureOfFairValueMeasurementOfAssetsLevel3ReconciliationTableTextBlock" xlink:to="gmab_DisclosureOfFairValueMeasurementOfAssetsLevel3ReconciliationTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gmab_DisclosureOfFairValueMeasurementOfAssetsLevel3ReconciliationTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tabular disclosure of level 3 reconciliation of assets measured at fair value.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gmab_DisclosureOfFairValueMeasurementOfAssetsLevel3ReconciliationTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure Of Fair Value Measurement Of Assets, Level 3 Reconciliation [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="gmab_DisclosureOfFairValueMeasurementOfAssetsLevel3ReconciliationTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of level 3 reconciliation of assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfFairValueMeasurementOfAssetsExplanatory" xlink:label="ifrs-full_DisclosureOfFairValueMeasurementOfAssetsExplanatory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfFairValueMeasurementOfAssetsExplanatory" xlink:to="ifrs-full_DisclosureOfFairValueMeasurementOfAssetsExplanatory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfFairValueMeasurementOfAssetsExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of fair value measurement of assets [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_DisclosureOfFairValueMeasurementOfAssetsExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of marketable securities</label>
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_ScheduleOfPortfolioOfMarketableSecurities" xlink:label="gmab_ScheduleOfPortfolioOfMarketableSecurities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmab_ScheduleOfPortfolioOfMarketableSecurities" xlink:to="gmab_ScheduleOfPortfolioOfMarketableSecurities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gmab_ScheduleOfPortfolioOfMarketableSecurities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tabular disclosure of portfolio of marketable securities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gmab_ScheduleOfPortfolioOfMarketableSecurities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule Of Portfolio Of Marketable Securities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="gmab_ScheduleOfPortfolioOfMarketableSecurities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of portfolio of marketable securities</label>
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_DisclosureOfNumberAndWeightedAverageExercisePricesOfWarrantsTableTextBlock" xlink:label="gmab_DisclosureOfNumberAndWeightedAverageExercisePricesOfWarrantsTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmab_DisclosureOfNumberAndWeightedAverageExercisePricesOfWarrantsTableTextBlock" xlink:to="gmab_DisclosureOfNumberAndWeightedAverageExercisePricesOfWarrantsTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gmab_DisclosureOfNumberAndWeightedAverageExercisePricesOfWarrantsTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The disclosure of the number and weighted average exercise prices of warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gmab_DisclosureOfNumberAndWeightedAverageExercisePricesOfWarrantsTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure Of Number And Weighted Average Exercise Prices Of Warrants [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="gmab_DisclosureOfNumberAndWeightedAverageExercisePricesOfWarrantsTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Weighted Average Exercise Prices Of Warrants</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfReservesAndOtherEquityInterestExplanatory" xlink:label="ifrs-full_DisclosureOfReservesAndOtherEquityInterestExplanatory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfReservesAndOtherEquityInterestExplanatory" xlink:to="ifrs-full_DisclosureOfReservesAndOtherEquityInterestExplanatory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfReservesAndOtherEquityInterestExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of reserves within equity [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfReservesAndOtherEquityInterestExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of changes in share capital</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfTreasurySharesExplanatory" xlink:label="ifrs-full_DisclosureOfTreasurySharesExplanatory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfTreasurySharesExplanatory" xlink:to="ifrs-full_DisclosureOfTreasurySharesExplanatory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfTreasurySharesExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of treasury shares [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfTreasurySharesExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule Of Treasury Shares</label>
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_DisclosureOfFinanceIncomeExpensesTableTextBlock" xlink:label="gmab_DisclosureOfFinanceIncomeExpensesTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmab_DisclosureOfFinanceIncomeExpensesTableTextBlock" xlink:to="gmab_DisclosureOfFinanceIncomeExpensesTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gmab_DisclosureOfFinanceIncomeExpensesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">na</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gmab_DisclosureOfFinanceIncomeExpensesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of financial income and expenses</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory" xlink:label="ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory" xlink:to="ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of number and weighted average exercise prices of other equity instruments [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of RSUs activity</label>
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_DisclosureOfWarrantsActivityTableTextBlock" xlink:label="gmab_DisclosureOfWarrantsActivityTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmab_DisclosureOfWarrantsActivityTableTextBlock" xlink:to="gmab_DisclosureOfWarrantsActivityTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gmab_DisclosureOfWarrantsActivityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tabular disclosure of warrants activity.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gmab_DisclosureOfWarrantsActivityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure Of Warrants Activity [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="gmab_DisclosureOfWarrantsActivityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of warrants activity</label>
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_ScheduleOfShareRepurchasesTableTextBlock" xlink:label="gmab_ScheduleOfShareRepurchasesTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmab_ScheduleOfShareRepurchasesTableTextBlock" xlink:to="gmab_ScheduleOfShareRepurchasesTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gmab_ScheduleOfShareRepurchasesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tabular disclosure of repurchase of shares.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gmab_ScheduleOfShareRepurchasesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Share Repurchases [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="gmab_ScheduleOfShareRepurchasesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of share repurchases</label>
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_DisclosureOfBalanceSheetInformationRelatingToLeasesTableTextBlock" xlink:label="gmab_DisclosureOfBalanceSheetInformationRelatingToLeasesTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmab_DisclosureOfBalanceSheetInformationRelatingToLeasesTableTextBlock" xlink:to="gmab_DisclosureOfBalanceSheetInformationRelatingToLeasesTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gmab_DisclosureOfBalanceSheetInformationRelatingToLeasesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tabular disclosure of balance sheet information relating to leases.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gmab_DisclosureOfBalanceSheetInformationRelatingToLeasesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of balance sheet amounts relating to leases</label>
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_DisclosureOfComprehensiveInformationRelatingToLeasesTableTextBlock" xlink:label="gmab_DisclosureOfComprehensiveInformationRelatingToLeasesTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmab_DisclosureOfComprehensiveInformationRelatingToLeasesTableTextBlock" xlink:to="gmab_DisclosureOfComprehensiveInformationRelatingToLeasesTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gmab_DisclosureOfComprehensiveInformationRelatingToLeasesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tabular disclosure of comprehensive information relating to leases.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gmab_DisclosureOfComprehensiveInformationRelatingToLeasesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of statement of comprehensive income amounts relating to leases</label>
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_NumberOfApprovedProductsCommercializedByThirdParties" xlink:label="gmab_NumberOfApprovedProductsCommercializedByThirdParties" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmab_NumberOfApprovedProductsCommercializedByThirdParties" xlink:to="gmab_NumberOfApprovedProductsCommercializedByThirdParties_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gmab_NumberOfApprovedProductsCommercializedByThirdParties_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of approved products commercialized by third parties.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gmab_NumberOfApprovedProductsCommercializedByThirdParties_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number Of Approved Products Commercialized By Third Parties</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="gmab_NumberOfApprovedProductsCommercializedByThirdParties_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of approved products commercialized by third parties</label>
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_NumberOfApprovedProductsJointlyCommercializedWithCollaboration" xlink:label="gmab_NumberOfApprovedProductsJointlyCommercializedWithCollaboration" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmab_NumberOfApprovedProductsJointlyCommercializedWithCollaboration" xlink:to="gmab_NumberOfApprovedProductsJointlyCommercializedWithCollaboration_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gmab_NumberOfApprovedProductsJointlyCommercializedWithCollaboration_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of approved products jointly commercialized by collaboration partner.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gmab_NumberOfApprovedProductsJointlyCommercializedWithCollaboration_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number Of Approved Products Jointly Commercialized With Collaboration</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="gmab_NumberOfApprovedProductsJointlyCommercializedWithCollaboration_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of approved products jointly commercialized by collaboration partner</label>
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_CollaborativeAgreementProfitSharingPercentage" xlink:label="gmab_CollaborativeAgreementProfitSharingPercentage" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmab_CollaborativeAgreementProfitSharingPercentage" xlink:to="gmab_CollaborativeAgreementProfitSharingPercentage_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gmab_CollaborativeAgreementProfitSharingPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Profit sharing percentage under the collaboration agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gmab_CollaborativeAgreementProfitSharingPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaborative Agreement, Profit Sharing Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="gmab_CollaborativeAgreementProfitSharingPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Profit sharing percentage under the collaboration agreement</label>
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_IfrsNumberOfReportingUnits" xlink:label="gmab_IfrsNumberOfReportingUnits" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmab_IfrsNumberOfReportingUnits" xlink:to="gmab_IfrsNumberOfReportingUnits_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gmab_IfrsNumberOfReportingUnits_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of reporting units tested for impairment of goodwill. A reporting unit is an operating segment or one level below an operating segment.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gmab_IfrsNumberOfReportingUnits_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of business unit</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" xlink:label="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" xlink:to="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of disaggregation of revenue from contracts with customers [table]</label>
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_TypesOfRevenuesAxis" xlink:label="gmab_TypesOfRevenuesAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmab_TypesOfRevenuesAxis" xlink:to="gmab_TypesOfRevenuesAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gmab_TypesOfRevenuesAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gmab_TypesOfRevenuesAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Types of revenues [axis]</label>
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_TypesOfRevenuesMember" xlink:label="gmab_TypesOfRevenuesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmab_TypesOfRevenuesMember" xlink:to="gmab_TypesOfRevenuesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gmab_TypesOfRevenuesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for This member stands for all types of revenues from customers. It also represents the standard value for the 'Types of revenues' axis if no other member is used.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gmab_TypesOfRevenuesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Types of revenues [member]</label>
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_RoyaltiesRevenueMember" xlink:label="gmab_RoyaltiesRevenueMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmab_RoyaltiesRevenueMember" xlink:to="gmab_RoyaltiesRevenueMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gmab_RoyaltiesRevenueMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for revenue form royalties.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gmab_RoyaltiesRevenueMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Royalties</label>
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_ReimbursementIncomeMember" xlink:label="gmab_ReimbursementIncomeMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmab_ReimbursementIncomeMember" xlink:to="gmab_ReimbursementIncomeMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gmab_ReimbursementIncomeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for reimbursement income.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gmab_ReimbursementIncomeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Reimbursement income</label>
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_MilestonePaymentsRevenueMember" xlink:label="gmab_MilestonePaymentsRevenueMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmab_MilestonePaymentsRevenueMember" xlink:to="gmab_MilestonePaymentsRevenueMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gmab_MilestonePaymentsRevenueMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for revenue from milestone payments.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gmab_MilestonePaymentsRevenueMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Milestone payments</label>
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_LicenseFeesMember" xlink:label="gmab_LicenseFeesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmab_LicenseFeesMember" xlink:to="gmab_LicenseFeesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gmab_LicenseFeesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for revenue from license fees.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gmab_LicenseFeesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">License fees</label>
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_CollaborationRevenueMember" xlink:label="gmab_CollaborationRevenueMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmab_CollaborationRevenueMember" xlink:to="gmab_CollaborationRevenueMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gmab_CollaborationRevenueMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for collaboration revenue.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gmab_CollaborationRevenueMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaboration revenue</label>
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis" xlink:label="gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis" xlink:to="gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ifrs Collaborative Arrangement and Arrangement Other Than Collaborative [Axis]</label>
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeDomain" xlink:label="gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeDomain" xlink:to="gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ifrs Collaborative Arrangement and Arrangement Other Than Collaborative [Domain]</label>
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_AgreementsWithJanssenMember" xlink:label="gmab_AgreementsWithJanssenMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmab_AgreementsWithJanssenMember" xlink:to="gmab_AgreementsWithJanssenMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gmab_AgreementsWithJanssenMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for collaborative arrangement with Janssen (Darzalex/Daratumumab &amp; DuoBody).</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gmab_AgreementsWithJanssenMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Janssen</label>
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_AgreementsWithAbbvieMember" xlink:label="gmab_AgreementsWithAbbvieMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmab_AgreementsWithAbbvieMember" xlink:to="gmab_AgreementsWithAbbvieMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gmab_AgreementsWithAbbvieMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for collaboration arrangement with Abbvie.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gmab_AgreementsWithAbbvieMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">AbbVie</label>
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_AgreementsWithRocheMember" xlink:label="gmab_AgreementsWithRocheMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmab_AgreementsWithRocheMember" xlink:to="gmab_AgreementsWithRocheMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gmab_AgreementsWithRocheMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for collaboration arrangement with Roche.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gmab_AgreementsWithRocheMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Roche</label>
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_AgreementsWithNovartisMember" xlink:label="gmab_AgreementsWithNovartisMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmab_AgreementsWithNovartisMember" xlink:to="gmab_AgreementsWithNovartisMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gmab_AgreementsWithNovartisMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for collaborative arrangement with Novartis (Arzaerra/Ofatumumab).</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gmab_AgreementsWithNovartisMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Novartis (Arzaerra/Ofatumumab)</label>
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_AgreementsWithBointechMember" xlink:label="gmab_AgreementsWithBointechMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmab_AgreementsWithBointechMember" xlink:to="gmab_AgreementsWithBointechMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gmab_AgreementsWithBointechMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for collaboration arrangements with BioNTech.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gmab_AgreementsWithBointechMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">BioNTech</label>
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_AgreementsWithSeagenMember" xlink:label="gmab_AgreementsWithSeagenMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmab_AgreementsWithSeagenMember" xlink:to="gmab_AgreementsWithSeagenMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gmab_AgreementsWithSeagenMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for collaboration arrangement with Seagen.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gmab_AgreementsWithSeagenMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Seagen</label>
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_OtherCollaborationPartnersMember" xlink:label="gmab_OtherCollaborationPartnersMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmab_OtherCollaborationPartnersMember" xlink:to="gmab_OtherCollaborationPartnersMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gmab_OtherCollaborationPartnersMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for collaborative arrangement with other collaboration partners.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gmab_OtherCollaborationPartnersMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other collaboration partners</label>
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_AgreementsWithSeatleGeneticsMember" xlink:label="gmab_AgreementsWithSeatleGeneticsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmab_AgreementsWithSeatleGeneticsMember" xlink:to="gmab_AgreementsWithSeatleGeneticsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gmab_AgreementsWithSeatleGeneticsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for collaboration arrangement with Seatle Genetics</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gmab_AgreementsWithSeatleGeneticsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Seattle Genetics</label>
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_IfrsRoyaltiesByProductAxis" xlink:label="gmab_IfrsRoyaltiesByProductAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmab_IfrsRoyaltiesByProductAxis" xlink:to="gmab_IfrsRoyaltiesByProductAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gmab_IfrsRoyaltiesByProductAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Information by royalties by product.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gmab_IfrsRoyaltiesByProductAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">ifrs Royalties by Product [Axis]</label>
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_IfrsRoyaltiesByProductDomain" xlink:label="gmab_IfrsRoyaltiesByProductDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmab_IfrsRoyaltiesByProductDomain" xlink:to="gmab_IfrsRoyaltiesByProductDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gmab_IfrsRoyaltiesByProductDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Information by royalties by product.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gmab_IfrsRoyaltiesByProductDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">ifrs Royalties by Product [Domain]</label>
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_DarzalexMember" xlink:label="gmab_DarzalexMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmab_DarzalexMember" xlink:to="gmab_DarzalexMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gmab_DarzalexMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for DARZALEX.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gmab_DarzalexMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">DARZALEX [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="gmab_DarzalexMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">DARZALEX</label>
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_TepezzaMember" xlink:label="gmab_TepezzaMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmab_TepezzaMember" xlink:to="gmab_TepezzaMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gmab_TepezzaMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for TEPEZZA.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gmab_TepezzaMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">TEPEZZA [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="gmab_TepezzaMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">TEPEZZA</label>
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_KesimptaMember" xlink:label="gmab_KesimptaMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmab_KesimptaMember" xlink:to="gmab_KesimptaMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gmab_KesimptaMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for Kesimpta.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gmab_KesimptaMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Kesimpta [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="gmab_KesimptaMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Kesimpta</label>
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_OtherRoyaltyProductMember" xlink:label="gmab_OtherRoyaltyProductMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmab_OtherRoyaltyProductMember" xlink:to="gmab_OtherRoyaltyProductMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gmab_OtherRoyaltyProductMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for other royalty product.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gmab_OtherRoyaltyProductMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Royalty Product [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="gmab_OtherRoyaltyProductMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Royalty Product</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:label="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:to="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of disaggregation of revenue from contracts with customers [line items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RevenueFromContractsWithCustomers" xlink:label="ifrs-full_RevenueFromContractsWithCustomers" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RevenueFromContractsWithCustomers" xlink:to="ifrs-full_RevenueFromContractsWithCustomers_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_RevenueFromContractsWithCustomers_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue from contracts with customers</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_RevenueFromContractsWithCustomers_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfCreditRiskExposureTable" xlink:label="ifrs-full_DisclosureOfCreditRiskExposureTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfCreditRiskExposureTable" xlink:to="ifrs-full_DisclosureOfCreditRiskExposureTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfCreditRiskExposureTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of credit risk exposure [table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TypesOfRisksAxis" xlink:label="ifrs-full_TypesOfRisksAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TypesOfRisksAxis" xlink:to="ifrs-full_TypesOfRisksAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TypesOfRisksAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Types of risks [axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TypesOfRisksMember" xlink:label="ifrs-full_TypesOfRisksMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TypesOfRisksMember" xlink:to="ifrs-full_TypesOfRisksMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TypesOfRisksMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Risks [member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CreditRiskMember" xlink:label="ifrs-full_CreditRiskMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CreditRiskMember" xlink:to="ifrs-full_CreditRiskMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CreditRiskMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Credit risk</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CurrencyRiskMember" xlink:label="ifrs-full_CurrencyRiskMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrencyRiskMember" xlink:to="ifrs-full_CurrencyRiskMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrencyRiskMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Currency risk [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CurrencyRiskMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Currency risk</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ExternalCreditGradesAxis" xlink:label="ifrs-full_ExternalCreditGradesAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ExternalCreditGradesAxis" xlink:to="ifrs-full_ExternalCreditGradesAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ExternalCreditGradesAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">External credit grades [axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_EntitysTotalForExternalCreditGradesMember" xlink:label="ifrs-full_EntitysTotalForExternalCreditGradesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EntitysTotalForExternalCreditGradesMember" xlink:to="ifrs-full_EntitysTotalForExternalCreditGradesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_EntitysTotalForExternalCreditGradesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity's total for external credit grades [member]</label>
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_TripleaRatingMember" xlink:label="gmab_TripleaRatingMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmab_TripleaRatingMember" xlink:to="gmab_TripleaRatingMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gmab_TripleaRatingMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for Triple A-rating.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gmab_TripleaRatingMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Triple A-rating from Moody's, S&amp;P or Fitch</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CurrencyAxis" xlink:label="srt_CurrencyAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CurrencyAxis" xlink:to="srt_CurrencyAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_CurrencyAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Currency [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2021/currency-2021.xsd#currency_AllCurrenciesDomain" xlink:label="currency_AllCurrenciesDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="currency_AllCurrenciesDomain" xlink:to="currency_AllCurrenciesDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="currency_AllCurrenciesDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">All Currencies [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2021/currency-2021.xsd#currency_USD" xlink:label="currency_USD" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="currency_USD" xlink:to="currency_USD_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="currency_USD_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">United States of America, Dollars</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2021/currency-2021.xsd#currency_DKK" xlink:label="currency_DKK" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="currency_DKK" xlink:to="currency_DKK_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="currency_DKK_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">DKK</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2021/currency-2021.xsd#currency_EUR" xlink:label="currency_EUR" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="currency_EUR" xlink:to="currency_EUR_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="currency_EUR_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Euro Member Countries, Euro</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2021/currency-2021.xsd#currency_GBP" xlink:label="currency_GBP" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="currency_GBP" xlink:to="currency_GBP_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="currency_GBP_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">United Kingdom, Pounds</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfCreditRiskExposureLineItems" xlink:label="ifrs-full_DisclosureOfCreditRiskExposureLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfCreditRiskExposureLineItems" xlink:to="ifrs-full_DisclosureOfCreditRiskExposureLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfCreditRiskExposureLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of credit risk exposure [line items]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_MaximumExposureToCreditRisk" xlink:label="ifrs-full_MaximumExposureToCreditRisk" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_MaximumExposureToCreditRisk" xlink:to="ifrs-full_MaximumExposureToCreditRisk_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_MaximumExposureToCreditRisk_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum exposure to credit risk</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_MaximumExposureToCreditRisk_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum credit exposure</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_MaximumExposureToCreditRiskOfLoansOrReceivables" xlink:label="ifrs-full_MaximumExposureToCreditRiskOfLoansOrReceivables" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_MaximumExposureToCreditRiskOfLoansOrReceivables" xlink:to="ifrs-full_MaximumExposureToCreditRiskOfLoansOrReceivables_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_MaximumExposureToCreditRiskOfLoansOrReceivables_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum exposure to credit risk of loans or receivables</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_MaximumExposureToCreditRiskOfLoansOrReceivables_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum credit exposure to receivables</label>
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_PercentageOfMarketableSecurities" xlink:label="gmab_PercentageOfMarketableSecurities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmab_PercentageOfMarketableSecurities" xlink:to="gmab_PercentageOfMarketableSecurities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gmab_PercentageOfMarketableSecurities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The percentage of marketable securities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gmab_PercentageOfMarketableSecurities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of Marketable Securities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="gmab_PercentageOfMarketableSecurities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of marketable securities</label>
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_MarketableSecuritiesIncludingInterestReceivables" xlink:label="gmab_MarketableSecuritiesIncludingInterestReceivables" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmab_MarketableSecuritiesIncludingInterestReceivables" xlink:to="gmab_MarketableSecuritiesIncludingInterestReceivables_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gmab_MarketableSecuritiesIncludingInterestReceivables_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of marketable securities including interest receivable.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gmab_MarketableSecuritiesIncludingInterestReceivables_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Marketable Securities Including Interest Receivables</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="gmab_MarketableSecuritiesIncludingInterestReceivables_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Marketable securities including interest receivables</label>
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_BankDepositsIncludingShortTermMarketableSecurities" xlink:label="gmab_BankDepositsIncludingShortTermMarketableSecurities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmab_BankDepositsIncludingShortTermMarketableSecurities" xlink:to="gmab_BankDepositsIncludingShortTermMarketableSecurities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gmab_BankDepositsIncludingShortTermMarketableSecurities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The value of bank deposits including short-term marketable securities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gmab_BankDepositsIncludingShortTermMarketableSecurities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Bank Deposits Including Short Term Marketable Securities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="gmab_BankDepositsIncludingShortTermMarketableSecurities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total value of bank deposits</label>
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_PercentageOfRevenue" xlink:label="gmab_PercentageOfRevenue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmab_PercentageOfRevenue" xlink:to="gmab_PercentageOfRevenue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gmab_PercentageOfRevenue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of revenue.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gmab_PercentageOfRevenue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of Revenue</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="gmab_PercentageOfRevenue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue (as a percent)</label>
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_PercentageOfMarketableSecuritiesInvested" xlink:label="gmab_PercentageOfMarketableSecuritiesInvested" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmab_PercentageOfMarketableSecuritiesInvested" xlink:to="gmab_PercentageOfMarketableSecuritiesInvested_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gmab_PercentageOfMarketableSecuritiesInvested_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of marketable securities invested.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gmab_PercentageOfMarketableSecuritiesInvested_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of Marketable Securities Invested</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="gmab_PercentageOfMarketableSecuritiesInvested_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Marketable securities were invested (as a percent)</label>
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_PercentageOfPossibleIncreaseDecreaseInExchangeRate" xlink:label="gmab_PercentageOfPossibleIncreaseDecreaseInExchangeRate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmab_PercentageOfPossibleIncreaseDecreaseInExchangeRate" xlink:to="gmab_PercentageOfPossibleIncreaseDecreaseInExchangeRate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gmab_PercentageOfPossibleIncreaseDecreaseInExchangeRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of possible increase or decrease in exchange rate.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gmab_PercentageOfPossibleIncreaseDecreaseInExchangeRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage Of Possible Increase (Decrease) In Exchange rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="gmab_PercentageOfPossibleIncreaseDecreaseInExchangeRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of possible increase or decrease in exchange rate</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfFairValueMeasurementOfAssetsTable" xlink:label="ifrs-full_DisclosureOfFairValueMeasurementOfAssetsTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfFairValueMeasurementOfAssetsTable" xlink:to="ifrs-full_DisclosureOfFairValueMeasurementOfAssetsTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfFairValueMeasurementOfAssetsTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of fair value measurement of assets [table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_MeasurementAxis" xlink:label="ifrs-full_MeasurementAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_MeasurementAxis" xlink:to="ifrs-full_MeasurementAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_MeasurementAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Measurement [axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AggregatedMeasurementMember" xlink:label="ifrs-full_AggregatedMeasurementMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AggregatedMeasurementMember" xlink:to="ifrs-full_AggregatedMeasurementMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AggregatedMeasurementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Aggregated measurement [member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AtFairValueMember" xlink:label="ifrs-full_AtFairValueMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AtFairValueMember" xlink:to="ifrs-full_AtFairValueMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AtFairValueMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Book value</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ClassesOfFinancialAssetsAxis" xlink:label="ifrs-full_ClassesOfFinancialAssetsAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ClassesOfFinancialAssetsAxis" xlink:to="ifrs-full_ClassesOfFinancialAssetsAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ClassesOfFinancialAssetsAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Classes of financial assets [axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_FinancialAssetsMember" xlink:label="ifrs-full_FinancialAssetsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FinancialAssetsMember" xlink:to="ifrs-full_FinancialAssetsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_FinancialAssetsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Financial assets, class [member]</label>
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_MarketableSecuritiesMember" xlink:label="gmab_MarketableSecuritiesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmab_MarketableSecuritiesMember" xlink:to="gmab_MarketableSecuritiesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gmab_MarketableSecuritiesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for marketable securities .</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gmab_MarketableSecuritiesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Marketable Securities</label>
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_OtherInvestmentMember" xlink:label="gmab_OtherInvestmentMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmab_OtherInvestmentMember" xlink:to="gmab_OtherInvestmentMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gmab_OtherInvestmentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to other investments.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gmab_OtherInvestmentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_LevelsOfFairValueHierarchyAxis" xlink:label="ifrs-full_LevelsOfFairValueHierarchyAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_LevelsOfFairValueHierarchyAxis" xlink:to="ifrs-full_LevelsOfFairValueHierarchyAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_LevelsOfFairValueHierarchyAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Levels of fair value hierarchy [axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AllLevelsOfFairValueHierarchyMember" xlink:label="ifrs-full_AllLevelsOfFairValueHierarchyMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AllLevelsOfFairValueHierarchyMember" xlink:to="ifrs-full_AllLevelsOfFairValueHierarchyMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AllLevelsOfFairValueHierarchyMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">All levels of fair value hierarchy [member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_Level1OfFairValueHierarchyMember" xlink:label="ifrs-full_Level1OfFairValueHierarchyMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Level1OfFairValueHierarchyMember" xlink:to="ifrs-full_Level1OfFairValueHierarchyMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_Level1OfFairValueHierarchyMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Level 1 of fair value hierarchy [member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_Level2OfFairValueHierarchyMember" xlink:label="ifrs-full_Level2OfFairValueHierarchyMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Level2OfFairValueHierarchyMember" xlink:to="ifrs-full_Level2OfFairValueHierarchyMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_Level2OfFairValueHierarchyMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Level 2 of fair value hierarchy [member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_Level3OfFairValueHierarchyMember" xlink:label="ifrs-full_Level3OfFairValueHierarchyMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Level3OfFairValueHierarchyMember" xlink:to="ifrs-full_Level3OfFairValueHierarchyMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_Level3OfFairValueHierarchyMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Level 3 of fair value hierarchy [member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfFairValueMeasurementOfAssetsLineItems" xlink:label="ifrs-full_DisclosureOfFairValueMeasurementOfAssetsLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfFairValueMeasurementOfAssetsLineItems" xlink:to="ifrs-full_DisclosureOfFairValueMeasurementOfAssetsLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfFairValueMeasurementOfAssetsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of fair value measurement of assets [line items]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ReconciliationOfChangesInFairValueMeasurementAssetsAbstract" xlink:label="ifrs-full_ReconciliationOfChangesInFairValueMeasurementAssetsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ReconciliationOfChangesInFairValueMeasurementAssetsAbstract" xlink:to="ifrs-full_ReconciliationOfChangesInFairValueMeasurementAssetsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ReconciliationOfChangesInFairValueMeasurementAssetsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Reconciliation of changes in fair value measurement, assets [abstract]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_FinancialAssets" xlink:label="ifrs-full_FinancialAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FinancialAssets" xlink:to="ifrs-full_FinancialAssets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_FinancialAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Financial assets</label>
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeTable" xlink:label="gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeTable" xlink:to="gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ifrs Collaborative Arrangement and Arrangement Other than Collaborative [Table]</label>
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_CurevacCollaborationMember" xlink:label="gmab_CurevacCollaborationMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmab_CurevacCollaborationMember" xlink:to="gmab_CurevacCollaborationMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gmab_CurevacCollaborationMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represent the information pertaining to CureVac Collaboration.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gmab_CurevacCollaborationMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">CureVac</label>
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_BoltBiotherapeuticsIncMember" xlink:label="gmab_BoltBiotherapeuticsIncMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmab_BoltBiotherapeuticsIncMember" xlink:to="gmab_BoltBiotherapeuticsIncMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gmab_BoltBiotherapeuticsIncMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to Bolt Biotherapeutics, Inc.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gmab_BoltBiotherapeuticsIncMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Bolt</label>
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_CollaborativeArrangementAndArrangementOtherThanCollaborativeLineItems" xlink:label="gmab_CollaborativeArrangementAndArrangementOtherThanCollaborativeLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmab_CollaborativeArrangementAndArrangementOtherThanCollaborativeLineItems" xlink:to="gmab_CollaborativeArrangementAndArrangementOtherThanCollaborativeLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gmab_CollaborativeArrangementAndArrangementOtherThanCollaborativeLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gmab_CollaborativeArrangementAndArrangementOtherThanCollaborativeLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="gmab_CollaborativeArrangementAndArrangementOtherThanCollaborativeLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaboration Agreements</label>
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_PercentageOfInvestmentInCommonShares" xlink:label="gmab_PercentageOfInvestmentInCommonShares" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmab_PercentageOfInvestmentInCommonShares" xlink:to="gmab_PercentageOfInvestmentInCommonShares_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gmab_PercentageOfInvestmentInCommonShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of investment in common shares.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gmab_PercentageOfInvestmentInCommonShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of Investment in Common Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="gmab_PercentageOfInvestmentInCommonShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of investment in common shares</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProceedsFromIssueOfOrdinaryShares" xlink:label="ifrs-full_ProceedsFromIssueOfOrdinaryShares" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProceedsFromIssueOfOrdinaryShares" xlink:to="ifrs-full_ProceedsFromIssueOfOrdinaryShares_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ProceedsFromIssueOfOrdinaryShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from issue of ordinary shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_ProceedsFromIssueOfOrdinaryShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from sale of shares</label>
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_FinanceIncomeAbstract" xlink:label="gmab_FinanceIncomeAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmab_FinanceIncomeAbstract" xlink:to="gmab_FinanceIncomeAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gmab_FinanceIncomeAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">na</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gmab_FinanceIncomeAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Financial Income:</label>
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_InterestAndOtherFinancialIncome" xlink:label="gmab_InterestAndOtherFinancialIncome" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmab_InterestAndOtherFinancialIncome" xlink:to="gmab_InterestAndOtherFinancialIncome_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gmab_InterestAndOtherFinancialIncome_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The interest and other financial income.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gmab_InterestAndOtherFinancialIncome_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest and Other Financial Income</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="gmab_InterestAndOtherFinancialIncome_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest and other financial income</label>
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_GainOnOtherInvestments" xlink:label="gmab_GainOnOtherInvestments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmab_GainOnOtherInvestments" xlink:to="gmab_GainOnOtherInvestments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gmab_GainOnOtherInvestments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The gains on other investments.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gmab_GainOnOtherInvestments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gain On Other Investments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="gmab_GainOnOtherInvestments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gain on other investments, net</label>
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_GainsOnHedgingInstruments" xlink:label="gmab_GainsOnHedgingInstruments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmab_GainsOnHedgingInstruments" xlink:to="gmab_GainsOnHedgingInstruments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gmab_GainsOnHedgingInstruments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The gains on hedging instruments in fair value hedges.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gmab_GainsOnHedgingInstruments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Realized and unrealized gains on fair value hedges, net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="gmab_GainsOnHedgingInstruments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Realized and unrealized gains on fair value hedges, net</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NetForeignExchangeGain" xlink:label="ifrs-full_NetForeignExchangeGain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NetForeignExchangeGain" xlink:to="ifrs-full_NetForeignExchangeGain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NetForeignExchangeGain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net foreign exchange gain</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_NetForeignExchangeGain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Foreign exchange rate gain, net</label>
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_FinanceExpensesAbstract" xlink:label="gmab_FinanceExpensesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmab_FinanceExpensesAbstract" xlink:to="gmab_FinanceExpensesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gmab_FinanceExpensesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">na</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gmab_FinanceExpensesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Financial expenses:</label>
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_InterestAndOtherFinancialExpenses" xlink:label="gmab_InterestAndOtherFinancialExpenses" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmab_InterestAndOtherFinancialExpenses" xlink:to="gmab_InterestAndOtherFinancialExpenses_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gmab_InterestAndOtherFinancialExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The interest and other financial expenses.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gmab_InterestAndOtherFinancialExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest and Other Financial Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="gmab_InterestAndOtherFinancialExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest and other financial expenses</label>
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_LossesOnMarketableSecurities" xlink:label="gmab_LossesOnMarketableSecurities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmab_LossesOnMarketableSecurities" xlink:to="gmab_LossesOnMarketableSecurities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gmab_LossesOnMarketableSecurities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The losses on marketable securities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gmab_LossesOnMarketableSecurities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Losses on Marketable Securities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="gmab_LossesOnMarketableSecurities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loss on marketable securities, net</label>
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_LossesOnOtherInvestmentsNet" xlink:label="gmab_LossesOnOtherInvestmentsNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmab_LossesOnOtherInvestmentsNet" xlink:to="gmab_LossesOnOtherInvestmentsNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gmab_LossesOnOtherInvestmentsNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Losses On Other Investments Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gmab_LossesOnOtherInvestmentsNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Losses On Other Investments Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="gmab_LossesOnOtherInvestmentsNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loss on other investments, net</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NetForeignExchangeLoss" xlink:label="ifrs-full_NetForeignExchangeLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NetForeignExchangeLoss" xlink:to="ifrs-full_NetForeignExchangeLoss_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NetForeignExchangeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net foreign exchange loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_NetForeignExchangeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Foreign exchange rate loss, net</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_FinanceIncomeCost" xlink:label="ifrs-full_FinanceIncomeCost" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FinanceIncomeCost" xlink:to="ifrs-full_FinanceIncomeCost_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_FinanceIncomeCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finance income (cost)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_FinanceIncomeCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net financial items</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:to="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of terms and conditions of share-based payment arrangement [table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_CategoriesOfRelatedPartiesAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Categories of related parties [axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="ifrs-full_EntitysTotalForRelatedPartiesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="ifrs-full_EntitysTotalForRelatedPartiesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_EntitysTotalForRelatedPartiesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity's total for related parties [member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:label="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:to="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Types of share-based payment arrangements [axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_SharebasedPaymentArrangementsMember" xlink:label="ifrs-full_SharebasedPaymentArrangementsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_SharebasedPaymentArrangementsMember" xlink:to="ifrs-full_SharebasedPaymentArrangementsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_SharebasedPaymentArrangementsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based payment arrangements [member]</label>
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_IfrsRestrictedStockUnitsRSUsMember" xlink:label="gmab_IfrsRestrictedStockUnitsRSUsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmab_IfrsRestrictedStockUnitsRSUsMember" xlink:to="gmab_IfrsRestrictedStockUnitsRSUsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gmab_IfrsRestrictedStockUnitsRSUsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gmab_IfrsRestrictedStockUnitsRSUsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">RSUs</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of terms and conditions of share-based payment arrangement [line items]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" xlink:label="ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" xlink:to="ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of other equity instruments outstanding in share-based payment arrangement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Outstanding at end of period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Outstanding at beginning of period</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted" xlink:label="ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted" xlink:to="ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of other equity instruments granted in share-based payment arrangement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Granted</label>
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_Weightedaveragefairvalueofotherequityinstrumentsgrantedinsharebasedpaymentarrangement" xlink:label="gmab_Weightedaveragefairvalueofotherequityinstrumentsgrantedinsharebasedpaymentarrangement" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmab_Weightedaveragefairvalueofotherequityinstrumentsgrantedinsharebasedpaymentarrangement" xlink:to="gmab_Weightedaveragefairvalueofotherequityinstrumentsgrantedinsharebasedpaymentarrangement_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gmab_Weightedaveragefairvalueofotherequityinstrumentsgrantedinsharebasedpaymentarrangement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The weighted average fair value of other equity instruments (i.e. other than share options) granted in a share-based payment arrangement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gmab_Weightedaveragefairvalueofotherequityinstrumentsgrantedinsharebasedpaymentarrangement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">WeightedAverageFairValueOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="gmab_Weightedaveragefairvalueofotherequityinstrumentsgrantedinsharebasedpaymentarrangement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average fair value of RSU granted</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" xlink:label="ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" xlink:to="ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of other equity instruments exercised or vested in share-based payment arrangement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vested</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" xlink:label="ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" xlink:to="ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of other equity instruments forfeited in share-based payment arrangement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Forfeited/Cancelled</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_SaleOrIssueOfTreasuryShares" xlink:label="ifrs-full_SaleOrIssueOfTreasuryShares" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_SaleOrIssueOfTreasuryShares" xlink:to="ifrs-full_SaleOrIssueOfTreasuryShares_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_SaleOrIssueOfTreasuryShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sale or issue of treasury shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_SaleOrIssueOfTreasuryShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Treasury shares issued</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TreasuryShares" xlink:label="ifrs-full_TreasuryShares" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TreasuryShares" xlink:to="ifrs-full_TreasuryShares_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TreasuryShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Treasury shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_TreasuryShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Treasury shares</label>
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_WarrantsGrantedFromAugust2004UntilApril2012Member" xlink:label="gmab_WarrantsGrantedFromAugust2004UntilApril2012Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmab_WarrantsGrantedFromAugust2004UntilApril2012Member" xlink:to="gmab_WarrantsGrantedFromAugust2004UntilApril2012Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gmab_WarrantsGrantedFromAugust2004UntilApril2012Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the warrants granted from August 2004 until April 2012.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gmab_WarrantsGrantedFromAugust2004UntilApril2012Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants Granted from August 2004 until April 2012</label>
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_WarrantsGrantedFromApril2012UntilMarch2017Member" xlink:label="gmab_WarrantsGrantedFromApril2012UntilMarch2017Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmab_WarrantsGrantedFromApril2012UntilMarch2017Member" xlink:to="gmab_WarrantsGrantedFromApril2012UntilMarch2017Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gmab_WarrantsGrantedFromApril2012UntilMarch2017Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the warrants granted from April 2012 until March 2017.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gmab_WarrantsGrantedFromApril2012UntilMarch2017Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants Granted from April 2012 until March 2017</label>
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_WarrantsGrantedFromMarch2017Member" xlink:label="gmab_WarrantsGrantedFromMarch2017Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmab_WarrantsGrantedFromMarch2017Member" xlink:to="gmab_WarrantsGrantedFromMarch2017Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gmab_WarrantsGrantedFromMarch2017Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the warrants granted from march 2017.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gmab_WarrantsGrantedFromMarch2017Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants Granted from March 2017</label>
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_WarrantsMember" xlink:label="gmab_WarrantsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmab_WarrantsMember" xlink:to="gmab_WarrantsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gmab_WarrantsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gmab_WarrantsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants [Member]</label>
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_WarrantVestingPeriod" xlink:label="gmab_WarrantVestingPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmab_WarrantVestingPeriod" xlink:to="gmab_WarrantVestingPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gmab_WarrantVestingPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Period which the right to exercise an warrant is no longer contingent on satisfaction of either a service condition, market condition or a performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gmab_WarrantVestingPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrant Vesting Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="gmab_WarrantVestingPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrant vesting period</label>
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_NumberOfWarrantsOutstanding" xlink:label="gmab_NumberOfWarrantsOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmab_NumberOfWarrantsOutstanding" xlink:to="gmab_NumberOfWarrantsOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gmab_NumberOfWarrantsOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The number of warrants held as of the balance sheet date.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gmab_NumberOfWarrantsOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number Of Warrants Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="gmab_NumberOfWarrantsOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance at end of period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="gmab_NumberOfWarrantsOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance at beginning of period</label>
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_NumberOfWarrantsGrantedDuringPeriod" xlink:label="gmab_NumberOfWarrantsGrantedDuringPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmab_NumberOfWarrantsGrantedDuringPeriod" xlink:to="gmab_NumberOfWarrantsGrantedDuringPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gmab_NumberOfWarrantsGrantedDuringPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The number of warrants granted during period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gmab_NumberOfWarrantsGrantedDuringPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number Of Warrants Granted During Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="gmab_NumberOfWarrantsGrantedDuringPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Granted</label>
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_NumberOfWarrantsExercisedDuringPeriod" xlink:label="gmab_NumberOfWarrantsExercisedDuringPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmab_NumberOfWarrantsExercisedDuringPeriod" xlink:to="gmab_NumberOfWarrantsExercisedDuringPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gmab_NumberOfWarrantsExercisedDuringPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The number of warrants exercised during period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gmab_NumberOfWarrantsExercisedDuringPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number Of Warrants Exercised During Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="gmab_NumberOfWarrantsExercisedDuringPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercised</label>
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_NumberOfWarrantsExpiredOrLapsedOrCancelledDuringPeriod" xlink:label="gmab_NumberOfWarrantsExpiredOrLapsedOrCancelledDuringPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmab_NumberOfWarrantsExpiredOrLapsedOrCancelledDuringPeriod" xlink:to="gmab_NumberOfWarrantsExpiredOrLapsedOrCancelledDuringPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gmab_NumberOfWarrantsExpiredOrLapsedOrCancelledDuringPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The number of warrants expired or lapsed or cancelled during period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gmab_NumberOfWarrantsExpiredOrLapsedOrCancelledDuringPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number Of Warrants Expired Or Lapsed Or Cancelled During Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="gmab_NumberOfWarrantsExpiredOrLapsedOrCancelledDuringPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expired/lapsed/cancelled</label>
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_WeightedAverageExercisePriceOfWarrantsGranted" xlink:label="gmab_WeightedAverageExercisePriceOfWarrantsGranted" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmab_WeightedAverageExercisePriceOfWarrantsGranted" xlink:to="gmab_WeightedAverageExercisePriceOfWarrantsGranted_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gmab_WeightedAverageExercisePriceOfWarrantsGranted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise price per share or per unit of warrants granted during the period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gmab_WeightedAverageExercisePriceOfWarrantsGranted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Exercise Price Of Warrants Granted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="gmab_WeightedAverageExercisePriceOfWarrantsGranted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average exercise price of warrants granted</label>
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_WeightedAverageExercisePriceOfFairValueOfWarrants" xlink:label="gmab_WeightedAverageExercisePriceOfFairValueOfWarrants" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmab_WeightedAverageExercisePriceOfFairValueOfWarrants" xlink:to="gmab_WeightedAverageExercisePriceOfFairValueOfWarrants_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gmab_WeightedAverageExercisePriceOfFairValueOfWarrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise price per share or per unit of fair value of warrants during the period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gmab_WeightedAverageExercisePriceOfFairValueOfWarrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Exercise Price Of Fair Value Of Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="gmab_WeightedAverageExercisePriceOfFairValueOfWarrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average exercise price of fair market value</label>
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_WeightedAverageExercisePriceOfWarrantsExercised" xlink:label="gmab_WeightedAverageExercisePriceOfWarrantsExercised" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmab_WeightedAverageExercisePriceOfWarrantsExercised" xlink:to="gmab_WeightedAverageExercisePriceOfWarrantsExercised_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gmab_WeightedAverageExercisePriceOfWarrantsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise price per share or per unit of warrants exercised during the period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gmab_WeightedAverageExercisePriceOfWarrantsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Exercise Price Of Warrants Exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="gmab_WeightedAverageExercisePriceOfWarrantsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average exercise price of warrants exercised</label>
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_PercentageOfShareCapitalAttributedToExerciseOfWarrants" xlink:label="gmab_PercentageOfShareCapitalAttributedToExerciseOfWarrants" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmab_PercentageOfShareCapitalAttributedToExerciseOfWarrants" xlink:to="gmab_PercentageOfShareCapitalAttributedToExerciseOfWarrants_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gmab_PercentageOfShareCapitalAttributedToExerciseOfWarrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of share capital attributed by exercise of warrants which increase the share capital.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gmab_PercentageOfShareCapitalAttributedToExerciseOfWarrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage Of Share Capital Attributed To Exercise Of Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="gmab_PercentageOfShareCapitalAttributedToExerciseOfWarrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of share capital attributed to exercise of warrants</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" xlink:label="ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" xlink:to="ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expense from share-based payment transactions in which goods or services received did not qualify for recognition as assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based compensation expenses</label>
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_NumberOfTreasurySharesOutstanding" xlink:label="gmab_NumberOfTreasurySharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmab_NumberOfTreasurySharesOutstanding" xlink:to="gmab_NumberOfTreasurySharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gmab_NumberOfTreasurySharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The number of shares that has been held in treasury.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gmab_NumberOfTreasurySharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of Treasury Shares Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="gmab_NumberOfTreasurySharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Treasury shares outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_StatementScenarioAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_StatementScenarioAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Scenario [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="srt_ScenarioUnspecifiedDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ScenarioUnspecifiedDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Scenario [Domain]</label>
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_StockRepurchaseFirstAuthorizationMember" xlink:label="gmab_StockRepurchaseFirstAuthorizationMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmab_StockRepurchaseFirstAuthorizationMember" xlink:to="gmab_StockRepurchaseFirstAuthorizationMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gmab_StockRepurchaseFirstAuthorizationMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the first authorization under the share repurchase arrangement by the board of directors.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gmab_StockRepurchaseFirstAuthorizationMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">First authorization</label>
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_StockRepurchaseSecondAuthorizationMember" xlink:label="gmab_StockRepurchaseSecondAuthorizationMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmab_StockRepurchaseSecondAuthorizationMember" xlink:to="gmab_StockRepurchaseSecondAuthorizationMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gmab_StockRepurchaseSecondAuthorizationMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the second authorization under the share repurchase arrangement by the board of directors.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gmab_StockRepurchaseSecondAuthorizationMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Second authorization</label>
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_ThirdAuthorizationMember" xlink:label="gmab_ThirdAuthorizationMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmab_ThirdAuthorizationMember" xlink:to="gmab_ThirdAuthorizationMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gmab_ThirdAuthorizationMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the third authorization under the share repurchase arrangement by the board of directors.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gmab_ThirdAuthorizationMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Third Authorization [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="gmab_ThirdAuthorizationMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Third authorization</label>
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_StockRepurchaseAuthorization2021Member" xlink:label="gmab_StockRepurchaseAuthorization2021Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmab_StockRepurchaseAuthorization2021Member" xlink:to="gmab_StockRepurchaseAuthorization2021Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gmab_StockRepurchaseAuthorization2021Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the 2021 authorization under the share repurchase arrangement by the board of directors.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gmab_StockRepurchaseAuthorization2021Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Repurchase Authorization 2021 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="gmab_StockRepurchaseAuthorization2021Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2021 Authorization</label>
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_StockRepurchaseAuthorization2019Member" xlink:label="gmab_StockRepurchaseAuthorization2019Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmab_StockRepurchaseAuthorization2019Member" xlink:to="gmab_StockRepurchaseAuthorization2019Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gmab_StockRepurchaseAuthorization2019Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the 2019 authorization under the share repurchase arrangement by the board of directors.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gmab_StockRepurchaseAuthorization2019Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Repurchase Authorization 2019 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="gmab_StockRepurchaseAuthorization2019Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2019 Authorization</label>
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_StockRepurchaseAuthorization2016Member" xlink:label="gmab_StockRepurchaseAuthorization2016Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmab_StockRepurchaseAuthorization2016Member" xlink:to="gmab_StockRepurchaseAuthorization2016Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gmab_StockRepurchaseAuthorization2016Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the 2016 authorization under the share repurchase arrangement by the board of directors.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gmab_StockRepurchaseAuthorization2016Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Repurchase Authorization 2016 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="gmab_StockRepurchaseAuthorization2016Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2016 Authorization</label>
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_RestrictedStockUnitsRSUsMember" xlink:label="gmab_RestrictedStockUnitsRSUsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmab_RestrictedStockUnitsRSUsMember" xlink:to="gmab_RestrictedStockUnitsRSUsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gmab_RestrictedStockUnitsRSUsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gmab_RestrictedStockUnitsRSUsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">RSU</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statistical Measurement [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statistical Measurement [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum [Member]</label>
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_NumberOfSharesAuthorizedToBeRepurchased" xlink:label="gmab_NumberOfSharesAuthorizedToBeRepurchased" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmab_NumberOfSharesAuthorizedToBeRepurchased" xlink:to="gmab_NumberOfSharesAuthorizedToBeRepurchased_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gmab_NumberOfSharesAuthorizedToBeRepurchased_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The number of shares authorized to be repurchased by an entity's Board of Directors under a stock repurchase plan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gmab_NumberOfSharesAuthorizedToBeRepurchased_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number Of Shares Authorized To Be Repurchased</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="gmab_NumberOfSharesAuthorizedToBeRepurchased_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of shares authorized for repurchase</label>
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_ShareRepurchasedDuringPeriodShares" xlink:label="gmab_ShareRepurchasedDuringPeriodShares" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmab_ShareRepurchasedDuringPeriodShares" xlink:to="gmab_ShareRepurchasedDuringPeriodShares_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gmab_ShareRepurchasedDuringPeriodShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of shares that have been repurchased during the period and have not been retired and are not held in treasury.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gmab_ShareRepurchasedDuringPeriodShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share Repurchased During Period Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="gmab_ShareRepurchasedDuringPeriodShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Actual shares repurchased under authorization</label>
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_SharesAvailableForRepurchase" xlink:label="gmab_SharesAvailableForRepurchase" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmab_SharesAvailableForRepurchase" xlink:to="gmab_SharesAvailableForRepurchase_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gmab_SharesAvailableForRepurchase_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of shares available for repurchase.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gmab_SharesAvailableForRepurchase_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares Available For Repurchase</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="gmab_SharesAvailableForRepurchase_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares available for repurchase</label>
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_IfrsShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod" xlink:label="gmab_IfrsShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmab_IfrsShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod" xlink:to="gmab_IfrsShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gmab_IfrsShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Period which the right to exercise an award is no longer contingent on satisfaction of either a service condition, market condition or a performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gmab_IfrsShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">IFRS Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="gmab_IfrsShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vesting period</label>
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_ShareBasedArrangementPeriodFromVestingDateHolderReceivesShares" xlink:label="gmab_ShareBasedArrangementPeriodFromVestingDateHolderReceivesShares" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmab_ShareBasedArrangementPeriodFromVestingDateHolderReceivesShares" xlink:to="gmab_ShareBasedArrangementPeriodFromVestingDateHolderReceivesShares_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gmab_ShareBasedArrangementPeriodFromVestingDateHolderReceivesShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Period from vesting date in which the holder receives shares in the account per RSU under the share based payments arrangement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gmab_ShareBasedArrangementPeriodFromVestingDateHolderReceivesShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share Based Arrangement, Period From Vesting Date The Holder Receives Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="gmab_ShareBasedArrangementPeriodFromVestingDateHolderReceivesShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Period from vesting date for crediting shares</label>
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_ShareBasedArrangementNumberOfSharesPerRsu" xlink:label="gmab_ShareBasedArrangementNumberOfSharesPerRsu" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmab_ShareBasedArrangementNumberOfSharesPerRsu" xlink:to="gmab_ShareBasedArrangementNumberOfSharesPerRsu_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gmab_ShareBasedArrangementNumberOfSharesPerRsu_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of shares credited for one share of RSU owned by the holder under the share based payment arrangements.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gmab_ShareBasedArrangementNumberOfSharesPerRsu_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share Based Arrangement, Number Of Shares Per RSU</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="gmab_ShareBasedArrangementNumberOfSharesPerRsu_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of shares per RSU</label>
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_ShareBasedArrangementNumberOfAuthorization" xlink:label="gmab_ShareBasedArrangementNumberOfAuthorization" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmab_ShareBasedArrangementNumberOfAuthorization" xlink:to="gmab_ShareBasedArrangementNumberOfAuthorization_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gmab_ShareBasedArrangementNumberOfAuthorization_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of authorization under the share based payment arrangements.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gmab_ShareBasedArrangementNumberOfAuthorization_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share Based Arrangement, Number Of Authorization</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="gmab_ShareBasedArrangementNumberOfAuthorization_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of authorization</label>
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_SharesRepurchasedNominalValue" xlink:label="gmab_SharesRepurchasedNominalValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmab_SharesRepurchasedNominalValue" xlink:to="gmab_SharesRepurchasedNominalValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gmab_SharesRepurchasedNominalValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Nominal value of share repurchased.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gmab_SharesRepurchasedNominalValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares Repurchased Nominal Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="gmab_SharesRepurchasedNominalValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Nominal value of shares repurchases</label>
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_StockRepurchaseThresholdPriceDeviationPercentage" xlink:label="gmab_StockRepurchaseThresholdPriceDeviationPercentage" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmab_StockRepurchaseThresholdPriceDeviationPercentage" xlink:to="gmab_StockRepurchaseThresholdPriceDeviationPercentage_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gmab_StockRepurchaseThresholdPriceDeviationPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the threshold price deviation percentage under stock repurchase arrangement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gmab_StockRepurchaseThresholdPriceDeviationPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Repurchase Threshold Price Deviation Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="gmab_StockRepurchaseThresholdPriceDeviationPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Threshold price deviation percentage</label>
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_ShareRepurchasedDuringPeriodValue" xlink:label="gmab_ShareRepurchasedDuringPeriodValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmab_ShareRepurchasedDuringPeriodValue" xlink:to="gmab_ShareRepurchasedDuringPeriodValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gmab_ShareRepurchasedDuringPeriodValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Value of stock that has been repurchased during the period and has not been retired and is not held in treasury.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gmab_ShareRepurchasedDuringPeriodValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share Repurchased During Period Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="gmab_ShareRepurchasedDuringPeriodValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share repurchased amount</label>
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_SharesAvailableForRepurchaseAmount" xlink:label="gmab_SharesAvailableForRepurchaseAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmab_SharesAvailableForRepurchaseAmount" xlink:to="gmab_SharesAvailableForRepurchaseAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gmab_SharesAvailableForRepurchaseAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Value of shares that are available for repurchase.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gmab_SharesAvailableForRepurchaseAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares Available For Repurchase Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="gmab_SharesAvailableForRepurchaseAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares available for repurchase amount</label>
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_TreasurySharesAcquired" xlink:label="gmab_TreasurySharesAcquired" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmab_TreasurySharesAcquired" xlink:to="gmab_TreasurySharesAcquired_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gmab_TreasurySharesAcquired_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of treasury shares acquired during period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gmab_TreasurySharesAcquired_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Purchase of treasury shares.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="gmab_TreasurySharesAcquired_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Treasury shares acquired</label>
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_PercentageOfShareCapitalRepurchased" xlink:label="gmab_PercentageOfShareCapitalRepurchased" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmab_PercentageOfShareCapitalRepurchased" xlink:to="gmab_PercentageOfShareCapitalRepurchased_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gmab_PercentageOfShareCapitalRepurchased_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of share capital repurchased.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gmab_PercentageOfShareCapitalRepurchased_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage Of Share Capital Repurchased</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="gmab_PercentageOfShareCapitalRepurchased_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of share capital repurchased</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:label="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:to="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of transactions between related parties [table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_KeyManagementPersonnelOfEntityOrParentMember" xlink:label="ifrs-full_KeyManagementPersonnelOfEntityOrParentMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_KeyManagementPersonnelOfEntityOrParentMember" xlink:to="ifrs-full_KeyManagementPersonnelOfEntityOrParentMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_KeyManagementPersonnelOfEntityOrParentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Board of Directors and Executive Management</label>
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_DeirdreP.ConnellyChairPernilleErenbjergDeputyChairRolfHoffmannDr.PaoloPaolettiAndDr.AndersGerselPedersenMember" xlink:label="gmab_DeirdreP.ConnellyChairPernilleErenbjergDeputyChairRolfHoffmannDr.PaoloPaolettiAndDr.AndersGerselPedersenMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmab_DeirdreP.ConnellyChairPernilleErenbjergDeputyChairRolfHoffmannDr.PaoloPaolettiAndDr.AndersGerselPedersenMember" xlink:to="gmab_DeirdreP.ConnellyChairPernilleErenbjergDeputyChairRolfHoffmannDr.PaoloPaolettiAndDr.AndersGerselPedersenMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gmab_DeirdreP.ConnellyChairPernilleErenbjergDeputyChairRolfHoffmannDr.PaoloPaolettiAndDr.AndersGerselPedersenMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to Deirdre P. Connelly (Chair), Pernille Erenbjerg (Deputy Chair), Rolf Hoffmann, Dr. Paolo Paoletti, and Dr. Anders Gersel Pedersen.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gmab_DeirdreP.ConnellyChairPernilleErenbjergDeputyChairRolfHoffmannDr.PaoloPaolettiAndDr.AndersGerselPedersenMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deirdre P. Connelly (Chair), Pernille Erenbjerg (Deputy Chair), Rolf Hoffmann, Dr. Paolo Paoletti, and Dr. Anders Gersel Pedersen [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="gmab_DeirdreP.ConnellyChairPernilleErenbjergDeputyChairRolfHoffmannDr.PaoloPaolettiAndDr.AndersGerselPedersenMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deirdre P. Connelly (Chair), Pernille Erenbjerg (Deputy Chair), Rolf Hoffmann, Dr. Paolo Paoletti, and Dr. Anders Gersel Pedersen</label>
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_ElizabethOfarrellMember" xlink:label="gmab_ElizabethOfarrellMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmab_ElizabethOfarrellMember" xlink:to="gmab_ElizabethOfarrellMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gmab_ElizabethOfarrellMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to Elizabeth O'Farrell.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gmab_ElizabethOfarrellMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Elizabeth O&amp;rsquo;Farrell [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="gmab_ElizabethOfarrellMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Elizabeth O'Farrell</label>
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_MijkeZachariasseMartinSchultzAndTakahiroHamataniMember" xlink:label="gmab_MijkeZachariasseMartinSchultzAndTakahiroHamataniMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmab_MijkeZachariasseMartinSchultzAndTakahiroHamataniMember" xlink:to="gmab_MijkeZachariasseMartinSchultzAndTakahiroHamataniMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gmab_MijkeZachariasseMartinSchultzAndTakahiroHamataniMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to Mijke Zachariasse, Martin Schultz and Takahiro Hamatani.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gmab_MijkeZachariasseMartinSchultzAndTakahiroHamataniMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Mijke Zachariasse, Martin Schultz and Takahiro Hamatani [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="gmab_MijkeZachariasseMartinSchultzAndTakahiroHamataniMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Mijke Zachariasse, Martin Schultz and Takahiro Hamatani</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:label="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of transactions between related parties [line items]</label>
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_NumberOfChangesToExecutiveManagementTeam" xlink:label="gmab_NumberOfChangesToExecutiveManagementTeam" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmab_NumberOfChangesToExecutiveManagementTeam" xlink:to="gmab_NumberOfChangesToExecutiveManagementTeam_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gmab_NumberOfChangesToExecutiveManagementTeam_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of changes to executive management team.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gmab_NumberOfChangesToExecutiveManagementTeam_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of Changes to Executive Management Team</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="gmab_NumberOfChangesToExecutiveManagementTeam_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of changes to executive management team</label>
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_NumberOfIndependentBoardMembers" xlink:label="gmab_NumberOfIndependentBoardMembers" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmab_NumberOfIndependentBoardMembers" xlink:to="gmab_NumberOfIndependentBoardMembers_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gmab_NumberOfIndependentBoardMembers_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of independent board members.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gmab_NumberOfIndependentBoardMembers_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of Independent Board Members</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="gmab_NumberOfIndependentBoardMembers_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of independent board members</label>
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_NumberOfNonIndependentBoardMembers" xlink:label="gmab_NumberOfNonIndependentBoardMembers" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmab_NumberOfNonIndependentBoardMembers" xlink:to="gmab_NumberOfNonIndependentBoardMembers_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gmab_NumberOfNonIndependentBoardMembers_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of non independent board members.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gmab_NumberOfNonIndependentBoardMembers_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of Non Independent Board Members</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="gmab_NumberOfNonIndependentBoardMembers_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of non independent board members</label>
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_NumberOfEmployeeElectedBoardMembers" xlink:label="gmab_NumberOfEmployeeElectedBoardMembers" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmab_NumberOfEmployeeElectedBoardMembers" xlink:to="gmab_NumberOfEmployeeElectedBoardMembers_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gmab_NumberOfEmployeeElectedBoardMembers_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of employee elected board members.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gmab_NumberOfEmployeeElectedBoardMembers_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of Employee Elected Board Members</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="gmab_NumberOfEmployeeElectedBoardMembers_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of employee elected board members</label>
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_ReElectionToBoardOfDirectorsTerm" xlink:label="gmab_ReElectionToBoardOfDirectorsTerm" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmab_ReElectionToBoardOfDirectorsTerm" xlink:to="gmab_ReElectionToBoardOfDirectorsTerm_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gmab_ReElectionToBoardOfDirectorsTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The term limit of board of directors who are re-elected.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gmab_ReElectionToBoardOfDirectorsTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Re-Election to the Board of Directors Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="gmab_ReElectionToBoardOfDirectorsTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Re-election to the board of directors term</label>
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_ElectionToBoardOfDirectorsTerm" xlink:label="gmab_ElectionToBoardOfDirectorsTerm" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmab_ElectionToBoardOfDirectorsTerm" xlink:to="gmab_ElectionToBoardOfDirectorsTerm_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gmab_ElectionToBoardOfDirectorsTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The term limit of board of directors.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gmab_ElectionToBoardOfDirectorsTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Election to the Board of Directors, Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="gmab_ElectionToBoardOfDirectorsTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Board of directors term</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable" xlink:label="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable" xlink:to="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of quantitative information about right-of-use assets [table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ClassesOfAssetsAxis" xlink:label="ifrs-full_ClassesOfAssetsAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ClassesOfAssetsAxis" xlink:to="ifrs-full_ClassesOfAssetsAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ClassesOfAssetsAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Classes of assets [axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ClassesOfAssetsMember" xlink:label="ifrs-full_ClassesOfAssetsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ClassesOfAssetsMember" xlink:to="ifrs-full_ClassesOfAssetsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ClassesOfAssetsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets [member]</label>
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_PropertiesMember" xlink:label="gmab_PropertiesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmab_PropertiesMember" xlink:to="gmab_PropertiesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gmab_PropertiesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to properties.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gmab_PropertiesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Properties</label>
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_IfrsEquipmentMember" xlink:label="gmab_IfrsEquipmentMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmab_IfrsEquipmentMember" xlink:to="gmab_IfrsEquipmentMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gmab_IfrsEquipmentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to equipment.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gmab_IfrsEquipmentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equipment</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:label="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:to="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Classes of property, plant and equipment [axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_PropertyPlantAndEquipmentMember" xlink:label="ifrs-full_PropertyPlantAndEquipmentMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PropertyPlantAndEquipmentMember" xlink:to="ifrs-full_PropertyPlantAndEquipmentMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_PropertyPlantAndEquipmentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, plant and equipment [member]</label>
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_OfficeAndLaboratorySpaceMember" xlink:label="gmab_OfficeAndLaboratorySpaceMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmab_OfficeAndLaboratorySpaceMember" xlink:to="gmab_OfficeAndLaboratorySpaceMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gmab_OfficeAndLaboratorySpaceMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for Office and laboratory space.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gmab_OfficeAndLaboratorySpaceMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Office and laboratory space</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_StatementGeographicalAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_StatementGeographicalAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Geographical [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_SegmentGeographicalDomain" xlink:to="srt_SegmentGeographicalDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_SegmentGeographicalDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Geographical [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_DK" xlink:label="country_DK" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_DK" xlink:to="country_DK_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="country_DK_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">DENMARK</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:label="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:to="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of quantitative information about right-of-use assets [line items]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_LeaseLiabilitiesAbstract" xlink:label="ifrs-full_LeaseLiabilitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_LeaseLiabilitiesAbstract" xlink:to="ifrs-full_LeaseLiabilitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_LeaseLiabilitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lease liabilities [abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_LeaseLiabilitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lease Liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_LeaseLiabilities" xlink:label="ifrs-full_LeaseLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_LeaseLiabilities" xlink:to="ifrs-full_LeaseLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_LeaseLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lease liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_LeaseLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total lease liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AdditionsToRightofuseAssets" xlink:label="ifrs-full_AdditionsToRightofuseAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdditionsToRightofuseAssets" xlink:to="ifrs-full_AdditionsToRightofuseAssets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdditionsToRightofuseAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additions to right-of-use assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_AdditionsToRightofuseAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additions to right of use assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DepreciationRightofuseAssets" xlink:label="ifrs-full_DepreciationRightofuseAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DepreciationRightofuseAssets" xlink:to="ifrs-full_DepreciationRightofuseAssets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DepreciationRightofuseAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Depreciation, right-of-use assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DepreciationRightofuseAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Depreciation charge of right-of-use assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_InterestExpenseOnLeaseLiabilities" xlink:label="ifrs-full_InterestExpenseOnLeaseLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_InterestExpenseOnLeaseLiabilities" xlink:to="ifrs-full_InterestExpenseOnLeaseLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_InterestExpenseOnLeaseLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest expense on lease liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_InterestExpenseOnLeaseLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest expense</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed" xlink:label="ifrs-full_ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed" xlink:to="ifrs-full_ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expense relating to short-term leases for which recognition exemption has been used</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expense relating to short-term leases</label>
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_FutureMinimumOperatingLeasePayments" xlink:label="gmab_FutureMinimumOperatingLeasePayments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmab_FutureMinimumOperatingLeasePayments" xlink:to="gmab_FutureMinimumOperatingLeasePayments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gmab_FutureMinimumOperatingLeasePayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of future minimum operating lease payments.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gmab_FutureMinimumOperatingLeasePayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Future Minimum Operating Lease Payments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="gmab_FutureMinimumOperatingLeasePayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total future minimum payments</label>
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_EstimatedCapitalExpenditureForLease" xlink:label="gmab_EstimatedCapitalExpenditureForLease" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmab_EstimatedCapitalExpenditureForLease" xlink:to="gmab_EstimatedCapitalExpenditureForLease_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gmab_EstimatedCapitalExpenditureForLease_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of estimated capital expenditure for lease.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gmab_EstimatedCapitalExpenditureForLease_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Estimated Capital Expenditure for Lease</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="gmab_EstimatedCapitalExpenditureForLease_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Estimated capital expenditure for lease</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OtherCurrentLiabilities" xlink:label="ifrs-full_OtherCurrentLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherCurrentLiabilities" xlink:to="ifrs-full_OtherCurrentLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherCurrentLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other current liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OtherNoncurrentLiabilities" xlink:label="ifrs-full_OtherNoncurrentLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherNoncurrentLiabilities" xlink:to="ifrs-full_OtherNoncurrentLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherNoncurrentLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other non-current liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_EmployeeBenefitsExpense" xlink:label="ifrs-full_EmployeeBenefitsExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EmployeeBenefitsExpense" xlink:to="ifrs-full_EmployeeBenefitsExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_EmployeeBenefitsExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee benefits expense</label>
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_StaffCostsIncludedInResearchAndDevelopmentExpense" xlink:label="gmab_StaffCostsIncludedInResearchAndDevelopmentExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmab_StaffCostsIncludedInResearchAndDevelopmentExpense" xlink:to="gmab_StaffCostsIncludedInResearchAndDevelopmentExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gmab_StaffCostsIncludedInResearchAndDevelopmentExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of staff cost included in research and development expenses.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gmab_StaffCostsIncludedInResearchAndDevelopmentExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Staff Costs Included In Research And Development Expense</label>
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_StaffCostsIncludedInGeneralAndAdministrativeExpenses" xlink:label="gmab_StaffCostsIncludedInGeneralAndAdministrativeExpenses" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmab_StaffCostsIncludedInGeneralAndAdministrativeExpenses" xlink:to="gmab_StaffCostsIncludedInGeneralAndAdministrativeExpenses_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gmab_StaffCostsIncludedInGeneralAndAdministrativeExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of staff cost included in research and development expenses.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gmab_StaffCostsIncludedInGeneralAndAdministrativeExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Staff Costs Included In General and administrative expenses</label>
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_StaffCostsIncludedInSellingGeneralAndAdministrativeExpenses" xlink:label="gmab_StaffCostsIncludedInSellingGeneralAndAdministrativeExpenses" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmab_StaffCostsIncludedInSellingGeneralAndAdministrativeExpenses" xlink:to="gmab_StaffCostsIncludedInSellingGeneralAndAdministrativeExpenses_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gmab_StaffCostsIncludedInSellingGeneralAndAdministrativeExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of staff cost included in selling, general and administrative expenses.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gmab_StaffCostsIncludedInSellingGeneralAndAdministrativeExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Staff Costs Included in Selling, General and Administrative Expenses</label>
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_StaffCostsIncludedInGovernmentGrantsRelatedToResearchAndDevelopmentExpenses" xlink:label="gmab_StaffCostsIncludedInGovernmentGrantsRelatedToResearchAndDevelopmentExpenses" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmab_StaffCostsIncludedInGovernmentGrantsRelatedToResearchAndDevelopmentExpenses" xlink:to="gmab_StaffCostsIncludedInGovernmentGrantsRelatedToResearchAndDevelopmentExpenses_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gmab_StaffCostsIncludedInGovernmentGrantsRelatedToResearchAndDevelopmentExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of staff cost included in government grants related to research and development expenses.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gmab_StaffCostsIncludedInGovernmentGrantsRelatedToResearchAndDevelopmentExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Staff Costs Included In Government Grants Related To Research And Development Expenses</label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>25
<FILENAME>gmab-20220630_pre.xml
<DESCRIPTION>EX-101.PRE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  9.6.8167.22744 -->
<!--Based on XBRL 2.1-->
<!--Created on: 8/10/2022 3:19:08 PM-->
<!--Modified on: 8/10/2022 3:19:08 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="gmab-20220630.xsd#DocumentDocumentAndEntityInformation" roleURI="http://www.genmab.com/role/DocumentDocumentAndEntityInformation" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="gmab-20220630.xsd#StatementStatementsOfComprehensiveIncome" roleURI="http://www.genmab.com/role/StatementStatementsOfComprehensiveIncome" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="gmab-20220630.xsd#StatementBalanceSheets" roleURI="http://www.genmab.com/role/StatementBalanceSheets" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="gmab-20220630.xsd#StatementStatementsOfCashFlows" roleURI="http://www.genmab.com/role/StatementStatementsOfCashFlows" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="gmab-20220630.xsd#StatementStatementsOfChangesInEquity" roleURI="http://www.genmab.com/role/StatementStatementsOfChangesInEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="gmab-20220630.xsd#DisclosureBasisOfPresentation" roleURI="http://www.genmab.com/role/DisclosureBasisOfPresentation" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="gmab-20220630.xsd#DisclosureRevenue" roleURI="http://www.genmab.com/role/DisclosureRevenue" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="gmab-20220630.xsd#DisclosureFinancialInstruments" roleURI="http://www.genmab.com/role/DisclosureFinancialInstruments" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="gmab-20220630.xsd#DisclosureFinancialIncomeAndExpenses" roleURI="http://www.genmab.com/role/DisclosureFinancialIncomeAndExpenses" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="gmab-20220630.xsd#DisclosureShareBasedInstruments" roleURI="http://www.genmab.com/role/DisclosureShareBasedInstruments" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="gmab-20220630.xsd#DisclosureRelatedParties" roleURI="http://www.genmab.com/role/DisclosureRelatedParties" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="gmab-20220630.xsd#DisclosureLeases" roleURI="http://www.genmab.com/role/DisclosureLeases" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="gmab-20220630.xsd#DisclosureSubsequentEventsToBalanceSheetDate" roleURI="http://www.genmab.com/role/DisclosureSubsequentEventsToBalanceSheetDate" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="gmab-20220630.xsd#DisclosureBasisOfPresentationPolicies" roleURI="http://www.genmab.com/role/DisclosureBasisOfPresentationPolicies" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="gmab-20220630.xsd#DisclosureRevenueTables" roleURI="http://www.genmab.com/role/DisclosureRevenueTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="gmab-20220630.xsd#DisclosureFinancialInstrumentsTables" roleURI="http://www.genmab.com/role/DisclosureFinancialInstrumentsTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="gmab-20220630.xsd#DisclosureFinancialIncomeAndExpensesTables" roleURI="http://www.genmab.com/role/DisclosureFinancialIncomeAndExpensesTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="gmab-20220630.xsd#DisclosureShareBasedInstrumentsTables" roleURI="http://www.genmab.com/role/DisclosureShareBasedInstrumentsTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="gmab-20220630.xsd#DisclosureLeasesTables" roleURI="http://www.genmab.com/role/DisclosureLeasesTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="gmab-20220630.xsd#DisclosureBasisOfPresentationDetails" roleURI="http://www.genmab.com/role/DisclosureBasisOfPresentationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="gmab-20220630.xsd#DisclosureRevenueDetails" roleURI="http://www.genmab.com/role/DisclosureRevenueDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="gmab-20220630.xsd#DisclosureFinancialInstrumentsFinancialRiskDetails" roleURI="http://www.genmab.com/role/DisclosureFinancialInstrumentsFinancialRiskDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="gmab-20220630.xsd#DisclosureFinancialInstrumentsFairValueMeasurementDetails" roleURI="http://www.genmab.com/role/DisclosureFinancialInstrumentsFairValueMeasurementDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="gmab-20220630.xsd#DisclosureFinancialInstrumentsOtherInvestmentsDetails" roleURI="http://www.genmab.com/role/DisclosureFinancialInstrumentsOtherInvestmentsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="gmab-20220630.xsd#DisclosureFinancialIncomeAndExpensesDetails" roleURI="http://www.genmab.com/role/DisclosureFinancialIncomeAndExpensesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="gmab-20220630.xsd#DisclosureShareBasedInstrumentsRestrictedStockUnitProgramDetails" roleURI="http://www.genmab.com/role/DisclosureShareBasedInstrumentsRestrictedStockUnitProgramDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="gmab-20220630.xsd#DisclosureShareBasedInstrumentsWarrantProgramDetails" roleURI="http://www.genmab.com/role/DisclosureShareBasedInstrumentsWarrantProgramDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="gmab-20220630.xsd#DisclosureShareBasedInstrumentsShareRepurchasesDetails" roleURI="http://www.genmab.com/role/DisclosureShareBasedInstrumentsShareRepurchasesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="gmab-20220630.xsd#DisclosureRelatedPartiesDetails" roleURI="http://www.genmab.com/role/DisclosureRelatedPartiesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="gmab-20220630.xsd#DisclosureLeasesDetails" roleURI="http://www.genmab.com/role/DisclosureLeasesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" />
  <presentationLink xlink:role="http://www.genmab.com/role/DocumentDocumentAndEntityInformation" xlink:type="extended" xlink:title="00090 - Document - Document and Entity Information" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_DocumentAndEntityInformationAbstract" xlink:label="gmab_DocumentAndEntityInformationAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable_637957415460485429" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gmab_DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentInformationTable_637957415460485429" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ClassesOfShareCapitalAxis" xlink:label="ifrs-full_ClassesOfShareCapitalAxis_637957415460485429" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable_637957415460485429" xlink:to="ifrs-full_ClassesOfShareCapitalAxis_637957415460485429" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ClassesOfShareCapitalMember" xlink:label="ifrs-full_ClassesOfShareCapitalMember_637957415460485429" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfShareCapitalAxis_637957415460485429" xlink:to="ifrs-full_ClassesOfShareCapitalMember_637957415460485429" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OrdinarySharesMember" xlink:label="ifrs-full_OrdinarySharesMember_637957415460485429" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfShareCapitalMember_637957415460485429" xlink:to="ifrs-full_OrdinarySharesMember_637957415460485429" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_AmericanDepositorySharesMember" xlink:label="gmab_AmericanDepositorySharesMember_637957415460495425" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfShareCapitalMember_637957415460485429" xlink:to="gmab_AmericanDepositorySharesMember_637957415460495425" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems_637957415460495425" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable_637957415460485429" xlink:to="dei_DocumentInformationLineItems_637957415460495425" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType" xlink:label="dei_DocumentType_637957415460495425" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_637957415460495425" xlink:to="dei_DocumentType_637957415460495425" order="1" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement_637957415460495425" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_637957415460495425" xlink:to="dei_DocumentRegistrationStatement_637957415460495425" order="2" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate_637957415460495425" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_637957415460495425" xlink:to="dei_DocumentPeriodEndDate_637957415460495425" order="3" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName_637957415460495425" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_637957415460495425" xlink:to="dei_EntityRegistrantName_637957415460495425" order="4" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport_637957415460495425" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_637957415460495425" xlink:to="dei_DocumentAnnualReport_637957415460495425" order="5" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding_637957415460495425" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_637957415460495425" xlink:to="dei_EntityCommonStockSharesOutstanding_637957415460495425" order="6" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer_637957415460495425" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_637957415460495425" xlink:to="dei_EntityWellKnownSeasonedIssuer_637957415460495425" order="7" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers_637957415460495425" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_637957415460495425" xlink:to="dei_EntityVoluntaryFilers_637957415460495425" order="8" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus_637957415460495425" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_637957415460495425" xlink:to="dei_EntityCurrentReportingStatus_637957415460495425" order="9" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent_637957415460495425" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_637957415460495425" xlink:to="dei_EntityInteractiveDataCurrent_637957415460495425" order="10" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory_637957415460495425" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_637957415460495425" xlink:to="dei_EntityFilerCategory_637957415460495425" order="11" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany_637957415460505426" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_637957415460495425" xlink:to="dei_EntityEmergingGrowthCompany_637957415460505426" order="12" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod_637957415460505426" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_637957415460495425" xlink:to="dei_EntityExTransitionPeriod_637957415460505426" order="13" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany_637957415460505426" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_637957415460495425" xlink:to="dei_EntityShellCompany_637957415460505426" order="14" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport_637957415460505426" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_637957415460495425" xlink:to="dei_DocumentShellCompanyReport_637957415460505426" order="15" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport_637957415460505426" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_637957415460495425" xlink:to="dei_DocumentTransitionReport_637957415460505426" order="16" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey_637957415460505426" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_637957415460495425" xlink:to="dei_EntityCentralIndexKey_637957415460505426" order="17" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate_637957415460505426" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_637957415460495425" xlink:to="dei_CurrentFiscalYearEndDate_637957415460505426" order="18" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus_637957415460505426" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_637957415460495425" xlink:to="dei_DocumentFiscalYearFocus_637957415460505426" order="19" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus_637957415460505426" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_637957415460495425" xlink:to="dei_DocumentFiscalPeriodFocus_637957415460505426" order="20" use="optional" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag_637957415460515425" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_637957415460495425" xlink:to="dei_AmendmentFlag_637957415460515425" order="21" use="optional" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.genmab.com/role/StatementStatementsOfComprehensiveIncome" xlink:type="extended" xlink:title="00100 - Statement - STATEMENTS OF COMPREHENSIVE INCOME" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_StatementOfProfitOrLossAndOtherComprehensiveIncomeAbstract" xlink:label="ifrs-full_StatementOfProfitOrLossAndOtherComprehensiveIncomeAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IncomeStatementAbstract" xlink:label="ifrs-full_IncomeStatementAbstract_637957415460515425" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfProfitOrLossAndOtherComprehensiveIncomeAbstract" xlink:to="ifrs-full_IncomeStatementAbstract_637957415460515425" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_Revenue" xlink:label="ifrs-full_Revenue_637957415460515425" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IncomeStatementAbstract_637957415460515425" xlink:to="ifrs-full_Revenue_637957415460515425" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ResearchAndDevelopmentExpense" xlink:label="ifrs-full_ResearchAndDevelopmentExpense_637957415460515425" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IncomeStatementAbstract_637957415460515425" xlink:to="ifrs-full_ResearchAndDevelopmentExpense_637957415460515425" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_GeneralAndAdministrativeExpense" xlink:label="ifrs-full_GeneralAndAdministrativeExpense_637957415460515425" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IncomeStatementAbstract_637957415460515425" xlink:to="ifrs-full_GeneralAndAdministrativeExpense_637957415460515425" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_SellingGeneralAndAdministrativeExpense" xlink:label="ifrs-full_SellingGeneralAndAdministrativeExpense_637957415460515425" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IncomeStatementAbstract_637957415460515425" xlink:to="ifrs-full_SellingGeneralAndAdministrativeExpense_637957415460515425" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OperatingExpense" xlink:label="ifrs-full_OperatingExpense_637957415460515425" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IncomeStatementAbstract_637957415460515425" xlink:to="ifrs-full_OperatingExpense_637957415460515425" order="5" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProfitLossFromOperatingActivities" xlink:label="ifrs-full_ProfitLossFromOperatingActivities_637957415460515425" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IncomeStatementAbstract_637957415460515425" xlink:to="ifrs-full_ProfitLossFromOperatingActivities_637957415460515425" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_FinanceIncome" xlink:label="ifrs-full_FinanceIncome_637957415460515425" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IncomeStatementAbstract_637957415460515425" xlink:to="ifrs-full_FinanceIncome_637957415460515425" order="7" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_FinanceCosts" xlink:label="ifrs-full_FinanceCosts_637957415460515425" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IncomeStatementAbstract_637957415460515425" xlink:to="ifrs-full_FinanceCosts_637957415460515425" order="8" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProfitLossBeforeTax" xlink:label="ifrs-full_ProfitLossBeforeTax_637957415460525422" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IncomeStatementAbstract_637957415460515425" xlink:to="ifrs-full_ProfitLossBeforeTax_637957415460525422" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:label="ifrs-full_IncomeTaxExpenseContinuingOperations_637957415460525422" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IncomeStatementAbstract_637957415460515425" xlink:to="ifrs-full_IncomeTaxExpenseContinuingOperations_637957415460525422" order="10" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProfitLoss" xlink:label="ifrs-full_ProfitLoss_637957415460525422" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IncomeStatementAbstract_637957415460515425" xlink:to="ifrs-full_ProfitLoss_637957415460525422" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_BasicEarningsLossPerShare" xlink:label="ifrs-full_BasicEarningsLossPerShare_637957415460525422" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IncomeStatementAbstract_637957415460515425" xlink:to="ifrs-full_BasicEarningsLossPerShare_637957415460525422" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DilutedEarningsLossPerShare" xlink:label="ifrs-full_DilutedEarningsLossPerShare_637957415460525422" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IncomeStatementAbstract_637957415460515425" xlink:to="ifrs-full_DilutedEarningsLossPerShare_637957415460525422" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_StatementOfComprehensiveIncomeAbstract" xlink:label="ifrs-full_StatementOfComprehensiveIncomeAbstract_637957415460525422" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IncomeStatementAbstract_637957415460515425" xlink:to="ifrs-full_StatementOfComprehensiveIncomeAbstract_637957415460525422" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProfitLoss" xlink:label="ifrs-full_ProfitLoss_6379574154605254221" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfComprehensiveIncomeAbstract_637957415460525422" xlink:to="ifrs-full_ProfitLoss_6379574154605254221" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OtherComprehensiveIncomeAbstract" xlink:label="ifrs-full_OtherComprehensiveIncomeAbstract_637957415460525422" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IncomeStatementAbstract_637957415460515425" xlink:to="ifrs-full_OtherComprehensiveIncomeAbstract_637957415460525422" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract" xlink:label="ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract_637957415460525422" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_OtherComprehensiveIncomeAbstract_637957415460525422" xlink:to="ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract_637957415460525422" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" xlink:label="ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation_637957415460525422" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract_637957415460525422" xlink:to="ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation_637957415460525422" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OtherComprehensiveIncomeBeforeTaxExchangeDifferencesOnTranslation" xlink:label="ifrs-full_OtherComprehensiveIncomeBeforeTaxExchangeDifferencesOnTranslation_637957415460525422" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract_637957415460525422" xlink:to="ifrs-full_OtherComprehensiveIncomeBeforeTaxExchangeDifferencesOnTranslation_637957415460525422" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IncomeTaxRelatingToExchangeDifferencesOnTranslationOfOtherComprehensiveIncome" xlink:label="ifrs-full_IncomeTaxRelatingToExchangeDifferencesOnTranslationOfOtherComprehensiveIncome_637957415460535430" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract_637957415460525422" xlink:to="ifrs-full_IncomeTaxRelatingToExchangeDifferencesOnTranslationOfOtherComprehensiveIncome_637957415460535430" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CashFlowHedgesAbstract" xlink:label="ifrs-full_CashFlowHedgesAbstract_637957415460535430" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_OtherComprehensiveIncomeAbstract_637957415460525422" xlink:to="ifrs-full_CashFlowHedgesAbstract_637957415460535430" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxChangeInFairValueOfFinancialLiabilityAttributableToChangeInCreditRiskOfLiability" xlink:label="ifrs-full_OtherComprehensiveIncomeNetOfTaxChangeInFairValueOfFinancialLiabilityAttributableToChangeInCreditRiskOfLiability_637957415460535430" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowHedgesAbstract_637957415460535430" xlink:to="ifrs-full_OtherComprehensiveIncomeNetOfTaxChangeInFairValueOfFinancialLiabilityAttributableToChangeInCreditRiskOfLiability_637957415460535430" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ReclassificationAdjustmentsOnCashFlowHedgesNetOfTax" xlink:label="ifrs-full_ReclassificationAdjustmentsOnCashFlowHedgesNetOfTax_637957415460535430" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowHedgesAbstract_637957415460535430" xlink:to="ifrs-full_ReclassificationAdjustmentsOnCashFlowHedgesNetOfTax_637957415460535430" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ComprehensiveIncome" xlink:label="ifrs-full_ComprehensiveIncome_637957415460535430" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_OtherComprehensiveIncomeAbstract_637957415460525422" xlink:to="ifrs-full_ComprehensiveIncome_637957415460535430" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="5" />
  </presentationLink>
  <presentationLink xlink:role="http://www.genmab.com/role/StatementBalanceSheets" xlink:type="extended" xlink:title="00200 - Statement - BALANCE SHEETS" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_StatementOfFinancialPositionAbstract" xlink:label="ifrs-full_StatementOfFinancialPositionAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AssetsAbstract" xlink:label="ifrs-full_AssetsAbstract_637957415460535430" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_AssetsAbstract_637957415460535430" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwill" xlink:label="ifrs-full_IntangibleAssetsOtherThanGoodwill_637957415460535430" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AssetsAbstract_637957415460535430" xlink:to="ifrs-full_IntangibleAssetsOtherThanGoodwill_637957415460535430" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_PropertyPlantAndEquipment" xlink:label="ifrs-full_PropertyPlantAndEquipment_637957415460535430" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AssetsAbstract_637957415460535430" xlink:to="ifrs-full_PropertyPlantAndEquipment_637957415460535430" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RightofuseAssets" xlink:label="ifrs-full_RightofuseAssets_637957415460535430" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AssetsAbstract_637957415460535430" xlink:to="ifrs-full_RightofuseAssets_637957415460535430" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="8" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NoncurrentReceivables" xlink:label="ifrs-full_NoncurrentReceivables_637957415460545424" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AssetsAbstract_637957415460535430" xlink:to="ifrs-full_NoncurrentReceivables_637957415460545424" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NetDeferredTaxAssets" xlink:label="ifrs-full_NetDeferredTaxAssets_637957415460545424" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AssetsAbstract_637957415460535430" xlink:to="ifrs-full_NetDeferredTaxAssets_637957415460545424" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_InvestmentAccountedForUsingEquityMethod" xlink:label="ifrs-full_InvestmentAccountedForUsingEquityMethod_637957415460545424" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AssetsAbstract_637957415460535430" xlink:to="ifrs-full_InvestmentAccountedForUsingEquityMethod_637957415460545424" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NoncurrentAssets" xlink:label="ifrs-full_NoncurrentAssets_637957415460545424" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AssetsAbstract_637957415460535430" xlink:to="ifrs-full_NoncurrentAssets_637957415460545424" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_CorporateTaxReceivable" xlink:label="gmab_CorporateTaxReceivable_637957415460545424" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AssetsAbstract_637957415460535430" xlink:to="gmab_CorporateTaxReceivable_637957415460545424" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TradeAndOtherCurrentReceivables" xlink:label="ifrs-full_TradeAndOtherCurrentReceivables_637957415460545424" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AssetsAbstract_637957415460535430" xlink:to="ifrs-full_TradeAndOtherCurrentReceivables_637957415460545424" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_IfrsMarketableSecuritiesCurrent" xlink:label="gmab_IfrsMarketableSecuritiesCurrent_637957415460545424" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AssetsAbstract_637957415460535430" xlink:to="gmab_IfrsMarketableSecuritiesCurrent_637957415460545424" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CashAndCashEquivalents" xlink:label="ifrs-full_CashAndCashEquivalents_637957415460545424" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AssetsAbstract_637957415460535430" xlink:to="ifrs-full_CashAndCashEquivalents_637957415460545424" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CurrentAssets" xlink:label="ifrs-full_CurrentAssets_637957415460545424" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AssetsAbstract_637957415460535430" xlink:to="ifrs-full_CurrentAssets_637957415460545424" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_Assets" xlink:label="ifrs-full_Assets_637957415460545424" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AssetsAbstract_637957415460535430" xlink:to="ifrs-full_Assets_637957415460545424" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_EquityAndLiabilitiesAbstract" xlink:label="ifrs-full_EquityAndLiabilitiesAbstract_637957415460545424" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_EquityAndLiabilitiesAbstract_637957415460545424" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IssuedCapital" xlink:label="ifrs-full_IssuedCapital_637957415460545424" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EquityAndLiabilitiesAbstract_637957415460545424" xlink:to="ifrs-full_IssuedCapital_637957415460545424" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_SharePremium" xlink:label="ifrs-full_SharePremium_637957415460555423" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EquityAndLiabilitiesAbstract_637957415460545424" xlink:to="ifrs-full_SharePremium_637957415460555423" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OtherReserves" xlink:label="ifrs-full_OtherReserves_637957415460555423" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EquityAndLiabilitiesAbstract_637957415460545424" xlink:to="ifrs-full_OtherReserves_637957415460555423" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RetainedEarnings" xlink:label="ifrs-full_RetainedEarnings_637957415460555423" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EquityAndLiabilitiesAbstract_637957415460545424" xlink:to="ifrs-full_RetainedEarnings_637957415460555423" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_Equity" xlink:label="ifrs-full_Equity_637957415460555423" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EquityAndLiabilitiesAbstract_637957415460545424" xlink:to="ifrs-full_Equity_637957415460555423" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NoncurrentProvisions" xlink:label="ifrs-full_NoncurrentProvisions_637957415460555423" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EquityAndLiabilitiesAbstract_637957415460545424" xlink:to="ifrs-full_NoncurrentProvisions_637957415460555423" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NoncurrentLeaseLiabilities" xlink:label="ifrs-full_NoncurrentLeaseLiabilities_637957415460555423" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EquityAndLiabilitiesAbstract_637957415460545424" xlink:to="ifrs-full_NoncurrentLeaseLiabilities_637957415460555423" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RentDeferredIncomeClassifiedAsNoncurrent" xlink:label="ifrs-full_RentDeferredIncomeClassifiedAsNoncurrent_637957415460555423" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EquityAndLiabilitiesAbstract_637957415460545424" xlink:to="ifrs-full_RentDeferredIncomeClassifiedAsNoncurrent_637957415460555423" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OtherNoncurrentPayables" xlink:label="ifrs-full_OtherNoncurrentPayables_637957415460555423" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EquityAndLiabilitiesAbstract_637957415460545424" xlink:to="ifrs-full_OtherNoncurrentPayables_637957415460555423" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NoncurrentLiabilities" xlink:label="ifrs-full_NoncurrentLiabilities_637957415460555423" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EquityAndLiabilitiesAbstract_637957415460545424" xlink:to="ifrs-full_NoncurrentLiabilities_637957415460555423" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CurrentProvisions" xlink:label="ifrs-full_CurrentProvisions_637957415460565425" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EquityAndLiabilitiesAbstract_637957415460545424" xlink:to="ifrs-full_CurrentProvisions_637957415460565425" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CurrentTaxLiabilitiesCurrent" xlink:label="ifrs-full_CurrentTaxLiabilitiesCurrent_637957415460565425" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EquityAndLiabilitiesAbstract_637957415460545424" xlink:to="ifrs-full_CurrentTaxLiabilitiesCurrent_637957415460565425" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CurrentLeaseLiabilities" xlink:label="ifrs-full_CurrentLeaseLiabilities_637957415460565425" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EquityAndLiabilitiesAbstract_637957415460545424" xlink:to="ifrs-full_CurrentLeaseLiabilities_637957415460565425" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RentDeferredIncomeClassifiedAsCurrent" xlink:label="ifrs-full_RentDeferredIncomeClassifiedAsCurrent_637957415460565425" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EquityAndLiabilitiesAbstract_637957415460545424" xlink:to="ifrs-full_RentDeferredIncomeClassifiedAsCurrent_637957415460565425" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OtherCurrentPayables" xlink:label="ifrs-full_OtherCurrentPayables_637957415460565425" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EquityAndLiabilitiesAbstract_637957415460545424" xlink:to="ifrs-full_OtherCurrentPayables_637957415460565425" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CurrentLiabilities" xlink:label="ifrs-full_CurrentLiabilities_637957415460565425" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EquityAndLiabilitiesAbstract_637957415460545424" xlink:to="ifrs-full_CurrentLiabilities_637957415460565425" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_Liabilities" xlink:label="ifrs-full_Liabilities_637957415460565425" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EquityAndLiabilitiesAbstract_637957415460545424" xlink:to="ifrs-full_Liabilities_637957415460565425" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_EquityAndLiabilities" xlink:label="ifrs-full_EquityAndLiabilities_637957415460565425" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EquityAndLiabilitiesAbstract_637957415460545424" xlink:to="ifrs-full_EquityAndLiabilities_637957415460565425" order="18" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="5" />
  </presentationLink>
  <presentationLink xlink:role="http://www.genmab.com/role/StatementStatementsOfCashFlows" xlink:type="extended" xlink:title="00300 - Statement - STATEMENTS OF CASH FLOWS" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_StatementOfCashFlowsAbstract" xlink:label="ifrs-full_StatementOfCashFlowsAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_637957415460575423" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_637957415460575423" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProfitLossBeforeTax" xlink:label="ifrs-full_ProfitLossBeforeTax_637957415460575423" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_637957415460575423" xlink:to="ifrs-full_ProfitLossBeforeTax_637957415460575423" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="9" />
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_ReversalOfFinancialItemsNet" xlink:label="gmab_ReversalOfFinancialItemsNet_637957415460575423" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_637957415460575423" xlink:to="gmab_ReversalOfFinancialItemsNet_637957415460575423" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_TotalAdjustmentsForNonCashTransactions" xlink:label="gmab_TotalAdjustmentsForNonCashTransactions_637957415460575423" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_637957415460575423" xlink:to="gmab_TotalAdjustmentsForNonCashTransactions_637957415460575423" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IncreaseDecreaseInWorkingCapital" xlink:label="ifrs-full_IncreaseDecreaseInWorkingCapital_637957415460575423" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_637957415460575423" xlink:to="ifrs-full_IncreaseDecreaseInWorkingCapital_637957415460575423" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" priority="8" />
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_CashFlowFromUsedInOperatingActivitiesBeforeFinancialItems" xlink:label="gmab_CashFlowFromUsedInOperatingActivitiesBeforeFinancialItems_637957415460575423" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_637957415460575423" xlink:to="gmab_CashFlowFromUsedInOperatingActivitiesBeforeFinancialItems_637957415460575423" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_InterestReceivedClassifiedAsOperatingActivities" xlink:label="ifrs-full_InterestReceivedClassifiedAsOperatingActivities_637957415460575423" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_637957415460575423" xlink:to="ifrs-full_InterestReceivedClassifiedAsOperatingActivities_637957415460575423" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="9" />
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_AdjustmentsForInterestOnLeasePayments" xlink:label="gmab_AdjustmentsForInterestOnLeasePayments_637957415460575423" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_637957415460575423" xlink:to="gmab_AdjustmentsForInterestOnLeasePayments_637957415460575423" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_InterestPaidClassifiedAsOperatingActivities" xlink:label="ifrs-full_InterestPaidClassifiedAsOperatingActivities_637957415460575423" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_637957415460575423" xlink:to="ifrs-full_InterestPaidClassifiedAsOperatingActivities_637957415460575423" order="8" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" priority="9" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AdjustmentsForIncomeTaxExpense" xlink:label="ifrs-full_AdjustmentsForIncomeTaxExpense_637957415460575423" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_637957415460575423" xlink:to="ifrs-full_AdjustmentsForIncomeTaxExpense_637957415460575423" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivities_637957415460575423" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_637957415460575423" xlink:to="ifrs-full_CashFlowsFromUsedInOperatingActivities_637957415460575423" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:label="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_637957415460585423" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_637957415460585423" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" xlink:label="ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities_637957415460585423" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_637957415460585423" xlink:to="ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities_637957415460585423" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:label="ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_637957415460585423" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_637957415460585423" xlink:to="ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_637957415460585423" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities" xlink:label="ifrs-full_CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities_637957415460585423" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_637957415460585423" xlink:to="ifrs-full_CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities_637957415460585423" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_PurchaseOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod" xlink:label="ifrs-full_PurchaseOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod_637957415460585423" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_637957415460585423" xlink:to="ifrs-full_PurchaseOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod_637957415460585423" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProceedsFromSalesOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod" xlink:label="ifrs-full_ProceedsFromSalesOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod_637957415460585423" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_637957415460585423" xlink:to="ifrs-full_ProceedsFromSalesOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod_637957415460585423" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_PurchaseOfInterestsInInvestmentsAccountedForUsingEquityMethod" xlink:label="ifrs-full_PurchaseOfInterestsInInvestmentsAccountedForUsingEquityMethod_637957415460585423" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_637957415460585423" xlink:to="ifrs-full_PurchaseOfInterestsInInvestmentsAccountedForUsingEquityMethod_637957415460585423" order="6" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProceedsFromSalesOfInvestmentsAccountedForUsingEquityMethod" xlink:label="ifrs-full_ProceedsFromSalesOfInvestmentsAccountedForUsingEquityMethod_637957415460585423" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_637957415460585423" xlink:to="ifrs-full_ProceedsFromSalesOfInvestmentsAccountedForUsingEquityMethod_637957415460585423" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:label="ifrs-full_CashFlowsFromUsedInInvestingActivities_637957415460585423" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_637957415460585423" xlink:to="ifrs-full_CashFlowsFromUsedInInvestingActivities_637957415460585423" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:label="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_637957415460585423" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_637957415460585423" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProceedsFromExerciseOfWarrants" xlink:label="ifrs-full_ProceedsFromExerciseOfWarrants_637957415460595424" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_637957415460585423" xlink:to="ifrs-full_ProceedsFromExerciseOfWarrants_637957415460595424" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProceedsFromIssuingShares" xlink:label="ifrs-full_ProceedsFromIssuingShares_637957415460595424" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_637957415460585423" xlink:to="ifrs-full_ProceedsFromIssuingShares_637957415460595424" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_PaymentsForShareIssueCosts" xlink:label="ifrs-full_PaymentsForShareIssueCosts_637957415460595424" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_637957415460585423" xlink:to="ifrs-full_PaymentsForShareIssueCosts_637957415460595424" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" xlink:label="ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities_637957415460595424" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_637957415460585423" xlink:to="ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities_637957415460595424" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_PaymentsToAcquireTreasuryShares" xlink:label="gmab_PaymentsToAcquireTreasuryShares_637957415460595424" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_637957415460585423" xlink:to="gmab_PaymentsToAcquireTreasuryShares_637957415460595424" order="5" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_PaymentOfWithholdingTaxesOnBehalfOfEmployeesOnNetSettledRSUs" xlink:label="gmab_PaymentOfWithholdingTaxesOnBehalfOfEmployeesOnNetSettledRSUs_637957415460595424" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_637957415460585423" xlink:to="gmab_PaymentOfWithholdingTaxesOnBehalfOfEmployeesOnNetSettledRSUs_637957415460595424" order="6" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:label="ifrs-full_CashFlowsFromUsedInFinancingActivities_637957415460595424" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_637957415460585423" xlink:to="ifrs-full_CashFlowsFromUsedInFinancingActivities_637957415460595424" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" xlink:label="ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges_637957415460595424" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges_637957415460595424" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CashAndCashEquivalents" xlink:label="ifrs-full_CashAndCashEquivalents_637957415460595424" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_CashAndCashEquivalents_637957415460595424" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents" xlink:label="ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents_637957415460605427" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents_637957415460605427" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CashAndCashEquivalents" xlink:label="ifrs-full_CashAndCashEquivalents_637957415460605427" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_CashAndCashEquivalents_637957415460605427" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CashAndCashEquivalentsAbstract" xlink:label="ifrs-full_CashAndCashEquivalentsAbstract_637957415460605427" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_CashAndCashEquivalentsAbstract_637957415460605427" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_Cash" xlink:label="ifrs-full_Cash_637957415460605427" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashAndCashEquivalentsAbstract_637957415460605427" xlink:to="ifrs-full_Cash_637957415460605427" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ShorttermInvestmentsClassifiedAsCashEquivalents" xlink:label="ifrs-full_ShorttermInvestmentsClassifiedAsCashEquivalents_637957415460605427" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashAndCashEquivalentsAbstract_637957415460605427" xlink:to="ifrs-full_ShorttermInvestmentsClassifiedAsCashEquivalents_637957415460605427" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.genmab.com/role/StatementStatementsOfChangesInEquity" xlink:type="extended" xlink:title="00400 - Statement - STATEMENTS OF CHANGES IN EQUITY" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_StatementOfChangesInEquityAbstract" xlink:label="ifrs-full_StatementOfChangesInEquityAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_StatementOfChangesInEquityTable" xlink:label="ifrs-full_StatementOfChangesInEquityTable_637957415460605427" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityAbstract" xlink:to="ifrs-full_StatementOfChangesInEquityTable_637957415460605427" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ComponentsOfEquityAxis" xlink:label="ifrs-full_ComponentsOfEquityAxis_637957415460605427" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityTable_637957415460605427" xlink:to="ifrs-full_ComponentsOfEquityAxis_637957415460605427" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IssuedCapitalMember" xlink:label="ifrs-full_IssuedCapitalMember_637957415460615425" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ComponentsOfEquityAxis_637957415460605427" xlink:to="ifrs-full_IssuedCapitalMember_637957415460615425" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_SharePremiumMember" xlink:label="ifrs-full_SharePremiumMember_637957415460615425" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ComponentsOfEquityAxis_637957415460605427" xlink:to="ifrs-full_SharePremiumMember_637957415460615425" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember" xlink:label="ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_637957415460615425" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ComponentsOfEquityAxis_637957415460605427" xlink:to="ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_637957415460615425" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CashFlowHedgesMember" xlink:label="ifrs-full_CashFlowHedgesMember_637957415460615425" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ComponentsOfEquityAxis_637957415460605427" xlink:to="ifrs-full_CashFlowHedgesMember_637957415460615425" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RetainedEarningsMember" xlink:label="ifrs-full_RetainedEarningsMember_637957415460615425" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ComponentsOfEquityAxis_637957415460605427" xlink:to="ifrs-full_RetainedEarningsMember_637957415460615425" order="5" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_EquityMember" xlink:label="ifrs-full_EquityMember_637957415460615425" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ComponentsOfEquityAxis_637957415460605427" xlink:to="ifrs-full_EquityMember_637957415460615425" order="6" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:label="ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis_637957415460615425" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityTable_637957415460605427" xlink:to="ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis_637957415460615425" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IncreaseDecreaseDueToApplicationOfIFRS15Member" xlink:label="ifrs-full_IncreaseDecreaseDueToApplicationOfIFRS15Member_637957415460615425" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis_637957415460615425" xlink:to="ifrs-full_IncreaseDecreaseDueToApplicationOfIFRS15Member_637957415460615425" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RestatedMember" xlink:label="ifrs-full_RestatedMember_637957415460615425" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis_637957415460615425" xlink:to="ifrs-full_RestatedMember_637957415460615425" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_StatementOfChangesInEquityLineItems" xlink:label="ifrs-full_StatementOfChangesInEquityLineItems_637957415460615425" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityTable_637957415460605427" xlink:to="ifrs-full_StatementOfChangesInEquityLineItems_637957415460615425" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_Equity" xlink:label="ifrs-full_Equity_637957415460615425" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems_637957415460615425" xlink:to="ifrs-full_Equity_637957415460615425" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NumberOfSharesOutstanding" xlink:label="ifrs-full_NumberOfSharesOutstanding_637957415460615425" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems_637957415460615425" xlink:to="ifrs-full_NumberOfSharesOutstanding_637957415460615425" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_IfrsCumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption" xlink:label="gmab_IfrsCumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_637957415460615425" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems_637957415460615425" xlink:to="gmab_IfrsCumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_637957415460615425" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_EquityAdjustedForCumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption" xlink:label="gmab_EquityAdjustedForCumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_637957415460625422" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems_637957415460615425" xlink:to="gmab_EquityAdjustedForCumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_637957415460625422" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProfitLoss" xlink:label="ifrs-full_ProfitLoss_637957415460625422" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems_637957415460615425" xlink:to="ifrs-full_ProfitLoss_637957415460625422" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_OtherComprehensiveIncome" xlink:label="ifrs-full_OtherComprehensiveIncome_637957415460625422" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems_637957415460615425" xlink:to="ifrs-full_OtherComprehensiveIncome_637957415460625422" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ComprehensiveIncome" xlink:label="ifrs-full_ComprehensiveIncome_637957415460625422" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems_637957415460615425" xlink:to="ifrs-full_ComprehensiveIncome_637957415460625422" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_TransactionsWithOwners" xlink:label="gmab_TransactionsWithOwners_637957415460625422" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems_637957415460615425" xlink:to="gmab_TransactionsWithOwners_637957415460625422" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity" xlink:label="ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity_637957415460625422" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gmab_TransactionsWithOwners_637957415460625422" xlink:to="ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity_637957415460625422" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_ExerciseOfWarrants" xlink:label="gmab_ExerciseOfWarrants_637957415460625422" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gmab_TransactionsWithOwners_637957415460625422" xlink:to="gmab_ExerciseOfWarrants_637957415460625422" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IssueOfEquity" xlink:label="ifrs-full_IssueOfEquity_637957415460625422" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gmab_TransactionsWithOwners_637957415460625422" xlink:to="ifrs-full_IssueOfEquity_637957415460625422" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_ExpensesRelatedToCapitalIncreaseDecrease" xlink:label="gmab_ExpensesRelatedToCapitalIncreaseDecrease_637957415460625422" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gmab_TransactionsWithOwners_637957415460625422" xlink:to="gmab_ExpensesRelatedToCapitalIncreaseDecrease_637957415460625422" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ChangesInEquity" xlink:label="ifrs-full_ChangesInEquity_637957415460625422" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gmab_TransactionsWithOwners_637957415460625422" xlink:to="ifrs-full_ChangesInEquity_637957415460625422" order="5" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_PurchaseOfTreasuryShares" xlink:label="ifrs-full_PurchaseOfTreasuryShares_637957415460635424" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gmab_TransactionsWithOwners_637957415460625422" xlink:to="ifrs-full_PurchaseOfTreasuryShares_637957415460635424" order="6" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions" xlink:label="ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions_637957415460635424" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gmab_TransactionsWithOwners_637957415460625422" xlink:to="ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions_637957415460635424" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_IncreaseDecreaseThroughNetSettlementOfRestrictedStockUnitsEquity" xlink:label="gmab_IncreaseDecreaseThroughNetSettlementOfRestrictedStockUnitsEquity_637957415460635424" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gmab_TransactionsWithOwners_637957415460625422" xlink:to="gmab_IncreaseDecreaseThroughNetSettlementOfRestrictedStockUnitsEquity_637957415460635424" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_TaxOnItemsRecognizedDirectlyInEquity" xlink:label="gmab_TaxOnItemsRecognizedDirectlyInEquity_637957415460635424" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gmab_TransactionsWithOwners_637957415460625422" xlink:to="gmab_TaxOnItemsRecognizedDirectlyInEquity_637957415460635424" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_IncreaseDecreaseThroughTaxOnItemsRecognizedDirectlyInEquity" xlink:label="gmab_IncreaseDecreaseThroughTaxOnItemsRecognizedDirectlyInEquity_637957415460635424" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gmab_TransactionsWithOwners_637957415460625422" xlink:to="gmab_IncreaseDecreaseThroughTaxOnItemsRecognizedDirectlyInEquity_637957415460635424" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_Equity" xlink:label="ifrs-full_Equity_637957415460635424" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems_637957415460615425" xlink:to="ifrs-full_Equity_637957415460635424" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NumberOfSharesOutstanding" xlink:label="ifrs-full_NumberOfSharesOutstanding_637957415460635424" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems_637957415460615425" xlink:to="ifrs-full_NumberOfSharesOutstanding_637957415460635424" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.genmab.com/role/DisclosureBasisOfPresentation" xlink:type="extended" xlink:title="10101 - Disclosure - Basis of Presentation" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_BasisOfPresentationAbstract" xlink:label="gmab_BasisOfPresentationAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory" xlink:label="ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory_637957415460645425" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gmab_BasisOfPresentationAbstract" xlink:to="ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory_637957415460645425" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
  </presentationLink>
  <presentationLink xlink:role="http://www.genmab.com/role/DisclosureRevenue" xlink:type="extended" xlink:title="10201 - Disclosure - Revenue" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RevenueAbstract" xlink:label="ifrs-full_RevenueAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfRevenueFromContractsWithCustomersExplanatory" xlink:label="ifrs-full_DisclosureOfRevenueFromContractsWithCustomersExplanatory_637957415460645425" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RevenueAbstract" xlink:to="ifrs-full_DisclosureOfRevenueFromContractsWithCustomersExplanatory_637957415460645425" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.genmab.com/role/DisclosureFinancialInstruments" xlink:type="extended" xlink:title="10301 - Disclosure - Financial Instruments" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfFinancialInstrumentsAbstract" xlink:label="ifrs-full_DisclosureOfFinancialInstrumentsAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory" xlink:label="ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory_637957415460645425" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsAbstract" xlink:to="ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory_637957415460645425" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.genmab.com/role/DisclosureFinancialIncomeAndExpenses" xlink:type="extended" xlink:title="10401 - Disclosure - Financial Income and Expenses" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_DisclosureOfFinanceIncomeExpensesAbstract" xlink:label="gmab_DisclosureOfFinanceIncomeExpensesAbstract_1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory" xlink:label="ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory_637957415460645425" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gmab_DisclosureOfFinanceIncomeExpensesAbstract_1" xlink:to="ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory_637957415460645425" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.genmab.com/role/DisclosureShareBasedInstruments" xlink:type="extended" xlink:title="10501 - Disclosure - Share-Based Instruments" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory" xlink:label="ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory_637957415460645425" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:to="ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory_637957415460645425" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.genmab.com/role/DisclosureRelatedParties" xlink:type="extended" xlink:title="10601 - Disclosure - Related Parties" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract" xlink:label="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfRelatedPartyExplanatory" xlink:label="ifrs-full_DisclosureOfRelatedPartyExplanatory_637957415460655425" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract" xlink:to="ifrs-full_DisclosureOfRelatedPartyExplanatory_637957415460655425" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.genmab.com/role/DisclosureLeases" xlink:type="extended" xlink:title="10701 - Disclosure - Leases" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_PresentationOfLeasesForLesseeAbstract" xlink:label="ifrs-full_PresentationOfLeasesForLesseeAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfLeasesExplanatory" xlink:label="ifrs-full_DisclosureOfLeasesExplanatory_637957415460655425" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_PresentationOfLeasesForLesseeAbstract" xlink:to="ifrs-full_DisclosureOfLeasesExplanatory_637957415460655425" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.genmab.com/role/DisclosureSubsequentEventsToBalanceSheetDate" xlink:type="extended" xlink:title="10801 - Disclosure - Subsequent Events to the Balance Sheet Date" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract" xlink:label="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory" xlink:label="ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory_637957415460655425" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract" xlink:to="ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory_637957415460655425" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.genmab.com/role/DisclosureBasisOfPresentationPolicies" xlink:type="extended" xlink:title="20102 - Disclosure - Basis of Presentation (Policies)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_BasisOfPresentationAbstract" xlink:label="gmab_BasisOfPresentationAbstract" />
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_DescriptionOfAccountingPolicyForBasisOfPresentationPolicyTextBlock" xlink:label="gmab_DescriptionOfAccountingPolicyForBasisOfPresentationPolicyTextBlock_637957415460655425" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gmab_BasisOfPresentationAbstract" xlink:to="gmab_DescriptionOfAccountingPolicyForBasisOfPresentationPolicyTextBlock_637957415460655425" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory" xlink:label="ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory_637957415460655425" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gmab_BasisOfPresentationAbstract" xlink:to="ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory_637957415460655425" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_DescriptionOfAccountingPolicyForRecentAccountingStandardsAdoptedPolicyTextBlock" xlink:label="gmab_DescriptionOfAccountingPolicyForRecentAccountingStandardsAdoptedPolicyTextBlock_637957415460655425" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gmab_BasisOfPresentationAbstract" xlink:to="gmab_DescriptionOfAccountingPolicyForRecentAccountingStandardsAdoptedPolicyTextBlock_637957415460655425" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_DisclosureOfNewAccountingPoliciesAndDisclosuresPolicyTextBlock" xlink:label="gmab_DisclosureOfNewAccountingPoliciesAndDisclosuresPolicyTextBlock_637957415460655425" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gmab_BasisOfPresentationAbstract" xlink:to="gmab_DisclosureOfNewAccountingPoliciesAndDisclosuresPolicyTextBlock_637957415460655425" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_DescriptionOfAccountingPolicyForJudgmentsAndEstimatesPolicyTextBlock" xlink:label="gmab_DescriptionOfAccountingPolicyForJudgmentsAndEstimatesPolicyTextBlock_637957415460655425" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gmab_BasisOfPresentationAbstract" xlink:to="gmab_DescriptionOfAccountingPolicyForJudgmentsAndEstimatesPolicyTextBlock_637957415460655425" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForSegmentReportingExplanatory" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForSegmentReportingExplanatory_637957415460665424" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gmab_BasisOfPresentationAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForSegmentReportingExplanatory_637957415460665424" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory_637957415460665424" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gmab_BasisOfPresentationAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory_637957415460665424" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory_637957415460665424" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gmab_BasisOfPresentationAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory_637957415460665424" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForInvestmentInAssociates" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForInvestmentInAssociates_637957415460665424" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gmab_BasisOfPresentationAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForInvestmentInAssociates_637957415460665424" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.genmab.com/role/DisclosureRevenueTables" xlink:type="extended" xlink:title="30203 - Disclosure - Revenue (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RevenueAbstract" xlink:label="ifrs-full_RevenueAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory" xlink:label="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory_637957415460665424" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RevenueAbstract" xlink:to="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory_637957415460665424" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_ScheduleOfSegmentDisclosuresInFinancialStatementsTableTextBlock" xlink:label="gmab_ScheduleOfSegmentDisclosuresInFinancialStatementsTableTextBlock_637957415460665424" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RevenueAbstract" xlink:to="gmab_ScheduleOfSegmentDisclosuresInFinancialStatementsTableTextBlock_637957415460665424" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_DisclosureOfStaffCostTableTextBlock" xlink:label="gmab_DisclosureOfStaffCostTableTextBlock_637957415460665424" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RevenueAbstract" xlink:to="gmab_DisclosureOfStaffCostTableTextBlock_637957415460665424" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_ValuationAssumptionsForWarrantsGrantedTableTextBlock" xlink:label="gmab_ValuationAssumptionsForWarrantsGrantedTableTextBlock_637957415460665424" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RevenueAbstract" xlink:to="gmab_ValuationAssumptionsForWarrantsGrantedTableTextBlock_637957415460665424" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_DisclosureOfCorporateAndDeferredTaxTableTextBlock" xlink:label="gmab_DisclosureOfCorporateAndDeferredTaxTableTextBlock_637957415460665424" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RevenueAbstract" xlink:to="gmab_DisclosureOfCorporateAndDeferredTaxTableTextBlock_637957415460665424" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfDeferredTaxesExplanatory" xlink:label="ifrs-full_DisclosureOfDeferredTaxesExplanatory_637957415460665424" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RevenueAbstract" xlink:to="ifrs-full_DisclosureOfDeferredTaxesExplanatory_637957415460665424" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_DisclosureOfNetResultTableTextBlock" xlink:label="gmab_DisclosureOfNetResultTableTextBlock_637957415460665424" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RevenueAbstract" xlink:to="gmab_DisclosureOfNetResultTableTextBlock_637957415460665424" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfEarningsPerShareExplanatory" xlink:label="ifrs-full_DisclosureOfEarningsPerShareExplanatory_637957415460665424" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RevenueAbstract" xlink:to="ifrs-full_DisclosureOfEarningsPerShareExplanatory_637957415460665424" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.genmab.com/role/DisclosureFinancialInstrumentsTables" xlink:type="extended" xlink:title="30303 - Disclosure - Financial Instruments (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfFinancialInstrumentsAbstract" xlink:label="ifrs-full_DisclosureOfFinancialInstrumentsAbstract" />
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_DisclosureOfMarketableSecuritiesByCurrencyTableTextBlock" xlink:label="gmab_DisclosureOfMarketableSecuritiesByCurrencyTableTextBlock_637957415460675426" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsAbstract" xlink:to="gmab_DisclosureOfMarketableSecuritiesByCurrencyTableTextBlock_637957415460675426" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_DisclosureOfImpactOfExchangeRateOnNetResultBeforeTaxTableTextBlock" xlink:label="gmab_DisclosureOfImpactOfExchangeRateOnNetResultBeforeTaxTableTextBlock_637957415460675426" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsAbstract" xlink:to="gmab_DisclosureOfImpactOfExchangeRateOnNetResultBeforeTaxTableTextBlock_637957415460675426" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_DisclosureOfMaturityProfileOfOurMarketableSecuritiesTableTextBlock" xlink:label="gmab_DisclosureOfMaturityProfileOfOurMarketableSecuritiesTableTextBlock_637957415460675426" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsAbstract" xlink:to="gmab_DisclosureOfMaturityProfileOfOurMarketableSecuritiesTableTextBlock_637957415460675426" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfOffsettingOfFinancialAssetsAndFinancialLiabilitiesExplanatory" xlink:label="ifrs-full_DisclosureOfOffsettingOfFinancialAssetsAndFinancialLiabilitiesExplanatory_637957415460675426" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsAbstract" xlink:to="ifrs-full_DisclosureOfOffsettingOfFinancialAssetsAndFinancialLiabilitiesExplanatory_637957415460675426" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_DisclosureOfFairValueMeasurementOfAssetsLevel3ReconciliationTableTextBlock" xlink:label="gmab_DisclosureOfFairValueMeasurementOfAssetsLevel3ReconciliationTableTextBlock_637957415460675426" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsAbstract" xlink:to="gmab_DisclosureOfFairValueMeasurementOfAssetsLevel3ReconciliationTableTextBlock_637957415460675426" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfFairValueMeasurementOfAssetsExplanatory" xlink:label="ifrs-full_DisclosureOfFairValueMeasurementOfAssetsExplanatory_637957415460675426" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsAbstract" xlink:to="ifrs-full_DisclosureOfFairValueMeasurementOfAssetsExplanatory_637957415460675426" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_ScheduleOfPortfolioOfMarketableSecurities" xlink:label="gmab_ScheduleOfPortfolioOfMarketableSecurities_637957415460675426" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsAbstract" xlink:to="gmab_ScheduleOfPortfolioOfMarketableSecurities_637957415460675426" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_DisclosureOfNumberAndWeightedAverageExercisePricesOfWarrantsTableTextBlock" xlink:label="gmab_DisclosureOfNumberAndWeightedAverageExercisePricesOfWarrantsTableTextBlock_637957415460675426" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsAbstract" xlink:to="gmab_DisclosureOfNumberAndWeightedAverageExercisePricesOfWarrantsTableTextBlock_637957415460675426" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfReservesAndOtherEquityInterestExplanatory" xlink:label="ifrs-full_DisclosureOfReservesAndOtherEquityInterestExplanatory_637957415460675426" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsAbstract" xlink:to="ifrs-full_DisclosureOfReservesAndOtherEquityInterestExplanatory_637957415460675426" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfTreasurySharesExplanatory" xlink:label="ifrs-full_DisclosureOfTreasurySharesExplanatory_637957415460675426" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsAbstract" xlink:to="ifrs-full_DisclosureOfTreasurySharesExplanatory_637957415460675426" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.genmab.com/role/DisclosureFinancialIncomeAndExpensesTables" xlink:type="extended" xlink:title="30403 - Disclosure - Financial Income and Expenses (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_DisclosureOfFinanceIncomeExpensesAbstract" xlink:label="gmab_DisclosureOfFinanceIncomeExpensesAbstract" />
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_DisclosureOfFinanceIncomeExpensesTableTextBlock" xlink:label="gmab_DisclosureOfFinanceIncomeExpensesTableTextBlock_637957415460685423" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gmab_DisclosureOfFinanceIncomeExpensesAbstract" xlink:to="gmab_DisclosureOfFinanceIncomeExpensesTableTextBlock_637957415460685423" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.genmab.com/role/DisclosureShareBasedInstrumentsTables" xlink:type="extended" xlink:title="30503 - Disclosure - Share-Based Instruments (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory" xlink:label="ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory_637957415460685423" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:to="ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory_637957415460685423" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_DisclosureOfWarrantsActivityTableTextBlock" xlink:label="gmab_DisclosureOfWarrantsActivityTableTextBlock_637957415460685423" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:to="gmab_DisclosureOfWarrantsActivityTableTextBlock_637957415460685423" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_ScheduleOfShareRepurchasesTableTextBlock" xlink:label="gmab_ScheduleOfShareRepurchasesTableTextBlock_637957415460685423" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:to="gmab_ScheduleOfShareRepurchasesTableTextBlock_637957415460685423" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.genmab.com/role/DisclosureLeasesTables" xlink:type="extended" xlink:title="30703 - Disclosure - Leases (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_PresentationOfLeasesForLesseeAbstract" xlink:label="ifrs-full_PresentationOfLeasesForLesseeAbstract" />
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_DisclosureOfBalanceSheetInformationRelatingToLeasesTableTextBlock" xlink:label="gmab_DisclosureOfBalanceSheetInformationRelatingToLeasesTableTextBlock_637957415460685423" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_PresentationOfLeasesForLesseeAbstract" xlink:to="gmab_DisclosureOfBalanceSheetInformationRelatingToLeasesTableTextBlock_637957415460685423" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_DisclosureOfComprehensiveInformationRelatingToLeasesTableTextBlock" xlink:label="gmab_DisclosureOfComprehensiveInformationRelatingToLeasesTableTextBlock_637957415460685423" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_PresentationOfLeasesForLesseeAbstract" xlink:to="gmab_DisclosureOfComprehensiveInformationRelatingToLeasesTableTextBlock_637957415460685423" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.genmab.com/role/DisclosureBasisOfPresentationDetails" xlink:type="extended" xlink:title="40101 - Disclosure - Basis of Presentation (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_BasisOfPresentationAbstract" xlink:label="gmab_BasisOfPresentationAbstract" />
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_NumberOfApprovedProductsCommercializedByThirdParties" xlink:label="gmab_NumberOfApprovedProductsCommercializedByThirdParties_637957415460695426" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gmab_BasisOfPresentationAbstract" xlink:to="gmab_NumberOfApprovedProductsCommercializedByThirdParties_637957415460695426" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_NumberOfApprovedProductsJointlyCommercializedWithCollaboration" xlink:label="gmab_NumberOfApprovedProductsJointlyCommercializedWithCollaboration_637957415460695426" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gmab_BasisOfPresentationAbstract" xlink:to="gmab_NumberOfApprovedProductsJointlyCommercializedWithCollaboration_637957415460695426" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_CollaborativeAgreementProfitSharingPercentage" xlink:label="gmab_CollaborativeAgreementProfitSharingPercentage_637957415460695426" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gmab_BasisOfPresentationAbstract" xlink:to="gmab_CollaborativeAgreementProfitSharingPercentage_637957415460695426" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_IfrsNumberOfReportingUnits" xlink:label="gmab_IfrsNumberOfReportingUnits_637957415460695426" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gmab_BasisOfPresentationAbstract" xlink:to="gmab_IfrsNumberOfReportingUnits_637957415460695426" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.genmab.com/role/DisclosureRevenueDetails" xlink:type="extended" xlink:title="40201 - Disclosure - Revenue (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RevenueAbstract" xlink:label="ifrs-full_RevenueAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" xlink:label="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_637957415460695426" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RevenueAbstract" xlink:to="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_637957415460695426" order="1" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_TypesOfRevenuesAxis" xlink:label="gmab_TypesOfRevenuesAxis_637957415460695426" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_637957415460695426" xlink:to="gmab_TypesOfRevenuesAxis_637957415460695426" order="1" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_TypesOfRevenuesMember" xlink:label="gmab_TypesOfRevenuesMember_637957415460695426" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gmab_TypesOfRevenuesAxis_637957415460695426" xlink:to="gmab_TypesOfRevenuesMember_637957415460695426" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_RoyaltiesRevenueMember" xlink:label="gmab_RoyaltiesRevenueMember_637957415460695426" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gmab_TypesOfRevenuesMember_637957415460695426" xlink:to="gmab_RoyaltiesRevenueMember_637957415460695426" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_ReimbursementIncomeMember" xlink:label="gmab_ReimbursementIncomeMember_637957415460695426" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gmab_TypesOfRevenuesMember_637957415460695426" xlink:to="gmab_ReimbursementIncomeMember_637957415460695426" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_MilestonePaymentsRevenueMember" xlink:label="gmab_MilestonePaymentsRevenueMember_637957415460695426" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gmab_TypesOfRevenuesMember_637957415460695426" xlink:to="gmab_MilestonePaymentsRevenueMember_637957415460695426" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_LicenseFeesMember" xlink:label="gmab_LicenseFeesMember_637957415460695426" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gmab_TypesOfRevenuesMember_637957415460695426" xlink:to="gmab_LicenseFeesMember_637957415460695426" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_CollaborationRevenueMember" xlink:label="gmab_CollaborationRevenueMember_637957415460695426" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gmab_TypesOfRevenuesMember_637957415460695426" xlink:to="gmab_CollaborationRevenueMember_637957415460695426" order="5" use="optional" />
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis" xlink:label="gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_637957415460695426" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_637957415460695426" xlink:to="gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_637957415460695426" order="2" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeDomain" xlink:label="gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeDomain_637957415460695426" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_637957415460695426" xlink:to="gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeDomain_637957415460695426" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_AgreementsWithJanssenMember" xlink:label="gmab_AgreementsWithJanssenMember_637957415460705423" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeDomain_637957415460695426" xlink:to="gmab_AgreementsWithJanssenMember_637957415460705423" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_AgreementsWithAbbvieMember" xlink:label="gmab_AgreementsWithAbbvieMember_637957415460705423" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeDomain_637957415460695426" xlink:to="gmab_AgreementsWithAbbvieMember_637957415460705423" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_AgreementsWithRocheMember" xlink:label="gmab_AgreementsWithRocheMember_637957415460705423" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeDomain_637957415460695426" xlink:to="gmab_AgreementsWithRocheMember_637957415460705423" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_AgreementsWithNovartisMember" xlink:label="gmab_AgreementsWithNovartisMember_637957415460705423" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeDomain_637957415460695426" xlink:to="gmab_AgreementsWithNovartisMember_637957415460705423" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_AgreementsWithBointechMember" xlink:label="gmab_AgreementsWithBointechMember_637957415460705423" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeDomain_637957415460695426" xlink:to="gmab_AgreementsWithBointechMember_637957415460705423" order="5" use="optional" />
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_AgreementsWithSeagenMember" xlink:label="gmab_AgreementsWithSeagenMember_637957415460705423" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeDomain_637957415460695426" xlink:to="gmab_AgreementsWithSeagenMember_637957415460705423" order="6" use="optional" />
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_OtherCollaborationPartnersMember" xlink:label="gmab_OtherCollaborationPartnersMember_637957415460705423" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeDomain_637957415460695426" xlink:to="gmab_OtherCollaborationPartnersMember_637957415460705423" order="7" use="optional" />
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_AgreementsWithSeatleGeneticsMember" xlink:label="gmab_AgreementsWithSeatleGeneticsMember_637957415460705423" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeDomain_637957415460695426" xlink:to="gmab_AgreementsWithSeatleGeneticsMember_637957415460705423" order="8" use="optional" />
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_IfrsRoyaltiesByProductAxis" xlink:label="gmab_IfrsRoyaltiesByProductAxis_637957415460705423" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_637957415460695426" xlink:to="gmab_IfrsRoyaltiesByProductAxis_637957415460705423" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_IfrsRoyaltiesByProductDomain" xlink:label="gmab_IfrsRoyaltiesByProductDomain_637957415460705423" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gmab_IfrsRoyaltiesByProductAxis_637957415460705423" xlink:to="gmab_IfrsRoyaltiesByProductDomain_637957415460705423" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_DarzalexMember" xlink:label="gmab_DarzalexMember_637957415460705423" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gmab_IfrsRoyaltiesByProductDomain_637957415460705423" xlink:to="gmab_DarzalexMember_637957415460705423" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_TepezzaMember" xlink:label="gmab_TepezzaMember_637957415460705423" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gmab_IfrsRoyaltiesByProductDomain_637957415460705423" xlink:to="gmab_TepezzaMember_637957415460705423" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_KesimptaMember" xlink:label="gmab_KesimptaMember_637957415460715427" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gmab_IfrsRoyaltiesByProductDomain_637957415460705423" xlink:to="gmab_KesimptaMember_637957415460715427" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_OtherRoyaltyProductMember" xlink:label="gmab_OtherRoyaltyProductMember_637957415460715427" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gmab_IfrsRoyaltiesByProductDomain_637957415460705423" xlink:to="gmab_OtherRoyaltyProductMember_637957415460715427" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:label="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_637957415460715427" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_637957415460695426" xlink:to="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_637957415460715427" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RevenueFromContractsWithCustomers" xlink:label="ifrs-full_RevenueFromContractsWithCustomers_637957415460715427" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_637957415460715427" xlink:to="ifrs-full_RevenueFromContractsWithCustomers_637957415460715427" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.genmab.com/role/DisclosureFinancialInstrumentsFinancialRiskDetails" xlink:type="extended" xlink:title="40301 - Disclosure - Financial Instruments - Financial Risk (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfFinancialInstrumentsAbstract" xlink:label="ifrs-full_DisclosureOfFinancialInstrumentsAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfCreditRiskExposureTable" xlink:label="ifrs-full_DisclosureOfCreditRiskExposureTable_637957415460715427" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsAbstract" xlink:to="ifrs-full_DisclosureOfCreditRiskExposureTable_637957415460715427" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TypesOfRisksAxis" xlink:label="ifrs-full_TypesOfRisksAxis_637957415460715427" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfCreditRiskExposureTable_637957415460715427" xlink:to="ifrs-full_TypesOfRisksAxis_637957415460715427" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TypesOfRisksMember" xlink:label="ifrs-full_TypesOfRisksMember_637957415460715427" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TypesOfRisksAxis_637957415460715427" xlink:to="ifrs-full_TypesOfRisksMember_637957415460715427" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CreditRiskMember" xlink:label="ifrs-full_CreditRiskMember_637957415460715427" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TypesOfRisksMember_637957415460715427" xlink:to="ifrs-full_CreditRiskMember_637957415460715427" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CurrencyRiskMember" xlink:label="ifrs-full_CurrencyRiskMember_637957415460715427" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TypesOfRisksMember_637957415460715427" xlink:to="ifrs-full_CurrencyRiskMember_637957415460715427" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ExternalCreditGradesAxis" xlink:label="ifrs-full_ExternalCreditGradesAxis_637957415460725426" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfCreditRiskExposureTable_637957415460715427" xlink:to="ifrs-full_ExternalCreditGradesAxis_637957415460725426" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_EntitysTotalForExternalCreditGradesMember" xlink:label="ifrs-full_EntitysTotalForExternalCreditGradesMember_637957415460725426" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ExternalCreditGradesAxis_637957415460725426" xlink:to="ifrs-full_EntitysTotalForExternalCreditGradesMember_637957415460725426" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_TripleaRatingMember" xlink:label="gmab_TripleaRatingMember_637957415460725426" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EntitysTotalForExternalCreditGradesMember_637957415460725426" xlink:to="gmab_TripleaRatingMember_637957415460725426" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CurrencyAxis" xlink:label="srt_CurrencyAxis_637957415460725426" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfCreditRiskExposureTable_637957415460715427" xlink:to="srt_CurrencyAxis_637957415460725426" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2021/currency-2021.xsd#currency_AllCurrenciesDomain" xlink:label="currency_AllCurrenciesDomain_637957415460725426" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CurrencyAxis_637957415460725426" xlink:to="currency_AllCurrenciesDomain_637957415460725426" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2021/currency-2021.xsd#currency_USD" xlink:label="currency_USD_637957415460725426" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="currency_AllCurrenciesDomain_637957415460725426" xlink:to="currency_USD_637957415460725426" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2021/currency-2021.xsd#currency_DKK" xlink:label="currency_DKK_637957415460725426" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="currency_AllCurrenciesDomain_637957415460725426" xlink:to="currency_DKK_637957415460725426" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2021/currency-2021.xsd#currency_EUR" xlink:label="currency_EUR_637957415460725426" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="currency_AllCurrenciesDomain_637957415460725426" xlink:to="currency_EUR_637957415460725426" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2021/currency-2021.xsd#currency_GBP" xlink:label="currency_GBP_637957415460725426" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="currency_AllCurrenciesDomain_637957415460725426" xlink:to="currency_GBP_637957415460725426" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis" xlink:label="gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_637957415460725426" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfCreditRiskExposureTable_637957415460715427" xlink:to="gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_637957415460725426" order="4" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeDomain" xlink:label="gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeDomain_637957415460725426" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_637957415460725426" xlink:to="gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeDomain_637957415460725426" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_AgreementsWithAbbvieMember" xlink:label="gmab_AgreementsWithAbbvieMember_637957415460725426" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeDomain_637957415460725426" xlink:to="gmab_AgreementsWithAbbvieMember_637957415460725426" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfCreditRiskExposureLineItems" xlink:label="ifrs-full_DisclosureOfCreditRiskExposureLineItems_637957415460735425" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfCreditRiskExposureTable_637957415460715427" xlink:to="ifrs-full_DisclosureOfCreditRiskExposureLineItems_637957415460735425" order="5" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_MaximumExposureToCreditRisk" xlink:label="ifrs-full_MaximumExposureToCreditRisk_637957415460735425" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfCreditRiskExposureLineItems_637957415460735425" xlink:to="ifrs-full_MaximumExposureToCreditRisk_637957415460735425" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_MaximumExposureToCreditRiskOfLoansOrReceivables" xlink:label="ifrs-full_MaximumExposureToCreditRiskOfLoansOrReceivables_637957415460735425" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfCreditRiskExposureLineItems_637957415460735425" xlink:to="ifrs-full_MaximumExposureToCreditRiskOfLoansOrReceivables_637957415460735425" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_PercentageOfMarketableSecurities" xlink:label="gmab_PercentageOfMarketableSecurities_637957415460735425" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfCreditRiskExposureLineItems_637957415460735425" xlink:to="gmab_PercentageOfMarketableSecurities_637957415460735425" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_MarketableSecuritiesIncludingInterestReceivables" xlink:label="gmab_MarketableSecuritiesIncludingInterestReceivables_637957415460735425" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfCreditRiskExposureLineItems_637957415460735425" xlink:to="gmab_MarketableSecuritiesIncludingInterestReceivables_637957415460735425" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_BankDepositsIncludingShortTermMarketableSecurities" xlink:label="gmab_BankDepositsIncludingShortTermMarketableSecurities_637957415460735425" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfCreditRiskExposureLineItems_637957415460735425" xlink:to="gmab_BankDepositsIncludingShortTermMarketableSecurities_637957415460735425" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_PercentageOfRevenue" xlink:label="gmab_PercentageOfRevenue_637957415460735425" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfCreditRiskExposureLineItems_637957415460735425" xlink:to="gmab_PercentageOfRevenue_637957415460735425" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_PercentageOfMarketableSecuritiesInvested" xlink:label="gmab_PercentageOfMarketableSecuritiesInvested_637957415460735425" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfCreditRiskExposureLineItems_637957415460735425" xlink:to="gmab_PercentageOfMarketableSecuritiesInvested_637957415460735425" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_PercentageOfPossibleIncreaseDecreaseInExchangeRate" xlink:label="gmab_PercentageOfPossibleIncreaseDecreaseInExchangeRate_637957415460735425" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfCreditRiskExposureLineItems_637957415460735425" xlink:to="gmab_PercentageOfPossibleIncreaseDecreaseInExchangeRate_637957415460735425" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.genmab.com/role/DisclosureFinancialInstrumentsFairValueMeasurementDetails" xlink:type="extended" xlink:title="40302 - Disclosure - Financial Instruments  - Fair Value Measurement (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfFinancialInstrumentsAbstract" xlink:label="ifrs-full_DisclosureOfFinancialInstrumentsAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfFairValueMeasurementOfAssetsTable" xlink:label="ifrs-full_DisclosureOfFairValueMeasurementOfAssetsTable_637957415460745435" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsAbstract" xlink:to="ifrs-full_DisclosureOfFairValueMeasurementOfAssetsTable_637957415460745435" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_MeasurementAxis" xlink:label="ifrs-full_MeasurementAxis_637957415460745435" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFairValueMeasurementOfAssetsTable_637957415460745435" xlink:to="ifrs-full_MeasurementAxis_637957415460745435" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AggregatedMeasurementMember" xlink:label="ifrs-full_AggregatedMeasurementMember_637957415460745435" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_MeasurementAxis_637957415460745435" xlink:to="ifrs-full_AggregatedMeasurementMember_637957415460745435" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AtFairValueMember" xlink:label="ifrs-full_AtFairValueMember_637957415460745435" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AggregatedMeasurementMember_637957415460745435" xlink:to="ifrs-full_AtFairValueMember_637957415460745435" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ClassesOfFinancialAssetsAxis" xlink:label="ifrs-full_ClassesOfFinancialAssetsAxis_637957415460745435" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFairValueMeasurementOfAssetsTable_637957415460745435" xlink:to="ifrs-full_ClassesOfFinancialAssetsAxis_637957415460745435" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_FinancialAssetsMember" xlink:label="ifrs-full_FinancialAssetsMember_637957415460745435" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfFinancialAssetsAxis_637957415460745435" xlink:to="ifrs-full_FinancialAssetsMember_637957415460745435" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_MarketableSecuritiesMember" xlink:label="gmab_MarketableSecuritiesMember_637957415460745435" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_FinancialAssetsMember_637957415460745435" xlink:to="gmab_MarketableSecuritiesMember_637957415460745435" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_OtherInvestmentMember" xlink:label="gmab_OtherInvestmentMember_637957415460745435" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_FinancialAssetsMember_637957415460745435" xlink:to="gmab_OtherInvestmentMember_637957415460745435" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_LevelsOfFairValueHierarchyAxis" xlink:label="ifrs-full_LevelsOfFairValueHierarchyAxis_637957415460745435" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFairValueMeasurementOfAssetsTable_637957415460745435" xlink:to="ifrs-full_LevelsOfFairValueHierarchyAxis_637957415460745435" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AllLevelsOfFairValueHierarchyMember" xlink:label="ifrs-full_AllLevelsOfFairValueHierarchyMember_637957415460745435" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_LevelsOfFairValueHierarchyAxis_637957415460745435" xlink:to="ifrs-full_AllLevelsOfFairValueHierarchyMember_637957415460745435" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_Level1OfFairValueHierarchyMember" xlink:label="ifrs-full_Level1OfFairValueHierarchyMember_637957415460745435" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AllLevelsOfFairValueHierarchyMember_637957415460745435" xlink:to="ifrs-full_Level1OfFairValueHierarchyMember_637957415460745435" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_Level2OfFairValueHierarchyMember" xlink:label="ifrs-full_Level2OfFairValueHierarchyMember_637957415460745435" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AllLevelsOfFairValueHierarchyMember_637957415460745435" xlink:to="ifrs-full_Level2OfFairValueHierarchyMember_637957415460745435" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_Level3OfFairValueHierarchyMember" xlink:label="ifrs-full_Level3OfFairValueHierarchyMember_637957415460755428" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AllLevelsOfFairValueHierarchyMember_637957415460745435" xlink:to="ifrs-full_Level3OfFairValueHierarchyMember_637957415460755428" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfFairValueMeasurementOfAssetsLineItems" xlink:label="ifrs-full_DisclosureOfFairValueMeasurementOfAssetsLineItems_637957415460755428" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFairValueMeasurementOfAssetsTable_637957415460745435" xlink:to="ifrs-full_DisclosureOfFairValueMeasurementOfAssetsLineItems_637957415460755428" order="4" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ReconciliationOfChangesInFairValueMeasurementAssetsAbstract" xlink:label="ifrs-full_ReconciliationOfChangesInFairValueMeasurementAssetsAbstract_637957415460755428" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFairValueMeasurementOfAssetsLineItems_637957415460755428" xlink:to="ifrs-full_ReconciliationOfChangesInFairValueMeasurementAssetsAbstract_637957415460755428" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_FinancialAssets" xlink:label="ifrs-full_FinancialAssets_637957415460755428" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ReconciliationOfChangesInFairValueMeasurementAssetsAbstract_637957415460755428" xlink:to="ifrs-full_FinancialAssets_637957415460755428" order="1" use="optional" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.genmab.com/role/DisclosureFinancialInstrumentsOtherInvestmentsDetails" xlink:type="extended" xlink:title="40303 - Disclosure - Financial Instruments - Other Investments (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfFinancialInstrumentsAbstract" xlink:label="ifrs-full_DisclosureOfFinancialInstrumentsAbstract" />
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeTable" xlink:label="gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeTable_637957415460755428" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsAbstract" xlink:to="gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeTable_637957415460755428" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis" xlink:label="gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_637957415460755428" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeTable_637957415460755428" xlink:to="gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_637957415460755428" order="1" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeDomain" xlink:label="gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeDomain_637957415460755428" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_637957415460755428" xlink:to="gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeDomain_637957415460755428" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_CurevacCollaborationMember" xlink:label="gmab_CurevacCollaborationMember_637957415460755428" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeDomain_637957415460755428" xlink:to="gmab_CurevacCollaborationMember_637957415460755428" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_BoltBiotherapeuticsIncMember" xlink:label="gmab_BoltBiotherapeuticsIncMember_637957415460755428" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeDomain_637957415460755428" xlink:to="gmab_BoltBiotherapeuticsIncMember_637957415460755428" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_CollaborativeArrangementAndArrangementOtherThanCollaborativeLineItems" xlink:label="gmab_CollaborativeArrangementAndArrangementOtherThanCollaborativeLineItems_637957415460755428" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeTable_637957415460755428" xlink:to="gmab_CollaborativeArrangementAndArrangementOtherThanCollaborativeLineItems_637957415460755428" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_InvestmentAccountedForUsingEquityMethod" xlink:label="ifrs-full_InvestmentAccountedForUsingEquityMethod_637957415460755428" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gmab_CollaborativeArrangementAndArrangementOtherThanCollaborativeLineItems_637957415460755428" xlink:to="ifrs-full_InvestmentAccountedForUsingEquityMethod_637957415460755428" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_PercentageOfInvestmentInCommonShares" xlink:label="gmab_PercentageOfInvestmentInCommonShares_637957415460755428" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gmab_CollaborativeArrangementAndArrangementOtherThanCollaborativeLineItems_637957415460755428" xlink:to="gmab_PercentageOfInvestmentInCommonShares_637957415460755428" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProceedsFromIssueOfOrdinaryShares" xlink:label="ifrs-full_ProceedsFromIssueOfOrdinaryShares_637957415460765424" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gmab_CollaborativeArrangementAndArrangementOtherThanCollaborativeLineItems_637957415460755428" xlink:to="ifrs-full_ProceedsFromIssueOfOrdinaryShares_637957415460765424" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
  </presentationLink>
  <presentationLink xlink:role="http://www.genmab.com/role/DisclosureFinancialIncomeAndExpensesDetails" xlink:type="extended" xlink:title="40401 - Disclosure - Financial Income and Expenses (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_DisclosureOfFinanceIncomeExpensesAbstract" xlink:label="gmab_DisclosureOfFinanceIncomeExpensesAbstract" />
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_FinanceIncomeAbstract" xlink:label="gmab_FinanceIncomeAbstract_637957415460765424" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gmab_DisclosureOfFinanceIncomeExpensesAbstract" xlink:to="gmab_FinanceIncomeAbstract_637957415460765424" order="1" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_InterestAndOtherFinancialIncome" xlink:label="gmab_InterestAndOtherFinancialIncome_637957415460765424" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gmab_FinanceIncomeAbstract_637957415460765424" xlink:to="gmab_InterestAndOtherFinancialIncome_637957415460765424" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_GainOnOtherInvestments" xlink:label="gmab_GainOnOtherInvestments_637957415460765424" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gmab_FinanceIncomeAbstract_637957415460765424" xlink:to="gmab_GainOnOtherInvestments_637957415460765424" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_GainsOnHedgingInstruments" xlink:label="gmab_GainsOnHedgingInstruments_637957415460825425" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gmab_FinanceIncomeAbstract_637957415460765424" xlink:to="gmab_GainsOnHedgingInstruments_637957415460825425" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NetForeignExchangeGain" xlink:label="ifrs-full_NetForeignExchangeGain_637957415460825425" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gmab_FinanceIncomeAbstract_637957415460765424" xlink:to="ifrs-full_NetForeignExchangeGain_637957415460825425" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_FinanceIncome" xlink:label="ifrs-full_FinanceIncome_637957415460825425" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gmab_FinanceIncomeAbstract_637957415460765424" xlink:to="ifrs-full_FinanceIncome_637957415460825425" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_FinanceExpensesAbstract" xlink:label="gmab_FinanceExpensesAbstract_637957415460825425" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gmab_DisclosureOfFinanceIncomeExpensesAbstract" xlink:to="gmab_FinanceExpensesAbstract_637957415460825425" order="2" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_InterestAndOtherFinancialExpenses" xlink:label="gmab_InterestAndOtherFinancialExpenses_637957415460835428" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gmab_FinanceExpensesAbstract_637957415460825425" xlink:to="gmab_InterestAndOtherFinancialExpenses_637957415460835428" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="9" />
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_LossesOnMarketableSecurities" xlink:label="gmab_LossesOnMarketableSecurities_637957415460835428" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gmab_FinanceExpensesAbstract_637957415460825425" xlink:to="gmab_LossesOnMarketableSecurities_637957415460835428" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="9" />
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_LossesOnOtherInvestmentsNet" xlink:label="gmab_LossesOnOtherInvestmentsNet_637957415460835428" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gmab_FinanceExpensesAbstract_637957415460825425" xlink:to="gmab_LossesOnOtherInvestmentsNet_637957415460835428" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NetForeignExchangeLoss" xlink:label="ifrs-full_NetForeignExchangeLoss_637957415460835428" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gmab_FinanceExpensesAbstract_637957415460825425" xlink:to="ifrs-full_NetForeignExchangeLoss_637957415460835428" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="9" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_FinanceCosts" xlink:label="ifrs-full_FinanceCosts_637957415460835428" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gmab_FinanceExpensesAbstract_637957415460825425" xlink:to="ifrs-full_FinanceCosts_637957415460835428" order="5" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" priority="9" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_FinanceIncomeCost" xlink:label="ifrs-full_FinanceIncomeCost_637957415460835428" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="gmab_DisclosureOfFinanceIncomeExpensesAbstract" xlink:to="ifrs-full_FinanceIncomeCost_637957415460835428" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.genmab.com/role/DisclosureShareBasedInstrumentsRestrictedStockUnitProgramDetails" xlink:type="extended" xlink:title="40501 - Disclosure - Share-Based Instruments - Restricted Stock Unit Program (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_637957415460835428" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:to="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_637957415460835428" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis_637957415460835428" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_637957415460835428" xlink:to="ifrs-full_CategoriesOfRelatedPartiesAxis_637957415460835428" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="ifrs-full_EntitysTotalForRelatedPartiesMember_637957415460835428" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis_637957415460835428" xlink:to="ifrs-full_EntitysTotalForRelatedPartiesMember_637957415460835428" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:label="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_637957415460835428" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_637957415460835428" xlink:to="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_637957415460835428" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_SharebasedPaymentArrangementsMember" xlink:label="ifrs-full_SharebasedPaymentArrangementsMember_637957415460835428" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_637957415460835428" xlink:to="ifrs-full_SharebasedPaymentArrangementsMember_637957415460835428" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_IfrsRestrictedStockUnitsRSUsMember" xlink:label="gmab_IfrsRestrictedStockUnitsRSUsMember_637957415460845423" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_SharebasedPaymentArrangementsMember_637957415460835428" xlink:to="gmab_IfrsRestrictedStockUnitsRSUsMember_637957415460845423" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_637957415460845423" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_637957415460835428" xlink:to="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_637957415460845423" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" xlink:label="ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_637957415460845423" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_637957415460845423" xlink:to="ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_637957415460845423" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted" xlink:label="ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted_637957415460845423" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_637957415460845423" xlink:to="ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted_637957415460845423" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_Weightedaveragefairvalueofotherequityinstrumentsgrantedinsharebasedpaymentarrangement" xlink:label="gmab_Weightedaveragefairvalueofotherequityinstrumentsgrantedinsharebasedpaymentarrangement_637957415460845423" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_637957415460845423" xlink:to="gmab_Weightedaveragefairvalueofotherequityinstrumentsgrantedinsharebasedpaymentarrangement_637957415460845423" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" xlink:label="ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement_637957415460845423" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_637957415460845423" xlink:to="ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement_637957415460845423" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="8" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" xlink:label="ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement_637957415460845423" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_637957415460845423" xlink:to="ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement_637957415460845423" order="5" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" xlink:label="ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_6379574154608454231" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_637957415460845423" xlink:to="ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_6379574154608454231" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_SaleOrIssueOfTreasuryShares" xlink:label="ifrs-full_SaleOrIssueOfTreasuryShares_637957415460845423" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_637957415460845423" xlink:to="ifrs-full_SaleOrIssueOfTreasuryShares_637957415460845423" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TreasuryShares" xlink:label="ifrs-full_TreasuryShares_637957415460845423" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_637957415460845423" xlink:to="ifrs-full_TreasuryShares_637957415460845423" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.genmab.com/role/DisclosureShareBasedInstrumentsWarrantProgramDetails" xlink:type="extended" xlink:title="40502 - Disclosure - Share-Based Instruments - Warrant Program (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_637957415460855426" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:to="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_637957415460855426" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:label="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_637957415460855426" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_637957415460855426" xlink:to="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_637957415460855426" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_SharebasedPaymentArrangementsMember" xlink:label="ifrs-full_SharebasedPaymentArrangementsMember_637957415460855426" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_637957415460855426" xlink:to="ifrs-full_SharebasedPaymentArrangementsMember_637957415460855426" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_WarrantsGrantedFromAugust2004UntilApril2012Member" xlink:label="gmab_WarrantsGrantedFromAugust2004UntilApril2012Member_637957415460855426" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_SharebasedPaymentArrangementsMember_637957415460855426" xlink:to="gmab_WarrantsGrantedFromAugust2004UntilApril2012Member_637957415460855426" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_WarrantsGrantedFromApril2012UntilMarch2017Member" xlink:label="gmab_WarrantsGrantedFromApril2012UntilMarch2017Member_637957415460855426" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_SharebasedPaymentArrangementsMember_637957415460855426" xlink:to="gmab_WarrantsGrantedFromApril2012UntilMarch2017Member_637957415460855426" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_WarrantsGrantedFromMarch2017Member" xlink:label="gmab_WarrantsGrantedFromMarch2017Member_637957415460855426" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_SharebasedPaymentArrangementsMember_637957415460855426" xlink:to="gmab_WarrantsGrantedFromMarch2017Member_637957415460855426" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_WarrantsMember" xlink:label="gmab_WarrantsMember_637957415460855426" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_SharebasedPaymentArrangementsMember_637957415460855426" xlink:to="gmab_WarrantsMember_637957415460855426" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_637957415460855426" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_637957415460855426" xlink:to="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_637957415460855426" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_WarrantVestingPeriod" xlink:label="gmab_WarrantVestingPeriod_637957415460855426" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_637957415460855426" xlink:to="gmab_WarrantVestingPeriod_637957415460855426" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_NumberOfWarrantsOutstanding" xlink:label="gmab_NumberOfWarrantsOutstanding_637957415460855426" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_637957415460855426" xlink:to="gmab_NumberOfWarrantsOutstanding_637957415460855426" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_NumberOfWarrantsGrantedDuringPeriod" xlink:label="gmab_NumberOfWarrantsGrantedDuringPeriod_637957415460855426" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_637957415460855426" xlink:to="gmab_NumberOfWarrantsGrantedDuringPeriod_637957415460855426" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_NumberOfWarrantsExercisedDuringPeriod" xlink:label="gmab_NumberOfWarrantsExercisedDuringPeriod_637957415460855426" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_637957415460855426" xlink:to="gmab_NumberOfWarrantsExercisedDuringPeriod_637957415460855426" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_NumberOfWarrantsExpiredOrLapsedOrCancelledDuringPeriod" xlink:label="gmab_NumberOfWarrantsExpiredOrLapsedOrCancelledDuringPeriod_637957415460855426" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_637957415460855426" xlink:to="gmab_NumberOfWarrantsExpiredOrLapsedOrCancelledDuringPeriod_637957415460855426" order="5" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_NumberOfWarrantsOutstanding" xlink:label="gmab_NumberOfWarrantsOutstanding_637957415460865427" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_637957415460855426" xlink:to="gmab_NumberOfWarrantsOutstanding_637957415460865427" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_WeightedAverageExercisePriceOfWarrantsGranted" xlink:label="gmab_WeightedAverageExercisePriceOfWarrantsGranted_637957415460865427" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_637957415460855426" xlink:to="gmab_WeightedAverageExercisePriceOfWarrantsGranted_637957415460865427" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_WeightedAverageExercisePriceOfFairValueOfWarrants" xlink:label="gmab_WeightedAverageExercisePriceOfFairValueOfWarrants_637957415460865427" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_637957415460855426" xlink:to="gmab_WeightedAverageExercisePriceOfFairValueOfWarrants_637957415460865427" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_WeightedAverageExercisePriceOfWarrantsExercised" xlink:label="gmab_WeightedAverageExercisePriceOfWarrantsExercised_637957415460865427" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_637957415460855426" xlink:to="gmab_WeightedAverageExercisePriceOfWarrantsExercised_637957415460865427" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ProceedsFromExerciseOfWarrants" xlink:label="ifrs-full_ProceedsFromExerciseOfWarrants_637957415460865427" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_637957415460855426" xlink:to="ifrs-full_ProceedsFromExerciseOfWarrants_637957415460865427" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_PercentageOfShareCapitalAttributedToExerciseOfWarrants" xlink:label="gmab_PercentageOfShareCapitalAttributedToExerciseOfWarrants_637957415460865427" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_637957415460855426" xlink:to="gmab_PercentageOfShareCapitalAttributedToExerciseOfWarrants_637957415460865427" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" xlink:label="ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets_637957415460865427" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_637957415460855426" xlink:to="ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets_637957415460865427" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_NumberOfTreasurySharesOutstanding" xlink:label="gmab_NumberOfTreasurySharesOutstanding_637957415460865427" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_637957415460855426" xlink:to="gmab_NumberOfTreasurySharesOutstanding_637957415460865427" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.genmab.com/role/DisclosureShareBasedInstrumentsShareRepurchasesDetails" xlink:type="extended" xlink:title="40503 - Disclosure - Share-Based Instruments - Share repurchases (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_637957415460875427" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:to="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_637957415460875427" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis_637957415460875427" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_637957415460875427" xlink:to="srt_StatementScenarioAxis_637957415460875427" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain_637957415460875427" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis_637957415460875427" xlink:to="srt_ScenarioUnspecifiedDomain_637957415460875427" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_StockRepurchaseFirstAuthorizationMember" xlink:label="gmab_StockRepurchaseFirstAuthorizationMember_637957415460875427" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain_637957415460875427" xlink:to="gmab_StockRepurchaseFirstAuthorizationMember_637957415460875427" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_StockRepurchaseSecondAuthorizationMember" xlink:label="gmab_StockRepurchaseSecondAuthorizationMember_637957415460875427" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain_637957415460875427" xlink:to="gmab_StockRepurchaseSecondAuthorizationMember_637957415460875427" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_ThirdAuthorizationMember" xlink:label="gmab_ThirdAuthorizationMember_637957415460875427" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain_637957415460875427" xlink:to="gmab_ThirdAuthorizationMember_637957415460875427" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_StockRepurchaseAuthorization2021Member" xlink:label="gmab_StockRepurchaseAuthorization2021Member_637957415460875427" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain_637957415460875427" xlink:to="gmab_StockRepurchaseAuthorization2021Member_637957415460875427" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_StockRepurchaseAuthorization2019Member" xlink:label="gmab_StockRepurchaseAuthorization2019Member_637957415460875427" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain_637957415460875427" xlink:to="gmab_StockRepurchaseAuthorization2019Member_637957415460875427" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_StockRepurchaseAuthorization2016Member" xlink:label="gmab_StockRepurchaseAuthorization2016Member_637957415460875427" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain_637957415460875427" xlink:to="gmab_StockRepurchaseAuthorization2016Member_637957415460875427" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:label="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_637957415460875427" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_637957415460875427" xlink:to="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_637957415460875427" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_SharebasedPaymentArrangementsMember" xlink:label="ifrs-full_SharebasedPaymentArrangementsMember_637957415460875427" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_637957415460875427" xlink:to="ifrs-full_SharebasedPaymentArrangementsMember_637957415460875427" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_RestrictedStockUnitsRSUsMember" xlink:label="gmab_RestrictedStockUnitsRSUsMember_637957415460875427" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_SharebasedPaymentArrangementsMember_637957415460875427" xlink:to="gmab_RestrictedStockUnitsRSUsMember_637957415460875427" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_637957415460875427" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_637957415460875427" xlink:to="srt_RangeAxis_637957415460875427" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember_637957415460875427" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_637957415460875427" xlink:to="srt_RangeMember_637957415460875427" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_637957415460885429" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_637957415460875427" xlink:to="srt_MaximumMember_637957415460885429" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_637957415460885429" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_637957415460875427" xlink:to="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_637957415460885429" order="4" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_NumberOfSharesAuthorizedToBeRepurchased" xlink:label="gmab_NumberOfSharesAuthorizedToBeRepurchased_637957415460885429" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_637957415460885429" xlink:to="gmab_NumberOfSharesAuthorizedToBeRepurchased_637957415460885429" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_ShareRepurchasedDuringPeriodShares" xlink:label="gmab_ShareRepurchasedDuringPeriodShares_637957415460885429" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_637957415460885429" xlink:to="gmab_ShareRepurchasedDuringPeriodShares_637957415460885429" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_SharesAvailableForRepurchase" xlink:label="gmab_SharesAvailableForRepurchase_637957415460885429" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_637957415460885429" xlink:to="gmab_SharesAvailableForRepurchase_637957415460885429" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_IfrsShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod" xlink:label="gmab_IfrsShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod_637957415460885429" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_637957415460885429" xlink:to="gmab_IfrsShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod_637957415460885429" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_ShareBasedArrangementPeriodFromVestingDateHolderReceivesShares" xlink:label="gmab_ShareBasedArrangementPeriodFromVestingDateHolderReceivesShares_637957415460885429" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_637957415460885429" xlink:to="gmab_ShareBasedArrangementPeriodFromVestingDateHolderReceivesShares_637957415460885429" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_ShareBasedArrangementNumberOfSharesPerRsu" xlink:label="gmab_ShareBasedArrangementNumberOfSharesPerRsu_637957415460885429" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_637957415460885429" xlink:to="gmab_ShareBasedArrangementNumberOfSharesPerRsu_637957415460885429" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_ShareBasedArrangementNumberOfAuthorization" xlink:label="gmab_ShareBasedArrangementNumberOfAuthorization_637957415460885429" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_637957415460885429" xlink:to="gmab_ShareBasedArrangementNumberOfAuthorization_637957415460885429" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_SharesRepurchasedNominalValue" xlink:label="gmab_SharesRepurchasedNominalValue_637957415460885429" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_637957415460885429" xlink:to="gmab_SharesRepurchasedNominalValue_637957415460885429" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_StockRepurchaseThresholdPriceDeviationPercentage" xlink:label="gmab_StockRepurchaseThresholdPriceDeviationPercentage_637957415460895428" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_637957415460885429" xlink:to="gmab_StockRepurchaseThresholdPriceDeviationPercentage_637957415460895428" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_ShareRepurchasedDuringPeriodValue" xlink:label="gmab_ShareRepurchasedDuringPeriodValue_637957415460895428" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_637957415460885429" xlink:to="gmab_ShareRepurchasedDuringPeriodValue_637957415460895428" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_SharesAvailableForRepurchaseAmount" xlink:label="gmab_SharesAvailableForRepurchaseAmount_637957415460895428" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_637957415460885429" xlink:to="gmab_SharesAvailableForRepurchaseAmount_637957415460895428" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_TreasurySharesAcquired" xlink:label="gmab_TreasurySharesAcquired_637957415460895428" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_637957415460885429" xlink:to="gmab_TreasurySharesAcquired_637957415460895428" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_PercentageOfShareCapitalRepurchased" xlink:label="gmab_PercentageOfShareCapitalRepurchased_637957415460895428" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_637957415460885429" xlink:to="gmab_PercentageOfShareCapitalRepurchased_637957415460895428" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_PurchaseOfTreasuryShares" xlink:label="ifrs-full_PurchaseOfTreasuryShares_637957415460895428" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_637957415460885429" xlink:to="ifrs-full_PurchaseOfTreasuryShares_637957415460895428" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.genmab.com/role/DisclosureRelatedPartiesDetails" xlink:type="extended" xlink:title="40601 - Disclosure - Related Parties (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract" xlink:label="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:label="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_637957415460895428" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract" xlink:to="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_637957415460895428" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis_637957415460895428" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_637957415460895428" xlink:to="ifrs-full_CategoriesOfRelatedPartiesAxis_637957415460895428" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="ifrs-full_EntitysTotalForRelatedPartiesMember_637957415460905428" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis_637957415460895428" xlink:to="ifrs-full_EntitysTotalForRelatedPartiesMember_637957415460905428" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_KeyManagementPersonnelOfEntityOrParentMember" xlink:label="ifrs-full_KeyManagementPersonnelOfEntityOrParentMember_637957415460905428" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember_637957415460905428" xlink:to="ifrs-full_KeyManagementPersonnelOfEntityOrParentMember_637957415460905428" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_DeirdreP.ConnellyChairPernilleErenbjergDeputyChairRolfHoffmannDr.PaoloPaolettiAndDr.AndersGerselPedersenMember" xlink:label="gmab_DeirdreP.ConnellyChairPernilleErenbjergDeputyChairRolfHoffmannDr.PaoloPaolettiAndDr.AndersGerselPedersenMember_637957415460905428" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember_637957415460905428" xlink:to="gmab_DeirdreP.ConnellyChairPernilleErenbjergDeputyChairRolfHoffmannDr.PaoloPaolettiAndDr.AndersGerselPedersenMember_637957415460905428" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_ElizabethOfarrellMember" xlink:label="gmab_ElizabethOfarrellMember_637957415460905428" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember_637957415460905428" xlink:to="gmab_ElizabethOfarrellMember_637957415460905428" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_MijkeZachariasseMartinSchultzAndTakahiroHamataniMember" xlink:label="gmab_MijkeZachariasseMartinSchultzAndTakahiroHamataniMember_637957415460905428" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember_637957415460905428" xlink:to="gmab_MijkeZachariasseMartinSchultzAndTakahiroHamataniMember_637957415460905428" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:label="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_637957415460905428" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_637957415460895428" xlink:to="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_637957415460905428" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_NumberOfChangesToExecutiveManagementTeam" xlink:label="gmab_NumberOfChangesToExecutiveManagementTeam_637957415460905428" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_637957415460905428" xlink:to="gmab_NumberOfChangesToExecutiveManagementTeam_637957415460905428" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_NumberOfIndependentBoardMembers" xlink:label="gmab_NumberOfIndependentBoardMembers_637957415460905428" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_637957415460905428" xlink:to="gmab_NumberOfIndependentBoardMembers_637957415460905428" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_NumberOfNonIndependentBoardMembers" xlink:label="gmab_NumberOfNonIndependentBoardMembers_637957415460905428" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_637957415460905428" xlink:to="gmab_NumberOfNonIndependentBoardMembers_637957415460905428" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_NumberOfEmployeeElectedBoardMembers" xlink:label="gmab_NumberOfEmployeeElectedBoardMembers_637957415460905428" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_637957415460905428" xlink:to="gmab_NumberOfEmployeeElectedBoardMembers_637957415460905428" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_ReElectionToBoardOfDirectorsTerm" xlink:label="gmab_ReElectionToBoardOfDirectorsTerm_637957415460905428" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_637957415460905428" xlink:to="gmab_ReElectionToBoardOfDirectorsTerm_637957415460905428" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_ElectionToBoardOfDirectorsTerm" xlink:label="gmab_ElectionToBoardOfDirectorsTerm_637957415460905428" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_637957415460905428" xlink:to="gmab_ElectionToBoardOfDirectorsTerm_637957415460905428" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.genmab.com/role/DisclosureLeasesDetails" xlink:type="extended" xlink:title="40701 - Disclosure - Leases (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_PresentationOfLeasesForLesseeAbstract" xlink:label="ifrs-full_PresentationOfLeasesForLesseeAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable" xlink:label="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable_637957415460915428" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_PresentationOfLeasesForLesseeAbstract" xlink:to="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable_637957415460915428" order="1" use="optional" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ClassesOfAssetsAxis" xlink:label="ifrs-full_ClassesOfAssetsAxis_637957415460915428" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable_637957415460915428" xlink:to="ifrs-full_ClassesOfAssetsAxis_637957415460915428" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ClassesOfAssetsMember" xlink:label="ifrs-full_ClassesOfAssetsMember_637957415460915428" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfAssetsAxis_637957415460915428" xlink:to="ifrs-full_ClassesOfAssetsMember_637957415460915428" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_PropertiesMember" xlink:label="gmab_PropertiesMember_637957415460915428" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfAssetsMember_637957415460915428" xlink:to="gmab_PropertiesMember_637957415460915428" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_IfrsEquipmentMember" xlink:label="gmab_IfrsEquipmentMember_637957415460915428" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfAssetsMember_637957415460915428" xlink:to="gmab_IfrsEquipmentMember_637957415460915428" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:label="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_637957415460915428" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable_637957415460915428" xlink:to="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_637957415460915428" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_PropertyPlantAndEquipmentMember" xlink:label="ifrs-full_PropertyPlantAndEquipmentMember_637957415460915428" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_637957415460915428" xlink:to="ifrs-full_PropertyPlantAndEquipmentMember_637957415460915428" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_OfficeAndLaboratorySpaceMember" xlink:label="gmab_OfficeAndLaboratorySpaceMember_637957415460915428" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_PropertyPlantAndEquipmentMember_637957415460915428" xlink:to="gmab_OfficeAndLaboratorySpaceMember_637957415460915428" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis_637957415460915428" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable_637957415460915428" xlink:to="srt_StatementGeographicalAxis_637957415460915428" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain_637957415460915428" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis_637957415460915428" xlink:to="srt_SegmentGeographicalDomain_637957415460915428" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_DK" xlink:label="country_DK_637957415460915428" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain_637957415460915428" xlink:to="country_DK_637957415460915428" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:label="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems_637957415460915428" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable_637957415460915428" xlink:to="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems_637957415460915428" order="4" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_RightofuseAssets" xlink:label="ifrs-full_RightofuseAssets_637957415460925428" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems_637957415460915428" xlink:to="ifrs-full_RightofuseAssets_637957415460925428" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_LeaseLiabilitiesAbstract" xlink:label="ifrs-full_LeaseLiabilitiesAbstract_637957415460925428" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems_637957415460915428" xlink:to="ifrs-full_LeaseLiabilitiesAbstract_637957415460925428" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_CurrentLeaseLiabilities" xlink:label="ifrs-full_CurrentLeaseLiabilities_637957415460925428" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_LeaseLiabilitiesAbstract_637957415460925428" xlink:to="ifrs-full_CurrentLeaseLiabilities_637957415460925428" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_NoncurrentLeaseLiabilities" xlink:label="ifrs-full_NoncurrentLeaseLiabilities_637957415460925428" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_LeaseLiabilitiesAbstract_637957415460925428" xlink:to="ifrs-full_NoncurrentLeaseLiabilities_637957415460925428" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_LeaseLiabilities" xlink:label="ifrs-full_LeaseLiabilities_637957415460925428" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_LeaseLiabilitiesAbstract_637957415460925428" xlink:to="ifrs-full_LeaseLiabilities_637957415460925428" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_AdditionsToRightofuseAssets" xlink:label="ifrs-full_AdditionsToRightofuseAssets_637957415460925428" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_LeaseLiabilitiesAbstract_637957415460925428" xlink:to="ifrs-full_AdditionsToRightofuseAssets_637957415460925428" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_DepreciationRightofuseAssets" xlink:label="ifrs-full_DepreciationRightofuseAssets_637957415460925428" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_LeaseLiabilitiesAbstract_637957415460925428" xlink:to="ifrs-full_DepreciationRightofuseAssets_637957415460925428" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_InterestExpenseOnLeaseLiabilities" xlink:label="ifrs-full_InterestExpenseOnLeaseLiabilities_637957415460925428" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_LeaseLiabilitiesAbstract_637957415460925428" xlink:to="ifrs-full_InterestExpenseOnLeaseLiabilities_637957415460925428" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd#ifrs-full_ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed" xlink:label="ifrs-full_ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed_637957415460925428" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_LeaseLiabilitiesAbstract_637957415460925428" xlink:to="ifrs-full_ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed_637957415460925428" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_FutureMinimumOperatingLeasePayments" xlink:label="gmab_FutureMinimumOperatingLeasePayments_637957415460925428" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_LeaseLiabilitiesAbstract_637957415460925428" xlink:to="gmab_FutureMinimumOperatingLeasePayments_637957415460925428" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="gmab-20220630.xsd#gmab_EstimatedCapitalExpenditureForLease" xlink:label="gmab_EstimatedCapitalExpenditureForLease_637957415460925428" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_LeaseLiabilitiesAbstract_637957415460925428" xlink:to="gmab_EstimatedCapitalExpenditureForLease_637957415460925428" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140047781858032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">6-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jun. 30,  2022<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Genmab A/S<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001434265<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2022<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140047782813024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STATEMENTS OF COMPREHENSIVE INCOME - DKK (kr)<br> kr in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncomeStatementAbstract', window );"><strong>Income Statement</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Revenue', window );">Revenue</a></td>
<td class="nump">kr 3,162<span></span>
</td>
<td class="nump">kr 1,972<span></span>
</td>
<td class="nump">kr 5,281<span></span>
</td>
<td class="nump">kr 3,553<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="num">(1,282)<span></span>
</td>
<td class="num">(921)<span></span>
</td>
<td class="num">(2,435)<span></span>
</td>
<td class="num">(1,769)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative expenses</a></td>
<td class="num">(633)<span></span>
</td>
<td class="num">(264)<span></span>
</td>
<td class="num">(1,085)<span></span>
</td>
<td class="num">(465)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OperatingExpense', window );">Operating expenses</a></td>
<td class="num">(1,915)<span></span>
</td>
<td class="num">(1,185)<span></span>
</td>
<td class="num">(3,520)<span></span>
</td>
<td class="num">(2,234)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProfitLossFromOperatingActivities', window );">Operating profit</a></td>
<td class="nump">1,247<span></span>
</td>
<td class="nump">787<span></span>
</td>
<td class="nump">1,761<span></span>
</td>
<td class="nump">1,319<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_FinanceIncome', window );">Financial income</a></td>
<td class="nump">1,442<span></span>
</td>
<td class="nump">65<span></span>
</td>
<td class="nump">1,879<span></span>
</td>
<td class="nump">700<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_FinanceCosts', window );">Financial expenses</a></td>
<td class="num">(200)<span></span>
</td>
<td class="num">(430)<span></span>
</td>
<td class="num">(539)<span></span>
</td>
<td class="num">(173)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProfitLossBeforeTax', window );">Net profit before tax</a></td>
<td class="nump">2,489<span></span>
</td>
<td class="nump">422<span></span>
</td>
<td class="nump">3,101<span></span>
</td>
<td class="nump">1,846<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncomeTaxExpenseContinuingOperations', window );">Corporate tax</a></td>
<td class="num">(598)<span></span>
</td>
<td class="num">(116)<span></span>
</td>
<td class="num">(745)<span></span>
</td>
<td class="num">(444)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Net profit</a></td>
<td class="nump">kr 1,891<span></span>
</td>
<td class="nump">kr 306<span></span>
</td>
<td class="nump">kr 2,356<span></span>
</td>
<td class="nump">kr 1,402<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_BasicEarningsLossPerShare', window );">Basic net profit per share</a></td>
<td class="nump">kr 28.87<span></span>
</td>
<td class="nump">kr 4.68<span></span>
</td>
<td class="nump">kr 35.97<span></span>
</td>
<td class="nump">kr 21.44<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DilutedEarningsLossPerShare', window );">Diluted net profit per share</a></td>
<td class="nump">kr 28.66<span></span>
</td>
<td class="nump">kr 4.64<span></span>
</td>
<td class="nump">kr 35.71<span></span>
</td>
<td class="nump">kr 21.25<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_StatementOfComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Net profit</a></td>
<td class="nump">kr 1,891<span></span>
</td>
<td class="nump">kr 306<span></span>
</td>
<td class="nump">kr 2,356<span></span>
</td>
<td class="nump">kr 1,402<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract', window );"><strong>Amounts which will be re-classified to the income statement:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation', window );">Adjustment of foreign currency fluctuations on subsidiaries</a></td>
<td class="nump">13<span></span>
</td>
<td class="num">(13)<span></span>
</td>
<td class="nump">29<span></span>
</td>
<td class="nump">28<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashFlowHedgesAbstract', window );"><strong>Fair value adjustments of cash flow hedges:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ComprehensiveIncome', window );">Total comprehensive income</a></td>
<td class="nump">kr 1,904<span></span>
</td>
<td class="nump">kr 293<span></span>
</td>
<td class="nump">kr 2,385<span></span>
</td>
<td class="nump">kr 1,430<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BasicEarningsLossPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator) divided by the weighted average number of ordinary shares outstanding during the period (the denominator).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2021-01-01<br> -Paragraph 66<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2021-01-01<br> -Paragraph 67<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_67&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BasicEarningsLossPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowHedgesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowHedgesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComprehensiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of change in equity resulting from transactions and other events, other than those changes resulting from transactions with owners in their capacity as owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2021-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause ix<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_B12_b_ix&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2021-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 106<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_106_a&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2021-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2021-03-24<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 81A<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_81A_c&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComprehensiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DilutedEarningsLossPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator), divided by the weighted average number of ordinary shares outstanding during the period (the denominator), both adjusted for the effects of all dilutive potential ordinary shares. [Refer: Ordinary shares [member]; Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2021-01-01<br> -Paragraph 66<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2021-01-01<br> -Paragraph 67<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_67&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DilutedEarningsLossPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of costs associated with financing activities of the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 82<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_82_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinanceIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of income associated with interest and other financing activities of the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 85<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinanceIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncomeTaxExpenseContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount included in the determination of profit (loss) for the period in respect of current tax and deferred tax. [Refer: Current tax expense (income); Deferred tax expense (income)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 26<br> -IssueDate 2021-01-01<br> -Paragraph 35<br> -Subparagraph b<br> -Clause viii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=26&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_35_b_viii&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2021-01-01<br> -Paragraph 23<br> -Subparagraph h<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_23_h&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2021-01-01<br> -Paragraph 79<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_79&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2021-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_81_c_i&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 82<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_82_d&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2021-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_81_c_ii&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2021-01-01<br> -Paragraph B13<br> -Subparagraph g<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_B13_g&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncomeTaxExpenseContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OperatingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of all operating expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 85<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OperatingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of other comprehensive income, net of tax, after reclassification adjustments, related to exchange differences when financial statements of foreign operations are translated. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 91<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_91_a&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 7<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_7&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 18<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_18_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2021-01-01<br> -Paragraph 28<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Note Effective on first application of IFRS 9<br> -Name IFRS<br> -Number 4<br> -IssueDate 2021-01-01<br> -Paragraph 39L<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=4&amp;code=ifrs-tx-2021-en-b&amp;anchor=para_39L_e&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2021-01-01<br> -Paragraph 23<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Note Effective 2023-01-01<br> -Name IFRS<br> -Number 17<br> -IssueDate 2021-01-01<br> -Paragraph 113<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=17&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_113_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2021-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2021-03-24<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_106_d_i&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 81A<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_81A_a&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The profit (loss) before tax expense or income. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2021-01-01<br> -Paragraph 28<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2021-01-01<br> -Paragraph 23<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 103<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 102<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_102&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 5<br> -IssueDate 2021-01-01<br> -Paragraph 33<br> -Subparagraph b<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=5&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_33_b_i&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossFromOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The profit (loss) from operating activities of the entity. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 32<br> -IssueDate 2021-01-01<br> -Paragraph IE33<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=32&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_IE33&amp;doctype=Illustrative%20Examples<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 85<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossFromOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expenditure directly attributable to research or development activities, recognised in profit or loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2021-01-01<br> -Paragraph 126<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_126&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Revenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The income arising in the course of an entity's ordinary activities. Income is increases in assets, or decreases in liabilities, that result in increases in equity, other than those relating to contributions from holders of equity claims.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2021-01-01<br> -Paragraph 28<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_28_a&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2021-01-01<br> -Paragraph 23<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_23_a&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2021-01-01<br> -Paragraph 32<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_32&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2021-01-01<br> -Paragraph 33<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_33_a&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2021-01-01<br> -Paragraph 34<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_34&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 82<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_82_a&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 103<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 102<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_102&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 5<br> -IssueDate 2021-01-01<br> -Paragraph 33<br> -Subparagraph b<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=5&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_33_b_i&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2021-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause v<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_B12_b_v&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2021-03-24<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2021-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Revenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense relating to selling, general and administrative activities of the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 85<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_StatementOfComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_StatementOfComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140047782960896">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>BALANCE SHEETS - DKK (kr)<br> kr in Millions</strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AssetsAbstract', window );"><strong>ASSETS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Intangible assets</a></td>
<td class="nump">kr 216<span></span>
</td>
<td class="nump">kr 254<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property and equipment</a></td>
<td class="nump">684<span></span>
</td>
<td class="nump">621<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RightofuseAssets', window );">Right-of-use assets</a></td>
<td class="nump">554<span></span>
</td>
<td class="nump">354<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NoncurrentReceivables', window );">Receivables</a></td>
<td class="nump">66<span></span>
</td>
<td class="nump">27<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NetDeferredTaxAssets', window );">Deferred tax assets</a></td>
<td class="nump">264<span></span>
</td>
<td class="nump">264<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_InvestmentAccountedForUsingEquityMethod', window );">Other investments</a></td>
<td class="nump">201<span></span>
</td>
<td class="nump">371<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NoncurrentAssets', window );">Total non-current assets</a></td>
<td class="nump">1,985<span></span>
</td>
<td class="nump">1,891<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gmab_CorporateTaxReceivable', window );">Corporate tax receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TradeAndOtherCurrentReceivables', window );">Receivables</a></td>
<td class="nump">3,876<span></span>
</td>
<td class="nump">3,367<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gmab_IfrsMarketableSecuritiesCurrent', window );">Marketable securities</a></td>
<td class="nump">11,799<span></span>
</td>
<td class="nump">10,381<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="nump">9,816<span></span>
</td>
<td class="nump">8,957<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentAssets', window );">Total current assets</a></td>
<td class="nump">25,491<span></span>
</td>
<td class="nump">22,736<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Assets', window );">Total assets</a></td>
<td class="nump">27,476<span></span>
</td>
<td class="nump">24,627<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_EquityAndLiabilitiesAbstract', window );"><strong>SHAREHOLDERS' EQUITY AND LIABILITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IssuedCapital', window );">Share capital</a></td>
<td class="nump">66<span></span>
</td>
<td class="nump">66<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SharePremium', window );">Share premium</a></td>
<td class="nump">12,063<span></span>
</td>
<td class="nump">12,029<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherReserves', window );">Other reserves</a></td>
<td class="nump">110<span></span>
</td>
<td class="nump">81<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RetainedEarnings', window );">Retained earnings</a></td>
<td class="nump">12,243<span></span>
</td>
<td class="nump">10,020<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Equity', window );">Total shareholders' equity</a></td>
<td class="nump">24,482<span></span>
</td>
<td class="nump">22,196<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NoncurrentProvisions', window );">Provisions</a></td>
<td class="nump">7<span></span>
</td>
<td class="nump">13<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NoncurrentLeaseLiabilities', window );">Lease liabilities</a></td>
<td class="nump">554<span></span>
</td>
<td class="nump">363<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RentDeferredIncomeClassifiedAsNoncurrent', window );">Deferred revenue</a></td>
<td class="nump">487<span></span>
</td>
<td class="nump">487<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherNoncurrentPayables', window );">Other payables</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NoncurrentLiabilities', window );">Total non-current liabilities</a></td>
<td class="nump">1,050<span></span>
</td>
<td class="nump">863<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentProvisions', window );">Provisions</a></td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentTaxLiabilitiesCurrent', window );">Corporate tax payable</a></td>
<td class="nump">257<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentLeaseLiabilities', window );">Lease liabilities</a></td>
<td class="nump">80<span></span>
</td>
<td class="nump">62<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RentDeferredIncomeClassifiedAsCurrent', window );">Deferred revenue</a></td>
<td class="nump">26<span></span>
</td>
<td class="nump">26<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherCurrentPayables', window );">Other payables</a></td>
<td class="nump">1,575<span></span>
</td>
<td class="nump">1,480<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentLiabilities', window );">Total current liabilities</a></td>
<td class="nump">1,944<span></span>
</td>
<td class="nump">1,568<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Liabilities', window );">Total liabilities</a></td>
<td class="nump">2,994<span></span>
</td>
<td class="nump">2,431<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_EquityAndLiabilities', window );">Total shareholders' equity and liabilities</a></td>
<td class="nump">kr 27,476<span></span>
</td>
<td class="nump">kr 24,627<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gmab_CorporateTaxReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Corporate Tax Receivable</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gmab_CorporateTaxReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gmab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gmab_IfrsMarketableSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investments in debt and equity securities which have original maturities over to 90 days, including, but not limited to, held-to-maturity, trading and available-for-sale expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gmab_IfrsMarketableSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gmab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of a present economic resource controlled by the entity as a result of past events. Economic resource is a right that has the potential to produce economic benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2021-01-01<br> -Paragraph 93<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2021-01-01<br> -Paragraph 28<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_28_c&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2021-01-01<br> -Paragraph 93<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2021-01-01<br> -Paragraph 93<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 55<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2021-01-01<br> -Paragraph 23<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 45<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2021-01-01<br> -Paragraph B13<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_B13_a&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2021-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 54<br> -Subparagraph i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_54_i&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of assets that the entity (a) expects to realise or intends to sell or consume in its normal operating cycle; (b) holds primarily for the purpose of trading; (c) expects to realise within twelve months after the reporting period; or (d) classifies as cash or cash equivalents (as defined in IAS 7) unless the asset is restricted from being exchanged or used to settle a liability for at least twelve months after the reporting period. [Refer: Assets]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2021-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_B12_b_i&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 66<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2021-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of current lease liabilities. [Refer: Lease liabilities]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2021-01-01<br> -Paragraph 47<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_47_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expiry date 2023-01-01: The amount of liabilities that: (a) the entity expects to settle in its normal operating cycle; (b) the entity holds primarily for the purpose of trading; (c) are due to be settled within twelve months after the reporting period; or (d) the entity does not have an unconditional right to defer settlement for at least twelve months after the reporting period.
Effective 2023-01-01: The amount of liabilities that: (a) the entity expects to settle in its normal operating cycle; (b) the entity holds primarily for the purpose of trading; (c) are due to be settled within twelve months after the reporting period; or (d) the entity does not have the right at the end of the reporting period to defer settlement for at least twelve months after the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2021-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause iii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_B12_b_iii&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 69<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_69&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2021-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentProvisions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of current provisions, including provisions for employee benefits. [Refer: Provisions]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 54<br> -Subparagraph l<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_54_l&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentProvisions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentTaxLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The current amount of current tax liabilities. [Refer: Current tax liabilities]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 54<br> -Subparagraph n<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_54_n&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentTaxLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Equity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of residual interest in the assets of the entity after deducting all its liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 24<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_24_a&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_32_a_i&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2021-01-01<br> -Paragraph 93<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2021-01-01<br> -Paragraph 93<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2021-01-01<br> -Paragraph 93<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 55<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Equity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EquityAndLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the entity's equity and liabilities. [Refer: Equity; Liabilities]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 55<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EquityAndLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EquityAndLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EquityAndLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of identifiable non-monetary assets without physical substance. This amount does not include goodwill. [Refer: Goodwill]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2021-01-01<br> -Paragraph 118<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_118_e&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 54<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_54_c&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InvestmentAccountedForUsingEquityMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of investments accounted for using the equity method. The equity method is a method of accounting whereby the investment is initially recognised at cost and adjusted thereafter for the post-acquisition change in the investor's share of net assets of the investee. The investor's profit or loss includes its share of the profit or loss of the investee. The investor's other comprehensive income includes its share of the other comprehensive income of the investee. [Refer: At cost [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2021-01-01<br> -Paragraph 24<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_24_a&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2021-01-01<br> -Paragraph B16<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_B16&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2021-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 54<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_54_e&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InvestmentAccountedForUsingEquityMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IssuedCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The nominal value of capital issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IssuedCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of a present obligation of the entity to transfer an economic resource as a result of past events. Economic resource is a right that has the potential to produce economic benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2021-01-01<br> -Paragraph 93<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2021-01-01<br> -Paragraph 93<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2021-01-01<br> -Paragraph 93<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2021-01-01<br> -Paragraph 28<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_28_d&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2021-01-01<br> -Paragraph 23<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 55<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NetDeferredTaxAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of deferred tax assets net of deferred tax liabilities, when the absolute amount of deferred tax assets is greater than the absolute amount of deferred tax liabilities. [Refer: Deferred tax assets; Deferred tax liabilities]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2021-01-01<br> -Paragraph 81<br> -Subparagraph g<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_81_g_i&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NetDeferredTaxAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of assets that do not meet the definition of current assets. [Refer: Current assets]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 66<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2021-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_B12_b_ii&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2021-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2021-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current lease liabilities. [Refer: Lease liabilities]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2021-01-01<br> -Paragraph 47<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_47_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of liabilities that do not meet the definition of current liabilities. [Refer: Current liabilities]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2021-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause iv<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_B12_b_iv&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 69<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_69&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2021-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentProvisions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current provisions, including provisions for employee benefits. [Refer: Provisions]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 54<br> -Subparagraph l<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_54_l&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentProvisions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current trade receivables and non-current other receivables. [Refer: Non-current trade receivables; Other non-current receivables]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 54<br> -Subparagraph h<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_54_h&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 78<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_78_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherCurrentPayables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of current payables that the entity does not separately disclose in the same statement or note.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 55<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherCurrentPayables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherNoncurrentPayables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current payables that the entity does not separately disclose in the same statement or note.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 55<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherNoncurrentPayables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A component of equity representing reserves within equity, not including retained earnings. [Refer: Retained earnings]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of tangible assets that: (a) are held for use in the production or supply of goods or services, for rental to others, or for administrative purposes; and (b) are expected to be used during more than one period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2021-01-01<br> -Paragraph 73<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_73_e&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 54<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_54_a&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RentDeferredIncomeClassifiedAsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of rent deferred income classified as current. [Refer: Rent deferred income]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 78<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_78&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RentDeferredIncomeClassifiedAsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RentDeferredIncomeClassifiedAsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of rent deferred income classified as non-current. [Refer: Rent deferred income]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 78<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_78&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RentDeferredIncomeClassifiedAsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RetainedEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A component of equity representing the entity's cumulative undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph IG6<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_IG6&amp;doctype=Implementation%20Guidance<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RetainedEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RightofuseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of assets that represent a lessee's right to use an underlying asset for the lease term. Underlying asset is an asset that is the subject of a lease, for which the right to use that asset has been provided by a lessor to a lessee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2021-01-01<br> -Paragraph 53<br> -Subparagraph j<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_53_j&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RightofuseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SharePremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount received or receivable from the issuance of the entity's shares in excess of nominal value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SharePremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherCurrentReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of current trade receivables and current other receivables. [Refer: Current trade receivables; Other current receivables]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 54<br> -Subparagraph h<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_54_h&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 78<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_78_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherCurrentReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140047782845312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STATEMENTS OF CASH FLOWS - DKK (kr)<br> kr in Millions</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProfitLossBeforeTax', window );">Net profit before tax</a></td>
<td class="nump">kr 3,101<span></span>
</td>
<td class="nump">kr 1,846<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gmab_ReversalOfFinancialItemsNet', window );">Reversal of financial items, net</a></td>
<td class="num">(1,340)<span></span>
</td>
<td class="num">(527)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gmab_TotalAdjustmentsForNonCashTransactions', window );">Adjustments for non-cash transactions</a></td>
<td class="nump">347<span></span>
</td>
<td class="nump">227<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInWorkingCapital', window );">Changes in operating assets and liabilities</a></td>
<td class="num">(179)<span></span>
</td>
<td class="num">(105)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gmab_CashFlowFromUsedInOperatingActivitiesBeforeFinancialItems', window );">Cash flows from operating activities before financial items</a></td>
<td class="nump">1,929<span></span>
</td>
<td class="nump">1,441<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_InterestReceivedClassifiedAsOperatingActivities', window );">Interest received</a></td>
<td class="nump">80<span></span>
</td>
<td class="nump">107<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gmab_AdjustmentsForInterestOnLeasePayments', window );">Interest elements of lease payments</a></td>
<td class="num">(7)<span></span>
</td>
<td class="num">(6)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_InterestPaidClassifiedAsOperatingActivities', window );">Interest paid</a></td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdjustmentsForIncomeTaxExpense', window );">Corporate taxes paid</a></td>
<td class="num">(455)<span></span>
</td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInOperatingActivities', window );">Net cash provided by operating activities</a></td>
<td class="nump">1,546<span></span>
</td>
<td class="nump">1,540<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities', window );">Investment in tangible assets</a></td>
<td class="num">(125)<span></span>
</td>
<td class="num">(107)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PurchaseOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod', window );">Marketable securities bought</a></td>
<td class="num">(4,061)<span></span>
</td>
<td class="num">(7,410)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProceedsFromSalesOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod', window );">Marketable securities sold</a></td>
<td class="nump">2,965<span></span>
</td>
<td class="nump">8,137<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PurchaseOfInterestsInInvestmentsAccountedForUsingEquityMethod', window );">Other investments bought</a></td>
<td class="num">(22)<span></span>
</td>
<td class="num">(92)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProceedsFromSalesOfInvestmentsAccountedForUsingEquityMethod', window );">Other investments sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">438<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInInvestingActivities', window );">Net cash (used in) / provided by investing activities</a></td>
<td class="num">(1,243)<span></span>
</td>
<td class="nump">966<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProceedsFromExerciseOfWarrants', window );">Warrants exercised</a></td>
<td class="nump">34<span></span>
</td>
<td class="nump">46<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities', window );">Principal elements of lease payments</a></td>
<td class="num">(30)<span></span>
</td>
<td class="num">(29)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gmab_PaymentsToAcquireTreasuryShares', window );">Purchase of treasury shares</a></td>
<td class="num">(211)<span></span>
</td>
<td class="num">(437)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gmab_PaymentOfWithholdingTaxesOnBehalfOfEmployeesOnNetSettledRSUs', window );">Payment of withholding taxes on behalf of employees on net settled RSUs</a></td>
<td class="num">(71)<span></span>
</td>
<td class="num">(40)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInFinancingActivities', window );">Net cash (used in) financing activities</a></td>
<td class="num">(278)<span></span>
</td>
<td class="num">(460)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges', window );">Change in cash and cash equivalents</a></td>
<td class="nump">25<span></span>
</td>
<td class="nump">2,046<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents at the beginning of the period</a></td>
<td class="nump">8,957<span></span>
</td>
<td class="nump">7,260<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents', window );">Exchange rate adjustments</a></td>
<td class="nump">834<span></span>
</td>
<td class="nump">171<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents at the end of the period</a></td>
<td class="nump">9,816<span></span>
</td>
<td class="nump">9,477<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalentsAbstract', window );"><strong>Cash and cash equivalents include:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Cash', window );">Bank deposits</a></td>
<td class="nump">8,810<span></span>
</td>
<td class="nump">6,908<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ShorttermInvestmentsClassifiedAsCashEquivalents', window );">Short-term marketable securities</a></td>
<td class="nump">kr 1,006<span></span>
</td>
<td class="nump">kr 2,569<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gmab_AdjustmentsForInterestOnLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments for interest on lease payments to reconcile profit (loss) to net cash flow from (used in) operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gmab_AdjustmentsForInterestOnLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gmab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gmab_CashFlowFromUsedInOperatingActivitiesBeforeFinancialItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash flows from (used in) operating activities, which are the principal revenue-producing activities of the entity and other activities before reconciling the financial items.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gmab_CashFlowFromUsedInOperatingActivitiesBeforeFinancialItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gmab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gmab_PaymentOfWithholdingTaxesOnBehalfOfEmployeesOnNetSettledRSUs">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for withholding taxes on behalf of employees on net settled restricted stock units (RSUs).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gmab_PaymentOfWithholdingTaxesOnBehalfOfEmployeesOnNetSettledRSUs</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gmab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gmab_PaymentsToAcquireTreasuryShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to acquire treasury shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gmab_PaymentsToAcquireTreasuryShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gmab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gmab_ReversalOfFinancialItemsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The reversal of financial items to the cash flow under operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gmab_ReversalOfFinancialItemsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gmab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gmab_TotalAdjustmentsForNonCashTransactions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments for total non-cash items to reconcile profit (loss) to net cash flow from (used in) operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gmab_TotalAdjustmentsForNonCashTransactions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gmab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForIncomeTaxExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments for income tax expense to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 35<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_35&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForIncomeTaxExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash on hand and demand deposits. [Refer: Cash on hand]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 45<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 45<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2021-01-01<br> -Paragraph B13<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_B13_a&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2021-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 54<br> -Subparagraph i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_54_i&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash flows from (used in) financing activities, which are activities that result in changes in the size and composition of the contributed equity and borrowings of the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 10<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_10&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 50<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_50_d&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash flows from (used in) investing activities, which are the acquisition and disposal of long-term assets and other investments not included in cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 10<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_10&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 50<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_50_d&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash flows from (used in) operating activities, which are the principal revenue-producing activities of the entity and other activities that are not investing or financing activities. [Refer: Revenue]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 10<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_10&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 50<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_50_d&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The effect of exchange rate changes on cash and cash equivalents held or due in a foreign currency. [Refer: Cash and cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 25<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_25&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 28<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_28&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in cash and cash equivalents before the effect of exchange rate changes on cash and cash equivalents held in foreign currencies. [Refer: Cash and cash equivalents; Effect of exchange rate changes on cash and cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 45<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseInWorkingCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in working capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 20<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseInWorkingCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InterestPaidClassifiedAsOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for interest paid, classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 31<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_31&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InterestPaidClassifiedAsOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InterestReceivedClassifiedAsOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from interest received, classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 31<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_31&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InterestReceivedClassifiedAsOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for payment of lease liabilities, classified as financing activities. [Refer: Lease liabilities]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 17<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_17_e&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProceedsFromExerciseOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the exercise of share purchase warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 17<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_17&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProceedsFromExerciseOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProceedsFromSalesOfInvestmentsAccountedForUsingEquityMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from sales of investments accounted for using the equity method. [Refer: Investments accounted for using equity method]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 16<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_16&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProceedsFromSalesOfInvestmentsAccountedForUsingEquityMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProceedsFromSalesOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from sales of investments other than investments accounted for using the equity method. [Refer: Investments accounted for using equity method; Investments other than investments accounted for using equity method]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 16<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_16&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProceedsFromSalesOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The profit (loss) before tax expense or income. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2021-01-01<br> -Paragraph 28<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2021-01-01<br> -Paragraph 23<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 103<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 102<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_102&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 5<br> -IssueDate 2021-01-01<br> -Paragraph 33<br> -Subparagraph b<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=5&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_33_b_i&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PurchaseOfInterestsInInvestmentsAccountedForUsingEquityMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for the purchase of interests in investments accounted for using the equity method. [Refer: Investments accounted for using equity method]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 16<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_16&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PurchaseOfInterestsInInvestmentsAccountedForUsingEquityMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PurchaseOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for the purchase of investments other than investments accounted for using equity method. [Refer: Investments accounted for using equity method; Investments other than investments accounted for using equity method]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 16<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_16&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PurchaseOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for the purchases of property, plant and equipment, classified as investing activities. [Refer: Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 16<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_16_a&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ShorttermInvestmentsClassifiedAsCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A classification of cash equivalents representing short-term investments. [Refer: Cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 45<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ShorttermInvestmentsClassifiedAsCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140047782969520">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>STATEMENTS OF CHANGES IN EQUITY - DKK (kr)<br> kr in Millions</strong></div></th>
<th class="th"><div>Issued capital [member]</div></th>
<th class="th"><div>Share premium [Member]</div></th>
<th class="th"><div>Translation reserves</div></th>
<th class="th"><div>Retained Earnings [Member]</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Equity', window );">Balance at beginning of period at Dec. 31, 2020</a></td>
<td class="nump">kr 66<span></span>
</td>
<td class="nump">kr 11,894<span></span>
</td>
<td class="nump">kr 54<span></span>
</td>
<td class="nump">kr 7,107<span></span>
</td>
<td class="nump">kr 19,121<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Net profit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,402<span></span>
</td>
<td class="nump">1,402<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncome', window );">Other comprehensive income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ComprehensiveIncome', window );">Total comprehensive income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28<span></span>
</td>
<td class="nump">1,402<span></span>
</td>
<td class="nump">1,430<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gmab_TransactionsWithOwners', window );"><strong>Transactions with owners:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity', window );">Exercise of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">46<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">46<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PurchaseOfTreasuryShares', window );">Purchase of treasury shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(447)<span></span>
</td>
<td class="num">(447)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions', window );">Share-based compensation expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">142<span></span>
</td>
<td class="nump">142<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gmab_IncreaseDecreaseThroughNetSettlementOfRestrictedStockUnitsEquity', window );">Net settlement of RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(40)<span></span>
</td>
<td class="num">(40)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Equity', window );">Balance at end of period at Jun. 30, 2021</a></td>
<td class="nump">66<span></span>
</td>
<td class="nump">11,940<span></span>
</td>
<td class="nump">82<span></span>
</td>
<td class="nump">8,164<span></span>
</td>
<td class="nump">20,252<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Equity', window );">Balance at beginning of period at Dec. 31, 2021</a></td>
<td class="nump">66<span></span>
</td>
<td class="nump">12,029<span></span>
</td>
<td class="nump">81<span></span>
</td>
<td class="nump">10,020<span></span>
</td>
<td class="nump">22,196<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Net profit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,356<span></span>
</td>
<td class="nump">2,356<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncome', window );">Other comprehensive income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ComprehensiveIncome', window );">Total comprehensive income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29<span></span>
</td>
<td class="nump">2,356<span></span>
</td>
<td class="nump">2,385<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gmab_TransactionsWithOwners', window );"><strong>Transactions with owners:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity', window );">Exercise of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PurchaseOfTreasuryShares', window );">Purchase of treasury shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(270)<span></span>
</td>
<td class="num">(270)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions', window );">Share-based compensation expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">208<span></span>
</td>
<td class="nump">208<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gmab_IncreaseDecreaseThroughNetSettlementOfRestrictedStockUnitsEquity', window );">Net settlement of RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(71)<span></span>
</td>
<td class="num">(71)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Equity', window );">Balance at end of period at Jun. 30, 2022</a></td>
<td class="nump">kr 66<span></span>
</td>
<td class="nump">kr 12,063<span></span>
</td>
<td class="nump">kr 110<span></span>
</td>
<td class="nump">kr 12,243<span></span>
</td>
<td class="nump">kr 24,482<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gmab_IncreaseDecreaseThroughNetSettlementOfRestrictedStockUnitsEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in equity resulting from net settlement of restricted stock units.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gmab_IncreaseDecreaseThroughNetSettlementOfRestrictedStockUnitsEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gmab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gmab_TransactionsWithOwners">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>n/a</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gmab_TransactionsWithOwners</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gmab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComprehensiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of change in equity resulting from transactions and other events, other than those changes resulting from transactions with owners in their capacity as owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2021-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause ix<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_B12_b_ix&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2021-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 106<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_106_a&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2021-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2021-03-24<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 81A<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_81A_c&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComprehensiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Equity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of residual interest in the assets of the entity after deducting all its liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 24<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_24_a&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_32_a_i&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2021-01-01<br> -Paragraph 93<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2021-01-01<br> -Paragraph 93<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2021-01-01<br> -Paragraph 93<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 55<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Equity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in equity resulting from the exercise of warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in equity resulting from share-based payment transactions. [Refer: Equity]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause iii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_106_d_iii&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherComprehensiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of income and expense (including reclassification adjustments) that is not recognised in profit or loss as required or permitted by IFRSs. [Refer: IFRSs [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_106_d_ii&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2021-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause viii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_B12_b_viii&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2021-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 81A<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_81A_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 91<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_91_a&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherComprehensiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 18<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_18_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2021-01-01<br> -Paragraph 28<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Note Effective on first application of IFRS 9<br> -Name IFRS<br> -Number 4<br> -IssueDate 2021-01-01<br> -Paragraph 39L<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=4&amp;code=ifrs-tx-2021-en-b&amp;anchor=para_39L_e&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2021-01-01<br> -Paragraph 23<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Note Effective 2023-01-01<br> -Name IFRS<br> -Number 17<br> -IssueDate 2021-01-01<br> -Paragraph 113<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=17&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_113_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2021-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2021-03-24<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_106_d_i&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 81A<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_81A_a&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PurchaseOfTreasuryShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The decrease in equity resulting from the purchase of treasury shares. [Refer: Treasury shares]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PurchaseOfTreasuryShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140047782002624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gmab_BasisOfPresentationAbstract', window );"><strong>Basis of Presentation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory', window );">Basis of Presentation</a></td>
<td class="text"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="color:#029c93;font-weight:bold;">Note 1 &#8211; Basis of Presentation</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Accounting Policies</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">These interim statements of the Genmab group (Genmab or the Company) have been prepared in accordance with IAS 34 as issued by the International Accounting Standards Board (IASB) and in accordance with IAS 34 as endorsed by the EU and additional Danish disclosure requirements for interim reports of listed companies. The interim report has not been reviewed or audited by Genmab&#8217;s external auditors. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">The interim report has been prepared using the same accounting policies as outlined in Section 1 &#8211; Basis of Presentation in the financial statements in the Genmab 2021 Annual Report (Annual Report). A number of new or amended standards became applicable for the current reporting period. Genmab was not required to change its accounting policies as a result of adopting these standards. These interim financial statements should be read in conjunction with the Annual Report. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Management Judgements and Estimates under IFRS</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">In preparing interim reports, certain provisions under IFRS require management to make judgements (various accounting estimates and assumptions), which may significantly impact the group&#8217;s financial statements. For a description of significant judgements and estimates, refer to Note 1.3 in the Annual Report.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Information about Geographical Areas</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Genmab is managed and operated as one business unit, which is reflected in the organizational structure and internal reporting. No separate lines of business or separate business entities have been identified with respect to any licensed products, product candidates or geographical markets and no segment information is currently prepared for internal reporting. Refer to Note 2.2 in the Annual Report for further details.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gmab_BasisOfPresentationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gmab_BasisOfPresentationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gmab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of the basis used for the preparation of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140047782028992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RevenueAbstract', window );"><strong>Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfRevenueFromContractsWithCustomersExplanatory', window );">Revenue</a></td>
<td class="text"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="color:#029c93;font-weight:bold;">Note 2 &#8211; Revenue </b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">The table below summarizes Genmab&#8217;s revenue by type and collaboration partner, and royalties by product, under Genmab&#8217;s agreements.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:55.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:19.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:19.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:55.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.51%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;">6 Months Ended</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.24%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;">6 Months Ended</p></td></tr><tr><td style="vertical-align:bottom;width:55.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.51%;background:#e6e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;">June 30, 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;">June 30, 2021</p></td></tr><tr><td style="vertical-align:bottom;width:55.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">(DKK million)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.51%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.24%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:55.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Revenue by type:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.51%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.24%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:55.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Royalties</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.51%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,727</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.24%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,595</p></td></tr><tr><td style="vertical-align:bottom;width:55.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Reimbursement revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.51%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 287</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.24%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 227</p></td></tr><tr><td style="vertical-align:bottom;width:55.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Milestone revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.51%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 176</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.24%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 731</p></td></tr><tr><td style="vertical-align:bottom;width:55.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Collaboration revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.51%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 91</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:55.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.51%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 5,281</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 3,553</b></p></td></tr><tr><td style="vertical-align:bottom;width:55.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.51%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.24%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:55.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Revenue by collaboration partner:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.51%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.24%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:55.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Janssen</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.51%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,206</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.24%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,846</p></td></tr><tr><td style="vertical-align:bottom;width:55.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">AbbVie</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.51%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.24%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 245</p></td></tr><tr><td style="vertical-align:bottom;width:55.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Roche</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.51%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 390</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.24%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 162</p></td></tr><tr><td style="vertical-align:bottom;width:55.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Novartis</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.51%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 305</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.24%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 73</p></td></tr><tr><td style="vertical-align:bottom;width:55.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">BioNTech</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.51%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 231</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.24%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 171</p></td></tr><tr><td style="vertical-align:bottom;width:55.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Seagen</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.51%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 138</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.24%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 56</p></td></tr><tr><td style="vertical-align:bottom;width:55.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.51%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:55.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.51%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 5,281</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 3,553</b></p></td></tr><tr><td style="vertical-align:bottom;width:55.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.51%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.24%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:55.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Royalties by product:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.51%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.24%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:55.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">DARZALEX </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.51%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.24%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,360</p></td></tr><tr><td style="vertical-align:bottom;width:55.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">TEPEZZA </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.51%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 390</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.24%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 162</p></td></tr><tr><td style="vertical-align:bottom;width:55.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Kesimpta </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.51%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 296</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.24%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 72</p></td></tr><tr><td style="vertical-align:bottom;width:55.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.51%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 17</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1</p></td></tr><tr><td style="vertical-align:bottom;width:55.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.51%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 4,727</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 2,595</b></p></td></tr><tr><td style="vertical-align:bottom;width:55.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.51%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.24%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">In September 2020, Genmab commenced binding arbitration of two matters arising under its license agreement with Janssen relating to daratumumab. Under the license agreement, Genmab is, among other things, entitled to royalties from Janssen on net sales of daratumumab (marketed as DARZALEX for IV administration and as DARZALEX <i style="font-style:italic;">FASPRO</i> in the United States and as DARZALEX SC in Europe for SC administration). In April 2022, the arbitral tribunal issued an award in the binding arbitration of the two matters. Genmab did not seek a review of the award, and the award is now final.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">The first matter concerned the question as to whether Janssen&#8217;s obligation to pay royalties on net sales of licensed product extends, in each applicable country, until the expiration or invalidation of the last-to-expire relevant Genmab-owned patent or the last-to-expire relevant Janssen-owned patent covering the product, as further defined and described in the license agreement.  As to that matter, the tribunal determined by majority opinion that Janssen&#8217;s obligation to pay royalties to Genmab on net sales of licensed product, in each applicable country, extends through the expiration or invalidation of the last-to-expire relevant Genmab-owned patent covering the product or use thereof, but not the relevant Janssen-owned patent. The relevant Genmab-owned issued U.S., European and Japanese patents will expire in the late 2020s and early 2030s. </span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">The second matter concerned the question as to whether Genmab is required to share in Janssen&#8217;s royalty payments to Halozyme for the Halozyme enzyme technology used in the SC formulation of daratumumab (marketed as DARZALEX <i style="font-style:italic;">FASPRO</i> in the U.S.). The royalties Janssen pays to Halozyme represent a mid-single digit percentage rate of SC daratumumab net sales. As to that matter, the tribunal ruled by majority opinion that Janssen is permitted to continue reducing its royalty payments to Genmab as an offset against a share of Janssen&#8217;s royalty payments made to Halozyme. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Refer to Note 2.1 in the Annual Report for further details regarding revenue.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfRevenueFromContractsWithCustomersExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for revenue from contracts with customers.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2021-01-01<br> -Section Presentation<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2021-en-r&amp;doctype=Standard&amp;dita_xref=IFRS15_g105-109_TI<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2021-01-01<br> -Section Disclosure<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2021-en-r&amp;doctype=Standard&amp;dita_xref=IFRS15_g110-129_TI<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfRevenueFromContractsWithCustomersExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RevenueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RevenueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140047782030848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsAbstract', window );"><strong>Financial Instruments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory', window );">Financial Instruments</a></td>
<td class="text"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="color:#029c93;font-weight:bold;">Note 3 &#8211; Financial Instruments</b> </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:50.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:20.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:20.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Genmab&#8217;s portfolio is spread over a number of different securities with a focus on liquidity and the preservation of capital. Genmab&#8217;s marketable securities in USD, DKK, EUR, and GBP as a percentage of total marketable securities was as follows: </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:33.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:28.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:28.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:33.48%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:31.28%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">June 30,</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:31.26%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">December&#160;31,&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:33.48%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:31.28%;background:#e6e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:31.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">2021</p></td></tr><tr><td style="vertical-align:bottom;width:33.48%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Percent</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:28.02%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:28.02%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.23%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:33.48%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:28.02%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:28.02%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.23%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:33.48%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">USD</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:28.02%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 79</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:28.02%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 75</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.23%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:33.48%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">DKK</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:28.02%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 13</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:28.02%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 16</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.23%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:33.48%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">EUR</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:28.02%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 7</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:28.02%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 8</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.23%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:33.48%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">GBP</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:28.02%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;background:#e6e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:28.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:33.48%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:28.02%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><b style="font-weight:bold;"> 100</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;background:#e6e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:28.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><b style="font-weight:bold;"> 100</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">%</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">As of June 30, 2022, 71% of Genmab&#8217;s marketable securities were long-term A rated or higher, or short-term A-1 / P-1 rated by S&amp;P, Moody&#8217;s or Fitch compared to 68% as of December 31, 2021. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">The table below shows the fair value measurements by level for Genmab&#8217;s financial assets measured at fair value through profit or loss:</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:26.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:10.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:10.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:6.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:6.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:5.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:6.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:6.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:6.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:middle;width:26.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">(DKK million)</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="7" style="vertical-align:middle;white-space:nowrap;width:39.58%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June 30, 2022</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="7" style="vertical-align:middle;white-space:nowrap;width:30.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2021</b></p></td></tr><tr><td style="vertical-align:middle;width:26.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Assets Measured at Fair Value</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:10.8%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level&#160;1</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.9%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:10.8%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level&#160;2</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.9%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:6.03%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level&#160;3</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.9%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:6.23%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:5.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level&#160;1</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:6.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level&#160;2</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:6.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level&#160;3</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:6.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:middle;width:26.28%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:10.8%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.9%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:10.8%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.9%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:6.03%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.9%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:6.23%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:5.85%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:6.03%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:6.03%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:6.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:26.28%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Marketable securities</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:10.8%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> 11,799</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.9%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.8%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.9%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.03%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.9%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:6.23%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> 11,799</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:5.85%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;">10,381</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.03%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.03%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:6.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;">10,381</p></td></tr><tr><td style="vertical-align:bottom;width:26.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Other investments</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:10.8%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;">150</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.9%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.8%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.9%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:6.03%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;">51</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.9%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:6.23%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> 201</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:5.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;">344</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:6.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;">27</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:6.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;">371</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Marketable Securities</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">All fair values are determined by reference to external sources using unadjusted quoted prices in established markets for Genmab&#8217;s marketable securities (Level 1). </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Other Investments </b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Other investments as of June 30, 2022 consist primarily of a DKK 138 million investment in common shares of CureVac, compared to DKK 318 million as of December 31, 2021. During the second quarter of 2021, Genmab made an investment in common shares of Bolt. As of June 30, 2022, the investment in Bolt was valued at DKK 12 million, compared to DKK 26 million as of December 31, 2021.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">The investments in CureVac and Bolt are recorded at fair value through profit or loss. The fair value of Genmab&#8217;s investments in CureVac and Bolt are determined using unadjusted quoted prices in established markets (Level 1).</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Refer to Note 4.3 and Note 4.4 in the Annual Report for further details regarding Genmab&#8217;s marketable securities and other investments.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of detailed information about financial instruments. [Refer: Financial instruments, class [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 31<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_31&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 7<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_7&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 35K<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_35K&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinancialInstrumentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinancialInstrumentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140047782031072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Income and Expenses<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gmab_DisclosureOfFinanceIncomeExpensesAbstract', window );"><strong>Financial Income and Expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory', window );">Financial Income and Expenses</a></td>
<td class="text"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="color:#029c93;font-weight:bold;">Note 4 &#8211; Financial Income and Expenses</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:57.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:18.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:18.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:57.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.69%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">6 Months Ended</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.66%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">6 Months Ended</p></td></tr><tr><td style="vertical-align:bottom;width:57.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.69%;background:#e6e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">June 30, 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">June 30, 2021</p></td></tr><tr><td style="vertical-align:bottom;width:57.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">(DKK million)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.69%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.66%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:57.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.69%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.66%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:57.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Financial income:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.69%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.66%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:57.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Interest and other financial income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.69%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 87</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.66%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 127</p></td></tr><tr><td style="vertical-align:bottom;width:57.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Foreign exchange rate gain, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.69%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1,792</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 573</p></td></tr><tr><td style="vertical-align:bottom;width:57.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.69%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> </b><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.66%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> </b><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:57.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total financial income</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.69%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><b style="font-weight:bold;"> 1,879</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><b style="font-weight:bold;"> 700</b></p></td></tr><tr><td style="vertical-align:bottom;width:57.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.69%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.66%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:57.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Financial expenses:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.69%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.66%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:57.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Interest and other financial expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.69%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (10)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.66%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (6)</p></td></tr><tr><td style="vertical-align:bottom;width:57.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Loss on marketable securities, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.69%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (315)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.66%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (134)</p></td></tr><tr><td style="vertical-align:bottom;width:57.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Loss on other investments, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.69%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (214)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (33)</p></td></tr><tr><td style="vertical-align:bottom;width:57.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.69%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.66%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:57.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total financial expenses</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.69%;background:#e6e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (539)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (173)</b></p></td></tr><tr><td style="vertical-align:bottom;width:57.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.69%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.66%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:57.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Net financial items</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.69%;background:#e6e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><b style="font-weight:bold;"> 1,340</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><b style="font-weight:bold;"> 527</b></p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Foreign exchange rate gain, net was DKK 1,792 million in the first six months of 2022 compared to DKK 573 million in the first six months of 2021. The USD strengthened against the DKK in each period which positively impacted our USD denominated marketable securities and cash holdings, but to a greater extent in 2022. Refer to Note 4.2 in the Annual Report for further details regarding foreign currency risk. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Loss on marketable securities, net was DKK 315 million in the first six months of 2022 compared to DKK 134 million in the first six months of 2021. The increase in fair value losses on marketable securities was primarily driven by increases in interest rates in the United States and Europe.<span style="white-space:pre-wrap;">  </span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="background:#ffffff;">Loss on other investments, net was DKK </span><span style="background:#ffffff;">214</span><span style="background:#ffffff;"> million in the first six months of 2022 compared to DKK </span><span style="background:#ffffff;">33</span><span style="background:#ffffff;"> million in the first six months of 2021. The change was driven&#160;by the decrease in fair value of Genmab&#8217;s investment in common shares of CureVac and Bolt.&#160;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gmab_DisclosureOfFinanceIncomeExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>NA</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gmab_DisclosureOfFinanceIncomeExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gmab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of finance income (cost). [Refer: Finance income (cost)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140047783598000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Instruments<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract', window );"><strong>Share-Based Instruments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory', window );">Share-Based Instruments</a></td>
<td class="text"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="color:#029c93;font-weight:bold;">Note 5 &#8211; Share-Based Instruments</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="color:#029c93;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Restricted Stock Unit Program</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Genmab A/S established RSU programs as an incentive for all Genmab employees, members of the registered Executive Management, and members of the Board of Directors. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:57.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:18.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:19.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:57.58%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.21%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><span style="font-size:8.5pt;">6 Months Ended</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.54%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><span style="font-size:8.5pt;">6 Months Ended</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:57.58%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8.5pt;">&#160;&#160;&#160;&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.21%;background:#e6e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><span style="font-size:8.5pt;">June 30, 2022</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8.5pt;">&#160;&#160;&#160;&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><span style="font-size:8.5pt;">June 30, 2021</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:57.58%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">RSUs granted</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.21%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:8.5pt;"> 240,741</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.54%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:8.5pt;"> 159,567</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:57.58%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><i style="font-size:8.5pt;font-style:italic;">Weighted average fair value per RSU granted (DKK) </i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.21%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><i style="font-size:8.5pt;font-style:italic;"> 2,178.22</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.54%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><i style="font-size:8.5pt;font-style:italic;"> 2,149.55</i></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:57.58%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.21%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.54%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:57.58%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">RSUs vested</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.21%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:8.5pt;"> 82,001</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:8.5pt;"> 49,012</span></p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Refer to Note 4.6 in the Annual Report for details on the RSU programs.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Warrant Program</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Genmab A/S established warrant programs as an incentive for all Genmab employees, and members of the registered Executive Management.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:63.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:63.09%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.61%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><span style="font-size:8.5pt;">6 Months Ended</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.99%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><span style="font-size:8.5pt;">6 Months Ended</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:63.09%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8.5pt;">&#160;&#160;&#160;&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.61%;background:#e6e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><span style="font-size:8.5pt;">June 30, 2022</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8.5pt;">&#160;&#160;&#160;&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><span style="font-size:8.5pt;">June 30, 2021</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:63.09%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">Warrants granted</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.61%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:8.5pt;"> 230,112</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.99%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:8.5pt;"> 147,568</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:63.09%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><i style="font-size:8.5pt;font-style:italic;">Weighted average exercise price per warrant granted (DKK) </i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.61%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><i style="font-size:8.5pt;font-style:italic;"> 2,178.40</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.99%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><i style="font-size:8.5pt;font-style:italic;"> 2,189.21</i></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:63.09%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><i style="font-size:8.5pt;font-style:italic;">Weighted average Black-Scholes fair value per warrant granted (DKK) </i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.61%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><i style="font-size:8.5pt;font-style:italic;"> 629.05</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.99%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><i style="font-size:8.5pt;font-style:italic;"> 683.79</i></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:63.09%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.61%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8.5pt;font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.99%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8.5pt;font-style:italic;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:63.09%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">Warrants exercised</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.61%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:8.5pt;"> 34,987</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.99%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:8.5pt;"> 74,992</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:63.09%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><i style="font-size:8.5pt;font-style:italic;">Weighted average exercise price on date of grant per warrant exercised (DKK)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.61%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><i style="font-size:8.5pt;font-style:italic;"> 983.98</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.99%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><i style="font-size:8.5pt;font-style:italic;"> 606.22</i></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:63.09%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><i style="font-size:8.5pt;font-style:italic;">% change in share capital - warrants exercised</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.61%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><i style="font-size:8.5pt;font-style:italic;">0.05%</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><i style="font-size:8.5pt;font-style:italic;">0.11%</i></p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Refer to Note 4.6 in the Annual Report for details on the warrant programs.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Share-based compensation expense</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:11.0pt;text-indent:0pt;margin:0pt 36pt 11pt 0pt;">Share-based compensation expenses related to Genmab RSU and warrant programs for the first six months of 2022 was DKK 208 million compared to DKK 142 million for the first six months of 2021. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Share repurchases</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">In general, Genmab intends to purchase its own shares in order to cover a portion of obligations in relation to RSUs. As of June 30, 2022, Genmab has two authorizations to repurchase shares: the 2021 and 2019 authorizations. The 2016 authorization expired in March 2021. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:49.62%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:14.63%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:15.73%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:15.68%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:49.62%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:14.63%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">2021 <br/>Authorization</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:15.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">2019 <br/>Authorization</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:15.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">2016 <br/>Authorization</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:49.62%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Number of shares authorized for repurchase</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.63%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 500,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.73%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 500,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.68%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 500,000</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:49.62%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Actual shares repurchased under authorization</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.63%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.73%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 294,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.68%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 255,000</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:49.62%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Shares available for repurchase as of June 30, 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.63%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 500,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 206,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">As announced on June 17, 2022, Genmab initiated a share buy-back program. During the first six months of 2022, Genmab acquired 124,000 of its own shares, representing approximately 0.2% of share capital as of December 31, 2021. The total amount paid to acquire the shares, including directly attributable costs, was DKK 270 million and was recognized as a deduction to shareholders&#8217; equity. During the first six months of 2021, Genmab acquired 200,000 of its own shares, representing approximately 0.3% of share capital as of December 31, 2020. The total amount paid to acquire the shares, including directly attributable costs, was DKK 447 million and was recognized as a deduction to shareholders&#8217; equity. These shares are classified as treasury shares and are presented within retained earnings on the balance sheet as of June 30, 2022.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;">As of June 30, 2022, 357,885 treasury shares were held by Genmab to cover obligations in relation to the RSU programs and to mitigate the dilutive effect of share capital increases resulting from future exercises of warrants.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2021-01-01<br> -Paragraph 44<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_44&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140047783368752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Parties<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract', window );"><strong>Related Parties</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfRelatedPartyExplanatory', window );">Related Parties</a></td>
<td class="text"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="color:#029c93;font-weight:bold;">Note 6 &#8211; Related Parties</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Genmab&#8217;s related parties are Genmab A/S&#8217; (parent company) subsidiaries, Board of Directors, the registered Executive Management, and close members of the family of these persons. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Genmab has not granted any loans, guarantees or other commitments to or on behalf of any of the members of the Board of Directors or members of the registered Executive Management.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Other than the remuneration and other transactions relating to the Board of Directors and the registered Executive Management described in Note&#160;5.1 in the Annual Report, there were no material related party transactions during the first six months of 2022.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Changes to the Executive Management Team and the Board of Directors</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">During the first six months of 2022, there were two changes to the Executive Management Team. Effective March 1, 2022, Chris Cozic was appointed Executive Vice President and Chief People Officer, and Birgitte Stephensen was appointed Executive Vice President and Chief Legal Officer. They join the existing Executive Management Team of Jan van de Winkel, President and Chief Executive Officer, Judith Klimovsky, Executive Vice President and Chief Development Officer, Anthony Pagano, Executive Vice President and Chief Financial Officer, Anthony Mancini, Executive Vice President and Chief Operating Officer, and Tahamtan Ahmadi, Executive Vice President and Chief Medical Officer. Chris Cozic and Birgitte Stephensen are not regarded as executive managers pursuant to the Danish Companies Act and will therefore not be registered with the Danish Business Authority.&#160;</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Following Genmab A/S&#8217; Annual General Meeting on March 29, 2022, the Board of Directors is comprised of five independent board members, one non-independent board member, and three employee-elected board members. Deirdre P. Connelly (Chair), Pernille Erenbjerg (Deputy Chair), Rolf Hoffmann, Dr. Paolo Paoletti, and Dr. Anders Gersel Pedersen were re-elected to the Board of Directors for a one-year period. Elizabeth O&#8217;Farrell was newly elected for a one-year period. Mijke Zachariasse, Martin Schultz and Takahiro Hamatani were elected to the Board of Directors by the employees for a three-year period. Peter Storm Kristensen and Rima Bawarshi Nassar stepped down from the Board of Directors.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;white-space:pre-wrap;">  </i><span style="visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfRelatedPartyExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related parties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2021-01-01<br> -Section Disclosures<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=24&amp;code=ifrs-tx-2021-en-r&amp;doctype=Standard&amp;dita_xref=IAS24_g13-24_TI<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfRelatedPartyExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140047783148272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PresentationOfLeasesForLesseeAbstract', window );"><strong>Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfLeasesExplanatory', window );">Leases</a></td>
<td class="text"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="color:#029c93;font-weight:bold;">Note 7 &#8211; Leases</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Amounts recognized in the balance sheet</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">The balance sheet shows the following amounts relating to leases:</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="color:#029c93;font-weight:bold;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:57.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:17.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:17.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:57.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.5%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">June 30,</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.47%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">December&#160;31,&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:57.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.5%;background:#e6e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">2021</p></td></tr><tr><td style="vertical-align:bottom;width:57.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">(DKK million)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.5%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.47%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:57.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Right-of-use assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.5%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.47%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:57.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Properties</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.5%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 553</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.47%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 352</p></td></tr><tr><td style="vertical-align:bottom;width:57.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.5%;background:#e6e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 2</p></td></tr><tr><td style="vertical-align:bottom;width:57.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.5%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.47%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:57.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total right-of-use assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.5%;background:#e6e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><b style="font-weight:bold;"> 554</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><b style="font-weight:bold;"> 354</b></p></td></tr><tr><td style="vertical-align:bottom;width:57.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.5%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.47%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:57.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Lease liabilities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.5%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.47%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:57.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Current</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.5%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 80</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.47%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 62</p></td></tr><tr><td style="vertical-align:bottom;width:57.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Non-current</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.5%;background:#e6e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 554</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 363</p></td></tr><tr><td style="vertical-align:bottom;width:57.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.5%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.47%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:57.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total lease liabilities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.5%;background:#e6e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><b style="font-weight:bold;"> 634</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><b style="font-weight:bold;"> 425</b></p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">During the first six months of 2022, there were additions to Genmab&#8217;s right-of-use assets and lease liabilities related to the commencement of leases in the Netherlands with respect to office and laboratory space. During the first six months of 2021, there were additions to Genmab&#8217;s right-of-use assets and lease liabilities related to the commencement of a lease in Japan with respect to office space.<span style="font-family:'Times New Roman','Times','serif';font-size:12pt;"> </span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Significant leases not yet commenced</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">During 2020, Genmab entered into a lease agreement with respect to the new headquarters in Denmark with a commencement date in March 2023 and is non-cancellable until March 2038. The total future minimum payments over the term of the lease are approximately DKK 339 million and estimated capital expenditures to fit out the space are approximately DKK 40 million.<span style="font-family:'Times New Roman','Times','serif';font-size:12pt;"> </span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Amounts recognized in the statement of comprehensive income</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">The statement of comprehensive income shows the following amounts relating to leases:</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:51.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:20.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:21.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.07%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.41%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">6 Months Ended</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.07%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.92%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">6 Months Ended</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.07%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';">&#160;&#160;&#160;&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.41%;background:#e6e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">June 30, 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.07%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';">&#160;&#160;&#160;&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">June 30, 2021</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">(DKK million)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.07%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.41%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.07%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.92%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Depreciation charge of right-of-use assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.07%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.41%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.07%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.92%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Properties</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.07%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.41%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 30</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.07%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.92%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 25</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.07%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.41%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.07%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.07%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.41%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.07%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.92%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total depreciation charge of right-of-use assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.07%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.41%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><b style="font-weight:bold;"> 31</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.07%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><b style="font-weight:bold;"> 26</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.07%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.41%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.07%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.92%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Interest expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.07%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.41%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 7</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.07%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.92%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 6</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Expense relating to short-term leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.07%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.41%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.07%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.92%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1</p></td></tr></table><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Interest expense is included in net financial items and expenses relating to short-term leases are included in operating expenses in the statement of comprehensive income.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfLeasesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2021-01-01<br> -Section Presentation<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2021-en-r&amp;doctype=Standard&amp;dita_xref=IFRS16_g47-50_TI<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2021-01-01<br> -Section Disclosure<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2021-en-r&amp;doctype=Standard&amp;dita_xref=IFRS16_g51-60_TI<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfLeasesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PresentationOfLeasesForLesseeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PresentationOfLeasesForLesseeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140047783562064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events to the Balance Sheet Date<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract', window );"><strong>Subsequent Events to the Balance Sheet Date</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory', window );">Subsequent Events to the Balance Sheet Date</a></td>
<td class="text"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="color:#029c93;font-weight:bold;">Note 8 - Subsequent Events to the Balance Sheet Date</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">No events have occurred subsequent to the balance sheet date that could significantly affect the financial statements as of June 30, 2022.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for events after the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 10<br> -IssueDate 2021-01-01<br> -Section Disclosure<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=10&amp;code=ifrs-tx-2021-en-r&amp;doctype=Standard&amp;dita_xref=IAS10_g17-22_TI<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140047781991888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation (Policies)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gmab_BasisOfPresentationAbstract', window );"><strong>Basis of Presentation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gmab_DescriptionOfAccountingPolicyForBasisOfPresentationPolicyTextBlock', window );">Accounting Policies</a></td>
<td class="text"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Accounting Policies</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">These interim statements of the Genmab group (Genmab or the Company) have been prepared in accordance with IAS 34 as issued by the International Accounting Standards Board (IASB) and in accordance with IAS 34 as endorsed by the EU and additional Danish disclosure requirements for interim reports of listed companies. The interim report has not been reviewed or audited by Genmab&#8217;s external auditors. </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">The interim report has been prepared using the same accounting policies as outlined in Section 1 &#8211; Basis of Presentation in the financial statements in the Genmab 2021 Annual Report (Annual Report). A number of new or amended standards became applicable for the current reporting period. Genmab was not required to change its accounting policies as a result of adopting these standards. These interim financial statements should be read in conjunction with the Annual Report. </p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gmab_DescriptionOfAccountingPolicyForJudgmentsAndEstimatesPolicyTextBlock', window );">Management Judgments and Estimates under IFRS</a></td>
<td class="text"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Management Judgements and Estimates under IFRS</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">In preparing interim reports, certain provisions under IFRS require management to make judgements (various accounting estimates and assumptions), which may significantly impact the group&#8217;s financial statements. For a description of significant judgements and estimates, refer to Note 1.3 in the Annual Report.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForSegmentReportingExplanatory', window );">Information about Geographical Areas</a></td>
<td class="text"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Information about Geographical Areas</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Genmab is managed and operated as one business unit, which is reflected in the organizational structure and internal reporting. No separate lines of business or separate business entities have been identified with respect to any licensed products, product candidates or geographical markets and no segment information is currently prepared for internal reporting. Refer to Note 2.2 in the Annual Report for further details.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gmab_BasisOfPresentationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gmab_BasisOfPresentationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gmab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gmab_DescriptionOfAccountingPolicyForBasisOfPresentationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's accounting policy for Basis of presentation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gmab_DescriptionOfAccountingPolicyForBasisOfPresentationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gmab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gmab_DescriptionOfAccountingPolicyForJudgmentsAndEstimatesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's accounting policy for Basis of presentation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gmab_DescriptionOfAccountingPolicyForJudgmentsAndEstimatesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gmab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForSegmentReportingExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 117<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_117_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForSegmentReportingExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140047818344528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RevenueAbstract', window );"><strong>Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory', window );">Schedule of revenue by type and collaboration partner under agreements</a></td>
<td class="text"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:55.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:19.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:19.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:55.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.51%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;">6 Months Ended</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.24%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;">6 Months Ended</p></td></tr><tr><td style="vertical-align:bottom;width:55.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.51%;background:#e6e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;">June 30, 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;">June 30, 2021</p></td></tr><tr><td style="vertical-align:bottom;width:55.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">(DKK million)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.51%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.24%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:55.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Revenue by type:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.51%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.24%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:55.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Royalties</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.51%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,727</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.24%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,595</p></td></tr><tr><td style="vertical-align:bottom;width:55.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Reimbursement revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.51%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 287</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.24%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 227</p></td></tr><tr><td style="vertical-align:bottom;width:55.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Milestone revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.51%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 176</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.24%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 731</p></td></tr><tr><td style="vertical-align:bottom;width:55.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Collaboration revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.51%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 91</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:55.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.51%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 5,281</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 3,553</b></p></td></tr><tr><td style="vertical-align:bottom;width:55.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.51%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.24%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:55.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Revenue by collaboration partner:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.51%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.24%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:55.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Janssen</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.51%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,206</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.24%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,846</p></td></tr><tr><td style="vertical-align:bottom;width:55.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">AbbVie</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.51%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.24%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 245</p></td></tr><tr><td style="vertical-align:bottom;width:55.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Roche</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.51%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 390</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.24%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 162</p></td></tr><tr><td style="vertical-align:bottom;width:55.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Novartis</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.51%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 305</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.24%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 73</p></td></tr><tr><td style="vertical-align:bottom;width:55.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">BioNTech</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.51%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 231</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.24%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 171</p></td></tr><tr><td style="vertical-align:bottom;width:55.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Seagen</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.51%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 138</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.24%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 56</p></td></tr><tr><td style="vertical-align:bottom;width:55.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.51%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:55.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.51%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 5,281</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 3,553</b></p></td></tr><tr><td style="vertical-align:bottom;width:55.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.51%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.24%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:55.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Royalties by product:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.51%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.24%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:55.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">DARZALEX </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.51%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.24%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,360</p></td></tr><tr><td style="vertical-align:bottom;width:55.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">TEPEZZA </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.51%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 390</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.24%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 162</p></td></tr><tr><td style="vertical-align:bottom;width:55.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Kesimpta </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.51%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 296</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.24%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 72</p></td></tr><tr><td style="vertical-align:bottom;width:55.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.51%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 17</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1</p></td></tr><tr><td style="vertical-align:bottom;width:55.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.51%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 4,727</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 2,595</b></p></td></tr><tr><td style="vertical-align:bottom;width:55.59%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.51%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.24%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of the disaggregation of revenue from contracts with customers. [Refer: Revenue from contracts with customers]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2021-01-01<br> -Paragraph 114<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_114&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RevenueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RevenueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140047783373408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsAbstract', window );"><strong>Financial Instruments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gmab_DisclosureOfMarketableSecuritiesByCurrencyTableTextBlock', window );">Schedule of total marketable securities by currency</a></td>
<td class="text"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:33.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:28.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:28.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:33.48%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:31.28%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">June 30,</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:31.26%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">December&#160;31,&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:33.48%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:31.28%;background:#e6e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:31.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">2021</p></td></tr><tr><td style="vertical-align:bottom;width:33.48%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Percent</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:28.02%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:28.02%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.23%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:33.48%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:28.02%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:28.02%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.23%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:33.48%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">USD</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:28.02%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 79</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:28.02%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 75</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.23%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:33.48%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">DKK</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:28.02%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 13</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:28.02%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 16</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.23%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:33.48%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">EUR</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:28.02%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 7</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:28.02%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 8</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.23%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:33.48%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">GBP</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:28.02%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;background:#e6e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:28.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:33.48%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:28.02%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><b style="font-weight:bold;"> 100</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;background:#e6e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:28.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><b style="font-weight:bold;"> 100</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">%</p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOffsettingOfFinancialAssetsAndFinancialLiabilitiesExplanatory', window );">Schedule of Financial Assets</a></td>
<td class="text"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:26.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:10.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:10.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:6.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:6.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:5.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:6.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:6.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:6.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:middle;width:26.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">(DKK million)</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="7" style="vertical-align:middle;white-space:nowrap;width:39.58%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June 30, 2022</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="7" style="vertical-align:middle;white-space:nowrap;width:30.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2021</b></p></td></tr><tr><td style="vertical-align:middle;width:26.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Assets Measured at Fair Value</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:10.8%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level&#160;1</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.9%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:10.8%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level&#160;2</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.9%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:6.03%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level&#160;3</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.9%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:6.23%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:5.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level&#160;1</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:6.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level&#160;2</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:6.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level&#160;3</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:6.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:middle;width:26.28%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:10.8%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.9%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:10.8%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.9%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:6.03%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.9%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:6.23%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:5.85%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:6.03%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:6.03%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:6.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:26.28%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Marketable securities</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:10.8%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> 11,799</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.9%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.8%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.9%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.03%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.9%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:6.23%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> 11,799</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:5.85%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;">10,381</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.03%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.03%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:6.69%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;">10,381</p></td></tr><tr><td style="vertical-align:bottom;width:26.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Other investments</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:10.8%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;">150</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.9%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.8%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.9%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:6.03%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;">51</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.9%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:6.23%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> 201</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:5.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;">344</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:6.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;">27</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:6.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;">371</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gmab_DisclosureOfMarketableSecuritiesByCurrencyTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of marketable securities in foreign currency.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gmab_DisclosureOfMarketableSecuritiesByCurrencyTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gmab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinancialInstrumentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinancialInstrumentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfOffsettingOfFinancialAssetsAndFinancialLiabilitiesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of the offsetting of financial assets and financial liabilities. [Refer: Financial assets; Financial liabilities]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Section Offsetting financial assets and financial liabilities<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;doctype=Standard&amp;dita_xref=IFRS07_g13A-13F_TI<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfOffsettingOfFinancialAssetsAndFinancialLiabilitiesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140047783474448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Income and Expenses (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gmab_DisclosureOfFinanceIncomeExpensesAbstract', window );"><strong>Financial Income and Expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gmab_DisclosureOfFinanceIncomeExpensesTableTextBlock', window );">Schedule of financial income and expenses</a></td>
<td class="text"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:57.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:18.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:18.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:57.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.69%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">6 Months Ended</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.66%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">6 Months Ended</p></td></tr><tr><td style="vertical-align:bottom;width:57.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.69%;background:#e6e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">June 30, 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">June 30, 2021</p></td></tr><tr><td style="vertical-align:bottom;width:57.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">(DKK million)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.69%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.66%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:57.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.69%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.66%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:57.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Financial income:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.69%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.66%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:57.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Interest and other financial income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.69%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 87</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.66%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 127</p></td></tr><tr><td style="vertical-align:bottom;width:57.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Foreign exchange rate gain, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.69%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1,792</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 573</p></td></tr><tr><td style="vertical-align:bottom;width:57.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.69%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> </b><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.66%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> </b><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:57.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total financial income</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.69%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><b style="font-weight:bold;"> 1,879</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><b style="font-weight:bold;"> 700</b></p></td></tr><tr><td style="vertical-align:bottom;width:57.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.69%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.66%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:57.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Financial expenses:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.69%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.66%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:57.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Interest and other financial expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.69%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (10)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.66%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (6)</p></td></tr><tr><td style="vertical-align:bottom;width:57.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Loss on marketable securities, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.69%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (315)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.66%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (134)</p></td></tr><tr><td style="vertical-align:bottom;width:57.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Loss on other investments, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.69%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (214)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"> (33)</p></td></tr><tr><td style="vertical-align:bottom;width:57.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.69%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.66%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:57.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total financial expenses</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.69%;background:#e6e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (539)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (173)</b></p></td></tr><tr><td style="vertical-align:bottom;width:57.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.69%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.66%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:57.08%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Net financial items</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.69%;background:#e6e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><b style="font-weight:bold;"> 1,340</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><b style="font-weight:bold;"> 527</b></p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gmab_DisclosureOfFinanceIncomeExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>NA</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gmab_DisclosureOfFinanceIncomeExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gmab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gmab_DisclosureOfFinanceIncomeExpensesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>na</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gmab_DisclosureOfFinanceIncomeExpensesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gmab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140047781882976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Instruments (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract', window );"><strong>Share-Based Instruments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory', window );">Summary of RSUs activity</a></td>
<td class="text"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:57.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:18.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:19.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:57.58%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.21%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><span style="font-size:8.5pt;">6 Months Ended</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.54%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><span style="font-size:8.5pt;">6 Months Ended</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:57.58%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8.5pt;">&#160;&#160;&#160;&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.21%;background:#e6e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><span style="font-size:8.5pt;">June 30, 2022</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8.5pt;">&#160;&#160;&#160;&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><span style="font-size:8.5pt;">June 30, 2021</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:57.58%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">RSUs granted</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.21%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:8.5pt;"> 240,741</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.54%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:8.5pt;"> 159,567</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:57.58%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><i style="font-size:8.5pt;font-style:italic;">Weighted average fair value per RSU granted (DKK) </i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.21%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><i style="font-size:8.5pt;font-style:italic;"> 2,178.22</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.54%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><i style="font-size:8.5pt;font-style:italic;"> 2,149.55</i></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:57.58%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.21%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.54%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:57.58%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">RSUs vested</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.21%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:8.5pt;"> 82,001</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:8.5pt;"> 49,012</span></p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gmab_DisclosureOfWarrantsActivityTableTextBlock', window );">Summary of warrants activity</a></td>
<td class="text"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:63.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:63.09%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.61%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><span style="font-size:8.5pt;">6 Months Ended</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.99%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><span style="font-size:8.5pt;">6 Months Ended</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:63.09%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8.5pt;">&#160;&#160;&#160;&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.61%;background:#e6e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><span style="font-size:8.5pt;">June 30, 2022</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8.5pt;">&#160;&#160;&#160;&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"><span style="font-size:8.5pt;">June 30, 2021</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:63.09%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">Warrants granted</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.61%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:8.5pt;"> 230,112</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.99%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:8.5pt;"> 147,568</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:63.09%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><i style="font-size:8.5pt;font-style:italic;">Weighted average exercise price per warrant granted (DKK) </i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.61%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><i style="font-size:8.5pt;font-style:italic;"> 2,178.40</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.99%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><i style="font-size:8.5pt;font-style:italic;"> 2,189.21</i></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:63.09%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><i style="font-size:8.5pt;font-style:italic;">Weighted average Black-Scholes fair value per warrant granted (DKK) </i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.61%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><i style="font-size:8.5pt;font-style:italic;"> 629.05</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.99%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><i style="font-size:8.5pt;font-style:italic;"> 683.79</i></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:63.09%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.61%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8.5pt;font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.99%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8.5pt;font-style:italic;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:63.09%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><span style="font-size:8.5pt;">Warrants exercised</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.61%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:8.5pt;"> 34,987</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.99%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:8.5pt;"> 74,992</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:63.09%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><i style="font-size:8.5pt;font-style:italic;">Weighted average exercise price on date of grant per warrant exercised (DKK)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.61%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><i style="font-size:8.5pt;font-style:italic;"> 983.98</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.99%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><i style="font-size:8.5pt;font-style:italic;"> 606.22</i></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:63.09%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><i style="font-size:8.5pt;font-style:italic;">% change in share capital - warrants exercised</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.61%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><i style="font-size:8.5pt;font-style:italic;">0.05%</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:8.5pt;font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><i style="font-size:8.5pt;font-style:italic;">0.11%</i></p></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gmab_ScheduleOfShareRepurchasesTableTextBlock', window );">Schedule of share repurchases</a></td>
<td class="text"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:49.62%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:14.63%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:15.73%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:15.68%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:49.62%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:14.63%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">2021 <br/>Authorization</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:15.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">2019 <br/>Authorization</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:15.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">2016 <br/>Authorization</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:49.62%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Number of shares authorized for repurchase</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.63%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 500,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.73%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 500,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.68%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 500,000</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:49.62%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Actual shares repurchased under authorization</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.63%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.73%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 294,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.68%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 255,000</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:49.62%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Shares available for repurchase as of June 30, 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.63%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 500,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 206,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gmab_DisclosureOfWarrantsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of warrants activity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gmab_DisclosureOfWarrantsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gmab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gmab_ScheduleOfShareRepurchasesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of repurchase of shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gmab_ScheduleOfShareRepurchasesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gmab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of the number and weighted average exercise prices of other equity instruments (ie other than share options).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2021-01-01<br> -Paragraph 45<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140047783561520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PresentationOfLeasesForLesseeAbstract', window );"><strong>Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gmab_DisclosureOfBalanceSheetInformationRelatingToLeasesTableTextBlock', window );">Summary of balance sheet amounts relating to leases</a></td>
<td class="text"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">The balance sheet shows the following amounts relating to leases:</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="color:#029c93;font-weight:bold;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:57.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:17.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:17.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:57.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.5%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">June 30,</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.47%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">December&#160;31,&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:57.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.5%;background:#e6e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">2021</p></td></tr><tr><td style="vertical-align:bottom;width:57.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">(DKK million)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.5%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.47%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:57.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Right-of-use assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.5%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.47%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:57.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Properties</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.5%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 553</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.47%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 352</p></td></tr><tr><td style="vertical-align:bottom;width:57.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.5%;background:#e6e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 2</p></td></tr><tr><td style="vertical-align:bottom;width:57.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.5%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.47%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:57.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total right-of-use assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.5%;background:#e6e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><b style="font-weight:bold;"> 554</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><b style="font-weight:bold;"> 354</b></p></td></tr><tr><td style="vertical-align:bottom;width:57.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.5%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.47%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:57.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Lease liabilities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.5%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.47%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:57.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Current</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.5%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 80</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.47%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 62</p></td></tr><tr><td style="vertical-align:bottom;width:57.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Non-current</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.5%;background:#e6e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 554</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 363</p></td></tr><tr><td style="vertical-align:bottom;width:57.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.5%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.47%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:57.82%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total lease liabilities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.5%;background:#e6e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><b style="font-weight:bold;"> 634</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.6%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><b style="font-weight:bold;"> 425</b></p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gmab_DisclosureOfComprehensiveInformationRelatingToLeasesTableTextBlock', window );">Summary of statement of comprehensive income amounts relating to leases</a></td>
<td class="text"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">The statement of comprehensive income shows the following amounts relating to leases:</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:51.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:20.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:21.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.07%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.41%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">6 Months Ended</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.07%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.92%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">6 Months Ended</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.07%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';">&#160;&#160;&#160;&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.41%;background:#e6e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">June 30, 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.07%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';">&#160;&#160;&#160;&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;">June 30, 2021</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">(DKK million)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.07%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.41%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.07%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.92%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Depreciation charge of right-of-use assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.07%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.41%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.07%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.92%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Properties</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.07%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.41%;background:#e6e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 30</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.07%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.92%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 25</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.07%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.41%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.07%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.07%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.41%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.07%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.92%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total depreciation charge of right-of-use assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.07%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.41%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><b style="font-weight:bold;"> 31</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.07%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><b style="font-weight:bold;"> 26</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.07%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.41%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.07%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.92%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Interest expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.07%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.41%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 7</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.07%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.92%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 6</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.5%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;">Expense relating to short-term leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.07%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.41%;background:#e7e6e6;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.07%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.92%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gmab_DisclosureOfBalanceSheetInformationRelatingToLeasesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of balance sheet information relating to leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gmab_DisclosureOfBalanceSheetInformationRelatingToLeasesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gmab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gmab_DisclosureOfComprehensiveInformationRelatingToLeasesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of comprehensive information relating to leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gmab_DisclosureOfComprehensiveInformationRelatingToLeasesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gmab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PresentationOfLeasesForLesseeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PresentationOfLeasesForLesseeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140047780664976">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Basis of Presentation (Details)<br></strong></div></th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>item</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gmab_BasisOfPresentationAbstract', window );"><strong>Basis of Presentation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gmab_IfrsNumberOfReportingUnits', window );">Number of business unit</a></td>
<td class="nump">1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gmab_BasisOfPresentationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gmab_BasisOfPresentationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gmab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gmab_IfrsNumberOfReportingUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of reporting units tested for impairment of goodwill. A reporting unit is an operating segment or one level below an operating segment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gmab_IfrsNumberOfReportingUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gmab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140047780277408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue (Details) - DKK (kr)<br> kr in Millions</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RevenueFromContractsWithCustomers', window );">Revenue</a></td>
<td class="nump">kr 5,281<span></span>
</td>
<td class="nump">kr 3,553<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis=gmab_AgreementsWithJanssenMember', window );">Janssen</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RevenueFromContractsWithCustomers', window );">Revenue</a></td>
<td class="nump">4,206<span></span>
</td>
<td class="nump">2,846<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis=gmab_AgreementsWithAbbvieMember', window );">AbbVie</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RevenueFromContractsWithCustomers', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">245<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis=gmab_AgreementsWithRocheMember', window );">Roche</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RevenueFromContractsWithCustomers', window );">Revenue</a></td>
<td class="nump">390<span></span>
</td>
<td class="nump">162<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis=gmab_AgreementsWithNovartisMember', window );">Novartis (Arzaerra/Ofatumumab)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RevenueFromContractsWithCustomers', window );">Revenue</a></td>
<td class="nump">305<span></span>
</td>
<td class="nump">73<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis=gmab_AgreementsWithBointechMember', window );">BioNTech</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RevenueFromContractsWithCustomers', window );">Revenue</a></td>
<td class="nump">231<span></span>
</td>
<td class="nump">171<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis=gmab_AgreementsWithSeagenMember', window );">Seagen</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RevenueFromContractsWithCustomers', window );">Revenue</a></td>
<td class="nump">138<span></span>
</td>
<td class="nump">56<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis=gmab_OtherCollaborationPartnersMember', window );">Other collaboration partners</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RevenueFromContractsWithCustomers', window );">Revenue</a></td>
<td class="nump">11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gmab_TypesOfRevenuesAxis=gmab_RoyaltiesRevenueMember', window );">Royalties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RevenueFromContractsWithCustomers', window );">Revenue</a></td>
<td class="nump">4,727<span></span>
</td>
<td class="nump">2,595<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gmab_TypesOfRevenuesAxis=gmab_RoyaltiesRevenueMember', window );">Royalties | DARZALEX</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RevenueFromContractsWithCustomers', window );">Revenue</a></td>
<td class="nump">4,024<span></span>
</td>
<td class="nump">2,360<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gmab_TypesOfRevenuesAxis=gmab_RoyaltiesRevenueMember', window );">Royalties | TEPEZZA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RevenueFromContractsWithCustomers', window );">Revenue</a></td>
<td class="nump">390<span></span>
</td>
<td class="nump">162<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gmab_TypesOfRevenuesAxis=gmab_RoyaltiesRevenueMember', window );">Royalties | Kesimpta</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RevenueFromContractsWithCustomers', window );">Revenue</a></td>
<td class="nump">296<span></span>
</td>
<td class="nump">72<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gmab_TypesOfRevenuesAxis=gmab_RoyaltiesRevenueMember', window );">Royalties | Other Royalty Product</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RevenueFromContractsWithCustomers', window );">Revenue</a></td>
<td class="nump">17<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gmab_TypesOfRevenuesAxis=gmab_ReimbursementIncomeMember', window );">Reimbursement income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RevenueFromContractsWithCustomers', window );">Revenue</a></td>
<td class="nump">287<span></span>
</td>
<td class="nump">227<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gmab_TypesOfRevenuesAxis=gmab_MilestonePaymentsRevenueMember', window );">Milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RevenueFromContractsWithCustomers', window );">Revenue</a></td>
<td class="nump">176<span></span>
</td>
<td class="nump">kr 731<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gmab_TypesOfRevenuesAxis=gmab_CollaborationRevenueMember', window );">Collaboration revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RevenueFromContractsWithCustomers', window );">Revenue</a></td>
<td class="nump">kr 91<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RevenueFromContractsWithCustomers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of revenue from contracts with customers. A customer is a party that has contracted with an entity to obtain goods or services that are an output of the entity&#8217;s ordinary activities in exchange for consideration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2021-01-01<br> -Paragraph 113<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_113_a&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2021-01-01<br> -Paragraph 114<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_114&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RevenueFromContractsWithCustomers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis=gmab_AgreementsWithJanssenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis=gmab_AgreementsWithJanssenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis=gmab_AgreementsWithAbbvieMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis=gmab_AgreementsWithAbbvieMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis=gmab_AgreementsWithRocheMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis=gmab_AgreementsWithRocheMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis=gmab_AgreementsWithNovartisMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis=gmab_AgreementsWithNovartisMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis=gmab_AgreementsWithBointechMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis=gmab_AgreementsWithBointechMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis=gmab_AgreementsWithSeagenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis=gmab_AgreementsWithSeagenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis=gmab_OtherCollaborationPartnersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis=gmab_OtherCollaborationPartnersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gmab_TypesOfRevenuesAxis=gmab_RoyaltiesRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gmab_TypesOfRevenuesAxis=gmab_RoyaltiesRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gmab_IfrsRoyaltiesByProductAxis=gmab_DarzalexMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gmab_IfrsRoyaltiesByProductAxis=gmab_DarzalexMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gmab_IfrsRoyaltiesByProductAxis=gmab_TepezzaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gmab_IfrsRoyaltiesByProductAxis=gmab_TepezzaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gmab_IfrsRoyaltiesByProductAxis=gmab_KesimptaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gmab_IfrsRoyaltiesByProductAxis=gmab_KesimptaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gmab_IfrsRoyaltiesByProductAxis=gmab_OtherRoyaltyProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gmab_IfrsRoyaltiesByProductAxis=gmab_OtherRoyaltyProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gmab_TypesOfRevenuesAxis=gmab_ReimbursementIncomeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gmab_TypesOfRevenuesAxis=gmab_ReimbursementIncomeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gmab_TypesOfRevenuesAxis=gmab_MilestonePaymentsRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gmab_TypesOfRevenuesAxis=gmab_MilestonePaymentsRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gmab_TypesOfRevenuesAxis=gmab_CollaborationRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gmab_TypesOfRevenuesAxis=gmab_CollaborationRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140047783040960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments - Financial Risk (Details)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfRisksAxis=ifrs-full_CreditRiskMember', window );">Credit risk | Triple A-rating from Moody's, S&amp;P or Fitch</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfCreditRiskExposureLineItems', window );"><strong>Disclosure of credit risk exposure [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gmab_PercentageOfMarketableSecurities', window );">Percentage of marketable securities</a></td>
<td class="nump">71.00%<span></span>
</td>
<td class="nump">68.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfRisksAxis=ifrs-full_CurrencyRiskMember', window );">Currency risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfCreditRiskExposureLineItems', window );"><strong>Disclosure of credit risk exposure [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gmab_PercentageOfMarketableSecuritiesInvested', window );">Marketable securities were invested (as a percent)</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfRisksAxis=ifrs-full_CurrencyRiskMember', window );">Currency risk | United States of America, Dollars</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfCreditRiskExposureLineItems', window );"><strong>Disclosure of credit risk exposure [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gmab_PercentageOfMarketableSecuritiesInvested', window );">Marketable securities were invested (as a percent)</a></td>
<td class="nump">79.00%<span></span>
</td>
<td class="nump">75.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfRisksAxis=ifrs-full_CurrencyRiskMember', window );">Currency risk | DKK</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfCreditRiskExposureLineItems', window );"><strong>Disclosure of credit risk exposure [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gmab_PercentageOfMarketableSecuritiesInvested', window );">Marketable securities were invested (as a percent)</a></td>
<td class="nump">13.00%<span></span>
</td>
<td class="nump">16.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfRisksAxis=ifrs-full_CurrencyRiskMember', window );">Currency risk | Euro Member Countries, Euro</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfCreditRiskExposureLineItems', window );"><strong>Disclosure of credit risk exposure [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gmab_PercentageOfMarketableSecuritiesInvested', window );">Marketable securities were invested (as a percent)</a></td>
<td class="nump">7.00%<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfRisksAxis=ifrs-full_CurrencyRiskMember', window );">Currency risk | United Kingdom, Pounds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfCreditRiskExposureLineItems', window );"><strong>Disclosure of credit risk exposure [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gmab_PercentageOfMarketableSecuritiesInvested', window );">Marketable securities were invested (as a percent)</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gmab_PercentageOfMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of marketable securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gmab_PercentageOfMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gmab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gmab_PercentageOfMarketableSecuritiesInvested">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of marketable securities invested.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gmab_PercentageOfMarketableSecuritiesInvested</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gmab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfCreditRiskExposureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfCreditRiskExposureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfRisksAxis=ifrs-full_CreditRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfRisksAxis=ifrs-full_CreditRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExternalCreditGradesAxis=gmab_TripleaRatingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExternalCreditGradesAxis=gmab_TripleaRatingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfRisksAxis=ifrs-full_CurrencyRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfRisksAxis=ifrs-full_CurrencyRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_USD">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_USD</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_DKK">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_DKK</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_EUR">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_EUR</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_GBP">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_GBP</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140047782926944">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments - Fair Value Measurement (Details) - Net Book value - DKK (kr)<br> kr in Millions</strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember', window );">Marketable Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ReconciliationOfChangesInFairValueMeasurementAssetsAbstract', window );"><strong>Reconciliation of changes in fair value measurement, assets [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_FinancialAssets', window );">Financial assets</a></td>
<td class="nump">kr 11,799<span></span>
</td>
<td class="nump">kr 10,381<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember', window );">Marketable Securities | Level 1 of fair value hierarchy [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ReconciliationOfChangesInFairValueMeasurementAssetsAbstract', window );"><strong>Reconciliation of changes in fair value measurement, assets [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_FinancialAssets', window );">Financial assets</a></td>
<td class="nump">11,799<span></span>
</td>
<td class="nump">10,381<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ReconciliationOfChangesInFairValueMeasurementAssetsAbstract', window );"><strong>Reconciliation of changes in fair value measurement, assets [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_FinancialAssets', window );">Financial assets</a></td>
<td class="nump">201<span></span>
</td>
<td class="nump">371<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember', window );">Other | Level 1 of fair value hierarchy [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ReconciliationOfChangesInFairValueMeasurementAssetsAbstract', window );"><strong>Reconciliation of changes in fair value measurement, assets [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_FinancialAssets', window );">Financial assets</a></td>
<td class="nump">150<span></span>
</td>
<td class="nump">344<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember', window );">Other | Level 3 of fair value hierarchy [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ReconciliationOfChangesInFairValueMeasurementAssetsAbstract', window );"><strong>Reconciliation of changes in fair value measurement, assets [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_FinancialAssets', window );">Financial assets</a></td>
<td class="nump">kr 51<span></span>
</td>
<td class="nump">kr 27<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinancialAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of assets that are: (a) cash; (b) an equity instrument of another entity; (c) a contractual right: (i) to receive cash or another financial asset from another entity; or (ii) to exchange financial assets or financial liabilities with another entity under conditions that are potentially favourable to the entity; or (d) a contract that will, or may be, settled in the entity&#8217;s own equity instruments and is: (i) a non-derivative for which the entity is, or may be, obliged to receive a variable number of the entity&#8217;s own equity instruments; or (ii) a derivative that will, or may be, settled other than by the exchange of a fixed amount of cash or another financial asset for a fixed number of the entity&#8217;s own equity instruments. For this purpose the entity&#8217;s own equity instruments do not include puttable financial instruments classified as equity instruments in accordance with paragraphs 16A-16B of IAS 32, instruments that impose on the entity an obligation to deliver to another party a pro rata share of the net assets of the entity only on liquidation and are classified as equity instruments in accordance with paragraphs 16C-16D of IAS 32, or instruments that are contracts for the future receipt or delivery of the entity&#8217;s own equity instruments. [Refer: Financial instruments, class [member]; Financial liabilities]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 25<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_25&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 35H<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_35H&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 35I<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_35I&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 35M<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_35M&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 35N<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_35N&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinancialAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ReconciliationOfChangesInFairValueMeasurementAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ReconciliationOfChangesInFairValueMeasurementAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialAssetsAxis=gmab_MarketableSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialAssetsAxis=gmab_MarketableSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LevelsOfFairValueHierarchyAxis=ifrs-full_Level1OfFairValueHierarchyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LevelsOfFairValueHierarchyAxis=ifrs-full_Level1OfFairValueHierarchyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialAssetsAxis=gmab_OtherInvestmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialAssetsAxis=gmab_OtherInvestmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LevelsOfFairValueHierarchyAxis=ifrs-full_Level3OfFairValueHierarchyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LevelsOfFairValueHierarchyAxis=ifrs-full_Level3OfFairValueHierarchyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140047783065328">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments - Other Investments (Details) - DKK (kr)<br> kr in Millions</strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gmab_CollaborativeArrangementAndArrangementOtherThanCollaborativeLineItems', window );"><strong>Collaboration Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_InvestmentAccountedForUsingEquityMethod', window );">Other investments</a></td>
<td class="nump">kr 201<span></span>
</td>
<td class="nump">kr 371<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis=gmab_CurevacCollaborationMember', window );">CureVac</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gmab_CollaborativeArrangementAndArrangementOtherThanCollaborativeLineItems', window );"><strong>Collaboration Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_InvestmentAccountedForUsingEquityMethod', window );">Other investments</a></td>
<td class="nump">138<span></span>
</td>
<td class="nump">318<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis=gmab_BoltBiotherapeuticsIncMember', window );">Bolt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gmab_CollaborativeArrangementAndArrangementOtherThanCollaborativeLineItems', window );"><strong>Collaboration Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_InvestmentAccountedForUsingEquityMethod', window );">Other investments</a></td>
<td class="nump">kr 12<span></span>
</td>
<td class="nump">kr 26<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gmab_CollaborativeArrangementAndArrangementOtherThanCollaborativeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gmab_CollaborativeArrangementAndArrangementOtherThanCollaborativeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gmab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InvestmentAccountedForUsingEquityMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of investments accounted for using the equity method. The equity method is a method of accounting whereby the investment is initially recognised at cost and adjusted thereafter for the post-acquisition change in the investor's share of net assets of the investee. The investor's profit or loss includes its share of the profit or loss of the investee. The investor's other comprehensive income includes its share of the other comprehensive income of the investee. [Refer: At cost [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2021-01-01<br> -Paragraph 24<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_24_a&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2021-01-01<br> -Paragraph B16<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_B16&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2021-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 54<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_54_e&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InvestmentAccountedForUsingEquityMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis=gmab_CurevacCollaborationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis=gmab_CurevacCollaborationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis=gmab_BoltBiotherapeuticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis=gmab_BoltBiotherapeuticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140047780805776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Income and Expenses (Details) - DKK (kr)<br> kr in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gmab_FinanceIncomeAbstract', window );"><strong>Financial Income:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gmab_InterestAndOtherFinancialIncome', window );">Interest and other financial income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">kr 87<span></span>
</td>
<td class="nump">kr 127<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NetForeignExchangeGain', window );">Foreign exchange rate gain, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,792<span></span>
</td>
<td class="nump">573<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_FinanceIncome', window );">Total financial income</a></td>
<td class="nump">kr 1,442<span></span>
</td>
<td class="nump">kr 65<span></span>
</td>
<td class="nump">1,879<span></span>
</td>
<td class="nump">700<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gmab_FinanceExpensesAbstract', window );"><strong>Financial expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gmab_InterestAndOtherFinancialExpenses', window );">Interest and other financial expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(10)<span></span>
</td>
<td class="num">(6)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gmab_LossesOnMarketableSecurities', window );">Loss on marketable securities, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(315)<span></span>
</td>
<td class="num">(134)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gmab_LossesOnOtherInvestmentsNet', window );">Loss on other investments, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(214)<span></span>
</td>
<td class="num">(33)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_FinanceCosts', window );">Total financial expenses</a></td>
<td class="num">kr (200)<span></span>
</td>
<td class="num">kr (430)<span></span>
</td>
<td class="num">(539)<span></span>
</td>
<td class="num">(173)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_FinanceIncomeCost', window );">Net financial items</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">kr 1,340<span></span>
</td>
<td class="nump">kr 527<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gmab_FinanceExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>na</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gmab_FinanceExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gmab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gmab_FinanceIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>na</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gmab_FinanceIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gmab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gmab_InterestAndOtherFinancialExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The interest and other financial expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gmab_InterestAndOtherFinancialExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gmab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gmab_InterestAndOtherFinancialIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The interest and other financial income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gmab_InterestAndOtherFinancialIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gmab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gmab_LossesOnMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The losses on marketable securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gmab_LossesOnMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gmab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gmab_LossesOnOtherInvestmentsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Losses On Other Investments Net</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gmab_LossesOnOtherInvestmentsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gmab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of costs associated with financing activities of the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 82<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_82_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinanceIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of income associated with interest and other financing activities of the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 85<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinanceIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinanceIncomeCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of income or cost associated with interest and other financing activities of the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 85<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinanceIncomeCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NetForeignExchangeGain">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net gain arising from exchange differences recognised in profit or loss, excluding those arising on financial instruments measured at fair value through profit or loss in accordance with IFRS 9. [Refer: Foreign exchange gain (loss)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 21<br> -IssueDate 2021-01-01<br> -Paragraph 52<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=21&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_52_a&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 35<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_35&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NetForeignExchangeGain</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140047781964960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Instruments - Restricted Stock Unit Program (Details) - RSUs<br></strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>EquityInstruments </div>
<div>kr / shares</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>EquityInstruments </div>
<div>kr / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Granted</a></td>
<td class="nump">240,741<span></span>
</td>
<td class="nump">159,567<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gmab_Weightedaveragefairvalueofotherequityinstrumentsgrantedinsharebasedpaymentarrangement', window );">Weighted average fair value of RSU granted | kr / shares</a></td>
<td class="nump">kr 2,178.22<span></span>
</td>
<td class="nump">kr 2,149.55<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement', window );">Vested</a></td>
<td class="nump">82,001<span></span>
</td>
<td class="nump">49,012<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gmab_Weightedaveragefairvalueofotherequityinstrumentsgrantedinsharebasedpaymentarrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value of other equity instruments (i.e. other than share options) granted in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gmab_Weightedaveragefairvalueofotherequityinstrumentsgrantedinsharebasedpaymentarrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gmab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of other equity instruments (ie other than share options) granted in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2021-01-01<br> -Paragraph 47<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_47_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2021-01-01<br> -Paragraph 45<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of other equity instruments (ie other than share options) exercised or vested in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2021-01-01<br> -Paragraph 45<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=gmab_IfrsRestrictedStockUnitsRSUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=gmab_IfrsRestrictedStockUnitsRSUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140047782816816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Instruments - Warrant Program (Details) - DKK (kr)<br> kr / shares in Units, kr in Millions</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProceedsFromExerciseOfWarrants', window );">Exercise of warrants</a></td>
<td class="nump">kr 34<span></span>
</td>
<td class="nump">kr 46<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets', window );">Share-based compensation expenses</a></td>
<td class="nump">kr 208<span></span>
</td>
<td class="nump">kr 142<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=gmab_WarrantsMember', window );">Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gmab_NumberOfWarrantsGrantedDuringPeriod', window );">Granted</a></td>
<td class="nump">230,112<span></span>
</td>
<td class="nump">147,568<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gmab_NumberOfWarrantsExercisedDuringPeriod', window );">Exercised</a></td>
<td class="nump">34,987<span></span>
</td>
<td class="nump">74,992<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gmab_WeightedAverageExercisePriceOfWarrantsGranted', window );">Weighted average exercise price of warrants granted</a></td>
<td class="nump">kr 2,178.40<span></span>
</td>
<td class="nump">kr 2,189.21<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gmab_WeightedAverageExercisePriceOfFairValueOfWarrants', window );">Weighted average exercise price of fair market value</a></td>
<td class="nump">629.05<span></span>
</td>
<td class="nump">683.79<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gmab_WeightedAverageExercisePriceOfWarrantsExercised', window );">Weighted average exercise price of warrants exercised</a></td>
<td class="nump">kr 983.98<span></span>
</td>
<td class="nump">kr 606.22<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gmab_PercentageOfShareCapitalAttributedToExerciseOfWarrants', window );">Percentage of share capital attributed to exercise of warrants</a></td>
<td class="nump">0.05%<span></span>
</td>
<td class="nump">0.11%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gmab_NumberOfWarrantsExercisedDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of warrants exercised during period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gmab_NumberOfWarrantsExercisedDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gmab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gmab_NumberOfWarrantsGrantedDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of warrants granted during period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gmab_NumberOfWarrantsGrantedDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gmab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gmab_PercentageOfShareCapitalAttributedToExerciseOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of share capital attributed by exercise of warrants which increase the share capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gmab_PercentageOfShareCapitalAttributedToExerciseOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gmab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gmab_WeightedAverageExercisePriceOfFairValueOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of fair value of warrants during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gmab_WeightedAverageExercisePriceOfFairValueOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gmab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gmab_WeightedAverageExercisePriceOfWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants exercised during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gmab_WeightedAverageExercisePriceOfWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gmab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gmab_WeightedAverageExercisePriceOfWarrantsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gmab_WeightedAverageExercisePriceOfWarrantsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gmab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense arising from share-based payment transactions in which the goods or services received did not qualify for recognition as assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2021-01-01<br> -Paragraph 51<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_51_a&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProceedsFromExerciseOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the exercise of share purchase warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2021-01-01<br> -Paragraph 17<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_17&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProceedsFromExerciseOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=gmab_WarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=gmab_WarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140047780294464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Instruments - Share repurchases (Details)<br> kr in Millions</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>DKK (kr) </div>
<div>item </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>DKK (kr) </div>
<div>shares</div>
</th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gmab_ShareBasedArrangementNumberOfAuthorization', window );">Number of authorization | item</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gmab_TreasurySharesAcquired', window );">Treasury shares acquired</a></td>
<td class="nump">124,000<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gmab_PercentageOfShareCapitalRepurchased', window );">Percentage of share capital repurchased</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.20%<span></span>
</td>
<td class="nump">0.30%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PurchaseOfTreasuryShares', window );">Acquisition of treasury shares | kr</a></td>
<td class="nump">kr 270<span></span>
</td>
<td class="nump">kr 447<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=gmab_RestrictedStockUnitsRSUsMember', window );">RSU</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gmab_TreasurySharesAcquired', window );">Treasury shares acquired</a></td>
<td class="nump">357,885<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementScenarioAxis=gmab_StockRepurchaseAuthorization2021Member', window );">2021 Authorization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gmab_NumberOfSharesAuthorizedToBeRepurchased', window );">Number of shares authorized for repurchase</a></td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gmab_SharesAvailableForRepurchase', window );">Shares available for repurchase</a></td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementScenarioAxis=gmab_StockRepurchaseAuthorization2019Member', window );">2019 Authorization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gmab_NumberOfSharesAuthorizedToBeRepurchased', window );">Number of shares authorized for repurchase</a></td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gmab_ShareRepurchasedDuringPeriodShares', window );">Actual shares repurchased under authorization</a></td>
<td class="nump">294,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gmab_SharesAvailableForRepurchase', window );">Shares available for repurchase</a></td>
<td class="nump">206,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementScenarioAxis=gmab_StockRepurchaseAuthorization2016Member', window );">2016 Authorization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gmab_NumberOfSharesAuthorizedToBeRepurchased', window );">Number of shares authorized for repurchase</a></td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gmab_ShareRepurchasedDuringPeriodShares', window );">Actual shares repurchased under authorization</a></td>
<td class="nump">255,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gmab_NumberOfSharesAuthorizedToBeRepurchased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares authorized to be repurchased by an entity's Board of Directors under a stock repurchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gmab_NumberOfSharesAuthorizedToBeRepurchased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gmab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gmab_PercentageOfShareCapitalRepurchased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of share capital repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gmab_PercentageOfShareCapitalRepurchased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gmab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gmab_ShareBasedArrangementNumberOfAuthorization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of authorization under the share based payment arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gmab_ShareBasedArrangementNumberOfAuthorization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gmab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gmab_ShareRepurchasedDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and have not been retired and are not held in treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gmab_ShareRepurchasedDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gmab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gmab_SharesAvailableForRepurchase">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares available for repurchase.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gmab_SharesAvailableForRepurchase</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gmab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gmab_TreasurySharesAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of treasury shares acquired during period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gmab_TreasurySharesAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gmab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PurchaseOfTreasuryShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The decrease in equity resulting from the purchase of treasury shares. [Refer: Treasury shares]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2021-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PurchaseOfTreasuryShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=gmab_RestrictedStockUnitsRSUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=gmab_RestrictedStockUnitsRSUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=gmab_StockRepurchaseAuthorization2021Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=gmab_StockRepurchaseAuthorization2021Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=gmab_StockRepurchaseAuthorization2019Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=gmab_StockRepurchaseAuthorization2019Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=gmab_StockRepurchaseAuthorization2016Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=gmab_StockRepurchaseAuthorization2016Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140047781875744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Parties (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Mar. 29, 2022 </div>
<div>director</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>item</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems', window );"><strong>Disclosure of transactions between related parties [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gmab_NumberOfChangesToExecutiveManagementTeam', window );">Number of changes to executive management team | item</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ifrs-full_KeyManagementPersonnelOfEntityOrParentMember', window );">Board of Directors and Executive Management</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems', window );"><strong>Disclosure of transactions between related parties [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gmab_NumberOfIndependentBoardMembers', window );">Number of independent board members</a></td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gmab_NumberOfNonIndependentBoardMembers', window );">Number of non independent board members</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gmab_NumberOfEmployeeElectedBoardMembers', window );">Number of employee elected board members</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=gmab_DeirdreP.ConnellyChairPernilleErenbjergDeputyChairRolfHoffmannDr.PaoloPaolettiAndDr.AndersGerselPedersenMember', window );">Deirdre P. Connelly (Chair), Pernille Erenbjerg (Deputy Chair), Rolf Hoffmann, Dr. Paolo Paoletti, and Dr. Anders Gersel Pedersen</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems', window );"><strong>Disclosure of transactions between related parties [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gmab_ReElectionToBoardOfDirectorsTerm', window );">Re-election to the board of directors term</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=gmab_ElizabethOfarrellMember', window );">Elizabeth O'Farrell</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems', window );"><strong>Disclosure of transactions between related parties [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gmab_ElectionToBoardOfDirectorsTerm', window );">Board of directors term</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=gmab_MijkeZachariasseMartinSchultzAndTakahiroHamataniMember', window );">Mijke Zachariasse, Martin Schultz and Takahiro Hamatani</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems', window );"><strong>Disclosure of transactions between related parties [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gmab_ElectionToBoardOfDirectorsTerm', window );">Board of directors term</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gmab_ElectionToBoardOfDirectorsTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The term limit of board of directors.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gmab_ElectionToBoardOfDirectorsTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gmab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gmab_NumberOfChangesToExecutiveManagementTeam">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of changes to executive management team.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gmab_NumberOfChangesToExecutiveManagementTeam</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gmab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gmab_NumberOfEmployeeElectedBoardMembers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of employee elected board members.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gmab_NumberOfEmployeeElectedBoardMembers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gmab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gmab_NumberOfIndependentBoardMembers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of independent board members.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gmab_NumberOfIndependentBoardMembers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gmab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gmab_NumberOfNonIndependentBoardMembers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of non independent board members.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gmab_NumberOfNonIndependentBoardMembers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gmab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gmab_ReElectionToBoardOfDirectorsTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The term limit of board of directors who are re-elected.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gmab_ReElectionToBoardOfDirectorsTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gmab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=ifrs-full_KeyManagementPersonnelOfEntityOrParentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=ifrs-full_KeyManagementPersonnelOfEntityOrParentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=gmab_DeirdreP.ConnellyChairPernilleErenbjergDeputyChairRolfHoffmannDr.PaoloPaolettiAndDr.AndersGerselPedersenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=gmab_DeirdreP.ConnellyChairPernilleErenbjergDeputyChairRolfHoffmannDr.PaoloPaolettiAndDr.AndersGerselPedersenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=gmab_ElizabethOfarrellMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=gmab_ElizabethOfarrellMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=gmab_MijkeZachariasseMartinSchultzAndTakahiroHamataniMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=gmab_MijkeZachariasseMartinSchultzAndTakahiroHamataniMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140047780181008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Details) - DKK (kr)<br> kr in Millions</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems', window );"><strong>Disclosure of quantitative information about right-of-use assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RightofuseAssets', window );">Right-of-use assets</a></td>
<td class="nump">kr 554<span></span>
</td>
<td class="nump">kr 354<span></span>
</td>
<td class="nump">kr 354<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_LeaseLiabilitiesAbstract', window );"><strong>Lease Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentLeaseLiabilities', window );">Current</a></td>
<td class="nump">80<span></span>
</td>
<td class="nump">62<span></span>
</td>
<td class="nump">62<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NoncurrentLeaseLiabilities', window );">Non-current</a></td>
<td class="nump">554<span></span>
</td>
<td class="nump">363<span></span>
</td>
<td class="nump">kr 363<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_LeaseLiabilities', window );">Total lease liabilities</a></td>
<td class="nump">634<span></span>
</td>
<td class="nump">425<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DepreciationRightofuseAssets', window );">Depreciation charge of right-of-use assets</a></td>
<td class="nump">31<span></span>
</td>
<td class="nump">26<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_InterestExpenseOnLeaseLiabilities', window );">Interest expense</a></td>
<td class="nump">7<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed', window );">Expense relating to short-term leases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=gmab_OfficeAndLaboratorySpaceMember', window );">Office and laboratory space | DENMARK</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_LeaseLiabilitiesAbstract', window );"><strong>Lease Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gmab_FutureMinimumOperatingLeasePayments', window );">Total future minimum payments</a></td>
<td class="nump">339<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gmab_EstimatedCapitalExpenditureForLease', window );">Estimated capital expenditure for lease</a></td>
<td class="nump">40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfAssetsAxis=gmab_PropertiesMember', window );">Properties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems', window );"><strong>Disclosure of quantitative information about right-of-use assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RightofuseAssets', window );">Right-of-use assets</a></td>
<td class="nump">553<span></span>
</td>
<td class="nump">352<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_LeaseLiabilitiesAbstract', window );"><strong>Lease Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DepreciationRightofuseAssets', window );">Depreciation charge of right-of-use assets</a></td>
<td class="nump">30<span></span>
</td>
<td class="nump">25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfAssetsAxis=gmab_IfrsEquipmentMember', window );">Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems', window );"><strong>Disclosure of quantitative information about right-of-use assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RightofuseAssets', window );">Right-of-use assets</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_LeaseLiabilitiesAbstract', window );"><strong>Lease Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DepreciationRightofuseAssets', window );">Depreciation charge of right-of-use assets</a></td>
<td class="nump">kr 1<span></span>
</td>
<td class="nump">kr 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gmab_EstimatedCapitalExpenditureForLease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of estimated capital expenditure for lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gmab_EstimatedCapitalExpenditureForLease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gmab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gmab_FutureMinimumOperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of future minimum operating lease payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gmab_FutureMinimumOperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gmab_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of current lease liabilities. [Refer: Lease liabilities]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2021-01-01<br> -Paragraph 47<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_47_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DepreciationRightofuseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of depreciation of right-of-use assets. [Refer: Depreciation and amortisation expense; Right-of-use assets]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2021-01-01<br> -Paragraph 53<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_53_a&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DepreciationRightofuseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the expense relating to short-term leases accounted for applying paragraph 6 of IFRS 16. This expense need not include the expense relating to leases with a lease term of one month or less. Short-term lease is a lease that, at the commencement date, has a lease term of 12 months or less. A lease that contains a purchase option is not a short-term lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2021-01-01<br> -Paragraph 53<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_53_c&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InterestExpenseOnLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of interest expense on lease liabilities. [Refer: Lease liabilities]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2021-01-01<br> -Paragraph 53<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_53_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InterestExpenseOnLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of liabilities related to the entity's leases. Lease is a contract, or part of a contract, that conveys the right to use an underlying asset for a period of time in exchange for consideration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2021-01-01<br> -Paragraph 47<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_47_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LeaseLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LeaseLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current lease liabilities. [Refer: Lease liabilities]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2021-01-01<br> -Paragraph 47<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_47_b&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RightofuseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of assets that represent a lessee's right to use an underlying asset for the lease term. Underlying asset is an asset that is the subject of a lease, for which the right to use that asset has been provided by a lessor to a lessee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2021-01-01<br> -Paragraph 53<br> -Subparagraph j<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2021-en-r&amp;anchor=para_53_j&amp;doctype=Standard<br> -URIDate 2021-03-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RightofuseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=gmab_OfficeAndLaboratorySpaceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=gmab_OfficeAndLaboratorySpaceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_DK">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_DK</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfAssetsAxis=gmab_PropertiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfAssetsAxis=gmab_PropertiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfAssetsAxis=gmab_IfrsEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfAssetsAxis=gmab_IfrsEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>gmab-20220630x6k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:country="http://xbrl.sec.gov/country/2021"
  xmlns:currency="http://xbrl.sec.gov/currency/2021"
  xmlns:dei="http://xbrl.sec.gov/dei/2021q4"
  xmlns:gmab="http://www.genmab.com/20220630"
  xmlns:ifrs-full="http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2021-01-31"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="gmab-20220630.xsd" xlink:type="simple"/>
    <context id="Duration_1_1_2022_To_6_30_2022_dNPMG5n7t0WcNVF9KG4Bdw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434265</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="As_Of_6_30_2022_ifrs-full_ClassesOfAssetsAxis_gmab_PropertiesMember_fzUIN40VJUem2qiuz7q2TQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434265</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">gmab:PropertiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2022_ifrs-full_ClassesOfAssetsAxis_gmab_IfrsEquipmentMember_24WDaUkWB0CzmGMa-Eqrcg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434265</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">gmab:IfrsEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2021_ifrs-full_ClassesOfAssetsAxis_gmab_PropertiesMember_Dk9Hxplwdkeo6iuYxEh2kg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434265</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">gmab:PropertiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2021_ifrs-full_ClassesOfAssetsAxis_gmab_IfrsEquipmentMember_JPHlDxvGukWnsD4CjDhIbQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434265</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">gmab:IfrsEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_6_30_2022_gmab_IfrsRoyaltiesByProductAxis_gmab_TepezzaMember_gmab_TypesOfRevenuesAxis_gmab_RoyaltiesRevenueMember_2vu0gXPmvEOPW1nFEg8xWQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434265</identifier>
            <segment>
                <xbrldi:explicitMember dimension="gmab:IfrsRoyaltiesByProductAxis">gmab:TepezzaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="gmab:TypesOfRevenuesAxis">gmab:RoyaltiesRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_6_30_2022_gmab_IfrsRoyaltiesByProductAxis_gmab_OtherRoyaltyProductMember_gmab_TypesOfRevenuesAxis_gmab_RoyaltiesRevenueMember_E0nJo5T9H0y4j-kEZUvZ1g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434265</identifier>
            <segment>
                <xbrldi:explicitMember dimension="gmab:IfrsRoyaltiesByProductAxis">gmab:OtherRoyaltyProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="gmab:TypesOfRevenuesAxis">gmab:RoyaltiesRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_6_30_2022_gmab_IfrsRoyaltiesByProductAxis_gmab_KesimptaMember_gmab_TypesOfRevenuesAxis_gmab_RoyaltiesRevenueMember_HHevdLOZHkKv8JPTDpOBMA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434265</identifier>
            <segment>
                <xbrldi:explicitMember dimension="gmab:IfrsRoyaltiesByProductAxis">gmab:KesimptaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="gmab:TypesOfRevenuesAxis">gmab:RoyaltiesRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_6_30_2022_gmab_IfrsRoyaltiesByProductAxis_gmab_DarzalexMember_gmab_TypesOfRevenuesAxis_gmab_RoyaltiesRevenueMember_B_UEY1hASUOrDlLXGgV7LQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434265</identifier>
            <segment>
                <xbrldi:explicitMember dimension="gmab:IfrsRoyaltiesByProductAxis">gmab:DarzalexMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="gmab:TypesOfRevenuesAxis">gmab:RoyaltiesRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_6_30_2022_gmab_TypesOfRevenuesAxis_gmab_RoyaltiesRevenueMember_l90laluy2ECUtYZD9oF94A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434265</identifier>
            <segment>
                <xbrldi:explicitMember dimension="gmab:TypesOfRevenuesAxis">gmab:RoyaltiesRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_6_30_2022_gmab_TypesOfRevenuesAxis_gmab_ReimbursementIncomeMember_SqLe6wdBT06OGFsFXaHuhQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434265</identifier>
            <segment>
                <xbrldi:explicitMember dimension="gmab:TypesOfRevenuesAxis">gmab:ReimbursementIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_6_30_2022_gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_gmab_OtherCollaborationPartnersMember_AsIPBfv6PU6XdKxKRQhUDA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434265</identifier>
            <segment>
                <xbrldi:explicitMember dimension="gmab:IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis">gmab:OtherCollaborationPartnersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_6_30_2022_gmab_TypesOfRevenuesAxis_gmab_MilestonePaymentsRevenueMember_fqNpjY-zG02ssbNiOllMzA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434265</identifier>
            <segment>
                <xbrldi:explicitMember dimension="gmab:TypesOfRevenuesAxis">gmab:MilestonePaymentsRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_6_30_2022_gmab_TypesOfRevenuesAxis_gmab_CollaborationRevenueMember_ht1RNX53n0-X7tAGYv75YQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434265</identifier>
            <segment>
                <xbrldi:explicitMember dimension="gmab:TypesOfRevenuesAxis">gmab:CollaborationRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_6_30_2022_gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_gmab_AgreementsWithSeagenMember_pZplyqrryEKRXEj8O7llZQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434265</identifier>
            <segment>
                <xbrldi:explicitMember dimension="gmab:IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis">gmab:AgreementsWithSeagenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_6_30_2022_gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_gmab_AgreementsWithRocheMember_F60ez68CiEaIHbxeNRu9_Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434265</identifier>
            <segment>
                <xbrldi:explicitMember dimension="gmab:IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis">gmab:AgreementsWithRocheMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_6_30_2022_gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_gmab_AgreementsWithNovartisMember_2Lw8aj2ROUe2xOEG0T2NEA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434265</identifier>
            <segment>
                <xbrldi:explicitMember dimension="gmab:IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis">gmab:AgreementsWithNovartisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_6_30_2022_gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_gmab_AgreementsWithJanssenMember_dtnNRTQ9qUWE18D-r3fXbQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434265</identifier>
            <segment>
                <xbrldi:explicitMember dimension="gmab:IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis">gmab:AgreementsWithJanssenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_6_30_2022_gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_gmab_AgreementsWithBointechMember_-wOkAaAFTU-q5bYOFz9Nag">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434265</identifier>
            <segment>
                <xbrldi:explicitMember dimension="gmab:IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis">gmab:AgreementsWithBointechMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_6_30_2021_gmab_IfrsRoyaltiesByProductAxis_gmab_TepezzaMember_gmab_TypesOfRevenuesAxis_gmab_RoyaltiesRevenueMember_fs7jJ3nvNUyKr8Sk5fXrGg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434265</identifier>
            <segment>
                <xbrldi:explicitMember dimension="gmab:IfrsRoyaltiesByProductAxis">gmab:TepezzaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="gmab:TypesOfRevenuesAxis">gmab:RoyaltiesRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_6_30_2021_gmab_IfrsRoyaltiesByProductAxis_gmab_OtherRoyaltyProductMember_gmab_TypesOfRevenuesAxis_gmab_RoyaltiesRevenueMember_L_QgZHefbEqkV9UUM69KBg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434265</identifier>
            <segment>
                <xbrldi:explicitMember dimension="gmab:IfrsRoyaltiesByProductAxis">gmab:OtherRoyaltyProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="gmab:TypesOfRevenuesAxis">gmab:RoyaltiesRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_6_30_2021_gmab_IfrsRoyaltiesByProductAxis_gmab_KesimptaMember_gmab_TypesOfRevenuesAxis_gmab_RoyaltiesRevenueMember_FICwJ-6ee0Gxe75faT4PZQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434265</identifier>
            <segment>
                <xbrldi:explicitMember dimension="gmab:IfrsRoyaltiesByProductAxis">gmab:KesimptaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="gmab:TypesOfRevenuesAxis">gmab:RoyaltiesRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_6_30_2021_gmab_IfrsRoyaltiesByProductAxis_gmab_DarzalexMember_gmab_TypesOfRevenuesAxis_gmab_RoyaltiesRevenueMember_ygn3CpbP8kelusDjXKa8kw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434265</identifier>
            <segment>
                <xbrldi:explicitMember dimension="gmab:IfrsRoyaltiesByProductAxis">gmab:DarzalexMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="gmab:TypesOfRevenuesAxis">gmab:RoyaltiesRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_6_30_2021_gmab_TypesOfRevenuesAxis_gmab_RoyaltiesRevenueMember_C14oZ_22m06-TU9BB9BNhw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434265</identifier>
            <segment>
                <xbrldi:explicitMember dimension="gmab:TypesOfRevenuesAxis">gmab:RoyaltiesRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_6_30_2021_gmab_TypesOfRevenuesAxis_gmab_ReimbursementIncomeMember_omlBYt5DuUO9i8c4hNlRbg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434265</identifier>
            <segment>
                <xbrldi:explicitMember dimension="gmab:TypesOfRevenuesAxis">gmab:ReimbursementIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_6_30_2021_gmab_TypesOfRevenuesAxis_gmab_MilestonePaymentsRevenueMember_RLx1u9QEf0yprcS3a5mwXA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434265</identifier>
            <segment>
                <xbrldi:explicitMember dimension="gmab:TypesOfRevenuesAxis">gmab:MilestonePaymentsRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_6_30_2021_gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_gmab_AgreementsWithSeagenMember_eK57WUE_IE2_OzKv8nQlDQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434265</identifier>
            <segment>
                <xbrldi:explicitMember dimension="gmab:IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis">gmab:AgreementsWithSeagenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_6_30_2021_gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_gmab_AgreementsWithRocheMember_z9PLyE_EZEK_NCj-F9C2xA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434265</identifier>
            <segment>
                <xbrldi:explicitMember dimension="gmab:IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis">gmab:AgreementsWithRocheMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_6_30_2021_gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_gmab_AgreementsWithNovartisMember_Q_C1sF5FrU2rD44CqxQPtw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434265</identifier>
            <segment>
                <xbrldi:explicitMember dimension="gmab:IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis">gmab:AgreementsWithNovartisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_6_30_2021_gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_gmab_AgreementsWithJanssenMember_vuVrCms2xECcbUwIJRfXzw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434265</identifier>
            <segment>
                <xbrldi:explicitMember dimension="gmab:IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis">gmab:AgreementsWithJanssenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_6_30_2021_gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_gmab_AgreementsWithBointechMember__Roy-36-pUSfv1AGtbDu3Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434265</identifier>
            <segment>
                <xbrldi:explicitMember dimension="gmab:IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis">gmab:AgreementsWithBointechMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_6_30_2021_gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_gmab_AgreementsWithAbbvieMember_KrVymjM9ekWDbOoEhonp8Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434265</identifier>
            <segment>
                <xbrldi:explicitMember dimension="gmab:IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis">gmab:AgreementsWithAbbvieMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="As_Of_6_30_2022_gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_gmab_CurevacCollaborationMember_qc8QNPN5vUSdmz2Y_v8bjg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434265</identifier>
            <segment>
                <xbrldi:explicitMember dimension="gmab:IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis">gmab:CurevacCollaborationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2022_gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_gmab_BoltBiotherapeuticsIncMember_Cb3qRuFzkUCdz53av0zSRg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434265</identifier>
            <segment>
                <xbrldi:explicitMember dimension="gmab:IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis">gmab:BoltBiotherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_gmab_CurevacCollaborationMember_0V_v61kjsUagGH7vU0HsPA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434265</identifier>
            <segment>
                <xbrldi:explicitMember dimension="gmab:IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis">gmab:CurevacCollaborationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_gmab_BoltBiotherapeuticsIncMember_dAp_IxgOu0O5Vly-wxDrdA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434265</identifier>
            <segment>
                <xbrldi:explicitMember dimension="gmab:IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis">gmab:BoltBiotherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_6_30_2022_ifrs-full_ComponentsOfEquityAxis_ifrs-full_SharePremiumMember_SdwhengxmEaD2aINUnRJ-w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434265</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_6_30_2021_ifrs-full_ComponentsOfEquityAxis_ifrs-full_SharePremiumMember_XMRWtYbFi0-RVZrBJKYdMw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434265</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="As_Of_6_30_2022_ifrs-full_ClassesOfFinancialAssetsAxis_gmab_OtherInvestmentMember_ifrs-full_LevelsOfFairValueHierarchyAxis_ifrs-full_Level3OfFairValueHierarchyMember_ifrs-full_MeasurementAxis_ifrs-full_AtFairValueMember_hoHfcpf2WkG8ZksGtffiJg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434265</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">gmab:OtherInvestmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2022_ifrs-full_ClassesOfFinancialAssetsAxis_gmab_OtherInvestmentMember_ifrs-full_LevelsOfFairValueHierarchyAxis_ifrs-full_Level1OfFairValueHierarchyMember_ifrs-full_MeasurementAxis_ifrs-full_AtFairValueMember_A8Z5M0xP50-MphyTG1XuyQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434265</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">gmab:OtherInvestmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2022_ifrs-full_ClassesOfFinancialAssetsAxis_gmab_MarketableSecuritiesMember_ifrs-full_LevelsOfFairValueHierarchyAxis_ifrs-full_Level1OfFairValueHierarchyMember_ifrs-full_MeasurementAxis_ifrs-full_AtFairValueMember_ZqdE8gsn6ku4IF-3riiPzw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434265</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">gmab:MarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2022_ifrs-full_ClassesOfFinancialAssetsAxis_gmab_OtherInvestmentMember_ifrs-full_MeasurementAxis_ifrs-full_AtFairValueMember_DxVED2HGdUitGp0y05MVqQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434265</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">gmab:OtherInvestmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2022_ifrs-full_ClassesOfFinancialAssetsAxis_gmab_MarketableSecuritiesMember_ifrs-full_MeasurementAxis_ifrs-full_AtFairValueMember_gMTFg1fkaU-2kMTWZGvA2A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434265</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">gmab:MarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_ifrs-full_ClassesOfFinancialAssetsAxis_gmab_OtherInvestmentMember_ifrs-full_LevelsOfFairValueHierarchyAxis_ifrs-full_Level3OfFairValueHierarchyMember_ifrs-full_MeasurementAxis_ifrs-full_AtFairValueMember_aMyaV8Vr-EO7hwMWUT9G9g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434265</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">gmab:OtherInvestmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_ifrs-full_ClassesOfFinancialAssetsAxis_gmab_OtherInvestmentMember_ifrs-full_LevelsOfFairValueHierarchyAxis_ifrs-full_Level1OfFairValueHierarchyMember_ifrs-full_MeasurementAxis_ifrs-full_AtFairValueMember_Obo46paYeU6NBT9bV_1jig">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434265</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">gmab:OtherInvestmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_ifrs-full_ClassesOfFinancialAssetsAxis_gmab_MarketableSecuritiesMember_ifrs-full_LevelsOfFairValueHierarchyAxis_ifrs-full_Level1OfFairValueHierarchyMember_ifrs-full_MeasurementAxis_ifrs-full_AtFairValueMember_QdkiKQXr4UeiSvq7C18kVg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434265</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">gmab:MarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_ifrs-full_ClassesOfFinancialAssetsAxis_gmab_OtherInvestmentMember_ifrs-full_MeasurementAxis_ifrs-full_AtFairValueMember_QtPH5pFRWEevfw8ugwnNCA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434265</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">gmab:OtherInvestmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_ifrs-full_ClassesOfFinancialAssetsAxis_gmab_MarketableSecuritiesMember_ifrs-full_MeasurementAxis_ifrs-full_AtFairValueMember_OovtmPjP8kG5XP6UcVoSpw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434265</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">gmab:MarketableSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2022_ifrs-full_ComponentsOfEquityAxis_ifrs-full_SharePremiumMember_c1xbYHnI60ydURKsrordAw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434265</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2022_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsMember_lUn1LjNR7EeooY5wvd9tfg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434265</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2022_ifrs-full_ComponentsOfEquityAxis_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_xwbw8UubEkGBVQFx7vgMbQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434265</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2022_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_yCKoTSQsEEOQZwa4oFi7oA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434265</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_ifrs-full_ComponentsOfEquityAxis_ifrs-full_SharePremiumMember_AoL9klgCl06NvjJ-Vt6Xlw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434265</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsMember_DT4Y_TJahk6Om4PoqoPzFg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434265</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_ifrs-full_ComponentsOfEquityAxis_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_yT7xpmSne0SrbvOgXluilQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434265</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_3hqv4rmeT0KprU066qSoRg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434265</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2021_ifrs-full_ComponentsOfEquityAxis_ifrs-full_SharePremiumMember_GV_3QWjql0Su3tgU-SgDXw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434265</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2021_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsMember_DjZRZNGrO0OpgJWJsdQZFQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434265</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2021_ifrs-full_ComponentsOfEquityAxis_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_4C8ErHNbuEyc6g9c8m0tEg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434265</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2021_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_pdtEW7BBIUqgf6EXtiJIaw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434265</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_ifrs-full_ComponentsOfEquityAxis_ifrs-full_SharePremiumMember_si1iRZkarUaeuSgvZfxZfw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434265</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsMember_MNr5zCVV90GEBvq8OjtfdQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434265</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_ifrs-full_ComponentsOfEquityAxis_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_1jjHlFLAike_v2Q-HdTGxw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434265</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_qxcDthXBpku77YP5whaVYg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434265</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_6_30_2022_ifrs-full_ClassesOfAssetsAxis_gmab_PropertiesMember_F5LrRJJceEih2g5m7wb9GA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434265</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">gmab:PropertiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_6_30_2022_ifrs-full_ClassesOfAssetsAxis_gmab_IfrsEquipmentMember_2Uc8kxVSSEeedQs5j0GsVg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434265</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">gmab:IfrsEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_6_30_2021_ifrs-full_ClassesOfAssetsAxis_gmab_PropertiesMember_G2NwEm7nQ0Kw6dT7ZkwBrQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434265</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">gmab:PropertiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_6_30_2021_ifrs-full_ClassesOfAssetsAxis_gmab_IfrsEquipmentMember_kM-fqB65HkSiWDPm7nBJiQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434265</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">gmab:IfrsEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_6_30_2022_ifrs-full_ComponentsOfEquityAxis_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_7kIYWvkWuEOdT0IirRs9kA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434265</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_6_30_2021_ifrs-full_ComponentsOfEquityAxis_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_ZmznApYSQ0yIovD2PRKBMA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434265</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="As_Of_6_30_2021_eEXLsHGqbE20an7xlGLjnw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434265</identifier>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="Duration_4_1_2022_To_6_30_2022_voh1lJjNhUCZyLqqP0N5aw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434265</identifier>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2021_To_6_30_2021_20IW8JtRlk6Ow-5ZeByISg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434265</identifier>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_6_30_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_gmab_IfrsRestrictedStockUnitsRSUsMember_4-5BFoS8HkmkHqZSV1-skg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434265</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">gmab:IfrsRestrictedStockUnitsRSUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_6_30_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_gmab_IfrsRestrictedStockUnitsRSUsMember_XTrx_EPo2kixh36V-j_AVw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434265</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">gmab:IfrsRestrictedStockUnitsRSUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_6_30_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_gmab_RestrictedStockUnitsRSUsMember_9ULLlFPCsE2o9A92MVOndw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434265</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">gmab:RestrictedStockUnitsRSUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_6_30_2022_srt_StatementScenarioAxis_gmab_StockRepurchaseAuthorization2021Member_rWOMBYvakU6yGwmAnDi9_w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434265</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">gmab:StockRepurchaseAuthorization2021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_6_30_2022_srt_StatementScenarioAxis_gmab_StockRepurchaseAuthorization2019Member_xfwDxjqmW02JCqvKbHtBaQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434265</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">gmab:StockRepurchaseAuthorization2019Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_6_30_2022_srt_StatementScenarioAxis_gmab_StockRepurchaseAuthorization2016Member_mmhw2ICcwkqWFdCPJ6rVhw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434265</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">gmab:StockRepurchaseAuthorization2016Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_3_29_2022_To_3_29_2022_ifrs-full_CategoriesOfRelatedPartiesAxis_gmab_DeirdreP.ConnellyChairPernilleErenbjergDeputyChairRolfHoffmannDr.PaoloPaolettiAndDr.AndersGerselPedersenMember_3rCJQ765kUqbhPx4A2vjig">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434265</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">gmab:DeirdreP.ConnellyChairPernilleErenbjergDeputyChairRolfHoffmannDr.PaoloPaolettiAndDr.AndersGerselPedersenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-03-29</startDate>
            <endDate>2022-03-29</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2020_ccHyN2oOokuDhNdvPg9fRQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434265</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_6_30_2022_ifrs-full_TypesOfRisksAxis_ifrs-full_CurrencyRiskMember_srt_CurrencyAxis_currency_USD_5UvDDDnrAUyD1gvej8S37Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434265</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CurrencyRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_6_30_2022_ifrs-full_TypesOfRisksAxis_ifrs-full_CurrencyRiskMember_srt_CurrencyAxis_currency_GBP_DSPHKvhiT02Od8W80WG6KQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434265</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:GBP</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CurrencyRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_6_30_2022_ifrs-full_TypesOfRisksAxis_ifrs-full_CurrencyRiskMember_srt_CurrencyAxis_currency_EUR_SstAsF5VjkaHxTdVOHBYpg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434265</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:EUR</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CurrencyRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_6_30_2022_ifrs-full_TypesOfRisksAxis_ifrs-full_CurrencyRiskMember_srt_CurrencyAxis_currency_DKK_wEFDGqiOE0meYqnyprgzqw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434265</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:DKK</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CurrencyRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_6_30_2022_ifrs-full_TypesOfRisksAxis_ifrs-full_CurrencyRiskMember_ASM5neKz9keFOK65fKS2gQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434265</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CurrencyRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_ifrs-full_TypesOfRisksAxis_ifrs-full_CurrencyRiskMember_srt_CurrencyAxis_currency_USD_CHnFrAUKTEWMyHR2NduwAw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434265</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CurrencyRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_ifrs-full_TypesOfRisksAxis_ifrs-full_CurrencyRiskMember_srt_CurrencyAxis_currency_GBP_nnosnR0H8kS3TQbqxqHACA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434265</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:GBP</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CurrencyRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_ifrs-full_TypesOfRisksAxis_ifrs-full_CurrencyRiskMember_srt_CurrencyAxis_currency_EUR_9Wybode0pUWKJkinsc2Cxw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434265</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:EUR</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CurrencyRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_ifrs-full_TypesOfRisksAxis_ifrs-full_CurrencyRiskMember_srt_CurrencyAxis_currency_DKK_ayp_YF4WHEe51vXOnYlL2A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434265</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:DKK</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CurrencyRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_ifrs-full_TypesOfRisksAxis_ifrs-full_CurrencyRiskMember_xIqg6PH6QUGf8y8gkPOHag">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434265</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CurrencyRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_6_30_2022_ifrs-full_ExternalCreditGradesAxis_gmab_TripleaRatingMember_ifrs-full_TypesOfRisksAxis_ifrs-full_CreditRiskMember_MchtLzCh3Uufn_bh-7kpNA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434265</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ExternalCreditGradesAxis">gmab:TripleaRatingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CreditRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_ifrs-full_ExternalCreditGradesAxis_gmab_TripleaRatingMember_ifrs-full_TypesOfRisksAxis_ifrs-full_CreditRiskMember_O0tp15gOUUSNGn0NNu-ntA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434265</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ExternalCreditGradesAxis">gmab:TripleaRatingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CreditRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_6_30_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_gmab_WarrantsMember_kH0r0sIdkU-S9yq6_erZfw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434265</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">gmab:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_6_30_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_gmab_WarrantsMember_sN8RX4-cR0-kSMFNCobg0Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434265</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">gmab:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="As_Of_6_30_2022_srt_StatementScenarioAxis_gmab_StockRepurchaseAuthorization2021Member_ll839TqkPUSnSuKvpYFvXQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434265</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">gmab:StockRepurchaseAuthorization2021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2022_srt_StatementScenarioAxis_gmab_StockRepurchaseAuthorization2019Member_Ey8o8eyD7UaKwBJF-khG6w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434265</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">gmab:StockRepurchaseAuthorization2019Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2022_srt_StatementScenarioAxis_gmab_StockRepurchaseAuthorization2016Member_rs9bpzaf80uIoq7-Gcmw6w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434265</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">gmab:StockRepurchaseAuthorization2016Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="Duration_3_29_2022_To_3_29_2022_ifrs-full_CategoriesOfRelatedPartiesAxis_ifrs-full_KeyManagementPersonnelOfEntityOrParentMember_wG1K_J98VEKINTE73Xhmyg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434265</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">ifrs-full:KeyManagementPersonnelOfEntityOrParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-03-29</startDate>
            <endDate>2022-03-29</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_6_30_2022_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsMember_Obfciab50kOeB1cRJrxSkw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434265</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_6_30_2021_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsMember_3at9FYujHUm7dtmVg4zXig">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434265</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="As_Of_6_30_2022_kBUEJjmpl0mHNogMyIvzJg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434265</identifier>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2022_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_gmab_OfficeAndLaboratorySpaceMember_srt_StatementGeographicalAxis_country_DK_B5VFPCgUJ0SOaI0R2W2tew">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434265</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:DK</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">gmab:OfficeAndLaboratorySpaceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="Duration_3_29_2022_To_3_29_2022_ifrs-full_CategoriesOfRelatedPartiesAxis_gmab_MijkeZachariasseMartinSchultzAndTakahiroHamataniMember_eVcKyLWOlE-Ky0qUaYmu0Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434265</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">gmab:MijkeZachariasseMartinSchultzAndTakahiroHamataniMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-03-29</startDate>
            <endDate>2022-03-29</endDate>
        </period>
    </context>
    <context id="Duration_3_29_2022_To_3_29_2022_ifrs-full_CategoriesOfRelatedPartiesAxis_gmab_ElizabethOfarrellMember_71bO48trL0yfIoKu2bbOIw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434265</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">gmab:ElizabethOfarrellMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-03-29</startDate>
            <endDate>2022-03-29</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2021_yeBwiJf1M0aAa25fFQy9Bg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434265</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_6_30_2021_MRS0_D_onUCNBOxf7Qx_Cw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434265</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <unit id="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg">
        <measure>iso4217:DKK</measure>
    </unit>
    <unit id="Unit_Standard_item_d-Yn30W8q0CdLFqZ4zWe8g">
        <measure>gmab:item</measure>
    </unit>
    <unit id="Unit_Standard_director_1-CkTK7-YkaxWNG_tkhy7g">
        <measure>gmab:director</measure>
    </unit>
    <unit id="Unit_Standard_shares_MrgY4vrrEUeN62nRwu-ZLA">
        <measure>shares</measure>
    </unit>
    <unit id="Unit_Standard_pure_ydC7mNX6akalcP_kj1H8wg">
        <measure>pure</measure>
    </unit>
    <unit id="Unit_Divide_DKK_shares_uaEdw-3-XkitvcC2Swh0EQ">
        <divide>
            <unitNumerator>
                <measure>iso4217:DKK</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Unit_Standard_EquityInstruments_bRFAkAsdz0ugOZctjovS4A">
        <measure>gmab:EquityInstruments</measure>
    </unit>
    <dei:EntityCentralIndexKey
      contextRef="Duration_1_1_2022_To_6_30_2022_dNPMG5n7t0WcNVF9KG4Bdw"
      id="Tc_B7JyuSE95E6WpedpSxwepA_2_1">0001434265</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate
      contextRef="Duration_1_1_2022_To_6_30_2022_dNPMG5n7t0WcNVF9KG4Bdw"
      id="Tc_aI5C-STwiUauJH8AwHpRcg_3_1">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="Duration_1_1_2022_To_6_30_2022_dNPMG5n7t0WcNVF9KG4Bdw"
      id="Tc_fgPHaeAwXUiwr-1K1wILTg_4_1">2022</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="Duration_1_1_2022_To_6_30_2022_dNPMG5n7t0WcNVF9KG4Bdw"
      id="Tc_9GvVmMoFbkSndCAEXAI8tA_5_1">Q2</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag
      contextRef="Duration_1_1_2022_To_6_30_2022_dNPMG5n7t0WcNVF9KG4Bdw"
      id="Tc_myxDIm84UkeCuBsGl6AyJg_6_1">false</dei:AmendmentFlag>
    <dei:EntityRegistrantName
      contextRef="Duration_1_1_2022_To_6_30_2022_dNPMG5n7t0WcNVF9KG4Bdw"
      id="Tc_pOCbcc1yy0KES6cRoghGTA_7_1">Genmab A/S</dei:EntityRegistrantName>
    <dei:DocumentType
      contextRef="Duration_1_1_2022_To_6_30_2022_dNPMG5n7t0WcNVF9KG4Bdw"
      id="Tc_QFMVRxmoYE2lWu4Y6WVxIQ_8_1">6-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="Duration_1_1_2022_To_6_30_2022_dNPMG5n7t0WcNVF9KG4Bdw"
      id="Tc_mFcLlEIyUUyenDkpUynyLw_9_1">2022-06-30</dei:DocumentPeriodEndDate>
    <ifrs-full:Revenue
      contextRef="Duration_4_1_2022_To_6_30_2022_voh1lJjNhUCZyLqqP0N5aw"
      decimals="-6"
      id="Tc_0v1fpp4G_kC3_h-_x4jrCQ_5_2"
      unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg">3162000000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="Duration_4_1_2021_To_6_30_2021_20IW8JtRlk6Ow-5ZeByISg"
      decimals="-6"
      id="Tc_2rNPwEjMykGF052n9a3Ewg_5_4"
      unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg">1972000000</ifrs-full:Revenue>
    <ifrs-full:ResearchAndDevelopmentExpense
      contextRef="Duration_4_1_2022_To_6_30_2022_voh1lJjNhUCZyLqqP0N5aw"
      decimals="-6"
      id="Tc_Qx23B6OsS0CK7__TmTDBPQ_7_2"
      unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg">1282000000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense
      contextRef="Duration_4_1_2021_To_6_30_2021_20IW8JtRlk6Ow-5ZeByISg"
      decimals="-6"
      id="Tc_EOGRs-n1E0WEbhlx7B6o2Q_7_4"
      unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg">921000000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:SellingGeneralAndAdministrativeExpense
      contextRef="Duration_4_1_2022_To_6_30_2022_voh1lJjNhUCZyLqqP0N5aw"
      decimals="-6"
      id="Tc_2c04FZcXjkWAKX95cL5xeQ_8_2"
      unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg">633000000</ifrs-full:SellingGeneralAndAdministrativeExpense>
    <ifrs-full:SellingGeneralAndAdministrativeExpense
      contextRef="Duration_4_1_2021_To_6_30_2021_20IW8JtRlk6Ow-5ZeByISg"
      decimals="-6"
      id="Tc_NZk0ZRTvN0C0E5CZH7lBZQ_8_4"
      unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg">264000000</ifrs-full:SellingGeneralAndAdministrativeExpense>
    <ifrs-full:OperatingExpense
      contextRef="Duration_4_1_2022_To_6_30_2022_voh1lJjNhUCZyLqqP0N5aw"
      decimals="-6"
      id="Tc_QqufzBDaCUSVMAcxxUyDWQ_9_2"
      unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg">1915000000</ifrs-full:OperatingExpense>
    <ifrs-full:OperatingExpense
      contextRef="Duration_4_1_2021_To_6_30_2021_20IW8JtRlk6Ow-5ZeByISg"
      decimals="-6"
      id="Tc_FC0vyLkQoU6reMCf7EjEiA_9_4"
      unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg">1185000000</ifrs-full:OperatingExpense>
    <ifrs-full:ProfitLossFromOperatingActivities
      contextRef="Duration_4_1_2022_To_6_30_2022_voh1lJjNhUCZyLqqP0N5aw"
      decimals="-6"
      id="Tc_4U1fHTAp0US-S7tYR1uePw_11_2"
      unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg">1247000000</ifrs-full:ProfitLossFromOperatingActivities>
    <ifrs-full:ProfitLossFromOperatingActivities
      contextRef="Duration_4_1_2021_To_6_30_2021_20IW8JtRlk6Ow-5ZeByISg"
      decimals="-6"
      id="Tc_pfB0I3LKr0uxUC2tOpIWqQ_11_4"
      unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg">787000000</ifrs-full:ProfitLossFromOperatingActivities>
    <ifrs-full:FinanceIncome
      contextRef="Duration_4_1_2022_To_6_30_2022_voh1lJjNhUCZyLqqP0N5aw"
      decimals="-6"
      id="Tc_kEcYZ6PXCkSz6yNE6Yxwgg_13_2"
      unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg">1442000000</ifrs-full:FinanceIncome>
    <ifrs-full:FinanceIncome
      contextRef="Duration_4_1_2021_To_6_30_2021_20IW8JtRlk6Ow-5ZeByISg"
      decimals="-6"
      id="Tc_BKJWCj6_9EyFhcVX4H4RKQ_13_4"
      unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg">65000000</ifrs-full:FinanceIncome>
    <ifrs-full:FinanceCosts
      contextRef="Duration_4_1_2022_To_6_30_2022_voh1lJjNhUCZyLqqP0N5aw"
      decimals="-6"
      id="Tc_bnUVCAu1Z0Of-9oP2NFKDA_14_2"
      unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg">200000000</ifrs-full:FinanceCosts>
    <ifrs-full:FinanceCosts
      contextRef="Duration_4_1_2021_To_6_30_2021_20IW8JtRlk6Ow-5ZeByISg"
      decimals="-6"
      id="Tc_M9Ng8ECU4kWDvrHNphQBDg_14_4"
      unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg">430000000</ifrs-full:FinanceCosts>
    <ifrs-full:ProfitLossBeforeTax
      contextRef="Duration_4_1_2022_To_6_30_2022_voh1lJjNhUCZyLqqP0N5aw"
      decimals="-6"
      id="Tc_W_rhsu6WAUuo4MA32wA28w_16_2"
      unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg">2489000000</ifrs-full:ProfitLossBeforeTax>
    <ifrs-full:ProfitLossBeforeTax
      contextRef="Duration_4_1_2021_To_6_30_2021_20IW8JtRlk6Ow-5ZeByISg"
      decimals="-6"
      id="Tc_ImgJSI5Gkkyl4MnwIWbT0w_16_4"
      unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg">422000000</ifrs-full:ProfitLossBeforeTax>
    <ifrs-full:IncomeTaxExpenseContinuingOperations
      contextRef="Duration_4_1_2022_To_6_30_2022_voh1lJjNhUCZyLqqP0N5aw"
      decimals="-6"
      id="Tc_axSnWTGds0GBgmTlaPWN0A_18_2"
      unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg">598000000</ifrs-full:IncomeTaxExpenseContinuingOperations>
    <ifrs-full:IncomeTaxExpenseContinuingOperations
      contextRef="Duration_4_1_2021_To_6_30_2021_20IW8JtRlk6Ow-5ZeByISg"
      decimals="-6"
      id="Tc_tmb3tpeoa0OWZpelFchESQ_18_4"
      unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg">116000000</ifrs-full:IncomeTaxExpenseContinuingOperations>
    <ifrs-full:ProfitLoss
      contextRef="Duration_4_1_2022_To_6_30_2022_voh1lJjNhUCZyLqqP0N5aw"
      decimals="-6"
      id="Tc_zfOPFR7Y-Ueb69suEJaQOQ_20_2"
      unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg">1891000000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="Duration_4_1_2021_To_6_30_2021_20IW8JtRlk6Ow-5ZeByISg"
      decimals="-6"
      id="Tc_vtgJ0n_PaE2n8iysHFedVA_20_4"
      unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg">306000000</ifrs-full:ProfitLoss>
    <ifrs-full:BasicEarningsLossPerShare
      contextRef="Duration_4_1_2022_To_6_30_2022_voh1lJjNhUCZyLqqP0N5aw"
      decimals="2"
      id="Tc_Ioj9VuBj0Uimljv3jlZi0Q_22_2"
      unitRef="Unit_Divide_DKK_shares_uaEdw-3-XkitvcC2Swh0EQ">28.87</ifrs-full:BasicEarningsLossPerShare>
    <ifrs-full:BasicEarningsLossPerShare
      contextRef="Duration_4_1_2021_To_6_30_2021_20IW8JtRlk6Ow-5ZeByISg"
      decimals="2"
      id="Tc_x6EnrD-3lEKMJaGCW5yDGA_22_4"
      unitRef="Unit_Divide_DKK_shares_uaEdw-3-XkitvcC2Swh0EQ">4.68</ifrs-full:BasicEarningsLossPerShare>
    <ifrs-full:DilutedEarningsLossPerShare
      contextRef="Duration_4_1_2022_To_6_30_2022_voh1lJjNhUCZyLqqP0N5aw"
      decimals="2"
      id="Tc_U7Atevg3ekm0HPsIMuC64A_23_2"
      unitRef="Unit_Divide_DKK_shares_uaEdw-3-XkitvcC2Swh0EQ">28.66</ifrs-full:DilutedEarningsLossPerShare>
    <ifrs-full:DilutedEarningsLossPerShare
      contextRef="Duration_4_1_2021_To_6_30_2021_20IW8JtRlk6Ow-5ZeByISg"
      decimals="2"
      id="Tc_EyB8F7d3akmCUgG3u1LXmQ_23_4"
      unitRef="Unit_Divide_DKK_shares_uaEdw-3-XkitvcC2Swh0EQ">4.64</ifrs-full:DilutedEarningsLossPerShare>
    <ifrs-full:ProfitLoss
      contextRef="Duration_4_1_2022_To_6_30_2022_voh1lJjNhUCZyLqqP0N5aw"
      decimals="-6"
      id="Tc_SEnaE6Sj00OdoKR43atstg_27_2"
      unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg">1891000000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="Duration_4_1_2021_To_6_30_2021_20IW8JtRlk6Ow-5ZeByISg"
      decimals="-6"
      id="Tc_87LWUtrVq0qabaZVt8qPVQ_27_4"
      unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg">306000000</ifrs-full:ProfitLoss>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation
      contextRef="Duration_4_1_2022_To_6_30_2022_voh1lJjNhUCZyLqqP0N5aw"
      decimals="-6"
      id="Tc_w3QHrQavGkKYU-tcsGndZQ_32_2"
      unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg">13000000</ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation
      contextRef="Duration_4_1_2021_To_6_30_2021_20IW8JtRlk6Ow-5ZeByISg"
      decimals="-6"
      id="Tc_2EdIuZAM0Uqh99bFJb5vBw_32_4"
      unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg">-13000000</ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation>
    <ifrs-full:ComprehensiveIncome
      contextRef="Duration_4_1_2022_To_6_30_2022_voh1lJjNhUCZyLqqP0N5aw"
      decimals="-6"
      id="Tc_ZPLKGvLZ60S24S4BiTOECg_34_2"
      unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg">1904000000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome
      contextRef="Duration_4_1_2021_To_6_30_2021_20IW8JtRlk6Ow-5ZeByISg"
      decimals="-6"
      id="Tc_gdmz45TNEUygA9YPXd4Ghw_34_4"
      unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg">293000000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:Revenue
      contextRef="Duration_1_1_2022_To_6_30_2022_dNPMG5n7t0WcNVF9KG4Bdw"
      decimals="-6"
      id="Tc_7H0dOdM7M0-0k21UTF76Dg_5_3"
      unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg">5281000000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="Duration_1_1_2021_To_6_30_2021_MRS0_D_onUCNBOxf7Qx_Cw"
      decimals="-6"
      id="Tc_AJyyYh4EVEqbWM39qoJrXw_5_5"
      unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg">3553000000</ifrs-full:Revenue>
    <ifrs-full:ResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2022_To_6_30_2022_dNPMG5n7t0WcNVF9KG4Bdw"
      decimals="-6"
      id="Tc_XZLspiZiKE2QllozNuGjEA_7_3"
      unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg">2435000000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2021_To_6_30_2021_MRS0_D_onUCNBOxf7Qx_Cw"
      decimals="-6"
      id="Tc_GMEtpCEjwUyQi9XXmMhVYA_7_5"
      unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg">1769000000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:SellingGeneralAndAdministrativeExpense
      contextRef="Duration_1_1_2022_To_6_30_2022_dNPMG5n7t0WcNVF9KG4Bdw"
      decimals="-6"
      id="Tc_erXfrjZh4kG12npXmmPg0w_8_3"
      unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg">1085000000</ifrs-full:SellingGeneralAndAdministrativeExpense>
    <ifrs-full:SellingGeneralAndAdministrativeExpense
      contextRef="Duration_1_1_2021_To_6_30_2021_MRS0_D_onUCNBOxf7Qx_Cw"
      decimals="-6"
      id="Tc_E-FEL5OwsUWgTNArVg6GYQ_8_5"
      unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg">465000000</ifrs-full:SellingGeneralAndAdministrativeExpense>
    <ifrs-full:OperatingExpense
      contextRef="Duration_1_1_2022_To_6_30_2022_dNPMG5n7t0WcNVF9KG4Bdw"
      decimals="-6"
      id="Tc_yqlZ70PPI0uMdbc-RD5orw_9_3"
      unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg">3520000000</ifrs-full:OperatingExpense>
    <ifrs-full:OperatingExpense
      contextRef="Duration_1_1_2021_To_6_30_2021_MRS0_D_onUCNBOxf7Qx_Cw"
      decimals="-6"
      id="Tc_lis5_iJrpEezRyq7wbX3cg_9_5"
      unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg">2234000000</ifrs-full:OperatingExpense>
    <ifrs-full:ProfitLossFromOperatingActivities
      contextRef="Duration_1_1_2022_To_6_30_2022_dNPMG5n7t0WcNVF9KG4Bdw"
      decimals="-6"
      id="Tc_TMQKido-TEG3XlbHIvKSlQ_11_3"
      unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg">1761000000</ifrs-full:ProfitLossFromOperatingActivities>
    <ifrs-full:ProfitLossFromOperatingActivities
      contextRef="Duration_1_1_2021_To_6_30_2021_MRS0_D_onUCNBOxf7Qx_Cw"
      decimals="-6"
      id="Tc_Z_4V1AYcu0yQ6-cVXss78g_11_5"
      unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg">1319000000</ifrs-full:ProfitLossFromOperatingActivities>
    <ifrs-full:FinanceIncome
      contextRef="Duration_1_1_2022_To_6_30_2022_dNPMG5n7t0WcNVF9KG4Bdw"
      decimals="-6"
      id="Tc_pvzlD-rwRUOzHV0BJXnoZw_13_3"
      unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg">1879000000</ifrs-full:FinanceIncome>
    <ifrs-full:FinanceIncome
      contextRef="Duration_1_1_2021_To_6_30_2021_MRS0_D_onUCNBOxf7Qx_Cw"
      decimals="-6"
      id="Tc_pxhmcV3SH0aoCaWc0j1sxQ_13_5"
      unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg">700000000</ifrs-full:FinanceIncome>
    <ifrs-full:FinanceCosts
      contextRef="Duration_1_1_2022_To_6_30_2022_dNPMG5n7t0WcNVF9KG4Bdw"
      decimals="-6"
      id="Tc_Xx9d1umZ0UuUfdxtdIXQkQ_14_3"
      unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg">539000000</ifrs-full:FinanceCosts>
    <ifrs-full:FinanceCosts
      contextRef="Duration_1_1_2021_To_6_30_2021_MRS0_D_onUCNBOxf7Qx_Cw"
      decimals="-6"
      id="Tc_nsXePR0_zkGp3jMcpgNafQ_14_5"
      unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg">173000000</ifrs-full:FinanceCosts>
    <ifrs-full:ProfitLossBeforeTax
      contextRef="Duration_1_1_2022_To_6_30_2022_dNPMG5n7t0WcNVF9KG4Bdw"
      decimals="-6"
      id="Tc_ZW-KVoHY20eoK_f5Wi4ygA_16_3"
      unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg">3101000000</ifrs-full:ProfitLossBeforeTax>
    <ifrs-full:ProfitLossBeforeTax
      contextRef="Duration_1_1_2021_To_6_30_2021_MRS0_D_onUCNBOxf7Qx_Cw"
      decimals="-6"
      id="Tc_l9ol58SEmkKYuio9VRYrwg_16_5"
      unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg">1846000000</ifrs-full:ProfitLossBeforeTax>
    <ifrs-full:IncomeTaxExpenseContinuingOperations
      contextRef="Duration_1_1_2022_To_6_30_2022_dNPMG5n7t0WcNVF9KG4Bdw"
      decimals="-6"
      id="Tc_H33A0pgCiEO05JDo1SVB_Q_18_3"
      unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg">745000000</ifrs-full:IncomeTaxExpenseContinuingOperations>
    <ifrs-full:IncomeTaxExpenseContinuingOperations
      contextRef="Duration_1_1_2021_To_6_30_2021_MRS0_D_onUCNBOxf7Qx_Cw"
      decimals="-6"
      id="Tc_YkOixXTlcUqSIg9vHjcp2A_18_5"
      unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg">444000000</ifrs-full:IncomeTaxExpenseContinuingOperations>
    <ifrs-full:ProfitLoss
      contextRef="Duration_1_1_2022_To_6_30_2022_dNPMG5n7t0WcNVF9KG4Bdw"
      decimals="-6"
      id="Tc_WQxVd5KteESBZn7rUwz0Vg_20_3"
      unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg">2356000000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="Duration_1_1_2021_To_6_30_2021_MRS0_D_onUCNBOxf7Qx_Cw"
      decimals="-6"
      id="Tc_mKrm8yPZ7EOtI26jr8RQJA_20_5"
      unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg">1402000000</ifrs-full:ProfitLoss>
    <ifrs-full:BasicEarningsLossPerShare
      contextRef="Duration_1_1_2022_To_6_30_2022_dNPMG5n7t0WcNVF9KG4Bdw"
      decimals="2"
      id="Tc_GTddy9SGfUyMYOFwf-lO8Q_22_3"
      unitRef="Unit_Divide_DKK_shares_uaEdw-3-XkitvcC2Swh0EQ">35.97</ifrs-full:BasicEarningsLossPerShare>
    <ifrs-full:BasicEarningsLossPerShare
      contextRef="Duration_1_1_2021_To_6_30_2021_MRS0_D_onUCNBOxf7Qx_Cw"
      decimals="2"
      id="Tc_xQf8ySVz60e0vBuM3LnJsQ_22_5"
      unitRef="Unit_Divide_DKK_shares_uaEdw-3-XkitvcC2Swh0EQ">21.44</ifrs-full:BasicEarningsLossPerShare>
    <ifrs-full:DilutedEarningsLossPerShare
      contextRef="Duration_1_1_2022_To_6_30_2022_dNPMG5n7t0WcNVF9KG4Bdw"
      decimals="2"
      id="Tc_Zw1Yqp2WdUO1r1ebfDvEjw_23_3"
      unitRef="Unit_Divide_DKK_shares_uaEdw-3-XkitvcC2Swh0EQ">35.71</ifrs-full:DilutedEarningsLossPerShare>
    <ifrs-full:DilutedEarningsLossPerShare
      contextRef="Duration_1_1_2021_To_6_30_2021_MRS0_D_onUCNBOxf7Qx_Cw"
      decimals="2"
      id="Tc_BzHlSiAYaU6-EOmpFGik6A_23_5"
      unitRef="Unit_Divide_DKK_shares_uaEdw-3-XkitvcC2Swh0EQ">21.25</ifrs-full:DilutedEarningsLossPerShare>
    <ifrs-full:ProfitLoss
      contextRef="Duration_1_1_2022_To_6_30_2022_dNPMG5n7t0WcNVF9KG4Bdw"
      decimals="-6"
      id="Tc_kZhZcSsaAUCVeAQIbp6BBg_27_3"
      unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg">2356000000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="Duration_1_1_2021_To_6_30_2021_MRS0_D_onUCNBOxf7Qx_Cw"
      decimals="-6"
      id="Tc_aYheMpMevkOsO24KnTfn-w_27_5"
      unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg">1402000000</ifrs-full:ProfitLoss>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation
      contextRef="Duration_1_1_2022_To_6_30_2022_dNPMG5n7t0WcNVF9KG4Bdw"
      decimals="-6"
      id="Tc_YZ8QYrlTXUC1Scje2KIYHA_32_3"
      unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg">29000000</ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation
      contextRef="Duration_1_1_2021_To_6_30_2021_MRS0_D_onUCNBOxf7Qx_Cw"
      decimals="-6"
      id="Tc_h5MtroS63UiRjzxWGFh74A_32_5"
      unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg">28000000</ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation>
    <ifrs-full:ComprehensiveIncome
      contextRef="Duration_1_1_2022_To_6_30_2022_dNPMG5n7t0WcNVF9KG4Bdw"
      decimals="-6"
      id="Tc_o0U4GN3_iEi77lY0MWL3MA_34_3"
      unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg">2385000000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome
      contextRef="Duration_1_1_2021_To_6_30_2021_MRS0_D_onUCNBOxf7Qx_Cw"
      decimals="-6"
      id="Tc_CVKkrbCTAUKL_No7HDss7A_34_5"
      unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg">1430000000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="As_Of_6_30_2022_kBUEJjmpl0mHNogMyIvzJg"
      decimals="-6"
      id="Tc_2zlhBD73I0ubHQMMMn5P8A_6_4"
      unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg">216000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="As_Of_12_31_2021_yeBwiJf1M0aAa25fFQy9Bg"
      decimals="-6"
      id="Tc_hiNFqikDkEmg58UqwvCgAw_6_6"
      unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg">254000000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="As_Of_6_30_2022_kBUEJjmpl0mHNogMyIvzJg"
      decimals="-6"
      id="Tc_LU9ihB3hzEqF_pfEZ-hxig_7_4"
      unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg">684000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="As_Of_12_31_2021_yeBwiJf1M0aAa25fFQy9Bg"
      decimals="-6"
      id="Tc_-aWFAb9XwUCqLcLOBXfAtg_7_6"
      unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg">621000000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:RightofuseAssets
      contextRef="As_Of_6_30_2022_kBUEJjmpl0mHNogMyIvzJg"
      decimals="-6"
      id="Tc_sWbs_K-oRkeRFnQjRilz8w_8_4"
      unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg">554000000</ifrs-full:RightofuseAssets>
    <ifrs-full:RightofuseAssets
      contextRef="As_Of_12_31_2021_yeBwiJf1M0aAa25fFQy9Bg"
      decimals="-6"
      id="Tc_RYdvUmRJMkuvGSzDb2IKUQ_8_6"
      unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg">354000000</ifrs-full:RightofuseAssets>
    <ifrs-full:NoncurrentReceivables
      contextRef="As_Of_6_30_2022_kBUEJjmpl0mHNogMyIvzJg"
      decimals="-6"
      id="Tc_lhRxP054zk2BkLzvAOyTkg_9_4"
      unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg">66000000</ifrs-full:NoncurrentReceivables>
    <ifrs-full:NoncurrentReceivables
      contextRef="As_Of_12_31_2021_yeBwiJf1M0aAa25fFQy9Bg"
      decimals="-6"
      id="Tc_l9KL2K_vh0SGHuL3Z4RS4g_9_6"
      unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg">27000000</ifrs-full:NoncurrentReceivables>
    <ifrs-full:NetDeferredTaxAssets
      contextRef="As_Of_6_30_2022_kBUEJjmpl0mHNogMyIvzJg"
      decimals="-6"
      id="Tc_t23CrV_DfUSn7FragaePsw_10_4"
      unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg">264000000</ifrs-full:NetDeferredTaxAssets>
    <ifrs-full:NetDeferredTaxAssets
      contextRef="As_Of_12_31_2021_yeBwiJf1M0aAa25fFQy9Bg"
      decimals="-6"
      id="Tc_mSXvvYmOGkiFXaMySs6EUQ_10_6"
      unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg">264000000</ifrs-full:NetDeferredTaxAssets>
    <ifrs-full:InvestmentAccountedForUsingEquityMethod
      contextRef="As_Of_6_30_2022_kBUEJjmpl0mHNogMyIvzJg"
      decimals="-6"
      id="Tc_VV3bksGzt0yJcGUVvyD1qA_11_4"
      unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg">201000000</ifrs-full:InvestmentAccountedForUsingEquityMethod>
    <ifrs-full:InvestmentAccountedForUsingEquityMethod
      contextRef="As_Of_12_31_2021_yeBwiJf1M0aAa25fFQy9Bg"
      decimals="-6"
      id="Tc_rSBCkECkMEO9EYkhHkRjFQ_11_6"
      unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg">371000000</ifrs-full:InvestmentAccountedForUsingEquityMethod>
    <ifrs-full:NoncurrentAssets
      contextRef="As_Of_6_30_2022_kBUEJjmpl0mHNogMyIvzJg"
      decimals="-6"
      id="Tc_2r0fG70ZkkGqVklVaGHIWA_13_4"
      unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg">1985000000</ifrs-full:NoncurrentAssets>
    <ifrs-full:NoncurrentAssets
      contextRef="As_Of_12_31_2021_yeBwiJf1M0aAa25fFQy9Bg"
      decimals="-6"
      id="Tc_U36ff-GT3kav7uITxoXuBA_13_6"
      unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg">1891000000</ifrs-full:NoncurrentAssets>
    <gmab:CorporateTaxReceivable
      contextRef="As_Of_12_31_2021_yeBwiJf1M0aAa25fFQy9Bg"
      decimals="-6"
      id="Tc_ZU2cUkzjYkCl_4T7_cw-Zw_15_6"
      unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg">31000000</gmab:CorporateTaxReceivable>
    <ifrs-full:TradeAndOtherCurrentReceivables
      contextRef="As_Of_6_30_2022_kBUEJjmpl0mHNogMyIvzJg"
      decimals="-6"
      id="Tc_206wA6QPBkKlLj1-PJwZXg_16_4"
      unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg">3876000000</ifrs-full:TradeAndOtherCurrentReceivables>
    <ifrs-full:TradeAndOtherCurrentReceivables
      contextRef="As_Of_12_31_2021_yeBwiJf1M0aAa25fFQy9Bg"
      decimals="-6"
      id="Tc_-uTQHypiqkeIoH2jkMiQfg_16_6"
      unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg">3367000000</ifrs-full:TradeAndOtherCurrentReceivables>
    <gmab:IfrsMarketableSecuritiesCurrent
      contextRef="As_Of_6_30_2022_kBUEJjmpl0mHNogMyIvzJg"
      decimals="-6"
      id="Tc_zlzSDxLOoUi3p-moi8b0_w_17_4"
      unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg">11799000000</gmab:IfrsMarketableSecuritiesCurrent>
    <gmab:IfrsMarketableSecuritiesCurrent
      contextRef="As_Of_12_31_2021_yeBwiJf1M0aAa25fFQy9Bg"
      decimals="-6"
      id="Tc_1oViucfx7kOeWrsLQBC41Q_17_6"
      unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg">10381000000</gmab:IfrsMarketableSecuritiesCurrent>
    <ifrs-full:CashAndCashEquivalents
      contextRef="As_Of_6_30_2022_kBUEJjmpl0mHNogMyIvzJg"
      decimals="-6"
      id="Tc_ZDpcJT6V5EWE_KN1RstJoQ_18_4"
      unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg">9816000000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents
      contextRef="As_Of_12_31_2021_yeBwiJf1M0aAa25fFQy9Bg"
      decimals="-6"
      id="Tc_a5NQ8ZUGfUa0qhLDms_A1g_18_6"
      unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg">8957000000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CurrentAssets
      contextRef="As_Of_6_30_2022_kBUEJjmpl0mHNogMyIvzJg"
      decimals="-6"
      id="Tc_ZWU71fQYokmJ0H19I_ZzzA_20_4"
      unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg">25491000000</ifrs-full:CurrentAssets>
    <ifrs-full:CurrentAssets
      contextRef="As_Of_12_31_2021_yeBwiJf1M0aAa25fFQy9Bg"
      decimals="-6"
      id="Tc_S7HpeHyqPkepn-lgqe75ww_20_6"
      unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg">22736000000</ifrs-full:CurrentAssets>
    <ifrs-full:Assets
      contextRef="As_Of_6_30_2022_kBUEJjmpl0mHNogMyIvzJg"
      decimals="-6"
      id="Tc_96KxMKQqKkKfXxkgBhqHaw_22_4"
      unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg">27476000000</ifrs-full:Assets>
    <ifrs-full:Assets
      contextRef="As_Of_12_31_2021_yeBwiJf1M0aAa25fFQy9Bg"
      decimals="-6"
      id="Tc_H85v_KLzH0Kgtd0YuERN_A_22_6"
      unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg">24627000000</ifrs-full:Assets>
    <ifrs-full:IssuedCapital
      contextRef="As_Of_6_30_2022_kBUEJjmpl0mHNogMyIvzJg"
      decimals="-6"
      id="Tc_6ZVE06BWE0aeV5xpb2pIgA_26_4"
      unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg">66000000</ifrs-full:IssuedCapital>
    <ifrs-full:IssuedCapital
      contextRef="As_Of_12_31_2021_yeBwiJf1M0aAa25fFQy9Bg"
      decimals="-6"
      id="Tc_bRSOeYSE8UuOIDCEGX13nw_26_6"
      unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg">66000000</ifrs-full:IssuedCapital>
    <ifrs-full:SharePremium
      contextRef="As_Of_6_30_2022_kBUEJjmpl0mHNogMyIvzJg"
      decimals="-6"
      id="Tc_wOqziu5L1Ui7QXX-UDQkdA_27_4"
      unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg">12063000000</ifrs-full:SharePremium>
    <ifrs-full:SharePremium
      contextRef="As_Of_12_31_2021_yeBwiJf1M0aAa25fFQy9Bg"
      decimals="-6"
      id="Tc_Qn2HuCaDdkGboc3uUoYzow_27_6"
      unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg">12029000000</ifrs-full:SharePremium>
    <ifrs-full:OtherReserves
      contextRef="As_Of_6_30_2022_kBUEJjmpl0mHNogMyIvzJg"
      decimals="-6"
      id="Tc_aCFOwRZr4kObTir0FVO-UA_28_4"
      unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg">110000000</ifrs-full:OtherReserves>
    <ifrs-full:OtherReserves
      contextRef="As_Of_12_31_2021_yeBwiJf1M0aAa25fFQy9Bg"
      decimals="-6"
      id="Tc_-kU2ns9FR0W6MIIkztv9Wg_28_6"
      unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg">81000000</ifrs-full:OtherReserves>
    <ifrs-full:RetainedEarnings
      contextRef="As_Of_6_30_2022_kBUEJjmpl0mHNogMyIvzJg"
      decimals="-6"
      id="Tc_pg1dU29twEWcXwkUAj5pZA_29_4"
      unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg">12243000000</ifrs-full:RetainedEarnings>
    <ifrs-full:RetainedEarnings
      contextRef="As_Of_12_31_2021_yeBwiJf1M0aAa25fFQy9Bg"
      decimals="-6"
      id="Tc_LSPmNG1jaUK5aXQ-5VXwXQ_29_6"
      unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg">10020000000</ifrs-full:RetainedEarnings>
    <ifrs-full:Equity
      contextRef="As_Of_6_30_2022_kBUEJjmpl0mHNogMyIvzJg"
      decimals="-6"
      id="Tc_RKPDvWQwc0Kv-dK94JxHYQ_31_4"
      unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg">24482000000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="As_Of_12_31_2021_yeBwiJf1M0aAa25fFQy9Bg"
      decimals="-6"
      id="Tc_vYQ8s8xSm0yhSzsnPwUG9g_31_6"
      unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg">22196000000</ifrs-full:Equity>
    <ifrs-full:NoncurrentProvisions
      contextRef="As_Of_6_30_2022_kBUEJjmpl0mHNogMyIvzJg"
      decimals="-6"
      id="Tc_zmx1kJT270K0iBL0_ecvSA_33_4"
      unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg">7000000</ifrs-full:NoncurrentProvisions>
    <ifrs-full:NoncurrentProvisions
      contextRef="As_Of_12_31_2021_yeBwiJf1M0aAa25fFQy9Bg"
      decimals="-6"
      id="Tc_SQcK9RRjVUOOj8tejMPV2A_33_6"
      unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg">13000000</ifrs-full:NoncurrentProvisions>
    <ifrs-full:NoncurrentLeaseLiabilities
      contextRef="As_Of_6_30_2022_kBUEJjmpl0mHNogMyIvzJg"
      decimals="-6"
      id="Tc_6EBUxCN2BUq-qsqpgJOHmg_34_4"
      unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg">554000000</ifrs-full:NoncurrentLeaseLiabilities>
    <ifrs-full:NoncurrentLeaseLiabilities
      contextRef="As_Of_12_31_2021_yeBwiJf1M0aAa25fFQy9Bg"
      decimals="-6"
      id="Tc_8LPWd9X9RES0ky07517lBQ_34_6"
      unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg">363000000</ifrs-full:NoncurrentLeaseLiabilities>
    <ifrs-full:RentDeferredIncomeClassifiedAsNoncurrent
      contextRef="As_Of_6_30_2022_kBUEJjmpl0mHNogMyIvzJg"
      decimals="-6"
      id="Tc_YkHK06Idu0iIZQ61ikj0Kg_35_4"
      unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg">487000000</ifrs-full:RentDeferredIncomeClassifiedAsNoncurrent>
    <ifrs-full:RentDeferredIncomeClassifiedAsNoncurrent
      contextRef="As_Of_12_31_2021_yeBwiJf1M0aAa25fFQy9Bg"
      decimals="-6"
      id="Tc_wPGcCcVKj0K6ZLusQsxmbg_35_6"
      unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg">487000000</ifrs-full:RentDeferredIncomeClassifiedAsNoncurrent>
    <ifrs-full:OtherNoncurrentPayables
      contextRef="As_Of_6_30_2022_kBUEJjmpl0mHNogMyIvzJg"
      decimals="-6"
      id="Tc_gXaivJEHRUiezYQThNLoww_36_4"
      unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg">2000000</ifrs-full:OtherNoncurrentPayables>
    <ifrs-full:NoncurrentLiabilities
      contextRef="As_Of_6_30_2022_kBUEJjmpl0mHNogMyIvzJg"
      decimals="-6"
      id="Tc_IRewDkedpkeB7kudHQztUg_38_4"
      unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg">1050000000</ifrs-full:NoncurrentLiabilities>
    <ifrs-full:NoncurrentLiabilities
      contextRef="As_Of_12_31_2021_yeBwiJf1M0aAa25fFQy9Bg"
      decimals="-6"
      id="Tc_5FbLJv5NuUS2oB-p2EWiFQ_38_6"
      unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg">863000000</ifrs-full:NoncurrentLiabilities>
    <ifrs-full:CurrentProvisions
      contextRef="As_Of_6_30_2022_kBUEJjmpl0mHNogMyIvzJg"
      decimals="-6"
      id="Tc_Sv6PrIC9A0aqSUnUigbEyg_40_4"
      unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg">6000000</ifrs-full:CurrentProvisions>
    <ifrs-full:CurrentTaxLiabilitiesCurrent
      contextRef="As_Of_6_30_2022_kBUEJjmpl0mHNogMyIvzJg"
      decimals="-6"
      id="Tc_r44WCbrqnEqYra3hWCz6nQ_41_4"
      unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg">257000000</ifrs-full:CurrentTaxLiabilitiesCurrent>
    <ifrs-full:CurrentLeaseLiabilities
      contextRef="As_Of_6_30_2022_kBUEJjmpl0mHNogMyIvzJg"
      decimals="-6"
      id="Tc_1z4ZCjUGDkajFlMR4-vuqA_42_4"
      unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg">80000000</ifrs-full:CurrentLeaseLiabilities>
    <ifrs-full:CurrentLeaseLiabilities
      contextRef="As_Of_12_31_2021_yeBwiJf1M0aAa25fFQy9Bg"
      decimals="-6"
      id="Tc_gtan8ENOLUGFsom7cZK1Vw_42_6"
      unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg">62000000</ifrs-full:CurrentLeaseLiabilities>
    <ifrs-full:RentDeferredIncomeClassifiedAsCurrent
      contextRef="As_Of_6_30_2022_kBUEJjmpl0mHNogMyIvzJg"
      decimals="-6"
      id="Tc_x8hk8smZ1Um1Ta3kK_g1og_43_4"
      unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg">26000000</ifrs-full:RentDeferredIncomeClassifiedAsCurrent>
    <ifrs-full:RentDeferredIncomeClassifiedAsCurrent
      contextRef="As_Of_12_31_2021_yeBwiJf1M0aAa25fFQy9Bg"
      decimals="-6"
      id="Tc_UIEQ1-t7y0OHjAdeYehpRQ_43_6"
      unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg">26000000</ifrs-full:RentDeferredIncomeClassifiedAsCurrent>
    <ifrs-full:OtherCurrentPayables
      contextRef="As_Of_6_30_2022_kBUEJjmpl0mHNogMyIvzJg"
      decimals="-6"
      id="Tc_SIOL3Prwn02hxnoIf2qHGg_44_4"
      unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg">1575000000</ifrs-full:OtherCurrentPayables>
    <ifrs-full:OtherCurrentPayables
      contextRef="As_Of_12_31_2021_yeBwiJf1M0aAa25fFQy9Bg"
      decimals="-6"
      id="Tc_FP8AEl2HZkyuvrRnsxKx3Q_44_6"
      unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg">1480000000</ifrs-full:OtherCurrentPayables>
    <ifrs-full:CurrentLiabilities
      contextRef="As_Of_6_30_2022_kBUEJjmpl0mHNogMyIvzJg"
      decimals="-6"
      id="Tc_p-4S2Obe406h70KmpihHRg_46_4"
      unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg">1944000000</ifrs-full:CurrentLiabilities>
    <ifrs-full:CurrentLiabilities
      contextRef="As_Of_12_31_2021_yeBwiJf1M0aAa25fFQy9Bg"
      decimals="-6"
      id="Tc_2KIMC7WZj0KilhuYV4qfZg_46_6"
      unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg">1568000000</ifrs-full:CurrentLiabilities>
    <ifrs-full:Liabilities
      contextRef="As_Of_6_30_2022_kBUEJjmpl0mHNogMyIvzJg"
      decimals="-6"
      id="Tc_wMm-AWNSP0WpkFrlZuwpTA_48_4"
      unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg">2994000000</ifrs-full:Liabilities>
    <ifrs-full:Liabilities
      contextRef="As_Of_12_31_2021_yeBwiJf1M0aAa25fFQy9Bg"
      decimals="-6"
      id="Tc_hrLJ9ejV8k28QaCF0AoLqQ_48_6"
      unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg">2431000000</ifrs-full:Liabilities>
    <ifrs-full:EquityAndLiabilities
      contextRef="As_Of_6_30_2022_kBUEJjmpl0mHNogMyIvzJg"
      decimals="-6"
      id="Tc_9GRKHmTUl0W5hnOvsFISKg_50_4"
      unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg">27476000000</ifrs-full:EquityAndLiabilities>
    <ifrs-full:EquityAndLiabilities
      contextRef="As_Of_12_31_2021_yeBwiJf1M0aAa25fFQy9Bg"
      decimals="-6"
      id="Tc_0tUy0vrJyEuqkVdcHRS_kQ_50_6"
      unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg">24627000000</ifrs-full:EquityAndLiabilities>
    <ifrs-full:ProfitLossBeforeTax
      contextRef="Duration_1_1_2022_To_6_30_2022_dNPMG5n7t0WcNVF9KG4Bdw"
      decimals="-6"
      id="Tc_T4POgn9W5E2MvnUDAlwfEA_5_4"
      unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg">3101000000</ifrs-full:ProfitLossBeforeTax>
    <ifrs-full:ProfitLossBeforeTax
      contextRef="Duration_1_1_2021_To_6_30_2021_MRS0_D_onUCNBOxf7Qx_Cw"
      decimals="-6"
      id="Tc_n7rd5Sczgkqbhhvjqz0ufg_5_6"
      unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg">1846000000</ifrs-full:ProfitLossBeforeTax>
    <gmab:ReversalOfFinancialItemsNet
      contextRef="Duration_1_1_2022_To_6_30_2022_dNPMG5n7t0WcNVF9KG4Bdw"
      decimals="-6"
      id="Tc_rD-1KQad0Emhub-m9JurzA_7_4"
      unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg">1340000000</gmab:ReversalOfFinancialItemsNet>
    <gmab:ReversalOfFinancialItemsNet
      contextRef="Duration_1_1_2021_To_6_30_2021_MRS0_D_onUCNBOxf7Qx_Cw"
      decimals="-6"
      id="Tc_UeKJT6rdHku4barvLuNOOA_7_6"
      unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg">527000000</gmab:ReversalOfFinancialItemsNet>
    <gmab:TotalAdjustmentsForNonCashTransactions
      contextRef="Duration_1_1_2022_To_6_30_2022_dNPMG5n7t0WcNVF9KG4Bdw"
      decimals="-6"
      id="Tc_Hq4H5jRkHUyurbT-GCTu3Q_8_4"
      unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg">347000000</gmab:TotalAdjustmentsForNonCashTransactions>
    <gmab:TotalAdjustmentsForNonCashTransactions
      contextRef="Duration_1_1_2021_To_6_30_2021_MRS0_D_onUCNBOxf7Qx_Cw"
      decimals="-6"
      id="Tc_8O2qwMT-NUuVmKnhT8dxZQ_8_6"
      unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg">227000000</gmab:TotalAdjustmentsForNonCashTransactions>
    <ifrs-full:IncreaseDecreaseInWorkingCapital
      contextRef="Duration_1_1_2022_To_6_30_2022_dNPMG5n7t0WcNVF9KG4Bdw"
      decimals="-6"
      id="Tc_FcwTsHacnEGbnZr0qxnjWA_9_4"
      unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg">179000000</ifrs-full:IncreaseDecreaseInWorkingCapital>
    <ifrs-full:IncreaseDecreaseInWorkingCapital
      contextRef="Duration_1_1_2021_To_6_30_2021_MRS0_D_onUCNBOxf7Qx_Cw"
      decimals="-6"
      id="Tc_0_3XErtBqkyeLOiGNxMWUg_9_6"
      unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg">105000000</ifrs-full:IncreaseDecreaseInWorkingCapital>
    <gmab:CashFlowFromUsedInOperatingActivitiesBeforeFinancialItems
      contextRef="Duration_1_1_2022_To_6_30_2022_dNPMG5n7t0WcNVF9KG4Bdw"
      decimals="-6"
      id="Tc_qsCC0Mw0VkarksDAwiZNTQ_11_4"
      unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg">1929000000</gmab:CashFlowFromUsedInOperatingActivitiesBeforeFinancialItems>
    <gmab:CashFlowFromUsedInOperatingActivitiesBeforeFinancialItems
      contextRef="Duration_1_1_2021_To_6_30_2021_MRS0_D_onUCNBOxf7Qx_Cw"
      decimals="-6"
      id="Tc_I5J_trDL_EmpZY7nNUursA_11_6"
      unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg">1441000000</gmab:CashFlowFromUsedInOperatingActivitiesBeforeFinancialItems>
    <ifrs-full:InterestReceivedClassifiedAsOperatingActivities
      contextRef="Duration_1_1_2022_To_6_30_2022_dNPMG5n7t0WcNVF9KG4Bdw"
      decimals="-6"
      id="Tc_d9UD8CvkDESoS-gTXJE0WA_13_4"
      unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg">80000000</ifrs-full:InterestReceivedClassifiedAsOperatingActivities>
    <ifrs-full:InterestReceivedClassifiedAsOperatingActivities
      contextRef="Duration_1_1_2021_To_6_30_2021_MRS0_D_onUCNBOxf7Qx_Cw"
      decimals="-6"
      id="Tc_fCzt3KmXQkqsdFGuwjhelA_13_6"
      unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg">107000000</ifrs-full:InterestReceivedClassifiedAsOperatingActivities>
    <gmab:AdjustmentsForInterestOnLeasePayments
      contextRef="Duration_1_1_2022_To_6_30_2022_dNPMG5n7t0WcNVF9KG4Bdw"
      decimals="-6"
      id="Tc_F-72-NgwU0aTqdnS8eaF2A_14_4"
      unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg">-7000000</gmab:AdjustmentsForInterestOnLeasePayments>
    <gmab:AdjustmentsForInterestOnLeasePayments
      contextRef="Duration_1_1_2021_To_6_30_2021_MRS0_D_onUCNBOxf7Qx_Cw"
      decimals="-6"
      id="Tc_qGZAuj2eAUianU2nWrX4tA_14_6"
      unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg">-6000000</gmab:AdjustmentsForInterestOnLeasePayments>
    <ifrs-full:InterestPaidClassifiedAsOperatingActivities
      contextRef="Duration_1_1_2022_To_6_30_2022_dNPMG5n7t0WcNVF9KG4Bdw"
      decimals="-6"
      id="Tc_sY816rOv0ECkr3wCfRX7uQ_15_4"
      unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg">1000000</ifrs-full:InterestPaidClassifiedAsOperatingActivities>
    <ifrs-full:AdjustmentsForIncomeTaxExpense
      contextRef="Duration_1_1_2022_To_6_30_2022_dNPMG5n7t0WcNVF9KG4Bdw"
      decimals="-6"
      id="Tc_KE4zaQ7fLUCZSXrPbOw_1g_16_4"
      unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg">-455000000</ifrs-full:AdjustmentsForIncomeTaxExpense>
    <ifrs-full:AdjustmentsForIncomeTaxExpense
      contextRef="Duration_1_1_2021_To_6_30_2021_MRS0_D_onUCNBOxf7Qx_Cw"
      decimals="-6"
      id="Tc_RAWYDqRAm0-e2_N2nEjSrA_16_6"
      unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg">-2000000</ifrs-full:AdjustmentsForIncomeTaxExpense>
    <ifrs-full:CashFlowsFromUsedInOperatingActivities
      contextRef="Duration_1_1_2022_To_6_30_2022_dNPMG5n7t0WcNVF9KG4Bdw"
      decimals="-6"
      id="Tc_zUpMIL7tcE6gVURup4OO1Q_18_4"
      unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg">1546000000</ifrs-full:CashFlowsFromUsedInOperatingActivities>
    <ifrs-full:CashFlowsFromUsedInOperatingActivities
      contextRef="Duration_1_1_2021_To_6_30_2021_MRS0_D_onUCNBOxf7Qx_Cw"
      decimals="-6"
      id="Tc_mEk3icI__0OR4L0j-h9qwA_18_6"
      unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg">1540000000</ifrs-full:CashFlowsFromUsedInOperatingActivities>
    <ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities
      contextRef="Duration_1_1_2022_To_6_30_2022_dNPMG5n7t0WcNVF9KG4Bdw"
      decimals="-6"
      id="Tc_SFa5_-5hO0itQw83Kuuj8w_20_4"
      unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg">125000000</ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities>
    <ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities
      contextRef="Duration_1_1_2021_To_6_30_2021_MRS0_D_onUCNBOxf7Qx_Cw"
      decimals="-6"
      id="Tc_FGKOOf5GM0O7-OK77xa89w_20_6"
      unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg">107000000</ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities>
    <ifrs-full:PurchaseOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod
      contextRef="Duration_1_1_2022_To_6_30_2022_dNPMG5n7t0WcNVF9KG4Bdw"
      decimals="-6"
      id="Tc_w_aClYSsNEuuyNyVIXrzrQ_21_4"
      unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg">4061000000</ifrs-full:PurchaseOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod>
    <ifrs-full:PurchaseOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod
      contextRef="Duration_1_1_2021_To_6_30_2021_MRS0_D_onUCNBOxf7Qx_Cw"
      decimals="-6"
      id="Tc_Xd6JuEiEw0S-SrmZzFpYsw_21_6"
      unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg">7410000000</ifrs-full:PurchaseOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod>
    <ifrs-full:ProceedsFromSalesOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod
      contextRef="Duration_1_1_2022_To_6_30_2022_dNPMG5n7t0WcNVF9KG4Bdw"
      decimals="-6"
      id="Tc_eq4T-RNUgE6YQIhzsHBQMw_22_4"
      unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg">2965000000</ifrs-full:ProceedsFromSalesOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod>
    <ifrs-full:ProceedsFromSalesOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod
      contextRef="Duration_1_1_2021_To_6_30_2021_MRS0_D_onUCNBOxf7Qx_Cw"
      decimals="-6"
      id="Tc_xTJz4qpAj0C9lhky1VOvow_22_6"
      unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg">8137000000</ifrs-full:ProceedsFromSalesOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod>
    <ifrs-full:PurchaseOfInterestsInInvestmentsAccountedForUsingEquityMethod
      contextRef="Duration_1_1_2022_To_6_30_2022_dNPMG5n7t0WcNVF9KG4Bdw"
      decimals="-6"
      id="Tc_wFjhp7Tp3E-s8MDw4jdxRg_23_4"
      unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg">22000000</ifrs-full:PurchaseOfInterestsInInvestmentsAccountedForUsingEquityMethod>
    <ifrs-full:PurchaseOfInterestsInInvestmentsAccountedForUsingEquityMethod
      contextRef="Duration_1_1_2021_To_6_30_2021_MRS0_D_onUCNBOxf7Qx_Cw"
      decimals="-6"
      id="Tc_Otn6fV81GUWElrhU_IIElA_23_6"
      unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg">92000000</ifrs-full:PurchaseOfInterestsInInvestmentsAccountedForUsingEquityMethod>
    <ifrs-full:ProceedsFromSalesOfInvestmentsAccountedForUsingEquityMethod
      contextRef="Duration_1_1_2021_To_6_30_2021_MRS0_D_onUCNBOxf7Qx_Cw"
      decimals="-6"
      id="Tc_b47bvPjxDUO8xucdTGmrkQ_24_6"
      unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg">438000000</ifrs-full:ProceedsFromSalesOfInvestmentsAccountedForUsingEquityMethod>
    <ifrs-full:CashFlowsFromUsedInInvestingActivities
      contextRef="Duration_1_1_2022_To_6_30_2022_dNPMG5n7t0WcNVF9KG4Bdw"
      decimals="-6"
      id="Tc_UeAP5ax-XU2wmFxixbeZGg_26_4"
      unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg">-1243000000</ifrs-full:CashFlowsFromUsedInInvestingActivities>
    <ifrs-full:CashFlowsFromUsedInInvestingActivities
      contextRef="Duration_1_1_2021_To_6_30_2021_MRS0_D_onUCNBOxf7Qx_Cw"
      decimals="-6"
      id="Tc_MYyo4qqRtUOHX69sCtCEmg_26_6"
      unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg">966000000</ifrs-full:CashFlowsFromUsedInInvestingActivities>
    <ifrs-full:ProceedsFromExerciseOfWarrants
      contextRef="Duration_1_1_2022_To_6_30_2022_dNPMG5n7t0WcNVF9KG4Bdw"
      decimals="-6"
      id="Tc_sZd4nSmUtkSUBYb010TaAg_28_4"
      unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg">34000000</ifrs-full:ProceedsFromExerciseOfWarrants>
    <ifrs-full:ProceedsFromExerciseOfWarrants
      contextRef="Duration_1_1_2021_To_6_30_2021_MRS0_D_onUCNBOxf7Qx_Cw"
      decimals="-6"
      id="Tc_8lNJ8igefke-uRmfS9BFZA_28_6"
      unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg">46000000</ifrs-full:ProceedsFromExerciseOfWarrants>
    <ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities
      contextRef="Duration_1_1_2022_To_6_30_2022_dNPMG5n7t0WcNVF9KG4Bdw"
      decimals="-6"
      id="Tc_HiBE72L6E0CTMRe1rxVvnQ_29_4"
      unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg">30000000</ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities>
    <ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities
      contextRef="Duration_1_1_2021_To_6_30_2021_MRS0_D_onUCNBOxf7Qx_Cw"
      decimals="-6"
      id="Tc_LXGVpVA_ZkKW9Ugef2K1bA_29_6"
      unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg">29000000</ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities>
    <gmab:PaymentsToAcquireTreasuryShares
      contextRef="Duration_1_1_2022_To_6_30_2022_dNPMG5n7t0WcNVF9KG4Bdw"
      decimals="-6"
      id="Tc_i3RDl-drtk6IGfJjHUdbQw_30_4"
      unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg">211000000</gmab:PaymentsToAcquireTreasuryShares>
    <gmab:PaymentsToAcquireTreasuryShares
      contextRef="Duration_1_1_2021_To_6_30_2021_MRS0_D_onUCNBOxf7Qx_Cw"
      decimals="-6"
      id="Tc_g76yUot8OEyAIZtLCsZbog_30_6"
      unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg">437000000</gmab:PaymentsToAcquireTreasuryShares>
    <gmab:PaymentOfWithholdingTaxesOnBehalfOfEmployeesOnNetSettledRSUs
      contextRef="Duration_1_1_2022_To_6_30_2022_dNPMG5n7t0WcNVF9KG4Bdw"
      decimals="-6"
      id="Tc_rq-So9QbC0yt7nKMb9fZzw_31_4"
      unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg">71000000</gmab:PaymentOfWithholdingTaxesOnBehalfOfEmployeesOnNetSettledRSUs>
    <gmab:PaymentOfWithholdingTaxesOnBehalfOfEmployeesOnNetSettledRSUs
      contextRef="Duration_1_1_2021_To_6_30_2021_MRS0_D_onUCNBOxf7Qx_Cw"
      decimals="-6"
      id="Tc_oUTcDeYqf0a1uiY3x1yoeA_31_6"
      unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg">40000000</gmab:PaymentOfWithholdingTaxesOnBehalfOfEmployeesOnNetSettledRSUs>
    <ifrs-full:CashFlowsFromUsedInFinancingActivities
      contextRef="Duration_1_1_2022_To_6_30_2022_dNPMG5n7t0WcNVF9KG4Bdw"
      decimals="-6"
      id="Tc_cT3CferTsU-Rkvk7XZY1tA_33_4"
      unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg">-278000000</ifrs-full:CashFlowsFromUsedInFinancingActivities>
    <ifrs-full:CashFlowsFromUsedInFinancingActivities
      contextRef="Duration_1_1_2021_To_6_30_2021_MRS0_D_onUCNBOxf7Qx_Cw"
      decimals="-6"
      id="Tc_uVoNyXDLB0ytmRp1uYUiAQ_33_6"
      unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg">-460000000</ifrs-full:CashFlowsFromUsedInFinancingActivities>
    <ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges
      contextRef="Duration_1_1_2022_To_6_30_2022_dNPMG5n7t0WcNVF9KG4Bdw"
      decimals="-6"
      id="Tc_QrbemPzlQk-TtyPWxiIn0g_35_4"
      unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg">25000000</ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges>
    <ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges
      contextRef="Duration_1_1_2021_To_6_30_2021_MRS0_D_onUCNBOxf7Qx_Cw"
      decimals="-6"
      id="Tc_pu6urxudukWVCah4wZG-lQ_35_6"
      unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg">2046000000</ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges>
    <ifrs-full:CashAndCashEquivalents
      contextRef="As_Of_12_31_2021_yeBwiJf1M0aAa25fFQy9Bg"
      decimals="-6"
      id="Tc_fXYVvTtfSEKF0UJL8tGD4g_37_4"
      unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg">8957000000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents
      contextRef="As_Of_12_31_2020_ccHyN2oOokuDhNdvPg9fRQ"
      decimals="-6"
      id="Tc_4iLXJM0C2Eeln0OwvX7Hsg_37_6"
      unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg">7260000000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents
      contextRef="Duration_1_1_2022_To_6_30_2022_dNPMG5n7t0WcNVF9KG4Bdw"
      decimals="-6"
      id="Tc_QM2FDDMftU2LeAVnggoPMQ_38_4"
      unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg">834000000</ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents>
    <ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents
      contextRef="Duration_1_1_2021_To_6_30_2021_MRS0_D_onUCNBOxf7Qx_Cw"
      decimals="-6"
      id="Tc_18uxgs5IMUGaUCUjBPO0Gw_38_6"
      unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg">171000000</ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents
      contextRef="As_Of_6_30_2022_kBUEJjmpl0mHNogMyIvzJg"
      decimals="-6"
      id="Tc_GwLHwD3btk-LxtZNMIIArA_40_4"
      unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg">9816000000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents
      contextRef="As_Of_6_30_2021_eEXLsHGqbE20an7xlGLjnw"
      decimals="-6"
      id="Tc_IVSC4JjhQ0KMuE_aJK1xQQ_40_6"
      unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg">9477000000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:Cash
      contextRef="As_Of_6_30_2022_kBUEJjmpl0mHNogMyIvzJg"
      decimals="-6"
      id="Tc_wl7T4-KFzUqjdBHlQO0g9w_43_4"
      unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg">8810000000</ifrs-full:Cash>
    <ifrs-full:Cash
      contextRef="As_Of_6_30_2021_eEXLsHGqbE20an7xlGLjnw"
      decimals="-6"
      id="Tc__Agr9ne3HUuf_JSkignRew_43_6"
      unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg">6908000000</ifrs-full:Cash>
    <ifrs-full:ShorttermInvestmentsClassifiedAsCashEquivalents
      contextRef="As_Of_6_30_2022_kBUEJjmpl0mHNogMyIvzJg"
      decimals="-6"
      id="Tc_EwlyW3aRM0Sywg1nfmc4TA_44_4"
      unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg">1006000000</ifrs-full:ShorttermInvestmentsClassifiedAsCashEquivalents>
    <ifrs-full:ShorttermInvestmentsClassifiedAsCashEquivalents
      contextRef="As_Of_6_30_2021_eEXLsHGqbE20an7xlGLjnw"
      decimals="-6"
      id="Tc_s6jmOpvF2kSVPsWTDVcyHA_44_6"
      unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg">2569000000</ifrs-full:ShorttermInvestmentsClassifiedAsCashEquivalents>
    <ifrs-full:CashAndCashEquivalents
      contextRef="As_Of_6_30_2022_kBUEJjmpl0mHNogMyIvzJg"
      decimals="-6"
      id="Tc_YuI1Jj-BmU2_XB05Wi3aaQ_46_4"
      unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg">9816000000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents
      contextRef="As_Of_6_30_2021_eEXLsHGqbE20an7xlGLjnw"
      decimals="-6"
      id="Tc_9YPXtOYBSUWyAEMH_H7fow_46_6"
      unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg">9477000000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:Equity
      contextRef="As_Of_12_31_2020_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_qxcDthXBpku77YP5whaVYg"
      decimals="-6"
      id="Tc_N_GrIbU_KkKluAbD1Kay9g_5_2"
      unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg">66000000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="As_Of_12_31_2020_ifrs-full_ComponentsOfEquityAxis_ifrs-full_SharePremiumMember_si1iRZkarUaeuSgvZfxZfw"
      decimals="-6"
      id="Tc_aDLqEw2UlkK-URF9KpmnVg_5_4"
      unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg">11894000000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="As_Of_12_31_2020_ifrs-full_ComponentsOfEquityAxis_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_1jjHlFLAike_v2Q-HdTGxw"
      decimals="-6"
      id="Tc_PKiod5YebUqHQM0nYQD1ew_5_6"
      unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg">54000000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="As_Of_12_31_2020_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsMember_MNr5zCVV90GEBvq8OjtfdQ"
      decimals="-6"
      id="Tc_5_L5_tomxE6ZZK6D9hDcYA_5_8"
      unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg">7107000000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="As_Of_12_31_2020_ccHyN2oOokuDhNdvPg9fRQ"
      decimals="-6"
      id="Tc_axvs1ohquEqVPQMhhrZfdQ_5_10"
      unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg">19121000000</ifrs-full:Equity>
    <ifrs-full:ProfitLoss
      contextRef="Duration_1_1_2021_To_6_30_2021_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsMember_3at9FYujHUm7dtmVg4zXig"
      decimals="-6"
      id="Tc_5yzUtvk0hEGRaE-dtc-sRw_7_8"
      unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg">1402000000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="Duration_1_1_2021_To_6_30_2021_MRS0_D_onUCNBOxf7Qx_Cw"
      decimals="-6"
      id="Tc_eb6Y6KUWK0W6Mvyv6ehjKQ_7_10"
      unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg">1402000000</ifrs-full:ProfitLoss>
    <ifrs-full:OtherComprehensiveIncome
      contextRef="Duration_1_1_2021_To_6_30_2021_ifrs-full_ComponentsOfEquityAxis_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_ZmznApYSQ0yIovD2PRKBMA"
      decimals="-6"
      id="Tc_jGbCcyQCCUK6Kt9_IwVbUQ_8_6"
      unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg">28000000</ifrs-full:OtherComprehensiveIncome>
    <ifrs-full:OtherComprehensiveIncome
      contextRef="Duration_1_1_2021_To_6_30_2021_MRS0_D_onUCNBOxf7Qx_Cw"
      decimals="-6"
      id="Tc_6Pm7lMkRB0SttoNK9kiAkg_8_10"
      unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg">28000000</ifrs-full:OtherComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome
      contextRef="Duration_1_1_2021_To_6_30_2021_ifrs-full_ComponentsOfEquityAxis_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_ZmznApYSQ0yIovD2PRKBMA"
      decimals="-6"
      id="Tc_LmQJTnEW-0WW7KLZ41K_sw_9_6"
      unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg">28000000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome
      contextRef="Duration_1_1_2021_To_6_30_2021_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsMember_3at9FYujHUm7dtmVg4zXig"
      decimals="-6"
      id="Tc_9DyE7iYiZky3MCGC9oNS2g_9_8"
      unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg">1402000000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome
      contextRef="Duration_1_1_2021_To_6_30_2021_MRS0_D_onUCNBOxf7Qx_Cw"
      decimals="-6"
      id="Tc_EKz4po-aU0KnyEV_QkPjfw_9_10"
      unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg">1430000000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity
      contextRef="Duration_1_1_2021_To_6_30_2021_ifrs-full_ComponentsOfEquityAxis_ifrs-full_SharePremiumMember_XMRWtYbFi0-RVZrBJKYdMw"
      decimals="-6"
      id="Tc_tNK1bYif-0e4RZ_AnOE2jA_12_4"
      unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg">46000000</ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity
      contextRef="Duration_1_1_2021_To_6_30_2021_MRS0_D_onUCNBOxf7Qx_Cw"
      decimals="-6"
      id="Tc_eDWIfNZa_k-04uq5PIulQw_12_10"
      unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg">46000000</ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity>
    <ifrs-full:PurchaseOfTreasuryShares
      contextRef="Duration_1_1_2021_To_6_30_2021_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsMember_3at9FYujHUm7dtmVg4zXig"
      decimals="-6"
      id="Tc_eCnSitHlb0aOoE9BAauwqA_13_8"
      unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg">447000000</ifrs-full:PurchaseOfTreasuryShares>
    <ifrs-full:PurchaseOfTreasuryShares
      contextRef="Duration_1_1_2021_To_6_30_2021_MRS0_D_onUCNBOxf7Qx_Cw"
      decimals="-6"
      id="Tc_DFfeTnD_xUGqDCxe2yqkGw_13_10"
      unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg">447000000</ifrs-full:PurchaseOfTreasuryShares>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="Duration_1_1_2021_To_6_30_2021_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsMember_3at9FYujHUm7dtmVg4zXig"
      decimals="-6"
      id="Tc_FmuHoGKbukqtUyuNZsqaaA_14_8"
      unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg">142000000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="Duration_1_1_2021_To_6_30_2021_MRS0_D_onUCNBOxf7Qx_Cw"
      decimals="-6"
      id="Tc_LDpmTBXAjkevstN0ctiSwQ_14_10"
      unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg">142000000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <gmab:IncreaseDecreaseThroughNetSettlementOfRestrictedStockUnitsEquity
      contextRef="Duration_1_1_2021_To_6_30_2021_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsMember_3at9FYujHUm7dtmVg4zXig"
      decimals="-6"
      id="Tc_lVDD6OOsQUGenRiGC4aAEg_15_8"
      unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg">-40000000</gmab:IncreaseDecreaseThroughNetSettlementOfRestrictedStockUnitsEquity>
    <gmab:IncreaseDecreaseThroughNetSettlementOfRestrictedStockUnitsEquity
      contextRef="Duration_1_1_2021_To_6_30_2021_MRS0_D_onUCNBOxf7Qx_Cw"
      decimals="-6"
      id="Tc_a0eFkqSNt0K2jzsNPhkZcw_15_10"
      unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg">-40000000</gmab:IncreaseDecreaseThroughNetSettlementOfRestrictedStockUnitsEquity>
    <ifrs-full:Equity
      contextRef="As_Of_6_30_2021_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_pdtEW7BBIUqgf6EXtiJIaw"
      decimals="-6"
      id="Tc_zHYRJrL6-k6iMrfP28ZkYw_17_2"
      unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg">66000000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="As_Of_6_30_2021_ifrs-full_ComponentsOfEquityAxis_ifrs-full_SharePremiumMember_GV_3QWjql0Su3tgU-SgDXw"
      decimals="-6"
      id="Tc_UZVH-1oLnk-kz7ksTq4UjA_17_4"
      unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg">11940000000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="As_Of_6_30_2021_ifrs-full_ComponentsOfEquityAxis_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_4C8ErHNbuEyc6g9c8m0tEg"
      decimals="-6"
      id="Tc_1w0kbnC5TUWryHDpekrQNQ_17_6"
      unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg">82000000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="As_Of_6_30_2021_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsMember_DjZRZNGrO0OpgJWJsdQZFQ"
      decimals="-6"
      id="Tc_2MspzCwWjUuQWKAtSilKDg_17_8"
      unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg">8164000000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="As_Of_6_30_2021_eEXLsHGqbE20an7xlGLjnw"
      decimals="-6"
      id="Tc_lMIdzHhEq0GqJR4EzHijQQ_17_10"
      unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg">20252000000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="As_Of_12_31_2021_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_3hqv4rmeT0KprU066qSoRg"
      decimals="-6"
      id="Tc_Md_aEe3tbEO0gAvrgxipmw_19_2"
      unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg">66000000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="As_Of_12_31_2021_ifrs-full_ComponentsOfEquityAxis_ifrs-full_SharePremiumMember_AoL9klgCl06NvjJ-Vt6Xlw"
      decimals="-6"
      id="Tc_DuKowYPjY06bG6zHsBYxQQ_19_4"
      unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg">12029000000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="As_Of_12_31_2021_ifrs-full_ComponentsOfEquityAxis_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_yT7xpmSne0SrbvOgXluilQ"
      decimals="-6"
      id="Tc_gxjzYILoBEexauLytLN8Dw_19_6"
      unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg">81000000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="As_Of_12_31_2021_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsMember_DT4Y_TJahk6Om4PoqoPzFg"
      decimals="-6"
      id="Tc_ZM2SjUnQCUKSsTtzP__q9Q_19_8"
      unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg">10020000000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="As_Of_12_31_2021_yeBwiJf1M0aAa25fFQy9Bg"
      decimals="-6"
      id="Tc_fvly8IJgJUmpxoEzRwA0-Q_19_10"
      unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg">22196000000</ifrs-full:Equity>
    <ifrs-full:ProfitLoss
      contextRef="Duration_1_1_2022_To_6_30_2022_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsMember_Obfciab50kOeB1cRJrxSkw"
      decimals="-6"
      id="Tc_-rwcUsXtTkCsIXt6F6Hl0Q_21_8"
      unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg">2356000000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="Duration_1_1_2022_To_6_30_2022_dNPMG5n7t0WcNVF9KG4Bdw"
      decimals="-6"
      id="Tc_QAhxsSLvOEWEoSZKIKVrhQ_21_10"
      unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg">2356000000</ifrs-full:ProfitLoss>
    <ifrs-full:OtherComprehensiveIncome
      contextRef="Duration_1_1_2022_To_6_30_2022_ifrs-full_ComponentsOfEquityAxis_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_7kIYWvkWuEOdT0IirRs9kA"
      decimals="-6"
      id="Tc_sdECepUK3kSMmhj_-mXNjg_22_6"
      unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg">29000000</ifrs-full:OtherComprehensiveIncome>
    <ifrs-full:OtherComprehensiveIncome
      contextRef="Duration_1_1_2022_To_6_30_2022_dNPMG5n7t0WcNVF9KG4Bdw"
      decimals="-6"
      id="Tc_RuMG45RVm0aaijx_FmaicQ_22_10"
      unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg">29000000</ifrs-full:OtherComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome
      contextRef="Duration_1_1_2022_To_6_30_2022_ifrs-full_ComponentsOfEquityAxis_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_7kIYWvkWuEOdT0IirRs9kA"
      decimals="-6"
      id="Tc_m-74vIdfQ0C9W0rioFflZQ_23_6"
      unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg">29000000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome
      contextRef="Duration_1_1_2022_To_6_30_2022_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsMember_Obfciab50kOeB1cRJrxSkw"
      decimals="-6"
      id="Tc_qYg_T3YBuEeeIdAuq-ea4w_23_8"
      unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg">2356000000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome
      contextRef="Duration_1_1_2022_To_6_30_2022_dNPMG5n7t0WcNVF9KG4Bdw"
      decimals="-6"
      id="Tc_t0yt_DvX4U-WLWkAHZcvrg_23_10"
      unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg">2385000000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity
      contextRef="Duration_1_1_2022_To_6_30_2022_ifrs-full_ComponentsOfEquityAxis_ifrs-full_SharePremiumMember_SdwhengxmEaD2aINUnRJ-w"
      decimals="-6"
      id="Tc_F__ymwA5ck-ZBG6494tJRQ_26_4"
      unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg">34000000</ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity
      contextRef="Duration_1_1_2022_To_6_30_2022_dNPMG5n7t0WcNVF9KG4Bdw"
      decimals="-6"
      id="Tc_7O2lrPU5IkSy1utB07idIw_26_10"
      unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg">34000000</ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity>
    <ifrs-full:PurchaseOfTreasuryShares
      contextRef="Duration_1_1_2022_To_6_30_2022_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsMember_Obfciab50kOeB1cRJrxSkw"
      decimals="-6"
      id="Tc_mClL9ihzr0CJinhuY0CdUw_27_8"
      unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg">270000000</ifrs-full:PurchaseOfTreasuryShares>
    <ifrs-full:PurchaseOfTreasuryShares
      contextRef="Duration_1_1_2022_To_6_30_2022_dNPMG5n7t0WcNVF9KG4Bdw"
      decimals="-6"
      id="Tc_ZFsdov3lBEGKVyafINEftg_27_10"
      unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg">270000000</ifrs-full:PurchaseOfTreasuryShares>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="Duration_1_1_2022_To_6_30_2022_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsMember_Obfciab50kOeB1cRJrxSkw"
      decimals="-6"
      id="Tc_LtGbSw2q6UuhYSws2rEg7Q_28_8"
      unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg">208000000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="Duration_1_1_2022_To_6_30_2022_dNPMG5n7t0WcNVF9KG4Bdw"
      decimals="-6"
      id="Tc_tbTp1fNU2UyjKNcaTjZFRQ_28_10"
      unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg">208000000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <gmab:IncreaseDecreaseThroughNetSettlementOfRestrictedStockUnitsEquity
      contextRef="Duration_1_1_2022_To_6_30_2022_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsMember_Obfciab50kOeB1cRJrxSkw"
      decimals="-6"
      id="Tc_R94rRjrM8U-q4vVbMWwIkw_29_8"
      unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg">-71000000</gmab:IncreaseDecreaseThroughNetSettlementOfRestrictedStockUnitsEquity>
    <gmab:IncreaseDecreaseThroughNetSettlementOfRestrictedStockUnitsEquity
      contextRef="Duration_1_1_2022_To_6_30_2022_dNPMG5n7t0WcNVF9KG4Bdw"
      decimals="-6"
      id="Tc_u4iH4EWQZEW1kQxfLRxiZQ_29_10"
      unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg">-71000000</gmab:IncreaseDecreaseThroughNetSettlementOfRestrictedStockUnitsEquity>
    <ifrs-full:Equity
      contextRef="As_Of_6_30_2022_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_yCKoTSQsEEOQZwa4oFi7oA"
      decimals="-6"
      id="Tc_xe_8SSfq1E6yRmhrdSdy7w_31_2"
      unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg">66000000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="As_Of_6_30_2022_ifrs-full_ComponentsOfEquityAxis_ifrs-full_SharePremiumMember_c1xbYHnI60ydURKsrordAw"
      decimals="-6"
      id="Tc_R9vavWv3ckiFNFLpjHqJjA_31_4"
      unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg">12063000000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="As_Of_6_30_2022_ifrs-full_ComponentsOfEquityAxis_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_xwbw8UubEkGBVQFx7vgMbQ"
      decimals="-6"
      id="Tc_cYvF0RgBdE6BU2G6odEM4Q_31_6"
      unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg">110000000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="As_Of_6_30_2022_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsMember_lUn1LjNR7EeooY5wvd9tfg"
      decimals="-6"
      id="Tc_UAuxumeZ102jJDpPurSJRg_31_8"
      unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg">12243000000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="As_Of_6_30_2022_kBUEJjmpl0mHNogMyIvzJg"
      decimals="-6"
      id="Tc_dnYSmE1SFkGWbEM8OdEVxw_31_10"
      unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg">24482000000</ifrs-full:Equity>
    <ifrs-full:DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory
      contextRef="Duration_1_1_2022_To_6_30_2022_dNPMG5n7t0WcNVF9KG4Bdw"
      id="Tb_xMKEEjNrXkyIrZf7mcrlcg">&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="color:#029c93;font-weight:bold;"&gt;Note 1 &#x2013; Basis of Presentation&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Accounting Policies&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;These interim statements of the Genmab group (Genmab or the Company) have been prepared in accordance with IAS 34 as issued by the International Accounting Standards Board (IASB) and in accordance with IAS 34 as endorsed by the EU and additional Danish disclosure requirements for interim reports of listed companies. The interim report has not been reviewed or audited by Genmab&#x2019;s external auditors. &lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;The interim report has been prepared using the same accounting policies as outlined in Section 1 &#x2013; Basis of Presentation in the financial statements in the Genmab 2021 Annual Report (Annual Report). A number of new or amended standards became applicable for the current reporting period. Genmab was not required to change its accounting policies as a result of adopting these standards. These interim financial statements should be read in conjunction with the Annual Report. &lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Management Judgements and Estimates under IFRS&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;In preparing interim reports, certain provisions under IFRS require management to make judgements (various accounting estimates and assumptions), which may significantly impact the group&#x2019;s financial statements. For a description of significant judgements and estimates, refer to Note 1.3 in the Annual Report.&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Information about Geographical Areas&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Genmab is managed and operated as one business unit, which is reflected in the organizational structure and internal reporting. No separate lines of business or separate business entities have been identified with respect to any licensed products, product candidates or geographical markets and no segment information is currently prepared for internal reporting. Refer to Note 2.2 in the Annual Report for further details.&lt;/p&gt;</ifrs-full:DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory>
    <gmab:DescriptionOfAccountingPolicyForBasisOfPresentationPolicyTextBlock
      contextRef="Duration_1_1_2022_To_6_30_2022_dNPMG5n7t0WcNVF9KG4Bdw"
      id="Tb_gLydBW7Cg0aWWe1EKsIqbg">&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Accounting Policies&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;These interim statements of the Genmab group (Genmab or the Company) have been prepared in accordance with IAS 34 as issued by the International Accounting Standards Board (IASB) and in accordance with IAS 34 as endorsed by the EU and additional Danish disclosure requirements for interim reports of listed companies. The interim report has not been reviewed or audited by Genmab&#x2019;s external auditors. &lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;The interim report has been prepared using the same accounting policies as outlined in Section 1 &#x2013; Basis of Presentation in the financial statements in the Genmab 2021 Annual Report (Annual Report). A number of new or amended standards became applicable for the current reporting period. Genmab was not required to change its accounting policies as a result of adopting these standards. These interim financial statements should be read in conjunction with the Annual Report. &lt;/p&gt;</gmab:DescriptionOfAccountingPolicyForBasisOfPresentationPolicyTextBlock>
    <gmab:DescriptionOfAccountingPolicyForJudgmentsAndEstimatesPolicyTextBlock
      contextRef="Duration_1_1_2022_To_6_30_2022_dNPMG5n7t0WcNVF9KG4Bdw"
      id="Tb_PFYQVNsFVka_BihArFEhKA">&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Management Judgements and Estimates under IFRS&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;In preparing interim reports, certain provisions under IFRS require management to make judgements (various accounting estimates and assumptions), which may significantly impact the group&#x2019;s financial statements. For a description of significant judgements and estimates, refer to Note 1.3 in the Annual Report.&lt;/p&gt;</gmab:DescriptionOfAccountingPolicyForJudgmentsAndEstimatesPolicyTextBlock>
    <ifrs-full:DescriptionOfAccountingPolicyForSegmentReportingExplanatory
      contextRef="Duration_1_1_2022_To_6_30_2022_dNPMG5n7t0WcNVF9KG4Bdw"
      id="Tb_Q9XNieVELEWFsrtgdtzQiw">&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Information about Geographical Areas&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Genmab is managed and operated as one business unit, which is reflected in the organizational structure and internal reporting. No separate lines of business or separate business entities have been identified with respect to any licensed products, product candidates or geographical markets and no segment information is currently prepared for internal reporting. Refer to Note 2.2 in the Annual Report for further details.&lt;/p&gt;</ifrs-full:DescriptionOfAccountingPolicyForSegmentReportingExplanatory>
    <gmab:IfrsNumberOfReportingUnits
      contextRef="As_Of_6_30_2022_kBUEJjmpl0mHNogMyIvzJg"
      decimals="INF"
      id="Narr_4e_DvdC5-0ujcF1JortDgA"
      unitRef="Unit_Standard_item_d-Yn30W8q0CdLFqZ4zWe8g">1</gmab:IfrsNumberOfReportingUnits>
    <ifrs-full:DisclosureOfRevenueFromContractsWithCustomersExplanatory
      contextRef="Duration_1_1_2022_To_6_30_2022_dNPMG5n7t0WcNVF9KG4Bdw"
      id="Tb_kqsmCdaxH0uSbUtRnQcEqA">&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="color:#029c93;font-weight:bold;"&gt;Note 2 &#x2013; Revenue &lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;The table below summarizes Genmab&#x2019;s revenue by type and collaboration partner, and royalties by product, under Genmab&#x2019;s agreements.&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:55.59%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.51%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.24%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.51%;background:#e6e6e6;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;6 Months Ended&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;6 Months Ended&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.51%;background:#e6e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;June 30, 2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;June 30, 2021&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;(DKK million)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.51%;background:#e7e6e6;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Revenue by type:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.51%;background:#e7e6e6;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;Royalties&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.51%;background:#e7e6e6;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,727&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,595&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;Reimbursement revenue&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.51%;background:#e7e6e6;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 287&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 227&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;Milestone revenue&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.51%;background:#e7e6e6;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 176&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 731&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;Collaboration revenue&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.51%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 91&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.51%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 5,281&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 3,553&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.51%;background:#e7e6e6;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Revenue by collaboration partner:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.51%;background:#e7e6e6;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;Janssen&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.51%;background:#e7e6e6;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,206&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,846&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;AbbVie&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.51%;background:#e7e6e6;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 245&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;Roche&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.51%;background:#e7e6e6;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 390&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 162&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;Novartis&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.51%;background:#e7e6e6;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 305&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 73&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;BioNTech&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.51%;background:#e7e6e6;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 231&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 171&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;Seagen&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.51%;background:#e7e6e6;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 138&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 56&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;Other&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.51%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 11&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.51%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 5,281&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 3,553&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.51%;background:#e7e6e6;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Royalties by product:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.51%;background:#e7e6e6;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;DARZALEX &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.51%;background:#e7e6e6;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,360&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;TEPEZZA &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.51%;background:#e7e6e6;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 390&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 162&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;Kesimpta &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.51%;background:#e7e6e6;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 296&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 72&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;Other&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.51%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 17&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.51%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 4,727&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 2,595&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;In September 2020, Genmab commenced binding arbitration of two matters arising under its license agreement with Janssen relating to daratumumab. Under the license agreement, Genmab is, among other things, entitled to royalties from Janssen on net sales of daratumumab (marketed as DARZALEX for IV administration and as DARZALEX &lt;i style="font-style:italic;"&gt;FASPRO&lt;/i&gt; in the United States and as DARZALEX SC in Europe for SC administration). In April 2022, the arbitral tribunal issued an award in the binding arbitration of the two matters. Genmab did not seek a review of the award, and the award is now final.&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;The first matter concerned the question as to whether Janssen&#x2019;s obligation to pay royalties on net sales of licensed product extends, in each applicable country, until the expiration or invalidation of the last-to-expire relevant Genmab-owned patent or the last-to-expire relevant Janssen-owned patent covering the product, as further defined and described in the license agreement.  As to that matter, the tribunal determined by majority opinion that Janssen&#x2019;s obligation to pay royalties to Genmab on net sales of licensed product, in each applicable country, extends through the expiration or invalidation of the last-to-expire relevant Genmab-owned patent covering the product or use thereof, but not the relevant Janssen-owned patent. The relevant Genmab-owned issued U.S., European and Japanese patents will expire in the late 2020s and early 2030s. &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;The second matter concerned the question as to whether Genmab is required to share in Janssen&#x2019;s royalty payments to Halozyme for the Halozyme enzyme technology used in the SC formulation of daratumumab (marketed as DARZALEX &lt;i style="font-style:italic;"&gt;FASPRO&lt;/i&gt; in the U.S.). The royalties Janssen pays to Halozyme represent a mid-single digit percentage rate of SC daratumumab net sales. As to that matter, the tribunal ruled by majority opinion that Janssen is permitted to continue reducing its royalty payments to Genmab as an offset against a share of Janssen&#x2019;s royalty payments made to Halozyme. &lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Refer to Note 2.1 in the Annual Report for further details regarding revenue.&lt;/p&gt;</ifrs-full:DisclosureOfRevenueFromContractsWithCustomersExplanatory>
    <ifrs-full:DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory
      contextRef="Duration_1_1_2022_To_6_30_2022_dNPMG5n7t0WcNVF9KG4Bdw"
      id="Tb_utMh08Y4PE-GAsML70b8PA">&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:55.59%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.51%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.24%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.51%;background:#e6e6e6;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;6 Months Ended&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;6 Months Ended&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.51%;background:#e6e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;June 30, 2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;June 30, 2021&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;(DKK million)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.51%;background:#e7e6e6;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Revenue by type:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.51%;background:#e7e6e6;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;Royalties&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.51%;background:#e7e6e6;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,727&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,595&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;Reimbursement revenue&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.51%;background:#e7e6e6;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 287&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 227&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;Milestone revenue&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.51%;background:#e7e6e6;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 176&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 731&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;Collaboration revenue&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.51%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 91&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.51%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 5,281&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 3,553&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.51%;background:#e7e6e6;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Revenue by collaboration partner:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.51%;background:#e7e6e6;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;Janssen&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.51%;background:#e7e6e6;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,206&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,846&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;AbbVie&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.51%;background:#e7e6e6;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 245&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;Roche&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.51%;background:#e7e6e6;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 390&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 162&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;Novartis&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.51%;background:#e7e6e6;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 305&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 73&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;BioNTech&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.51%;background:#e7e6e6;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 231&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 171&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;Seagen&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.51%;background:#e7e6e6;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 138&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 56&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;Other&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.51%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 11&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.51%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 5,281&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 3,553&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.51%;background:#e7e6e6;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Royalties by product:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.51%;background:#e7e6e6;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;DARZALEX &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.51%;background:#e7e6e6;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,360&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;TEPEZZA &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.51%;background:#e7e6e6;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 390&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 162&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;Kesimpta &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.51%;background:#e7e6e6;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 296&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 72&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;Other&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.51%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 17&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.51%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 4,727&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 2,595&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</ifrs-full:DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory>
    <ifrs-full:RevenueFromContractsWithCustomers
      contextRef="Duration_1_1_2022_To_6_30_2022_gmab_TypesOfRevenuesAxis_gmab_RoyaltiesRevenueMember_l90laluy2ECUtYZD9oF94A"
      decimals="-6"
      id="Tc_FtKZ8XD7Dkq0ET9dqNUx1w_5_2"
      unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg">4727000000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers
      contextRef="Duration_1_1_2021_To_6_30_2021_gmab_TypesOfRevenuesAxis_gmab_RoyaltiesRevenueMember_C14oZ_22m06-TU9BB9BNhw"
      decimals="-6"
      id="Tc_rxwPUQRFl0OW3k4dW8Yk8g_5_4"
      unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg">2595000000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers
      contextRef="Duration_1_1_2022_To_6_30_2022_gmab_TypesOfRevenuesAxis_gmab_ReimbursementIncomeMember_SqLe6wdBT06OGFsFXaHuhQ"
      decimals="-6"
      id="Tc_k9OBL8I_QU2qFy002zATvQ_6_2"
      unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg">287000000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers
      contextRef="Duration_1_1_2021_To_6_30_2021_gmab_TypesOfRevenuesAxis_gmab_ReimbursementIncomeMember_omlBYt5DuUO9i8c4hNlRbg"
      decimals="-6"
      id="Tc_65-kUxz-0k6cmflPiTDEQw_6_4"
      unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg">227000000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers
      contextRef="Duration_1_1_2022_To_6_30_2022_gmab_TypesOfRevenuesAxis_gmab_MilestonePaymentsRevenueMember_fqNpjY-zG02ssbNiOllMzA"
      decimals="-6"
      id="Tc_zGfi-Sce6U-B-YXLn4r-cg_7_2"
      unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg">176000000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers
      contextRef="Duration_1_1_2021_To_6_30_2021_gmab_TypesOfRevenuesAxis_gmab_MilestonePaymentsRevenueMember_RLx1u9QEf0yprcS3a5mwXA"
      decimals="-6"
      id="Tc_64ZgU1lXqkqfNqBQFYQhJw_7_4"
      unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg">731000000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers
      contextRef="Duration_1_1_2022_To_6_30_2022_gmab_TypesOfRevenuesAxis_gmab_CollaborationRevenueMember_ht1RNX53n0-X7tAGYv75YQ"
      decimals="-6"
      id="Tc_hBgs_uE9uUiQG7vzxE2-sw_8_2"
      unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg">91000000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers
      contextRef="Duration_1_1_2022_To_6_30_2022_dNPMG5n7t0WcNVF9KG4Bdw"
      decimals="-6"
      id="Tc_2Y7aR3A-OkmguvDAK2IdZg_9_2"
      unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg">5281000000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers
      contextRef="Duration_1_1_2021_To_6_30_2021_MRS0_D_onUCNBOxf7Qx_Cw"
      decimals="-6"
      id="Tc_iWxh9sY2xkuS7fFCic-xPA_9_4"
      unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg">3553000000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers
      contextRef="Duration_1_1_2022_To_6_30_2022_gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_gmab_AgreementsWithJanssenMember_dtnNRTQ9qUWE18D-r3fXbQ"
      decimals="-6"
      id="Tc_3Ucl492jLEWoHj_ZVCocAg_12_2"
      unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg">4206000000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers
      contextRef="Duration_1_1_2021_To_6_30_2021_gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_gmab_AgreementsWithJanssenMember_vuVrCms2xECcbUwIJRfXzw"
      decimals="-6"
      id="Tc_wkOHgjwkOEqB9bN7aHpPIQ_12_4"
      unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg">2846000000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers
      contextRef="Duration_1_1_2021_To_6_30_2021_gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_gmab_AgreementsWithAbbvieMember_KrVymjM9ekWDbOoEhonp8Q"
      decimals="-6"
      id="Tc_8goY_2yOYkGbNKxSKsYJyQ_13_4"
      unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg">245000000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers
      contextRef="Duration_1_1_2022_To_6_30_2022_gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_gmab_AgreementsWithRocheMember_F60ez68CiEaIHbxeNRu9_Q"
      decimals="-6"
      id="Tc_slFrypWBlEGeuPqwgtk45Q_14_2"
      unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg">390000000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers
      contextRef="Duration_1_1_2021_To_6_30_2021_gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_gmab_AgreementsWithRocheMember_z9PLyE_EZEK_NCj-F9C2xA"
      decimals="-6"
      id="Tc_CuSPBksEBUWwZFDN8TOM_Q_14_4"
      unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg">162000000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers
      contextRef="Duration_1_1_2022_To_6_30_2022_gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_gmab_AgreementsWithNovartisMember_2Lw8aj2ROUe2xOEG0T2NEA"
      decimals="-6"
      id="Tc_gyYFa4NQzUOmHoCVuq1MNg_15_2"
      unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg">305000000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers
      contextRef="Duration_1_1_2021_To_6_30_2021_gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_gmab_AgreementsWithNovartisMember_Q_C1sF5FrU2rD44CqxQPtw"
      decimals="-6"
      id="Tc_xV4uXnjaJkG5UFiXs7Jzww_15_4"
      unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg">73000000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers
      contextRef="Duration_1_1_2022_To_6_30_2022_gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_gmab_AgreementsWithBointechMember_-wOkAaAFTU-q5bYOFz9Nag"
      decimals="-6"
      id="Tc_ITNohEayQk-V88lnIa1-Vw_16_2"
      unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg">231000000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers
      contextRef="Duration_1_1_2021_To_6_30_2021_gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_gmab_AgreementsWithBointechMember__Roy-36-pUSfv1AGtbDu3Q"
      decimals="-6"
      id="Tc_faaFtXDl2UGLmmlWSB7i0w_16_4"
      unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg">171000000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers
      contextRef="Duration_1_1_2022_To_6_30_2022_gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_gmab_AgreementsWithSeagenMember_pZplyqrryEKRXEj8O7llZQ"
      decimals="-6"
      id="Tc_q9Ei4W0XsUuGNAnZ70JtrQ_17_2"
      unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg">138000000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers
      contextRef="Duration_1_1_2021_To_6_30_2021_gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_gmab_AgreementsWithSeagenMember_eK57WUE_IE2_OzKv8nQlDQ"
      decimals="-6"
      id="Tc_86gw4zxdaEaJKr3Z2aqcUg_17_4"
      unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg">56000000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers
      contextRef="Duration_1_1_2022_To_6_30_2022_gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_gmab_OtherCollaborationPartnersMember_AsIPBfv6PU6XdKxKRQhUDA"
      decimals="-6"
      id="Tc_yT1rA4DkwUWu9NarluGXwQ_18_2"
      unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg">11000000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers
      contextRef="Duration_1_1_2022_To_6_30_2022_dNPMG5n7t0WcNVF9KG4Bdw"
      decimals="-6"
      id="Tc_ngsABpEkrkmecjITLpQLXQ_19_2"
      unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg">5281000000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers
      contextRef="Duration_1_1_2021_To_6_30_2021_MRS0_D_onUCNBOxf7Qx_Cw"
      decimals="-6"
      id="Tc_EYRujR8lNES66MXwsYsYxA_19_4"
      unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg">3553000000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers
      contextRef="Duration_1_1_2022_To_6_30_2022_gmab_IfrsRoyaltiesByProductAxis_gmab_DarzalexMember_gmab_TypesOfRevenuesAxis_gmab_RoyaltiesRevenueMember_B_UEY1hASUOrDlLXGgV7LQ"
      decimals="-6"
      id="Tc_353p1M6QrUKJuQT-VPpkuQ_22_2"
      unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg">4024000000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers
      contextRef="Duration_1_1_2021_To_6_30_2021_gmab_IfrsRoyaltiesByProductAxis_gmab_DarzalexMember_gmab_TypesOfRevenuesAxis_gmab_RoyaltiesRevenueMember_ygn3CpbP8kelusDjXKa8kw"
      decimals="-6"
      id="Tc_VFidr4Nt_0emNOJ3qiA1eg_22_4"
      unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg">2360000000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers
      contextRef="Duration_1_1_2022_To_6_30_2022_gmab_IfrsRoyaltiesByProductAxis_gmab_TepezzaMember_gmab_TypesOfRevenuesAxis_gmab_RoyaltiesRevenueMember_2vu0gXPmvEOPW1nFEg8xWQ"
      decimals="-6"
      id="Tc_7KTPAM8DhUyoNhk72qYtyw_23_2"
      unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg">390000000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers
      contextRef="Duration_1_1_2021_To_6_30_2021_gmab_IfrsRoyaltiesByProductAxis_gmab_TepezzaMember_gmab_TypesOfRevenuesAxis_gmab_RoyaltiesRevenueMember_fs7jJ3nvNUyKr8Sk5fXrGg"
      decimals="-6"
      id="Tc_bSagtqOGBEq65tnFb5RsqQ_23_4"
      unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg">162000000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers
      contextRef="Duration_1_1_2022_To_6_30_2022_gmab_IfrsRoyaltiesByProductAxis_gmab_KesimptaMember_gmab_TypesOfRevenuesAxis_gmab_RoyaltiesRevenueMember_HHevdLOZHkKv8JPTDpOBMA"
      decimals="-6"
      id="Tc_CcC9mb_BwkCx2VbfMMtaiw_24_2"
      unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg">296000000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers
      contextRef="Duration_1_1_2021_To_6_30_2021_gmab_IfrsRoyaltiesByProductAxis_gmab_KesimptaMember_gmab_TypesOfRevenuesAxis_gmab_RoyaltiesRevenueMember_FICwJ-6ee0Gxe75faT4PZQ"
      decimals="-6"
      id="Tc_4MoCsxa9J063RfS5s7CCRg_24_4"
      unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg">72000000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers
      contextRef="Duration_1_1_2022_To_6_30_2022_gmab_IfrsRoyaltiesByProductAxis_gmab_OtherRoyaltyProductMember_gmab_TypesOfRevenuesAxis_gmab_RoyaltiesRevenueMember_E0nJo5T9H0y4j-kEZUvZ1g"
      decimals="-6"
      id="Tc_LCRwhmjbfku-mq0d5Z669Q_25_2"
      unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg">17000000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers
      contextRef="Duration_1_1_2021_To_6_30_2021_gmab_IfrsRoyaltiesByProductAxis_gmab_OtherRoyaltyProductMember_gmab_TypesOfRevenuesAxis_gmab_RoyaltiesRevenueMember_L_QgZHefbEqkV9UUM69KBg"
      decimals="-6"
      id="Tc_zD90qj2Ge0u-ZYtGh2pONg_25_4"
      unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg">1000000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers
      contextRef="Duration_1_1_2022_To_6_30_2022_gmab_TypesOfRevenuesAxis_gmab_RoyaltiesRevenueMember_l90laluy2ECUtYZD9oF94A"
      decimals="-6"
      id="Tc_Fw9wUAkiuEeN3z6ZeywO-Q_26_2"
      unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg">4727000000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers
      contextRef="Duration_1_1_2021_To_6_30_2021_gmab_TypesOfRevenuesAxis_gmab_RoyaltiesRevenueMember_C14oZ_22m06-TU9BB9BNhw"
      decimals="-6"
      id="Tc_B2cp3vnNhkag09pU6Clw-g_26_4"
      unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg">2595000000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory
      contextRef="Duration_1_1_2022_To_6_30_2022_dNPMG5n7t0WcNVF9KG4Bdw"
      id="Tb_fDkc_ZjDBUK1nxt1b9NPxg">&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="color:#029c93;font-weight:bold;"&gt;Note 3 &#x2013; Financial Instruments&lt;/b&gt; &lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:50.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.09%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.09%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Genmab&#x2019;s portfolio is spread over a number of different securities with a focus on liquidity and the preservation of capital. Genmab&#x2019;s marketable securities in USD, DKK, EUR, and GBP as a percentage of total marketable securities was as follows: &lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:33.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:28.02%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:28.02%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.23%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:33.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:31.28%;background:#e6e6e6;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;June 30,&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:31.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;December&#160;31,&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:33.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:31.28%;background:#e6e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:31.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;2021&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:33.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Percent&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:28.02%;background:#e6e6e6;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.25%;background:#e6e6e6;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:28.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:33.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:28.02%;background:#e6e6e6;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.25%;background:#e6e6e6;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:28.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:33.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;USD&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:28.02%;background:#e7e6e6;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 79&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.25%;background:#e6e6e6;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:28.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 75&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:33.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;DKK&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:28.02%;background:#e7e6e6;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 13&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.25%;background:#e6e6e6;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:28.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 16&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:33.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;EUR&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:28.02%;background:#e7e6e6;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 7&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.25%;background:#e6e6e6;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:28.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 8&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:33.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;GBP&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:28.02%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 1&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.25%;background:#e6e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:28.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 1&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:33.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:28.02%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 100&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.25%;background:#e6e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:28.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 100&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;As of June 30, 2022, 71% of Genmab&#x2019;s marketable securities were long-term A rated or higher, or short-term A-1 / P-1 rated by S&amp;amp;P, Moody&#x2019;s or Fitch compared to 68% as of December 31, 2021. &lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;The table below shows the fair value measurements by level for Genmab&#x2019;s financial assets measured at fair value through profit or loss:&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:middle;width:26.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:10.8%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:10.8%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:6.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:6.23%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:5.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:6.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:6.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:6.69%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:26.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(DKK million)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:middle;white-space:nowrap;width:39.58%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;June 30, 2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:middle;white-space:nowrap;width:30.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:26.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Assets Measured at Fair Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:10.8%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level&#160;1&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.9%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:10.8%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level&#160;2&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.9%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:6.03%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level&#160;3&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.9%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:6.23%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:5.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level&#160;1&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:6.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level&#160;2&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:6.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level&#160;3&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:6.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:26.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:10.8%;background:#e7e6e6;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.9%;background:#e7e6e6;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:10.8%;background:#e7e6e6;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.9%;background:#e7e6e6;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:6.03%;background:#e7e6e6;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.9%;background:#e7e6e6;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:6.23%;background:#e7e6e6;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:5.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:6.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:6.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:6.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:26.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;Marketable securities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:10.8%;background:#e7e6e6;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"&gt; 11,799&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.9%;background:#e7e6e6;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.8%;background:#e7e6e6;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.9%;background:#e7e6e6;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.03%;background:#e7e6e6;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.9%;background:#e7e6e6;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:6.23%;background:#e7e6e6;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"&gt; 11,799&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:5.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"&gt;10,381&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:6.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"&gt;10,381&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:26.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;Other investments&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:10.8%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"&gt;150&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.9%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.8%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.9%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:6.03%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"&gt;51&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.9%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:6.23%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"&gt; 201&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:5.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"&gt;344&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:6.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"&gt;27&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:6.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"&gt;371&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Marketable Securities&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;All fair values are determined by reference to external sources using unadjusted quoted prices in established markets for Genmab&#x2019;s marketable securities (Level 1). &lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Other Investments &lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Other investments as of June 30, 2022 consist primarily of a DKK 138 million investment in common shares of CureVac, compared to DKK 318 million as of December 31, 2021. During the second quarter of 2021, Genmab made an investment in common shares of Bolt. As of June 30, 2022, the investment in Bolt was valued at DKK 12 million, compared to DKK 26 million as of December 31, 2021.&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;The investments in CureVac and Bolt are recorded at fair value through profit or loss. The fair value of Genmab&#x2019;s investments in CureVac and Bolt are determined using unadjusted quoted prices in established markets (Level 1).&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Refer to Note 4.3 and Note 4.4 in the Annual Report for further details regarding Genmab&#x2019;s marketable securities and other investments.&lt;/p&gt;</ifrs-full:DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory>
    <gmab:DisclosureOfMarketableSecuritiesByCurrencyTableTextBlock
      contextRef="Duration_1_1_2022_To_6_30_2022_dNPMG5n7t0WcNVF9KG4Bdw"
      id="Tb_i4NebAuDckO0oTB0wAEexg">&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:33.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:28.02%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:28.02%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.23%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:33.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:31.28%;background:#e6e6e6;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;June 30,&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:31.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;December&#160;31,&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:33.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:31.28%;background:#e6e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:31.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;2021&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:33.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Percent&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:28.02%;background:#e6e6e6;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.25%;background:#e6e6e6;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:28.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:33.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:28.02%;background:#e6e6e6;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.25%;background:#e6e6e6;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:28.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:33.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;USD&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:28.02%;background:#e7e6e6;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 79&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.25%;background:#e6e6e6;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:28.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 75&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:33.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;DKK&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:28.02%;background:#e7e6e6;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 13&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.25%;background:#e6e6e6;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:28.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 16&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:33.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;EUR&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:28.02%;background:#e7e6e6;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 7&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.25%;background:#e6e6e6;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:28.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 8&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:33.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;GBP&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:28.02%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 1&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.25%;background:#e6e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:28.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 1&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:33.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:28.02%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 100&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.25%;background:#e6e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:28.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 100&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</gmab:DisclosureOfMarketableSecuritiesByCurrencyTableTextBlock>
    <gmab:PercentageOfMarketableSecuritiesInvested
      contextRef="Duration_1_1_2022_To_6_30_2022_ifrs-full_TypesOfRisksAxis_ifrs-full_CurrencyRiskMember_srt_CurrencyAxis_currency_USD_5UvDDDnrAUyD1gvej8S37Q"
      decimals="4"
      id="Tc_-mdeghWIuk2v49MUd-dENg_5_2"
      unitRef="Unit_Standard_pure_ydC7mNX6akalcP_kj1H8wg">0.79</gmab:PercentageOfMarketableSecuritiesInvested>
    <gmab:PercentageOfMarketableSecuritiesInvested
      contextRef="Duration_1_1_2021_To_12_31_2021_ifrs-full_TypesOfRisksAxis_ifrs-full_CurrencyRiskMember_srt_CurrencyAxis_currency_USD_CHnFrAUKTEWMyHR2NduwAw"
      decimals="4"
      id="Tc_8pXVizxzMEOMpBCjJfxffg_5_5"
      unitRef="Unit_Standard_pure_ydC7mNX6akalcP_kj1H8wg">0.75</gmab:PercentageOfMarketableSecuritiesInvested>
    <gmab:PercentageOfMarketableSecuritiesInvested
      contextRef="Duration_1_1_2022_To_6_30_2022_ifrs-full_TypesOfRisksAxis_ifrs-full_CurrencyRiskMember_srt_CurrencyAxis_currency_DKK_wEFDGqiOE0meYqnyprgzqw"
      decimals="4"
      id="Tc_xjw2Z7-kRk-kTHT-3f2cgw_6_2"
      unitRef="Unit_Standard_pure_ydC7mNX6akalcP_kj1H8wg">0.13</gmab:PercentageOfMarketableSecuritiesInvested>
    <gmab:PercentageOfMarketableSecuritiesInvested
      contextRef="Duration_1_1_2021_To_12_31_2021_ifrs-full_TypesOfRisksAxis_ifrs-full_CurrencyRiskMember_srt_CurrencyAxis_currency_DKK_ayp_YF4WHEe51vXOnYlL2A"
      decimals="4"
      id="Tc_cHnWNvY2RkySdIRd6Lu5tw_6_5"
      unitRef="Unit_Standard_pure_ydC7mNX6akalcP_kj1H8wg">0.16</gmab:PercentageOfMarketableSecuritiesInvested>
    <gmab:PercentageOfMarketableSecuritiesInvested
      contextRef="Duration_1_1_2022_To_6_30_2022_ifrs-full_TypesOfRisksAxis_ifrs-full_CurrencyRiskMember_srt_CurrencyAxis_currency_EUR_SstAsF5VjkaHxTdVOHBYpg"
      decimals="4"
      id="Tc__RNqHgfyYUmz6m5gAylJiw_7_2"
      unitRef="Unit_Standard_pure_ydC7mNX6akalcP_kj1H8wg">0.07</gmab:PercentageOfMarketableSecuritiesInvested>
    <gmab:PercentageOfMarketableSecuritiesInvested
      contextRef="Duration_1_1_2021_To_12_31_2021_ifrs-full_TypesOfRisksAxis_ifrs-full_CurrencyRiskMember_srt_CurrencyAxis_currency_EUR_9Wybode0pUWKJkinsc2Cxw"
      decimals="4"
      id="Tc_vVUEysNNoEyxnu2se3HGmA_7_5"
      unitRef="Unit_Standard_pure_ydC7mNX6akalcP_kj1H8wg">0.08</gmab:PercentageOfMarketableSecuritiesInvested>
    <gmab:PercentageOfMarketableSecuritiesInvested
      contextRef="Duration_1_1_2022_To_6_30_2022_ifrs-full_TypesOfRisksAxis_ifrs-full_CurrencyRiskMember_srt_CurrencyAxis_currency_GBP_DSPHKvhiT02Od8W80WG6KQ"
      decimals="4"
      id="Tc_Elmqc1sIuEyDdFaIb4bfBA_8_2"
      unitRef="Unit_Standard_pure_ydC7mNX6akalcP_kj1H8wg">0.01</gmab:PercentageOfMarketableSecuritiesInvested>
    <gmab:PercentageOfMarketableSecuritiesInvested
      contextRef="Duration_1_1_2021_To_12_31_2021_ifrs-full_TypesOfRisksAxis_ifrs-full_CurrencyRiskMember_srt_CurrencyAxis_currency_GBP_nnosnR0H8kS3TQbqxqHACA"
      decimals="4"
      id="Tc__HlKwEpoaU2mtpgEr_UiIg_8_5"
      unitRef="Unit_Standard_pure_ydC7mNX6akalcP_kj1H8wg">0.01</gmab:PercentageOfMarketableSecuritiesInvested>
    <gmab:PercentageOfMarketableSecuritiesInvested
      contextRef="Duration_1_1_2022_To_6_30_2022_ifrs-full_TypesOfRisksAxis_ifrs-full_CurrencyRiskMember_ASM5neKz9keFOK65fKS2gQ"
      decimals="4"
      id="Tc_eVTFTb6vpkGW4tlhYMCIGA_9_2"
      unitRef="Unit_Standard_pure_ydC7mNX6akalcP_kj1H8wg">1</gmab:PercentageOfMarketableSecuritiesInvested>
    <gmab:PercentageOfMarketableSecuritiesInvested
      contextRef="Duration_1_1_2021_To_12_31_2021_ifrs-full_TypesOfRisksAxis_ifrs-full_CurrencyRiskMember_xIqg6PH6QUGf8y8gkPOHag"
      decimals="4"
      id="Tc_J1uxK3G9NkyHbyhb10EtbQ_9_5"
      unitRef="Unit_Standard_pure_ydC7mNX6akalcP_kj1H8wg">1</gmab:PercentageOfMarketableSecuritiesInvested>
    <gmab:PercentageOfMarketableSecurities
      contextRef="As_Of_6_30_2022_ifrs-full_ExternalCreditGradesAxis_gmab_TripleaRatingMember_ifrs-full_TypesOfRisksAxis_ifrs-full_CreditRiskMember_MchtLzCh3Uufn_bh-7kpNA"
      decimals="4"
      id="Narr_aCJ0_lk5UkGXd6p-T8I8FA"
      unitRef="Unit_Standard_pure_ydC7mNX6akalcP_kj1H8wg">0.71</gmab:PercentageOfMarketableSecurities>
    <gmab:PercentageOfMarketableSecurities
      contextRef="As_Of_12_31_2021_ifrs-full_ExternalCreditGradesAxis_gmab_TripleaRatingMember_ifrs-full_TypesOfRisksAxis_ifrs-full_CreditRiskMember_O0tp15gOUUSNGn0NNu-ntA"
      decimals="4"
      id="Narr_0Ppjc64mrUehxgJjBJhxhQ"
      unitRef="Unit_Standard_pure_ydC7mNX6akalcP_kj1H8wg">0.68</gmab:PercentageOfMarketableSecurities>
    <ifrs-full:DisclosureOfOffsettingOfFinancialAssetsAndFinancialLiabilitiesExplanatory
      contextRef="Duration_1_1_2022_To_6_30_2022_dNPMG5n7t0WcNVF9KG4Bdw"
      id="Tb_yv9G2nx9AkCN1yipez55jw">&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:middle;width:26.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:10.8%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:10.8%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:6.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:6.23%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:5.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:6.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:6.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:6.69%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:26.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(DKK million)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:middle;white-space:nowrap;width:39.58%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;June 30, 2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:middle;white-space:nowrap;width:30.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:26.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Assets Measured at Fair Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:10.8%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level&#160;1&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.9%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:10.8%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level&#160;2&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.9%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:6.03%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level&#160;3&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.9%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:6.23%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:5.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level&#160;1&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:6.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level&#160;2&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:6.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level&#160;3&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:6.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:26.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:10.8%;background:#e7e6e6;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.9%;background:#e7e6e6;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:10.8%;background:#e7e6e6;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.9%;background:#e7e6e6;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:6.03%;background:#e7e6e6;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.9%;background:#e7e6e6;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:6.23%;background:#e7e6e6;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:5.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:6.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:6.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:6.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:26.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;Marketable securities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:10.8%;background:#e7e6e6;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"&gt; 11,799&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.9%;background:#e7e6e6;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.8%;background:#e7e6e6;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.9%;background:#e7e6e6;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.03%;background:#e7e6e6;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.9%;background:#e7e6e6;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:6.23%;background:#e7e6e6;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"&gt; 11,799&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:5.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"&gt;10,381&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:6.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"&gt;10,381&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:26.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;Other investments&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:10.8%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"&gt;150&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.9%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.8%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.9%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:6.03%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"&gt;51&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.9%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:6.23%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"&gt; 201&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:5.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"&gt;344&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:6.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"&gt;27&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:6.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"&gt;371&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</ifrs-full:DisclosureOfOffsettingOfFinancialAssetsAndFinancialLiabilitiesExplanatory>
    <ifrs-full:FinancialAssets
      contextRef="As_Of_6_30_2022_ifrs-full_ClassesOfFinancialAssetsAxis_gmab_MarketableSecuritiesMember_ifrs-full_LevelsOfFairValueHierarchyAxis_ifrs-full_Level1OfFairValueHierarchyMember_ifrs-full_MeasurementAxis_ifrs-full_AtFairValueMember_ZqdE8gsn6ku4IF-3riiPzw"
      decimals="-6"
      id="Tc_BvAtnXhDxEGiwipyAPOvTA_4_2"
      unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg">11799000000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets
      contextRef="As_Of_6_30_2022_ifrs-full_ClassesOfFinancialAssetsAxis_gmab_MarketableSecuritiesMember_ifrs-full_MeasurementAxis_ifrs-full_AtFairValueMember_gMTFg1fkaU-2kMTWZGvA2A"
      decimals="-6"
      id="Tc_yGvVjYTJJ0qJcnnk6gZd1g_4_8"
      unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg">11799000000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets
      contextRef="As_Of_12_31_2021_ifrs-full_ClassesOfFinancialAssetsAxis_gmab_MarketableSecuritiesMember_ifrs-full_LevelsOfFairValueHierarchyAxis_ifrs-full_Level1OfFairValueHierarchyMember_ifrs-full_MeasurementAxis_ifrs-full_AtFairValueMember_QdkiKQXr4UeiSvq7C18kVg"
      decimals="-6"
      id="Tc_zK2hDj3HX0SRQcwY6ozn0g_4_10"
      unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg">10381000000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets
      contextRef="As_Of_12_31_2021_ifrs-full_ClassesOfFinancialAssetsAxis_gmab_MarketableSecuritiesMember_ifrs-full_MeasurementAxis_ifrs-full_AtFairValueMember_OovtmPjP8kG5XP6UcVoSpw"
      decimals="-6"
      id="Tc_-6fsE6a8Nk-xg9GcdiJleA_4_16"
      unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg">10381000000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets
      contextRef="As_Of_6_30_2022_ifrs-full_ClassesOfFinancialAssetsAxis_gmab_OtherInvestmentMember_ifrs-full_LevelsOfFairValueHierarchyAxis_ifrs-full_Level1OfFairValueHierarchyMember_ifrs-full_MeasurementAxis_ifrs-full_AtFairValueMember_A8Z5M0xP50-MphyTG1XuyQ"
      decimals="-6"
      id="Tc_CgmrykCxvESyhKsCGe6KgA_5_2"
      unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg">150000000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets
      contextRef="As_Of_6_30_2022_ifrs-full_ClassesOfFinancialAssetsAxis_gmab_OtherInvestmentMember_ifrs-full_LevelsOfFairValueHierarchyAxis_ifrs-full_Level3OfFairValueHierarchyMember_ifrs-full_MeasurementAxis_ifrs-full_AtFairValueMember_hoHfcpf2WkG8ZksGtffiJg"
      decimals="-6"
      id="Tc_H2ymA3nj4kWJzbypPhEUkg_5_6"
      unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg">51000000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets
      contextRef="As_Of_6_30_2022_ifrs-full_ClassesOfFinancialAssetsAxis_gmab_OtherInvestmentMember_ifrs-full_MeasurementAxis_ifrs-full_AtFairValueMember_DxVED2HGdUitGp0y05MVqQ"
      decimals="-6"
      id="Tc_wyXFwalKKE6AIrz-spQwUQ_5_8"
      unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg">201000000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets
      contextRef="As_Of_12_31_2021_ifrs-full_ClassesOfFinancialAssetsAxis_gmab_OtherInvestmentMember_ifrs-full_LevelsOfFairValueHierarchyAxis_ifrs-full_Level1OfFairValueHierarchyMember_ifrs-full_MeasurementAxis_ifrs-full_AtFairValueMember_Obo46paYeU6NBT9bV_1jig"
      decimals="-6"
      id="Tc_zRYmCpsI4EeQMIOfrdnwEg_5_10"
      unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg">344000000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets
      contextRef="As_Of_12_31_2021_ifrs-full_ClassesOfFinancialAssetsAxis_gmab_OtherInvestmentMember_ifrs-full_LevelsOfFairValueHierarchyAxis_ifrs-full_Level3OfFairValueHierarchyMember_ifrs-full_MeasurementAxis_ifrs-full_AtFairValueMember_aMyaV8Vr-EO7hwMWUT9G9g"
      decimals="-6"
      id="Tc_2rcuUxeIfUOxTGsoVt3RRw_5_14"
      unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg">27000000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets
      contextRef="As_Of_12_31_2021_ifrs-full_ClassesOfFinancialAssetsAxis_gmab_OtherInvestmentMember_ifrs-full_MeasurementAxis_ifrs-full_AtFairValueMember_QtPH5pFRWEevfw8ugwnNCA"
      decimals="-6"
      id="Tc_6qRWG91dYkSDmO_746M9sg_5_16"
      unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg">371000000</ifrs-full:FinancialAssets>
    <ifrs-full:InvestmentAccountedForUsingEquityMethod
      contextRef="As_Of_6_30_2022_gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_gmab_CurevacCollaborationMember_qc8QNPN5vUSdmz2Y_v8bjg"
      decimals="-6"
      id="Narr_uli7Qf9dJEqf9CMjFvGFbQ"
      unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg">138000000</ifrs-full:InvestmentAccountedForUsingEquityMethod>
    <ifrs-full:InvestmentAccountedForUsingEquityMethod
      contextRef="As_Of_12_31_2021_gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_gmab_CurevacCollaborationMember_0V_v61kjsUagGH7vU0HsPA"
      decimals="-6"
      id="Narr_WWWCs-km50CdQ3uberwnKQ"
      unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg">318000000</ifrs-full:InvestmentAccountedForUsingEquityMethod>
    <ifrs-full:InvestmentAccountedForUsingEquityMethod
      contextRef="As_Of_6_30_2022_gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_gmab_BoltBiotherapeuticsIncMember_Cb3qRuFzkUCdz53av0zSRg"
      decimals="-6"
      id="Narr_fXHhSLdXPkuGAwcIB7sgLw"
      unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg">12000000</ifrs-full:InvestmentAccountedForUsingEquityMethod>
    <ifrs-full:InvestmentAccountedForUsingEquityMethod
      contextRef="As_Of_12_31_2021_gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_gmab_BoltBiotherapeuticsIncMember_dAp_IxgOu0O5Vly-wxDrdA"
      decimals="-6"
      id="Narr_fOFeEGFzZUu7fYFgQjsxvA"
      unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg">26000000</ifrs-full:InvestmentAccountedForUsingEquityMethod>
    <ifrs-full:DisclosureOfFinanceIncomeExpenseExplanatory
      contextRef="Duration_1_1_2022_To_6_30_2022_dNPMG5n7t0WcNVF9KG4Bdw"
      id="Tb_eoSkG1XwFE-x3mB6MwxTzA">&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="color:#029c93;font-weight:bold;"&gt;Note 4 &#x2013; Financial Income and Expenses&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:57.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.69%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.66%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.69%;background:#e6e6e6;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;6 Months Ended&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;6 Months Ended&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.69%;background:#e6e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;June 30, 2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;June 30, 2021&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;(DKK million)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.69%;background:#e6e6e6;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.69%;background:#e7e6e6;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Financial income:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.69%;background:#e7e6e6;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Interest and other financial income&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.69%;background:#e7e6e6;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 87&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 127&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Foreign exchange rate gain, net&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.69%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 1,792&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 573&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.69%;background:#e7e6e6;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &lt;/b&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &lt;/b&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total financial income&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.69%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 1,879&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 700&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.69%;background:#e7e6e6;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Financial expenses:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.69%;background:#e7e6e6;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Interest and other financial expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.69%;background:#e7e6e6;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (10)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (6)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Loss on marketable securities, net&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.69%;background:#e7e6e6;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (315)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (134)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Loss on other investments, net&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.69%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (214)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (33)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.69%;background:#e7e6e6;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total financial expenses&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.69%;background:#e6e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; (539)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; (173)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.69%;background:#e6e6e6;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Net financial items&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.69%;background:#e6e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 1,340&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 527&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Foreign exchange rate gain, net was DKK 1,792 million in the first six months of 2022 compared to DKK 573 million in the first six months of 2021. The USD strengthened against the DKK in each period which positively impacted our USD denominated marketable securities and cash holdings, but to a greater extent in 2022. Refer to Note 4.2 in the Annual Report for further details regarding foreign currency risk. &lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Loss on marketable securities, net was DKK 315 million in the first six months of 2022 compared to DKK 134 million in the first six months of 2021. The increase in fair value losses on marketable securities was primarily driven by increases in interest rates in the United States and Europe.&lt;span style="white-space:pre-wrap;"&gt;  &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="background:#ffffff;"&gt;Loss on other investments, net was DKK &lt;/span&gt;&lt;span style="background:#ffffff;"&gt;214&lt;/span&gt;&lt;span style="background:#ffffff;"&gt; million in the first six months of 2022 compared to DKK &lt;/span&gt;&lt;span style="background:#ffffff;"&gt;33&lt;/span&gt;&lt;span style="background:#ffffff;"&gt; million in the first six months of 2021. The change was driven&#160;by the decrease in fair value of Genmab&#x2019;s investment in common shares of CureVac and Bolt.&#160;&lt;/span&gt;&lt;/p&gt;</ifrs-full:DisclosureOfFinanceIncomeExpenseExplanatory>
    <gmab:DisclosureOfFinanceIncomeExpensesTableTextBlock
      contextRef="Duration_1_1_2022_To_6_30_2022_dNPMG5n7t0WcNVF9KG4Bdw"
      id="Tb_chB1aFF23Ui5BE3G3VKAGQ">&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:57.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.69%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.66%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.69%;background:#e6e6e6;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;6 Months Ended&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;6 Months Ended&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.69%;background:#e6e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;June 30, 2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;June 30, 2021&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;(DKK million)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.69%;background:#e6e6e6;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.69%;background:#e7e6e6;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Financial income:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.69%;background:#e7e6e6;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Interest and other financial income&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.69%;background:#e7e6e6;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 87&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 127&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Foreign exchange rate gain, net&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.69%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 1,792&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 573&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.69%;background:#e7e6e6;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &lt;/b&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &lt;/b&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total financial income&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.69%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 1,879&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 700&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.69%;background:#e7e6e6;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Financial expenses:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.69%;background:#e7e6e6;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Interest and other financial expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.69%;background:#e7e6e6;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (10)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (6)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Loss on marketable securities, net&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.69%;background:#e7e6e6;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (315)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (134)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Loss on other investments, net&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.69%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (214)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (33)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.69%;background:#e7e6e6;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total financial expenses&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.69%;background:#e6e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; (539)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; (173)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.69%;background:#e6e6e6;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Net financial items&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.69%;background:#e6e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 1,340&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 527&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</gmab:DisclosureOfFinanceIncomeExpensesTableTextBlock>
    <gmab:InterestAndOtherFinancialIncome
      contextRef="Duration_1_1_2022_To_6_30_2022_dNPMG5n7t0WcNVF9KG4Bdw"
      decimals="-6"
      id="Tc_UQ4UgRpSTUybjIJMGgj-jg_6_2"
      unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg">87000000</gmab:InterestAndOtherFinancialIncome>
    <gmab:InterestAndOtherFinancialIncome
      contextRef="Duration_1_1_2021_To_6_30_2021_MRS0_D_onUCNBOxf7Qx_Cw"
      decimals="-6"
      id="Tc_EEMWg_qX4k-JXujVj2qACQ_6_4"
      unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg">127000000</gmab:InterestAndOtherFinancialIncome>
    <ifrs-full:NetForeignExchangeGain
      contextRef="Duration_1_1_2022_To_6_30_2022_dNPMG5n7t0WcNVF9KG4Bdw"
      decimals="-6"
      id="Tc_vKnD3EdTMU2sZN85qQqhlg_7_2"
      unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg">1792000000</ifrs-full:NetForeignExchangeGain>
    <ifrs-full:NetForeignExchangeGain
      contextRef="Duration_1_1_2021_To_6_30_2021_MRS0_D_onUCNBOxf7Qx_Cw"
      decimals="-6"
      id="Tc_GIIJITqw10aXHH5sIqQnow_7_4"
      unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg">573000000</ifrs-full:NetForeignExchangeGain>
    <ifrs-full:FinanceIncome
      contextRef="Duration_1_1_2022_To_6_30_2022_dNPMG5n7t0WcNVF9KG4Bdw"
      decimals="-6"
      id="Tc_uH7VtLD3dECv4AnVM_Z30w_9_2"
      unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg">1879000000</ifrs-full:FinanceIncome>
    <ifrs-full:FinanceIncome
      contextRef="Duration_1_1_2021_To_6_30_2021_MRS0_D_onUCNBOxf7Qx_Cw"
      decimals="-6"
      id="Tc_5-f5HmHzskOvY4sBc1Hwzg_9_4"
      unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg">700000000</ifrs-full:FinanceIncome>
    <gmab:InterestAndOtherFinancialExpenses
      contextRef="Duration_1_1_2022_To_6_30_2022_dNPMG5n7t0WcNVF9KG4Bdw"
      decimals="-6"
      id="Tc_aocd7lOMmkKxaDWDdRwRzw_12_2"
      unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg">10000000</gmab:InterestAndOtherFinancialExpenses>
    <gmab:InterestAndOtherFinancialExpenses
      contextRef="Duration_1_1_2021_To_6_30_2021_MRS0_D_onUCNBOxf7Qx_Cw"
      decimals="-6"
      id="Tc_86BSbl45gUe7ydA2BOqhJw_12_4"
      unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg">6000000</gmab:InterestAndOtherFinancialExpenses>
    <gmab:LossesOnMarketableSecurities
      contextRef="Duration_1_1_2022_To_6_30_2022_dNPMG5n7t0WcNVF9KG4Bdw"
      decimals="-6"
      id="Tc_Gho02hPpO0GVWyHI_70-vg_13_2"
      unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg">315000000</gmab:LossesOnMarketableSecurities>
    <gmab:LossesOnMarketableSecurities
      contextRef="Duration_1_1_2021_To_6_30_2021_MRS0_D_onUCNBOxf7Qx_Cw"
      decimals="-6"
      id="Tc_euYOdXooQUyG6z6x1QQTZA_13_4"
      unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg">134000000</gmab:LossesOnMarketableSecurities>
    <gmab:LossesOnOtherInvestmentsNet
      contextRef="Duration_1_1_2022_To_6_30_2022_dNPMG5n7t0WcNVF9KG4Bdw"
      decimals="-6"
      id="Tc_lm6on6VfRkO5PkxSW9K5wQ_14_2"
      unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg">214000000</gmab:LossesOnOtherInvestmentsNet>
    <gmab:LossesOnOtherInvestmentsNet
      contextRef="Duration_1_1_2021_To_6_30_2021_MRS0_D_onUCNBOxf7Qx_Cw"
      decimals="-6"
      id="Tc_6bbsrPplV0SzsJoEpm7q-Q_14_4"
      unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg">33000000</gmab:LossesOnOtherInvestmentsNet>
    <ifrs-full:FinanceCosts
      contextRef="Duration_1_1_2022_To_6_30_2022_dNPMG5n7t0WcNVF9KG4Bdw"
      decimals="-6"
      id="Tc_56wJCp_vsk-J4BRWBykKbw_16_2"
      unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg">539000000</ifrs-full:FinanceCosts>
    <ifrs-full:FinanceCosts
      contextRef="Duration_1_1_2021_To_6_30_2021_MRS0_D_onUCNBOxf7Qx_Cw"
      decimals="-6"
      id="Tc_ar8pilXT90Oq7GJidihDIg_16_4"
      unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg">173000000</ifrs-full:FinanceCosts>
    <ifrs-full:FinanceIncomeCost
      contextRef="Duration_1_1_2022_To_6_30_2022_dNPMG5n7t0WcNVF9KG4Bdw"
      decimals="-6"
      id="Tc_FDjGwcKupk6OoCy-r6S06w_18_2"
      unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg">1340000000</ifrs-full:FinanceIncomeCost>
    <ifrs-full:FinanceIncomeCost
      contextRef="Duration_1_1_2021_To_6_30_2021_MRS0_D_onUCNBOxf7Qx_Cw"
      decimals="-6"
      id="Tc_k9PLJ3l8b0qGVBr0twW7SA_18_4"
      unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg">527000000</ifrs-full:FinanceIncomeCost>
    <ifrs-full:NetForeignExchangeGain
      contextRef="Duration_1_1_2022_To_6_30_2022_dNPMG5n7t0WcNVF9KG4Bdw"
      decimals="-6"
      id="Narr_-yBjmymaok6ynfdktj2HEQ"
      unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg">1792000000</ifrs-full:NetForeignExchangeGain>
    <ifrs-full:NetForeignExchangeGain
      contextRef="Duration_1_1_2021_To_6_30_2021_MRS0_D_onUCNBOxf7Qx_Cw"
      decimals="-6"
      id="Narr_bi3mP7ptfkOIXzvc8TqI2Q"
      unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg">573000000</ifrs-full:NetForeignExchangeGain>
    <gmab:LossesOnMarketableSecurities
      contextRef="Duration_1_1_2022_To_6_30_2022_dNPMG5n7t0WcNVF9KG4Bdw"
      decimals="-6"
      id="Narr_-F6sJSQwKkeRW8Eo4piyYQ"
      unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg">315000000</gmab:LossesOnMarketableSecurities>
    <gmab:LossesOnMarketableSecurities
      contextRef="Duration_1_1_2021_To_6_30_2021_MRS0_D_onUCNBOxf7Qx_Cw"
      decimals="-6"
      id="Narr_Xjz56Rj7UUqVtQqdNl_bSg"
      unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg">134000000</gmab:LossesOnMarketableSecurities>
    <gmab:LossesOnOtherInvestmentsNet
      contextRef="Duration_1_1_2022_To_6_30_2022_dNPMG5n7t0WcNVF9KG4Bdw"
      decimals="-6"
      id="Narr_9okgvapJgkO7KL7jbHDEfA"
      unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg">214000000</gmab:LossesOnOtherInvestmentsNet>
    <gmab:LossesOnOtherInvestmentsNet
      contextRef="Duration_1_1_2021_To_6_30_2021_MRS0_D_onUCNBOxf7Qx_Cw"
      decimals="-6"
      id="Narr_HaPoKeOxjkGW5f6Aaq8BGQ"
      unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg">33000000</gmab:LossesOnOtherInvestmentsNet>
    <ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory
      contextRef="Duration_1_1_2022_To_6_30_2022_dNPMG5n7t0WcNVF9KG4Bdw"
      id="Tb_8wFGEOrLlkS6G4ICEnJvZA">&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="color:#029c93;font-weight:bold;"&gt;Note 5 &#x2013; Share-Based Instruments&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#029c93;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Restricted Stock Unit Program&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Genmab A/S established RSU programs as an incentive for all Genmab employees, members of the registered Executive Management, and members of the Board of Directors. &lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:57.58%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.21%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.54%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:57.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8.5pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8.5pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.21%;background:#e6e6e6;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8.5pt;"&gt;6 Months Ended&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8.5pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8.5pt;"&gt;6 Months Ended&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:57.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8.5pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8.5pt;"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.21%;background:#e6e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8.5pt;"&gt;June 30, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8.5pt;"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8.5pt;"&gt;June 30, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:57.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&lt;span style="font-size:8.5pt;"&gt;RSUs granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8.5pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.21%;background:#e7e6e6;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;span style="font-size:8.5pt;"&gt; 240,741&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8.5pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;span style="font-size:8.5pt;"&gt; 159,567&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:57.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&lt;i style="font-size:8.5pt;font-style:italic;"&gt;Weighted average fair value per RSU granted (DKK) &lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8.5pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.21%;background:#e7e6e6;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;i style="font-size:8.5pt;font-style:italic;"&gt; 2,178.22&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8.5pt;font-style:italic;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;i style="font-size:8.5pt;font-style:italic;"&gt; 2,149.55&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:57.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8.5pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8.5pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.21%;background:#e7e6e6;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:8.5pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8.5pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:8.5pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:57.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&lt;span style="font-size:8.5pt;"&gt;RSUs vested&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8.5pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.21%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;span style="font-size:8.5pt;"&gt; 82,001&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8.5pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;span style="font-size:8.5pt;"&gt; 49,012&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Refer to Note 4.6 in the Annual Report for details on the RSU programs.&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Warrant Program&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Genmab A/S established warrant programs as an incentive for all Genmab employees, and members of the registered Executive Management.&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:63.09%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.61%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.99%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:63.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8.5pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8.5pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.61%;background:#e6e6e6;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8.5pt;"&gt;6 Months Ended&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8.5pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8.5pt;"&gt;6 Months Ended&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:63.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8.5pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8.5pt;"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.61%;background:#e6e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8.5pt;"&gt;June 30, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8.5pt;"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8.5pt;"&gt;June 30, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:63.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&lt;span style="font-size:8.5pt;"&gt;Warrants granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8.5pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.61%;background:#e7e6e6;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;span style="font-size:8.5pt;"&gt; 230,112&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8.5pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;span style="font-size:8.5pt;"&gt; 147,568&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:63.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&lt;i style="font-size:8.5pt;font-style:italic;"&gt;Weighted average exercise price per warrant granted (DKK) &lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8.5pt;font-style:italic;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.61%;background:#e7e6e6;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;i style="font-size:8.5pt;font-style:italic;"&gt; 2,178.40&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8.5pt;font-style:italic;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;i style="font-size:8.5pt;font-style:italic;"&gt; 2,189.21&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:63.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&lt;i style="font-size:8.5pt;font-style:italic;"&gt;Weighted average Black-Scholes fair value per warrant granted (DKK) &lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8.5pt;font-style:italic;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.61%;background:#e7e6e6;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;i style="font-size:8.5pt;font-style:italic;"&gt; 629.05&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8.5pt;font-style:italic;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;i style="font-size:8.5pt;font-style:italic;"&gt; 683.79&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:63.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8.5pt;font-style:italic;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8.5pt;font-style:italic;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.61%;background:#e7e6e6;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:8.5pt;font-style:italic;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8.5pt;font-style:italic;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:8.5pt;font-style:italic;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:63.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&lt;span style="font-size:8.5pt;"&gt;Warrants exercised&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8.5pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.61%;background:#e7e6e6;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;span style="font-size:8.5pt;"&gt; 34,987&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8.5pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;span style="font-size:8.5pt;"&gt; 74,992&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:63.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&lt;i style="font-size:8.5pt;font-style:italic;"&gt;Weighted average exercise price on date of grant per warrant exercised (DKK)&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8.5pt;font-style:italic;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.61%;background:#e7e6e6;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;i style="font-size:8.5pt;font-style:italic;"&gt; 983.98&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8.5pt;font-style:italic;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;i style="font-size:8.5pt;font-style:italic;"&gt; 606.22&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:63.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&lt;i style="font-size:8.5pt;font-style:italic;"&gt;% change in share capital - warrants exercised&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8.5pt;font-style:italic;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.61%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;i style="font-size:8.5pt;font-style:italic;"&gt;0.05%&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8.5pt;font-style:italic;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;i style="font-size:8.5pt;font-style:italic;"&gt;0.11%&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Refer to Note 4.6 in the Annual Report for details on the warrant programs.&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Share-based compensation expense&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:11.0pt;text-indent:0pt;margin:0pt 36pt 11pt 0pt;"&gt;Share-based compensation expenses related to Genmab RSU and warrant programs for the first six months of 2022 was DKK 208 million compared to DKK 142 million for the first six months of 2021. &lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Share repurchases&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;In general, Genmab intends to purchase its own shares in order to cover a portion of obligations in relation to RSUs. As of June 30, 2022, Genmab has two authorizations to repurchase shares: the 2021 and 2019 authorizations. The 2016 authorization expired in March 2021. &lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:49.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:14.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:15.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:15.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:49.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:14.63%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;2021 &lt;br/&gt;Authorization&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:15.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;2019 &lt;br/&gt;Authorization&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:15.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;2016 &lt;br/&gt;Authorization&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:49.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Number of shares authorized for repurchase&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.63%;background:#e7e6e6;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 500,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 500,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 500,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:49.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Actual shares repurchased under authorization&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.63%;background:#e7e6e6;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 294,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 255,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:49.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Shares available for repurchase as of June 30, 2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.63%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 500,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 206,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;As announced on June 17, 2022, Genmab initiated a share buy-back program. During the first six months of 2022, Genmab acquired 124,000 of its own shares, representing approximately 0.2% of share capital as of December 31, 2021. The total amount paid to acquire the shares, including directly attributable costs, was DKK 270 million and was recognized as a deduction to shareholders&#x2019; equity. During the first six months of 2021, Genmab acquired 200,000 of its own shares, representing approximately 0.3% of share capital as of December 31, 2020. The total amount paid to acquire the shares, including directly attributable costs, was DKK 447 million and was recognized as a deduction to shareholders&#x2019; equity. These shares are classified as treasury shares and are presented within retained earnings on the balance sheet as of June 30, 2022.&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"&gt;As of June 30, 2022, 357,885 treasury shares were held by Genmab to cover obligations in relation to the RSU programs and to mitigate the dilutive effect of share capital increases resulting from future exercises of warrants.&lt;/p&gt;</ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory>
    <ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory
      contextRef="Duration_1_1_2022_To_6_30_2022_dNPMG5n7t0WcNVF9KG4Bdw"
      id="Tb_NEmt93u8N0GI9XqxiKs17A">&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:57.58%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.21%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.54%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:57.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8.5pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8.5pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.21%;background:#e6e6e6;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8.5pt;"&gt;6 Months Ended&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8.5pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8.5pt;"&gt;6 Months Ended&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:57.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8.5pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8.5pt;"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.21%;background:#e6e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8.5pt;"&gt;June 30, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8.5pt;"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8.5pt;"&gt;June 30, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:57.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&lt;span style="font-size:8.5pt;"&gt;RSUs granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8.5pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.21%;background:#e7e6e6;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;span style="font-size:8.5pt;"&gt; 240,741&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8.5pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;span style="font-size:8.5pt;"&gt; 159,567&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:57.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&lt;i style="font-size:8.5pt;font-style:italic;"&gt;Weighted average fair value per RSU granted (DKK) &lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8.5pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.21%;background:#e7e6e6;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;i style="font-size:8.5pt;font-style:italic;"&gt; 2,178.22&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8.5pt;font-style:italic;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;i style="font-size:8.5pt;font-style:italic;"&gt; 2,149.55&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:57.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8.5pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8.5pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.21%;background:#e7e6e6;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:8.5pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8.5pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:8.5pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:57.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&lt;span style="font-size:8.5pt;"&gt;RSUs vested&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8.5pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.21%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;span style="font-size:8.5pt;"&gt; 82,001&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8.5pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;span style="font-size:8.5pt;"&gt; 49,012&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="Duration_1_1_2022_To_6_30_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_gmab_IfrsRestrictedStockUnitsRSUsMember_4-5BFoS8HkmkHqZSV1-skg"
      decimals="INF"
      id="Tc_3wCY4gYu5kq2yRWtzwct4Q_3_2"
      unitRef="Unit_Standard_EquityInstruments_bRFAkAsdz0ugOZctjovS4A">240741</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="Duration_1_1_2021_To_6_30_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_gmab_IfrsRestrictedStockUnitsRSUsMember_XTrx_EPo2kixh36V-j_AVw"
      decimals="INF"
      id="Tc_Vet3RymnW02KqmU9Yn7jgg_3_4"
      unitRef="Unit_Standard_EquityInstruments_bRFAkAsdz0ugOZctjovS4A">159567</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <gmab:Weightedaveragefairvalueofotherequityinstrumentsgrantedinsharebasedpaymentarrangement
      contextRef="Duration_1_1_2022_To_6_30_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_gmab_IfrsRestrictedStockUnitsRSUsMember_4-5BFoS8HkmkHqZSV1-skg"
      decimals="2"
      id="Tc_4VDE6ePlo0m_SKaaNlmZEg_4_2"
      unitRef="Unit_Divide_DKK_shares_uaEdw-3-XkitvcC2Swh0EQ">2178.22</gmab:Weightedaveragefairvalueofotherequityinstrumentsgrantedinsharebasedpaymentarrangement>
    <gmab:Weightedaveragefairvalueofotherequityinstrumentsgrantedinsharebasedpaymentarrangement
      contextRef="Duration_1_1_2021_To_6_30_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_gmab_IfrsRestrictedStockUnitsRSUsMember_XTrx_EPo2kixh36V-j_AVw"
      decimals="2"
      id="Tc_zZpJbWn3CkuVrWJHnDU4pg_4_4"
      unitRef="Unit_Divide_DKK_shares_uaEdw-3-XkitvcC2Swh0EQ">2149.55</gmab:Weightedaveragefairvalueofotherequityinstrumentsgrantedinsharebasedpaymentarrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement
      contextRef="Duration_1_1_2022_To_6_30_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_gmab_IfrsRestrictedStockUnitsRSUsMember_4-5BFoS8HkmkHqZSV1-skg"
      decimals="INF"
      id="Tc_O81ExK3GT0aYnl63-l67jA_6_2"
      unitRef="Unit_Standard_EquityInstruments_bRFAkAsdz0ugOZctjovS4A">82001</ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement
      contextRef="Duration_1_1_2021_To_6_30_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_gmab_IfrsRestrictedStockUnitsRSUsMember_XTrx_EPo2kixh36V-j_AVw"
      decimals="INF"
      id="Tc_v690y_2Ei0CwtCNozZe4kQ_6_4"
      unitRef="Unit_Standard_EquityInstruments_bRFAkAsdz0ugOZctjovS4A">49012</ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement>
    <gmab:DisclosureOfWarrantsActivityTableTextBlock
      contextRef="Duration_1_1_2022_To_6_30_2022_dNPMG5n7t0WcNVF9KG4Bdw"
      id="Tb_jLUoFwcip0WRTM-0aqIUjw">&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:63.09%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.61%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.99%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:63.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8.5pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8.5pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.61%;background:#e6e6e6;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8.5pt;"&gt;6 Months Ended&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8.5pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8.5pt;"&gt;6 Months Ended&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:63.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8.5pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8.5pt;"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.61%;background:#e6e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8.5pt;"&gt;June 30, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8.5pt;"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8.5pt;"&gt;June 30, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:63.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&lt;span style="font-size:8.5pt;"&gt;Warrants granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8.5pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.61%;background:#e7e6e6;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;span style="font-size:8.5pt;"&gt; 230,112&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8.5pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;span style="font-size:8.5pt;"&gt; 147,568&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:63.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&lt;i style="font-size:8.5pt;font-style:italic;"&gt;Weighted average exercise price per warrant granted (DKK) &lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8.5pt;font-style:italic;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.61%;background:#e7e6e6;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;i style="font-size:8.5pt;font-style:italic;"&gt; 2,178.40&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8.5pt;font-style:italic;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;i style="font-size:8.5pt;font-style:italic;"&gt; 2,189.21&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:63.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&lt;i style="font-size:8.5pt;font-style:italic;"&gt;Weighted average Black-Scholes fair value per warrant granted (DKK) &lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8.5pt;font-style:italic;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.61%;background:#e7e6e6;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;i style="font-size:8.5pt;font-style:italic;"&gt; 629.05&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8.5pt;font-style:italic;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;i style="font-size:8.5pt;font-style:italic;"&gt; 683.79&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:63.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8.5pt;font-style:italic;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8.5pt;font-style:italic;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.61%;background:#e7e6e6;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:8.5pt;font-style:italic;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8.5pt;font-style:italic;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:8.5pt;font-style:italic;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:63.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&lt;span style="font-size:8.5pt;"&gt;Warrants exercised&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8.5pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.61%;background:#e7e6e6;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;span style="font-size:8.5pt;"&gt; 34,987&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8.5pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;span style="font-size:8.5pt;"&gt; 74,992&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:63.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&lt;i style="font-size:8.5pt;font-style:italic;"&gt;Weighted average exercise price on date of grant per warrant exercised (DKK)&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8.5pt;font-style:italic;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.61%;background:#e7e6e6;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;i style="font-size:8.5pt;font-style:italic;"&gt; 983.98&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8.5pt;font-style:italic;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;i style="font-size:8.5pt;font-style:italic;"&gt; 606.22&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:63.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"&gt;&lt;i style="font-size:8.5pt;font-style:italic;"&gt;% change in share capital - warrants exercised&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8.5pt;font-style:italic;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.61%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;i style="font-size:8.5pt;font-style:italic;"&gt;0.05%&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8.5pt;font-style:italic;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;i style="font-size:8.5pt;font-style:italic;"&gt;0.11%&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</gmab:DisclosureOfWarrantsActivityTableTextBlock>
    <gmab:NumberOfWarrantsGrantedDuringPeriod
      contextRef="Duration_1_1_2022_To_6_30_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_gmab_WarrantsMember_kH0r0sIdkU-S9yq6_erZfw"
      decimals="INF"
      id="Tc_BP6V1d2eF0Os2a4GxVnixA_3_2"
      unitRef="Unit_Standard_shares_MrgY4vrrEUeN62nRwu-ZLA">230112</gmab:NumberOfWarrantsGrantedDuringPeriod>
    <gmab:NumberOfWarrantsGrantedDuringPeriod
      contextRef="Duration_1_1_2021_To_6_30_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_gmab_WarrantsMember_sN8RX4-cR0-kSMFNCobg0Q"
      decimals="INF"
      id="Tc_m9w_9HTojE67Rm-RzdV0KQ_3_4"
      unitRef="Unit_Standard_shares_MrgY4vrrEUeN62nRwu-ZLA">147568</gmab:NumberOfWarrantsGrantedDuringPeriod>
    <gmab:WeightedAverageExercisePriceOfWarrantsGranted
      contextRef="Duration_1_1_2022_To_6_30_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_gmab_WarrantsMember_kH0r0sIdkU-S9yq6_erZfw"
      decimals="2"
      id="Tc_w_XZ0TbsaUOe3VTG_nWagg_4_2"
      unitRef="Unit_Divide_DKK_shares_uaEdw-3-XkitvcC2Swh0EQ">2178.40</gmab:WeightedAverageExercisePriceOfWarrantsGranted>
    <gmab:WeightedAverageExercisePriceOfWarrantsGranted
      contextRef="Duration_1_1_2021_To_6_30_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_gmab_WarrantsMember_sN8RX4-cR0-kSMFNCobg0Q"
      decimals="2"
      id="Tc_oxr4f8uqh0ysclOLbDDvOA_4_4"
      unitRef="Unit_Divide_DKK_shares_uaEdw-3-XkitvcC2Swh0EQ">2189.21</gmab:WeightedAverageExercisePriceOfWarrantsGranted>
    <gmab:WeightedAverageExercisePriceOfFairValueOfWarrants
      contextRef="Duration_1_1_2022_To_6_30_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_gmab_WarrantsMember_kH0r0sIdkU-S9yq6_erZfw"
      decimals="2"
      id="Tc_u5i_vX8UYUSh7eCfjyMqrg_5_2"
      unitRef="Unit_Divide_DKK_shares_uaEdw-3-XkitvcC2Swh0EQ">629.05</gmab:WeightedAverageExercisePriceOfFairValueOfWarrants>
    <gmab:WeightedAverageExercisePriceOfFairValueOfWarrants
      contextRef="Duration_1_1_2021_To_6_30_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_gmab_WarrantsMember_sN8RX4-cR0-kSMFNCobg0Q"
      decimals="2"
      id="Tc_5f8uC3r3BUmicAHiaXo5vA_5_4"
      unitRef="Unit_Divide_DKK_shares_uaEdw-3-XkitvcC2Swh0EQ">683.79</gmab:WeightedAverageExercisePriceOfFairValueOfWarrants>
    <gmab:NumberOfWarrantsExercisedDuringPeriod
      contextRef="Duration_1_1_2022_To_6_30_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_gmab_WarrantsMember_kH0r0sIdkU-S9yq6_erZfw"
      decimals="INF"
      id="Tc_nplCpQSFZUGuQB9Buq-S1A_7_2"
      unitRef="Unit_Standard_shares_MrgY4vrrEUeN62nRwu-ZLA">34987</gmab:NumberOfWarrantsExercisedDuringPeriod>
    <gmab:NumberOfWarrantsExercisedDuringPeriod
      contextRef="Duration_1_1_2021_To_6_30_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_gmab_WarrantsMember_sN8RX4-cR0-kSMFNCobg0Q"
      decimals="INF"
      id="Tc_nA6qNWoNHEqVvZPNCvi0sg_7_4"
      unitRef="Unit_Standard_shares_MrgY4vrrEUeN62nRwu-ZLA">74992</gmab:NumberOfWarrantsExercisedDuringPeriod>
    <gmab:WeightedAverageExercisePriceOfWarrantsExercised
      contextRef="Duration_1_1_2022_To_6_30_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_gmab_WarrantsMember_kH0r0sIdkU-S9yq6_erZfw"
      decimals="2"
      id="Tc_2NE3av02bkKIigCzSjWR-A_8_2"
      unitRef="Unit_Divide_DKK_shares_uaEdw-3-XkitvcC2Swh0EQ">983.98</gmab:WeightedAverageExercisePriceOfWarrantsExercised>
    <gmab:WeightedAverageExercisePriceOfWarrantsExercised
      contextRef="Duration_1_1_2021_To_6_30_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_gmab_WarrantsMember_sN8RX4-cR0-kSMFNCobg0Q"
      decimals="2"
      id="Tc_TRQX923kZ0mkSFSOsFCxFg_8_4"
      unitRef="Unit_Divide_DKK_shares_uaEdw-3-XkitvcC2Swh0EQ">606.22</gmab:WeightedAverageExercisePriceOfWarrantsExercised>
    <gmab:PercentageOfShareCapitalAttributedToExerciseOfWarrants
      contextRef="Duration_1_1_2022_To_6_30_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_gmab_WarrantsMember_kH0r0sIdkU-S9yq6_erZfw"
      decimals="4"
      id="Tc_s0_xESGFG0ejeTl7h30RRg_9_2"
      unitRef="Unit_Standard_pure_ydC7mNX6akalcP_kj1H8wg">0.0005</gmab:PercentageOfShareCapitalAttributedToExerciseOfWarrants>
    <gmab:PercentageOfShareCapitalAttributedToExerciseOfWarrants
      contextRef="Duration_1_1_2021_To_6_30_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_gmab_WarrantsMember_sN8RX4-cR0-kSMFNCobg0Q"
      decimals="4"
      id="Tc_UHwWc4PCMU6oXiEkoK1Mkg_9_4"
      unitRef="Unit_Standard_pure_ydC7mNX6akalcP_kj1H8wg">0.0011</gmab:PercentageOfShareCapitalAttributedToExerciseOfWarrants>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets
      contextRef="Duration_1_1_2022_To_6_30_2022_dNPMG5n7t0WcNVF9KG4Bdw"
      decimals="-6"
      id="Narr_0_C6Dtxxy0CGfuY4mariDg"
      unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg">208000000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets
      contextRef="Duration_1_1_2021_To_6_30_2021_MRS0_D_onUCNBOxf7Qx_Cw"
      decimals="-6"
      id="Narr_NTYDFcd1o0iJeEXEd5xGKQ"
      unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg">142000000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets>
    <gmab:ShareBasedArrangementNumberOfAuthorization
      contextRef="Duration_1_1_2022_To_6_30_2022_dNPMG5n7t0WcNVF9KG4Bdw"
      decimals="INF"
      id="Narr_iWk-gF53FEiJu3fu7UAtJg"
      unitRef="Unit_Standard_item_d-Yn30W8q0CdLFqZ4zWe8g">2</gmab:ShareBasedArrangementNumberOfAuthorization>
    <gmab:ScheduleOfShareRepurchasesTableTextBlock
      contextRef="Duration_1_1_2022_To_6_30_2022_dNPMG5n7t0WcNVF9KG4Bdw"
      id="Tb_4LmmJNnYlEGkjGXRi42bNw">&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:49.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:14.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:15.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:15.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:49.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:14.63%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;2021 &lt;br/&gt;Authorization&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:15.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;2019 &lt;br/&gt;Authorization&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:15.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;2016 &lt;br/&gt;Authorization&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:49.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Number of shares authorized for repurchase&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.63%;background:#e7e6e6;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 500,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 500,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 500,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:49.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Actual shares repurchased under authorization&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.63%;background:#e7e6e6;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 294,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 255,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:49.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Shares available for repurchase as of June 30, 2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.63%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 500,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 206,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</gmab:ScheduleOfShareRepurchasesTableTextBlock>
    <gmab:NumberOfSharesAuthorizedToBeRepurchased
      contextRef="As_Of_6_30_2022_srt_StatementScenarioAxis_gmab_StockRepurchaseAuthorization2021Member_ll839TqkPUSnSuKvpYFvXQ"
      decimals="INF"
      id="Tc_lk5283eMY0SV7nznOKH-Eg_2_2"
      unitRef="Unit_Standard_shares_MrgY4vrrEUeN62nRwu-ZLA">500000</gmab:NumberOfSharesAuthorizedToBeRepurchased>
    <gmab:NumberOfSharesAuthorizedToBeRepurchased
      contextRef="As_Of_6_30_2022_srt_StatementScenarioAxis_gmab_StockRepurchaseAuthorization2019Member_Ey8o8eyD7UaKwBJF-khG6w"
      decimals="INF"
      id="Tc_NwwmoudN0Eq2HCXW0yvYtQ_2_4"
      unitRef="Unit_Standard_shares_MrgY4vrrEUeN62nRwu-ZLA">500000</gmab:NumberOfSharesAuthorizedToBeRepurchased>
    <gmab:NumberOfSharesAuthorizedToBeRepurchased
      contextRef="As_Of_6_30_2022_srt_StatementScenarioAxis_gmab_StockRepurchaseAuthorization2016Member_rs9bpzaf80uIoq7-Gcmw6w"
      decimals="INF"
      id="Tc_V8vufYQbD0OJaJTFYNlkIA_2_6"
      unitRef="Unit_Standard_shares_MrgY4vrrEUeN62nRwu-ZLA">500000</gmab:NumberOfSharesAuthorizedToBeRepurchased>
    <gmab:ShareRepurchasedDuringPeriodShares
      contextRef="Duration_1_1_2022_To_6_30_2022_srt_StatementScenarioAxis_gmab_StockRepurchaseAuthorization2019Member_xfwDxjqmW02JCqvKbHtBaQ"
      decimals="INF"
      id="Tc_HW2HqBYZskeKQXoc16JlGg_3_4"
      unitRef="Unit_Standard_shares_MrgY4vrrEUeN62nRwu-ZLA">294000</gmab:ShareRepurchasedDuringPeriodShares>
    <gmab:ShareRepurchasedDuringPeriodShares
      contextRef="Duration_1_1_2022_To_6_30_2022_srt_StatementScenarioAxis_gmab_StockRepurchaseAuthorization2016Member_mmhw2ICcwkqWFdCPJ6rVhw"
      decimals="INF"
      id="Tc_t97WbSmo60qeTd1KZwp28w_3_6"
      unitRef="Unit_Standard_shares_MrgY4vrrEUeN62nRwu-ZLA">255000</gmab:ShareRepurchasedDuringPeriodShares>
    <gmab:SharesAvailableForRepurchase
      contextRef="Duration_1_1_2022_To_6_30_2022_srt_StatementScenarioAxis_gmab_StockRepurchaseAuthorization2021Member_rWOMBYvakU6yGwmAnDi9_w"
      decimals="INF"
      id="Tc_4qyHxVRPzUq9xItN0cuQKQ_4_2"
      unitRef="Unit_Standard_shares_MrgY4vrrEUeN62nRwu-ZLA">500000</gmab:SharesAvailableForRepurchase>
    <gmab:SharesAvailableForRepurchase
      contextRef="Duration_1_1_2022_To_6_30_2022_srt_StatementScenarioAxis_gmab_StockRepurchaseAuthorization2019Member_xfwDxjqmW02JCqvKbHtBaQ"
      decimals="INF"
      id="Tc_ep-LdCpiRkSwtgNSluQipA_4_4"
      unitRef="Unit_Standard_shares_MrgY4vrrEUeN62nRwu-ZLA">206000</gmab:SharesAvailableForRepurchase>
    <gmab:TreasurySharesAcquired
      contextRef="Duration_1_1_2022_To_6_30_2022_dNPMG5n7t0WcNVF9KG4Bdw"
      decimals="INF"
      id="Narr_oIFJ60l7hUGwz1hVXPwkgQ"
      unitRef="Unit_Standard_shares_MrgY4vrrEUeN62nRwu-ZLA">124000</gmab:TreasurySharesAcquired>
    <gmab:PercentageOfShareCapitalRepurchased
      contextRef="As_Of_12_31_2021_yeBwiJf1M0aAa25fFQy9Bg"
      decimals="3"
      id="Narr_GDsfVP5DbUaOn53aL1VpnQ"
      unitRef="Unit_Standard_pure_ydC7mNX6akalcP_kj1H8wg">0.002</gmab:PercentageOfShareCapitalRepurchased>
    <ifrs-full:PurchaseOfTreasuryShares
      contextRef="Duration_1_1_2022_To_6_30_2022_dNPMG5n7t0WcNVF9KG4Bdw"
      decimals="-6"
      id="Narr_Ap97m7GHZE6gnRKPjOfAAQ"
      unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg">270000000</ifrs-full:PurchaseOfTreasuryShares>
    <gmab:TreasurySharesAcquired
      contextRef="Duration_1_1_2021_To_6_30_2021_MRS0_D_onUCNBOxf7Qx_Cw"
      decimals="INF"
      id="Narr_jwfdPKDKx0iG21yrvStogg"
      unitRef="Unit_Standard_shares_MrgY4vrrEUeN62nRwu-ZLA">200000</gmab:TreasurySharesAcquired>
    <gmab:PercentageOfShareCapitalRepurchased
      contextRef="As_Of_12_31_2020_ccHyN2oOokuDhNdvPg9fRQ"
      decimals="3"
      id="Narr_1ZBNS4gNzkS0gLGQjGFnwA"
      unitRef="Unit_Standard_pure_ydC7mNX6akalcP_kj1H8wg">0.003</gmab:PercentageOfShareCapitalRepurchased>
    <ifrs-full:PurchaseOfTreasuryShares
      contextRef="Duration_1_1_2021_To_6_30_2021_MRS0_D_onUCNBOxf7Qx_Cw"
      decimals="-6"
      id="Narr_gkYP3vElV06OtxXwyONakQ"
      unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg">447000000</ifrs-full:PurchaseOfTreasuryShares>
    <gmab:TreasurySharesAcquired
      contextRef="Duration_1_1_2022_To_6_30_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_gmab_RestrictedStockUnitsRSUsMember_9ULLlFPCsE2o9A92MVOndw"
      decimals="INF"
      id="Narr_hxrBqrbIKkqGdPhjByPrJw"
      unitRef="Unit_Standard_shares_MrgY4vrrEUeN62nRwu-ZLA">357885</gmab:TreasurySharesAcquired>
    <ifrs-full:DisclosureOfRelatedPartyExplanatory
      contextRef="Duration_1_1_2022_To_6_30_2022_dNPMG5n7t0WcNVF9KG4Bdw"
      id="Tb_vAX7-KJ6yU-rd5j2l8DjWw">&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="color:#029c93;font-weight:bold;"&gt;Note 6 &#x2013; Related Parties&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Genmab&#x2019;s related parties are Genmab A/S&#x2019; (parent company) subsidiaries, Board of Directors, the registered Executive Management, and close members of the family of these persons. &lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Genmab has not granted any loans, guarantees or other commitments to or on behalf of any of the members of the Board of Directors or members of the registered Executive Management.&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Other than the remuneration and other transactions relating to the Board of Directors and the registered Executive Management described in Note&#160;5.1 in the Annual Report, there were no material related party transactions during the first six months of 2022.&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Changes to the Executive Management Team and the Board of Directors&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;During the first six months of 2022, there were two changes to the Executive Management Team. Effective March 1, 2022, Chris Cozic was appointed Executive Vice President and Chief People Officer, and Birgitte Stephensen was appointed Executive Vice President and Chief Legal Officer. They join the existing Executive Management Team of Jan van de Winkel, President and Chief Executive Officer, Judith Klimovsky, Executive Vice President and Chief Development Officer, Anthony Pagano, Executive Vice President and Chief Financial Officer, Anthony Mancini, Executive Vice President and Chief Operating Officer, and Tahamtan Ahmadi, Executive Vice President and Chief Medical Officer. Chris Cozic and Birgitte Stephensen are not regarded as executive managers pursuant to the Danish Companies Act and will therefore not be registered with the Danish Business Authority.&#160;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Following Genmab A/S&#x2019; Annual General Meeting on March 29, 2022, the Board of Directors is comprised of five independent board members, one non-independent board member, and three employee-elected board members. Deirdre P. Connelly (Chair), Pernille Erenbjerg (Deputy Chair), Rolf Hoffmann, Dr. Paolo Paoletti, and Dr. Anders Gersel Pedersen were re-elected to the Board of Directors for a one-year period. Elizabeth O&#x2019;Farrell was newly elected for a one-year period. Mijke Zachariasse, Martin Schultz and Takahiro Hamatani were elected to the Board of Directors by the employees for a three-year period. Peter Storm Kristensen and Rima Bawarshi Nassar stepped down from the Board of Directors.&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-style:italic;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;i style="font-style:italic;white-space:pre-wrap;"&gt;  &lt;/i&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</ifrs-full:DisclosureOfRelatedPartyExplanatory>
    <gmab:NumberOfChangesToExecutiveManagementTeam
      contextRef="Duration_1_1_2022_To_6_30_2022_dNPMG5n7t0WcNVF9KG4Bdw"
      decimals="INF"
      id="Narr_Mxlu5INlf0GxEepzCe-o1g"
      unitRef="Unit_Standard_item_d-Yn30W8q0CdLFqZ4zWe8g">2</gmab:NumberOfChangesToExecutiveManagementTeam>
    <gmab:NumberOfIndependentBoardMembers
      contextRef="Duration_3_29_2022_To_3_29_2022_ifrs-full_CategoriesOfRelatedPartiesAxis_ifrs-full_KeyManagementPersonnelOfEntityOrParentMember_wG1K_J98VEKINTE73Xhmyg"
      decimals="INF"
      id="Narr_C9kK-L_B2UK2gafoxTSMgw"
      unitRef="Unit_Standard_director_1-CkTK7-YkaxWNG_tkhy7g">5</gmab:NumberOfIndependentBoardMembers>
    <gmab:NumberOfNonIndependentBoardMembers
      contextRef="Duration_3_29_2022_To_3_29_2022_ifrs-full_CategoriesOfRelatedPartiesAxis_ifrs-full_KeyManagementPersonnelOfEntityOrParentMember_wG1K_J98VEKINTE73Xhmyg"
      decimals="INF"
      id="Narr_sxpAjemCaEKZLRJd7zio7Q"
      unitRef="Unit_Standard_director_1-CkTK7-YkaxWNG_tkhy7g">1</gmab:NumberOfNonIndependentBoardMembers>
    <gmab:NumberOfEmployeeElectedBoardMembers
      contextRef="Duration_3_29_2022_To_3_29_2022_ifrs-full_CategoriesOfRelatedPartiesAxis_ifrs-full_KeyManagementPersonnelOfEntityOrParentMember_wG1K_J98VEKINTE73Xhmyg"
      decimals="INF"
      id="Narr_w3bD0LbdD0aJGkZzcNFhFw"
      unitRef="Unit_Standard_director_1-CkTK7-YkaxWNG_tkhy7g">3</gmab:NumberOfEmployeeElectedBoardMembers>
    <gmab:ReElectionToBoardOfDirectorsTerm
      contextRef="Duration_3_29_2022_To_3_29_2022_ifrs-full_CategoriesOfRelatedPartiesAxis_gmab_DeirdreP.ConnellyChairPernilleErenbjergDeputyChairRolfHoffmannDr.PaoloPaolettiAndDr.AndersGerselPedersenMember_3rCJQ765kUqbhPx4A2vjig"
      id="Narr_eCyUHvBn00isy4hWLFntWA">P1Y</gmab:ReElectionToBoardOfDirectorsTerm>
    <gmab:ElectionToBoardOfDirectorsTerm
      contextRef="Duration_3_29_2022_To_3_29_2022_ifrs-full_CategoriesOfRelatedPartiesAxis_gmab_ElizabethOfarrellMember_71bO48trL0yfIoKu2bbOIw"
      id="Narr_Tya1cfS47kWSG6odXUMb3g">P1Y</gmab:ElectionToBoardOfDirectorsTerm>
    <gmab:ElectionToBoardOfDirectorsTerm
      contextRef="Duration_3_29_2022_To_3_29_2022_ifrs-full_CategoriesOfRelatedPartiesAxis_gmab_MijkeZachariasseMartinSchultzAndTakahiroHamataniMember_eVcKyLWOlE-Ky0qUaYmu0Q"
      id="Narr_G9ZRKHb3PUmFS4w8t4w0bQ">P3Y</gmab:ElectionToBoardOfDirectorsTerm>
    <ifrs-full:DisclosureOfLeasesExplanatory
      contextRef="Duration_1_1_2022_To_6_30_2022_dNPMG5n7t0WcNVF9KG4Bdw"
      id="Tb_xHNOF0510Eevvp8NFxSHmQ">&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="color:#029c93;font-weight:bold;"&gt;Note 7 &#x2013; Leases&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Amounts recognized in the balance sheet&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;The balance sheet shows the following amounts relating to leases:&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#029c93;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:57.82%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.6%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.6%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.47%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.5%;background:#e6e6e6;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;June 30,&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;December&#160;31,&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.5%;background:#e6e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;2021&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;(DKK million)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.5%;background:#e6e6e6;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Right-of-use assets&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.5%;background:#e6e6e6;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Properties&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.5%;background:#e6e6e6;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 553&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 352&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.5%;background:#e6e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 1&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 2&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.5%;background:#e6e6e6;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total right-of-use assets&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.5%;background:#e6e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 554&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 354&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.5%;background:#e6e6e6;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Lease liabilities&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.5%;background:#e6e6e6;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Current&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.5%;background:#e6e6e6;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 80&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 62&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Non-current&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.5%;background:#e6e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 554&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 363&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.5%;background:#e6e6e6;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total lease liabilities&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.5%;background:#e6e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 634&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 425&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;During the first six months of 2022, there were additions to Genmab&#x2019;s right-of-use assets and lease liabilities related to the commencement of leases in the Netherlands with respect to office and laboratory space. During the first six months of 2021, there were additions to Genmab&#x2019;s right-of-use assets and lease liabilities related to the commencement of a lease in Japan with respect to office space.&lt;span style="font-family:'Times New Roman','Times','serif';font-size:12pt;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Significant leases not yet commenced&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;During 2020, Genmab entered into a lease agreement with respect to the new headquarters in Denmark with a commencement date in March 2023 and is non-cancellable until March 2038. The total future minimum payments over the term of the lease are approximately DKK 339 million and estimated capital expenditures to fit out the space are approximately DKK 40 million.&lt;span style="font-family:'Times New Roman','Times','serif';font-size:12pt;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Amounts recognized in the statement of comprehensive income&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;The statement of comprehensive income shows the following amounts relating to leases:&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:51.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.07%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.07%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.92%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:51.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.41%;background:#e6e6e6;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;6 Months Ended&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;6 Months Ended&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:51.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.41%;background:#e6e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;June 30, 2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;June 30, 2021&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:51.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;(DKK million)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.41%;background:#e6e6e6;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:51.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Depreciation charge of right-of-use assets&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.41%;background:#e6e6e6;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:51.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Properties&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.41%;background:#e6e6e6;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 30&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 25&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:51.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.41%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 1&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 1&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:51.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.41%;background:#e7e6e6;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:51.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total depreciation charge of right-of-use assets&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.41%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 31&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 26&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:51.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.41%;background:#e7e6e6;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:51.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Interest expense&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.41%;background:#e7e6e6;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 7&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 6&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:51.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Expense relating to short-term leases&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.41%;background:#e7e6e6;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 1&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Interest expense is included in net financial items and expenses relating to short-term leases are included in operating expenses in the statement of comprehensive income.&lt;/p&gt;</ifrs-full:DisclosureOfLeasesExplanatory>
    <gmab:DisclosureOfBalanceSheetInformationRelatingToLeasesTableTextBlock
      contextRef="Duration_1_1_2022_To_6_30_2022_dNPMG5n7t0WcNVF9KG4Bdw"
      id="Tb_bBA3B06pPUeV7V4al21XaA">&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;The balance sheet shows the following amounts relating to leases:&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#029c93;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:57.82%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.6%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.6%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.47%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.5%;background:#e6e6e6;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;June 30,&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;December&#160;31,&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.5%;background:#e6e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;2021&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;(DKK million)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.5%;background:#e6e6e6;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Right-of-use assets&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.5%;background:#e6e6e6;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Properties&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.5%;background:#e6e6e6;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 553&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 352&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.5%;background:#e6e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 1&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 2&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.5%;background:#e6e6e6;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total right-of-use assets&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.5%;background:#e6e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 554&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 354&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.5%;background:#e6e6e6;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Lease liabilities&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.5%;background:#e6e6e6;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Current&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.5%;background:#e6e6e6;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 80&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 62&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Non-current&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.5%;background:#e6e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 554&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 363&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.5%;background:#e6e6e6;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total lease liabilities&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.5%;background:#e6e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 634&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 425&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</gmab:DisclosureOfBalanceSheetInformationRelatingToLeasesTableTextBlock>
    <ifrs-full:RightofuseAssets
      contextRef="As_Of_6_30_2022_ifrs-full_ClassesOfAssetsAxis_gmab_PropertiesMember_fzUIN40VJUem2qiuz7q2TQ"
      decimals="-6"
      id="Tc_IMvhQTyRrUKp-pIoUisq_A_5_2"
      unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg">553000000</ifrs-full:RightofuseAssets>
    <ifrs-full:RightofuseAssets
      contextRef="As_Of_6_30_2021_ifrs-full_ClassesOfAssetsAxis_gmab_PropertiesMember_Dk9Hxplwdkeo6iuYxEh2kg"
      decimals="-6"
      id="Tc_ckAqwMJB4EWoVE3dhNBo0A_5_4"
      unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg">352000000</ifrs-full:RightofuseAssets>
    <ifrs-full:RightofuseAssets
      contextRef="As_Of_6_30_2022_ifrs-full_ClassesOfAssetsAxis_gmab_IfrsEquipmentMember_24WDaUkWB0CzmGMa-Eqrcg"
      decimals="-6"
      id="Tc_3AHmAaDnRUmKLsgcQrnOkg_6_2"
      unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg">1000000</ifrs-full:RightofuseAssets>
    <ifrs-full:RightofuseAssets
      contextRef="As_Of_6_30_2021_ifrs-full_ClassesOfAssetsAxis_gmab_IfrsEquipmentMember_JPHlDxvGukWnsD4CjDhIbQ"
      decimals="-6"
      id="Tc_g3LmZwvDdUuZHN5kDg2mxw_6_4"
      unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg">2000000</ifrs-full:RightofuseAssets>
    <ifrs-full:RightofuseAssets
      contextRef="As_Of_6_30_2022_kBUEJjmpl0mHNogMyIvzJg"
      decimals="-6"
      id="Tc_6l2PBYe7nUC32P6pmDb8Vg_8_2"
      unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg">554000000</ifrs-full:RightofuseAssets>
    <ifrs-full:RightofuseAssets
      contextRef="As_Of_6_30_2021_eEXLsHGqbE20an7xlGLjnw"
      decimals="-6"
      id="Tc_pku0n_yZeEKVqtWbyRNvyg_8_4"
      unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg">354000000</ifrs-full:RightofuseAssets>
    <ifrs-full:CurrentLeaseLiabilities
      contextRef="As_Of_6_30_2022_kBUEJjmpl0mHNogMyIvzJg"
      decimals="-6"
      id="Tc_Bfrxn_mSdkKV2aNEen5HMA_11_2"
      unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg">80000000</ifrs-full:CurrentLeaseLiabilities>
    <ifrs-full:CurrentLeaseLiabilities
      contextRef="As_Of_6_30_2021_eEXLsHGqbE20an7xlGLjnw"
      decimals="-6"
      id="Tc_W3h9nUX9wkC6ZMAqhTrGOg_11_4"
      unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg">62000000</ifrs-full:CurrentLeaseLiabilities>
    <ifrs-full:NoncurrentLeaseLiabilities
      contextRef="As_Of_6_30_2022_kBUEJjmpl0mHNogMyIvzJg"
      decimals="-6"
      id="Tc_bNkm3wEO70qtbPDjTOxIEg_12_2"
      unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg">554000000</ifrs-full:NoncurrentLeaseLiabilities>
    <ifrs-full:NoncurrentLeaseLiabilities
      contextRef="As_Of_6_30_2021_eEXLsHGqbE20an7xlGLjnw"
      decimals="-6"
      id="Tc_eLscrGqOP0-r83q-J_XfbA_12_4"
      unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg">363000000</ifrs-full:NoncurrentLeaseLiabilities>
    <ifrs-full:LeaseLiabilities
      contextRef="As_Of_6_30_2022_kBUEJjmpl0mHNogMyIvzJg"
      decimals="-6"
      id="Tc_RBwatGppJUWisNElSxzTgA_14_2"
      unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg">634000000</ifrs-full:LeaseLiabilities>
    <ifrs-full:LeaseLiabilities
      contextRef="As_Of_6_30_2021_eEXLsHGqbE20an7xlGLjnw"
      decimals="-6"
      id="Tc_pid4gnMfKk-j1ZXTPFSkXg_14_4"
      unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg">425000000</ifrs-full:LeaseLiabilities>
    <gmab:FutureMinimumOperatingLeasePayments
      contextRef="As_Of_6_30_2022_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_gmab_OfficeAndLaboratorySpaceMember_srt_StatementGeographicalAxis_country_DK_B5VFPCgUJ0SOaI0R2W2tew"
      decimals="-6"
      id="Narr_8XlJfrRKQkiPtpLRZvj1hg"
      unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg">339000000</gmab:FutureMinimumOperatingLeasePayments>
    <gmab:EstimatedCapitalExpenditureForLease
      contextRef="As_Of_6_30_2022_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_gmab_OfficeAndLaboratorySpaceMember_srt_StatementGeographicalAxis_country_DK_B5VFPCgUJ0SOaI0R2W2tew"
      decimals="-6"
      id="Narr_C4sZdSx_GkKBt1VDSnDwxw"
      unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg">40000000</gmab:EstimatedCapitalExpenditureForLease>
    <gmab:DisclosureOfComprehensiveInformationRelatingToLeasesTableTextBlock
      contextRef="Duration_1_1_2022_To_6_30_2022_dNPMG5n7t0WcNVF9KG4Bdw"
      id="Tb_RxIr6qVlo0SU7FoD7tpk3A">&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;The statement of comprehensive income shows the following amounts relating to leases:&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:51.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.07%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.07%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.92%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:51.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.41%;background:#e6e6e6;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;6 Months Ended&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;6 Months Ended&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:51.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.41%;background:#e6e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;June 30, 2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;June 30, 2021&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:51.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;(DKK million)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.41%;background:#e6e6e6;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:51.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Depreciation charge of right-of-use assets&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.41%;background:#e6e6e6;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:51.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Properties&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.41%;background:#e6e6e6;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 30&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 25&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:51.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.41%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 1&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 1&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:51.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.41%;background:#e7e6e6;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:51.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total depreciation charge of right-of-use assets&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.41%;background:#e7e6e6;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 31&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 26&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:51.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.41%;background:#e7e6e6;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:51.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Interest expense&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.41%;background:#e7e6e6;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 7&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 6&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:51.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;Expense relating to short-term leases&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.41%;background:#e7e6e6;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 1&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</gmab:DisclosureOfComprehensiveInformationRelatingToLeasesTableTextBlock>
    <ifrs-full:DepreciationRightofuseAssets
      contextRef="Duration_1_1_2022_To_6_30_2022_ifrs-full_ClassesOfAssetsAxis_gmab_PropertiesMember_F5LrRJJceEih2g5m7wb9GA"
      decimals="-6"
      id="Tc_l3ECn8HpeUeuR8IYqP-1Og_5_2"
      unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg">30000000</ifrs-full:DepreciationRightofuseAssets>
    <ifrs-full:DepreciationRightofuseAssets
      contextRef="Duration_1_1_2021_To_6_30_2021_ifrs-full_ClassesOfAssetsAxis_gmab_PropertiesMember_G2NwEm7nQ0Kw6dT7ZkwBrQ"
      decimals="-6"
      id="Tc_trp1hg-NakOeT_J2UtxZeg_5_4"
      unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg">25000000</ifrs-full:DepreciationRightofuseAssets>
    <ifrs-full:DepreciationRightofuseAssets
      contextRef="Duration_1_1_2022_To_6_30_2022_ifrs-full_ClassesOfAssetsAxis_gmab_IfrsEquipmentMember_2Uc8kxVSSEeedQs5j0GsVg"
      decimals="-6"
      id="Tc_8-fqDRt6Uk-SUzhut2V6Pg_6_2"
      unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg">1000000</ifrs-full:DepreciationRightofuseAssets>
    <ifrs-full:DepreciationRightofuseAssets
      contextRef="Duration_1_1_2021_To_6_30_2021_ifrs-full_ClassesOfAssetsAxis_gmab_IfrsEquipmentMember_kM-fqB65HkSiWDPm7nBJiQ"
      decimals="-6"
      id="Tc_-s3gjfG6g0KU1ifMZI8_KQ_6_4"
      unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg">1000000</ifrs-full:DepreciationRightofuseAssets>
    <ifrs-full:DepreciationRightofuseAssets
      contextRef="Duration_1_1_2022_To_6_30_2022_dNPMG5n7t0WcNVF9KG4Bdw"
      decimals="-6"
      id="Tc_8DHvSUZgjkyjoSgleVG7eQ_8_2"
      unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg">31000000</ifrs-full:DepreciationRightofuseAssets>
    <ifrs-full:DepreciationRightofuseAssets
      contextRef="Duration_1_1_2021_To_6_30_2021_MRS0_D_onUCNBOxf7Qx_Cw"
      decimals="-6"
      id="Tc_Pd2BPJEX9U28wZNiE1guHQ_8_4"
      unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg">26000000</ifrs-full:DepreciationRightofuseAssets>
    <ifrs-full:InterestExpenseOnLeaseLiabilities
      contextRef="Duration_1_1_2022_To_6_30_2022_dNPMG5n7t0WcNVF9KG4Bdw"
      decimals="-6"
      id="Tc_l_-wofoBcUuQO9ko1RObLw_10_2"
      unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg">7000000</ifrs-full:InterestExpenseOnLeaseLiabilities>
    <ifrs-full:InterestExpenseOnLeaseLiabilities
      contextRef="Duration_1_1_2021_To_6_30_2021_MRS0_D_onUCNBOxf7Qx_Cw"
      decimals="-6"
      id="Tc_QvE5tELjEkC5-VMjt9p1Sw_10_4"
      unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg">6000000</ifrs-full:InterestExpenseOnLeaseLiabilities>
    <ifrs-full:ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed
      contextRef="Duration_1_1_2021_To_6_30_2021_MRS0_D_onUCNBOxf7Qx_Cw"
      decimals="-6"
      id="Tc_mV3bSlNbsUCFHLSkK4TnAg_11_4"
      unitRef="Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg">1000000</ifrs-full:ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed>
    <ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory
      contextRef="Duration_1_1_2022_To_6_30_2022_dNPMG5n7t0WcNVF9KG4Bdw"
      id="Tb_I7iVrujR0ESFxtvYGdwfjw">&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="color:#029c93;font-weight:bold;"&gt;Note 8 - Subsequent Events to the Balance Sheet Date&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt;"&gt;No events have occurred subsequent to the balance sheet date that could significantly affect the financial statements as of June 30, 2022.&lt;/p&gt;</ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>57
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0    ( "E;"E4'04UB@0   +$    0    9&]C4')O<',O87!P+GAM
M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG
M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGD<Z,STA)8*O4'J@)I9GF
M3?X.CD:?<@X>K7A.YNJQ<&4GPZ4A!0W_<FW>J=0U[R;UEA_6\#MI7E!+ P04
M    "  I6PI5])B'I^X    K @  $0   &1O8U!R;W!S+V-O<F4N>&ULS9+/
M2@,Q$(=?17+?G4U*1<)V+Q5/"H(%Q5M(IFUP\X=D9+=O;W9MMX@^@,?,_/+-
M-S"MCE*'A,\I1$QD,=^,KO=9ZKAA1Z(H ;(^HE.Y+@E?FON0G*+R3 >(2G^H
M X)HFEMP2,HH4C !J[@06=<:+75"12&=\48O^/B9^AEF-&"/#CUEX#4'UDT3
MXVGL6[@")AAA<OF[@&8ASM4_L7,'V#DY9KNDAF&HA]6<*SMP>'MZ?)G7K:S/
MI+S&\BM;2:>(&W:9_+K:WN\>6"<:(:KFKN+-CJ^E6$LNWB?7'WY781>,W=M_
M;'P1[%KX=1?=%U!+ P04    "  I6PI5F5R<(Q &  "<)P  $P   'AL+W1H
M96UE+W1H96UE,2YX;6SM6EMSVC@4?N^OT'AG]FT+QC:!MK03<VEVV[29A.U.
M'X416(UL>621A'^_1S80RY8-[9)-NIL\!"SI^\Y%1^?H.'GS[BYBZ(:(E/)X
M8-DOV]:[MR_>X%<R)!%!,!FGK_# "J5,7K5::0##.'W)$Q+#W(*+"$MX%,O6
M7.!;&B\CUNJTV]U6A&ELH1A'9&!]7BQH0-!445IO7R"TY1\S^!7+5(UEHP$3
M5T$FN8BT\OELQ?S:WCYES^DZ'3*!;C ;6"!_SF^GY$Y:B.%4PL3 :F<_5FO'
MT=)(@(+)?90%NDGVH],5"#(-.SJ=6,YV?/;$[9^,RMIT-&T:X./Q>#BVR]*+
M<!P$X%&[GL*=]&R_I$$)M*-IT&38]MJND::JC5-/T_=]W^N;:)P*C5M/TVMW
MW=..B<:MT'@-OO%/A\.NB<:KT'3K:28G_:YKI.D6:$)&X^MZ$A6UY4#3( !8
M<';6S-(#EEXI^G64&MD=N]U!7/!8[CF)$?[&Q036:=(9EC1&<IV0!0X -\31
M3%!\KT&VBN#"DM)<D-;/*;50&@B:R('U1X(AQ=RO_?67N\FD,WJ=?3K.:Y1_
M::L!I^V[F\^3_'/HY)^GD]=-0LYPO"P)\?LC6V&')VX[$W(Z'&="?,_V]I&E
M)3+/[_D*ZTX\9Q]6EK!=S\_DGHQR([O=]EA]]D]';B/7J<"S(M>41B1%G\@M
MNN01.+5)#3(3/PB=AIAJ4!P"I DQEJ&&^+3&K!'@$WVWO@C(WXV(]ZMOFCU7
MH5A)VH3X$$8:XIQSYG/1;/L'I4;1]E6\W*.76!4!EQC?-*HU+,76>)7 \:V<
M/!T3$LV4"P9!AI<D)A*I.7Y-2!/^*Z7:_IS30/"4+R3Z2I&/:;,CIW0FS>@S
M&L%&KQMUAVC2/'K^!?F<-0H<D1L= F<;LT8AA&F[\!ZO)(Z:K<(1*T(^8ADV
M&G*U%H&V<:F$8%H2QM%X3M*T$?Q9K#63/F#([,V1=<[6D0X1DEXW0CYBSHN0
M$;\>ACA*FNVB<5@$_9Y>PTG!Z(++9OVX?H;5,VPLCO='U!=*Y \FIS_I,C0'
MHYI9";V$5FJ?JH<T/J@>,@H%\;D>/N5Z> HWEL:\4*Z">P'_T=HWPJOX@L Y
M?RY]SZ7ON?0]H=*W-R-]9\'3BUO>1FY;Q/NN,=K7-"XH8U=RS<C'5*^3*=@Y
MG\#L_6@^GO'M^MDDA*^:62TC%I!+@;-!)+C\B\KP*L0)Z&1;)0G+5--E-XH2
MGD(;;NE3]4J5U^6ON2BX/%ODZ:^A=#XLS_D\7^>TS0LS0[=R2^JVE+ZU)CA*
M]+',<$X>RPP[9SR2';9WH!TU^_9==N0CI3!3ET.X&D*^ VVZG=PZ.)Z8D;D*
MTU*0;\/YZ<5X&N(YV02Y?9A7;>?8T='[Y\%1L*/O/)8=QXCRHB'NH8:8S\-#
MAWE[7YAGE<90-!1M;*PD+$:W8+C7\2P4X&1@+: '@Z]1 O)256 Q6\8#*Y"B
M?$R,1>APYY=<7^/1DN/;IF6U;J\I=QEM(E(YPFF8$V>KRMYEL<%5'<]56_*P
MOFH]M!5.S_Y9K<B?#!%.%@L22&.4%Z9*HO,94[[G*TG$53B_13.V$I<8O./F
MQW%.4[@2=K8/ C*YNSFI>F4Q9Z;RWRT,"2Q;B%D2XDU=[=7GFYRN>B)V^I=W
MP6#R_7#)1P_E.^=?]%U#KG[VW>/Z;I,[2$R<><41 71% B.5' 86%S+D4.Z2
MD 83 <V4R43P H)DIAR F/H+O?(,N2D5SJT^.7]%+(.&3E[2)1(4BK ,!2$7
M<N/O[Y-J=XS7^BR!;814,F35%\I#B<$],W)#V%0E\Z[:)@N%V^)4S;L:OB9@
M2\-Z;ITM)__;7M0]M!<]1O.CF> >LX=SFWJXPD6L_UC6'ODRWSEPVSK> U[F
M$RQ#I'[!?8J*@!&K8KZZKT_Y)9P[M'OQ@2";_-;;I/;=X Q\U*M:I60K$3]+
M!WP?D@9CC%OT-%^/%&*MIK&MQMHQ#'F 6/,,H68XWX=%FAHSU8NL.8T*;T'5
M0.4_V]0-:/8--!R1!5XQF;8VH^1."CS<_N\-L,+$CN'MB[\!4$L#!!0    (
M "E;"E4R7G8:O (  +((   8    >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL
ME99;;YLP%(#_BL6D/2WEEM#+DDA)NFY9UREK=]$T[<&!$[ *-K--T_S['0.A
MF42=[B7!QN?S=VS#8;P5\EYE )H\%CE7$R?3NKQP715G4%!U(DK@>&<C9$$U
M-F7JJE("3>J@(G<#SXO<@C+N3,=UWTI.QZ+2.>.PDD1514'E;@ZYV$X<W]EW
MW+(TTZ;#G8Y+FL(=Z&_E2F++[2@)*X K)CB1L)DX,_]B[M<!]8CO#+;JX)J8
M5-9"W)O&,IDXGC&"'&)M$!3_'F !>6Y(Z/&GA3K=G";P\'I/OZJ3QV365,%"
MY#]8HK.)<^:0!#:TRO6MV'Z -J&1X<4B5_4OV39CPZ%#XDII4;3!:% PWOS3
MQW8A#@*0TQ\0M %![=U,5%M>4DVG8RFV1)K12#,7=:IU-,HQ;G;E3DN\RS!.
M3R]%7.$B:T)Y0MYQS?2.+'FSV[AJ8U?C)&:H&[? >0,,G@%&Y$9PG2F$)9#\
M&^^B7&<8[ WG@17XL>(G)/3>D, + @LO[#(.:UYX+..#-,FO3SB*+#44ZG=?
MS@URV(\T3\Z%*FD,$P<?#07R 9SIZU=^Y+VU" \[X:&-_B3\=5="GYP]/!I<
M6R1&G<3H91(KD$R8HY(0/'"]/G92MY_'-C3JU"(KL#VUMY RI25%Q\^TZ!6S
M<]X#+^B:S-P[B]1I)W7Z$JD%+IFD.9ZU!![)->SZM.PDS_/\83@,HI%%ZZS3
M.K/"%I649A>OF(I1ZR=0:=U*.VTP\(-!Z%N\SCNO\Y<=KT.Q*^Q4?59VUI%C
MY7M/KT;OOZ3:H_^LUA'<%ZO5P0O;MV)FJ)0T6CE->SWL@ W-%?2IN =EI "9
MUL52D5A47#<5I>OM"O*L*4-/PYMJ?D-ERK@B.6PPU#LYQ7>"; IDT]"BK(O2
M6F@L<?5EAA\5(,T O+\10N\;9H+N,V7Z%U!+ P04    "  I6PI5"A3 )+$%
M  #S&0  &    'AL+W=O<FMS:&5E=',O<VAE970R+GAM;*U9;7/B-A#^*QHZ
MTVEG&K#D5]*$F00[<^E-<IDDO7Y6C  UMD4E ;E_7]F  7GMXUJ^)+9Y]ED]
MJ_5J)5^MA7Q7<\8T^LBS0EWWYEHO+@<#E<Y93E5?+%AA?ID*F5-M;N5LH!:2
MT4EEE&<#XCC!(*>\Z(VNJF=/<G0EECKC!7N22"WSG,IOMRP3Z^L>[NT>///9
M7)</!J.K!9VQ%Z;_7#Q)<S>H628\9X7BHD"23:][-_@R(95!A?C*V5H=7*-2
MRIL0[^7-_>2ZYY0C8AE+=4E!S;\5&[,L*YG,./[9DO9JGZ7AX?6._:X2;\2\
M4<7&(ON+3_3\NA?UT(1-Z3+3SV+]B6T%^25?*C)5_47K#38P'M.ETB+?&IO[
MG!>;__1C&X@# \,#&Y"M ;$-O!8#=VO@GNK!VQIXIWKPMP:5],%&>Q6XF&HZ
MNI)BC62)-FSE117]RMK$BQ=EHKQH:7[EQDZ/7EYO7I.'Y/'U!7VY0^,O#T_/
MR:?D\>7^:X+N'\U]@BY0_/DS^N5=_HK>)>(%>N!99B9970VT&4'),TBWWFXW
MWDB+-Q<]B$+/%4J*"9L ]G&W?=!A/S#*:_ED)_^6=!+^L2SZR'5^0\0A!!C/
M^'1S#,GY?]Z3_^S]*!ANG0MNQ>>V\-T7J<@9>M%4,U,+-#2_&P8/9BBKVJ5:
MT)1=]TS94DRN6&_T\T\X<'Z'@GM.LOB<9,F9R(ZFP:NGP>MB'SVS%2N6#(K^
MQM"O#,LE8#5R<6 R9W48U28(#T,+%#=!/HGP,2@!W/F^6X..U/FU.O\[ZA2C
M,ITC6DQ,15^9I6I1)AMB'V;Q4PRL*AO*X& @%YA$MG  -226IA@ $<_U+>60
MPS 8PM*#6GK0*?W%+(>\F/V&9JQ@DF95".C$5'6NM*3EBMD9A: YJ,!UK2
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MQ6R"QNE9XI<=L87%=!+N"# /"F@EE?)Y][,!3L 26VJ\Q]3).QSUJILNQ&K
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M9+SQ(1Q2-1Y!NF0*36!E6&J_D+*5<%@<;VJ-C^$.,1Q'K5$4'>VY_>/5MUM
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MIGP&*0=.K_S3PTP[IW/_N>0,:4$"N#[7>'VI!F2@>8LZ_P]02P,$%     @
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MDY/=0).'Z&H\#7+:2%#N@\.JQKDPFRNO/=DEW3KV;(**6AW=VE)GFOWQY2#
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M10,GQPG\9M?4H4[YOR;,59I25FF5UPO[;9+>KC?3^?/TU]N_*&L!ZU/6HB2
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M#8Y:V":J&.&%8.3,C<V1-#B$W7:*7SV@K &>CZ4T2\%>4'U']?X"4$L#!!0
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M+15Z WS?<JZ.A@[0C<C+OP%02P,$%     @ *5L*5=*UX7,W P  ]PD  !D
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M)*MW5Y38Z<5- 9H^WO+>H'\S<=KY)@4;$OQ^:PR>@O!PEK:O_@)02P,$%
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MT2+;XF<GBB_L+GG,E=YSV\,(R 2$"=#WIYRKAQ.S\2X^M S_ 5!+ P04
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M".EU^I@P6??Z>J/%TK;+F=#8?.TRQ_$(TAC@_5P(O=F8 .W C7\#4$L#!!0
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M$MP>:4#M.*2VBZD8_1!2:5K5N %(MB6/:<Z10J[4+!XUA]) 1-MC0[!:+#Y
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MT(.K5J[XD% %XA8KN!,\WQ'V6$RC5^$;RRCS4']62;P4_Y)&OMF0!&YYDF?
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M* D?M(:@=?B@#01MP@>E$)2&#]I"T#9\T Z"=N&#]A"T#Q]$,<H8"TAZP5J
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M2CQS[[5'.HM,WK8>,-L8;7&:-S'Z!\:P;,!(+)P'FW9J%XR,Z34LF)?E4BZ
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M              "  <P!  !X;"]T:&5M92]T:&5M93$N>&UL4$L! A0#%
M  @ *5L*53)>=AJ\ @  L@@  !@              ("!#0@  'AL+W=O<FMS
M:&5E=',O<VAE970Q+GAM;%!+ 0(4 Q0    ( "E;"E4*%, DL04  /,9   8
M              " @?\*  !X;"]W;W)K<VAE971S+W-H965T,BYX;6Q02P$"
M% ,4    "  I6PI5CUT3TH %  !L&0  &               @('F$   >&PO
M=V]R:W-H965T<R]S:&5E=#,N>&UL4$L! A0#%     @ *5L*5?#W.BXZ!@
M!1L  !@              ("!G!8  'AL+W=O<FMS:&5E=',O<VAE970T+GAM
M;%!+ 0(4 Q0    ( "E;"E7/[&<76@4  +,B   8              " @0P=
M  !X;"]W;W)K<VAE971S+W-H965T-2YX;6Q02P$"% ,4    "  I6PI59WT8
M#N,$  "6"P  &               @(&<(@  >&PO=V]R:W-H965T<R]S:&5E
M=#8N>&UL4$L! A0#%     @ *5L*58!&ZGF.!0  J0X  !@
M ("!M2<  'AL+W=O<FMS:&5E=',O<VAE970W+GAM;%!+ 0(4 Q0    ( "E;
M"E6TN)&S)04  %4/   8              " @7DM  !X;"]W;W)K<VAE971S
M+W-H965T."YX;6Q02P$"% ,4    "  I6PI50?/GX2@$   C#   &
M        @('4,@  >&PO=V]R:W-H965T<R]S:&5E=#DN>&UL4$L! A0#%
M  @ *5L*571M_QM !@  EQ(  !D              ("!,C<  'AL+W=O<FMS
M:&5E=',O<VAE970Q,"YX;6Q02P$"% ,4    "  I6PI5[6C%2WT%  "O#0
M&0              @(&I/0  >&PO=V]R:W-H965T<R]S:&5E=#$Q+GAM;%!+
M 0(4 Q0    ( "E;"E6>=SU G@0  )T-   9              " @5U#  !X
M;"]W;W)K<VAE971S+W-H965T,3(N>&UL4$L! A0#%     @ *5L*5=E6^XU/
M @  E@4  !D              ("!,D@  'AL+W=O<FMS:&5E=',O<VAE970Q
M,RYX;6Q02P$"% ,4    "  I6PI52P VX0X%  "Q#   &0
M@(&X2@  >&PO=V]R:W-H965T<R]S:&5E=#$T+GAM;%!+ 0(4 Q0    ( "E;
M"E4MAJRX- ,  #4(   9              " @?U/  !X;"]W;W)K<VAE971S
M+W-H965T,34N>&UL4$L! A0#%     @ *5L*5>%,KCH$ P  4PD  !D
M         ("!:%,  'AL+W=O<FMS:&5E=',O<VAE970Q-BYX;6Q02P$"% ,4
M    "  I6PI5/I! 7.$"   8"   &0              @(&C5@  >&PO=V]R
M:W-H965T<R]S:&5E=#$W+GAM;%!+ 0(4 Q0    ( "E;"E4L!]D]HP,  "X+
M   9              " @;M9  !X;"]W;W)K<VAE971S+W-H965T,3@N>&UL
M4$L! A0#%     @ *5L*5=*UX7,W P  ]PD  !D              ("!E5T
M 'AL+W=O<FMS:&5E=',O<VAE970Q.2YX;6Q02P$"% ,4    "  I6PI5\] U
MV^,!   "!   &0              @($#80  >&PO=V]R:W-H965T<R]S:&5E
M=#(P+GAM;%!+ 0(4 Q0    ( "E;"E5O\]FYU 4  &4J   9
M  " @1UC  !X;"]W;W)K<VAE971S+W-H965T,C$N>&UL4$L! A0#%     @
M*5L*59HG\RP7!   'Q4  !D              ("!*&D  'AL+W=O<FMS:&5E
M=',O<VAE970R,BYX;6Q02P$"% ,4    "  I6PI5]]M127\#  !T$0  &0
M            @(%V;0  >&PO=V]R:W-H965T<R]S:&5E=#(S+GAM;%!+ 0(4
M Q0    ( "E;"E6>]80:H0(  / )   9              " @2QQ  !X;"]W
M;W)K<VAE971S+W-H965T,C0N>&UL4$L! A0#%     @ *5L*5=5C&,O8 P
MXQ$  !D              ("!!'0  'AL+W=O<FMS:&5E=',O<VAE970R-2YX
M;6Q02P$"% ,4    "  I6PI5_.UGV>D"  !\!P  &0              @($3
M>   >&PO=V]R:W-H965T<R]S:&5E=#(V+GAM;%!+ 0(4 Q0    ( "E;"E4[
M+VOPV0,  "L-   9              " @3-[  !X;"]W;W)K<VAE971S+W-H
M965T,C<N>&UL4$L! A0#%     @ *5L*55@ ZM M!0  ;B4  !D
M     ("!0W\  'AL+W=O<FMS:&5E=',O<VAE970R."YX;6Q02P$"% ,4
M"  I6PI5D\L<R$D$   ;%   &0              @(&GA   >&PO=V]R:W-H
M965T<R]S:&5E=#(Y+GAM;%!+ 0(4 Q0    ( "E;"E7KZR[X#P4  /X=   9
M              " @2>)  !X;"]W;W)K<VAE971S+W-H965T,S N>&UL4$L!
M A0#%     @ *5L*5?;2Q=PF P  \!$   T              ( !;8X  'AL
M+W-T>6QE<RYX;6Q02P$"% ,4    "  I6PI5EXJ[',     3 @  "P
M        @ &^D0  7W)E;',O+G)E;'-02P$"% ,4    "  I6PI57]$;F!\#
M  !=%   #P              @ &GD@  >&PO=V]R:V)O;VLN>&UL4$L! A0#
M%     @ *5L*562$U7I7 0  D1(  !H              ( !\Y4  'AL+U]R
M96QS+W=O<FMB;V]K+GAM;"YR96QS4$L! A0#%     @ *5L*53EI(W6" 0
M3!,  !,              ( !@I<  %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&
2     "8 )@!!"@  -9D

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>107</ContextCount>
  <ElementCount>141</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>47</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>7</UnitCount>
  <MyReports>
    <Report instance="gmab-20220630x6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00090 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.genmab.com/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="gmab-20220630x6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>00100 - Statement - STATEMENTS OF COMPREHENSIVE INCOME</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.genmab.com/role/StatementStatementsOfComprehensiveIncome</Role>
      <ShortName>STATEMENTS OF COMPREHENSIVE INCOME</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="gmab-20220630x6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>00200 - Statement - BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.genmab.com/role/StatementBalanceSheets</Role>
      <ShortName>BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="gmab-20220630x6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>00300 - Statement - STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.genmab.com/role/StatementStatementsOfCashFlows</Role>
      <ShortName>STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="gmab-20220630x6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>00400 - Statement - STATEMENTS OF CHANGES IN EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.genmab.com/role/StatementStatementsOfChangesInEquity</Role>
      <ShortName>STATEMENTS OF CHANGES IN EQUITY</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="gmab-20220630x6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>10101 - Disclosure - Basis of Presentation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.genmab.com/role/DisclosureBasisOfPresentation</Role>
      <ShortName>Basis of Presentation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="gmab-20220630x6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>10201 - Disclosure - Revenue</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.genmab.com/role/DisclosureRevenue</Role>
      <ShortName>Revenue</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="gmab-20220630x6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>10301 - Disclosure - Financial Instruments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.genmab.com/role/DisclosureFinancialInstruments</Role>
      <ShortName>Financial Instruments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="gmab-20220630x6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>10401 - Disclosure - Financial Income and Expenses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.genmab.com/role/DisclosureFinancialIncomeAndExpenses</Role>
      <ShortName>Financial Income and Expenses</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="gmab-20220630x6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>10501 - Disclosure - Share-Based Instruments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.genmab.com/role/DisclosureShareBasedInstruments</Role>
      <ShortName>Share-Based Instruments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="gmab-20220630x6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>10601 - Disclosure - Related Parties</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.genmab.com/role/DisclosureRelatedParties</Role>
      <ShortName>Related Parties</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="gmab-20220630x6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>10701 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.genmab.com/role/DisclosureLeases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="gmab-20220630x6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>10801 - Disclosure - Subsequent Events to the Balance Sheet Date</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.genmab.com/role/DisclosureSubsequentEventsToBalanceSheetDate</Role>
      <ShortName>Subsequent Events to the Balance Sheet Date</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="gmab-20220630x6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>20102 - Disclosure - Basis of Presentation (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.genmab.com/role/DisclosureBasisOfPresentationPolicies</Role>
      <ShortName>Basis of Presentation (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="gmab-20220630x6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>30203 - Disclosure - Revenue (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.genmab.com/role/DisclosureRevenueTables</Role>
      <ShortName>Revenue (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.genmab.com/role/DisclosureRevenue</ParentRole>
      <Position>15</Position>
    </Report>
    <Report instance="gmab-20220630x6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>30303 - Disclosure - Financial Instruments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.genmab.com/role/DisclosureFinancialInstrumentsTables</Role>
      <ShortName>Financial Instruments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.genmab.com/role/DisclosureFinancialInstruments</ParentRole>
      <Position>16</Position>
    </Report>
    <Report instance="gmab-20220630x6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>30403 - Disclosure - Financial Income and Expenses (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.genmab.com/role/DisclosureFinancialIncomeAndExpensesTables</Role>
      <ShortName>Financial Income and Expenses (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.genmab.com/role/DisclosureFinancialIncomeAndExpenses</ParentRole>
      <Position>17</Position>
    </Report>
    <Report instance="gmab-20220630x6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>30503 - Disclosure - Share-Based Instruments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.genmab.com/role/DisclosureShareBasedInstrumentsTables</Role>
      <ShortName>Share-Based Instruments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.genmab.com/role/DisclosureShareBasedInstruments</ParentRole>
      <Position>18</Position>
    </Report>
    <Report instance="gmab-20220630x6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>30703 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.genmab.com/role/DisclosureLeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.genmab.com/role/DisclosureLeases</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="gmab-20220630x6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>40101 - Disclosure - Basis of Presentation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.genmab.com/role/DisclosureBasisOfPresentationDetails</Role>
      <ShortName>Basis of Presentation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.genmab.com/role/DisclosureBasisOfPresentationPolicies</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="gmab-20220630x6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>40201 - Disclosure - Revenue (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.genmab.com/role/DisclosureRevenueDetails</Role>
      <ShortName>Revenue (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.genmab.com/role/DisclosureRevenueTables</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="gmab-20220630x6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>40301 - Disclosure - Financial Instruments - Financial Risk (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.genmab.com/role/DisclosureFinancialInstrumentsFinancialRiskDetails</Role>
      <ShortName>Financial Instruments - Financial Risk (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="gmab-20220630x6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>40302 - Disclosure - Financial Instruments - Fair Value Measurement (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.genmab.com/role/DisclosureFinancialInstrumentsFairValueMeasurementDetails</Role>
      <ShortName>Financial Instruments - Fair Value Measurement (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="gmab-20220630x6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>40303 - Disclosure - Financial Instruments - Other Investments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.genmab.com/role/DisclosureFinancialInstrumentsOtherInvestmentsDetails</Role>
      <ShortName>Financial Instruments - Other Investments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="gmab-20220630x6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>40401 - Disclosure - Financial Income and Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.genmab.com/role/DisclosureFinancialIncomeAndExpensesDetails</Role>
      <ShortName>Financial Income and Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.genmab.com/role/DisclosureFinancialIncomeAndExpensesTables</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="gmab-20220630x6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>40501 - Disclosure - Share-Based Instruments - Restricted Stock Unit Program (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.genmab.com/role/DisclosureShareBasedInstrumentsRestrictedStockUnitProgramDetails</Role>
      <ShortName>Share-Based Instruments - Restricted Stock Unit Program (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="gmab-20220630x6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>40502 - Disclosure - Share-Based Instruments - Warrant Program (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.genmab.com/role/DisclosureShareBasedInstrumentsWarrantProgramDetails</Role>
      <ShortName>Share-Based Instruments - Warrant Program (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="gmab-20220630x6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>40503 - Disclosure - Share-Based Instruments - Share repurchases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.genmab.com/role/DisclosureShareBasedInstrumentsShareRepurchasesDetails</Role>
      <ShortName>Share-Based Instruments - Share repurchases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="gmab-20220630x6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>40601 - Disclosure - Related Parties (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.genmab.com/role/DisclosureRelatedPartiesDetails</Role>
      <ShortName>Related Parties (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.genmab.com/role/DisclosureRelatedParties</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="gmab-20220630x6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>40701 - Disclosure - Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.genmab.com/role/DisclosureLeasesDetails</Role>
      <ShortName>Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.genmab.com/role/DisclosureLeasesTables</ParentRole>
      <Position>30</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="6-K" original="gmab-20220630x6k.htm">gmab-20220630x6k.htm</File>
    <File doctype="6-K" original="gmab-20220630xex99d1.htm">gmab-20220630xex99d1.htm</File>
    <File>gmab-20220630.xsd</File>
    <File>gmab-20220630_cal.xml</File>
    <File>gmab-20220630_def.xml</File>
    <File>gmab-20220630_lab.xml</File>
    <File>gmab-20220630_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>gmab-20220630xex99d1002.jpg</File>
    <File>gmab-20220630xex99d1005.jpg</File>
    <File>gmab-20220630xex99d1006.jpg</File>
    <File>gmab-20220630xex99d1007.jpg</File>
    <File>gmab-20220630xex99d1008.jpg</File>
    <File>gmab-20220630xex99d1009.jpg</File>
    <File>gmab-20220630xex99d1010.jpg</File>
    <File>gmab-20220630xex99d1011.jpg</File>
    <File>gmab-20220630xex99d1012.jpg</File>
    <File>gmab-20220630xex99d1013.jpg</File>
    <File>gmab-20220630xex99d1014.jpg</File>
    <File>gmab-20220630xex99d1015.jpg</File>
    <File>gmab-20220630xex99d1016.jpg</File>
    <File>gmab-20220630xex99d1017.jpg</File>
    <File>gmab-20220630xex99d1018.jpg</File>
    <File>gmab-20220630xex99d1019.jpg</File>
    <File>gmab-20220630xex99d1020.jpg</File>
    <File>gmab-20220630xex99d1021.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="301">http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full</BaseTaxonomy>
    <BaseTaxonomy items="8">http://xbrl.sec.gov/dei/2021q4</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>62
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "gmab-20220630x6k.htm gmab-20220630xex99d1.htm": {
   "axisCustom": 3,
   "axisStandard": 13,
   "contextCount": 107,
   "dts": {
    "calculationLink": {
     "local": [
      "gmab-20220630_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "gmab-20220630_def.xml"
     ]
    },
    "inline": {
     "local": [
      "gmab-20220630x6k.htm",
      "gmab-20220630xex99d1.htm"
     ]
    },
    "labelLink": {
     "local": [
      "gmab-20220630_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "gmab-20220630_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "gmab-20220630.xsd",
      "reference-2009-12-16.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd",
      "https://xbrl.sec.gov/country/2021/country-2021.xsd",
      "https://xbrl.sec.gov/currency/2021/currency-2021.xsd",
      "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd"
     ]
    }
   },
   "elementCount": 376,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2021q4": 8,
    "total": 8
   },
   "keyCustom": 45,
   "keyStandard": 96,
   "memberCustom": 32,
   "memberStandard": 15,
   "nsprefix": "gmab",
   "nsuri": "http://www.genmab.com/20220630",
   "report": {
    "R1": {
     "firstAnchor": null,
     "groupType": "document",
     "isDefault": "true",
     "longName": "00090 - Document - Document and Entity Information",
     "role": "http://www.genmab.com/role/DocumentDocumentAndEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": null
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gmab-20220630xex99d1.htm",
      "contextRef": "Duration_1_1_2022_To_6_30_2022_dNPMG5n7t0WcNVF9KG4Bdw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10501 - Disclosure - Share-Based Instruments",
     "role": "http://www.genmab.com/role/DisclosureShareBasedInstruments",
     "shortName": "Share-Based Instruments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gmab-20220630xex99d1.htm",
      "contextRef": "Duration_1_1_2022_To_6_30_2022_dNPMG5n7t0WcNVF9KG4Bdw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gmab-20220630xex99d1.htm",
      "contextRef": "Duration_1_1_2022_To_6_30_2022_dNPMG5n7t0WcNVF9KG4Bdw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfRelatedPartyExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10601 - Disclosure - Related Parties",
     "role": "http://www.genmab.com/role/DisclosureRelatedParties",
     "shortName": "Related Parties",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gmab-20220630xex99d1.htm",
      "contextRef": "Duration_1_1_2022_To_6_30_2022_dNPMG5n7t0WcNVF9KG4Bdw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfRelatedPartyExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gmab-20220630xex99d1.htm",
      "contextRef": "Duration_1_1_2022_To_6_30_2022_dNPMG5n7t0WcNVF9KG4Bdw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfLeasesExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10701 - Disclosure - Leases",
     "role": "http://www.genmab.com/role/DisclosureLeases",
     "shortName": "Leases",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gmab-20220630xex99d1.htm",
      "contextRef": "Duration_1_1_2022_To_6_30_2022_dNPMG5n7t0WcNVF9KG4Bdw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfLeasesExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gmab-20220630xex99d1.htm",
      "contextRef": "Duration_1_1_2022_To_6_30_2022_dNPMG5n7t0WcNVF9KG4Bdw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10801 - Disclosure - Subsequent Events to the Balance Sheet Date",
     "role": "http://www.genmab.com/role/DisclosureSubsequentEventsToBalanceSheetDate",
     "shortName": "Subsequent Events to the Balance Sheet Date",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gmab-20220630xex99d1.htm",
      "contextRef": "Duration_1_1_2022_To_6_30_2022_dNPMG5n7t0WcNVF9KG4Bdw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "ifrs-full:DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gmab-20220630xex99d1.htm",
      "contextRef": "Duration_1_1_2022_To_6_30_2022_dNPMG5n7t0WcNVF9KG4Bdw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "gmab:DescriptionOfAccountingPolicyForBasisOfPresentationPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "20102 - Disclosure - Basis of Presentation (Policies)",
     "role": "http://www.genmab.com/role/DisclosureBasisOfPresentationPolicies",
     "shortName": "Basis of Presentation (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ifrs-full:DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gmab-20220630xex99d1.htm",
      "contextRef": "Duration_1_1_2022_To_6_30_2022_dNPMG5n7t0WcNVF9KG4Bdw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "gmab:DescriptionOfAccountingPolicyForBasisOfPresentationPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "ifrs-full:DisclosureOfRevenueFromContractsWithCustomersExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gmab-20220630xex99d1.htm",
      "contextRef": "Duration_1_1_2022_To_6_30_2022_dNPMG5n7t0WcNVF9KG4Bdw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30203 - Disclosure - Revenue (Tables)",
     "role": "http://www.genmab.com/role/DisclosureRevenueTables",
     "shortName": "Revenue (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ifrs-full:DisclosureOfRevenueFromContractsWithCustomersExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gmab-20220630xex99d1.htm",
      "contextRef": "Duration_1_1_2022_To_6_30_2022_dNPMG5n7t0WcNVF9KG4Bdw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "ifrs-full:DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gmab-20220630xex99d1.htm",
      "contextRef": "Duration_1_1_2022_To_6_30_2022_dNPMG5n7t0WcNVF9KG4Bdw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "gmab:DisclosureOfMarketableSecuritiesByCurrencyTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30303 - Disclosure - Financial Instruments (Tables)",
     "role": "http://www.genmab.com/role/DisclosureFinancialInstrumentsTables",
     "shortName": "Financial Instruments (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ifrs-full:DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gmab-20220630xex99d1.htm",
      "contextRef": "Duration_1_1_2022_To_6_30_2022_dNPMG5n7t0WcNVF9KG4Bdw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "gmab:DisclosureOfMarketableSecuritiesByCurrencyTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "ifrs-full:DisclosureOfFinanceIncomeExpenseExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gmab-20220630xex99d1.htm",
      "contextRef": "Duration_1_1_2022_To_6_30_2022_dNPMG5n7t0WcNVF9KG4Bdw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "gmab:DisclosureOfFinanceIncomeExpensesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30403 - Disclosure - Financial Income and Expenses (Tables)",
     "role": "http://www.genmab.com/role/DisclosureFinancialIncomeAndExpensesTables",
     "shortName": "Financial Income and Expenses (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ifrs-full:DisclosureOfFinanceIncomeExpenseExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gmab-20220630xex99d1.htm",
      "contextRef": "Duration_1_1_2022_To_6_30_2022_dNPMG5n7t0WcNVF9KG4Bdw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "gmab:DisclosureOfFinanceIncomeExpensesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gmab-20220630xex99d1.htm",
      "contextRef": "Duration_1_1_2022_To_6_30_2022_dNPMG5n7t0WcNVF9KG4Bdw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30503 - Disclosure - Share-Based Instruments (Tables)",
     "role": "http://www.genmab.com/role/DisclosureShareBasedInstrumentsTables",
     "shortName": "Share-Based Instruments (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gmab-20220630xex99d1.htm",
      "contextRef": "Duration_1_1_2022_To_6_30_2022_dNPMG5n7t0WcNVF9KG4Bdw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "ifrs-full:DisclosureOfLeasesExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gmab-20220630xex99d1.htm",
      "contextRef": "Duration_1_1_2022_To_6_30_2022_dNPMG5n7t0WcNVF9KG4Bdw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "gmab:DisclosureOfBalanceSheetInformationRelatingToLeasesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30703 - Disclosure - Leases (Tables)",
     "role": "http://www.genmab.com/role/DisclosureLeasesTables",
     "shortName": "Leases (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ifrs-full:DisclosureOfLeasesExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gmab-20220630xex99d1.htm",
      "contextRef": "Duration_1_1_2022_To_6_30_2022_dNPMG5n7t0WcNVF9KG4Bdw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "gmab:DisclosureOfBalanceSheetInformationRelatingToLeasesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "b",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gmab-20220630xex99d1.htm",
      "contextRef": "Duration_4_1_2022_To_6_30_2022_voh1lJjNhUCZyLqqP0N5aw",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "ifrs-full:Revenue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00100 - Statement - STATEMENTS OF COMPREHENSIVE INCOME",
     "role": "http://www.genmab.com/role/StatementStatementsOfComprehensiveIncome",
     "shortName": "STATEMENTS OF COMPREHENSIVE INCOME",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "b",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gmab-20220630xex99d1.htm",
      "contextRef": "Duration_4_1_2022_To_6_30_2022_voh1lJjNhUCZyLqqP0N5aw",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "ifrs-full:Revenue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ifrs-full:DescriptionOfAccountingPolicyForSegmentReportingExplanatory",
       "ifrs-full:DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gmab-20220630xex99d1.htm",
      "contextRef": "As_Of_6_30_2022_kBUEJjmpl0mHNogMyIvzJg",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "gmab:IfrsNumberOfReportingUnits",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_item_d-Yn30W8q0CdLFqZ4zWe8g",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40101 - Disclosure - Basis of Presentation (Details)",
     "role": "http://www.genmab.com/role/DisclosureBasisOfPresentationDetails",
     "shortName": "Basis of Presentation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ifrs-full:DescriptionOfAccountingPolicyForSegmentReportingExplanatory",
       "ifrs-full:DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gmab-20220630xex99d1.htm",
      "contextRef": "As_Of_6_30_2022_kBUEJjmpl0mHNogMyIvzJg",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "gmab:IfrsNumberOfReportingUnits",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_item_d-Yn30W8q0CdLFqZ4zWe8g",
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "b",
       "p",
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory",
       "ifrs-full:DisclosureOfRevenueFromContractsWithCustomersExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gmab-20220630xex99d1.htm",
      "contextRef": "Duration_1_1_2022_To_6_30_2022_dNPMG5n7t0WcNVF9KG4Bdw",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "ifrs-full:RevenueFromContractsWithCustomers",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40201 - Disclosure - Revenue (Details)",
     "role": "http://www.genmab.com/role/DisclosureRevenueDetails",
     "shortName": "Revenue (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "b",
       "p",
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory",
       "ifrs-full:DisclosureOfRevenueFromContractsWithCustomersExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gmab-20220630xex99d1.htm",
      "contextRef": "Duration_1_1_2022_To_6_30_2022_dNPMG5n7t0WcNVF9KG4Bdw",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "ifrs-full:RevenueFromContractsWithCustomers",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg",
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ifrs-full:DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gmab-20220630xex99d1.htm",
      "contextRef": "As_Of_6_30_2022_ifrs-full_ExternalCreditGradesAxis_gmab_TripleaRatingMember_ifrs-full_TypesOfRisksAxis_ifrs-full_CreditRiskMember_MchtLzCh3Uufn_bh-7kpNA",
      "decimals": "4",
      "first": true,
      "lang": null,
      "name": "gmab:PercentageOfMarketableSecurities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_pure_ydC7mNX6akalcP_kj1H8wg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40301 - Disclosure - Financial Instruments - Financial Risk (Details)",
     "role": "http://www.genmab.com/role/DisclosureFinancialInstrumentsFinancialRiskDetails",
     "shortName": "Financial Instruments - Financial Risk (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ifrs-full:DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gmab-20220630xex99d1.htm",
      "contextRef": "As_Of_6_30_2022_ifrs-full_ExternalCreditGradesAxis_gmab_TripleaRatingMember_ifrs-full_TypesOfRisksAxis_ifrs-full_CreditRiskMember_MchtLzCh3Uufn_bh-7kpNA",
      "decimals": "4",
      "first": true,
      "lang": null,
      "name": "gmab:PercentageOfMarketableSecurities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_pure_ydC7mNX6akalcP_kj1H8wg",
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfOffsettingOfFinancialAssetsAndFinancialLiabilitiesExplanatory",
       "ifrs-full:DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gmab-20220630xex99d1.htm",
      "contextRef": "As_Of_6_30_2022_ifrs-full_ClassesOfFinancialAssetsAxis_gmab_MarketableSecuritiesMember_ifrs-full_MeasurementAxis_ifrs-full_AtFairValueMember_gMTFg1fkaU-2kMTWZGvA2A",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "ifrs-full:FinancialAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40302 - Disclosure - Financial Instruments - Fair Value Measurement (Details)",
     "role": "http://www.genmab.com/role/DisclosureFinancialInstrumentsFairValueMeasurementDetails",
     "shortName": "Financial Instruments - Fair Value Measurement (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfOffsettingOfFinancialAssetsAndFinancialLiabilitiesExplanatory",
       "ifrs-full:DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gmab-20220630xex99d1.htm",
      "contextRef": "As_Of_6_30_2022_ifrs-full_ClassesOfFinancialAssetsAxis_gmab_MarketableSecuritiesMember_ifrs-full_MeasurementAxis_ifrs-full_AtFairValueMember_gMTFg1fkaU-2kMTWZGvA2A",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "ifrs-full:FinancialAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg",
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gmab-20220630xex99d1.htm",
      "contextRef": "As_Of_6_30_2022_kBUEJjmpl0mHNogMyIvzJg",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "ifrs-full:InvestmentAccountedForUsingEquityMethod",
      "reportCount": 1,
      "unitRef": "Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40303 - Disclosure - Financial Instruments - Other Investments (Details)",
     "role": "http://www.genmab.com/role/DisclosureFinancialInstrumentsOtherInvestmentsDetails",
     "shortName": "Financial Instruments - Other Investments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ifrs-full:DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gmab-20220630xex99d1.htm",
      "contextRef": "As_Of_6_30_2022_gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_gmab_CurevacCollaborationMember_qc8QNPN5vUSdmz2Y_v8bjg",
      "decimals": "-6",
      "lang": null,
      "name": "ifrs-full:InvestmentAccountedForUsingEquityMethod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg",
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "gmab:DisclosureOfFinanceIncomeExpensesTableTextBlock",
       "ifrs-full:DisclosureOfFinanceIncomeExpenseExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gmab-20220630xex99d1.htm",
      "contextRef": "Duration_1_1_2022_To_6_30_2022_dNPMG5n7t0WcNVF9KG4Bdw",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "gmab:InterestAndOtherFinancialIncome",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40401 - Disclosure - Financial Income and Expenses (Details)",
     "role": "http://www.genmab.com/role/DisclosureFinancialIncomeAndExpensesDetails",
     "shortName": "Financial Income and Expenses (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "gmab:DisclosureOfFinanceIncomeExpensesTableTextBlock",
       "ifrs-full:DisclosureOfFinanceIncomeExpenseExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gmab-20220630xex99d1.htm",
      "contextRef": "Duration_1_1_2022_To_6_30_2022_dNPMG5n7t0WcNVF9KG4Bdw",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "gmab:InterestAndOtherFinancialIncome",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg",
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory",
       "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gmab-20220630xex99d1.htm",
      "contextRef": "Duration_1_1_2022_To_6_30_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_gmab_IfrsRestrictedStockUnitsRSUsMember_4-5BFoS8HkmkHqZSV1-skg",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_EquityInstruments_bRFAkAsdz0ugOZctjovS4A",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40501 - Disclosure - Share-Based Instruments - Restricted Stock Unit Program (Details)",
     "role": "http://www.genmab.com/role/DisclosureShareBasedInstrumentsRestrictedStockUnitProgramDetails",
     "shortName": "Share-Based Instruments - Restricted Stock Unit Program (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory",
       "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gmab-20220630xex99d1.htm",
      "contextRef": "Duration_1_1_2022_To_6_30_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_gmab_IfrsRestrictedStockUnitsRSUsMember_4-5BFoS8HkmkHqZSV1-skg",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_EquityInstruments_bRFAkAsdz0ugOZctjovS4A",
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gmab-20220630xex99d1.htm",
      "contextRef": "Duration_1_1_2022_To_6_30_2022_dNPMG5n7t0WcNVF9KG4Bdw",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "ifrs-full:ProceedsFromExerciseOfWarrants",
      "reportCount": 1,
      "unitRef": "Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40502 - Disclosure - Share-Based Instruments - Warrant Program (Details)",
     "role": "http://www.genmab.com/role/DisclosureShareBasedInstrumentsWarrantProgramDetails",
     "shortName": "Share-Based Instruments - Warrant Program (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gmab-20220630xex99d1.htm",
      "contextRef": "Duration_1_1_2022_To_6_30_2022_dNPMG5n7t0WcNVF9KG4Bdw",
      "decimals": "-6",
      "lang": null,
      "name": "ifrs-full:ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg",
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gmab-20220630xex99d1.htm",
      "contextRef": "Duration_1_1_2022_To_6_30_2022_dNPMG5n7t0WcNVF9KG4Bdw",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "gmab:ShareBasedArrangementNumberOfAuthorization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_item_d-Yn30W8q0CdLFqZ4zWe8g",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40503 - Disclosure - Share-Based Instruments - Share repurchases (Details)",
     "role": "http://www.genmab.com/role/DisclosureShareBasedInstrumentsShareRepurchasesDetails",
     "shortName": "Share-Based Instruments - Share repurchases (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gmab-20220630xex99d1.htm",
      "contextRef": "Duration_1_1_2022_To_6_30_2022_dNPMG5n7t0WcNVF9KG4Bdw",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "gmab:ShareBasedArrangementNumberOfAuthorization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_item_d-Yn30W8q0CdLFqZ4zWe8g",
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ifrs-full:DisclosureOfRelatedPartyExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gmab-20220630xex99d1.htm",
      "contextRef": "Duration_1_1_2022_To_6_30_2022_dNPMG5n7t0WcNVF9KG4Bdw",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "gmab:NumberOfChangesToExecutiveManagementTeam",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_item_d-Yn30W8q0CdLFqZ4zWe8g",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40601 - Disclosure - Related Parties (Details)",
     "role": "http://www.genmab.com/role/DisclosureRelatedPartiesDetails",
     "shortName": "Related Parties (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ifrs-full:DisclosureOfRelatedPartyExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gmab-20220630xex99d1.htm",
      "contextRef": "Duration_1_1_2022_To_6_30_2022_dNPMG5n7t0WcNVF9KG4Bdw",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "gmab:NumberOfChangesToExecutiveManagementTeam",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_item_d-Yn30W8q0CdLFqZ4zWe8g",
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gmab-20220630xex99d1.htm",
      "contextRef": "As_Of_6_30_2022_kBUEJjmpl0mHNogMyIvzJg",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "ifrs-full:IntangibleAssetsOtherThanGoodwill",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00200 - Statement - BALANCE SHEETS",
     "role": "http://www.genmab.com/role/StatementBalanceSheets",
     "shortName": "BALANCE SHEETS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gmab-20220630xex99d1.htm",
      "contextRef": "As_Of_6_30_2022_kBUEJjmpl0mHNogMyIvzJg",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "ifrs-full:IntangibleAssetsOtherThanGoodwill",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gmab-20220630xex99d1.htm",
      "contextRef": "As_Of_6_30_2022_kBUEJjmpl0mHNogMyIvzJg",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "ifrs-full:RightofuseAssets",
      "reportCount": 1,
      "unitRef": "Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40701 - Disclosure - Leases (Details)",
     "role": "http://www.genmab.com/role/DisclosureLeasesDetails",
     "shortName": "Leases (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "b",
       "p",
       "td",
       "tr",
       "table",
       "gmab:DisclosureOfBalanceSheetInformationRelatingToLeasesTableTextBlock",
       "ifrs-full:DisclosureOfLeasesExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gmab-20220630xex99d1.htm",
      "contextRef": "As_Of_6_30_2021_eEXLsHGqbE20an7xlGLjnw",
      "decimals": "-6",
      "lang": null,
      "name": "ifrs-full:RightofuseAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "b",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gmab-20220630xex99d1.htm",
      "contextRef": "Duration_1_1_2022_To_6_30_2022_dNPMG5n7t0WcNVF9KG4Bdw",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "ifrs-full:ProfitLossBeforeTax",
      "reportCount": 1,
      "unitRef": "Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00300 - Statement - STATEMENTS OF CASH FLOWS",
     "role": "http://www.genmab.com/role/StatementStatementsOfCashFlows",
     "shortName": "STATEMENTS OF CASH FLOWS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gmab-20220630xex99d1.htm",
      "contextRef": "Duration_1_1_2022_To_6_30_2022_dNPMG5n7t0WcNVF9KG4Bdw",
      "decimals": "-6",
      "lang": null,
      "name": "gmab:ReversalOfFinancialItemsNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "b",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gmab-20220630xex99d1.htm",
      "contextRef": "As_Of_12_31_2020_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_qxcDthXBpku77YP5whaVYg",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "ifrs-full:Equity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00400 - Statement - STATEMENTS OF CHANGES IN EQUITY",
     "role": "http://www.genmab.com/role/StatementStatementsOfChangesInEquity",
     "shortName": "STATEMENTS OF CHANGES IN EQUITY",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "b",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gmab-20220630xex99d1.htm",
      "contextRef": "As_Of_12_31_2020_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_qxcDthXBpku77YP5whaVYg",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "ifrs-full:Equity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_DKK_kl1yCoNxBkGxYOHLPhn2Sg",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gmab-20220630xex99d1.htm",
      "contextRef": "Duration_1_1_2022_To_6_30_2022_dNPMG5n7t0WcNVF9KG4Bdw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10101 - Disclosure - Basis of Presentation",
     "role": "http://www.genmab.com/role/DisclosureBasisOfPresentation",
     "shortName": "Basis of Presentation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gmab-20220630xex99d1.htm",
      "contextRef": "Duration_1_1_2022_To_6_30_2022_dNPMG5n7t0WcNVF9KG4Bdw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gmab-20220630xex99d1.htm",
      "contextRef": "Duration_1_1_2022_To_6_30_2022_dNPMG5n7t0WcNVF9KG4Bdw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfRevenueFromContractsWithCustomersExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10201 - Disclosure - Revenue",
     "role": "http://www.genmab.com/role/DisclosureRevenue",
     "shortName": "Revenue",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gmab-20220630xex99d1.htm",
      "contextRef": "Duration_1_1_2022_To_6_30_2022_dNPMG5n7t0WcNVF9KG4Bdw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfRevenueFromContractsWithCustomersExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gmab-20220630xex99d1.htm",
      "contextRef": "Duration_1_1_2022_To_6_30_2022_dNPMG5n7t0WcNVF9KG4Bdw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10301 - Disclosure - Financial Instruments",
     "role": "http://www.genmab.com/role/DisclosureFinancialInstruments",
     "shortName": "Financial Instruments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gmab-20220630xex99d1.htm",
      "contextRef": "Duration_1_1_2022_To_6_30_2022_dNPMG5n7t0WcNVF9KG4Bdw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gmab-20220630xex99d1.htm",
      "contextRef": "Duration_1_1_2022_To_6_30_2022_dNPMG5n7t0WcNVF9KG4Bdw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfFinanceIncomeExpenseExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10401 - Disclosure - Financial Income and Expenses",
     "role": "http://www.genmab.com/role/DisclosureFinancialIncomeAndExpenses",
     "shortName": "Financial Income and Expenses",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "gmab-20220630xex99d1.htm",
      "contextRef": "Duration_1_1_2022_To_6_30_2022_dNPMG5n7t0WcNVF9KG4Bdw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfFinanceIncomeExpenseExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 47,
   "tag": {
    "country_DK": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "DENMARK"
       }
      }
     },
     "localname": "DK",
     "nsuri": "http://xbrl.sec.gov/country/2021",
     "presentation": [
      "http://www.genmab.com/role/DisclosureLeasesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "currency_AllCurrenciesDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Currencies [Domain]"
       }
      }
     },
     "localname": "AllCurrenciesDomain",
     "nsuri": "http://xbrl.sec.gov/currency/2021",
     "presentation": [
      "http://www.genmab.com/role/DisclosureFinancialInstrumentsFinancialRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "currency_DKK": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "DKK"
       }
      }
     },
     "localname": "DKK",
     "nsuri": "http://xbrl.sec.gov/currency/2021",
     "presentation": [
      "http://www.genmab.com/role/DisclosureFinancialInstrumentsFinancialRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "currency_EUR": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Euro Member Countries, Euro"
       }
      }
     },
     "localname": "EUR",
     "nsuri": "http://xbrl.sec.gov/currency/2021",
     "presentation": [
      "http://www.genmab.com/role/DisclosureFinancialInstrumentsFinancialRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "currency_GBP": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "United Kingdom, Pounds"
       }
      }
     },
     "localname": "GBP",
     "nsuri": "http://xbrl.sec.gov/currency/2021",
     "presentation": [
      "http://www.genmab.com/role/DisclosureFinancialInstrumentsFinancialRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "currency_USD": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "United States of America, Dollars"
       }
      }
     },
     "localname": "USD",
     "nsuri": "http://xbrl.sec.gov/currency/2021",
     "presentation": [
      "http://www.genmab.com/role/DisclosureFinancialInstrumentsFinancialRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.genmab.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.genmab.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r184",
      "r185",
      "r186"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.genmab.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.genmab.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.genmab.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Document Information [Line Items]"
       }
      }
     },
     "localname": "DocumentInformationLineItems",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.genmab.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_DocumentInformationTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package.",
        "label": "Document Information [Table]"
       }
      }
     },
     "localname": "DocumentInformationTable",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.genmab.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.genmab.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentRegistrationStatement": {
     "auth_ref": [
      "r182"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a registration statement.",
        "label": "Document Registration Statement"
       }
      }
     },
     "localname": "DocumentRegistrationStatement",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.genmab.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentShellCompanyReport": {
     "auth_ref": [
      "r185"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.",
        "label": "Document Shell Company Report"
       }
      }
     },
     "localname": "DocumentShellCompanyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.genmab.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r187"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.genmab.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.genmab.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r183"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.genmab.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.genmab.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.genmab.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r183"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.genmab.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r190"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Entity Ex Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.genmab.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r183"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.genmab.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r188"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.genmab.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r183"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.genmab.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r183"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.genmab.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.genmab.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r189"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.genmab.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "gmab_AdjustmentsForInterestOnLeasePayments": {
     "auth_ref": [],
     "calculation": {
      "http://www.genmab.com/role/StatementStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Adjustments for interest on lease payments to reconcile profit (loss) to net cash flow from (used in) operating activities.",
        "label": "Adjustments For Interest On Lease Payments",
        "terseLabel": "Interest elements of lease payments"
       }
      }
     },
     "localname": "AdjustmentsForInterestOnLeasePayments",
     "nsuri": "http://www.genmab.com/20220630",
     "presentation": [
      "http://www.genmab.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gmab_AgreementsWithAbbvieMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for collaboration arrangement with Abbvie.",
        "label": "AbbVie"
       }
      }
     },
     "localname": "AgreementsWithAbbvieMember",
     "nsuri": "http://www.genmab.com/20220630",
     "presentation": [
      "http://www.genmab.com/role/DisclosureFinancialInstrumentsFinancialRiskDetails",
      "http://www.genmab.com/role/DisclosureRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gmab_AgreementsWithBointechMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for collaboration arrangements with BioNTech.",
        "label": "BioNTech"
       }
      }
     },
     "localname": "AgreementsWithBointechMember",
     "nsuri": "http://www.genmab.com/20220630",
     "presentation": [
      "http://www.genmab.com/role/DisclosureRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gmab_AgreementsWithJanssenMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for collaborative arrangement with Janssen (Darzalex/Daratumumab &amp; DuoBody).",
        "label": "Janssen"
       }
      }
     },
     "localname": "AgreementsWithJanssenMember",
     "nsuri": "http://www.genmab.com/20220630",
     "presentation": [
      "http://www.genmab.com/role/DisclosureRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gmab_AgreementsWithNovartisMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for collaborative arrangement with Novartis (Arzaerra/Ofatumumab).",
        "label": "Novartis (Arzaerra/Ofatumumab)"
       }
      }
     },
     "localname": "AgreementsWithNovartisMember",
     "nsuri": "http://www.genmab.com/20220630",
     "presentation": [
      "http://www.genmab.com/role/DisclosureRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gmab_AgreementsWithRocheMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for collaboration arrangement with Roche.",
        "label": "Roche"
       }
      }
     },
     "localname": "AgreementsWithRocheMember",
     "nsuri": "http://www.genmab.com/20220630",
     "presentation": [
      "http://www.genmab.com/role/DisclosureRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gmab_AgreementsWithSeagenMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for collaboration arrangement with Seagen.",
        "label": "Seagen"
       }
      }
     },
     "localname": "AgreementsWithSeagenMember",
     "nsuri": "http://www.genmab.com/20220630",
     "presentation": [
      "http://www.genmab.com/role/DisclosureRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gmab_AgreementsWithSeatleGeneticsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for collaboration arrangement with Seatle Genetics",
        "label": "Seattle Genetics"
       }
      }
     },
     "localname": "AgreementsWithSeatleGeneticsMember",
     "nsuri": "http://www.genmab.com/20220630",
     "presentation": [
      "http://www.genmab.com/role/DisclosureRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gmab_AmericanDepositorySharesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for American Depository Shares.",
        "label": "ADS"
       }
      }
     },
     "localname": "AmericanDepositorySharesMember",
     "nsuri": "http://www.genmab.com/20220630",
     "presentation": [
      "http://www.genmab.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "domainItemType"
    },
    "gmab_BankDepositsIncludingShortTermMarketableSecurities": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The value of bank deposits including short-term marketable securities.",
        "label": "Bank Deposits Including Short Term Marketable Securities",
        "terseLabel": "Total value of bank deposits"
       }
      }
     },
     "localname": "BankDepositsIncludingShortTermMarketableSecurities",
     "nsuri": "http://www.genmab.com/20220630",
     "presentation": [
      "http://www.genmab.com/role/DisclosureFinancialInstrumentsFinancialRiskDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gmab_BasisOfPresentationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "No definition available.",
        "label": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfPresentationAbstract",
     "nsuri": "http://www.genmab.com/20220630",
     "xbrltype": "stringItemType"
    },
    "gmab_BoltBiotherapeuticsIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to Bolt Biotherapeutics, Inc.",
        "label": "Bolt"
       }
      }
     },
     "localname": "BoltBiotherapeuticsIncMember",
     "nsuri": "http://www.genmab.com/20220630",
     "presentation": [
      "http://www.genmab.com/role/DisclosureFinancialInstrumentsOtherInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gmab_CashFlowFromUsedInOperatingActivitiesBeforeFinancialItems": {
     "auth_ref": [],
     "calculation": {
      "http://www.genmab.com/role/StatementStatementsOfCashFlows": {
       "order": 5.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash flows from (used in) operating activities, which are the principal revenue-producing activities of the entity and other activities before reconciling the financial items.",
        "label": "Cash Flow From (Used In) Operating Activities Before Financial Items",
        "totalLabel": "Cash flows from operating activities before financial items"
       }
      }
     },
     "localname": "CashFlowFromUsedInOperatingActivitiesBeforeFinancialItems",
     "nsuri": "http://www.genmab.com/20220630",
     "presentation": [
      "http://www.genmab.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gmab_CollaborationRevenueMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for collaboration revenue.",
        "label": "Collaboration revenue"
       }
      }
     },
     "localname": "CollaborationRevenueMember",
     "nsuri": "http://www.genmab.com/20220630",
     "presentation": [
      "http://www.genmab.com/role/DisclosureRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gmab_CollaborativeAgreementProfitSharingPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Profit sharing percentage under the collaboration agreement.",
        "label": "Collaborative Agreement, Profit Sharing Percentage",
        "terseLabel": "Profit sharing percentage under the collaboration agreement"
       }
      }
     },
     "localname": "CollaborativeAgreementProfitSharingPercentage",
     "nsuri": "http://www.genmab.com/20220630",
     "presentation": [
      "http://www.genmab.com/role/DisclosureBasisOfPresentationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "gmab_CollaborativeArrangementAndArrangementOtherThanCollaborativeLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "terseLabel": "Collaboration Agreements"
       }
      }
     },
     "localname": "CollaborativeArrangementAndArrangementOtherThanCollaborativeLineItems",
     "nsuri": "http://www.genmab.com/20220630",
     "presentation": [
      "http://www.genmab.com/role/DisclosureFinancialInstrumentsOtherInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "gmab_CorporateTaxReceivable": {
     "auth_ref": [],
     "calculation": {
      "http://www.genmab.com/role/StatementBalanceSheets": {
       "order": 4.0,
       "parentTag": "ifrs-full_CurrentAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Corporate Tax Receivable",
        "label": "Corporate Tax Receivable",
        "terseLabel": "Corporate tax receivable"
       }
      }
     },
     "localname": "CorporateTaxReceivable",
     "nsuri": "http://www.genmab.com/20220630",
     "presentation": [
      "http://www.genmab.com/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gmab_CurevacCollaborationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represent the information pertaining to CureVac Collaboration.",
        "label": "CureVac"
       }
      }
     },
     "localname": "CurevacCollaborationMember",
     "nsuri": "http://www.genmab.com/20220630",
     "presentation": [
      "http://www.genmab.com/role/DisclosureFinancialInstrumentsOtherInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gmab_DarzalexMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for DARZALEX.",
        "label": "DARZALEX [Member]",
        "terseLabel": "DARZALEX"
       }
      }
     },
     "localname": "DarzalexMember",
     "nsuri": "http://www.genmab.com/20220630",
     "presentation": [
      "http://www.genmab.com/role/DisclosureRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gmab_DeirdreP.ConnellyChairPernilleErenbjergDeputyChairRolfHoffmannDr.PaoloPaolettiAndDr.AndersGerselPedersenMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to Deirdre P. Connelly (Chair), Pernille Erenbjerg (Deputy Chair), Rolf Hoffmann, Dr. Paolo Paoletti, and Dr. Anders Gersel Pedersen.",
        "label": "Deirdre P. Connelly (Chair), Pernille Erenbjerg (Deputy Chair), Rolf Hoffmann, Dr. Paolo Paoletti, and Dr. Anders Gersel Pedersen [Member]",
        "terseLabel": "Deirdre P. Connelly (Chair), Pernille Erenbjerg (Deputy Chair), Rolf Hoffmann, Dr. Paolo Paoletti, and Dr. Anders Gersel Pedersen"
       }
      }
     },
     "localname": "DeirdreP.ConnellyChairPernilleErenbjergDeputyChairRolfHoffmannDr.PaoloPaolettiAndDr.AndersGerselPedersenMember",
     "nsuri": "http://www.genmab.com/20220630",
     "presentation": [
      "http://www.genmab.com/role/DisclosureRelatedPartiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gmab_DescriptionOfAccountingPolicyForBasisOfPresentationPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The description of the entity's accounting policy for Basis of presentation.",
        "label": "Description Of Accounting Policy For Basis Of Presentation Policy [Text Block]",
        "terseLabel": "Accounting Policies"
       }
      }
     },
     "localname": "DescriptionOfAccountingPolicyForBasisOfPresentationPolicyTextBlock",
     "nsuri": "http://www.genmab.com/20220630",
     "presentation": [
      "http://www.genmab.com/role/DisclosureBasisOfPresentationPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "gmab_DescriptionOfAccountingPolicyForJudgmentsAndEstimatesPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The description of the entity's accounting policy for Basis of presentation.",
        "label": "Description Of Accounting Policy For Judgments And Estimates [Policy Text Block]",
        "terseLabel": "Management Judgments and Estimates under IFRS"
       }
      }
     },
     "localname": "DescriptionOfAccountingPolicyForJudgmentsAndEstimatesPolicyTextBlock",
     "nsuri": "http://www.genmab.com/20220630",
     "presentation": [
      "http://www.genmab.com/role/DisclosureBasisOfPresentationPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "gmab_DescriptionOfAccountingPolicyForRecentAccountingStandardsAdoptedPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The description of the entity's accounting policy for recently adopted new accounting standards.",
        "label": "New Accounting Standards - Recently Adopted",
        "terseLabel": "New Accounting Policies and Disclosures"
       }
      }
     },
     "localname": "DescriptionOfAccountingPolicyForRecentAccountingStandardsAdoptedPolicyTextBlock",
     "nsuri": "http://www.genmab.com/20220630",
     "presentation": [
      "http://www.genmab.com/role/DisclosureBasisOfPresentationPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "gmab_DisclosureOfBalanceSheetInformationRelatingToLeasesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of balance sheet information relating to leases.",
        "label": "Summary of balance sheet amounts relating to leases"
       }
      }
     },
     "localname": "DisclosureOfBalanceSheetInformationRelatingToLeasesTableTextBlock",
     "nsuri": "http://www.genmab.com/20220630",
     "presentation": [
      "http://www.genmab.com/role/DisclosureLeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "gmab_DisclosureOfComprehensiveInformationRelatingToLeasesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of comprehensive information relating to leases.",
        "label": "Summary of statement of comprehensive income amounts relating to leases"
       }
      }
     },
     "localname": "DisclosureOfComprehensiveInformationRelatingToLeasesTableTextBlock",
     "nsuri": "http://www.genmab.com/20220630",
     "presentation": [
      "http://www.genmab.com/role/DisclosureLeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "gmab_DisclosureOfCorporateAndDeferredTaxTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for corporate and deferred Tax.",
        "label": "Disclosure Of Corporate And Deferred Tax [Table Text Block]",
        "terseLabel": "Schedule of corporate and deferred Tax"
       }
      }
     },
     "localname": "DisclosureOfCorporateAndDeferredTaxTableTextBlock",
     "nsuri": "http://www.genmab.com/20220630",
     "presentation": [
      "http://www.genmab.com/role/DisclosureRevenueTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "gmab_DisclosureOfFairValueMeasurementOfAssetsLevel3ReconciliationTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of level 3 reconciliation of assets measured at fair value.",
        "label": "Disclosure Of Fair Value Measurement Of Assets, Level 3 Reconciliation [Table Text Block]",
        "terseLabel": "Schedule of level 3 reconciliation of assets"
       }
      }
     },
     "localname": "DisclosureOfFairValueMeasurementOfAssetsLevel3ReconciliationTableTextBlock",
     "nsuri": "http://www.genmab.com/20220630",
     "presentation": [
      "http://www.genmab.com/role/DisclosureFinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "gmab_DisclosureOfFinanceIncomeExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "NA",
        "label": "Financial Income and Expenses"
       }
      }
     },
     "localname": "DisclosureOfFinanceIncomeExpensesAbstract",
     "nsuri": "http://www.genmab.com/20220630",
     "xbrltype": "stringItemType"
    },
    "gmab_DisclosureOfFinanceIncomeExpensesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "na",
        "label": "Schedule of financial income and expenses"
       }
      }
     },
     "localname": "DisclosureOfFinanceIncomeExpensesTableTextBlock",
     "nsuri": "http://www.genmab.com/20220630",
     "presentation": [
      "http://www.genmab.com/role/DisclosureFinancialIncomeAndExpensesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "gmab_DisclosureOfImpactOfExchangeRateOnNetResultBeforeTaxTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of impact of exchange rate on our net result before tax.",
        "label": "Disclosure Of Impact Of Exchange Rate On Net Result Before Tax [Table Text Block]",
        "terseLabel": "Schedule of impact of exchange rate on our net result before tax"
       }
      }
     },
     "localname": "DisclosureOfImpactOfExchangeRateOnNetResultBeforeTaxTableTextBlock",
     "nsuri": "http://www.genmab.com/20220630",
     "presentation": [
      "http://www.genmab.com/role/DisclosureFinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "gmab_DisclosureOfMarketableSecuritiesByCurrencyTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of marketable securities in foreign currency.",
        "label": "Disclosure Of Marketable Securities By Currency [Table Text Block]",
        "terseLabel": "Schedule of total marketable securities by currency"
       }
      }
     },
     "localname": "DisclosureOfMarketableSecuritiesByCurrencyTableTextBlock",
     "nsuri": "http://www.genmab.com/20220630",
     "presentation": [
      "http://www.genmab.com/role/DisclosureFinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "gmab_DisclosureOfMaturityProfileOfOurMarketableSecuritiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of maturity profile of our marketable securities.",
        "label": "Disclosure Of Maturity Profile Of Our Marketable Securities [Table Text Block]",
        "terseLabel": "Schedule of maturity profile of our marketable securities"
       }
      }
     },
     "localname": "DisclosureOfMaturityProfileOfOurMarketableSecuritiesTableTextBlock",
     "nsuri": "http://www.genmab.com/20220630",
     "presentation": [
      "http://www.genmab.com/role/DisclosureFinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "gmab_DisclosureOfNetResultTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of net result for the year.",
        "label": "Disclosure Of Net Result [Table Text Block]",
        "terseLabel": "Schedule of net result"
       }
      }
     },
     "localname": "DisclosureOfNetResultTableTextBlock",
     "nsuri": "http://www.genmab.com/20220630",
     "presentation": [
      "http://www.genmab.com/role/DisclosureRevenueTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "gmab_DisclosureOfNewAccountingPoliciesAndDisclosuresPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for new accounting policy and disclosures.",
        "label": "Disclosure Of New Accounting policies And Disclosures [Policy Text Block]",
        "terseLabel": "New Accounting Policies and Disclosures"
       }
      }
     },
     "localname": "DisclosureOfNewAccountingPoliciesAndDisclosuresPolicyTextBlock",
     "nsuri": "http://www.genmab.com/20220630",
     "presentation": [
      "http://www.genmab.com/role/DisclosureBasisOfPresentationPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "gmab_DisclosureOfNumberAndWeightedAverageExercisePricesOfWarrantsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The disclosure of the number and weighted average exercise prices of warrants.",
        "label": "Disclosure Of Number And Weighted Average Exercise Prices Of Warrants [Table Text Block]",
        "terseLabel": "Schedule of Weighted Average Exercise Prices Of Warrants"
       }
      }
     },
     "localname": "DisclosureOfNumberAndWeightedAverageExercisePricesOfWarrantsTableTextBlock",
     "nsuri": "http://www.genmab.com/20220630",
     "presentation": [
      "http://www.genmab.com/role/DisclosureFinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "gmab_DisclosureOfStaffCostTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of staff cost.",
        "label": "Disclosure Of Staff Cost [Table Text Block]",
        "terseLabel": "Schedule of staff cost"
       }
      }
     },
     "localname": "DisclosureOfStaffCostTableTextBlock",
     "nsuri": "http://www.genmab.com/20220630",
     "presentation": [
      "http://www.genmab.com/role/DisclosureRevenueTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "gmab_DisclosureOfWarrantsActivityTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of warrants activity.",
        "label": "Disclosure Of Warrants Activity [Table Text Block]",
        "terseLabel": "Summary of warrants activity"
       }
      }
     },
     "localname": "DisclosureOfWarrantsActivityTableTextBlock",
     "nsuri": "http://www.genmab.com/20220630",
     "presentation": [
      "http://www.genmab.com/role/DisclosureShareBasedInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "gmab_DocumentAndEntityInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document and Entity Information [Abstract]"
       }
      }
     },
     "localname": "DocumentAndEntityInformationAbstract",
     "nsuri": "http://www.genmab.com/20220630",
     "xbrltype": "stringItemType"
    },
    "gmab_ElectionToBoardOfDirectorsTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The term limit of board of directors.",
        "label": "Election to the Board of Directors, Term",
        "terseLabel": "Board of directors term"
       }
      }
     },
     "localname": "ElectionToBoardOfDirectorsTerm",
     "nsuri": "http://www.genmab.com/20220630",
     "presentation": [
      "http://www.genmab.com/role/DisclosureRelatedPartiesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "gmab_ElizabethOfarrellMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to Elizabeth O'Farrell.",
        "label": "Elizabeth O&amp;rsquo;Farrell [Member]",
        "terseLabel": "Elizabeth O'Farrell"
       }
      }
     },
     "localname": "ElizabethOfarrellMember",
     "nsuri": "http://www.genmab.com/20220630",
     "presentation": [
      "http://www.genmab.com/role/DisclosureRelatedPartiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gmab_EquityAdjustedForCumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of stockholder's equity, after the cumulative effect adjustment of a new accounting principle applied in the period of adoption.",
        "label": "Equity Adjusted For Cumulative Effect Of New Accounting Principle In Period Of Adoption",
        "terseLabel": "Adjusted total equity at January 1, 2018"
       }
      }
     },
     "localname": "EquityAdjustedForCumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption",
     "nsuri": "http://www.genmab.com/20220630",
     "presentation": [
      "http://www.genmab.com/role/StatementStatementsOfChangesInEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gmab_EstimatedCapitalExpenditureForLease": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of estimated capital expenditure for lease.",
        "label": "Estimated Capital Expenditure for Lease",
        "terseLabel": "Estimated capital expenditure for lease"
       }
      }
     },
     "localname": "EstimatedCapitalExpenditureForLease",
     "nsuri": "http://www.genmab.com/20220630",
     "presentation": [
      "http://www.genmab.com/role/DisclosureLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gmab_ExerciseOfWarrants": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of warrants exercised.",
        "label": "Exercise of Warrants",
        "terseLabel": "Exercise of warrants (in shares)"
       }
      }
     },
     "localname": "ExerciseOfWarrants",
     "nsuri": "http://www.genmab.com/20220630",
     "presentation": [
      "http://www.genmab.com/role/StatementStatementsOfChangesInEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "gmab_ExpensesRelatedToCapitalIncreaseDecrease": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expenses Related To Capital Increase Decrease",
        "label": "Expenses Related To Capital Increase Decrease",
        "terseLabel": "Expenses related to capital increases"
       }
      }
     },
     "localname": "ExpensesRelatedToCapitalIncreaseDecrease",
     "nsuri": "http://www.genmab.com/20220630",
     "presentation": [
      "http://www.genmab.com/role/StatementStatementsOfChangesInEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gmab_FinanceExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "na",
        "label": "Financial expenses:"
       }
      }
     },
     "localname": "FinanceExpensesAbstract",
     "nsuri": "http://www.genmab.com/20220630",
     "presentation": [
      "http://www.genmab.com/role/DisclosureFinancialIncomeAndExpensesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "gmab_FinanceIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "na",
        "label": "Financial Income:"
       }
      }
     },
     "localname": "FinanceIncomeAbstract",
     "nsuri": "http://www.genmab.com/20220630",
     "presentation": [
      "http://www.genmab.com/role/DisclosureFinancialIncomeAndExpensesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "gmab_FutureMinimumOperatingLeasePayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of future minimum operating lease payments.",
        "label": "Future Minimum Operating Lease Payments",
        "terseLabel": "Total future minimum payments"
       }
      }
     },
     "localname": "FutureMinimumOperatingLeasePayments",
     "nsuri": "http://www.genmab.com/20220630",
     "presentation": [
      "http://www.genmab.com/role/DisclosureLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gmab_GainOnOtherInvestments": {
     "auth_ref": [],
     "calculation": {
      "http://www.genmab.com/role/DisclosureFinancialIncomeAndExpensesDetails": {
       "order": 3.0,
       "parentTag": "ifrs-full_FinanceIncome",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The gains on other investments.",
        "label": "Gain On Other Investments",
        "terseLabel": "Gain on other investments, net"
       }
      }
     },
     "localname": "GainOnOtherInvestments",
     "nsuri": "http://www.genmab.com/20220630",
     "presentation": [
      "http://www.genmab.com/role/DisclosureFinancialIncomeAndExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gmab_GainsOnHedgingInstruments": {
     "auth_ref": [],
     "calculation": {
      "http://www.genmab.com/role/DisclosureFinancialIncomeAndExpensesDetails": {
       "order": 2.0,
       "parentTag": "ifrs-full_FinanceIncome",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The gains on hedging instruments in fair value hedges.",
        "label": "Realized and unrealized gains on fair value hedges, net",
        "terseLabel": "Realized and unrealized gains on fair value hedges, net"
       }
      }
     },
     "localname": "GainsOnHedgingInstruments",
     "nsuri": "http://www.genmab.com/20220630",
     "presentation": [
      "http://www.genmab.com/role/DisclosureFinancialIncomeAndExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Ifrs Collaborative Arrangement and Arrangement Other Than Collaborative [Axis]"
       }
      }
     },
     "localname": "IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis",
     "nsuri": "http://www.genmab.com/20220630",
     "presentation": [
      "http://www.genmab.com/role/DisclosureFinancialInstrumentsFinancialRiskDetails",
      "http://www.genmab.com/role/DisclosureFinancialInstrumentsOtherInvestmentsDetails",
      "http://www.genmab.com/role/DisclosureRevenueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Ifrs Collaborative Arrangement and Arrangement Other Than Collaborative [Domain]"
       }
      }
     },
     "localname": "IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeDomain",
     "nsuri": "http://www.genmab.com/20220630",
     "presentation": [
      "http://www.genmab.com/role/DisclosureFinancialInstrumentsFinancialRiskDetails",
      "http://www.genmab.com/role/DisclosureFinancialInstrumentsOtherInvestmentsDetails",
      "http://www.genmab.com/role/DisclosureRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gmab_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Ifrs Collaborative Arrangement and Arrangement Other than Collaborative [Table]"
       }
      }
     },
     "localname": "IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeTable",
     "nsuri": "http://www.genmab.com/20220630",
     "presentation": [
      "http://www.genmab.com/role/DisclosureFinancialInstrumentsOtherInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "gmab_IfrsCumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) to equity or (increase) decrease to net assets, resulting from the cumulative effect adjustment of a new accounting principle applied in the period of adoption.",
        "label": "Ifrs Cumulative Effect of New Accounting Principle in Period of Adoption",
        "terseLabel": "Change in accounting policy: Adoption of IFRS 15"
       }
      }
     },
     "localname": "IfrsCumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption",
     "nsuri": "http://www.genmab.com/20220630",
     "presentation": [
      "http://www.genmab.com/role/StatementStatementsOfChangesInEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gmab_IfrsEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to equipment.",
        "label": "Equipment"
       }
      }
     },
     "localname": "IfrsEquipmentMember",
     "nsuri": "http://www.genmab.com/20220630",
     "presentation": [
      "http://www.genmab.com/role/DisclosureLeasesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gmab_IfrsMarketableSecuritiesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.genmab.com/role/StatementBalanceSheets": {
       "order": 2.0,
       "parentTag": "ifrs-full_CurrentAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investments in debt and equity securities which have original maturities over to 90 days, including, but not limited to, held-to-maturity, trading and available-for-sale expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer.",
        "label": "Ifrs Marketable Securities Current",
        "terseLabel": "Marketable securities"
       }
      }
     },
     "localname": "IfrsMarketableSecuritiesCurrent",
     "nsuri": "http://www.genmab.com/20220630",
     "presentation": [
      "http://www.genmab.com/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gmab_IfrsNumberOfReportingUnits": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of reporting units tested for impairment of goodwill. A reporting unit is an operating segment or one level below an operating segment.",
        "label": "Number of business unit"
       }
      }
     },
     "localname": "IfrsNumberOfReportingUnits",
     "nsuri": "http://www.genmab.com/20220630",
     "presentation": [
      "http://www.genmab.com/role/DisclosureBasisOfPresentationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "gmab_IfrsRestrictedStockUnitsRSUsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "RSUs"
       }
      }
     },
     "localname": "IfrsRestrictedStockUnitsRSUsMember",
     "nsuri": "http://www.genmab.com/20220630",
     "presentation": [
      "http://www.genmab.com/role/DisclosureShareBasedInstrumentsRestrictedStockUnitProgramDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gmab_IfrsRoyaltiesByProductAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by royalties by product.",
        "label": "ifrs Royalties by Product [Axis]"
       }
      }
     },
     "localname": "IfrsRoyaltiesByProductAxis",
     "nsuri": "http://www.genmab.com/20220630",
     "presentation": [
      "http://www.genmab.com/role/DisclosureRevenueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "gmab_IfrsRoyaltiesByProductDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by royalties by product.",
        "label": "ifrs Royalties by Product [Domain]"
       }
      }
     },
     "localname": "IfrsRoyaltiesByProductDomain",
     "nsuri": "http://www.genmab.com/20220630",
     "presentation": [
      "http://www.genmab.com/role/DisclosureRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gmab_IfrsShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period which the right to exercise an award is no longer contingent on satisfaction of either a service condition, market condition or a performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "IFRS Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period",
        "terseLabel": "Vesting period"
       }
      }
     },
     "localname": "IfrsShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod",
     "nsuri": "http://www.genmab.com/20220630",
     "presentation": [
      "http://www.genmab.com/role/DisclosureShareBasedInstrumentsShareRepurchasesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "gmab_IncreaseDecreaseThroughNetSettlementOfRestrictedStockUnitsEquity": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) in equity resulting from net settlement of restricted stock units.",
        "label": "Increase Decrease Through Net Settlement Of Restricted Stock Units, Equity",
        "terseLabel": "Net settlement of RSUs"
       }
      }
     },
     "localname": "IncreaseDecreaseThroughNetSettlementOfRestrictedStockUnitsEquity",
     "nsuri": "http://www.genmab.com/20220630",
     "presentation": [
      "http://www.genmab.com/role/StatementStatementsOfChangesInEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gmab_IncreaseDecreaseThroughTaxOnItemsRecognizedDirectlyInEquity": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) in equity resulting from tax on items recognized directly in equity.",
        "label": "Increase Decrease Through Tax On Items Recognized Directly In Equity",
        "terseLabel": "Tax on items recognized directly in equity"
       }
      }
     },
     "localname": "IncreaseDecreaseThroughTaxOnItemsRecognizedDirectlyInEquity",
     "nsuri": "http://www.genmab.com/20220630",
     "presentation": [
      "http://www.genmab.com/role/StatementStatementsOfChangesInEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gmab_InterestAndOtherFinancialExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.genmab.com/role/DisclosureFinancialIncomeAndExpensesDetails": {
       "order": 3.0,
       "parentTag": "ifrs-full_FinanceCosts",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The interest and other financial expenses.",
        "label": "Interest and Other Financial Expenses",
        "negatedLabel": "Interest and other financial expenses"
       }
      }
     },
     "localname": "InterestAndOtherFinancialExpenses",
     "nsuri": "http://www.genmab.com/20220630",
     "presentation": [
      "http://www.genmab.com/role/DisclosureFinancialIncomeAndExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gmab_InterestAndOtherFinancialIncome": {
     "auth_ref": [],
     "calculation": {
      "http://www.genmab.com/role/DisclosureFinancialIncomeAndExpensesDetails": {
       "order": 4.0,
       "parentTag": "ifrs-full_FinanceIncome",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The interest and other financial income.",
        "label": "Interest and Other Financial Income",
        "terseLabel": "Interest and other financial income"
       }
      }
     },
     "localname": "InterestAndOtherFinancialIncome",
     "nsuri": "http://www.genmab.com/20220630",
     "presentation": [
      "http://www.genmab.com/role/DisclosureFinancialIncomeAndExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gmab_KesimptaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for Kesimpta.",
        "label": "Kesimpta [Member]",
        "terseLabel": "Kesimpta"
       }
      }
     },
     "localname": "KesimptaMember",
     "nsuri": "http://www.genmab.com/20220630",
     "presentation": [
      "http://www.genmab.com/role/DisclosureRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gmab_LicenseFeesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for revenue from license fees.",
        "label": "License fees"
       }
      }
     },
     "localname": "LicenseFeesMember",
     "nsuri": "http://www.genmab.com/20220630",
     "presentation": [
      "http://www.genmab.com/role/DisclosureRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gmab_LossesOnMarketableSecurities": {
     "auth_ref": [],
     "calculation": {
      "http://www.genmab.com/role/DisclosureFinancialIncomeAndExpensesDetails": {
       "order": 2.0,
       "parentTag": "ifrs-full_FinanceCosts",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The losses on marketable securities.",
        "label": "Losses on Marketable Securities",
        "negatedLabel": "Loss on marketable securities, net"
       }
      }
     },
     "localname": "LossesOnMarketableSecurities",
     "nsuri": "http://www.genmab.com/20220630",
     "presentation": [
      "http://www.genmab.com/role/DisclosureFinancialIncomeAndExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gmab_LossesOnOtherInvestmentsNet": {
     "auth_ref": [],
     "calculation": {
      "http://www.genmab.com/role/DisclosureFinancialIncomeAndExpensesDetails": {
       "order": 4.0,
       "parentTag": "ifrs-full_FinanceCosts",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Losses On Other Investments Net",
        "label": "Losses On Other Investments Net",
        "negatedLabel": "Loss on other investments, net"
       }
      }
     },
     "localname": "LossesOnOtherInvestmentsNet",
     "nsuri": "http://www.genmab.com/20220630",
     "presentation": [
      "http://www.genmab.com/role/DisclosureFinancialIncomeAndExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gmab_MarketableSecuritiesIncludingInterestReceivables": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of marketable securities including interest receivable.",
        "label": "Marketable Securities Including Interest Receivables",
        "terseLabel": "Marketable securities including interest receivables"
       }
      }
     },
     "localname": "MarketableSecuritiesIncludingInterestReceivables",
     "nsuri": "http://www.genmab.com/20220630",
     "presentation": [
      "http://www.genmab.com/role/DisclosureFinancialInstrumentsFinancialRiskDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gmab_MarketableSecuritiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for marketable securities .",
        "label": "Marketable Securities"
       }
      }
     },
     "localname": "MarketableSecuritiesMember",
     "nsuri": "http://www.genmab.com/20220630",
     "presentation": [
      "http://www.genmab.com/role/DisclosureFinancialInstrumentsFairValueMeasurementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gmab_MijkeZachariasseMartinSchultzAndTakahiroHamataniMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to Mijke Zachariasse, Martin Schultz and Takahiro Hamatani.",
        "label": "Mijke Zachariasse, Martin Schultz and Takahiro Hamatani [Member]",
        "terseLabel": "Mijke Zachariasse, Martin Schultz and Takahiro Hamatani"
       }
      }
     },
     "localname": "MijkeZachariasseMartinSchultzAndTakahiroHamataniMember",
     "nsuri": "http://www.genmab.com/20220630",
     "presentation": [
      "http://www.genmab.com/role/DisclosureRelatedPartiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gmab_MilestonePaymentsRevenueMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for revenue from milestone payments.",
        "label": "Milestone payments"
       }
      }
     },
     "localname": "MilestonePaymentsRevenueMember",
     "nsuri": "http://www.genmab.com/20220630",
     "presentation": [
      "http://www.genmab.com/role/DisclosureRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gmab_NumberOfApprovedProductsCommercializedByThirdParties": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of approved products commercialized by third parties.",
        "label": "Number Of Approved Products Commercialized By Third Parties",
        "terseLabel": "Number of approved products commercialized by third parties"
       }
      }
     },
     "localname": "NumberOfApprovedProductsCommercializedByThirdParties",
     "nsuri": "http://www.genmab.com/20220630",
     "presentation": [
      "http://www.genmab.com/role/DisclosureBasisOfPresentationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "gmab_NumberOfApprovedProductsJointlyCommercializedWithCollaboration": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of approved products jointly commercialized by collaboration partner.",
        "label": "Number Of Approved Products Jointly Commercialized With Collaboration",
        "terseLabel": "Number of approved products jointly commercialized by collaboration partner"
       }
      }
     },
     "localname": "NumberOfApprovedProductsJointlyCommercializedWithCollaboration",
     "nsuri": "http://www.genmab.com/20220630",
     "presentation": [
      "http://www.genmab.com/role/DisclosureBasisOfPresentationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "gmab_NumberOfChangesToExecutiveManagementTeam": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of changes to executive management team.",
        "label": "Number of Changes to Executive Management Team",
        "terseLabel": "Number of changes to executive management team"
       }
      }
     },
     "localname": "NumberOfChangesToExecutiveManagementTeam",
     "nsuri": "http://www.genmab.com/20220630",
     "presentation": [
      "http://www.genmab.com/role/DisclosureRelatedPartiesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "gmab_NumberOfEmployeeElectedBoardMembers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of employee elected board members.",
        "label": "Number of Employee Elected Board Members",
        "terseLabel": "Number of employee elected board members"
       }
      }
     },
     "localname": "NumberOfEmployeeElectedBoardMembers",
     "nsuri": "http://www.genmab.com/20220630",
     "presentation": [
      "http://www.genmab.com/role/DisclosureRelatedPartiesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "gmab_NumberOfIndependentBoardMembers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of independent board members.",
        "label": "Number of Independent Board Members",
        "terseLabel": "Number of independent board members"
       }
      }
     },
     "localname": "NumberOfIndependentBoardMembers",
     "nsuri": "http://www.genmab.com/20220630",
     "presentation": [
      "http://www.genmab.com/role/DisclosureRelatedPartiesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "gmab_NumberOfNonIndependentBoardMembers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of non independent board members.",
        "label": "Number of Non Independent Board Members",
        "terseLabel": "Number of non independent board members"
       }
      }
     },
     "localname": "NumberOfNonIndependentBoardMembers",
     "nsuri": "http://www.genmab.com/20220630",
     "presentation": [
      "http://www.genmab.com/role/DisclosureRelatedPartiesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "gmab_NumberOfSharesAuthorizedToBeRepurchased": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares authorized to be repurchased by an entity's Board of Directors under a stock repurchase plan.",
        "label": "Number Of Shares Authorized To Be Repurchased",
        "terseLabel": "Number of shares authorized for repurchase"
       }
      }
     },
     "localname": "NumberOfSharesAuthorizedToBeRepurchased",
     "nsuri": "http://www.genmab.com/20220630",
     "presentation": [
      "http://www.genmab.com/role/DisclosureShareBasedInstrumentsShareRepurchasesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "gmab_NumberOfTreasurySharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares that has been held in treasury.",
        "label": "Number of Treasury Shares Outstanding",
        "terseLabel": "Treasury shares outstanding"
       }
      }
     },
     "localname": "NumberOfTreasurySharesOutstanding",
     "nsuri": "http://www.genmab.com/20220630",
     "presentation": [
      "http://www.genmab.com/role/DisclosureShareBasedInstrumentsWarrantProgramDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "gmab_NumberOfWarrantsExercisedDuringPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of warrants exercised during period.",
        "label": "Number Of Warrants Exercised During Period",
        "terseLabel": "Exercised"
       }
      }
     },
     "localname": "NumberOfWarrantsExercisedDuringPeriod",
     "nsuri": "http://www.genmab.com/20220630",
     "presentation": [
      "http://www.genmab.com/role/DisclosureShareBasedInstrumentsWarrantProgramDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "gmab_NumberOfWarrantsExpiredOrLapsedOrCancelledDuringPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of warrants expired or lapsed or cancelled during period.",
        "label": "Number Of Warrants Expired Or Lapsed Or Cancelled During Period",
        "negatedLabel": "Expired/lapsed/cancelled"
       }
      }
     },
     "localname": "NumberOfWarrantsExpiredOrLapsedOrCancelledDuringPeriod",
     "nsuri": "http://www.genmab.com/20220630",
     "presentation": [
      "http://www.genmab.com/role/DisclosureShareBasedInstrumentsWarrantProgramDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "gmab_NumberOfWarrantsGrantedDuringPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of warrants granted during period.",
        "label": "Number Of Warrants Granted During Period",
        "terseLabel": "Granted"
       }
      }
     },
     "localname": "NumberOfWarrantsGrantedDuringPeriod",
     "nsuri": "http://www.genmab.com/20220630",
     "presentation": [
      "http://www.genmab.com/role/DisclosureShareBasedInstrumentsWarrantProgramDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "gmab_NumberOfWarrantsOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of warrants held as of the balance sheet date.",
        "label": "Number Of Warrants Outstanding",
        "periodEndLabel": "Balance at end of period",
        "periodStartLabel": "Balance at beginning of period"
       }
      }
     },
     "localname": "NumberOfWarrantsOutstanding",
     "nsuri": "http://www.genmab.com/20220630",
     "presentation": [
      "http://www.genmab.com/role/DisclosureShareBasedInstrumentsWarrantProgramDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "gmab_OfficeAndLaboratorySpaceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for Office and laboratory space.",
        "label": "Office and laboratory space"
       }
      }
     },
     "localname": "OfficeAndLaboratorySpaceMember",
     "nsuri": "http://www.genmab.com/20220630",
     "presentation": [
      "http://www.genmab.com/role/DisclosureLeasesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gmab_OtherCollaborationPartnersMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for collaborative arrangement with other collaboration partners.",
        "label": "Other collaboration partners"
       }
      }
     },
     "localname": "OtherCollaborationPartnersMember",
     "nsuri": "http://www.genmab.com/20220630",
     "presentation": [
      "http://www.genmab.com/role/DisclosureRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gmab_OtherInvestmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to other investments.",
        "label": "Other"
       }
      }
     },
     "localname": "OtherInvestmentMember",
     "nsuri": "http://www.genmab.com/20220630",
     "presentation": [
      "http://www.genmab.com/role/DisclosureFinancialInstrumentsFairValueMeasurementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gmab_OtherRoyaltyProductMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for other royalty product.",
        "label": "Other Royalty Product [Member]",
        "terseLabel": "Other Royalty Product"
       }
      }
     },
     "localname": "OtherRoyaltyProductMember",
     "nsuri": "http://www.genmab.com/20220630",
     "presentation": [
      "http://www.genmab.com/role/DisclosureRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gmab_PaymentOfWithholdingTaxesOnBehalfOfEmployeesOnNetSettledRSUs": {
     "auth_ref": [],
     "calculation": {
      "http://www.genmab.com/role/StatementStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for withholding taxes on behalf of employees on net settled restricted stock units (RSUs).",
        "label": "Payment Of Withholding Taxes On Behalf Of Employees On Net Settled R S Us",
        "negatedLabel": "Payment of withholding taxes on behalf of employees on net settled RSUs"
       }
      }
     },
     "localname": "PaymentOfWithholdingTaxesOnBehalfOfEmployeesOnNetSettledRSUs",
     "nsuri": "http://www.genmab.com/20220630",
     "presentation": [
      "http://www.genmab.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gmab_PaymentsToAcquireTreasuryShares": {
     "auth_ref": [],
     "calculation": {
      "http://www.genmab.com/role/StatementStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow to acquire treasury shares.",
        "label": "Payments To Acquire Treasury Shares",
        "negatedLabel": "Purchase of treasury shares"
       }
      }
     },
     "localname": "PaymentsToAcquireTreasuryShares",
     "nsuri": "http://www.genmab.com/20220630",
     "presentation": [
      "http://www.genmab.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gmab_PercentageOfInvestmentInCommonShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of investment in common shares.",
        "label": "Percentage of Investment in Common Shares",
        "terseLabel": "Percentage of investment in common shares"
       }
      }
     },
     "localname": "PercentageOfInvestmentInCommonShares",
     "nsuri": "http://www.genmab.com/20220630",
     "presentation": [
      "http://www.genmab.com/role/DisclosureFinancialInstrumentsOtherInvestmentsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "gmab_PercentageOfMarketableSecurities": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage of marketable securities.",
        "label": "Percentage of Marketable Securities",
        "terseLabel": "Percentage of marketable securities"
       }
      }
     },
     "localname": "PercentageOfMarketableSecurities",
     "nsuri": "http://www.genmab.com/20220630",
     "presentation": [
      "http://www.genmab.com/role/DisclosureFinancialInstrumentsFinancialRiskDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "gmab_PercentageOfMarketableSecuritiesInvested": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of marketable securities invested.",
        "label": "Percentage of Marketable Securities Invested",
        "terseLabel": "Marketable securities were invested (as a percent)"
       }
      }
     },
     "localname": "PercentageOfMarketableSecuritiesInvested",
     "nsuri": "http://www.genmab.com/20220630",
     "presentation": [
      "http://www.genmab.com/role/DisclosureFinancialInstrumentsFinancialRiskDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "gmab_PercentageOfPossibleIncreaseDecreaseInExchangeRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of possible increase or decrease in exchange rate.",
        "label": "Percentage Of Possible Increase (Decrease) In Exchange rate",
        "terseLabel": "Percentage of possible increase or decrease in exchange rate"
       }
      }
     },
     "localname": "PercentageOfPossibleIncreaseDecreaseInExchangeRate",
     "nsuri": "http://www.genmab.com/20220630",
     "presentation": [
      "http://www.genmab.com/role/DisclosureFinancialInstrumentsFinancialRiskDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "gmab_PercentageOfRevenue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of revenue.",
        "label": "Percentage of Revenue",
        "terseLabel": "Revenue (as a percent)"
       }
      }
     },
     "localname": "PercentageOfRevenue",
     "nsuri": "http://www.genmab.com/20220630",
     "presentation": [
      "http://www.genmab.com/role/DisclosureFinancialInstrumentsFinancialRiskDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "gmab_PercentageOfShareCapitalAttributedToExerciseOfWarrants": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of share capital attributed by exercise of warrants which increase the share capital.",
        "label": "Percentage Of Share Capital Attributed To Exercise Of Warrants",
        "terseLabel": "Percentage of share capital attributed to exercise of warrants"
       }
      }
     },
     "localname": "PercentageOfShareCapitalAttributedToExerciseOfWarrants",
     "nsuri": "http://www.genmab.com/20220630",
     "presentation": [
      "http://www.genmab.com/role/DisclosureShareBasedInstrumentsWarrantProgramDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "gmab_PercentageOfShareCapitalRepurchased": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of share capital repurchased.",
        "label": "Percentage Of Share Capital Repurchased",
        "terseLabel": "Percentage of share capital repurchased"
       }
      }
     },
     "localname": "PercentageOfShareCapitalRepurchased",
     "nsuri": "http://www.genmab.com/20220630",
     "presentation": [
      "http://www.genmab.com/role/DisclosureShareBasedInstrumentsShareRepurchasesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "gmab_PropertiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to properties.",
        "label": "Properties"
       }
      }
     },
     "localname": "PropertiesMember",
     "nsuri": "http://www.genmab.com/20220630",
     "presentation": [
      "http://www.genmab.com/role/DisclosureLeasesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gmab_ReElectionToBoardOfDirectorsTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The term limit of board of directors who are re-elected.",
        "label": "Re-Election to the Board of Directors Term",
        "terseLabel": "Re-election to the board of directors term"
       }
      }
     },
     "localname": "ReElectionToBoardOfDirectorsTerm",
     "nsuri": "http://www.genmab.com/20220630",
     "presentation": [
      "http://www.genmab.com/role/DisclosureRelatedPartiesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "gmab_ReimbursementIncomeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for reimbursement income.",
        "label": "Reimbursement income"
       }
      }
     },
     "localname": "ReimbursementIncomeMember",
     "nsuri": "http://www.genmab.com/20220630",
     "presentation": [
      "http://www.genmab.com/role/DisclosureRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gmab_RestrictedStockUnitsRSUsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "RSU"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUsMember",
     "nsuri": "http://www.genmab.com/20220630",
     "presentation": [
      "http://www.genmab.com/role/DisclosureShareBasedInstrumentsShareRepurchasesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gmab_ReversalOfFinancialItemsNet": {
     "auth_ref": [],
     "calculation": {
      "http://www.genmab.com/role/StatementStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "gmab_CashFlowFromUsedInOperatingActivitiesBeforeFinancialItems",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The reversal of financial items to the cash flow under operating activities.",
        "label": "Reversal Of Financial Items, Net",
        "negatedLabel": "Reversal of financial items, net"
       }
      }
     },
     "localname": "ReversalOfFinancialItemsNet",
     "nsuri": "http://www.genmab.com/20220630",
     "presentation": [
      "http://www.genmab.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gmab_RoyaltiesRevenueMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for revenue form royalties.",
        "label": "Royalties"
       }
      }
     },
     "localname": "RoyaltiesRevenueMember",
     "nsuri": "http://www.genmab.com/20220630",
     "presentation": [
      "http://www.genmab.com/role/DisclosureRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gmab_ScheduleOfPortfolioOfMarketableSecurities": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of portfolio of marketable securities.",
        "label": "Schedule Of Portfolio Of Marketable Securities",
        "terseLabel": "Schedule of portfolio of marketable securities"
       }
      }
     },
     "localname": "ScheduleOfPortfolioOfMarketableSecurities",
     "nsuri": "http://www.genmab.com/20220630",
     "presentation": [
      "http://www.genmab.com/role/DisclosureFinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "gmab_ScheduleOfSegmentDisclosuresInFinancialStatementsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for segment disclosures in the financial statements as the group's business activities.",
        "label": "Schedule Of Segment Disclosures In Financial Statements [Table Text Block]",
        "terseLabel": "Schedule of segment disclosures in the financial statements as the group's business activities."
       }
      }
     },
     "localname": "ScheduleOfSegmentDisclosuresInFinancialStatementsTableTextBlock",
     "nsuri": "http://www.genmab.com/20220630",
     "presentation": [
      "http://www.genmab.com/role/DisclosureRevenueTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "gmab_ScheduleOfShareRepurchasesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of repurchase of shares.",
        "label": "Schedule of Share Repurchases [Table Text Block]",
        "terseLabel": "Schedule of share repurchases"
       }
      }
     },
     "localname": "ScheduleOfShareRepurchasesTableTextBlock",
     "nsuri": "http://www.genmab.com/20220630",
     "presentation": [
      "http://www.genmab.com/role/DisclosureShareBasedInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "gmab_ShareBasedArrangementNumberOfAuthorization": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of authorization under the share based payment arrangements.",
        "label": "Share Based Arrangement, Number Of Authorization",
        "terseLabel": "Number of authorization"
       }
      }
     },
     "localname": "ShareBasedArrangementNumberOfAuthorization",
     "nsuri": "http://www.genmab.com/20220630",
     "presentation": [
      "http://www.genmab.com/role/DisclosureShareBasedInstrumentsShareRepurchasesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "gmab_ShareBasedArrangementNumberOfSharesPerRsu": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares credited for one share of RSU owned by the holder under the share based payment arrangements.",
        "label": "Share Based Arrangement, Number Of Shares Per RSU",
        "terseLabel": "Number of shares per RSU"
       }
      }
     },
     "localname": "ShareBasedArrangementNumberOfSharesPerRsu",
     "nsuri": "http://www.genmab.com/20220630",
     "presentation": [
      "http://www.genmab.com/role/DisclosureShareBasedInstrumentsShareRepurchasesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "gmab_ShareBasedArrangementPeriodFromVestingDateHolderReceivesShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period from vesting date in which the holder receives shares in the account per RSU under the share based payments arrangement.",
        "label": "Share Based Arrangement, Period From Vesting Date The Holder Receives Shares",
        "terseLabel": "Period from vesting date for crediting shares"
       }
      }
     },
     "localname": "ShareBasedArrangementPeriodFromVestingDateHolderReceivesShares",
     "nsuri": "http://www.genmab.com/20220630",
     "presentation": [
      "http://www.genmab.com/role/DisclosureShareBasedInstrumentsShareRepurchasesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "gmab_ShareRepurchasedDuringPeriodShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares that have been repurchased during the period and have not been retired and are not held in treasury.",
        "label": "Share Repurchased During Period Shares",
        "terseLabel": "Actual shares repurchased under authorization"
       }
      }
     },
     "localname": "ShareRepurchasedDuringPeriodShares",
     "nsuri": "http://www.genmab.com/20220630",
     "presentation": [
      "http://www.genmab.com/role/DisclosureShareBasedInstrumentsShareRepurchasesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "gmab_ShareRepurchasedDuringPeriodValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock that has been repurchased during the period and has not been retired and is not held in treasury.",
        "label": "Share Repurchased During Period Value",
        "terseLabel": "Share repurchased amount"
       }
      }
     },
     "localname": "ShareRepurchasedDuringPeriodValue",
     "nsuri": "http://www.genmab.com/20220630",
     "presentation": [
      "http://www.genmab.com/role/DisclosureShareBasedInstrumentsShareRepurchasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gmab_SharesAvailableForRepurchase": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares available for repurchase.",
        "label": "Shares Available For Repurchase",
        "terseLabel": "Shares available for repurchase"
       }
      }
     },
     "localname": "SharesAvailableForRepurchase",
     "nsuri": "http://www.genmab.com/20220630",
     "presentation": [
      "http://www.genmab.com/role/DisclosureShareBasedInstrumentsShareRepurchasesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "gmab_SharesAvailableForRepurchaseAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of shares that are available for repurchase.",
        "label": "Shares Available For Repurchase Amount",
        "terseLabel": "Shares available for repurchase amount"
       }
      }
     },
     "localname": "SharesAvailableForRepurchaseAmount",
     "nsuri": "http://www.genmab.com/20220630",
     "presentation": [
      "http://www.genmab.com/role/DisclosureShareBasedInstrumentsShareRepurchasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gmab_SharesRepurchasedNominalValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nominal value of share repurchased.",
        "label": "Shares Repurchased Nominal Value",
        "terseLabel": "Nominal value of shares repurchases"
       }
      }
     },
     "localname": "SharesRepurchasedNominalValue",
     "nsuri": "http://www.genmab.com/20220630",
     "presentation": [
      "http://www.genmab.com/role/DisclosureShareBasedInstrumentsShareRepurchasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gmab_StaffCostsIncludedInGeneralAndAdministrativeExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.genmab.com/role/DisclosureResultsForYearStaffCostsDetailsCalc2": {
       "order": 2.0,
       "parentTag": "ifrs-full_EmployeeBenefitsExpense",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of staff cost included in research and development expenses.",
        "label": "Staff Costs Included In General and administrative expenses"
       }
      }
     },
     "localname": "StaffCostsIncludedInGeneralAndAdministrativeExpenses",
     "nsuri": "http://www.genmab.com/20220630",
     "xbrltype": "monetaryItemType"
    },
    "gmab_StaffCostsIncludedInGovernmentGrantsRelatedToResearchAndDevelopmentExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.genmab.com/role/DisclosureResultsForYearStaffCostsDetailsCalc2": {
       "order": 4.0,
       "parentTag": "ifrs-full_EmployeeBenefitsExpense",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of staff cost included in government grants related to research and development expenses.",
        "label": "Staff Costs Included In Government Grants Related To Research And Development Expenses"
       }
      }
     },
     "localname": "StaffCostsIncludedInGovernmentGrantsRelatedToResearchAndDevelopmentExpenses",
     "nsuri": "http://www.genmab.com/20220630",
     "xbrltype": "monetaryItemType"
    },
    "gmab_StaffCostsIncludedInResearchAndDevelopmentExpense": {
     "auth_ref": [],
     "calculation": {
      "http://www.genmab.com/role/DisclosureResultsForYearStaffCostsDetailsCalc2": {
       "order": 1.0,
       "parentTag": "ifrs-full_EmployeeBenefitsExpense",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of staff cost included in research and development expenses.",
        "label": "Staff Costs Included In Research And Development Expense"
       }
      }
     },
     "localname": "StaffCostsIncludedInResearchAndDevelopmentExpense",
     "nsuri": "http://www.genmab.com/20220630",
     "xbrltype": "monetaryItemType"
    },
    "gmab_StaffCostsIncludedInSellingGeneralAndAdministrativeExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.genmab.com/role/DisclosureResultsForYearStaffCostsDetailsCalc2": {
       "order": 3.0,
       "parentTag": "ifrs-full_EmployeeBenefitsExpense",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of staff cost included in selling, general and administrative expenses.",
        "label": "Staff Costs Included in Selling, General and Administrative Expenses"
       }
      }
     },
     "localname": "StaffCostsIncludedInSellingGeneralAndAdministrativeExpenses",
     "nsuri": "http://www.genmab.com/20220630",
     "xbrltype": "monetaryItemType"
    },
    "gmab_StockRepurchaseAuthorization2016Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the 2016 authorization under the share repurchase arrangement by the board of directors.",
        "label": "Stock Repurchase Authorization 2016 [Member]",
        "terseLabel": "2016 Authorization"
       }
      }
     },
     "localname": "StockRepurchaseAuthorization2016Member",
     "nsuri": "http://www.genmab.com/20220630",
     "presentation": [
      "http://www.genmab.com/role/DisclosureShareBasedInstrumentsShareRepurchasesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gmab_StockRepurchaseAuthorization2019Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the 2019 authorization under the share repurchase arrangement by the board of directors.",
        "label": "Stock Repurchase Authorization 2019 [Member]",
        "terseLabel": "2019 Authorization"
       }
      }
     },
     "localname": "StockRepurchaseAuthorization2019Member",
     "nsuri": "http://www.genmab.com/20220630",
     "presentation": [
      "http://www.genmab.com/role/DisclosureShareBasedInstrumentsShareRepurchasesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gmab_StockRepurchaseAuthorization2021Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the 2021 authorization under the share repurchase arrangement by the board of directors.",
        "label": "Stock Repurchase Authorization 2021 [Member]",
        "terseLabel": "2021 Authorization"
       }
      }
     },
     "localname": "StockRepurchaseAuthorization2021Member",
     "nsuri": "http://www.genmab.com/20220630",
     "presentation": [
      "http://www.genmab.com/role/DisclosureShareBasedInstrumentsShareRepurchasesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gmab_StockRepurchaseFirstAuthorizationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the first authorization under the share repurchase arrangement by the board of directors.",
        "label": "First authorization"
       }
      }
     },
     "localname": "StockRepurchaseFirstAuthorizationMember",
     "nsuri": "http://www.genmab.com/20220630",
     "presentation": [
      "http://www.genmab.com/role/DisclosureShareBasedInstrumentsShareRepurchasesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gmab_StockRepurchaseSecondAuthorizationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the second authorization under the share repurchase arrangement by the board of directors.",
        "label": "Second authorization"
       }
      }
     },
     "localname": "StockRepurchaseSecondAuthorizationMember",
     "nsuri": "http://www.genmab.com/20220630",
     "presentation": [
      "http://www.genmab.com/role/DisclosureShareBasedInstrumentsShareRepurchasesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gmab_StockRepurchaseThresholdPriceDeviationPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the threshold price deviation percentage under stock repurchase arrangement.",
        "label": "Stock Repurchase Threshold Price Deviation Percentage",
        "terseLabel": "Threshold price deviation percentage"
       }
      }
     },
     "localname": "StockRepurchaseThresholdPriceDeviationPercentage",
     "nsuri": "http://www.genmab.com/20220630",
     "presentation": [
      "http://www.genmab.com/role/DisclosureShareBasedInstrumentsShareRepurchasesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "gmab_TaxOnItemsRecognizedDirectlyInEquity": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax on items recognized directly in equity.",
        "label": "Tax On Items Recognized Directly In Equity"
       }
      }
     },
     "localname": "TaxOnItemsRecognizedDirectlyInEquity",
     "nsuri": "http://www.genmab.com/20220630",
     "presentation": [
      "http://www.genmab.com/role/StatementStatementsOfChangesInEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gmab_TepezzaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for TEPEZZA.",
        "label": "TEPEZZA [Member]",
        "terseLabel": "TEPEZZA"
       }
      }
     },
     "localname": "TepezzaMember",
     "nsuri": "http://www.genmab.com/20220630",
     "presentation": [
      "http://www.genmab.com/role/DisclosureRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gmab_ThirdAuthorizationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the third authorization under the share repurchase arrangement by the board of directors.",
        "label": "Third Authorization [Member]",
        "terseLabel": "Third authorization"
       }
      }
     },
     "localname": "ThirdAuthorizationMember",
     "nsuri": "http://www.genmab.com/20220630",
     "presentation": [
      "http://www.genmab.com/role/DisclosureShareBasedInstrumentsShareRepurchasesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gmab_TotalAdjustmentsForNonCashTransactions": {
     "auth_ref": [],
     "calculation": {
      "http://www.genmab.com/role/StatementStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "gmab_CashFlowFromUsedInOperatingActivitiesBeforeFinancialItems",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Adjustments for total non-cash items to reconcile profit (loss) to net cash flow from (used in) operating activities.",
        "label": "Total Adjustments For Non Cash Transactions",
        "terseLabel": "Adjustments for non-cash transactions"
       }
      }
     },
     "localname": "TotalAdjustmentsForNonCashTransactions",
     "nsuri": "http://www.genmab.com/20220630",
     "presentation": [
      "http://www.genmab.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gmab_TransactionsWithOwners": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "n/a",
        "label": "Transactions With Owners",
        "terseLabel": "Transactions with owners:"
       }
      }
     },
     "localname": "TransactionsWithOwners",
     "nsuri": "http://www.genmab.com/20220630",
     "presentation": [
      "http://www.genmab.com/role/StatementStatementsOfChangesInEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "gmab_TreasurySharesAcquired": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of treasury shares acquired during period.",
        "label": "Purchase of treasury shares.",
        "terseLabel": "Treasury shares acquired"
       }
      }
     },
     "localname": "TreasurySharesAcquired",
     "nsuri": "http://www.genmab.com/20220630",
     "presentation": [
      "http://www.genmab.com/role/DisclosureShareBasedInstrumentsShareRepurchasesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "gmab_TripleaRatingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for Triple A-rating.",
        "label": "Triple A-rating from Moody's, S&amp;P or Fitch"
       }
      }
     },
     "localname": "TripleaRatingMember",
     "nsuri": "http://www.genmab.com/20220630",
     "presentation": [
      "http://www.genmab.com/role/DisclosureFinancialInstrumentsFinancialRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gmab_TypesOfRevenuesAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table.",
        "label": "Types of revenues [axis]"
       }
      }
     },
     "localname": "TypesOfRevenuesAxis",
     "nsuri": "http://www.genmab.com/20220630",
     "presentation": [
      "http://www.genmab.com/role/DisclosureRevenueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "gmab_TypesOfRevenuesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for This member stands for all types of revenues from customers. It also represents the standard value for the 'Types of revenues' axis if no other member is used.",
        "label": "Types of revenues [member]"
       }
      }
     },
     "localname": "TypesOfRevenuesMember",
     "nsuri": "http://www.genmab.com/20220630",
     "presentation": [
      "http://www.genmab.com/role/DisclosureRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gmab_ValuationAssumptionsForWarrantsGrantedTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of fair value of each warrant granted.",
        "label": "Valuation Assumptions for Warrants Granted [Table Text Block]",
        "terseLabel": "Fair value of each warrant granted"
       }
      }
     },
     "localname": "ValuationAssumptionsForWarrantsGrantedTableTextBlock",
     "nsuri": "http://www.genmab.com/20220630",
     "presentation": [
      "http://www.genmab.com/role/DisclosureRevenueTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "gmab_WarrantVestingPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period which the right to exercise an warrant is no longer contingent on satisfaction of either a service condition, market condition or a performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Warrant Vesting Period",
        "terseLabel": "Warrant vesting period"
       }
      }
     },
     "localname": "WarrantVestingPeriod",
     "nsuri": "http://www.genmab.com/20220630",
     "presentation": [
      "http://www.genmab.com/role/DisclosureShareBasedInstrumentsWarrantProgramDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "gmab_WarrantsGrantedFromApril2012UntilMarch2017Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the warrants granted from April 2012 until March 2017.",
        "label": "Warrants Granted from April 2012 until March 2017"
       }
      }
     },
     "localname": "WarrantsGrantedFromApril2012UntilMarch2017Member",
     "nsuri": "http://www.genmab.com/20220630",
     "presentation": [
      "http://www.genmab.com/role/DisclosureShareBasedInstrumentsWarrantProgramDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gmab_WarrantsGrantedFromAugust2004UntilApril2012Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the warrants granted from August 2004 until April 2012.",
        "label": "Warrants Granted from August 2004 until April 2012"
       }
      }
     },
     "localname": "WarrantsGrantedFromAugust2004UntilApril2012Member",
     "nsuri": "http://www.genmab.com/20220630",
     "presentation": [
      "http://www.genmab.com/role/DisclosureShareBasedInstrumentsWarrantProgramDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gmab_WarrantsGrantedFromMarch2017Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the warrants granted from march 2017.",
        "label": "Warrants Granted from March 2017"
       }
      }
     },
     "localname": "WarrantsGrantedFromMarch2017Member",
     "nsuri": "http://www.genmab.com/20220630",
     "presentation": [
      "http://www.genmab.com/role/DisclosureShareBasedInstrumentsWarrantProgramDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gmab_WarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants [Member]",
        "label": "Warrants [Member]"
       }
      }
     },
     "localname": "WarrantsMember",
     "nsuri": "http://www.genmab.com/20220630",
     "presentation": [
      "http://www.genmab.com/role/DisclosureShareBasedInstrumentsWarrantProgramDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gmab_WeightedAverageExercisePriceOfFairValueOfWarrants": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price per share or per unit of fair value of warrants during the period.",
        "label": "Weighted Average Exercise Price Of Fair Value Of Warrants",
        "terseLabel": "Weighted average exercise price of fair market value"
       }
      }
     },
     "localname": "WeightedAverageExercisePriceOfFairValueOfWarrants",
     "nsuri": "http://www.genmab.com/20220630",
     "presentation": [
      "http://www.genmab.com/role/DisclosureShareBasedInstrumentsWarrantProgramDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "gmab_WeightedAverageExercisePriceOfWarrantsExercised": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price per share or per unit of warrants exercised during the period.",
        "label": "Weighted Average Exercise Price Of Warrants Exercised",
        "terseLabel": "Weighted average exercise price of warrants exercised"
       }
      }
     },
     "localname": "WeightedAverageExercisePriceOfWarrantsExercised",
     "nsuri": "http://www.genmab.com/20220630",
     "presentation": [
      "http://www.genmab.com/role/DisclosureShareBasedInstrumentsWarrantProgramDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "gmab_WeightedAverageExercisePriceOfWarrantsGranted": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price per share or per unit of warrants granted during the period.",
        "label": "Weighted Average Exercise Price Of Warrants Granted",
        "terseLabel": "Weighted average exercise price of warrants granted"
       }
      }
     },
     "localname": "WeightedAverageExercisePriceOfWarrantsGranted",
     "nsuri": "http://www.genmab.com/20220630",
     "presentation": [
      "http://www.genmab.com/role/DisclosureShareBasedInstrumentsWarrantProgramDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "gmab_Weightedaveragefairvalueofotherequityinstrumentsgrantedinsharebasedpaymentarrangement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value of other equity instruments (i.e. other than share options) granted in a share-based payment arrangement.",
        "label": "WeightedAverageFairValueOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement",
        "terseLabel": "Weighted average fair value of RSU granted"
       }
      }
     },
     "localname": "Weightedaveragefairvalueofotherequityinstrumentsgrantedinsharebasedpaymentarrangement",
     "nsuri": "http://www.genmab.com/20220630",
     "presentation": [
      "http://www.genmab.com/role/DisclosureShareBasedInstrumentsRestrictedStockUnitProgramDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "ifrs-full_AdditionsToRightofuseAssets": {
     "auth_ref": [
      "r121"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of additions to right-of-use assets. [Refer: Right-of-use assets]"
       }
      },
      "en-us": {
       "role": {
        "label": "Additions to right-of-use assets",
        "terseLabel": "Additions to right of use assets"
       }
      }
     },
     "localname": "AdditionsToRightofuseAssets",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/DisclosureLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_AdjustmentsForIncomeTaxExpense": {
     "auth_ref": [
      "r86"
     ],
     "calculation": {
      "http://www.genmab.com/role/StatementStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "Adjustments for income tax expense to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Adjustments for income tax expense",
        "terseLabel": "Corporate taxes paid"
       }
      }
     },
     "localname": "AdjustmentsForIncomeTaxExpense",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_AggregatedMeasurementMember": {
     "auth_ref": [
      "r73",
      "r74",
      "r108"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for all types of measurement. It also represents the standard value for the 'Measurement' axis if no other member is used."
       }
      },
      "en-us": {
       "role": {
        "label": "Aggregated measurement [member]"
       }
      }
     },
     "localname": "AggregatedMeasurementMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/DisclosureFinancialInstrumentsFairValueMeasurementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_AllLevelsOfFairValueHierarchyMember": {
     "auth_ref": [
      "r55",
      "r109"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for all levels of the fair value hierarchy. It also represents the standard value for the 'Levels of fair value hierarchy' axis if no other member is used."
       }
      },
      "en-us": {
       "role": {
        "label": "All levels of fair value hierarchy [member]"
       }
      }
     },
     "localname": "AllLevelsOfFairValueHierarchyMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/DisclosureFinancialInstrumentsFairValueMeasurementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_Assets": {
     "auth_ref": [
      "r24",
      "r108",
      "r109",
      "r110",
      "r156",
      "r160"
     ],
     "calculation": {
      "http://www.genmab.com/role/StatementBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of a present economic resource controlled by the entity as a result of past events. Economic resource is a right that has the potential to produce economic benefits."
       }
      },
      "en-us": {
       "role": {
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [abstract]",
        "terseLabel": "ASSETS"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/StatementBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_AtFairValueMember": {
     "auth_ref": [
      "r73",
      "r74",
      "r108"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for measurement based on fair value. Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date."
       }
      },
      "en-us": {
       "role": {
        "label": "Net Book value"
       }
      }
     },
     "localname": "AtFairValueMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/DisclosureFinancialInstrumentsFairValueMeasurementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_BasicEarningsLossPerShare": {
     "auth_ref": [
      "r64",
      "r65"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator) divided by the weighted average number of ordinary shares outstanding during the period (the denominator)."
       }
      },
      "en-us": {
       "role": {
        "label": "Basic earnings (loss) per share",
        "terseLabel": "Basic net profit per share"
       }
      }
     },
     "localname": "BasicEarningsLossPerShare",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/StatementStatementsOfComprehensiveIncome"
     ],
     "xbrltype": "perShareItemType"
    },
    "ifrs-full_Cash": {
     "auth_ref": [
      "r88"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of cash on hand and demand deposits. [Refer: Cash on hand]"
       }
      },
      "en-us": {
       "role": {
        "label": "Cash",
        "terseLabel": "Bank deposits"
       }
      }
     },
     "localname": "Cash",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CashAndCashEquivalents": {
     "auth_ref": [
      "r21",
      "r88",
      "r105"
     ],
     "calculation": {
      "http://www.genmab.com/role/StatementBalanceSheets": {
       "order": 1.0,
       "parentTag": "ifrs-full_CurrentAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]"
       }
      },
      "en-us": {
       "role": {
        "label": "Cash and cash equivalents",
        "periodEndLabel": "Cash and cash equivalents at the end of the period",
        "periodStartLabel": "Cash and cash equivalents at the beginning of the period",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalents",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/StatementBalanceSheets",
      "http://www.genmab.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CashAndCashEquivalentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and cash equivalents [abstract]",
        "terseLabel": "Cash and cash equivalents include:"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAbstract",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_CashFlowHedgesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flow hedges [abstract]",
        "terseLabel": "Fair value adjustments of cash flow hedges:"
       }
      }
     },
     "localname": "CashFlowHedgesAbstract",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/StatementStatementsOfComprehensiveIncome"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_CashFlowHedgesMember": {
     "auth_ref": [
      "r72",
      "r132",
      "r133",
      "r135"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for hedges of the exposure to variability in cash flows that (a) are attributable to a particular risk associated with a recognised asset or liability (such as all or some future interest payments on variable rate debt) or a highly probable forecast transaction; and (b) could affect profit or loss. [Refer: Hedges [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Cash flow hedges [member]"
       }
      }
     },
     "localname": "CashFlowHedgesMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/StatementStatementsOfChangesInEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_CashFlowsFromUsedInFinancingActivities": {
     "auth_ref": [
      "r75",
      "r89"
     ],
     "calculation": {
      "http://www.genmab.com/role/StatementStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash flows from (used in) financing activities, which are activities that result in changes in the size and composition of the contributed equity and borrowings of the entity."
       }
      },
      "en-us": {
       "role": {
        "label": "Cash flows from (used in) financing activities",
        "totalLabel": "Net cash (used in) financing activities"
       }
      }
     },
     "localname": "CashFlowsFromUsedInFinancingActivities",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from (used in) financing activities [abstract]",
        "terseLabel": "Cash flows from financing activities:"
       }
      }
     },
     "localname": "CashFlowsFromUsedInFinancingActivitiesAbstract",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_CashFlowsFromUsedInInvestingActivities": {
     "auth_ref": [
      "r75",
      "r89"
     ],
     "calculation": {
      "http://www.genmab.com/role/StatementStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash flows from (used in) investing activities, which are the acquisition and disposal of long-term assets and other investments not included in cash equivalents."
       }
      },
      "en-us": {
       "role": {
        "label": "Cash flows from (used in) investing activities",
        "totalLabel": "Net cash (used in) / provided by investing activities"
       }
      }
     },
     "localname": "CashFlowsFromUsedInInvestingActivities",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from (used in) investing activities [abstract]",
        "terseLabel": "Cash flows from investing activities:"
       }
      }
     },
     "localname": "CashFlowsFromUsedInInvestingActivitiesAbstract",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_CashFlowsFromUsedInOperatingActivities": {
     "auth_ref": [
      "r75",
      "r89"
     ],
     "calculation": {
      "http://www.genmab.com/role/StatementStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges",
       "weight": 1.0
      }
     },
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash flows from (used in) operating activities, which are the principal revenue-producing activities of the entity and other activities that are not investing or financing activities. [Refer: Revenue]"
       }
      },
      "en-us": {
       "role": {
        "label": "Cash flows from (used in) operating activities",
        "totalLabel": "Net cash provided by operating activities"
       }
      }
     },
     "localname": "CashFlowsFromUsedInOperatingActivities",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from (used in) operating activities [abstract]",
        "terseLabel": "Cash flows from operating activities:"
       }
      }
     },
     "localname": "CashFlowsFromUsedInOperatingActivitiesAbstract",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities": {
     "auth_ref": [
      "r87"
     ],
     "calculation": {
      "http://www.genmab.com/role/StatementStatementsOfCashFlows": {
       "order": 7.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The aggregate cash flows used in obtaining control of subsidiaries or other businesses, classified as investing activities. [Refer: Subsidiaries [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Cash flows used in obtaining control of subsidiaries or other businesses, classified as investing activities",
        "terseLabel": "Transactions with subsidiaries"
       }
      }
     },
     "localname": "CashFlowsUsedInObtainingControlOfSubsidiariesOrOtherBusinessesClassifiedAsInvestingActivities",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CategoriesOfRelatedPartiesAxis": {
     "auth_ref": [
      "r59"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Categories of related parties [axis]"
       }
      }
     },
     "localname": "CategoriesOfRelatedPartiesAxis",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/DisclosureRelatedPartiesDetails",
      "http://www.genmab.com/role/DisclosureShareBasedInstrumentsRestrictedStockUnitProgramDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_ChangesInEquity": {
     "auth_ref": [
      "r9"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The increase (decrease) in equity. [Refer: Equity]"
       }
      },
      "en-us": {
       "role": {
        "label": "Increase (decrease) in equity",
        "negatedLabel": "Expenses related to capital increases"
       }
      }
     },
     "localname": "ChangesInEquity",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/StatementStatementsOfChangesInEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ClassesOfAssetsAxis": {
     "auth_ref": [
      "r67",
      "r69",
      "r111",
      "r123"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Classes of assets [axis]"
       }
      }
     },
     "localname": "ClassesOfAssetsAxis",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/DisclosureLeasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_ClassesOfAssetsMember": {
     "auth_ref": [
      "r67",
      "r111",
      "r123"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for a present economic resource controlled by the entity as a result of past events. Economic resource is a right that has the potential to produce economic benefits. It also represents the standard value for the 'Classes of assets' axis if no other member is used."
       }
      },
      "en-us": {
       "role": {
        "label": "Assets [member]"
       }
      }
     },
     "localname": "ClassesOfAssetsMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/DisclosureLeasesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_ClassesOfFinancialAssetsAxis": {
     "auth_ref": [
      "r148",
      "r149",
      "r165",
      "r172",
      "r173",
      "r174"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Classes of financial assets [axis]"
       }
      }
     },
     "localname": "ClassesOfFinancialAssetsAxis",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/DisclosureFinancialInstrumentsFairValueMeasurementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis": {
     "auth_ref": [
      "r54"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Classes of property, plant and equipment [axis]"
       }
      }
     },
     "localname": "ClassesOfPropertyPlantAndEquipmentAxis",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/DisclosureLeasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_ClassesOfShareCapitalAxis": {
     "auth_ref": [
      "r32"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Classes of share capital [axis]"
       }
      }
     },
     "localname": "ClassesOfShareCapitalAxis",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_ClassesOfShareCapitalMember": {
     "auth_ref": [
      "r32"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for share capital of the entity. It also represents the standard value for the 'Classes of share capital' axis if no other member is used."
       }
      },
      "en-us": {
       "role": {
        "label": "Share capital [member]"
       }
      }
     },
     "localname": "ClassesOfShareCapitalMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_ComponentsOfEquityAxis": {
     "auth_ref": [
      "r10"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Components of equity [axis]"
       }
      }
     },
     "localname": "ComponentsOfEquityAxis",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/StatementStatementsOfChangesInEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Components of other comprehensive income that will be reclassified to profit or loss, net of tax [abstract]",
        "verboseLabel": "Amounts which will be re-classified to the income statement:"
       }
      }
     },
     "localname": "ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/StatementStatementsOfComprehensiveIncome"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_ComprehensiveIncome": {
     "auth_ref": [
      "r4",
      "r36",
      "r94",
      "r96",
      "r97",
      "r102"
     ],
     "calculation": {
      "http://www.genmab.com/role/StatementStatementsOfComprehensiveIncome": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of change in equity resulting from transactions and other events, other than those changes resulting from transactions with owners in their capacity as owners."
       }
      },
      "en-us": {
       "role": {
        "label": "Comprehensive income",
        "terseLabel": "Total comprehensive income",
        "totalLabel": "Total comprehensive income"
       }
      }
     },
     "localname": "ComprehensiveIncome",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/StatementStatementsOfChangesInEquity",
      "http://www.genmab.com/role/StatementStatementsOfComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CreditRiskMember": {
     "auth_ref": [
      "r139",
      "r167",
      "r168",
      "r169"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for the risk that one party to a financial instrument will cause a financial loss for the other party by failing to discharge an obligation. [Refer: Financial instruments, class [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Credit risk"
       }
      }
     },
     "localname": "CreditRiskMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/DisclosureFinancialInstrumentsFinancialRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_CurrencyRiskMember": {
     "auth_ref": [
      "r152",
      "r167",
      "r168",
      "r169",
      "r170"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for a type of market risk representing the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in foreign exchange rates. [Refer: Financial instruments, class [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Currency risk [member]",
        "terseLabel": "Currency risk"
       }
      }
     },
     "localname": "CurrencyRiskMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/DisclosureFinancialInstrumentsFinancialRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_CurrentAssets": {
     "auth_ref": [
      "r25",
      "r97",
      "r98"
     ],
     "calculation": {
      "http://www.genmab.com/role/StatementBalanceSheets": {
       "order": 1.0,
       "parentTag": "ifrs-full_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of assets that the entity (a) expects to realise or intends to sell or consume in its normal operating cycle; (b) holds primarily for the purpose of trading; (c) expects to realise within twelve months after the reporting period; or (d) classifies as cash or cash equivalents (as defined in IAS 7) unless the asset is restricted from being exchanged or used to settle a liability for at least twelve months after the reporting period. [Refer: Assets]"
       }
      },
      "en-us": {
       "role": {
        "label": "Current assets",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "CurrentAssets",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CurrentLeaseLiabilities": {
     "auth_ref": [
      "r117"
     ],
     "calculation": {
      "http://www.genmab.com/role/DisclosureLeasesDetails": {
       "order": 2.0,
       "parentTag": "ifrs-full_LeaseLiabilities",
       "weight": 1.0
      },
      "http://www.genmab.com/role/StatementBalanceSheets": {
       "order": 2.0,
       "parentTag": "ifrs-full_CurrentLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of current lease liabilities. [Refer: Lease liabilities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Current lease liabilities",
        "terseLabel": "Lease liabilities",
        "verboseLabel": "Current"
       }
      }
     },
     "localname": "CurrentLeaseLiabilities",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/DisclosureLeasesDetails",
      "http://www.genmab.com/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CurrentLiabilities": {
     "auth_ref": [
      "r26",
      "r97",
      "r100"
     ],
     "calculation": {
      "http://www.genmab.com/role/StatementBalanceSheets": {
       "order": 1.0,
       "parentTag": "ifrs-full_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "Expiry date 2023-01-01: The amount of liabilities that: (a) the entity expects to settle in its normal operating cycle; (b) the entity holds primarily for the purpose of trading; (c) are due to be settled within twelve months after the reporting period; or (d) the entity does not have an unconditional right to defer settlement for at least twelve months after the reporting period.\nEffective 2023-01-01: The amount of liabilities that: (a) the entity expects to settle in its normal operating cycle; (b) the entity holds primarily for the purpose of trading; (c) are due to be settled within twelve months after the reporting period; or (d) the entity does not have the right at the end of the reporting period to defer settlement for at least twelve months after the reporting period."
       }
      },
      "en-us": {
       "role": {
        "label": "Current liabilities",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "CurrentLiabilities",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CurrentProvisions": {
     "auth_ref": [
      "r22"
     ],
     "calculation": {
      "http://www.genmab.com/role/StatementBalanceSheets": {
       "order": 1.0,
       "parentTag": "ifrs-full_CurrentLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of current provisions, including provisions for employee benefits. [Refer: Provisions]"
       }
      },
      "en-us": {
       "role": {
        "label": "Current provisions",
        "terseLabel": "Provisions"
       }
      }
     },
     "localname": "CurrentProvisions",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CurrentTaxLiabilitiesCurrent": {
     "auth_ref": [
      "r23"
     ],
     "calculation": {
      "http://www.genmab.com/role/StatementBalanceSheets": {
       "order": 5.0,
       "parentTag": "ifrs-full_CurrentLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The current amount of current tax liabilities. [Refer: Current tax liabilities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Current tax liabilities, current",
        "terseLabel": "Corporate tax payable"
       }
      }
     },
     "localname": "CurrentTaxLiabilitiesCurrent",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_DepreciationRightofuseAssets": {
     "auth_ref": [
      "r118"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of depreciation of right-of-use assets. [Refer: Depreciation and amortisation expense; Right-of-use assets]"
       }
      },
      "en-us": {
       "role": {
        "label": "Depreciation, right-of-use assets",
        "terseLabel": "Depreciation charge of right-of-use assets"
       }
      }
     },
     "localname": "DepreciationRightofuseAssets",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/DisclosureLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The description of the entity's accounting policy for fair value measurement. [Refer: At fair value [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Description of accounting policy for fair value measurement [text block]",
        "terseLabel": "Fair Value Measurement"
       }
      }
     },
     "localname": "DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/DisclosureBasisOfPresentationPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The description of the entity's accounting policy for financial instruments. [Refer: Financial instruments, class [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Description of accounting policy for financial instruments [text block]",
        "terseLabel": "Marketable Securities"
       }
      }
     },
     "localname": "DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/DisclosureBasisOfPresentationPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DescriptionOfAccountingPolicyForInvestmentInAssociates": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The description of the entity's accounting policy for investments in associates. [Refer: Associates [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Description of accounting policy for investment in associates [text block]",
        "terseLabel": "Other Investments"
       }
      }
     },
     "localname": "DescriptionOfAccountingPolicyForInvestmentInAssociates",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/DisclosureBasisOfPresentationPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DescriptionOfAccountingPolicyForSegmentReportingExplanatory": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The description of the entity's accounting policy for segment reporting."
       }
      },
      "en-us": {
       "role": {
        "label": "Description of accounting policy for segment reporting [text block]",
        "terseLabel": "Information about Geographical Areas"
       }
      }
     },
     "localname": "DescriptionOfAccountingPolicyForSegmentReportingExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/DisclosureBasisOfPresentationPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DilutedEarningsLossPerShare": {
     "auth_ref": [
      "r64",
      "r65"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator), divided by the weighted average number of ordinary shares outstanding during the period (the denominator), both adjusted for the effects of all dilutive potential ordinary shares. [Refer: Ordinary shares [member]; Weighted average [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Diluted earnings (loss) per share",
        "terseLabel": "Diluted net profit per share"
       }
      }
     },
     "localname": "DilutedEarningsLossPerShare",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/StatementStatementsOfComprehensiveIncome"
     ],
     "xbrltype": "perShareItemType"
    },
    "ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of the basis used for the preparation of the financial statements."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of basis of preparation of financial statements [text block]",
        "verboseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/DisclosureBasisOfPresentation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfCreditRiskExposureLineItems": {
     "auth_ref": [],
     "lang": {
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of credit risk exposure [line items]"
       }
      }
     },
     "localname": "DisclosureOfCreditRiskExposureLineItems",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/DisclosureFinancialInstrumentsFinancialRiskDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfCreditRiskExposureTable": {
     "auth_ref": [
      "r146"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to the credit risk exposure."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of credit risk exposure [table]"
       }
      }
     },
     "localname": "DisclosureOfCreditRiskExposureTable",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/DisclosureFinancialInstrumentsFinancialRiskDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfDeferredTaxesExplanatory": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of deferred taxes. [Refer: Deferred tax liabilities; Deferred tax assets]"
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of deferred taxes [text block]",
        "verboseLabel": "Schedule of components of the deferred tax asset"
       }
      }
     },
     "localname": "DisclosureOfDeferredTaxesExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/DisclosureRevenueTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory": {
     "auth_ref": [
      "r138",
      "r145",
      "r150"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of detailed information about financial instruments. [Refer: Financial instruments, class [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of detailed information about financial instruments [text block]",
        "verboseLabel": "Financial Instruments"
       }
      }
     },
     "localname": "DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/DisclosureFinancialInstruments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory": {
     "auth_ref": [
      "r113"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of the disaggregation of revenue from contracts with customers. [Refer: Revenue from contracts with customers]"
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of disaggregation of revenue from contracts with customers [text block]",
        "terseLabel": "Schedule of revenue by type and collaboration partner under agreements"
       }
      }
     },
     "localname": "DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/DisclosureRevenueTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems": {
     "auth_ref": [],
     "lang": {
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of disaggregation of revenue from contracts with customers [line items]",
        "verboseLabel": "Revenue"
       }
      }
     },
     "localname": "DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/DisclosureRevenueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable": {
     "auth_ref": [
      "r113"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to the disaggregation of revenue from contracts with customers."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of disaggregation of revenue from contracts with customers [table]"
       }
      }
     },
     "localname": "DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/DisclosureRevenueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfEarningsPerShareExplanatory": {
     "auth_ref": [
      "r66"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The entire disclosure for earnings per share."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of earnings per share [text block]",
        "terseLabel": "Schedule of Result Per Share"
       }
      }
     },
     "localname": "DisclosureOfEarningsPerShareExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/DisclosureRevenueTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory": {
     "auth_ref": [
      "r47"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The entire disclosure for events after the reporting period."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of events after reporting period [text block]",
        "terseLabel": "Subsequent Events to the Balance Sheet Date"
       }
      }
     },
     "localname": "DisclosureOfEventsAfterReportingPeriodExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/DisclosureSubsequentEventsToBalanceSheetDate"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfFairValueMeasurementOfAssetsExplanatory": {
     "auth_ref": [
      "r111"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of the fair value measurement of assets."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of fair value measurement of assets [text block]",
        "verboseLabel": "Schedule of marketable securities"
       }
      }
     },
     "localname": "DisclosureOfFairValueMeasurementOfAssetsExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/DisclosureFinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfFairValueMeasurementOfAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of fair value measurement of assets [line items]"
       }
      }
     },
     "localname": "DisclosureOfFairValueMeasurementOfAssetsLineItems",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/DisclosureFinancialInstrumentsFairValueMeasurementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfFairValueMeasurementOfAssetsTable": {
     "auth_ref": [
      "r111"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to the fair value measurement of assets."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of fair value measurement of assets [table]"
       }
      }
     },
     "localname": "DisclosureOfFairValueMeasurementOfAssetsTable",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/DisclosureFinancialInstrumentsFairValueMeasurementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of finance income (cost). [Refer: Finance income (cost)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of finance income (cost) [text block]",
        "terseLabel": "Financial Income and Expenses"
       }
      }
     },
     "localname": "DisclosureOfFinanceIncomeExpenseExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/DisclosureFinancialIncomeAndExpenses"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfFinancialInstrumentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instruments"
       }
      }
     },
     "localname": "DisclosureOfFinancialInstrumentsAbstract",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfLeasesExplanatory": {
     "auth_ref": [
      "r124",
      "r125"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The entire disclosure for leases."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of leases [text block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "DisclosureOfLeasesExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/DisclosureLeases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events to the Balance Sheet Date"
       }
      }
     },
     "localname": "DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory": {
     "auth_ref": [
      "r127"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of the number and weighted average exercise prices of other equity instruments (ie other than share options)."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of number and weighted average exercise prices of other equity instruments [text block]",
        "terseLabel": "Summary of RSUs activity"
       }
      }
     },
     "localname": "DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/DisclosureShareBasedInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfOffsettingOfFinancialAssetsAndFinancialLiabilitiesExplanatory": {
     "auth_ref": [
      "r153"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of the offsetting of financial assets and financial liabilities. [Refer: Financial assets; Financial liabilities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of offsetting of financial assets and financial liabilities [text block]",
        "terseLabel": "Schedule of Financial Assets"
       }
      }
     },
     "localname": "DisclosureOfOffsettingOfFinancialAssetsAndFinancialLiabilitiesExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/DisclosureFinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of quantitative information about right-of-use assets [line items]"
       }
      }
     },
     "localname": "DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/DisclosureLeasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable": {
     "auth_ref": [
      "r123"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to right-of-use assets."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of quantitative information about right-of-use assets [table]"
       }
      }
     },
     "localname": "DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/DisclosureLeasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfRelatedPartyExplanatory": {
     "auth_ref": [
      "r60"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The entire disclosure for related parties."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of related party [text block]",
        "terseLabel": "Related Parties"
       }
      }
     },
     "localname": "DisclosureOfRelatedPartyExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/DisclosureRelatedParties"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfReservesAndOtherEquityInterestExplanatory": {
     "auth_ref": [
      "r33"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of reserves within equity. [Refer: Other reserves [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of reserves within equity [text block]",
        "terseLabel": "Schedule of changes in share capital"
       }
      }
     },
     "localname": "DisclosureOfReservesAndOtherEquityInterestExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/DisclosureFinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfRevenueFromContractsWithCustomersExplanatory": {
     "auth_ref": [
      "r115",
      "r116"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The entire disclosure for revenue from contracts with customers."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of revenue from contracts with customers [text block]",
        "terseLabel": "Revenue"
       }
      }
     },
     "localname": "DisclosureOfRevenueFromContractsWithCustomersExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/DisclosureRevenue"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory": {
     "auth_ref": [
      "r126"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangements."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of share-based payment arrangements [text block]",
        "verboseLabel": "Share-Based Instruments"
       }
      }
     },
     "localname": "DisclosureOfSharebasedPaymentArrangementsExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/DisclosureShareBasedInstruments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The entire disclosure for significant accounting policies applied by the entity."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of significant accounting policies [text block]",
        "terseLabel": "Nature of Business and Accounting Policies"
       }
      }
     },
     "localname": "DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/DisclosureBasisOfPresentationPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Instruments"
       }
      }
     },
     "localname": "DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems": {
     "auth_ref": [],
     "lang": {
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of terms and conditions of share-based payment arrangement [line items]"
       }
      }
     },
     "localname": "DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/DisclosureShareBasedInstrumentsRestrictedStockUnitProgramDetails",
      "http://www.genmab.com/role/DisclosureShareBasedInstrumentsShareRepurchasesDetails",
      "http://www.genmab.com/role/DisclosureShareBasedInstrumentsWarrantProgramDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable": {
     "auth_ref": [
      "r127"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to terms and conditions of share-based payment arrangements."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of terms and conditions of share-based payment arrangement [table]"
       }
      }
     },
     "localname": "DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/DisclosureShareBasedInstrumentsRestrictedStockUnitProgramDetails",
      "http://www.genmab.com/role/DisclosureShareBasedInstrumentsShareRepurchasesDetails",
      "http://www.genmab.com/role/DisclosureShareBasedInstrumentsWarrantProgramDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Parties"
       }
      }
     },
     "localname": "DisclosureOfTransactionsBetweenRelatedPartiesAbstract",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of transactions between related parties [line items]"
       }
      }
     },
     "localname": "DisclosureOfTransactionsBetweenRelatedPartiesLineItems",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/DisclosureRelatedPartiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable": {
     "auth_ref": [
      "r59"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to transactions between related parties."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of transactions between related parties [table]"
       }
      }
     },
     "localname": "DisclosureOfTransactionsBetweenRelatedPartiesTable",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/DisclosureRelatedPartiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfTreasurySharesExplanatory": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of treasury shares. [Refer: Treasury shares]"
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of treasury shares [text block]",
        "terseLabel": "Schedule Of Treasury Shares"
       }
      }
     },
     "localname": "DisclosureOfTreasurySharesExplanatory",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/DisclosureFinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents": {
     "auth_ref": [
      "r83",
      "r84"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The effect of exchange rate changes on cash and cash equivalents held or due in a foreign currency. [Refer: Cash and cash equivalents]"
       }
      },
      "en-us": {
       "role": {
        "label": "Effect of exchange rate changes on cash and cash equivalents",
        "terseLabel": "Exchange rate adjustments"
       }
      }
     },
     "localname": "EffectOfExchangeRateChangesOnCashAndCashEquivalents",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_EmployeeBenefitsExpense": {
     "auth_ref": [
      "r1",
      "r3",
      "r45"
     ],
     "calculation": {
      "http://www.genmab.com/role/DisclosureResultsForYearStaffCostsDetailsCalc2": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The expense of all forms of consideration given by an entity in exchange for a service rendered by employees or for the termination of employment."
       }
      },
      "en-us": {
       "role": {
        "label": "Employee benefits expense"
       }
      }
     },
     "localname": "EmployeeBenefitsExpense",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_EntitysTotalForExternalCreditGradesMember": {
     "auth_ref": [
      "r146",
      "r151",
      "r176",
      "r179",
      "r181"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for the standard value for the 'External credit grades' axis if no other member is used."
       }
      },
      "en-us": {
       "role": {
        "label": "Entity's total for external credit grades [member]"
       }
      }
     },
     "localname": "EntitysTotalForExternalCreditGradesMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/DisclosureFinancialInstrumentsFinancialRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_EntitysTotalForRelatedPartiesMember": {
     "auth_ref": [
      "r59"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for the standard value for the 'Categories of related parties' axis if no other member is used."
       }
      },
      "en-us": {
       "role": {
        "label": "Entity's total for related parties [member]"
       }
      }
     },
     "localname": "EntitysTotalForRelatedPartiesMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/DisclosureRelatedPartiesDetails",
      "http://www.genmab.com/role/DisclosureShareBasedInstrumentsRestrictedStockUnitProgramDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_Equity": {
     "auth_ref": [
      "r24",
      "r29",
      "r93",
      "r95",
      "r108",
      "r109",
      "r110"
     ],
     "calculation": {
      "http://www.genmab.com/role/StatementBalanceSheets": {
       "order": 1.0,
       "parentTag": "ifrs-full_EquityAndLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of residual interest in the assets of the entity after deducting all its liabilities."
       }
      },
      "en-us": {
       "role": {
        "label": "Equity",
        "periodEndLabel": "Balance at end of period",
        "periodStartLabel": "Balance at beginning of period",
        "totalLabel": "Total shareholders' equity"
       }
      }
     },
     "localname": "Equity",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/StatementBalanceSheets",
      "http://www.genmab.com/role/StatementStatementsOfChangesInEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_EquityAndLiabilities": {
     "auth_ref": [
      "r24"
     ],
     "calculation": {
      "http://www.genmab.com/role/StatementBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of the entity's equity and liabilities. [Refer: Equity; Liabilities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Equity and liabilities",
        "totalLabel": "Total shareholders' equity and liabilities"
       }
      }
     },
     "localname": "EquityAndLiabilities",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_EquityAndLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity and liabilities [abstract]",
        "terseLabel": "SHAREHOLDERS' EQUITY AND LIABILITIES"
       }
      }
     },
     "localname": "EquityAndLiabilitiesAbstract",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/StatementBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_EquityMember": {
     "auth_ref": [
      "r10"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for the residual interest in the assets of the entity after deducting all its liabilities. It also represents the standard value for the 'Components of equity' axis if no other member is used."
       }
      },
      "en-us": {
       "role": {
        "label": "Equity [member]"
       }
      }
     },
     "localname": "EquityMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/StatementStatementsOfChangesInEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets": {
     "auth_ref": [
      "r129"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of expense arising from share-based payment transactions in which the goods or services received did not qualify for recognition as assets."
       }
      },
      "en-us": {
       "role": {
        "label": "Expense from share-based payment transactions in which goods or services received did not qualify for recognition as assets",
        "terseLabel": "Share-based compensation expenses"
       }
      }
     },
     "localname": "ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/DisclosureShareBasedInstrumentsWarrantProgramDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed": {
     "auth_ref": [
      "r120"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of the expense relating to short-term leases accounted for applying paragraph 6 of IFRS 16. This expense need not include the expense relating to leases with a lease term of one month or less. Short-term lease is a lease that, at the commencement date, has a lease term of 12 months or less. A lease that contains a purchase option is not a short-term lease."
       }
      },
      "en-us": {
       "role": {
        "label": "Expense relating to short-term leases for which recognition exemption has been used",
        "terseLabel": "Expense relating to short-term leases"
       }
      }
     },
     "localname": "ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/DisclosureLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ExternalCreditGradesAxis": {
     "auth_ref": [
      "r146",
      "r151",
      "r176",
      "r179",
      "r181"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "External credit grades [axis]"
       }
      }
     },
     "localname": "ExternalCreditGradesAxis",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/DisclosureFinancialInstrumentsFinancialRiskDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_FinanceCosts": {
     "auth_ref": [
      "r38"
     ],
     "calculation": {
      "http://www.genmab.com/role/DisclosureFinancialIncomeAndExpensesDetails": {
       "order": 1.0,
       "parentTag": "ifrs-full_FinanceIncomeCost",
       "weight": -1.0
      },
      "http://www.genmab.com/role/StatementStatementsOfComprehensiveIncome": {
       "order": 2.0,
       "parentTag": "ifrs-full_ProfitLossBeforeTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of costs associated with financing activities of the entity."
       }
      },
      "en-us": {
       "role": {
        "label": "Finance costs",
        "negatedLabel": "Financial expenses",
        "negatedTotalLabel": "Total financial expenses"
       }
      }
     },
     "localname": "FinanceCosts",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/DisclosureFinancialIncomeAndExpensesDetails",
      "http://www.genmab.com/role/StatementStatementsOfComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_FinanceIncome": {
     "auth_ref": [
      "r40"
     ],
     "calculation": {
      "http://www.genmab.com/role/DisclosureFinancialIncomeAndExpensesDetails": {
       "order": 2.0,
       "parentTag": "ifrs-full_FinanceIncomeCost",
       "weight": 1.0
      },
      "http://www.genmab.com/role/StatementStatementsOfComprehensiveIncome": {
       "order": 1.0,
       "parentTag": "ifrs-full_ProfitLossBeforeTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of income associated with interest and other financing activities of the entity."
       }
      },
      "en-us": {
       "role": {
        "label": "Financial income",
        "totalLabel": "Total financial income"
       }
      }
     },
     "localname": "FinanceIncome",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/DisclosureFinancialIncomeAndExpensesDetails",
      "http://www.genmab.com/role/StatementStatementsOfComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_FinanceIncomeCost": {
     "auth_ref": [
      "r40"
     ],
     "calculation": {
      "http://www.genmab.com/role/DisclosureFinancialIncomeAndExpensesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of income or cost associated with interest and other financing activities of the entity."
       }
      },
      "en-us": {
       "role": {
        "label": "Finance income (cost)",
        "totalLabel": "Net financial items"
       }
      }
     },
     "localname": "FinanceIncomeCost",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/DisclosureFinancialIncomeAndExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_FinancialAssets": {
     "auth_ref": [
      "r137",
      "r142",
      "r143",
      "r146",
      "r147"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of assets that are: (a) cash; (b) an equity instrument of another entity; (c) a contractual right: (i) to receive cash or another financial asset from another entity; or (ii) to exchange financial assets or financial liabilities with another entity under conditions that are potentially favourable to the entity; or (d) a contract that will, or may be, settled in the entity\u2019s own equity instruments and is: (i) a non-derivative for which the entity is, or may be, obliged to receive a variable number of the entity\u2019s own equity instruments; or (ii) a derivative that will, or may be, settled other than by the exchange of a fixed amount of cash or another financial asset for a fixed number of the entity\u2019s own equity instruments. For this purpose the entity\u2019s own equity instruments do not include puttable financial instruments classified as equity instruments in accordance with paragraphs 16A-16B of IAS 32, instruments that impose on the entity an obligation to deliver to another party a pro rata share of the net assets of the entity only on liquidation and are classified as equity instruments in accordance with paragraphs 16C-16D of IAS 32, or instruments that are contracts for the future receipt or delivery of the entity\u2019s own equity instruments. [Refer: Financial instruments, class [member]; Financial liabilities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Financial assets"
       }
      }
     },
     "localname": "FinancialAssets",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/DisclosureFinancialInstrumentsFairValueMeasurementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_FinancialAssetsMember": {
     "auth_ref": [
      "r148",
      "r149",
      "r165",
      "r172",
      "r173",
      "r174"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for aggregated classes of financial assets. It also represents the standard value for the 'Classes of financial assets' axis if no other member is used. [Refer: Financial assets]"
       }
      },
      "en-us": {
       "role": {
        "label": "Financial assets, class [member]"
       }
      }
     },
     "localname": "FinancialAssetsMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/DisclosureFinancialInstrumentsFairValueMeasurementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r12"
     ],
     "calculation": {
      "http://www.genmab.com/role/StatementStatementsOfComprehensiveIncome": {
       "order": 2.0,
       "parentTag": "ifrs-full_OperatingExpense",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of expense relating to general and administrative activities of the entity."
       }
      },
      "en-us": {
       "role": {
        "label": "General and administrative expense",
        "negatedLabel": "General and administrative expenses"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/StatementStatementsOfComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Profit or loss [abstract]",
        "terseLabel": "Income Statement"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/StatementStatementsOfComprehensiveIncome"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_IncomeTaxExpenseContinuingOperations": {
     "auth_ref": [
      "r39",
      "r48",
      "r50",
      "r51",
      "r61",
      "r106",
      "r155"
     ],
     "calculation": {
      "http://www.genmab.com/role/StatementStatementsOfComprehensiveIncome": {
       "order": 1.0,
       "parentTag": "ifrs-full_ProfitLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The aggregate amount included in the determination of profit (loss) for the period in respect of current tax and deferred tax. [Refer: Current tax expense (income); Deferred tax expense (income)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Tax expense (income), continuing operations",
        "negatedLabel": "Corporate tax"
       }
      }
     },
     "localname": "IncomeTaxExpenseContinuingOperations",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/StatementStatementsOfComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_IncomeTaxRelatingToExchangeDifferencesOnTranslationOfOtherComprehensiveIncome": {
     "auth_ref": [
      "r41",
      "r49"
     ],
     "calculation": {
      "http://www.genmab.com/role/StatementStatementsOfComprehensiveIncome": {
       "order": 5.0,
       "parentTag": "ifrs-full_ComprehensiveIncome",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of income tax relating to amounts recognised in other comprehensive income in relation to exchange differences on the translation of financial statements of foreign operations. [Refer: Other comprehensive income; Reserve of exchange differences on translation]"
       }
      },
      "en-us": {
       "role": {
        "label": "Income tax relating to exchange differences on translation of other comprehensive income",
        "negatedLabel": "Excess tax benefits"
       }
      }
     },
     "localname": "IncomeTaxRelatingToExchangeDifferencesOnTranslationOfOtherComprehensiveIncome",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/StatementStatementsOfComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_IncreaseDecreaseDueToApplicationOfIFRS15Member": {
     "auth_ref": [
      "r114"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for IFRS 15 Revenue with Contracts with Customers."
       }
      },
      "en-us": {
       "role": {
        "label": "Increase (decrease) due to application of IFRS 15 [member]"
       }
      }
     },
     "localname": "IncreaseDecreaseDueToApplicationOfIFRS15Member",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/StatementStatementsOfChangesInEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges": {
     "auth_ref": [
      "r88"
     ],
     "calculation": {
      "http://www.genmab.com/role/StatementStatementsOfCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The increase (decrease) in cash and cash equivalents before the effect of exchange rate changes on cash and cash equivalents held in foreign currencies. [Refer: Cash and cash equivalents; Effect of exchange rate changes on cash and cash equivalents]"
       }
      },
      "en-us": {
       "role": {
        "label": "Increase (decrease) in cash and cash equivalents before effect of exchange rate changes",
        "totalLabel": "Change in cash and cash equivalents"
       }
      }
     },
     "localname": "IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_IncreaseDecreaseInWorkingCapital": {
     "auth_ref": [
      "r82"
     ],
     "calculation": {
      "http://www.genmab.com/role/StatementStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "gmab_CashFlowFromUsedInOperatingActivitiesBeforeFinancialItems",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The increase (decrease) in working capital."
       }
      },
      "en-us": {
       "role": {
        "label": "Increase (decrease) in working capital",
        "negatedTerseLabel": "Changes in operating assets and liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInWorkingCapital",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity": {
     "auth_ref": [
      "r9"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The increase (decrease) in equity resulting from the exercise of warrants."
       }
      },
      "en-us": {
       "role": {
        "label": "Increase (decrease) through exercise of warrants, equity",
        "terseLabel": "Exercise of warrants"
       }
      }
     },
     "localname": "IncreaseDecreaseThroughExerciseOfWarrantsEquity",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/StatementStatementsOfChangesInEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions": {
     "auth_ref": [
      "r8"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The increase (decrease) in equity resulting from share-based payment transactions. [Refer: Equity]"
       }
      },
      "en-us": {
       "role": {
        "label": "Increase (decrease) through share-based payment transactions, equity",
        "terseLabel": "Share-based compensation expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseThroughSharebasedPaymentTransactions",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/StatementStatementsOfChangesInEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_IntangibleAssetsOtherThanGoodwill": {
     "auth_ref": [
      "r18",
      "r70"
     ],
     "calculation": {
      "http://www.genmab.com/role/StatementBalanceSheets": {
       "order": 2.0,
       "parentTag": "ifrs-full_NoncurrentAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of identifiable non-monetary assets without physical substance. This amount does not include goodwill. [Refer: Goodwill]"
       }
      },
      "en-us": {
       "role": {
        "label": "Intangible assets other than goodwill",
        "terseLabel": "Intangible assets"
       }
      }
     },
     "localname": "IntangibleAssetsOtherThanGoodwill",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_InterestExpenseOnLeaseLiabilities": {
     "auth_ref": [
      "r119"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of interest expense on lease liabilities. [Refer: Lease liabilities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Interest expense on lease liabilities",
        "terseLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpenseOnLeaseLiabilities",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/DisclosureLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_InterestPaidClassifiedAsOperatingActivities": {
     "auth_ref": [
      "r85"
     ],
     "calculation": {
      "http://www.genmab.com/role/StatementStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash outflow for interest paid, classified as operating activities."
       }
      },
      "en-us": {
       "role": {
        "label": "Interest paid, classified as operating activities",
        "negatedTerseLabel": "Interest paid"
       }
      }
     },
     "localname": "InterestPaidClassifiedAsOperatingActivities",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_InterestReceivedClassifiedAsOperatingActivities": {
     "auth_ref": [
      "r85"
     ],
     "calculation": {
      "http://www.genmab.com/role/StatementStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash inflow from interest received, classified as operating activities."
       }
      },
      "en-us": {
       "role": {
        "label": "Interest received, classified as operating activities",
        "terseLabel": "Interest received"
       }
      }
     },
     "localname": "InterestReceivedClassifiedAsOperatingActivities",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_InvestmentAccountedForUsingEquityMethod": {
     "auth_ref": [
      "r19",
      "r107",
      "r157"
     ],
     "calculation": {
      "http://www.genmab.com/role/StatementBalanceSheets": {
       "order": 1.0,
       "parentTag": "ifrs-full_NoncurrentAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of investments accounted for using the equity method. The equity method is a method of accounting whereby the investment is initially recognised at cost and adjusted thereafter for the post-acquisition change in the investor's share of net assets of the investee. The investor's profit or loss includes its share of the profit or loss of the investee. The investor's other comprehensive income includes its share of the other comprehensive income of the investee. [Refer: At cost [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Investments accounted for using equity method",
        "verboseLabel": "Other investments"
       }
      }
     },
     "localname": "InvestmentAccountedForUsingEquityMethod",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/DisclosureFinancialInstrumentsOtherInvestmentsDetails",
      "http://www.genmab.com/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_IssueOfEquity": {
     "auth_ref": [
      "r8"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The increase in equity through the issue of equity instruments."
       }
      },
      "en-us": {
       "role": {
        "label": "Issue of equity",
        "verboseLabel": "Shares issued for cash"
       }
      }
     },
     "localname": "IssueOfEquity",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/StatementStatementsOfChangesInEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_IssuedCapital": {
     "auth_ref": [
      "r29"
     ],
     "calculation": {
      "http://www.genmab.com/role/StatementBalanceSheets": {
       "order": 1.0,
       "parentTag": "ifrs-full_Equity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The nominal value of capital issued."
       }
      },
      "en-us": {
       "role": {
        "label": "Issued capital",
        "terseLabel": "Share capital"
       }
      }
     },
     "localname": "IssuedCapital",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_IssuedCapitalMember": {
     "auth_ref": [
      "r10"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for a component of equity representing issued capital."
       }
      },
      "en-us": {
       "role": {
        "label": "Issued capital [member]"
       }
      }
     },
     "localname": "IssuedCapitalMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/StatementStatementsOfChangesInEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_KeyManagementPersonnelOfEntityOrParentMember": {
     "auth_ref": [
      "r58"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for those persons having authority and responsibility for planning, directing and controlling the activities of the entity, directly or indirectly, including any director (whether executive or otherwise) of that entity."
       }
      },
      "en-us": {
       "role": {
        "label": "Board of Directors and Executive Management"
       }
      }
     },
     "localname": "KeyManagementPersonnelOfEntityOrParentMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/DisclosureRelatedPartiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_LeaseLiabilities": {
     "auth_ref": [
      "r117"
     ],
     "calculation": {
      "http://www.genmab.com/role/DisclosureLeasesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of liabilities related to the entity's leases. Lease is a contract, or part of a contract, that conveys the right to use an underlying asset for a period of time in exchange for consideration."
       }
      },
      "en-us": {
       "role": {
        "label": "Lease liabilities",
        "totalLabel": "Total lease liabilities"
       }
      }
     },
     "localname": "LeaseLiabilities",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/DisclosureLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_LeaseLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease liabilities [abstract]",
        "terseLabel": "Lease Liabilities"
       }
      }
     },
     "localname": "LeaseLiabilitiesAbstract",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/DisclosureLeasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_Level1OfFairValueHierarchyMember": {
     "auth_ref": [
      "r55",
      "r109"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for a category of the fair value hierarchy where inputs to the valuation techniques are quoted prices (unadjusted) in active markets for identical assets or liabilities that the entity can access at the measurement date."
       }
      },
      "en-us": {
       "role": {
        "label": "Level 1 of fair value hierarchy [member]"
       }
      }
     },
     "localname": "Level1OfFairValueHierarchyMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/DisclosureFinancialInstrumentsFairValueMeasurementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_Level2OfFairValueHierarchyMember": {
     "auth_ref": [
      "r109"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for a category of the fair value hierarchy where inputs to the valuation techniques are inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly."
       }
      },
      "en-us": {
       "role": {
        "label": "Level 2 of fair value hierarchy [member]"
       }
      }
     },
     "localname": "Level2OfFairValueHierarchyMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/DisclosureFinancialInstrumentsFairValueMeasurementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_Level3OfFairValueHierarchyMember": {
     "auth_ref": [
      "r109"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for a category of the fair value hierarchy where inputs to the valuation techniques are unobservable inputs for the asset or liability. Unobservable inputs are inputs for which market data are not available and that are developed using the best information available about the assumptions that the market participants would use when pricing the asset or liability."
       }
      },
      "en-us": {
       "role": {
        "label": "Level 3 of fair value hierarchy [member]"
       }
      }
     },
     "localname": "Level3OfFairValueHierarchyMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/DisclosureFinancialInstrumentsFairValueMeasurementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_LevelsOfFairValueHierarchyAxis": {
     "auth_ref": [
      "r55",
      "r109"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Levels of fair value hierarchy [axis]"
       }
      }
     },
     "localname": "LevelsOfFairValueHierarchyAxis",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/DisclosureFinancialInstrumentsFairValueMeasurementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_Liabilities": {
     "auth_ref": [
      "r24",
      "r108",
      "r109",
      "r110",
      "r156",
      "r161"
     ],
     "calculation": {
      "http://www.genmab.com/role/StatementBalanceSheets": {
       "order": 2.0,
       "parentTag": "ifrs-full_EquityAndLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of a present obligation of the entity to transfer an economic resource as a result of past events. Economic resource is a right that has the potential to produce economic benefits."
       }
      },
      "en-us": {
       "role": {
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_MaximumExposureToCreditRisk": {
     "auth_ref": [
      "r144",
      "r178"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount that best represents the maximum exposure to credit risk without taking into account any collateral held or other credit enhancements (for example, netting agreements that do not qualify for offset in accordance with IAS 32). [Refer: Credit risk [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Maximum exposure to credit risk",
        "terseLabel": "Maximum credit exposure"
       }
      }
     },
     "localname": "MaximumExposureToCreditRisk",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/DisclosureFinancialInstrumentsFinancialRiskDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_MaximumExposureToCreditRiskOfLoansOrReceivables": {
     "auth_ref": [
      "r180"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The maximum exposure to the credit risk of loans or receivables. [Refer: Loans and receivables; Credit risk [member]; Maximum exposure to credit risk]"
       }
      },
      "en-us": {
       "role": {
        "label": "Maximum exposure to credit risk of loans or receivables",
        "terseLabel": "Maximum credit exposure to receivables"
       }
      }
     },
     "localname": "MaximumExposureToCreditRiskOfLoansOrReceivables",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/DisclosureFinancialInstrumentsFinancialRiskDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_MeasurementAxis": {
     "auth_ref": [
      "r73",
      "r74",
      "r108"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Measurement [axis]"
       }
      }
     },
     "localname": "MeasurementAxis",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/DisclosureFinancialInstrumentsFairValueMeasurementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_NetDeferredTaxAssets": {
     "auth_ref": [
      "r52"
     ],
     "calculation": {
      "http://www.genmab.com/role/StatementBalanceSheets": {
       "order": 6.0,
       "parentTag": "ifrs-full_NoncurrentAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of deferred tax assets net of deferred tax liabilities, when the absolute amount of deferred tax assets is greater than the absolute amount of deferred tax liabilities. [Refer: Deferred tax assets; Deferred tax liabilities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Net deferred tax assets",
        "terseLabel": "Deferred tax assets"
       }
      }
     },
     "localname": "NetDeferredTaxAssets",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_NetForeignExchangeGain": {
     "auth_ref": [
      "r16",
      "r56"
     ],
     "calculation": {
      "http://www.genmab.com/role/DisclosureFinancialIncomeAndExpensesDetails": {
       "order": 1.0,
       "parentTag": "ifrs-full_FinanceIncome",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The net gain arising from exchange differences recognised in profit or loss, excluding those arising on financial instruments measured at fair value through profit or loss in accordance with IFRS 9. [Refer: Foreign exchange gain (loss)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Net foreign exchange gain",
        "terseLabel": "Foreign exchange rate gain, net"
       }
      }
     },
     "localname": "NetForeignExchangeGain",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/DisclosureFinancialIncomeAndExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_NetForeignExchangeLoss": {
     "auth_ref": [
      "r16",
      "r56"
     ],
     "calculation": {
      "http://www.genmab.com/role/DisclosureFinancialIncomeAndExpensesDetails": {
       "order": 1.0,
       "parentTag": "ifrs-full_FinanceCosts",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The net loss arising from exchange differences recognised in profit or loss, excluding those arising on financial instruments measured at fair value through profit or loss in accordance with IFRS 9. [Refer: Foreign exchange gain (loss)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Net foreign exchange loss",
        "negatedLabel": "Foreign exchange rate loss, net"
       }
      }
     },
     "localname": "NetForeignExchangeLoss",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/DisclosureFinancialIncomeAndExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_NoncurrentAssets": {
     "auth_ref": [
      "r25",
      "r97",
      "r99"
     ],
     "calculation": {
      "http://www.genmab.com/role/StatementBalanceSheets": {
       "order": 2.0,
       "parentTag": "ifrs-full_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of assets that do not meet the definition of current assets. [Refer: Current assets]"
       }
      },
      "en-us": {
       "role": {
        "label": "Non-current assets",
        "totalLabel": "Total non-current assets"
       }
      }
     },
     "localname": "NoncurrentAssets",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_NoncurrentLeaseLiabilities": {
     "auth_ref": [
      "r117"
     ],
     "calculation": {
      "http://www.genmab.com/role/DisclosureLeasesDetails": {
       "order": 1.0,
       "parentTag": "ifrs-full_LeaseLiabilities",
       "weight": 1.0
      },
      "http://www.genmab.com/role/StatementBalanceSheets": {
       "order": 1.0,
       "parentTag": "ifrs-full_NoncurrentLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of non-current lease liabilities. [Refer: Lease liabilities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Non-current lease liabilities",
        "terseLabel": "Lease liabilities",
        "verboseLabel": "Non-current"
       }
      }
     },
     "localname": "NoncurrentLeaseLiabilities",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/DisclosureLeasesDetails",
      "http://www.genmab.com/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_NoncurrentLiabilities": {
     "auth_ref": [
      "r26",
      "r97",
      "r101"
     ],
     "calculation": {
      "http://www.genmab.com/role/StatementBalanceSheets": {
       "order": 2.0,
       "parentTag": "ifrs-full_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of liabilities that do not meet the definition of current liabilities. [Refer: Current liabilities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Non-current liabilities",
        "totalLabel": "Total non-current liabilities"
       }
      }
     },
     "localname": "NoncurrentLiabilities",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_NoncurrentProvisions": {
     "auth_ref": [
      "r22"
     ],
     "calculation": {
      "http://www.genmab.com/role/StatementBalanceSheets": {
       "order": 3.0,
       "parentTag": "ifrs-full_NoncurrentLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of non-current provisions, including provisions for employee benefits. [Refer: Provisions]"
       }
      },
      "en-us": {
       "role": {
        "label": "Non-current provisions",
        "verboseLabel": "Provisions"
       }
      }
     },
     "localname": "NoncurrentProvisions",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_NoncurrentReceivables": {
     "auth_ref": [
      "r20",
      "r28"
     ],
     "calculation": {
      "http://www.genmab.com/role/StatementBalanceSheets": {
       "order": 5.0,
       "parentTag": "ifrs-full_NoncurrentAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of non-current trade receivables and non-current other receivables. [Refer: Non-current trade receivables; Other non-current receivables]"
       }
      },
      "en-us": {
       "role": {
        "label": "Trade and other non-current receivables",
        "terseLabel": "Receivables"
       }
      }
     },
     "localname": "NoncurrentReceivables",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted": {
     "auth_ref": [
      "r127",
      "r128"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The number of other equity instruments (ie other than share options) granted in a share-based payment arrangement."
       }
      },
      "en-us": {
       "role": {
        "label": "Number of other equity instruments granted in share-based payment arrangement",
        "terseLabel": "Granted"
       }
      }
     },
     "localname": "NumberOfInstrumentsOtherEquityInstrumentsGranted",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/DisclosureShareBasedInstrumentsRestrictedStockUnitProgramDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement": {
     "auth_ref": [
      "r127"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The number of other equity instruments (ie other than share options) exercised or vested in a share-based payment arrangement."
       }
      },
      "en-us": {
       "role": {
        "label": "Number of other equity instruments exercised or vested in share-based payment arrangement",
        "terseLabel": "Vested"
       }
      }
     },
     "localname": "NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/DisclosureShareBasedInstrumentsRestrictedStockUnitProgramDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement": {
     "auth_ref": [
      "r127"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The number of other equity instruments (ie other than share options) forfeited in a share-based payment arrangement."
       }
      },
      "en-us": {
       "role": {
        "label": "Number of other equity instruments forfeited in share-based payment arrangement",
        "negatedLabel": "Forfeited/Cancelled"
       }
      }
     },
     "localname": "NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/DisclosureShareBasedInstrumentsRestrictedStockUnitProgramDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement": {
     "auth_ref": [
      "r127"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The number of other equity instruments (ie other than share options) outstanding in a share-based payment arrangement."
       }
      },
      "en-us": {
       "role": {
        "label": "Number of other equity instruments outstanding in share-based payment arrangement",
        "periodEndLabel": "Outstanding at end of period",
        "periodStartLabel": "Outstanding at beginning of period"
       }
      }
     },
     "localname": "NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/DisclosureShareBasedInstrumentsRestrictedStockUnitProgramDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "ifrs-full_NumberOfSharesOutstanding": {
     "auth_ref": [
      "r31"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The number of shares that have been authorised and issued, reduced by treasury shares held. [Refer: Treasury shares]"
       }
      },
      "en-us": {
       "role": {
        "label": "Number of shares outstanding",
        "periodEndLabel": "Number of shares, at end of period",
        "periodStartLabel": "Number of shares, at beginning of period"
       }
      }
     },
     "localname": "NumberOfSharesOutstanding",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/StatementStatementsOfChangesInEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "ifrs-full_OperatingExpense": {
     "auth_ref": [
      "r40"
     ],
     "calculation": {
      "http://www.genmab.com/role/StatementStatementsOfComprehensiveIncome": {
       "order": 1.0,
       "parentTag": "ifrs-full_ProfitLossFromOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of all operating expenses."
       }
      },
      "en-us": {
       "role": {
        "label": "Operating expense",
        "negatedTotalLabel": "Operating expenses"
       }
      }
     },
     "localname": "OperatingExpense",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/StatementStatementsOfComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_OrdinarySharesMember": {
     "auth_ref": [
      "r32",
      "r64"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for equity instruments that are subordinate to all other classes of equity instruments. It also represents the standard value for the 'Classes of ordinary shares' axis if no other member is used."
       }
      },
      "en-us": {
       "role": {
        "label": "Ordinary shares [member]"
       }
      }
     },
     "localname": "OrdinarySharesMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_OtherComprehensiveIncome": {
     "auth_ref": [
      "r7",
      "r35",
      "r42",
      "r104"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of income and expense (including reclassification adjustments) that is not recognised in profit or loss as required or permitted by IFRSs. [Refer: IFRSs [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Other comprehensive income",
        "terseLabel": "Other comprehensive income"
       }
      }
     },
     "localname": "OtherComprehensiveIncome",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/StatementStatementsOfChangesInEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_OtherComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other comprehensive income [abstract]",
        "terseLabel": "Other comprehensive income:"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeAbstract",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/StatementStatementsOfComprehensiveIncome"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_OtherComprehensiveIncomeBeforeTaxExchangeDifferencesOnTranslation": {
     "auth_ref": [
      "r27",
      "r43"
     ],
     "calculation": {
      "http://www.genmab.com/role/StatementStatementsOfComprehensiveIncome": {
       "order": 6.0,
       "parentTag": "ifrs-full_ComprehensiveIncome",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of other comprehensive income, before tax, after reclassification adjustments, related to exchange differences on translation of financial statements of foreign operations. [Refer: Other comprehensive income, before tax]"
       }
      },
      "en-us": {
       "role": {
        "label": "Other comprehensive income, before tax, exchange differences on translation",
        "terseLabel": "Adjustment of foreign currency fluctuations on subsidiaries"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeBeforeTaxExchangeDifferencesOnTranslation",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/StatementStatementsOfComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_OtherComprehensiveIncomeNetOfTaxChangeInFairValueOfFinancialLiabilityAttributableToChangeInCreditRiskOfLiability": {
     "auth_ref": [
      "r27",
      "r42"
     ],
     "calculation": {
      "http://www.genmab.com/role/StatementStatementsOfComprehensiveIncome": {
       "order": 2.0,
       "parentTag": "ifrs-full_ComprehensiveIncome",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of other comprehensive income, net of tax, related to changes in the fair value of financial liabilities attributable to the changes in the credit risk of those liabilities. [Refer: Other comprehensive income; Credit risk [member]; Financial liabilities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Other comprehensive income, net of tax, change in fair value of financial liability attributable to change in credit risk of liability",
        "terseLabel": "Fair value adjustments during the period"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeNetOfTaxChangeInFairValueOfFinancialLiabilityAttributableToChangeInCreditRiskOfLiability",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/StatementStatementsOfComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation": {
     "auth_ref": [
      "r27",
      "r42"
     ],
     "calculation": {
      "http://www.genmab.com/role/StatementStatementsOfComprehensiveIncome": {
       "order": 1.0,
       "parentTag": "ifrs-full_ComprehensiveIncome",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of other comprehensive income, net of tax, after reclassification adjustments, related to exchange differences when financial statements of foreign operations are translated. [Refer: Other comprehensive income]"
       }
      },
      "en-us": {
       "role": {
        "label": "Other comprehensive income, net of tax, exchange differences on translation",
        "terseLabel": "Adjustment of foreign currency fluctuations on subsidiaries"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/StatementStatementsOfComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_OtherCurrentLiabilities": {
     "auth_ref": [
      "r24"
     ],
     "calculation": {
      "http://www.genmab.com/role/StatementBalanceSheets": {
       "order": 6.0,
       "parentTag": "ifrs-full_CurrentLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of current liabilities that the entity does not separately disclose in the same statement or note. [Refer: Current liabilities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Other current liabilities"
       }
      }
     },
     "localname": "OtherCurrentLiabilities",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_OtherCurrentPayables": {
     "auth_ref": [
      "r24"
     ],
     "calculation": {
      "http://www.genmab.com/role/StatementBalanceSheets": {
       "order": 4.0,
       "parentTag": "ifrs-full_CurrentLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of current payables that the entity does not separately disclose in the same statement or note."
       }
      },
      "en-us": {
       "role": {
        "label": "Other current payables",
        "verboseLabel": "Other payables"
       }
      }
     },
     "localname": "OtherCurrentPayables",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_OtherNoncurrentLiabilities": {
     "auth_ref": [
      "r24"
     ],
     "calculation": {
      "http://www.genmab.com/role/StatementBalanceSheets": {
       "order": 5.0,
       "parentTag": "ifrs-full_NoncurrentLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of non-current liabilities that the entity does not separately disclose in the same statement or note. [Refer: Non-current liabilities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Other non-current liabilities"
       }
      }
     },
     "localname": "OtherNoncurrentLiabilities",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_OtherNoncurrentPayables": {
     "auth_ref": [
      "r24"
     ],
     "calculation": {
      "http://www.genmab.com/role/StatementBalanceSheets": {
       "order": 4.0,
       "parentTag": "ifrs-full_NoncurrentLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of non-current payables that the entity does not separately disclose in the same statement or note."
       }
      },
      "en-us": {
       "role": {
        "label": "Other non-current payables",
        "verboseLabel": "Other payables"
       }
      }
     },
     "localname": "OtherNoncurrentPayables",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_OtherReserves": {
     "auth_ref": [
      "r29"
     ],
     "calculation": {
      "http://www.genmab.com/role/StatementBalanceSheets": {
       "order": 2.0,
       "parentTag": "ifrs-full_Equity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "A component of equity representing reserves within equity, not including retained earnings. [Refer: Retained earnings]"
       }
      },
      "en-us": {
       "role": {
        "label": "Other reserves",
        "terseLabel": "Other reserves"
       }
      }
     },
     "localname": "OtherReserves",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_PaymentsForShareIssueCosts": {
     "auth_ref": [
      "r80"
     ],
     "calculation": {
      "http://www.genmab.com/role/StatementStatementsOfCashFlows": {
       "order": 6.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash outflow for share issue costs."
       }
      },
      "en-us": {
       "role": {
        "label": "Payments for share issue costs",
        "negatedLabel": "Costs related to issuance of shares"
       }
      }
     },
     "localname": "PaymentsForShareIssueCosts",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities": {
     "auth_ref": [
      "r79"
     ],
     "calculation": {
      "http://www.genmab.com/role/StatementStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash outflow for payment of lease liabilities, classified as financing activities. [Refer: Lease liabilities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Payments of lease liabilities, classified as financing activities",
        "negatedLabel": "Principal elements of lease payments"
       }
      }
     },
     "localname": "PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_PresentationOfLeasesForLesseeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases"
       }
      }
     },
     "localname": "PresentationOfLeasesForLesseeAbstract",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "xbrltype": "stringItemType"
    },
    "ifrs-full_ProceedsFromExerciseOfWarrants": {
     "auth_ref": [
      "r80"
     ],
     "calculation": {
      "http://www.genmab.com/role/StatementStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash inflow from the exercise of share purchase warrants."
       }
      },
      "en-us": {
       "role": {
        "label": "Proceeds From Exercise Of Warrants",
        "terseLabel": "Warrants exercised",
        "verboseLabel": "Exercise of warrants"
       }
      }
     },
     "localname": "ProceedsFromExerciseOfWarrants",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/DisclosureShareBasedInstrumentsWarrantProgramDetails",
      "http://www.genmab.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ProceedsFromIssueOfOrdinaryShares": {
     "auth_ref": [
      "r80"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash inflow from the issuing of ordinary shares. [Refer: Ordinary shares [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Proceeds from issue of ordinary shares",
        "verboseLabel": "Proceeds from sale of shares"
       }
      }
     },
     "localname": "ProceedsFromIssueOfOrdinaryShares",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/DisclosureFinancialInstrumentsOtherInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ProceedsFromIssuingShares": {
     "auth_ref": [
      "r78"
     ],
     "calculation": {
      "http://www.genmab.com/role/StatementStatementsOfCashFlows": {
       "order": 5.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash inflow from issuing shares."
       }
      },
      "en-us": {
       "role": {
        "label": "Proceeds from issuing shares",
        "terseLabel": "Shares issued for cash"
       }
      }
     },
     "localname": "ProceedsFromIssuingShares",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ProceedsFromSalesOfInvestmentsAccountedForUsingEquityMethod": {
     "auth_ref": [
      "r77"
     ],
     "calculation": {
      "http://www.genmab.com/role/StatementStatementsOfCashFlows": {
       "order": 6.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash inflow from sales of investments accounted for using the equity method. [Refer: Investments accounted for using equity method]"
       }
      },
      "en-us": {
       "role": {
        "label": "Proceeds from sales of investments accounted for using equity method",
        "terseLabel": "Other investments sold"
       }
      }
     },
     "localname": "ProceedsFromSalesOfInvestmentsAccountedForUsingEquityMethod",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ProceedsFromSalesOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod": {
     "auth_ref": [
      "r77"
     ],
     "calculation": {
      "http://www.genmab.com/role/StatementStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash inflow from sales of investments other than investments accounted for using the equity method. [Refer: Investments accounted for using equity method; Investments other than investments accounted for using equity method]"
       }
      },
      "en-us": {
       "role": {
        "label": "Proceeds from sales of investments other than investments accounted for using equity method",
        "terseLabel": "Marketable securities sold"
       }
      }
     },
     "localname": "ProceedsFromSalesOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ProfitLoss": {
     "auth_ref": [
      "r6",
      "r34",
      "r81",
      "r94",
      "r96",
      "r97",
      "r156",
      "r159",
      "r166",
      "r175"
     ],
     "calculation": {
      "http://www.genmab.com/role/StatementStatementsOfComprehensiveIncome": {
       "order": 4.0,
       "parentTag": "ifrs-full_ComprehensiveIncome",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]"
       }
      },
      "en-us": {
       "role": {
        "label": "Profit (loss)",
        "terseLabel": "Net profit",
        "totalLabel": "Net profit"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/StatementStatementsOfChangesInEquity",
      "http://www.genmab.com/role/StatementStatementsOfComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ProfitLossBeforeTax": {
     "auth_ref": [
      "r1",
      "r2",
      "r130",
      "r156",
      "r159"
     ],
     "calculation": {
      "http://www.genmab.com/role/StatementStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "gmab_CashFlowFromUsedInOperatingActivitiesBeforeFinancialItems",
       "weight": 1.0
      },
      "http://www.genmab.com/role/StatementStatementsOfComprehensiveIncome": {
       "order": 2.0,
       "parentTag": "ifrs-full_ProfitLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The profit (loss) before tax expense or income. [Refer: Profit (loss)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Profit (loss) before tax",
        "totalLabel": "Net profit before tax",
        "verboseLabel": "Net profit before tax"
       }
      }
     },
     "localname": "ProfitLossBeforeTax",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/StatementStatementsOfCashFlows",
      "http://www.genmab.com/role/StatementStatementsOfComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ProfitLossFromOperatingActivities": {
     "auth_ref": [
      "r40",
      "r63"
     ],
     "calculation": {
      "http://www.genmab.com/role/StatementStatementsOfComprehensiveIncome": {
       "order": 3.0,
       "parentTag": "ifrs-full_ProfitLossBeforeTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The profit (loss) from operating activities of the entity. [Refer: Profit (loss)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Profit (loss) from operating activities",
        "totalLabel": "Operating profit"
       }
      }
     },
     "localname": "ProfitLossFromOperatingActivities",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/StatementStatementsOfComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_PropertyPlantAndEquipment": {
     "auth_ref": [
      "r17",
      "r53"
     ],
     "calculation": {
      "http://www.genmab.com/role/StatementBalanceSheets": {
       "order": 3.0,
       "parentTag": "ifrs-full_NoncurrentAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of tangible assets that: (a) are held for use in the production or supply of goods or services, for rental to others, or for administrative purposes; and (b) are expected to be used during more than one period."
       }
      },
      "en-us": {
       "role": {
        "label": "Property, plant and equipment",
        "terseLabel": "Property and equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipment",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_PropertyPlantAndEquipmentMember": {
     "auth_ref": [
      "r54",
      "r68",
      "r123"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for property, plant and equipment. It also represents the standard value for the 'Classes of property, plant and equipment' axis if no other member is used. [Refer: Property, plant and equipment]"
       }
      },
      "en-us": {
       "role": {
        "label": "Property, plant and equipment [member]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/DisclosureLeasesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities": {
     "auth_ref": [
      "r76"
     ],
     "calculation": {
      "http://www.genmab.com/role/StatementStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash outflow for the purchases of intangible assets, classified as investing activities. [Refer: Intangible assets other than goodwill]"
       }
      },
      "en-us": {
       "role": {
        "label": "Purchase of intangible assets, classified as investing activities",
        "negatedLabel": "Investment in intangible assets"
       }
      }
     },
     "localname": "PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_PurchaseOfInterestsInInvestmentsAccountedForUsingEquityMethod": {
     "auth_ref": [
      "r77"
     ],
     "calculation": {
      "http://www.genmab.com/role/StatementStatementsOfCashFlows": {
       "order": 5.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash outflow for the purchase of interests in investments accounted for using the equity method. [Refer: Investments accounted for using equity method]"
       }
      },
      "en-us": {
       "role": {
        "label": "Purchase of interests in investments accounted for using equity method",
        "negatedLabel": "Other investments bought"
       }
      }
     },
     "localname": "PurchaseOfInterestsInInvestmentsAccountedForUsingEquityMethod",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_PurchaseOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod": {
     "auth_ref": [
      "r77"
     ],
     "calculation": {
      "http://www.genmab.com/role/StatementStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash outflow for the purchase of investments other than investments accounted for using equity method. [Refer: Investments accounted for using equity method; Investments other than investments accounted for using equity method]"
       }
      },
      "en-us": {
       "role": {
        "label": "Purchase of investments other than investments accounted for using equity method",
        "negatedLabel": "Marketable securities bought"
       }
      }
     },
     "localname": "PurchaseOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities": {
     "auth_ref": [
      "r76"
     ],
     "calculation": {
      "http://www.genmab.com/role/StatementStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash outflow for the purchases of property, plant and equipment, classified as investing activities. [Refer: Property, plant and equipment]"
       }
      },
      "en-us": {
       "role": {
        "label": "Purchase of property, plant and equipment, classified as investing activities",
        "negatedLabel": "Investment in tangible assets"
       }
      }
     },
     "localname": "PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_PurchaseOfTreasuryShares": {
     "auth_ref": [
      "r9"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The decrease in equity resulting from the purchase of treasury shares. [Refer: Treasury shares]"
       }
      },
      "en-us": {
       "role": {
        "label": "Purchase of treasury shares",
        "negatedLabel": "Purchase of treasury shares",
        "terseLabel": "Acquisition of treasury shares"
       }
      }
     },
     "localname": "PurchaseOfTreasuryShares",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/DisclosureShareBasedInstrumentsShareRepurchasesDetails",
      "http://www.genmab.com/role/StatementStatementsOfChangesInEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ReclassificationAdjustmentsOnCashFlowHedgesNetOfTax": {
     "auth_ref": [
      "r44",
      "r134",
      "r136",
      "r177"
     ],
     "calculation": {
      "http://www.genmab.com/role/StatementStatementsOfComprehensiveIncome": {
       "order": 3.0,
       "parentTag": "ifrs-full_ComprehensiveIncome",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of reclassification adjustments related to cash flow hedges, net of tax. Reclassification adjustments are amounts reclassified to profit (loss) in the current period that were recognised in other comprehensive income in the current or previous periods. [Refer: Cash flow hedges [member]; Other comprehensive income]"
       }
      },
      "en-us": {
       "role": {
        "label": "Reclassification adjustments on cash flow hedges, net of tax",
        "negatedLabel": "Fair value adjustments reclassified to the income statement to financial income"
       }
      }
     },
     "localname": "ReclassificationAdjustmentsOnCashFlowHedgesNetOfTax",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/StatementStatementsOfComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ReconciliationOfChangesInFairValueMeasurementAssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reconciliation of changes in fair value measurement, assets [abstract]"
       }
      }
     },
     "localname": "ReconciliationOfChangesInFairValueMeasurementAssetsAbstract",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/DisclosureFinancialInstrumentsFairValueMeasurementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_RentDeferredIncomeClassifiedAsCurrent": {
     "auth_ref": [
      "r30"
     ],
     "calculation": {
      "http://www.genmab.com/role/StatementBalanceSheets": {
       "order": 3.0,
       "parentTag": "ifrs-full_CurrentLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of rent deferred income classified as current. [Refer: Rent deferred income]"
       }
      },
      "en-us": {
       "role": {
        "label": "Rent deferred income classified as current",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "RentDeferredIncomeClassifiedAsCurrent",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_RentDeferredIncomeClassifiedAsNoncurrent": {
     "auth_ref": [
      "r30"
     ],
     "calculation": {
      "http://www.genmab.com/role/StatementBalanceSheets": {
       "order": 2.0,
       "parentTag": "ifrs-full_NoncurrentLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of rent deferred income classified as non-current. [Refer: Rent deferred income]"
       }
      },
      "en-us": {
       "role": {
        "label": "Rent deferred income classified as non-current",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "RentDeferredIncomeClassifiedAsNoncurrent",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r71"
     ],
     "calculation": {
      "http://www.genmab.com/role/StatementStatementsOfComprehensiveIncome": {
       "order": 3.0,
       "parentTag": "ifrs-full_OperatingExpense",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of expenditure directly attributable to research or development activities, recognised in profit or loss."
       }
      },
      "en-us": {
       "role": {
        "label": "Research and development expense",
        "negatedLabel": "Research and development expenses"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/StatementStatementsOfComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember": {
     "auth_ref": [
      "r11",
      "r57"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for a component of equity representing accumulated exchange differences on the translation of financial statements recognised in other comprehensive income. [Refer: Other comprehensive income]"
       }
      },
      "en-us": {
       "role": {
        "label": "Translation reserves"
       }
      }
     },
     "localname": "ReserveOfExchangeDifferencesOnTranslationMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/StatementStatementsOfChangesInEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_RestatedMember": {
     "auth_ref": [
      "r5",
      "r15",
      "r90",
      "r91",
      "r92",
      "r166"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for the information currently stated in the financial statements. It also represents the standard value for the 'Retrospective application and retrospective restatement' and 'Departure from requirement of IFRS' axes if no other member is used."
       }
      },
      "en-us": {
       "role": {
        "label": "Currently stated [member]"
       }
      }
     },
     "localname": "RestatedMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/StatementStatementsOfChangesInEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_RetainedEarnings": {
     "auth_ref": [
      "r29",
      "r46"
     ],
     "calculation": {
      "http://www.genmab.com/role/StatementBalanceSheets": {
       "order": 3.0,
       "parentTag": "ifrs-full_Equity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "A component of equity representing the entity's cumulative undistributed earnings or deficit."
       }
      },
      "en-us": {
       "role": {
        "label": "Retained earnings",
        "verboseLabel": "Retained earnings"
       }
      }
     },
     "localname": "RetainedEarnings",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_RetainedEarningsMember": {
     "auth_ref": [
      "r10",
      "r11"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for a component of equity representing an entity's cumulative undistributed earnings or deficit."
       }
      },
      "en-us": {
       "role": {
        "label": "Retained Earnings [Member]"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/StatementStatementsOfChangesInEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis": {
     "auth_ref": [
      "r5",
      "r90",
      "r91",
      "r92"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Retrospective application and retrospective restatement [axis]"
       }
      }
     },
     "localname": "RetrospectiveApplicationAndRetrospectiveRestatementAxis",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/StatementStatementsOfChangesInEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_Revenue": {
     "auth_ref": [
      "r1",
      "r2",
      "r37",
      "r97",
      "r103",
      "r130",
      "r154",
      "r158",
      "r162",
      "r163",
      "r164"
     ],
     "calculation": {
      "http://www.genmab.com/role/StatementStatementsOfComprehensiveIncome": {
       "order": 2.0,
       "parentTag": "ifrs-full_ProfitLossFromOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The income arising in the course of an entity's ordinary activities. Income is increases in assets, or decreases in liabilities, that result in increases in equity, other than those relating to contributions from holders of equity claims."
       }
      },
      "en-us": {
       "role": {
        "label": "Revenue.",
        "terseLabel": "Revenue"
       }
      }
     },
     "localname": "Revenue",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/StatementStatementsOfComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_RevenueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue"
       }
      }
     },
     "localname": "RevenueAbstract",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "xbrltype": "stringItemType"
    },
    "ifrs-full_RevenueFromContractsWithCustomers": {
     "auth_ref": [
      "r112",
      "r113"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of revenue from contracts with customers. A customer is a party that has contracted with an entity to obtain goods or services that are an output of the entity\u2019s ordinary activities in exchange for consideration."
       }
      },
      "en-us": {
       "role": {
        "label": "Revenue from contracts with customers",
        "terseLabel": "Revenue"
       }
      }
     },
     "localname": "RevenueFromContractsWithCustomers",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/DisclosureRevenueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_RightofuseAssets": {
     "auth_ref": [
      "r122"
     ],
     "calculation": {
      "http://www.genmab.com/role/StatementBalanceSheets": {
       "order": 4.0,
       "parentTag": "ifrs-full_NoncurrentAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of assets that represent a lessee's right to use an underlying asset for the lease term. Underlying asset is an asset that is the subject of a lease, for which the right to use that asset has been provided by a lessor to a lessee."
       }
      },
      "en-us": {
       "role": {
        "label": "Right-of-use assets",
        "verboseLabel": "Right-of-use assets"
       }
      }
     },
     "localname": "RightofuseAssets",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/DisclosureLeasesDetails",
      "http://www.genmab.com/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_SaleOrIssueOfTreasuryShares": {
     "auth_ref": [
      "r9"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The increase in equity resulting from the sale or issue of treasury shares. [Refer: Treasury shares]"
       }
      },
      "en-us": {
       "role": {
        "label": "Sale or issue of treasury shares",
        "terseLabel": "Treasury shares issued"
       }
      }
     },
     "localname": "SaleOrIssueOfTreasuryShares",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/DisclosureShareBasedInstrumentsRestrictedStockUnitProgramDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_SellingGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r40"
     ],
     "calculation": {
      "http://www.genmab.com/role/StatementStatementsOfComprehensiveIncome": {
       "order": 1.0,
       "parentTag": "ifrs-full_OperatingExpense",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of expense relating to selling, general and administrative activities of the entity."
       }
      },
      "en-us": {
       "role": {
        "label": "Selling, general and administrative expense",
        "negatedLabel": "Selling, general and administrative expenses"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpense",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/StatementStatementsOfComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_SharePremium": {
     "auth_ref": [
      "r29"
     ],
     "calculation": {
      "http://www.genmab.com/role/StatementBalanceSheets": {
       "order": 4.0,
       "parentTag": "ifrs-full_Equity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount received or receivable from the issuance of the entity's shares in excess of nominal value."
       }
      },
      "en-us": {
       "role": {
        "label": "Share premium",
        "terseLabel": "Share premium"
       }
      }
     },
     "localname": "SharePremium",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_SharePremiumMember": {
     "auth_ref": [
      "r10"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for the amount received or receivable from issuance of the entity's shares in excess of nominal value."
       }
      },
      "en-us": {
       "role": {
        "label": "Share premium [Member]"
       }
      }
     },
     "localname": "SharePremiumMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/StatementStatementsOfChangesInEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_SharebasedPaymentArrangementsMember": {
     "auth_ref": [
      "r127"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for an agreement between the entity or another group entity or any shareholder of the group entity and another party (including an employee) that entitles the other party to receive (a) cash or other assets of the entity for amounts that are based on the price (or value) of equity instruments (including shares or share options) of the entity or another group entity; or (b) equity instruments (including shares or share options) of the entity or another group entity, provided that the specified vesting conditions, if any, are met. It also represents the standard value for the 'Types of share-based payment arrangements' axis if no other member is used."
       }
      },
      "en-us": {
       "role": {
        "label": "Share-based payment arrangements [member]"
       }
      }
     },
     "localname": "SharebasedPaymentArrangementsMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/DisclosureShareBasedInstrumentsRestrictedStockUnitProgramDetails",
      "http://www.genmab.com/role/DisclosureShareBasedInstrumentsShareRepurchasesDetails",
      "http://www.genmab.com/role/DisclosureShareBasedInstrumentsWarrantProgramDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_ShorttermInvestmentsClassifiedAsCashEquivalents": {
     "auth_ref": [
      "r88"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "A classification of cash equivalents representing short-term investments. [Refer: Cash equivalents]"
       }
      },
      "en-us": {
       "role": {
        "label": "Short-term investments, classified as cash equivalents",
        "terseLabel": "Short-term marketable securities"
       }
      }
     },
     "localname": "ShorttermInvestmentsClassifiedAsCashEquivalents",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "STATEMENTS OF CASH FLOWS"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "xbrltype": "stringItemType"
    },
    "ifrs-full_StatementOfChangesInEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "STATEMENTS OF CHANGES IN EQUITY"
       }
      }
     },
     "localname": "StatementOfChangesInEquityAbstract",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "xbrltype": "stringItemType"
    },
    "ifrs-full_StatementOfChangesInEquityLineItems": {
     "auth_ref": [],
     "lang": {
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Statement of changes in equity [line items]",
        "terseLabel": "STATEMENT OF CHANGES IN EQUITY"
       }
      }
     },
     "localname": "StatementOfChangesInEquityLineItems",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/StatementStatementsOfChangesInEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_StatementOfChangesInEquityTable": {
     "auth_ref": [
      "r10"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to changes in equity."
       }
      },
      "en-us": {
       "role": {
        "label": "Statement of changes in equity [table]"
       }
      }
     },
     "localname": "StatementOfChangesInEquityTable",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/StatementStatementsOfChangesInEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_StatementOfComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of comprehensive income [abstract]",
        "terseLabel": "Statement of Comprehensive Income"
       }
      }
     },
     "localname": "StatementOfComprehensiveIncomeAbstract",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/StatementStatementsOfComprehensiveIncome"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "BALANCE SHEETS"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "xbrltype": "stringItemType"
    },
    "ifrs-full_StatementOfProfitOrLossAndOtherComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "STATEMENTS OF COMPREHENSIVE INCOME"
       }
      }
     },
     "localname": "StatementOfProfitOrLossAndOtherComprehensiveIncomeAbstract",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "xbrltype": "stringItemType"
    },
    "ifrs-full_TradeAndOtherCurrentReceivables": {
     "auth_ref": [
      "r20",
      "r28"
     ],
     "calculation": {
      "http://www.genmab.com/role/StatementBalanceSheets": {
       "order": 3.0,
       "parentTag": "ifrs-full_CurrentAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of current trade receivables and current other receivables. [Refer: Current trade receivables; Other current receivables]"
       }
      },
      "en-us": {
       "role": {
        "label": "Trade and other current receivables",
        "terseLabel": "Receivables"
       }
      }
     },
     "localname": "TradeAndOtherCurrentReceivables",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_TreasuryShares": {
     "auth_ref": [
      "r29",
      "r62"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "An entity\u2019s own equity instruments, held by the entity or other members of the consolidated group."
       }
      },
      "en-us": {
       "role": {
        "label": "Treasury shares",
        "terseLabel": "Treasury shares"
       }
      }
     },
     "localname": "TreasuryShares",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/DisclosureShareBasedInstrumentsRestrictedStockUnitProgramDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_TypesOfRisksAxis": {
     "auth_ref": [
      "r131",
      "r140",
      "r141",
      "r167",
      "r168",
      "r169",
      "r171"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Types of risks [axis]"
       }
      }
     },
     "localname": "TypesOfRisksAxis",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/DisclosureFinancialInstrumentsFinancialRiskDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_TypesOfRisksMember": {
     "auth_ref": [
      "r131",
      "r140",
      "r141",
      "r167",
      "r168",
      "r169",
      "r171"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for all types of risks. It also represents the standard value for the 'Types of risks' axis if no other member is used."
       }
      },
      "en-us": {
       "role": {
        "label": "Risks [member]"
       }
      }
     },
     "localname": "TypesOfRisksMember",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/DisclosureFinancialInstrumentsFinancialRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_TypesOfSharebasedPaymentArrangementsAxis": {
     "auth_ref": [
      "r127"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Types of share-based payment arrangements [axis]"
       }
      }
     },
     "localname": "TypesOfSharebasedPaymentArrangementsAxis",
     "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full",
     "presentation": [
      "http://www.genmab.com/role/DisclosureShareBasedInstrumentsRestrictedStockUnitProgramDetails",
      "http://www.genmab.com/role/DisclosureShareBasedInstrumentsShareRepurchasesDetails",
      "http://www.genmab.com/role/DisclosureShareBasedInstrumentsWarrantProgramDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_CurrencyAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Currency [Axis]"
       }
      }
     },
     "localname": "CurrencyAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.genmab.com/role/DisclosureFinancialInstrumentsFinancialRiskDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.genmab.com/role/DisclosureShareBasedInstrumentsShareRepurchasesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.genmab.com/role/DisclosureShareBasedInstrumentsShareRepurchasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.genmab.com/role/DisclosureShareBasedInstrumentsShareRepurchasesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioUnspecifiedDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Domain]"
       }
      }
     },
     "localname": "ScenarioUnspecifiedDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.genmab.com/role/DisclosureShareBasedInstrumentsShareRepurchasesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.genmab.com/role/DisclosureLeasesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.genmab.com/role/DisclosureLeasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_StatementScenarioAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Axis]"
       }
      }
     },
     "localname": "StatementScenarioAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.genmab.com/role/DisclosureShareBasedInstrumentsShareRepurchasesDetails"
     ],
     "xbrltype": "stringItemType"
    }
   },
   "unitCount": 7
  }
 },
 "std_ref": {
  "r0": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "10",
   "Subparagraph": "e",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_10_e&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r1": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "102",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_102&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r10": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "106",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_106&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r100": {
   "Clause": "iii",
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "12",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2021-en-r&anchor=para_B12_b_iii&doctype=Appendix&subtype=B",
   "URIDate": "2021-03-24"
  },
  "r101": {
   "Clause": "iv",
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "12",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2021-en-r&anchor=para_B12_b_iv&doctype=Appendix&subtype=B",
   "URIDate": "2021-03-24"
  },
  "r102": {
   "Clause": "ix",
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "12",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2021-en-r&anchor=para_B12_b_ix&doctype=Appendix&subtype=B",
   "URIDate": "2021-03-24"
  },
  "r103": {
   "Clause": "v",
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "12",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2021-en-r&anchor=para_B12_b_v&doctype=Appendix&subtype=B",
   "URIDate": "2021-03-24"
  },
  "r104": {
   "Clause": "viii",
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "12",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2021-en-r&anchor=para_B12_b_viii&doctype=Appendix&subtype=B",
   "URIDate": "2021-03-24"
  },
  "r105": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "12",
   "Paragraph": "B13",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2021-en-r&anchor=para_B13_a&doctype=Appendix&subtype=B",
   "URIDate": "2021-03-24"
  },
  "r106": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "12",
   "Paragraph": "B13",
   "Subparagraph": "g",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2021-en-r&anchor=para_B13_g&doctype=Appendix&subtype=B",
   "URIDate": "2021-03-24"
  },
  "r107": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "12",
   "Paragraph": "B16",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2021-en-r&anchor=para_B16&doctype=Appendix&subtype=B",
   "URIDate": "2021-03-24"
  },
  "r108": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "13",
   "Paragraph": "93",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2021-en-r&anchor=para_93_a&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r109": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "13",
   "Paragraph": "93",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2021-en-r&anchor=para_93_b&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r11": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "108",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_108&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r110": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "13",
   "Paragraph": "93",
   "Subparagraph": "e",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2021-en-r&anchor=para_93_e&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r111": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "13",
   "Paragraph": "93",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2021-en-r&anchor=para_93&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r112": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "15",
   "Paragraph": "113",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2021-en-r&anchor=para_113_a&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r113": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "15",
   "Paragraph": "114",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2021-en-r&anchor=para_114&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r114": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "15",
   "Paragraph": "C8",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2021-en-r&anchor=para_C8_a&doctype=Appendix&subtype=C",
   "URIDate": "2021-03-24"
  },
  "r115": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "15",
   "Section": "Disclosure",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2021-en-r&doctype=Standard&dita_xref=IFRS15_g110-129_TI",
   "URIDate": "2021-03-24"
  },
  "r116": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "15",
   "Section": "Presentation",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2021-en-r&doctype=Standard&dita_xref=IFRS15_g105-109_TI",
   "URIDate": "2021-03-24"
  },
  "r117": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "16",
   "Paragraph": "47",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2021-en-r&anchor=para_47_b&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r118": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "16",
   "Paragraph": "53",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2021-en-r&anchor=para_53_a&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r119": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "16",
   "Paragraph": "53",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2021-en-r&anchor=para_53_b&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r12": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "112",
   "Subparagraph": "c",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_112_c&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r120": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "16",
   "Paragraph": "53",
   "Subparagraph": "c",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2021-en-r&anchor=para_53_c&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r121": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "16",
   "Paragraph": "53",
   "Subparagraph": "h",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2021-en-r&anchor=para_53_h&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r122": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "16",
   "Paragraph": "53",
   "Subparagraph": "j",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2021-en-r&anchor=para_53_j&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r123": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "16",
   "Paragraph": "53",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2021-en-r&anchor=para_53&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r124": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "16",
   "Section": "Disclosure",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2021-en-r&doctype=Standard&dita_xref=IFRS16_g51-60_TI",
   "URIDate": "2021-03-24"
  },
  "r125": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "16",
   "Section": "Presentation",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2021-en-r&doctype=Standard&dita_xref=IFRS16_g47-50_TI",
   "URIDate": "2021-03-24"
  },
  "r126": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "2",
   "Paragraph": "44",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2021-en-r&anchor=para_44&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r127": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "2",
   "Paragraph": "45",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2021-en-r&anchor=para_45&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r128": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "2",
   "Paragraph": "47",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2021-en-r&anchor=para_47_b&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r129": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "2",
   "Paragraph": "51",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2021-en-r&anchor=para_51_a&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r13": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "117",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_117_b&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r130": {
   "Clause": "i",
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "5",
   "Paragraph": "33",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=5&code=ifrs-tx-2021-en-r&anchor=para_33_b_i&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r131": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "21C",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_21C&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r132": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "24A",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_24A&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r133": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "24B",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_24B&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r134": {
   "Clause": "iv",
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "24C",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_24C_b_iv&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r135": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "24C",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_24C&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r136": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "24E",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_24E_a&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r137": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "25",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_25&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r138": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "31",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_31&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r139": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "32",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_32&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r14": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "117",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_117&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r140": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "33",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_33&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r141": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "34",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_34&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r142": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "35H",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_35H&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r143": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "35I",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_35I&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r144": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "35K",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_35K_a&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r145": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "35K",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_35K&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r146": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "35M",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_35M&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r147": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "35N",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_35N&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r148": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "42I",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_42I&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r149": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "6",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_6&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r15": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "20",
   "Subparagraph": "d",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_20_d&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r150": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "7",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_7&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r151": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "IG20C",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_IG20C&doctype=Implementation%20Guidance",
   "URIDate": "2021-03-24"
  },
  "r152": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "7",
   "Section": "Defined terms",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&doctype=Appendix&subtype=A&dita_xref=IFRS07_APPA_TI",
   "URIDate": "2021-03-24"
  },
  "r153": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "7",
   "Section": "Offsetting financial assets and financial liabilities",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&doctype=Standard&dita_xref=IFRS07_g13A-13F_TI",
   "URIDate": "2021-03-24"
  },
  "r154": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "8",
   "Paragraph": "23",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2021-en-r&anchor=para_23_a&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r155": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "8",
   "Paragraph": "23",
   "Subparagraph": "h",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2021-en-r&anchor=para_23_h&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r156": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "8",
   "Paragraph": "23",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2021-en-r&anchor=para_23&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r157": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "8",
   "Paragraph": "24",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2021-en-r&anchor=para_24_a&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r158": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "8",
   "Paragraph": "28",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2021-en-r&anchor=para_28_a&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r159": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "8",
   "Paragraph": "28",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2021-en-r&anchor=para_28_b&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r16": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "35",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_35&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r160": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "8",
   "Paragraph": "28",
   "Subparagraph": "c",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2021-en-r&anchor=para_28_c&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r161": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "8",
   "Paragraph": "28",
   "Subparagraph": "d",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2021-en-r&anchor=para_28_d&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r162": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "8",
   "Paragraph": "32",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2021-en-r&anchor=para_32&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r163": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "8",
   "Paragraph": "33",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2021-en-r&anchor=para_33_a&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r164": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "8",
   "Paragraph": "34",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2021-en-r&anchor=para_34&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r165": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "9",
   "Paragraph": "7.2.34",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=9&code=ifrs-tx-2021-en-r&anchor=para_7.2.34&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r166": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Note": "Effective 2023-01-01",
   "Number": "17",
   "Paragraph": "113",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2021-en-r&anchor=para_113_b&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r167": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Note": "Effective 2023-01-01",
   "Number": "17",
   "Paragraph": "124",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2021-en-r&anchor=para_124&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r168": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Note": "Effective 2023-01-01",
   "Number": "17",
   "Paragraph": "125",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2021-en-r&anchor=para_125&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r169": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Note": "Effective 2023-01-01",
   "Number": "17",
   "Paragraph": "127",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2021-en-r&anchor=para_127&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r17": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "54",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_54_a&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r170": {
   "Clause": "ii",
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Note": "Effective 2023-01-01",
   "Number": "17",
   "Paragraph": "128",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2021-en-r&anchor=para_128_a_ii&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r171": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Note": "Effective 2023-01-01",
   "Number": "17",
   "Paragraph": "128",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2021-en-r&anchor=para_128_a&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r172": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Note": "Effective 2023-01-01",
   "Number": "17",
   "Paragraph": "C32",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2021-en-r&anchor=para_C32&doctype=Appendix&subtype=C",
   "URIDate": "2021-03-24"
  },
  "r173": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Note": "Effective 2023-01-01",
   "Number": "9",
   "Paragraph": "7.2.42",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=9&code=ifrs-tx-2021-en-r&anchor=para_7.2.42&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r174": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Note": "Effective on first application of IFRS 9",
   "Number": "4",
   "Paragraph": "39L",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=4&code=ifrs-tx-2021-en-b&anchor=para_39L_b&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r175": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Note": "Effective on first application of IFRS 9",
   "Number": "4",
   "Paragraph": "39L",
   "Subparagraph": "e",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=4&code=ifrs-tx-2021-en-b&anchor=para_39L_e&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r176": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Note": "Expiry date 2023-01-01",
   "Number": "4",
   "Paragraph": "39G",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=4&code=ifrs-tx-2021-en-b&anchor=para_39G_a&doctype=Standard&book=b",
   "URIDate": "2021-03-24"
  },
  "r177": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Note": "Expiry date 2023-01-01",
   "Number": "7",
   "Paragraph": "23",
   "Subparagraph": "d",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2017-en-b&anchor=para_23_d&doctype=Standard&book=b",
   "URIDate": "2021-03-24"
  },
  "r178": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Note": "Expiry date 2023-01-01",
   "Number": "7",
   "Paragraph": "36",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2017-en-b&anchor=para_36_a&doctype=Standard&book=b",
   "URIDate": "2021-03-24"
  },
  "r179": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Note": "Expiry date 2023-01-01",
   "Number": "7",
   "Paragraph": "36",
   "Subparagraph": "c",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2017-en-b&anchor=para_36_c&doctype=Standard&book=b",
   "URIDate": "2021-03-24"
  },
  "r18": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "54",
   "Subparagraph": "c",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_54_c&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r180": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Note": "Expiry date 2023-01-01",
   "Number": "7",
   "Paragraph": "9",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2017-en-b&anchor=para_9_a&doctype=Standard&book=b",
   "URIDate": "2021-03-24"
  },
  "r181": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Note": "Expiry date 2023-01-01",
   "Number": "7",
   "Paragraph": "IG24",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2017-en-b&anchor=para_IG24_a&doctype=Implementation%20Guidance&book=b",
   "URIDate": "2021-03-24"
  },
  "r182": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12"
  },
  "r183": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r184": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310"
  },
  "r185": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f"
  },
  "r186": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f"
  },
  "r187": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r188": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r189": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r19": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "54",
   "Subparagraph": "e",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_54_e&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r190": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2"
  },
  "r2": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "103",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_103&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r20": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "54",
   "Subparagraph": "h",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_54_h&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r21": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "54",
   "Subparagraph": "i",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_54_i&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r22": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "54",
   "Subparagraph": "l",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_54_l&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r23": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "54",
   "Subparagraph": "n",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_54_n&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r24": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "55",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_55&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r25": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "66",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_66&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r26": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "69",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_69&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r27": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "7",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_7&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r28": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "78",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_78_b&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r29": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "78",
   "Subparagraph": "e",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_78_e&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r3": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "104",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_104&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r30": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "78",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_78&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r31": {
   "Clause": "iv",
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "79",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_79_a_iv&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r32": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "79",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_79_a&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r33": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "79",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_79_b&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r34": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "81A",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_81A_a&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r35": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "81A",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_81A_b&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r36": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "81A",
   "Subparagraph": "c",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_81A_c&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r37": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "82",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_82_a&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r38": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "82",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_82_b&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r39": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "82",
   "Subparagraph": "d",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_82_d&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r4": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "106",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_106_a&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r40": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "85",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_85&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r41": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "90",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_90&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r42": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "91",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_91_a&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r43": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "91",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_91_b&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r44": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "92",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_92&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r45": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "99",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_99&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r46": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "IG6",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_IG6&doctype=Implementation%20Guidance",
   "URIDate": "2021-03-24"
  },
  "r47": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "10",
   "Section": "Disclosure",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=10&code=ifrs-tx-2021-en-r&doctype=Standard&dita_xref=IAS10_g17-22_TI",
   "URIDate": "2021-03-24"
  },
  "r48": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "12",
   "Paragraph": "79",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=12&code=ifrs-tx-2021-en-r&anchor=para_79&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r49": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "12",
   "Paragraph": "81",
   "Subparagraph": "ab",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=12&code=ifrs-tx-2021-en-r&anchor=para_81_ab&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r5": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "106",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_106_b&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r50": {
   "Clause": "i",
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "12",
   "Paragraph": "81",
   "Subparagraph": "c",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=12&code=ifrs-tx-2021-en-r&anchor=para_81_c_i&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r51": {
   "Clause": "ii",
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "12",
   "Paragraph": "81",
   "Subparagraph": "c",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=12&code=ifrs-tx-2021-en-r&anchor=para_81_c_ii&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r52": {
   "Clause": "i",
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "12",
   "Paragraph": "81",
   "Subparagraph": "g",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=12&code=ifrs-tx-2021-en-r&anchor=para_81_g_i&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r53": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "16",
   "Paragraph": "73",
   "Subparagraph": "e",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=16&code=ifrs-tx-2021-en-r&anchor=para_73_e&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r54": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "16",
   "Paragraph": "73",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=16&code=ifrs-tx-2021-en-r&anchor=para_73&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r55": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "19",
   "Paragraph": "142",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=19&code=ifrs-tx-2021-en-r&anchor=para_142&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r56": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "21",
   "Paragraph": "52",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=21&code=ifrs-tx-2021-en-r&anchor=para_52_a&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r57": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "21",
   "Paragraph": "52",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=21&code=ifrs-tx-2021-en-r&anchor=para_52_b&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r58": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "24",
   "Paragraph": "19",
   "Subparagraph": "f",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=24&code=ifrs-tx-2021-en-r&anchor=para_19_f&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r59": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "24",
   "Paragraph": "19",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=24&code=ifrs-tx-2021-en-r&anchor=para_19&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r6": {
   "Clause": "i",
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "106",
   "Subparagraph": "d",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_106_d_i&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r60": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "24",
   "Section": "Disclosures",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=24&code=ifrs-tx-2021-en-r&doctype=Standard&dita_xref=IAS24_g13-24_TI",
   "URIDate": "2021-03-24"
  },
  "r61": {
   "Clause": "viii",
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "26",
   "Paragraph": "35",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=26&code=ifrs-tx-2021-en-r&anchor=para_35_b_viii&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r62": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "32",
   "Paragraph": "34",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=32&code=ifrs-tx-2021-en-r&anchor=para_34&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r63": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "32",
   "Paragraph": "IE33",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=32&code=ifrs-tx-2021-en-r&anchor=para_IE33&doctype=Illustrative%20Examples",
   "URIDate": "2021-03-24"
  },
  "r64": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "33",
   "Paragraph": "66",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=33&code=ifrs-tx-2021-en-r&anchor=para_66&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r65": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "33",
   "Paragraph": "67",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=33&code=ifrs-tx-2021-en-r&anchor=para_67&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r66": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "33",
   "Section": "Disclosure",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=33&code=ifrs-tx-2021-en-r&doctype=Standard&dita_xref=IAS33_g70-73A_TI",
   "URIDate": "2021-03-24"
  },
  "r67": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "36",
   "Paragraph": "126",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=36&code=ifrs-tx-2021-en-r&anchor=para_126&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r68": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "36",
   "Paragraph": "127",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=36&code=ifrs-tx-2021-en-r&anchor=para_127&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r69": {
   "Clause": "ii",
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "36",
   "Paragraph": "130",
   "Subparagraph": "d",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=36&code=ifrs-tx-2021-en-r&anchor=para_130_d_ii&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r7": {
   "Clause": "ii",
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "106",
   "Subparagraph": "d",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_106_d_ii&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r70": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "38",
   "Paragraph": "118",
   "Subparagraph": "e",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=38&code=ifrs-tx-2021-en-r&anchor=para_118_e&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r71": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "38",
   "Paragraph": "126",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=38&code=ifrs-tx-2021-en-r&anchor=para_126&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r72": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "39",
   "Paragraph": "86",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=39&code=ifrs-tx-2021-en-r&anchor=para_86_b&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r73": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "40",
   "Paragraph": "32A",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=40&code=ifrs-tx-2021-en-r&anchor=para_32A&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r74": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "41",
   "Paragraph": "50",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=41&code=ifrs-tx-2021-en-r&anchor=para_50&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r75": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "10",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_10&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r76": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "16",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_16_a&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r77": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "16",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_16&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r78": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "17",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_17_a&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r79": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "17",
   "Subparagraph": "e",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_17_e&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r8": {
   "Clause": "iii",
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "106",
   "Subparagraph": "d",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_106_d_iii&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r80": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "17",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_17&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r81": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "18",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_18_b&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r82": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "20",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_20&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r83": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "25",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_25&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r84": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "28",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_28&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r85": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "31",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_31&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r86": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "35",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_35&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r87": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "39",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_39&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r88": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "45",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_45&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r89": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "50",
   "Subparagraph": "d",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_50_d&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r9": {
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "106",
   "Subparagraph": "d",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_106_d&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r90": {
   "Clause": "i",
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "8",
   "Paragraph": "28",
   "Subparagraph": "f",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=8&code=ifrs-tx-2021-en-r&anchor=para_28_f_i&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r91": {
   "Clause": "i",
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "8",
   "Paragraph": "29",
   "Subparagraph": "c",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=8&code=ifrs-tx-2021-en-r&anchor=para_29_c_i&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r92": {
   "Clause": "i",
   "IssueDate": "2021-01-01",
   "Name": "IAS",
   "Number": "8",
   "Paragraph": "49",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=8&code=ifrs-tx-2021-en-r&anchor=para_49_b_i&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r93": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "1",
   "Paragraph": "24",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2021-en-r&anchor=para_24_a&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r94": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "1",
   "Paragraph": "24",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2021-en-r&anchor=para_24_b&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r95": {
   "Clause": "i",
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "1",
   "Paragraph": "32",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2021-en-r&anchor=para_32_a_i&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r96": {
   "Clause": "ii",
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "1",
   "Paragraph": "32",
   "Subparagraph": "a",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2021-en-r&anchor=para_32_a_ii&doctype=Standard",
   "URIDate": "2021-03-24"
  },
  "r97": {
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "12",
   "Paragraph": "B10",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2021-en-r&anchor=para_B10_b&doctype=Appendix&subtype=B",
   "URIDate": "2021-03-24"
  },
  "r98": {
   "Clause": "i",
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "12",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2021-en-r&anchor=para_B12_b_i&doctype=Appendix&subtype=B",
   "URIDate": "2021-03-24"
  },
  "r99": {
   "Clause": "ii",
   "IssueDate": "2021-01-01",
   "Name": "IFRS",
   "Number": "12",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2021-en-r&anchor=para_B12_b_ii&doctype=Appendix&subtype=B",
   "URIDate": "2021-03-24"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>63
<FILENAME>0001558370-22-012999-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001558370-22-012999-xbrl.zip
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M*<N9[/1T4JJ)^.75JAL_I9RDCL+,[C=C9.5A-%6KD5(*O+;(3#6@F\A-%;2
MN$_G"SO0M2BXBC@\Q3&IKO%O,C3BPSZ;]M"WM88Q46\W__Y*?;L2-GM*[)HP
MB#-"L:2,?%?5BUIV)W\5ZL*HHH'375\=O9D*R[ CNWDG<ST0,4;G ;*D]<4F
M(XGWJH;?Y"\8R7]^A8Y=F1*?GJUF\DPT??:1GHF;TR*24!YLC$66+Q=\HIZ#
MU38Y66->/#6W-Q=C39$$0I&DH-*4AUJM&RJ\?*"DE;8POCOI5ZZA49! /+S
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MUSWJSWT>C 63G;@H_*41F)S_>.97_NW_4$L#!!0    ( "E;"E7>0!OEL"4
M !<S @ 5    9VUA8BTR,#(R,#8S,%]D968N>&UL[5U9=]LXEGZ?<^8_:-PO
M,P_REE2JDE/I/HJ7E*;LR&T[5=WSD@-3D(0.1:A TDO]^@% :B&)C11(0&H_
M5,J2+L#[W>]>K!?@SW][GH>]1TABA*./!R>'QP<]& 5XC*+IQX,T[H,X0.C@
M;W_]S__X^;_Z_7]\NKWJC7&0SF&4] ("00+'O2>4S'KW>+$ 4>\:$H+"L/>)
MH/$4]GKO#]\=_G3R[L?#T],?W[[M]?MY39] 3$OBJ,>K/#T\6?UREM>*HP^]
MGXY.CH].CT]/>V\^G+S_</Q3[^9Z)7A-M9P@K62(HN\?V#\/])$]"C>*/SS'
MZ./!+$D6'XZ.GIZ>#I_>'&(RI>6/3X[^<7UU%\S@'/11%"<@"N!!7HI54BCV
M_$#"9<$W1\MG+,79K^-D56!3^(>C[,=-4:2HNJS)<T65',')^_?OC_BO5#1&
M'V*.Y H'(.$$:Y7O2278I_Y2K,^^ZI^<]M^<'#['XP-JZ%[O9X)#> LG/:[
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M_O\4WN,-[*,)NXKEY ?M'3KUJO%C)B%VV/*E.O60><JSO(&J+/_56"2Z<GD
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M"L@LO-+^T\M:9(GM"9 Q_T=[*L[Z(_;YY(AU8W43ZER5#0VSI[.<IER=<Y#
M7W!(39IG+,6:%GR+&O?YS,FVMG'C#L4Q!57W-DZ-F1<7WN<S)S7,X);/PCY
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M$-&4JL<N.PK2!#W"]5#D'H*Y*@M27]:/7G9[TFO"[NP:G2'MMQ=LG21*/F%
MQED#),R9T1;QHS^US)44;6<4?<%1 Y94I?SH3RT3I0+<&5<7\T6(7R"D#3$[
M3F5*EK*8A[F(V[.E1-PZ7;?9<VF5]Y@_>C0Y1X1^@TG,ULY%7.G+>)@4V)PH
M/=S66:K/D5<,F67T-6=H>W[:V9NY@O6O;/NQNB>35;,O6S%_3P&;/@(VV!M&
M$TSF6<;U TZ36W9M,)Y0BK);%,UW91K4ZLM4\BQD\^%X-,FT4^_*B&1]W8II
MS'1I5T:$V=-E@9*NFI5YB;0_VRURSU12U.8:W W!U"VE.UL2&3]V-93>L<XL
MJ6C?R<&DBS]2M)C+MI/D8GZL2YB95@A@%Y)T5O!RYWBY"6G;.HC&*S1FW8:F
MN*_WZ=CN231F\-0)I%IKNAEM.?\Z'",WK[QE0(VRC89S-)F@ -*G78$'3%BQ
ME[L%",37@AB5\*.G,G2U5<.J0^7L5MWE7;2?(9X2L)BA (2Z2Y"KLKY>I;-5
MNZC![(RR;,-F4R'Y1<AR60^NW-$ZWXH%.0Q[+,0P.)SBQZ. 9?R3K"=:?N \
M< ;R+[Z=_UHR]^8/KJ_?T;H(,^RFPIYVZ$U#N;(29FUIY,J_K>6M#"/?96[0
M=':_X=R>ZY4A2CVI*NC'A*\E%ZG"W87I(5\AOD+@ 86(9\,^Q D!0?D\G$D!
M_[:N+;(KA[T++)^EA"6OED'(9_TR>3_F&#JG+<W=96!V@;DO. IJDJ<JXD<+
M7(\_%9Y=H-"8.,=T29O4>G3M)DF#<7[([QX;#W"49?S(#ZI'G1+0+K!X#A<$
M!MG-$,8TJ@OYD3E4CT<UHET@<DAG1@3&2?[6Q5%DW(@:E/0CQZ@>I0:P=H'7
M7'V>GH.BZ3V^FV&24&CS+%7E$A/^^LR-]V)>/,,YQ_$+B#]!&'VM7BS00OU^
M9#G5\Q%KX%O?-;Y,$SI!NZ:&G:?ST0(2KC#7,C]8+TSU-"KFQ_UD)LR98VH_
M33!.T)QES.5W47!7HH,!JAKU&JZ-,%?0I)@?]XX9$V*$J5%>X,]'F0%1EF+W
MU_\'4$L#!!0    ( "E;"E6U@1?,-5X  !'Q!0 5    9VUA8BTR,#(R,#8S
M,%]L86(N>&UL[7WID^.VDN?WC=C_ >N-6-L15=UN^XUG['DS&ZK+KG%UJZ:D
MMN>-8\.!(B$)KRE2)JDZ_-<O+IXB2) $R:1GOMA=$I"7,G](7(F__M^7O8>>
M2!C1P/^7S]Z]^>HS1'PG<*F__9?/CM$YCAQ*/_N___H__\=?_]?Y^7]</-PA
M-W".>^+'R D)CHF+GFF\0^O@<, ^>D_"D'H>N@BINR4(???FVS?_].[;?WSS
M]=?_^)>_H/-S1>D"1ZQGX"-!\NLW[])O+A75P/\>_=/;=U^]_?JKK[]&WWS_
M[KOOO_HG=/\^;?B>2;FAC2T]ZG_ZGO_GD;%$3%T_^OXEHO_RV2Z.#]^_??O\
M_/SF^9LW0;AE_;]Z]_8_WM^MG!W9XW/J1S'V'?*9ZL6)%+J]/(9>TO&;MPF/
MI#G_UHW3#OG&__!6?IDV/2&M)'KWW7??O17?LJ81_3X2DMT%#H[%#]8H#-*V
MX'^=)\W.^4?G[[X^_^;=FY?(_8P9#J&_AH%''L@&"0&^CU\/Y%\^B^C^X'$=
MQ6>[D&RJI?#"\"WO_]8G6_Y[<@[?<0[OON4<_K?Z^ X_$N\SQ%M^?+C5*O1=
M@9;J)&QG](.\'4V?=1!CKY-2^9X@-6,@0;IIENO96C,9OKSS'?M704'R$A/?
M)6ZB(N=90UJ()$))4.:T Z= T.-Q%81%DVWW^/&<(\M7WW[SE3 (_^2W*X6"
M"]^]]F,:O][ZFR#<B[A</$9QB)TX(23$EY1,^[4T$U>&,UF$18UPZ"1"L'\V
M&$BU>.L$#/0.\;FG?C+1?1,&^W8J2#&"%IU^\QX[N$BB>T'QD$3!,71(*]_(
MZ]OV-TME9SWYV$G\\X^K%LK\:\($8=]%D@W*\4&_)IS^WU^EI*V\F L0):-0
M1)PWV^#IK4LH'S/?_?X7_L]S^4_AXNS/5.N<$&O\F"&*LE!#4Z".;*(@]]VZ
M=@#=U4C<WAY:<$M!N[-/)BY)-V$D>,;X)?"#_:MPS'.6E'S]E[>;H^?]QEMD
M_SIW@O"WK(EP6O&Y:''IX2@BT7*SVN&07.(#96/KXH5&)7.9]0#JPBW4Y9YL
MT!R@0[>1NJM?*\HHV*"(TT:.)(Y^Q8S\'%S[/=D_DK"=Z=(^\W3OHLH&#BX[
MS,_%2W)W=?)5T;/W@BHPWUZ&+O5Q^"IDC1J<6M,8O#?7*5ETXZJ6H/VW5N"N
MCIL0E=@<]7)=S5QNL2<A=;!_10Y!1%FO.@\TZP'4#5NHF\[<ZIM/[)#)8J1(
M1MO_4KV]<[VC$9(>B?AJH1LAEANCA"O*V"+)]TW9;X>=N@ZL_N)J-=UL]([Z
MY#8F^W)6;] <:'B:*EHS,TW; APIC$6V.T/E])%@,/;2R9I1K;&!^GH&SIA7
MI.Q\_#O@SE80L;=S<6HC.](#V5*^^L<=>L4&.\(_K%%8UWX&KE:K:MGW*AL#
M=\9ZF7M[9YX\2NF/[*_W+.L(W&O?O6+\:VQ1;C<#_ZQ4K>R7A4; _;%:UMY^
M*,DB1A=QPB,YH-PX26+ CS_@?97_:9H!=K\ZQ1+OJVH#U/EJ1>WJ>VK7+*.*
M.-F1H6_A^T?L/;#Y5E@W0I>: ?:\.L7*N)=O ]3S:D7MC7J2*I)D1\6\RV"_
MYPE%X'R24_SE,18K$M3?:@.PH1-@KS17NHB.=3V >FP+P7LBI^2!!),SM6"%
M<GQ&=>A?B.?]Y ?/_HK@*/")>QM%QY/E6)/VX-VX0=6B!VL:@W;>)IE[^BTG
M?_Z)TT<) R0YC.JQ/P?>T8]Q^'I#/1)6+4OJVH'W4(UJ1<\L-0+MD3I9>WIB
M2A9)NN.F ,<P% L,//E@<,UG_T>]&VJ;@_?&>D5+ WYE6]"^V2!RWT%>4D<I
M>23IC^JJMWY,^&%&^D2N<(R53%J+:)N#=]5Z18NN6MT6M*LVB-S357/4^2(2
M3GQW5%<50'Z)8[(-PE>M(<JMP#MFI5I%?RPT >V&U9+V]#Y!%"541_6YZST)
MMPR:?PB#YWC'IF4'[.M]3]<:O _6JEGTQ<JFH'VR7N*>OID01Y(Z4N3'==*7
M=8C]B/*=)KG:K[=%55/X[JE5L.2;)^U@.Z9>W+Y>^8(RTFH':%277.V(YS7!
M9:D1>#>L4JKH@/D6H%VO4M">3B=HC@R R7I_7I_&+9_*QH"]KUG)\O;/:4N@
MWF@@<.^MH()?CKLCE)Y[2L&XT3DKFL[ -74*GIQ1*[4#[I9:<?N?7<N&YRGV
M*)D((?9N?9>\_$3T(_1I.\"^6*M::2VRV BH%];+VG?U49)%@BYBA$=R0+5R
M=$,C!WM_(SC4'TZK:0K8#9L43#Q1UPZH,S:*V_G6IUH&EY01)SWV8;4$E3/E
M;M@G==<93EL"]L@&]<IC=*D94']LDK;W")WW1T%Z$F>4<W<S=RRVG8U#5JA8
M[9*YAK-PRBIY;;FE.M4[IF,N&']7:.?AJI-LY>\!.V"E*HG3%;X$ZFC5,G:^
M/9A00YP<K+OHZ<V)Y>8^##8T7H9W010M?'<9[TC(I_4AV1$VF7HBM[X3[(FF
MZI,EDD"]VJ;!BK??N],#&#M6U>I< F*]6%^_O_ZP7J'E#;I<OK]_N/[Q^L/J
M]N=K=/N!_7T-*P2E^JG!&N-+WQY\\#2H6HP,36/0;M\D<U>?EC&$@A!Y+(K0
MKUA7),V*CG&^DN&XBDJZ_2_T#1.J#^2)^,?R8DK5]^!#L:1*,?34EZ!#K2QC
M5X]3=(8I6&$029;U@!8P$9O@.SLV[E\Q^;S@P(/Z^N7 1OZZ,*KO-8/@,E"[
M''(U78 'HHGDW=U:4A?U0MV,/B*2@=VPK2[ #%'OSLL2PP3Z#\0G(?:8+1;N
MGOKJ:OX3:0KUYG[@@]U0]6*X-W0"'?"FLG=U?45?>#XN<)@^Z*?7'5C@KXCG
M\=.?'>/?N#MX&&AGB-(BD%%?T*#04H7.BSN2S1G: @8)>+8 !AK+ ^'R^=LF
M>*AH"!X(=,J5JIZ66H$.;JVPG:N=)@3'"-;"DR-3*0@L N6"(E^2OV'NFTJ[
MX)?0:$R)OH2\24_P,6JL?C%H&[N!CF)SZ7LN4W_!%ZF_1-SH*$@# :=\AEEJ
M:X[RX0V0A?U!\((5]#?4YP]]R35VK97*K< '<Z5:Q< M- $=I-62=O5'28VR
MW) *@E-%GEVMQ(".-@VZ@8BURR"*]6-IJ=%<(JV@5&6@B19SB+.BH/W"C""'
M4YMNWCF 3CR\=!GLR#FZ5>W*$ (]2[\@FR D:_QBD-SDVX*'E!H5=;EWVA T
MP-3):R>_?A1T$?.TZ1-J>SI^(+%*GH=6\(F$CT'3]OQD*D(XE,:450LBEX'/
MIC5'-K-14YS UZ<UAIW!8U,;(U2=7:OO"1J]6BG0>1#&+\G B[Z02?R79RR)
M2E@EBP>,UW1)U2B6N S"0\"( 42"#  -,'(.47VJD"[1 !VA%6):22NF.@=G
M49]L?)T^,1I0F6EQX0)'U+G&H<^0,.*:WI-0E%+6&J6N!WC4:%2W""+:YJ Q
MI5GJKEXL*".B2"<SF -_3H[3GPITAE;8SS)]K:[3AO$5]8XL!VH5R/5]P(>R
M@<K%8*[I #J<3>3N?&-6TH87TF,H#3^L<_?O>M[A_//<U^QS-_-/< ]ST#N7
M"1O^NKR39Z0VYP!<69O"% 5&Z!;@/F7G:]Y_ALO<W:YLS_IB]N#7KP4#J!@P
MH?;?PXI[;H3 9S 5+3<ZJZQW./Z%>MX%>2".AZ.(;BC?JLW?Z/] &)ZN\4LC
M7@S($#S.#&WL(CX-Q0TTK@VN=/>E_40PGA $>G2,F73HF8F''@D*<P*B.$AF
M&ZH P)F8@3!R# J&1E6C75*PUE_L@R,W_?...KN<=<^+YF4B)S]#E.1OP !;
M9];$9-<OSH[9B%S1S8:$A*%2M/1%'51/;%*U'A-;$ 8/P+:,9Y8(FE(%#:C6
ME+.?2N7A[PP1)0AR,TE0X*,XDP5:NCF:#1?NWX]1G,Q&^5$3NO61(VJ".J]H
MXQV=^"CWL+G)HN-C1%V*PXI#^C#1+SV48QW^VE">+?ZU-I\9 !J3G24"MM=N
M" C,3H[-$@+',^*?!@/3DT@/Q!.7C-9!D_'TV7CS>2=+7,!CXR!FU1P'M,$"
M-&8.HVG/:G)\EAPJ>?ALSP NZ^?J $XC@K O8TVB2-CWD?B$3>.!0>8ECG8W
M7O#\(W&W)&I>H]0U!P]B]8J6U@<KVX*&E0:1.Z_-,;(L 0B>T4X0!K!#,9"F
M-YB&Z E[1X)PF@^)%4FG9(.9+7M="NR[];F"/W/]EIOTYMH=Q8_4H_'K(HY#
M^GB,\:-'UD'2Y3(D+HT?:/1IN4F;=I[+#R (>-29ZL=IMPQG6PK02#F9,89>
MYE,I&_71)L,R/J%+[W!ZB4P(Y^3G"5_6UQ$ZH) IP3NG7:!-C\'^7)J!Q#V&
M(KG>$7XBKL=[J,.,(MF.DR-RXFQ-@.7*Q2$WL;SV)^M&"SR6]S!1N9)M:T*@
M$;6//MVKOQ9Y%I,V_R1IRT/EE!5QQ[>4!H_*^^=5&[S\<]A%1-JLV\UT]<UX
M#6UN*V%#K+=<#KX6U6*B.H!^LBK'\"MNYA?YIM42S!V"-.>\#^2SNFUN$-1U
M!H]/;8R@O3V@[0D:P5HIT/F>W.)N\>'R&JU^O+Y>KV %P"**2-R\:GS2#+Q3
M5RM6=-]B&]".JA&U\X:Q( =@+=BV7JL5N!"[]6.F#'WTB%16K(>L=]C_(0A<
M?ERS9B>LN2?X0#16O[R?W- -=+B:2]]]WS?A@+ ,9KF7&S,F:*NX3/=TVNCJ
MPXKY^Y#7]8E?[YEZ\<)WKW\_4O&VC=9D=3W QWBCNB?E9ZJ;@X[I9JE[%*<1
ME,_0@=,6CQR0A/J$Q6H&5K=>SXE7T^EV%P>;8Z003+\@>-H0?+CJE"LM<I=:
M@0Y.K;"=EZ<YP?-@<\Y(:H88*VH9W3V:0KMIX^\#\V-Q?#5^( ZA3WS?3Q^$
MNM;@([%6S6(X5C8%'9/U$G=>6@RQ2\30(1->/_#/%1N^)9+PF6K8'$;I![UB
M$\<IB:_(AC"%77ZGL7ZLU#2&'Z4U2I:"M*(E[!BM$[A//3]7414G9P<</TU"
M<@@=KYKUFWK9Z8G(K>*%X_ ;PL2]"<*/$7\!BN7<\>M[$N\"MV8.;]H??/RV
M-$5Y(<JH,^@H;ZM#]U69A$^$<,*)WT="QT@\%":8H;W@-ETZ/98YY+D_FAD%
M%D)DJ4K3N'W:$'S,ZY33)=5S&*MUPG8>IW.I\Y!#=/,9!.NJR0,(?J.")A&X
MW>/'<Q9%7W_U[3=?B1CBG_R6%C075Y62_+RD8GU+H%%DH!X/HYIF$\>1&SA'
M#KA5U^)-I.Y?XY[7_<\(#Q)656#QIU%.F]:/HZ&\3JG3<-IA6RR +'Q7GJLW
M7R1K[@<4CEJK7ASC&SJ!'O)-9;>UF 9H(6UHU7LNJ6F2@ELF_WL<?B+BILJ*
M,(.*9U>5 E5@UMP%:%RV43C-%QK:0T\<3,7O5\R-7W/(31OYK2Z7/&8;PVP.
M':6L5>&W'7XB* CIEOHL\]WC./DZ>.+'0@+TW5?(Q:_1&3^(ZQU=-MD]0X_'
MF"7),?+HGL;B&L$9VA'//8^#<T7B]8P7#7#%\\:,/7["U..ZG[-I_7F$/2+>
M-W)D;UYYCGD,XZC^YK<XSE 4>"XO[)=4)7#1,XUW3*O )^B5X)!_R>\O^$&X
M9])G+RH[KXY'F,@;Y 6L8_AFW%1JZ)^;TT<9 Y1Q0(K%!-G5T$KG],V\&%:.
MQ6_RL+&'_X^O"#TQ-_=K%DBTS8$BMZFBIT453MN"SI\:1.Y55(&CH;BD1C+*
M@T2KO&UZ[3=<31M;5X1C@=F$9X^;FGNQ%HVPBG$8PS3#(V$CKR^>]!O<&(9%
M-J;T_(GQVVA=N]P*/EHWKVA?SF8YNUK2SHX)8AW;KD[J%EWO!>RAKP]IS3&?
MR*H+J1G$DB6'6TP:/%:C!F*TR,UE-BHGM4JH0<&VAD[@(\M$Z6*\U?4 '85&
M@G<N1"C7?7CNY67D 5SA&U3KU8^+A^L?EW=7UP^KS]'UOW^\7?\-+3Y<H;O;
MQ<7MW>WZ]AK:=;\H.A*6=Q\H@R&MT<JMP(=QI5JEDU+Y)J #M5K2SHMX@AJ;
M$0ERD]VYLZJ3>$Q2I]+$-1NX:/<AV=/C7FN-4B/PX56E5*G60JX%Z."J%+2?
M'QXDM<F>51Q-(P"%2!](1,*GFG,$Y5;@8ZM2K8KZFDD3T-%5+6F_$ZJA(C=I
MA<B1=)JZ2&.,J9\]W:PU245#\'&F4ZY<.['8"G2T:87M?NI$$DP?%9_P4NGH
MND%8?6F8QLXASHJ*5*V=@(ZIDHC]UD.FW'"UI,@%9AT=PO<1U58JA&U4^\H5
M-DB'W!QM7FFVI)Q<:8YX0K\+/)<E.I^KXUFPD"^[77$?!D\TXN] :6VC:0P>
M%>N4U%WZR5J"1LQ:@6U<_CFD9*=+1P91\EZK&)2(O"-,T-S*N8%]*KK,*#IU
M"NMBM-Q^)I&J%=M&O'J<>'X;:/IJ%];UO1M%QY;0-.2O"@NA'IA$28T#613Z
M,JTVOX@RB]1,+XT)@$>OML8HKWB8]0:-;*V5Z+Z*X.>JAZ@'#7(O'> H?ZUW
M*N ;S1QIG9&0/!'_".PNHEAKS65N^+7^#J*^/7@,:%"U8C_AM#'H"&^2N=]Z
M?/XJ_D&1GFY$'U97G7Y@YASMIANSG6FTF&3,;WXQU-1BZ$E%FV(@-I4\K0A2
MHRJ(VPL&BW55+<%'J%:]RIL,,UFCTTO;]T;#P(MS)G>)_LNLRRE-U_@E!SW5
M=_>-.\TE'FN5K@S-RAYSB-)ZP?L&+"\>DQM;SI(;/!.'[T!*%VKFJ,P79% ;
MK[3KV\\EE,W6V#6-YQ# UM=AD]@%L[(^E** EM4'_BUA@5#]@F%3BF':&SQ
MM3)#FV7T.60?[308< $=].*Y+3O,8.4\F5@9+9N?-@8?[75*5BR8EUJ"CN5:
M@?LM'P-;)A]&29AKY$E*TF*6,,\)@NG<8&;3@B%F!-,OB ^@7;&T"-B5<)-
MG%D$-H;>7&+.ZJQT^B"S'UU@HZJJ8H/6+IK&X..L3LGF>B.@(Z]68+OU1::]
MH6%91?U]C2:U)ZYX$..8\$K RPVOOW?C!<_-=8,:.H&/7Q.E2Q42:GJ CF<C
MP3O7&U@OUM?OKS^L5VAY@RX7JQ_1S=WR%V!5<U*];Y@;?(SXNM R*0*]<&+Z
M9%8LJS49\&'0S3"GA7O-:8 .E8ZJ]"IWNN'\$/]AT!?'2*RI?IDK48Y3M@"*
M<4ULGRJK?&_Q>84'\L1L@+WEYH;ZV'<H]FX9=$8?2.73"O7-@<:^J:+IDPHU
M;:$_IV B>N=L;T?$TC^GSZ\<;Q(.B'(6_'4"7J;925P8'7V6$E:Z\,BO#@QI
ME80V6FY02AT)\F>(,;"KZ7=24Y]L6893>9U^/(5/7> ,^:<*]T G,;]8N'\_
MJG<[;@)^QIQCY#K$?L3]Z?0P9[N>D#&KG?HI?)EU@XYD+;7H7*$WXR#>58VS
M4\T<QU)D"PG_M:C'*XT%&QJC+[P@BK[D7S&?SX&>05HS,OJ-9$FY&)"W)V.$
M&"<DDIH\KPG>8)G(G5)'BFO4G_I=:R?D)X:NB/S_K?]+$'YB'MM8<K6Y(U!T
M;:]\^0GK^EZ@9WS&PG<NWZH8H"]<Q>)+_N#6L^0R3%G78EZT-JCN.K05+L7#
M7.*IL=P8((JHVU@<U;VAJZ:KM;/5"\*@B10SPRK,[$,,:.3;,5+V6&]72M"S
MK_Z*]9EE.JU6B<[4@WV\#*QX)RBD3)X#2T;40;5SEK*Y1Z>TMJ1>%6)62/8K
MY).=N2:/0L$T]^,$>)?2K&?D=&ZZGT;D<9PUNA&_"N>.;MFOD@J ,@F0%*$\
M)QYW_PN"P1I6\Q(G*SD5M!R19=<D4N_%$C=_O+3"F#6C;ELZ0,>1WJ8I)Y2M
MB #/+[OITCW=E/S4&\O$/2L=SJZ*NLD>%9C:.!9SS>)L.N&T],7]DWO\*KZI
M F33CD!CO[WR:;YHU MZ;MA."5LK*33QY,!7E\H.BM7,E^?&-R=?ETN!8>DC
M>84M837!XMPX)DA5)AZ1AF!3@*(KP<RZ[C'MG7&9T0"*N+U,4IUI&1"819;5
M1H_>@7-@S,;/KCJL[4UD&UCP4495?B]PC5^N7P[$CXC6>HW=P(.$F>*E-TEK
M^X"& D/1[25BX@(LKTY!)(NI)E,#*UZHQ$$B@!%N=CA-:S_C[N COITANASF
M!(T +548Y_#F9)?[QC'&AV1:*<J)N<P0CZ]&=@ '&;?^$TM@>I\+KR<S1P@Q
M,$PCE-30F!NDF*AB'UIHPA7\N? Q[5-EE4[GPH=#FGMF]1T3?KEA<R2F-7WT
MB'R1/C\GJS":UN9]*(+'G][F*D)19W*@4:F_5IT+;"K.?,V0IKS5@9[RFDA5
M=(Y]#AR"T21-/D'CQZ!.S 85K^Y#GL?%K_=,[7CAN_SN[(%KT1^X>I">$8+U
M-: .RKK2G0FF]5;/!K@=E!!GZ,#%$ >C2"+(7(!N,DL6$0\TWJ49K)HC/_+'
M9OD!V,"/F<V7F]7Q,:(NQ2$SS#(45:8NCA'U"5.F<PXW-%?P*#F*V373TB%8
M@L;6<32W,*E3TUT4)!(B1XK((3G*"8F"4)U3?4SE'!^5.\R30?X"^;L_Z)G&
MNX*M8>%U/HU/!IE(V&N]PW[NLX7C!$>?C98W0?B167(K:[^\)_$N<(UF";W(
M@T=@NX;43[N[TP:-J995M#,A3YDJ<(R9*(6/<2*,V,/D +--2A7MA4 0TM9)
M#?H>AY](S&N(HH@XQU"=3@^.VQVPTM\LNW<(<<72ZPI[;-P8"!*M\X&/C<.8
MM@22=IG 1LN!=.WQ4)"01VXC1%PBF AJGF)",W$UD$:!!^ST2&%=6!QBBV[M
MYI%=J,*'2!MFJ]FL:4L2-OQ9T<S2IHWD+[<B9I<9CF\]65<^;ZKY)8-#)'[S
M1[#^)FN3T,T8O2SH-6"B-M.,;&S4@I=YF1T>ZGGV: Y(U,X070[;@<:7EBJ,
M<[@.T+G=(8R1GMO-K/"V<(;7Q";@X$,5KNA[AK>>S!SAQ, PC;!20V-N\&*B
MBGV8V21<P9_A'=,^55:!=H8WE\A=OY#0H7PR^@L.0WQ:VZ%%-_!(8J:X?A9T
MV@<T4AB*WGLN(^I&)0QXQ>2$!829R@"*)X004;2'F9(9O3TXL*KIK\HFJ<^:
M7Q4.F-U&T9$A[XH_76.&8^4>LX*P2G7UZ%5H/AO@JI;:SOH+E;3E6T<@T,JN
MMI*,4%,M)_$Y$K#X545:;H)0B,LM0"Z#J"X1J>L"/X(;%2Z%L+8][!AN%KMS
M$"<EHKA'B]B5+HX<3G["C9WA5!944$@\+@6O?\459O,,,3!7PQ>,L%YN1+FG
MW/MT^=.?%1.S1NMVH3@;4.ALKFK,:$UN%I#27:O>B)/6%LL5^BX?U*Y: 9@>
ME"8P6EJQV6YI-DWARD31=;!P?C_2D*QY"?AC^%HY'3#L A0XVBB<EJEL: ^]
M0*6I^+U+E ?'6!259*,LEIQ0K%BIH7;D6I)#:YZBVSI B@-*6*#5 ',CP_>N
M!M<[=Y"H] O;QZ7EYA<:[_B#N@QEU[STU-*_(#OL;9:;Z_W!"UX)_^@#B5<D
MCCWB/JP^UH%65WHS0+1>IBK#72=B,\'"?KI9 TH^#7O.!%&%U0(?/0I9>'B1
M1!K^,:_=&TF!$#_^%E*'SVJB.' ^H:-/&1)]P27]<AJ<G<:JBKE8/L_94O#G
MY7RE!/SK5 ;^,=_X5F*@![1"'R>%ZFE-Q]>H.[HAEP/6!-IL&[/G+BC<\:"K
M(;IL^X.>]+9489QM?D"GB88P1L5I(A,K3%U7O/SV&;?6PG?Y__AAS"?L\6Q:
MOHESO=D0A^'U]8LCGC1[8/"N'C?36M\F!_"P8]V<38\-=B0/&KSL:]F]A$OE
M\X4BRGDQ'/$/DDF4/.!$A$PB=U!2(5$\6/Y[,B"$8UA)I]:6L'"RQAA+C16U
M/T,W6N"QKX>)BBC7@1!H/.NC3^<C./4(Q&<RQI$WUI&&2>Q4L [.JLC#@I]J
M[8V.===V P\J9HJ?SM_T?4!#A:'HO>9KE8D+C!/8DZA.?<<[N@38<6LN;ZVM
MYA*]^A@%'XE6G&[*>.JMP 7V/R&7'(*(0AL25[L@C)D=]KGKI/G#":;9>'LZ
MX,.NHVF*$=J2".A@[JI+]R.TC-\Y9YB_?5P^\@,E[Y[0.ONJ^CC <"9F,P.Y
M3:4F([>^O*7>F'X;=86/)L8&* %(8S_8F&$N?N= 6"_6U^^O/ZQ7:'F#+G]<
M?/CA>H5N/Z#K?_]XN_[;7.)@S>.W@QV3?C..@(+JINXO.LW4]XNR=W;\A#Y?
MH$J6I*B?5"SY58P()S/1B2=DP?X0^/)0K,*!%UJSE:YK#M[;ZQ4M3>,JVX+V
M[0:1N]^U2,B*15?ER)B1!N;'286=_2,)M48J-0+OLU5*E385<BU ^V>EH)V7
MMY4?[@4Y8)XH;CJYE_A 8^PU.&1U6_!^6:-B:6?_M"%H+ZV3M_-NN[QQZDBB
M0)U6G"*_#\F>'O<-/EO9%+S+ZA4LKP^5VX%VV!IQ>UV41@=)$_WZ'J*[/I"(
MA$\DVU2]HIL-"0ESA&CIBS<O/'%@O,&7V],![^@=35.,@I9$0(=(5UUZO;@B
M*?(3_9PWL+6_Y.3HC\1E,]2&$-$T!A\'=4I6'XS.MP3MT;4"]S[TC':"+-!$
MY8'PYY6(>XU#_LA2D_=JFX/WWWI%RW!=U1:T#S>(W-6+$[(HH0LV@8G#(#H0
M?GZ>+ X'CSIBQ%CX;N$K-G@EBXJUZW+=Z<TA$/J8ZB12NA"#'DJ]=.H1:QEQ
MA#/&XD!26/@VS'B#7#Y4MG&;YPO%9C.(GBK%3K+]7!O@OEXI:N>DYQBRB4#L
MO2))%FC24[[A<'4DZR 7Z<O-[<W#ZMT_-*TVMB4#WKN[&:;^]E$]#=#1T5$5
MF_>(W",1Q4)RHT&P09PM>O</0,-+OR]\QW+)6_9=S3D[H[[@ ZF%"4S/ Z0=
M08=,&_F'.A? 6A)$.:O)CJF/8H;D7- ,C@5].'*<6FYD=9WE,6;Y@<\K*6@M
M6-<#?/@WJEL,>FUST*'>+'7G._*"<E9^DE>#28@/$M$'$M+ O?8;ZMV-I_$9
MPC$B;-K'/I'"#:@W ZLP!J7Y(]E27SQJK]6_1]6L6Z;6Y7%_Y)L*3^D%Y@_D
M6;TSQ?BJ^H(>N?7O!?OE9N$&!UW-I-X4@2*:17.EM;/ZD8->/<N2=EVC:;'G
M3!#>Q/Q!7OPB'X [G5:P*87*EH(0?9&T8-,-U8(WX#6,<!01?B6!V>KHB2>.
M1 67F)?I2K5,"AED]V(Y6\P(/"<OSO&>AT1O.9L1Q4\$)1G@HH^RP\C%N2;^
MT3A[E/%'V:UL)@+*9$"I$-QR]ZG5$D'&378A6"XK$)'WLX!-E5^_3\V2FS!;
M'$34H5#A\N)A0KLCBEWRD(>7 0R9CC46:4,?>(90M><HQ',Z7G>1%\TCX>>1
M&G+.DN'ISS6(0/H!U('>1!C$I*D88)8U \QM.L L)QU@(%DU-:<HHI0D4&RZ
M\F_8/^+P%;T[0U]_]>Z?8"V]B.=M^;V#D.R('S'#W?I.L-=?Q:KI '0<,5>V
MN.ZB:PUZV:51Z*[N+=]!=O*4^=R!D9YJ%16 JCTR1'%PD5=T#/R(EZY=/OM,
MY2J0T[8$&F\&ZJ4I6'4SZ-E4@]1=_<Y_B\=-2@;2(T]6E)1&DO $"<(8&O+*
MSR@0A('5_RGO4*]W87#<[DY?:Y1YE/%.=S,=H-#4VS3UAQD:B(!.'+KJ8O,X
M0RQYIJ^;YM_^/%,9]539QMCVL?7^J6Z!JNGU97TKH+'=H%:VZ@/M*>7FQ1O[
MK^N>[J%F7I8]+CSV&LFPKPA/\S;T&)JEO]P7U%<_Z)? ,A%^+3>IE:#'V%(K
MH$C3H%;%I>RD">P,H%+27A>QLS(6T[U3;E<M>P\;:P?F _$C$CW(%U?7@;H?
M7\X_JF'&N"_0T.ID@MS0;M81_H#?4H_N@XADA!0G_@Z?XH72!#WA-G8R\%_&
M!DVYP]B&R#WVG-312,Z 0+M;73P]JQT#3ML!Q;]&U4J7J8N-0*<7.EDMOZLR
M1+K1YM5CVVK.,"J3UTV7F]J'D(TZ@(_3)F5+SZ-K6H..W$:AN_IVBV=PQPO@
M^6MKOJ@YF*[BV>2()@?L++QQ//HNB; $U\95KWSF-WW:+A,W$0,/<WV,9+1I
M4DL)-#SV4FB([1,19.>"-3JH%VKC''.@6RG#&FR5,PH_VL&2*GEAEJ@$R^85
MDFH%T\>'Y=6_A_0!ZA4_!_F1/S]=.8^Q11,HR%@U67:1I"=!Z&M$UO3K? 9B
M1RHOCV17;4O70K)7KY/SN]5/L(]]O6-J0YXL,B$E0NZ)]>2!]DP,).1 0I S
M=#T!H,.PWH<3K^KZHKKNH!Y^6?KB3O8#<8*M3_\@[A4-B1-[KYJ%IS;]((-R
M&]6S(WT&G:"#:RL=.@,HOX#GRU($# H3/LA5C#(D'1D11]-^Z2/!!F5\4,*(
MWS&H1C7[B5G7$.]'#G+D6S!44R;V9\ )&ZJ-EG_%4/%F2BOJDZ_N #5=V@5L
MW+*(W!<XHM%R<\]K/*N U#R=9M <,O(:*)HB:TU;Z,AI(GKG*4& 7+*AOEQ^
MQD^8>OPMJ)%1;4@-!6T^U\E3A[6J?D4CQPNB8TB6F\P4!QRJVG@WU,>^0[&7
M%L.*KE\.S!Y<2/U.?F^R0&/?MN&*:^[]:()>?;>D6M=(S-CS<'Q,XO*0B<#_
MW"1"H+0P;X1^C<E+C!Y97'X:IA*=T?'(B>TW R1[($_$/Y+&EUI/VX''&HUJ
MY8+%A4:@T4 G:_>JVX(>+(?,AZP2\(;]L)>!+Y06%QTOCU$<[-D<HNV@VI(@
M>!?O:RS]0-J&&NB@Z:V4G<$SE*SE8H63,)?7:YV$_?"CIL$&]F0& P]':;9P
MZS,$%E/ J''@;$%@5G!C8@P]O-3UG@V<&"G1-1I2XBA''6YL7/'7<CSBWOJ;
M(-RK!8'@&%?9J.VHW9WVK"*JIPGUP=:1\&SBL*]^=D9X5TF!:"8&PER.W R9
M9I( G")/94AK6*=97S\%;55-*;E_4+?:WJ8S4+SI9H1T)=ZX)_1U^?:*=%ZE
M7XR['C^>9OE8Y0S$"UW7/8Z9CIF[%XW2-@]II@$T_GN9I"F)UQ*83?Y@JH>=
M/$$F TG1/?2%$T3QE^!F_D/;9*8PLB;A/EKX[F7@NV('-E(/0^2/]B]XP9*M
M?!VQS?) #^*S IZ^1M0C4E?*LX&JW@KVNV%R(6Z8S&)!HLXJK5<@6A";522V
M-9(^\DPIS2;26BMD)SNHNMZ&<YP!KAJ,9JG985#^CM\%B9\)\56ADWL<QE2[
M[M"?VJQ0J+69:A( 4U*SP:'V&G7??Y,U.!1=N&&5T_^U_0D 7=]9A4R#">KV
M]2L[SB8<FN2WM5LO0^' V8";FP]E ]  D#]"M]S<B<I -T%X1Z*(-!]?,^T-
M'@1:F:%4GL>D*V@@:*=!US"X UAU*A_^4KZV U]5+_#>;J2V?K [Z0+:N\TD
MMS/ >8(^N)'-OMK0@_E#X,MGWZB_O7X2)XCX"W$/Y!"$XE$O\9)7JWEB:Y*S
M@H%N!M-C1#MZLP&0CFIU7IHY/D;D]R-?K9+<>"5'_C;A!?;$;M=J1TB,KEA^
M"3<6]79J.]B:4II5Y+4RCS[@C,C,)L[::6-G\"8RPN13HF'"-7D&%-J8/HZ%
M!@8@W<$R$CDA/<CY2.XE3O$,,YN95%R3E=^MV6]TP7^BRL,\-J@"A1;+9LO.
MJ/4F"?[PFCT-^U3E<#,Q1/%3]A%C1^/7SZ/3E\C%&Q(7N7NCJ6@CWU<'8+R<
M".)AX=S3P])6-ZFMEL4;HTF#7[DPZ&("9(=BP[+1P*U2%O9%C_L]#E_9/^C6
MIQOJ8#\NF8VV7\?I0A7H6&#9;#6'$]J2G$WZV5TS2\<5,K8GZ$\!+C"-;Z\/
M.%:VNCA&U"=1)(XZ6D*RCGGI W%(7O%5S&3"H1N)!^.):R%);<\"*$H-:5#C
M]+4E_;GGLEW5'3>Q#864WBO"4BKDD^=\TRB1&EBR.[9U/S"SY/ N98?.T4-B
M0L4:8%H[L;62T4&,&ME0-M3U.,;]=#Q<^&Z.L\G@T)<BZ+' BKDJ;]>U)P<>
MZ>UH9R=;K8;Q$FJK;WBXN9E@8T,X&+,M-ZB$2&EROR@B$OI5K5-,O$PQK>DF
M@.^& >S?CNY6UJ;PW>LHIGL<FX&X';J@H=RBZ8QS>1.BX&'=IH[_O1P]B?F,
M%J13203:I[) P7H(=GR/?2QON^2LA0O6.OHN"='MS<,*V')U@_U61*B3[ML:
M+5;WH@ETM+!JLM)"=7>"L)>I+>AE ]JT>7\D!<B=H "Q6CVAV6Y/*A?]0()M
MB \[ZF /+7@U_GD!V VFX<_8.Y+WXHU.@=(V0*R9[NR!S-!T[<"L@>BL <U4
MMT%!;<.$0$]<"K3/Q)@%L@UM/TX?"08HQV%F>-:UG&)ONO/'LTYE%/L1G3>>
M#5T^T0C/IBF=: /.!C;?>QQ^(C%_^P6MB',,*;P[FTTFNO6?2!1SR]SZBR@*
MF+78;+FSQ;7D9H]=]89J!UG5M&:-5 TJ#0I0-.7-GP;#*?=98-1 AEO&.[[<
ME1*'!DOYDK<TPMMM2+;J4K'U)R=Z,H /79:-65/&N@=UV/!F6TE+!:T+HLSW
M$8M)3;IR=L0]>H4W0!Y?$5=>[!$X@<>$#]1K6KS>B,^@4^X78"8TL5T+.Q%H
MN5$KB;E-Z5N_XD&L-4\Q:S>*^Y,$BG(V#99N#_>D!WUGV)9ZG3>%\>/1PV'N
M[$YAL3]WI(?G:WR_N/+].AR)[[9A<#Q\'J''].RV$],G,=4:><MX:KNF0+;<
M("5!X?#/K8^RFKZKW$. 0HZ)]XG!&(]?F1C>$RV=!67FV&PN@RAN'@+,ND&&
M^1:*5Q[=U/2!#M=M5+!T98AS0;SJ^81G*D=0E>.D4)6S@0&#8UB@ '7I3VT1
MH?@.CGR:)HJ.>[&VP8N _2*JY,;1#_R_Q&V&K(YT(&-8'].DH-:%"'24ZZ63
MQ4R4/_^0;=#R4A[8V:%G*08;XH48(\/B)+9)F:(<5Y&H)WR18@P#.2<QTDVC
MJPR4^%T&X8$O21!^5)YL2!ARW5[:I8&F1" #:F>C5*:(1A2@0VEWA2S/Z)V$
MN;RJH]@CQG_"O'(<BQ2SS)2GO)"3,P0,[!S?/OD<5.\F@#>E,LNT+Q!2TQDH
MU'8S0MU[I]4]Y[,)U*2 I0V>)!ABS@?@RR*#V:$($/M#X(NE-G6!*&\7OJ-/
M;$Y?B]<3XP<2';V6"VSZ;D #O*WBFKO1E7WFE"\UJ6!WIND3?K>!LQ/Y$O?L
M5X+#26\R#Z-_^;IRC"0;>/G/4!;( UKVN\/-<*YQZ%-_&]V34+SJU+K ;FU_
MH##8V10UQ73UG6>3[9CH8*EPKN+$2^7*E]; '589TAAYD%  R=@@P6>@#"<[
MI)R=4;YXO3RR],IW7MNE/2UI 04!*R:J3)#:$)I3UM1)+[NIU#X[:Q^E,O!=
M>Y98$;KUD:.DF3"Y&M5,Q8RK\BH"NGA%"7=XB=BHULH#;QS$V-,XU.-KZD@#
MX?'M_H"=F TS+\Z.O]'Y@&.R]-.L]()PAVZ]U-^9ZEPPNI_9*M&Z&\DYX79/
M#>TB.!7"B"10B8/$HC _V'P,\W/E1R$77_N9$,PGLET1UJ40_%^)&(C+@99^
M?HXM98&YW3"1&?-XW\7Q!DO&8S[2O-Z'P8;RPY#+8U@U#K9-RSM2G0OX]S.;
M)E7O0G).X-]30]OINQ0&':0T_#,>?)59V*0I_"1&*R?SREA*"OX9DT.3Y(.#
M_(ELF(?\5NX&=XUVN=E$).;W19>;](C\@F^'\7)JZ2=W%#]23^C2=A6W+P>@
M(\B YM2O!/<B/YNU8CM:VEE-#E)9Q+G.].Z&V#&6%0"S#[U,(G!KSM,:-8^<
MV0TBR7Z@1+BJTM!R(UG>D2?B??- >'PS;46RTRXA[DT=**P-9,;*!+D?Z3DE
MRI8TM9LP>YPQ^H:_<)%C+8I@2'!3M<5<A./<B?8)4^>)S5A,H:LKC8DBNT*@
M,W2G#%P4"EXV/;%9\V-#DT_"3:3KC-@V93:G!704L6(B?1IL2&@V"6];?>RD
MMIHJDAG^PSLK.I:ABA-]2Q/ZQEH=]T$8;P*/!M4[EU4PWJ8S4*SH9H2*2AL-
M/:'GB^T5L9L.'A*N6J>?K!C&T ;)E[U(>6G//$Q:VF(T4QAYQ%!'YH_[1Q(N
M?/<70K>[F+@+-E+@+;E^(:%#(W(?4H=$RTUR,[/ER?J^U"$#J7TS5I_3[T4:
M.A0/H&FOYV\*.,V/^/M"*+'Z^*S$0EC*A8@2#!V$9+R+NE \Z?MFTYJQ='E
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M8(7S]X>0[(@?T2=B#9LZ4YT+./4SFZ;6?A>2<X*GGAK:Q2<G+PQ<?)K(9CF
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MP9)_GK2#[:%Z<3O[J"(I<U,=D(XU&1U:05AA>/W"3.)C3^+$#R%V*U^Q,^H
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M(8>HK21.RA A2N%*9Y )PZ]W-L3_(!F+3*.N_:9C"4",FN.$<(R(+S) J<2
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M]/RN2>;.I_ Y7>1(PG"W2(68'Y@GM/1F79=Y.'2MPA4^7=D>OEO7B]W/L_W
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MDLE=OMA;-"G5 ":H2*;IV.0)X$=D<,40OW@8C(#'WKU$L=OKKF'+'^UR=1N
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MY*Z@0K!\*AXJ6U,\#I TN%:^A9DDBJ<!RX:IU8]-!OO\7"J@C]P@*]Q86[M
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M4SS4A5G:5)M+D33>K5;J[?K2)"U&4#0U1](M]2<\K@1-;WB5[@8LG6%BU5M
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M\@7DZIUQ K0K+66E*<0[Q-22(7;=!]"NZ$W9Z4+Z *0/8%/'@W0!R/.BQ"Z
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M%XJ'B 2/X=HV'?GL)/XC.R-<IFC)AO0)KG4"H-_W8F%@B=PP..E93\R<6(K
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ML,?,KG$*XRXUOFCP1#/T<#N"296>OPP?T'!#VR1(IL@7()5HK\<)E-_BAW8
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M+0U?+0X)@#>,#LWD'1/%;54AK*@U;IOW&'Q;Q$J%0;1GTMJ[[1[K4>G/WUI
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M<&U+H9X).GK!1JHO:2.A6J?5GS.2E$6,)+VQ20MI4QO3REO'8%\G.Q6U9Y@
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MX5[[D<NC9V[? 0Y.Z\),Z6&2/O>-/@V#V4S@B(3< W+J>R#Y!+ H 5#QMFI
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M5(_\0,U6H]92#B-AC=D3DYL31QS0OY1N9I2(35$G0BM6Z$CB9(D,UOSCHM/
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MAVIHFMX\S"9M5$D':]E'Z!1>7M7P0DN K[&;19J %0-P)E9P:D*XXT<.<X&
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M8+)0(^\SDT$>H,X"1.8$'%O""WS#-WBZ \F8QQ[K>=0(7&],AO').!0G(YD
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M2+AX?H6"KJS=09+7>6\9IFF1OX>P%K#(:.21[R,$*$K-=[[85W=:['\%PYV
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MQPG:M#M.2D.D'F1=6RZZPD--2N-ML2I-28-=^0#5]UMB4["@!C .&E'A,(Z
M1,$J:AC,]WE8(Q[5)"9#1_++4:MD26*R5-N+OLDT63;?2I5Z(:DRZIGYR?ZA
MU-I:K:DT551JUM+Q,8FBPG;T/<KKQ? 0P8?S#J&CD0=D:W.)??.OTYN+/SI7
M=T .'L;*<+U]9KA !Q-!B HGCL@YXH==G_T9 B798Y@^7F@">1ANW['^PG$R
MT;L)8DD>&=,57B0"'&Y AA1/E6AVS](-_+[.QG8KV61-:ZQMDR>9LF>'1A!&
M70)[GCO$Z*CE<KZ*_L+8(;)]&@:-0J VC&'CRD9AHG3'*K@1<,(YQ @]CSG&
M.!\@%2)C"-<0K(UC]= V$P.G-7[6&L44$<PB4<&FRU#E"MFOOR?HS,+Y4X6I
MU-8;RE(M7-)J3E&J%*3 $1MJX^6*5!0#^!871G-Z;Q+:]YAX:4Y[IY9[=<?@
M2$51=1ZZIZXY/CH[UVM/^I%R>KJ9H'HIC*'%:3FME#Y)QQG1JBOM6K.QON-S
MJEQ[HM<HS3?H-=JBV (\:D'WRI-T/847<)IN(DW/HN?AC&ZR+SPO0_$S.LOF
M&]#NN*2=WOLA'2=G*QQR<!3R0XYK/K./V4BS1A.2+WM@#5$E@L6.-B3JF U+
MC#^#"<%A2D*"XF4,KH,] Z/4,D/@Z&1+,QME6P9S?%&_;HZ8VLQ>E46TY*N?
MK_^8O'3(+1L%;-AE7L35D?*,6W;+N*.>1H&MK'X.EIC-/ [?R>GJ=]:#27\@
M+X^ -BTW]%'/ B$1Z=Y</PM0-@Q90+$UNV40@WD/J)(1H%CXNTIF%H%/!%Q[
M\6;>FR.N4AUO-ZR'"$67?+ <6'*<\2ULA= ;KEP0(:H0QY8OD%C6$'8A<:'U
M0@_3OT#\!]2R04ATW3!1LC:RY"]TG2\"=[\P1=P$GU$/A"B':Z)QXX[X!EP\
MC5!JKK5B:_;99N;9+'KVM*I<T;5%L8,SW'B59J/]1G6YT<@CG%LO()RI^4#C
M<#R>5R/#]:R HG";ISQSE5EH%)7Y(TVKT<\/&.O@E>0TS:)G'?9( D:'(!!1
M"G-KT@]'G-GP6M@1V%0<#!Z-3XC-WY$U8A@OD3K\TC1N&!&1HU1KM'_")0YX
MSI4[PM,--9[DZM?0?!/&>I'*Y;9M2LY+>+"$!TMPI(0'[_P&2'BPA =+>'"Q
M\'42'EPX*MM5>'!#PH.W3UP2'BSAP1(>+.'!I7?+2'BPA =O)3)RRVS@]#Z/
M13(/>(,'^DV8J>4''I_V)H(DR33ZF6G0_#02[S '!XI01ZVU?*!$;[RQU5U#
MS<.*%%#K9L5)%@U!1 %=H)L@0N=F(R.YX,0D@@[>;<@\C"Y:?XEPB$%'E!.T
M)?SI\4/@YEX8A+""XA$(Z1,HWP?F!]QB@JN[GDMYF,7K4R<:$G;%<GH>A0U!
M](/'*OAF=FAR,$,(_,R,@0,$UQ\3?%3/A9614>&WTWL^=J(IJXN=J,K+L9,2
MQ1ZV*DFODZWXYKD]"ZNEK$U<IL\:B6<E@+1*L[%<R1IQMZ:\(G0L6?N-)(-Y
M)"DLY#)@PW6>L05!U.%+]Y*7MO"EQ8F.U.A9F&>"X@TIS[5M]Q%-\B*M2$E[
MHC9J557V1-U$F.BE0I9JM5F7&U& C5":545N1 $V0G)$039"<L2F(]FO.Z,+
MH@*ME]O7U=!I^M^KJ$K-.69&C?,UO]_JFE*NJ#SWYG=U@=+CL[9\)6_[DJ L
M]!XO)Y4*T\1@V]V<!:479CFV(\3GRKWBU.=_-<^LHX5SP8EE>9CW*JAG-TCE
M;8V<-ZWS34A/'I9E?L #$"Y/-<LXYQS#';)2*@?K5/"VWPP1^SZ\MKM3:X4]
MP+:@[&WKB"O;-BOJ]#[OEL+W(2I DV_,T:>64\$Z-3MY:*]?G!7G,%X1'U2:
M[>G.H#M$$MM3^G>,4NI-;<<EY@*-#Z>5OETU?S;7L&X71.WKF]@IE5:S+<EG
M#X7MZVFE6:N5RGC>EX!),1R*V[:SY6[OK&W]IK<NN)!ZC8>/)=#^$M+M+OOX
M%C5>#I3:H90]I98]<[>V,;VSY1(]7UR?U_O&S&(6X6:Q+B%/2EFMLVXO:+:<
M$DI3ZE)$[:B(4C1]54*J,%;^'"$F5*<T36[% JPPKU\P 5=<!\C"3*(J,YA$
MDLLN.\<6/QRU79>?KPH^L,E4\YWCE6V&'XJ&T)O%-:]W(A_4M?8.8SMEP.%M
MU*$TM<.]Q3_/2+:5G+*/HG4UD5U-KTGRV7E!NPI:J2,,<4KH%JR"W<Y.8U:-
MA;2-9W?,JWVT%"TM7P3[: Q$'8893:1.-E+K8PT5&-XTQZ2R7?I-7,ON^?+J
M<9E"\8IY32.ZK"5^FQ DN3G?64/FDROV2&[<(75@QOP;G/G,24^6ND0&Y_4N
MY\JAUI1LP>6NGWUX/SFQ"0DTE4*RY#J+CS@.S,P;4CM7)27Z"D.8:0&MWO/H
MW[C9%M8/B6EFP[/%SKM^X#&G#Y-P>"<OG)XO>HP@YT7,1GW1*+-''UR/TS1,
M' MIS8F7\-9>U!^D?[ _0^N!VKQ]V O%?BH)!TU)8\E/>\9/S\;E,L7KXB.#
M$Y<5XPA$F]>(W+X[%A8FXRVM1 N[B]!S1XQ3JR0Y27(3)#<51<D*[*3')<IY
M:GD$9%O(9M4[S [ VP /0=J)/L)<XIV%'ON#&IP@3UT[J,XGQ8(H-=OH/*>_
MOO,<;I,SK5UNJTK@&BO#97MWU]IJ6VO5D=O7TF'V%37CSEQOY'*=YXX^K;%:
M7/J<@#[%?OF7N[#'A0B;>EI<=:KPJJXOVE5RLO(JY_59$[.RS9QQ0! $H1W,
MDAU1@V>DXNBB+D.M$L<3CV.]'C85?Q"/X,]ZJ90B"AK>.A<70-5_VDQU1-F4
M2S;EDDVYBM,32C;EVO(&R*9<Z]J <G6XD4VY-O@"LBF7;,JU;2H33;F:LBG7
M]HE+-N7:NJ4GFW*EOE[9E$LVY9)-N68MIFS*5="F7 C?6'\3&7S*_\_>E_:F
MKF3M?K_2_0_6OFK=;MV0XPD;[_/VD0R8(<R#&?+%,G8!!F.#!Z9??ZL,)"0X
MTTX"-JEN:9^$%'95K6?-JU;MKX]Y=UB7OF&2W(N!7>J&A4KRS^[4"KDV*RA;
MT8&K.<8 OD0=0%?\C+?.?!B&%\5,V5CXA@[G&(2B,^K<0)7U3>#:OJ-]Z]UM
M,;G)Z1MF&=.K8)+\+8?;_)\C./EV%2R3PH2( "&HU"WUHON/*7%6EL"R*1*$
MH(1;&M_*<]8,2IB6CLP1B<M?NX!T962VXZTM^.X+2'8**])GD")R </K^N1\
MLF-GH[^,BR\[&[\3W#'&019HP>W8!$-]P0T+;[H[WRLH*V%%UE\F#\\)[*_K
MM_:B\+KDH;<_Z#&.FHP+7]G:XPQ ?3VJ_74T?LM\C"1!R1LF17VV(<>%!4[F
MI2-"6.A<@] 1;E(4AV7.U<B<U(V0_/25+1%W%EOH8,X8&G? <?]O()*\S4]U
M"7^0 _@5[$&S-VSJ2R]RB0"CG%<>1G>Q?P0(^H823A7@.8NQ?GCZ4+CE<=8J
M"B%Z^I9_L5H2$^(;"+%;$W?+OUAAB[<=X_]Z"7&P/$F\[1=,#.[T;V3<GH\D
M!H/85 Y2G?BFF]GI"&W,F5*$QTHITN[@A_- '%'9E8Q*E@YTXION9_^QD-G)
M\>O$QR=3AF^Y.&>(X,\=>VGHNW9]]APX4!6B5F*H+\77I1!?MY^B',U_4=[%
M*YI!W239+XWFGX&BYXI>O65G1I6>Y*>C^1$0/__V4:M0P_H/\=<34;3KO(5%
M4;1%T7OA^F_JAF9#KJ"(-AVQ 'HE/<R]$!N/J_C9=YJ+O\"YQ#4Y<19--)^Z
M+L%T"0!<6H2]F]HL%W*1Z75%QJ0G+:M5?>+O6YA>91SC#/95=$(77U((Q+!?
M+>ZBNT'?8*=%=[%_Y$CR+]2AQJO&X7O:%FCO"9 ][0D;))-VK0I0B_W'+^Q:
M(-P0.]D<M),^>IKK F_7U]PTU&#!02M^!T",NJJ)FAF$M$/>]>H_DO#'K[=L
M*Q$LP'/@DM%\;<N])=X5] O:), 9HD8PQ,KPQJ^V6 B[R@/.[$D[W><;@;Z[
M:]+[V,G!'@[A-ASZ,GC&# V'XYZVXIVKF]U:#T]()H][0>R;6;W92=<;J][N
M(A++1AUZ%[[A!*[ Z]TDHM 6XEA%#>'_H- Y.U=\)&[SA#V&)M!0.W9C.(2;
M;VGPSP/@K0#8;3Q\E@: CI"L 8@EG1@Z]BSX$^0#$ !^IGKH?,L&$04QV7&7
M]H A9G!OO$/W=J#OV 0]8L?0*I36J!7)L^[N'F1, Y5*[;CQEJC[#N16=]?J
M?19ZB0%8H]G"6:+)N<>S,\#;=V40JS% '!+^[;=?.G^8X)M-4')O-,"^":><
M:KHVXF/3U\%3^CPERU$O_,?N^ %W,JD#=P:=6""_[9ENOVA$PY-F_6]L7"2X
M\((L%Q:K>%$-!53; P5MH(<0YSN;/:%N()R HQF[/ZY4!VH+=.FT&4CN@[#=
ML=#^MV @5 JHTAI- DIE$-RZ, #C?3,G,)N;]@;L/D::"W*49\()-2&-'4/;
M7>9A:]/@9@^7^'>S);O_V?7J.;Z>(5CX?MWARS[T%(+ZQ;#U9]OPJ([VG+]7
M'0]?>GE?'@',O[?5T/'M5L&-.RZTTHPA)+>%;C10K6,9](&9O*7*]C.E*>J!
MU:+4%?[KI_&BAXLNEH [AC!ZN, )2DVD9C;!W4UPSQS"M%UW!\SG+?M?O/7H
M)A132/>\?%'2GCM0:RG+AJ9,P(^0E'(K>WK; 'AE1>CN@"-Y^_:]3Y#I56+F
M0RB.X L\*%NASX#VY"T@'3?:NK@5%)$>3OCN WSW ;[[(#JM]_'=!Q<F +[[
MX'(%NE%J)([O/CCC O#=!_CN@TNC;'?W00K??7!Y<.&[#R[NZ>&[#W9N++[[
M -]]<):2G@CEAO'=!]&\^^!Y/!>%2H^CKZ_$=W>YM[!LVT-(&3X@Q?\K[*I7
MST9-\/_HZ6H05'URY.Q)&#8%)?QNS$FWPI]U1\&+[<8.Z4EH^HPAAR4@N\U>
MV.Q]HH2Z(<G'VR7>HD"06A&>CP^A1A'^3=.@IE:A"[:KFD 9 O29;^U*'VS3
MT#8WQU,ZY'WTW1?4)\EM$[CN+G%D0:T$/].A94"HNTB_CC(%<)"JP;W8<1P!
MYTQHINJZQM! 5UF\DM*X)=Z^N)OY^,7=:,6AFW_M.8/W7Z&15LT (:TQ -XW
M2GWQ%-@W>U&UKS<*,I4!OOD;EG_YPA6:O>'HQS2H;87!/_1UQR^:J="ZV@0/
M=PR$^!<+' Y\&O2]/+SVYI5<V_X+0<^Z1T9%(X/LG[>O)D'O>1C,W*0>E[S+
MR(6-UFS+-5SO* &(>&Y?87*49G?L#;0L@XPTRM0%N4&4MAB@RJ5@.B,'!+QU
M[:SP"NZ.BMN.P'<C".S+V+MA&>H-Z#W/IIZ^;$_S),<\P@G*,)KYUTU0Z_9D
MZY[75PV'<%4A">#]-NYN$7KQZOBYN@GPK?L K>FY[1!Z/_RN8.FA  [5Y<QV
M0#LJ@-N9%;LZC>.U/JO]@!LZ X>@8*!4CBN&J@ )<2B0='>G@>!<YD#S@@+&
MX=#0=B57>QS;J"@!U9"^O5^W9\S11L5&.>X_>*#PO@UAJ)GQ<-U5T'SN918(
M6I%]A <.%2$W=(I[ GB*W -^#^)'5 \VH=#<5VLB# 35*(E!8*R@*0++W4DV
ML$8_@^? ,US7#Q0=G,V^D@5"!$[Z^7OV14?!2YHM&;USY*BHO!5N@Q=(W./"
MT-=*972H0E!%TD-!T.W)V_;T"*1RL!4IX5]O&H$">6$S/"+5$*%QDL")-R!I
MK2==X&CNEGK;-OK#*>Y^14_];=G.3#7#+*TV4&=$)2#7_F:R\^L]5,D<J"/+
M#V"#0(NF-=M-*T @=<.RR2=X@RX*+82@,NPZN[#2)/1:R)9PY@=+"+HAP 1[
M6V1?.#LWY@#1$=EI4!^;R##<:[-#+>9!3SP^+,3_#52,@SP(8[M[@:;.C\K8
M=QX:8DS7GS\X$&UCJ:M3Z!1!Z\I4?4O;&7=#'SI 8/\)V&NY@6.K2'38SDBU
M]B]!5?#6T%%=S_$U])U(V55Q[;I(W>*FB^<HJGC[9)6 ;PJ+!"$HW/XO(I3
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M9D@IF;DO\&;Z'L$>:C&:8^.MQ5Z-W]7FP-E=]?>HR'#&XZJUV^OQW+BKO@=
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M.DB&C?_6#7=NJIO? 6SW[SK(*R9X/?Q]O ,3P\'?]_*-)/^%IG/TT"=/2FC
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MER)U02=3@C(05%IAA[H.?V($A=.H84KE.'[(:D]HT]84KL[#R<Q]0=HXRZE
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M21;K7ZQ_OT7_O@.;J7*]JPL]H2FUR.F&Y),4;Z8;")M0"S.OGLV+O!K.@B&
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MD/8[:$[FZ4B1)DV\)5(Z"P8S,)TYX^EVBT:>K3/G\84,)S9X3NV08WJR&*S
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MJ,"#OX$3"BY\_'Y1>S#N>3K[+USP-H" OA\#UY[$PL3.5Z&Z2W![3$*NC8@
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M+V^(7-F9%5WJUE$C61!*SKBHDURYL5SJHWX^K>(!5R$7-QWILY5]@.X_CL5
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MA^^%F6WJK@/^A6L-UG4][+\;PO?\<OC[HBOS& '/.BTQ FZ#@&<]Y1@!;T3
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M-GQ%KWOLRA0X<NFL%-;B.;6J0'F2NIX\H3Z<WJ)K$CVYJ.!QX\D!:FKS<.M
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MW_K4\\TMK("(R8FO$? 8* I06 EAF"+0Z3UD#1+:(Y>Z4Z"P3M*QG+*B5)I
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M2%PAZ)@8*T@($?&-!1+^7J-Z<.@%J_#='E@WH+R--WSSQD4?(/&:]3EZ2XU
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M:<Y>6X,T'H*++&F>NY["A1]L35]77<(>1&U(8FR@W?<K<F3$O#RUZH6F_#3
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MY NRZ*L@2&Y"P)L?F_ZGN8<]]04>/OK"6U#Y3?U/+$XE:):FV 2;/'@#!_'
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M^(Y6<0O^MI6JIA.B1'*P+R$0;^@!_!,B7 47+JU4/WG54>A603(%1[6(_$(
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M=21(9=8BU'>V&/WS"=54@9:D(B<VP#1%:+\)-0MY\B#0;$H\DJ5=AI%5U2<
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MVE<WQ/W \N!P*S=3NCEC;M^_ M"\ '9D4O=+[Q>;=*BJ_VY(.!CO7E5B-1*
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M:\N*65^H]$;<EG+E'*C+=]O?]2(=_E<]@9XR]]/WPYSS@D(O:/YYS-R&(>*
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MQN_[SKPS[\S<F;G/O<]S__B=9#]/SLY9>Z^U]F>M]=DG)[B?N&6 YJ&ZECI
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MPR6;E\".'592.+/J-I+4$41T@:$K"/ P]/K.TC72ZM*S=^B7<\\:)PN>T.$
MA[((;_#TKLAEA1@9NT+G:R6N0#64:%<MF-.350-!=1\C2$EG_KU<:,<]E7^
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M3F*NEJS3;O7[W(9V\:>ZZ0Y1/S[>I6SCX!0XYXK]!:)WD6M_FU(*WV%N>8"
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M\NQE)0Y(CV@HSD'F+'%A-?=/]5N:\-!2^ >TN+!B&I@;V=PX(#^\ @<LWTK
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M&L1-,#)RV1;O"0P^Z9WG99!_J_J! ] >GK%6O\3Q'@V]@/YQ^+\_SYET\7N
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MALQ\8W +]"I&80)BA6C7[3&=F%NPZ)?TF!/&:BR)_,R*^:8TS%Q"V@SCPDZ
M:$1^)\36NC#+T**?:$UA^#(4V$2*SX,6ROT6G^8]BB&_':"5KGP[L3K8*B/>
M<?Y^RA_/G98O4HUMSFV8\+B[=PO-7^^LG9DD4D'+:!B/B]FSJ,V]3EUE%UO"
MIN/A][OJ T3^P@%<9(1.<+7U7J&Z,]<ECM& H;U.FGZS6IY56M,I^''SL"C3
M/M53?OGRL2P1R)SH'?]&4._?4!VKB6$N4*6)$K(U_@I0#4T  >?\F!(>Y.,X
MILM4L4JD*F3HV\W7AUO[9]/[#-Z*JR?X!4P)ZF-#BVIH9>O;A&KPUGIX:(GH
M0DVXCO,@S 6?$-:V+.]I.AMES,-V=\K.#-?Q4BM_GZM,E-*YQ7?0C^FDA.%;
M(6.GC=+-I_&Z^?P8P2> P9A6:QI+GYR:,3XUJ_U7?XF@"GZZ6@%)#$1&(%C1
MZ2=9S%VNRY<N[O:>GA#/7->-ZWS8@?V;V?)Q0AUVS8$O:#_T#X0L.A$YG6\D
M$X8H<B'[]T90U,K54Q4KH]9-,T*2[0;CPMHFL.H@&?.D]00Z59*6$?$.OZ86
M",_KA+N0J:A2R*T918Y'6#Z48H*C;=Y Y=9IF.9,T41N@O[=.4L5Y'RF9NHX
M*970X_#7*K:QK$2VGDO@W)! /;+-_G L.3JF/YME'*+Q"?S $AS@#U%SY PO
MM#!68R#<U#_F;HJKN@$>I(Q\^ITNHI/T[@\OBT]+-=!HX?(V>R_/O)\#50.5
M8,--C2G.HWN5J? ^>=X6[O44.S*:X7MP<_K^H>@+70:;D#^/S?\;#X&A^V0H
M@XF5Q?J5+/ZM<[7IO*JV$LX\Q'WS;5,W0L:%Z@-IT*%9,-W=9L\/F^M5+ZJD
MT;#E'"9PC2 S<K$@C\6&^OI&%").8K_%]TC,@#6TID6.\<<[S;,/-.";1>Y1
M[Y^F?*I\^0YCAI0);Q,K&%D-DL?25%@>W;N5K F5_IVG:??4_[2K7''H?=R;
M/<97-<EU20(*HBCF[H"<F-]!K))#=_IU)^JA>ST=R0:V)\5OTZ]OI=Y@*#E[
M%4I!4*]] /(YRF#>*T) @6YG[Q51>J=7IEG3*;X%.W?GG:E/V)T<FUU#W/),
M)-AZ!G]4RXM_45B>N@#]Q/(_[YAPF(G-D!H:$'L068[5&B--;P3++B5NV%&^
M.BW"UY8+-NB/CM4\M#]*XFL.O8)_L5,P6VW\^?"<=H*^Z]'M-TU)&G&O/D6W
M%CQG*8]^^&7XOLM(6 <O1 &UV%ZZG;^T9UJ17>3_68C9]<[];J7P#9]O0#'=
M/4Q0KQ8R;044 Q%$I$TKZ%<ZLZ4EYL]M&;[;-J0SPQXP\^KPR%<+K;+J'U7*
M#NMXI^& VM-8MS8+[ZJMCAMC)(.F0^N_DUR8)%IB EM]H\%KLS<&ROCM[+]^
M[>18PR?1P+^45C5"GR%5'\L%+6Q&";VR--. ,OY0\^)U)4X2[Y>,+S7D=537
M&ZFSLRFW@#BA%3-\F&MV7*#CEJ.F,>S=KY(>5-<>-)!OE)9&?JR]H5=H)GM/
M 18&L\O$ 5?1//K("W0J1:WWRK[, _I,=?V6:<2&X;O*@U@18&[.>6VCTL6J
M-BVZ+B<FF!L=M>))NRVVRU9WW']B8=JG]5S;V;W"QOJ]KZ>8Y9@QQ_[-Z'>R
MS_^DAZ=_TD._&A05L;S_IL9DH/+GMYM?8O1>-6IM1 EG$40-1A:J(PN>#YO'
M\M^.WL%0>RW#(DTY&ENN4F1*INQ_CG=R:$QE53HK2!)0:7,CSO$-D7T>&'U\
MG_W$J&540715F%O85GO*R&S\5[OBS;+M8 A[!9W2OI#R5V[UY!LW2>0Y7EN^
M1G*M-%0C6[MDV RKRJ_K%+8Z[^\G(380[%=><9?3:GGS_/AQE>DL,W0- /"Y
M"?&WC-9OP14FZ=2X5ZVVE/7385,^ZA [%^SS#BRAT?#*:<_6T#9)548!G]%(
M//0U) Y ]KIG1O/6MT/KG.;E?O:QV))YOYJ+QP%[HNM:MU__TM+$UQ5W%B[\
MKG%WB\3SCP1G7\Y155-7$](P[A60VB?#PI/J<1%1=>%^-O$9Z9#P0NQ6K)M$
M3MOBI_/S:LRN1_2]'*^_ 8 >2[-P0YV'29.!1FE^,?<<!]2 [MS$BWCDV=8\
M("(BR&R8]\,!UM [<_E_"LA?I3>,.532V/C]ES@M%EF'7_U5A7?PM,K$4MF6
MQ6_8S-L[:_:/=;ZM:GB87?XE\ ;"6""YZ%R=,#CLY^'1?'MF,N,8"C?K"G@*
M!3IN/&IPXHM1;;%S'^JD7?/[_0Q3-NLZ"'.N.I.!12Z=$/ZY6:WSC%71OF3$
M,@5D#_)U.^>**"M9$)CG>ZZYMAQX$9AAM:]=<8%9;9TA++T6MJUM^?WL>IK-
M]\G*&(_C3,4FSL7%KK>3E<: @XV<#Z-I-.% M7V]_&>+SPX\$T1+&!V!*9'H
ME.-,LI_0B/9G^2$U>Z8Z!MND3*^(MNZWMX>[@%5._!6>%/2,)[,OJI07<<3M
M8@F_N-IVPHYDMG)^7U!CWPK<CQ/XM%&W$\C\?W'WWE%-K'N@:! 0$ %%I$MH
M"HB =*E!D:*(@"!(ER(MTD$Z$1"0&@$!Z4@1I?<.$>F]M]![AX02 H'DA5W.
MWON<<]]][][WQUUOK<Q*9N;+S*^WF>_WM=:P $-3[T?0Y]XI<DGW). @,$BH
M_IR\!\HYV3/4^8\4IE2R%<CV465*;30Z*>%)YZ<8] NF$#5D8F1H)CF[<7EW
MN/V#+,SC=+.>!V=W);G)V=7*GPJ'4(&>R@YR=U(Z']Z\19(-B 8]E!;,@HO[
M>_-?)3^P0F772,< 9<[[U_1XLN"*E!-:ED5<9SZ;0')(1^R",890#[)>HB>Z
MJXZE\:'J<.Y\8N$Z!+'^O#2XPV[;>2G/<QGCA;GR>#!_R;;[4M!1)^H8=?-=
MZ&Q[<#__"D>F;MP,RF7:ZP K>_@D<[+[>%[Q[/S\O-<P(XQU+=XI:8,VFI^1
MF .) S :;R?)^4D'PB4I?1K.@U>TU],E5J;7RPVO-&.O8UYBA.;K$QADF\?A
M^5S!+NL'E:.7/?=]\%=2^\^'!:T7#PN@V.CPP849"7,A<JU9S^0T",3Y9,!;
M*L=CUGY2IV>KCFM<MB);@??C'(+.OUQ5<\?>]5N35)N.M<-S2:_?1'K[-MIM
MH?,]52:\F)#P+J2M%,MPWKV7BP/H[?*NEFA&%_ *G](%.7SQ3%!E>)ZL;[T;
M_\[9'K'77/K8S)9]Y.NFV.^W3*,\DV!^&Y:E%_AVV586BUT[*(P.74'%[/9_
M/XVDP_HH[1HO.U?B %1G("O2@*=5'UGJ'JY]\O$)E!0@6+]_3?-9H/(IYG>(
MUKFS\32]=^<6[UWPKI(,#D!*Z;=*A^T)\!5,2QIF*5>=OW5YX;CSVZ-MJ919
M+ ZP@T\2&;GQ9&[,D\?Z%-704[LSR<<&B*60O78BO2<5L[5KO3??RZ+P$LQY
MM_KG]+3+,0Y@[ONR1H'?VHU'/:LR%!/^&&$1&5*LRVI \+YW9V\;=%>Y_F;F
MH_ 0,\8\5P+\/1N/:O Z6V/TNS$)P^<C][;C!'^\7=ZU<TZ#H*!KC]QY%2,U
MV2?:F)-WIV=KC@K@?POUA.<+Z#LX,41>[3[XJV,[SG[<P9NC!^JHZ\5&"19+
M.;#BWX;_D>^$2^#OK48?J4(_"6@C%X?!:K+M+UOMT<6-*6NFBE_L_\-.48,N
M;USG(7O#&( /@T4F\*'@5-K,1%N:HKT]Q.1$>^=O8>!-A&QHH<$K1?IP2V>7
M-AF?[P6;/(;0WW(:YA%C2F\)$N@:LM9:O2@T9SCF28QFMT>$3:E'&*UP.,E)
MK>5L-93:MS.-3-KP30Y\LY%DN#"CV"LG8#66GCQDUF,PP4"X;;]CU\Q4\YZO
MWE&:(*01)"G=BD6?;=#UU*5:%V%[< !R?#XC(]#J&>_ODI3BIOJ*%K[6=3==
M'IOI8O,(%'_&-%KYVK:-^.$BU:3]@GVH!?)9;4[ ]FX64J:'KC:/X;9QN<$C
M9YIF,)3_X?DA7,T)/%)_<8/U SK,TD&Z1+QSKPMP,F<A/G!LU*6(9.)5=M74
M66R8.QEJ5*'NYPP.P$?+W80#N)C=)&[?KD-4[CTR9+2__$KE6V$$7? 8B="U
M2L$^KLAK;LO$G\D(+1U>DTKK?#\).T>>#*X*'+>OR3GSKT7"MCT0CH<B@U,_
M/1V'AW;VQJ@/')T0]ZAD=S#US8S< BF33&5UJT5*""4_$:H@[,WA,_&%E+M3
M"@/;'/L%^06:-JQ]:C6<T4]^^X#M>XSWH'W0WVA%F. F#5]"@=%OG!$H8T)8
M@,O@@K6 O@:V+X+A)K^>VOV><'I)V:5FWDLDA(2AF;G8+B"9*(S"W5ZN'G$G
MAC]J84X8(S3!\?V]LMM3(7HZ:O&>A6X2Z6*NQ"/(7[Q8IWPSO6]HCWJ*EE]4
M]A:ES9F7N8L"4>JUFWW+SUU6L MG8+-/.B[Q%Z)6[4Y&=N9AN<\391G0_2V>
MJ0WYZ*==QR]'AD8%[!B6C:7U:^N98@UXN#NJ'_1=EG0TBO^-2$I?8'/ %(*>
MNF2*JI_ 8%1,NX@L0WGDJS,E@;"7 ;**!:QLN]CC.39H584GL?@_T0<J"/]/
M#]R73 TGR[D1>CD%11MJ$@6J_Q,Q.J%=V5#+W^[.8HH#>/NZD/S_YXB5@^<U
MW\]!<I+%P C"VFD?FOZ_L?1_#?-7$O&.AYK2_]"?_\D!FO^'\#X83_ =!NW;
M&U^';1-[X  9B0T"O_&QOAN5$*6V?8RDN4R4<F7O*P[P3?7ES3V.JX_C2U,;
M&-!O):FR^0B>DY#D9/,/KT/NHOH[B#+BK0]!L4QJ7\^^$W!GPWVH5A0O3KV^
M_<_2J+FM;/!^ 83DDK1A!C.D>QMT2O_#BU'SO]='B]"P_E8H@QDVX/?Z:.O%
MX_X.4U $2.<D1(&?NU6W[S9-=28-X#/+Y^HL&0JV@OX!O/'Z1YB0MO VC0BM
MCL*V_5XDO0^>_GK&?0J$KH74_UXC#5"DL'=QU_;Q#[UOU92Q?@]#3/-Z,.#H
MXM>MR# <@)4)=+R,-2UXJ4I_T2YDN*J?Z^ F6/;H=^<^^H=S#\R(D3VT^'1K
MK1E4XW-DO&78Z@"CH+]K;+X4NX4>=\0KW?A!T1<\BHQ*AV[DG1!S]?',LXE-
MGD8\.WP@DO+LOWTMR>9=:(_2ZO<E)ZS+Q3EW7]/WJX;M@\_PK&T^H/$(.S_Z
MS3K\+ENPW]CI[NNRS=Q=?<J3^CMO/2Z,X="_!OW-IOQO'.#&_YZ'+3P\D^Z#
M+-P8=H)L)."1 2T\],9[_J\JJC@ S/(,O)CF[P:YYLMQ9HZT'3U?:^$S5AS&
MLAE9YWV?]'X4V:Q66AEJU=4"]Q([>4GH1..]4!EZF$;F"S<2J4:J!>U6S! V
M[\V?V[><]@=2\[%;+X^R59<*ES[O>*(:7OR^\SAH_J29.'<UWIDJ3QVK<,RQ
M/H=6-Z:"K+\8ANQ-_A=HUKA!M@*,:*_YT;D6"/7Z[-6:LM%R*4/G9OB=J/PN
M4=*XQ54I]Z&=6\_7/_4R1"^(Y59JFCP0O5.#T3]3053,PN;K9DA^)4);9+A:
MC("#<;M=7I\'=\U&PTBA$G'BX87TU)/ ^\SSS$.[0.VO9V&[2H,@1'HC"]7)
MY\,Y# K2!OTG=.CV5@BS+-\&5CI&:5BTC@^D!;Q9#J*T"5))RDN2J)\B3LCP
MNQ7B/YEB[,1VM=F>@R^U6^^\UEOWJ_>3$9&B;1^2EXB=F:H04*G 6]/&ET\.
M\W2YV%5"-#AJKIJ9.UY:O'/B5L*0F6C8O#D"BO+I.'7&TM USYW2E/\W6$Z
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MT;Z[_Z%Q)&.4GE3K>6E$G4H'VPO#]PL?-=,:$<+)SENJ5E$_KX;*23#<HBH
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M8E3L#<Z^Q_[B6(J4!"N]VD=*\JT?%7QRV6_)D+?3VFUZ6_T)#B"?](  JIJ
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M5?[&H4(2[C<1U_1",>:9OEMX-QQJI+:<ZBVQ>"S!3]:3Q7Z#T!CX>'Y[(JV
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M]E9ZM1AVOLR% $HT"*1;'#?K/KE&[V:@76N2VV*F1S#C]ZL:)'@'ZAKQRA/
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MTS2Q7UR9C)_IRQ(EGZ-:4D%[.\&\CJR#(KH#PDGTE.E%NVL62@.1FW5J><*
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M.T6\:RE/\^;[Y3 LROSIC"=L-Q>:M&*WTOY52E6JX#=(^.I5 "?\%;W6/1_
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MI=&BAZC3"*7IP$93JU/%;#6-B(E=Z*E+>!Z#^,)J$#^_K3%9I8J]F/H!VYO
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M@X?"J[XY\U$V D\MA;:Y<'M5-.R4?H77/[*CZ?_R4_&YE6\LZP+$+-$.N&P
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M#>?'9,42] WY=\BX5OT52)9-@AB'5G.7IBFIBA&DRX>ZR)&28N(P(ZY&ORN
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MXJ"^K\D>IY7A=#A^M^QE"[L3$(:G:3?C,@1_EY,+F]M^.9-(KE;%1T$V)S1
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M;8H :)]\*:^"%.8VM)LGG[2-;LY0XZ$U#LVQFC*'6% !F@P]1$@LJ/2L6PF
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MM/[WW"[_RA%310"48/;P?KX<1)7TZ20 @)FGHC O6S/VOUWG+^_=4OQ* ,2
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M-F\#U3:!E^SKY% H3,EA!WZ%K#1J:W+=+<9T1MU$A#M,BBTE]"F 9!>>Z$H
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M6/CV'(LY-\RK;SN=I8DGC6UO+,&-UO?EX<^.V;LPEZ?1=".FUPZ^Y(S4547
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MW\X\^/BR?&,,2J7(X9'3QHB7\6]-?/+CBX6A^8CO]^X8L4&A /:S:Q*?NF8
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M;V]AZL(1T+9YBO54^J@+C;20L6$*DX]+592.G>:F[K_9T7@3,H//S%ZD (]
MU.Q#EB;4'T"D'\C*U/[[RFU2%[/E _P?'_#^?R;V_R"$L<'(1O^B;/5/:)D$
MGB*W/.%O,9T#.AH=FI]LZP6\);57;"8],I1&7&\,VTN;RJ[JP-Q.U5^:>^H#
MO?@IN#DPA8YT0 2X2W_I<;0']5Y3([.0E* 7!0C"HL@W!PH E2*XC1\=]CA%
M164(GG^27.S\E=][#ZPVYSO&*?P5D^*SX.E]+Q=I@!=7^MR>41]A=P/+77*'
MA5P<S5;<]#&E4UY: WY]RZ>;/^A\J@;E52ZAWHDSMY=BO)[PC+GDG)Z;WI3!
M#[ 5BE\'EEVL+06"0.S8ZL5$[ G&_5356Q5]F&.=L]$@%@L>*:\7;3/O,"/%
M=P0QH)R:J9#31[G,T4Z;[.;?K?9N_.#,^(#*RFEKI.DY9=U(S,[]C/'[IG#V
M9+%U2B\EL]O>\8SI!1=';8$/ 06.K#%Y"5RI6#G8!S>0=MU[_ ;^#HP75 .Z
M DYJI ;9]H><S+?,LV_4I+4+ZBBD!1:4J]2&=<S]V-$:-WN:\>"2FFWT]L<5
MT:NJD($BI557>[#OZ)PTU/^UT-1.9#G-!>\[HUB=+^M3*9\AAVZ,B:0#=_H2
M7\3.J/"K""Y+:)087A-ZHL[2_*IDRV<Q'Y-S>T DHV+DP.>&=M4'91Y]=_&[
M6Y(1;]KH)*.-D#S<<OJ[#,>BB_T<AE@]-+@51N]! !"[*+6MIH?1?GET P\:
M:#_(/((Z5!GJT:MJ7WOZ;?(Z!3.7L)LO$V8;V0_ LF'T/VDLICQ"D =M8TD4
M,W(V3N*2$R-.?A1>G(D63CNY>W=+/._>N\\%@7PJI%OGPH.O;_G&;=R(,])*
MCG<O;8;8,_=\ERNPR;BY' 58"HO3OL9OI,\?_67&]"N LQK> Y[:6;2&R3]#
M=7:<D,.\-43?[O 062Z\C  @$8EF9EW:*W#:(/<.&8)=?6(Q%54KWY@DOSKO
M*AH"IL5JH0_W%GAJRMOTCBJWD22%4.NF;_(B8P:G HMD#9.G?FT.@K&)(HRF
ML )YX47X18^)F4AR@Z^CD:7V'XWN%3T:6!Q86-B_>5/ZDWOANJSO)\@S9Q]K
M!Q_/M%)C30F>4O.B=CYAV%.[52"UM\#//7DR3#?-F%'E\6T*#E[&G1G&&YM/
M+30,C0RGD#9-=\_Q3+XD>3$W7^<KOL Z,T\IA'5'O\,/FK'Z:")5"( 0X574
M89(UZ>Y&R7HD_=EOPB)WKVMHD.:M,((_WGKY.3R<J$A*\>VL%S;)-4R-']@_
ME!FV$#&7)(E8M'*W9M_/AW^!H#=H)Z2_U\QKL"0()XRH=YTG\SO@HCMSLU/Z
M&(*6 06Z*TKA\K:P:I"<?O2=%3P9RN0:>:RAW?S7] "CC\VQKSYV)K-;\U9U
MP^]BHD'!4OVPM/.\5>5V\Y%NB0T!\H]RE$E;]498"ACDI^7BGH=;,EI %B/O
M.EUJ3C#4X.W\5@N$&F+"549>!A86Y3QS=G*Z*];/5MT)?L^.-O*]!W7QO=.@
M@DO$G_<&0:>TD=91=>(+N!NM8[X,U01 @*8FOK]"K*#RK'0<?GGO*+DL_SSW
MF^)*4ZR/CTI+S]?^7Z:C%I,V"WR7,TB\4PR,25\"T'S-B4XT$CBK\4)MB>](
M;4G ^SU^#1NH&';VSW]Y@+"<L/YUGBG.Q3(%NJ*K'X,?U4O</FIRH&]%[-?$
MH3^']X=U.J9J*DFP946(]AHT\0)$>S46DW6(9N1^."<P("HL6I0^6K9>6&":
M49,H]W%2>,*53NSF'07JZ_9L)D/R*K;CLD]P<5DO"W2R2Q.NJ;RLXM5@67($
MT^,'] D 4KCO)6]E<)";K,E4/H;QT"Z\G[(M-Z?=JD,AU.-JBV>!JKF^[N*+
M1I>7_2K.CJB@4^1U$^];I<-\J/+&8&EUK"V>O-RRPDZ2W8H_;>N34I6(.Q=+
M[--XYN],U$\F3NJQVNF=.2+I4T7)%<)70E]&]CZ_NO#NL8SC.R7F/@]I=ZV&
MKV/">BL=R+G=V="SQNZ&E]+REO3;3N[/4:'F@Q1O;CR$<%Y"CP?;/](><?%P
M29$&WHE:1L2P>;F^":4W.6LNT1L09QA[1>:-;QZ&&Y6OA9%&S6N@.E+HU>T'
M>MREQ N>(S>4&SS=OIQQ5S<(! #$ ( S*JT?W.1@?Y;<OR%+ED!R%*Q+SWMJ
M+O9<\;E87ESRZ\PUR[#V%27Y$,FXQWW(<S1<;H4LDE\7"[U-TTV]A8:E0+3&
MWO>'N48:A* M^BX6E14!L$LS]XZBIIP-JZ8%=%YR30R*1=X1XWFV5F7HICBP
M^^@T8Y>!HU7)[D*/0!3_.T9K[^M?.#3XTN&Q+O#(5,G83J.K!I@0C'_;> /_
MB$NA/F)/N$XC>^(.WVXV%??>H^6H6>RJE=JI*F#Y=O[I'>Q]M-9L3LB^-N.&
M,L(M>8ZZMJZTS,] M"/_M>EGFPMEAO&VS/VQE_0=0+>.52\$QIMOKHT)Z!C*
M2'SMLFPF?3U<]TM-O;4SL-:8-VD,PF5D8]M2QIH*^O>&"EP$=H1'X4(\E97"
M8N6GDC/W^AM>W(_)NQ+\[FRU#%8;/8XLC_?'/AT;]S7+6'@<KC[F8%&L/N:5
M '_G4V;)HF->?-;ISOM'B@8W[_#_['IGG)<!7Q %;^"UY&CZ%]]84!*O9).I
M/7(#U*$!1(N\0*0N"8NFCTQ1AU\K*^8$1O>%E<%:=';NINH]E<H0QAMQYY]%
M(0(*5)^;!3^3>S^6%H8'>?BK#E[UH5DDK6D(=B1R_J-#6!A8NY1(QQ^/NW<S
MM CL>G^J873;-35$[C:;[U'^]*]5?[%,SK_X 4GM,%^%<:R2]:=UT"5X-FIW
M9I, L$*3-:38K6ZX'<95]%/0,4>\H//DB^AF!2 E9)?&P"&^TMX/4)W!\C=N
MH5^,;R*%@7=&I2],5VT+90PU#&WQB6LN2;2R64G-7N^ZO&,=8_.S\PN_Y$Z?
MJFO-IH;;%5R$DWNK8^+1 )L3B]1;]B(S$W9'RKJ#3RNK8[:,M&SCVK-C)LUC
M(7%/K$+/:I0]/9 >PO>PSF7!L3:8X-Q-UJRVRA-XL+?D%US4PU 6":-O%AZQ
M-E>4EUZIDW4I?#4QR2\^N!2IGTZR)FY&@ZY<?)"#:EUT:$WA%795T+X])N1J
M*/I"RIZC_$(N3^ S<;''NAMYIB5J[!'C]>.\1=Y20\2@)$21 QW978T?&R@L
MVK8G=4)>C3]#FC3.GC9;1*UZ:U/=S1@H@W$_G"P9?.$*PF@\YWO4B!;)@F0:
M;)Z[>*G9THZC5BRAB)+LE15 T'*B!OU&?:L(^D)+QDMT6X&M:>I']>=6\QQ;
MIGBW72/NV_&PJW?]9&(E;MI,OS(3DV!&T1BZGXIB3,L%RNU!#\?*3)VT[NWI
MFNIUK( 496K4AY"\\VPY[UN8^X8R_=[XG2\\#[)VN-!LF6=T?%*0GVL,&:ND
MTWYM^2&N.P5IOT4A=#_",%2N/G?FEKYY()I\V]4244BN4S_BS2N3YIH)UC;/
M4_EB.R8S,"VOTR[P.&'IK)7-:D0>%T]*TR++%Y>TJ<^K.F/P3/\6IL0HF,^Y
M*#RGIE6@B$CJ"?=5H>;,MMO4FC<H:6N6]+4*?;OG:$>QX'R/!-'R>I#>J-GJ
M=JR1:?K>U=2;= ;Q+O;+N8R#E[J>-/>Q6].OXMY[7XL[_#JY881/CG-C=4U)
MFQ1M2;(N1DXM4RB?+IOD\EW_IFXI]5.4+7:@\L=3T*BR7)']6AR;^G!9O>,!
MCF+[<^+FMEM0;\?5Z ?L#-7?/G#)H)-IWTYJG:J8&9EJ?9KUEAM[BLZ9LE^H
M'&@8M-V4[8V5U3Q\@S?Z7%@WO??M0]/%#]_C<3'8BRX1#GV%N?W2%1D.GLZN
MOO<KL_=;5WNX^8&*PDC*1S:WWYPQF)/!)14A!CGW6J?B,I T3.4'A<-VLC]J
M>0LWLFID5;_V4_%R<VGR7;P@> RKXY@\3X3ZZOQAR;#ER(,<UVR[*6^WFI?9
MUU 3Y64)J1M3^+F!M]=OR?7&DCVD;F$OI7UK5I^.P>^NMDR-Y<(]M!^B9L=B
MZ[Y;OT+?O_9$ZQ3Q@4)?EUJR@_F2FO,*)PD.MF_G0,'FP#AC.K]Q]-#VX4Q]
M^6E)AZ@H=\WSD@_Z$%I$2.B#X7</!M^1YWHX(U2B A';#O>K1LLCG4PMBNM'
MI(V+A=L2(E3/;C^Y>T;MS"6JI7<:/+5$(NC)A)6AK1R*RO5!#9L6#S.I5Z(O
MSRC,)@4,6ZZ+,"HGG%/:#>;AK.YB4.3!C[M-"1^%U(E"LCGXVL"34^]K[@^9
M&<Y\XRWWT]#LMXWJIZ1EN6X!O %XF[A?KWGH@$K-1T#**-)T&>DPKVFHBC7?
M ;>B?5JHYQL[A4_T94'F,-)G5^QF70NX?%2VA1JF_ 3-O6.RNDU46;HO=_MS
MWS)!W4;^)*L6&/!A<%74MZ&N"3"FMOUU\MC888T)!&*51 "4/J]-B;O3Y&E;
MT*OI/?V1G_1Y@1E^S T-N?AE"D,"K@H;UTPR&,F(WG[NQ>;QDI/BL3]?/[]X
M\?G,()(=RJ3.QM+W<4;229@KUV3KF(I-"GNGAB=,;M/U&EFQQ%'HKT0^EI5_
MP<S8_,A/U%L!]W%_FP91D'BNT=/1\PMXK=1F*F*L\L&WYW&>5O8P+I%>JC;/
MR!YS'JI?C=9#BVX;IV,>(46B$4DXSKO!3VJ#.H;6P$9LH98?& ;;TZ%RW<=^
M">>9;RU$V<FIX;ZZY'^_*OQ(!V56F34)7F=B[8NY83RC!:67R'SPEMMYN1IB
M/L6\X!^C*FY*XMN=2FWO6$[B67C^03%-B&)3I0W7J0N$E>(!]USK"\U=R??L
M[]+W]+)Q<?*7G=/7$N4W<[7,,VW&C3AJDEH*#SWG;K@)I7,@/M\I$(_0>;5L
M&N7>UEC&DTHW6I8/8[1YO>J?X2>LBMS1$C.:;7>E9\R&BENK\@%((I-W2&\P
M\S%IX:J]^7(][(Q&XC4?.6:':W!<&15:*5<O,HVYD;C-WGYN**>7VBF!0^F[
M.^Q4#&/^*($/?2X'[O%YU;+763M_/A@2XP4MK1&[>SO]VJM+HKV:[+&)Q3F^
M?8>R+Y,<SWJT=M"9556HNPI(ZZP:=YYS4\WCII5(?H>W>&G1WV=,0O:3U8#/
M>*2"V#&/M,?:81.,VQ?.:[4Q<?NIZAF8+KK>[+)\J<0"6*+V[];^ >O2ET1-
M(SIB4:4M@S9&H-2Q?*EQ4>&>H!A#R^C,Z&F;)V0)H2UOR)\*YGU>+-E26\HA
MTEC!7@( \O&];S^4-N3A^8&B$YH3B]'UE7]:032"Q"TY(^D.'PUG@"XJW61/
M32VS.$G\ZY:!7%1ICU2U<S^' 21\M%@4L\/X =T'TL4+0]KA90^TL7])C=)9
M"#M' '3-?X:.;X%.F#,/I7+0G2.'-.%8;P-T&BY(I''?3I\;D]97L_-/DX 6
MBO3>0=R8X8-GF,2+])P?K,[CWF&8Z"J;X:1+) 0 G9=9!CXA[$==X#[X6Q7L
M+7A7M>XRL>%>8!RC8"T\+M:[%P]K5?$Z#QGTO>M[YT1T6>U=@_]N+G^6<TZ<
M0@@V -CRDR4V$EEB+G\F>SZ1\?\\SR"""E^Z?H^?R'IAOP#6/1; #1Y3^M#_
MD!-IE?]%,_A^D<M<_L__8/U$)I!_3!D3)O*KI)^WLOY"#DY^TB267[@+_.7?
M&BI,%_[/)67\JO31VO_,G<R_,%E>>A.A6MJ/EXCL"QM(O K\5LNI#\?Z#KJ
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MPN5#&]3!& RUL?FPYM1$K<UH)1_)7^C@$3-WH:?;.DA"XO]J[[WCFMR"M=$
M(B@(BO06%!"4)M*D!F4C("+2.U%0Z2 =)! ! >D"TJ5)4VDBO8:.B/0J/:&7
M0"(( 4+R!7=3V>?LO<\]OWN^>W_GCU#>9*W,FGEFUC-OF7&+8LG@&Z3G" L!
M?'5Z$N$M;"P4($>!<6X"G\:JSB;0;^^T['W)8F 8"YB=8+3K75>UI(LX_U18
MH%A)*R95>$I#GE0TG8O5Z>+@'1(WRL6,3+.Y;_\0 \AN&O[%+8G/P_K[Y,_D
M\R:7OWUM'O/DN/J;;/VA&W37(^6%U5\]87R>95.FH_-XAO*DF[#JGY6V.5DI
M1\),<;T.XKEO3"Q!U+5*B+13ECM:^M.8H%O*Y"J<5Q.,&OI/%!*+ZX3=]'EP
MM^;9^;K$$:>H5;"0A_\,0V0^!%C@P=*,7G9:&K"62(H(1A A^ X$-VYY564E
M:8F*+T$V6;K.75L@O5=Z65/B-+4/'O!TI\F_!;W$T\)\W2-"FZK:R/27BK!D
M5?]Y"Q]QOTDI8B]M^K2SM71ON[S8*D*V6#I<EL*'^EM?-RT,"P\K-4-"1'8B
MR,0VQWPZ?01"VZ=<]J*M]Q0P?LU@[YN+!JD7IATH3X[G#P-3-7O9"A^.E]^Z
M+'VS?ND@L4P9Q[Z<1*FQ%#6A #>Q4$BSNL?2Y2FJ&0&I?<'-6JZDU=M+]FX9
M#Z"'D.9;BY>7RPFCD,B#EG#26OJ]E]3\$9<-3A_OX+C[G$_(%/-UQIM/?MC5
M2.B,E>'*,LNI+6;3C&/]1H'/E:H:H"^(;ZO>?>3-]ZE6:5]L-7Z*']U=G,-V
M<K(L\O2287GJ0)Y$+%N88Q[9G91KNF/I,_YAA38![P[BY+A-C< =>6H9)I,J
M<)?>88HZQ:PRS[B%*?/WO$AS98'DCW<Y=1X"PN+2J?.Q(@AOLM8DQQK4=E[N
M*KUPU=.>G DE&>O9M_,G &$1LJU.-G;PZ? [TX:F5N]E(X-J%<\V\L9;=WE:
MHF]QL5 KQI]4<.5U$M;&,6$X6Y@%:V:+:%:&J^V3O1%\S[B";@T4&EHB].]^
M&9I[WI:<Y3P8T* 3YARR[$/G<7NCT92D?ZONAG::-K%JZ+*9V<<=$>7^3]<X
M:"0^C')1"3>D4[V^\3;]TA-  \"%_87HS8_:KSG"3BMI$"#(S*ES!P @>@)8
MXB5/7R21%;G]K1#K/WJ=/EJ65O3(H;<@&DDTL"F-P#D.*])F'5XZK"M!HWXO
M8/HCI<A_/(IRP(;O_5&,S?PFF-5;XVB#XIJ_:&SS78-BC6O+VG<K0/=QI- .
M9I3Z@2\2NJ5?N%ZI_C.QB(]OZ5EFE4"=6X)QO JY=/OY/RBX^K<%687]57\O
M[=L%$*!-S!0%W#G.V_5]5=E?R\W^5M_WC\,AWP8I_OT'"8=/-'1!"FSV#8QZ
M]C5[X&<1!908[XW[J$^&ESH886J*' Q Z[O*T(O)KN^,S3V.N79YJY\//EWH
M&#7(;M,=/\/P5 _^%>;?FM^9V^A6[6=RHMA-L+5GS*=O8?:"NO0B3X:,.>L=
MLM#//H.I?,48!Z>QG:#Y@:\%"C>'[6M!>?S//PCEEIR5&RX'>'J&2^2H4)Y>
MM.)@PP/.X'JG> 8HKUC[ .,;=WR ]0-%90?B5AGU^S<BW?JO+7)%A64J<@BN
M'%>*EN=G<76-@[Y/\[-[!?.S<DVYWHWH_M(V-;RI%:V\M57#;Y\TZAH^-S4M
MKG+G4<TUCG4/]QF)(%$VEI;'WJUM;Q D" IH,7AR-;['72:NT4 3T+5C+K_Q
MA(P[,:&$QI+DDQ@X<JP@K27*V_%UA\-,&D;9HM<.B;0[#RWUCE2KKJI-G S$
M>K[F)*)R-XIJFWV!VD$*D[6%DVF\*Q\0*SAIQ7]WB+\0 I(<Y+)DU]91P?4P
M>7#M]G8P^S52Q$+>< X4X $6/61&&.?&,>!G0>Z!6OXO'0]8=P3.167[67*+
M""]<7W6\:/M5(*D,U3-3'X,JU[.3UAOYRA@W:5L@4.:M:_3:UNY%^+NFH).
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M.B/]@2)!%Q6LK*M8EAZ#VQ)P+3J[#9'\/(XFD,/6]O4LWP]FF?H''A^)%8N
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MEZ[PIE-MSD"Q+XQ >_-"N"<VRR/[.2%\GUJPEON0Y(//>VE CVF<$ILS#O:
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MSJ;S=)08N@13=B>Z?Z_#GFXWA&H:U,GI;:MHM% <]MG6T(R)DBM+8M!%O)V
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M!V-*P-UQZ^) 1EA!8MZ,)3/<:>3;10?JW+!<_H)3%Q0E&+FA].59*%!=Z@K
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MKJB]E._%?YKGW_W'E<'?4_0,P]=CW&XSH3)3?C S&A>(\SJE0AH]\:Q(9+S
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M??C+)\XI>U5$..V8ZU.J<7'&&K)95T##J*!9(M@0GA4F&D3I NWW4I(E,5X
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MV#>4]7.Q^ND-J_ L!.D[25<WEY0N+:NVM'?*+EA_$(-(CD8)I#SM,@H-558
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MNJ\?^A:X40P\4O33PG7R7@$FQX//[ G!O=K@;S[(Y$L_G2O A^Q6CZ#MFU>
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MWW71E<M=]XM_]GPUC45TO%<A"^*<E*)TZ/5]9&5MM0LS@!3:6MCN77OAYO;
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M*CYKCY^(4.'J0#(D1_ PS2N8AAK6C3J I9AD?KZ'C4J(O](T#/$*(RV@YEH
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MA>7GR+^5IZ:3X&_&4^"]W.Y?TE6?J^;><)W3O['_M2V&2W1]_S+8B1K,",6
MT=\L"^.$Z/;"X@0*_E+XV;X$'E'67@%J@+,+=_[N9';D].CPW/]'MSA^ON3,
M7ZL]@OE///V0(^+F*X!/YXHW5!M?R+X5Z5ZM2#U98D*5[?S*5B\1X=[1Q!>)
M%(B$:3K,PA]!6IA!3P>$MA+3QI[?*9AYE:(V*">0]&+L'F=XRJ?=(B;9YZ\1
M]Z20M=OEV"R?BSMS^7795D/(FHQRYU\<U<T5E6,?U\N_+*0-E=LFV]P-!9QP
M9M3>-8AI$2B=B\0C%\!68**O #>2;/G1*4VS3V=*,+LXE5G#B,&$A]Z'2CF@
M>C8?M2WWXQ9.JGO=RGOVZ'?S(;>P^IB62DQ_?Q?#'%;+$^DQ_5E(WURO/4R1
MW/V9),-:N:-FZO.,A]QJS>+:/#N0R7'9(3N6'"N46JS[/K#6,8E2RS3C61S]
M^TU+5AY1KS;30K%<@BWN47D \FP@^<:N L=:999/NUEN=M[7W)FU47HR893N
M5)M)!P7S!^YMWB>(4*!LEZ1+%A>[DCL*BN"/Q%+"@6S.[G HM2L%[ !R9[[*
MT=W348CE)6$]]#UKU M-'CYIHE+!$*$](*"+=RU(#./E"?4S4!8=Z\]^OL:-
M24>0^VW.UKQT2%3*431_\J5AA&#-ZZ+ XGFS1DCN8+D?6*^=T7/%I3E+8KA3
MM5XSZ4>EM:+:*.#Y+X)TFZZ&36"T%>/[LEW)5>?DIX'EZL7+*];"$D,+$C)S
MR:^_41G*[XQ*$2#%]@5%*U!%P\WSW22=(GB9]W63G9#+8X%@>$<Y3U/][(J&
M$M6#-,%,Z:;8Q\04/:,S;R%ZF."+QT&*S9>ET$Y_!(C>)81I)L@8>::5OWRA
M"18[ZW9NE1B@DG_^Y+-64W"OQR_;!/_(:FX=<HHA8W4&8EF#UAM>.\FNPQ>@
M\#LI_) /BK&X$:8@XO-AB- ESJL%V@0(<0JZ/]=)5Q6R"&21%G%XC%$1!OTO
M]MX[KJEM6QN.HJ#21.DM"@@H4J1*#8IT 4$1 >F]B[10@R"]@Q1I05!ZE5XD
M($VD29=0$WI/*"% 2+ZX]S[GGKOWN?><][[W^^_U]UN2M;+6G&.,.<;SC#'G
MREI Q8;/&4C-#+'%H>LOE*:WIMCD=:ZL2@X^'6G2@G^0D2[QLSJU"7;?5MM$
M8)(_V4%1-1 $DT?LQ*+6/J>O"L:4P2.<WOPC#?4%)$S9<O2 )52??5XSOIDQ
MN,8UJ^O!1;=8%3AX.\Z^./L&*JO&K;,I)>Z:*F_0,X:KA7:,KZ)%^FA^L*OD
M4(.PAV@R=9365@>RXKJMVU3M6P.2UI0?T=.]K?R5%Z9Q/*_/Q7;J]8$HY)CG
M\#W0RULXEPHP$%$#'ZB+H<N/$ RM*4FJ,+%_6ESJVBM3JL @H$ '?,Q;T>32
M\@"Q:>'V\<OXVU3Z2B:HNBJGW7,QIJ'DS$7VG\7X*^B*,/PM,$1CO*;7K"'V
MQ<T6E5OWWF^W=%*\^7&]JM*69/\(XS;NH14,N2K'2\V.M>F28_LR*<-PUERJ
M_HH#J@W[$NMU^FBBES9:O'B0[OJ-D.A7?*%8)Z3))1QHN,4\FTF+$CRXV=%*
MV=(PC/-%B*9_W[J,?^!0K  5, P5$#)TO<!^;OWD?:%]$_O[8@-E7V\SN\(9
M:VG+[!<C=OZZYVY <XI3M! J%?G#VRS*ZHVSY;<JWW[E2GASG)7'FI3],1*
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M31NY",IN6+%_AEKBSLF\>K(C_]R!DL6UY;Y'_14--^\^$7:1"?)5A=AJ41F
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M]>'.#*?2>A.'KKRUC[_!(XWY\D7:M.KND;6V9]?NU#PA&R1F"9]?POFC['R
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M^Q5F-K9'ZH:Y?>\8&0\NIJ<(:"_"?23J31J0J?V]X]>03;9!43K 8[863@+
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M/)@;B:&TZ132?ZE?FZM!G<S95#OLZOQ!5]7B9DP;"<]R:0P0\P%K43[;Y>*
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M^P/*K5K8D??7.8_4R/*UL*.\Q#&XP\[FVPE[C_Q2TIY0C;LQ\M[2$@B?A-X
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M2.&3.7A61FVMUH$MT0$1N3@28GF8$8>C(W:!+@;]^0!"I@=_"IE7BKM'E(@
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M;0;^ZCZR.XB?B9&S-#+WH@7/O4I359"X\@7KUJ1Z=$%'#'4;/3M?_1@.9+&
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M"3#_[$EC8D&#>_E493/^4+KW-]<22N &O+6_V%?"Y%\/_K6O _#O+FYELAS
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M:?V6_@!GVU8Q9!!^Q!M*D&$D##*LC.8Z/7(\ _2L_?'&9GT7<TZZTLM)XS,
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MB ?BI6VC1!N(;+8ES@"#N2WI/S=M.Z?B _EQ<)Q+%[V5S[D6A#V!:K,6Z3,
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MF6,@NWSLM_?(Z\)58V-N^%Z@HUO*@_LK9@;7V0"]+U[9FO7<_@(XU L-8IL
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MU3/+UNX'Q@)OCZ<?KV!=ZD6+1& CU1VD6<1%)W%&#AXO8F(X@>.U_YQU :>
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M;:5M<><'E;;@6>G:8HFU.0X[&[S%\_R<G7E\WG3;4S*QB&^QU;Z(L?V]?9.
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M3GTTH1I8R:TL,UBQQ:F$%+<:W<U CD^I9L_(V\;1^P@\R'CS_?:23#5]T%G
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MR2N"]D?VX<"6Y@[L.12&"@(%T[>]&W33EP]>;Y'WGU5[,N!N?7GL]J3Y6X_
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M>\%<M6^Y*2^\?<O>YYC\'027CV2;\DK=V_#;_X''\XOYXY(2?T]1W8K'IW!
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MQ7B9$+_$[MUNG[Y-GV'U*6RGAPT^,;:5!#LO@,FG5N]<CY ;8E*VM\OD>*\
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M4YET.-1#;FYE/S,1;^CI[">?C"<Q?'I&@<8Q8<B/$GNY'\<ZXKB?8*4P]'9
MZ<D3B0@W7463&O;(&HIIRQ2[!SW7G\EO]70V\Q9_;ED8JP) ?DH%[%(?FO,^
MR2^)L#2I7.SQX\-8M;3ZL0W,#+DI[MB6P\OY.X2#A:^^?FQS!V/<5#(#"G?U
MM&XL0$)IL)J#*IP=A9[^Z:BIM'>=->LY=2D:,7NC](A[[I&G_$D-*A]!)\-G
ML1RHV5G-%MI@!=G72@*SF@E'")H2A.<#Z4<F)HXE^7JB!E<S#4T^10V$!9N3
M13<_!>MYT,(^Y]L=;J0A*35J^B5N#X@9V3M]&>HCTY,48K_(\'!6>.6SYMUL
M=R946H /$YJY'SD4*QCI(X&6,AI@4U*1IC:_,I0ZK-LOVO=9ICX:(]U&&7:E
MW=!S<JZ[4P-A-7A$C56!!8-HE;011VDTG@&7X)5H\;=]*J6B?6H>#)-?]K;&
MV01\<I_WDMYF<=T0JPZ[2[03Q:A_B>0_W6?D<[+YI(EFS>368U'FK=PB9:BA
M-VA:K=KAXHV$;Y0G)9^47/#U!T2&/;A?KM4&^1R_]019ANPM#V.-#G6;/1V@
M(7O)#\R2]"9D^J:[^*[0[C\[_\#+^ N8&DN"Q@-ZJ.Z8NFQT>4PK6YU@@2;,
MU6>+0UG32(YX;=-)NA+*^C#U3N1X"SV)CRPY(]'A*22$P\Z/QNF,>]%5+IER
MI\MBXJW7M8[4!_PC720X2T\^\*5V@G+C@9=^?I98G@$E6#K&^&I/'1D:TN+'
M#@EE9YI<4Q$=FH];8*4?6X8*5I[U2)TD\AR<HY%C(56NDD^>GM&+V84R>2JV
ML+_,C0KQW_D*[3B_H?MHZRPSR?/E$]I#+J*A6BJFC_FW4T]UDDWG/,4#NT8J
M\;-B+)9#NU]!>@-W:@=VM#,#],LCX_8^:M-WL5?MVHV:>+-CYP>5.- UBXC-
M$(,V;BY,4A'FI0^)DPWBR0[U97.7[-5/HBM;*^;.UA.MOB\.XLAN/GU&22I8
MC]YL 8<_7$E5;*CK]5'/7_8*B<#*/$&:U E)F4TZFKDI\)^?C) UI?L<46[Y
M.;K0\#HMZ5.5O0EP9_:4,AX0QB[6]BIYY]CC 9H'6(C-;!*6"!SJHR83$I")
M9AG%:HG6Y8U?DWI?K6UC0EY]'R)_X(!.HB0I9F@:2VNU5Z' 4N/:T"I%KH58
MLSZH$A-,8*AP4SD%9O])<L6.-6XM >YP>45#\^6S\V5$AP7JAOVBO'T[J^;R
ME*^<D"99DM6/Q]*)$I3B_3\I)9=?(KDY5)X"HEG:'RO.]6 *3K$^F6@L9_#>
M!!'&6%K+T'OYF?8.T^.ZH[W@_N)RV-,T^L('3F_K&FI0WW)/,@\M66G?<]1F
MTK_UR"0.(([3!101W1UX(!@/L$@4%]:QS4:1M>XGY DDCU^#1]M;7W:I2[\X
M_IIJEHVW=J9Q>)'EV4X,E^>T*H9%\*D2&1)$B^E"=/N[4RJK6:!)0]TPV74*
M>J/K:[$+8_VP['5G(D/BQT_D4Q#<\>C/> "A&;E+J6S;IE.RE.SWLE MU^'Y
MBOXGU\)QK?OUY=-/OJ1ZD89K(4FGO36L^>_=(%OZ<%M$O*,M624726V@5C90
M5"P3)2XOT/ Q^I)-A7; *]/A=R%;T]RU>CE^'EB]B-FA# 2$S#-N:[$M62,-
M.314/EY+2937[9HY=<W@2/A+QSU"]LBX=:[PI(:U1,I3=:AGO :FPQH<LWNO
M GT&WM"')4WE']C1$:P<<"Z<->]>E[I+ZO(PH__1&=':$1J72Z#T\3:.D"(_
M9TQ!FY4P:CWWV;IS.21L#T*]"PG=-K>_H"TPMCIL=KJ?6"M(\]#@\EGM<)$8
MQ2XRXL=C);,@C.4FJJ71RF8XNFA'Z,QP^QM%M;RN M&W2S!KCNS2UO8[T+AG
MLW3.K(F$T!1"EK#8-9#U+ RY'U\?UNQ+]YR-V]I2Y=3JT_K03LE-9.NFOV)"
MT8F)0GLTP<C+QBW5VE,%^Y4D;-SE1F>J!L6-3L;IYE3D*U\GDB_Q]U.T@S$H
M7?8QR/'\W-\QMAB:'=$<DWXVS-[U.$R4?"\JO[Q5GSD,LD[)=_YY*97Z^Y<G
MAROP0-.ELJ)'RPW4#F:B?F>BW-+8!-:'LA!%/"L>1G24]IJO>;;FC)IX[KQX
MIJ=V":2+X4"R!#><Q7AQ>31[$;*Q,K>Q7=_^M2I3I&@N5>T+E.H*K4S/?;CL
MCJ]!QS2)"HOG,'+ Q3/V@304I(Y4#"M?->S=Q!KG=CMQE8^D=CI%*578V*$*
M:KN^M5E#G/R^<7.@04$-%)B;P^WL;Z9*D-5%) L%KMXBBA'YK[KX;Z=>UH!T
MZ8_>H !V:LYE/J7X?F\Y@L=:$"3[T=FH!Y#3;GH8[=EZ7YFR47&E:I6!H@\9
M)$])]JF<R"Z6F,@<M!3X@#'^2' (A*6!U@PK@S8LKD9.AWDD#R4A\]>0,5<_
ME#MB;,U+']Z;((\FXQ'>$'A!0PA36@0A9I9PPD[Z;BE+FRDZ#?&Z=73$1RFO
MFA,CY]R)AG,YAQH0FY!4.%L#._;6D!A6;7X<,^D4TRKV>&]H[)MB1(%BBFQ9
M!?/;>Y4UP?-W14O)DWD-.2OFYLX'=."H,9.%F/BF?:EE%=G>#986=OJE7+54
M7U4WRRLZN->55-"[4>,<E,HCKR5/2)+/$>]H/NR&?8[WW,<6S)SR$4([+^Z5
M<9]YC]J/DO8]OUHS'X6-G9KXZN1R>RA.+*I96Z:I\D8?H,_G?^7*V7TEVW!4
M2,MF3(UQ$SS4C#DF$U/X2:8X7JFF.,/5V_'=U+OK?N..G Q66F]=F9']YMKT
MGYZ_4^4#0&\S_-D*H>2>'>KH_>"RS=,8[QL11KWNY(%#E16C%[X$QE9?5WCH
MV &VAE%[QK> J'?S9/I+VFQEJ]UE8ZV16MG1*WW=Y 7L!Y5R] ?J0YKZHBDX
MU]0+$ [[M-+IMA*,(?++TI1T/]1-+XC9/FO,_O#EUV3-$LTG%T3FVX0+/O,]
M?/R>CRRV[RE8ITX'N0YJVC/:3Q[$FKF7MTTP7]"1O?1D(?9N\(6-;RM9$[V(
M$H*CSI=5U_26S Z(K1<OOD]"DIU2DF2=)WC*^"9M7\,)M$=+3%CJ64QZ/R:^
M.55I"*LF&.5S\=VH([-<=#)U11C#J-(''>CBP7VM>>VD%^IU\E,<MWE6/&L;
M\0#=+7L)9!H5]@I:XAE#ZY1X\K8FJCA+FCW@D]BX;*+*3;N)1MXI!NH/.E3%
MY.FT/2<:O7"&GV/"&TX[:;0W@T^/Z+G[YNMDC7><S-3=_Z!Q+X&J^)*;X5W5
M]O.JB^$8:V1BH(JX0QI#G8!O-L:X8\S]6S".]0*DZ]W$"K6+@^P;56=ND1?E
M-($OG[/:/#%W?<8X9X410UEWP&GJU-\N'8*#Z[0SVFS1FA;PZIKZJF1'H9V#
M!\5!D6V110OJ52VU\@*=8@D+3\&7*@/PP$K60P*#MKV;_$YBOM1P%W"GI?MH
M]-5IX@%REE"Q.EMWI-AU[9FA\MP 9MVW>"!;,F2[\J5=POG3_@/A2S[:*#TD
M*'@'S&R?K.ASV4G.$)467+R1$Z-?/9#KJP_EG'X:9Y'UNI7A:S@;GX#VZ @A
MPY,_Z!L.P+4S-YSO]Z/4S,5TJU;WE#PH5ZP2(YF?'.B;' OY;,%4$Z>=0:.S
M'C89_J[DVHQW&\"HKTZXM;QND%'*=8"!<4Q,F]G)!N'^S"$E,=OCC"+3NEJK
MYNG;,-EKT2R.0MU5NT7P$YBC%CS H"1T!PFE='COZ$6-N5_QO64]9WSOP3W;
M8"/0#<<96 RH%-*JQ^3CA]XH01Q3[-BGRJ))2H)V'3.X^>)5DUNN.T9$C1Y]
MJ,_N#8AFO\_W7.1%GPJ]CSZJHQE*N<S>\0S'VWT'BK"\.WZI7TG0:R_.WNQH
M)3%.C9#J]$"?[WK?C1SOH1XU^ KXI6]^[ZQN]KFO*UJ&(W45]BB7UC<$RI+6
MYVCXDF6%^.]%1Q92O%\AY]D2F4G"TJ%KKQUG*E$7KB3#PNH,\RZG<@?<DE!N
M9;_VX+WPM(4YX:M0E0D[%"?RROP+M+;J-%DI[K,5?<H,'@C"B8Y7!BKIVWLX
M(M_<Q3'"XTR'#2L<D^;*95/OE525J1-S"MD^J)C=OD%6NP1C\!%!ZK&NXAC[
M=E=%-NF6>,\.2H_84,NDOW".\5R//7!Y?;_$TK-#XP-:-R1X<8 WPA)>D;PU
MU%:ZH$-U+4(DKT-=D@>\28'% QA;E-KL8@N$W=, &5ES-N:X%OG)701ZNB-'
M4W%%=M& U%.@@?Y"1%=IJJ(-[_FKZ7>"YP;!0:#2_6@?&Z289)=AC\H9C(%Q
M2J-"0U0Q)JU5(;N49SC'VXA%-FHOY%Q.%A4%HR8Y0.S(#ASS37SOS^1HU0Z,
M%]LV@_UD/&L1+9[Q'2J,: 7'*2$T=7!:OCV[48Z;1DRNJ9FTQHSYF"[E9\'J
M;1OA.![%S*X[&K=1L"98&$X111NX@P=856>[GDAWA[#OB(/+G0O?.MV1(5'P
M^FR=(@E^N<U;>O[,)8&G%X%C&D)KF.59\A0K@X"&,6"V6^323OM<0.M9#&7W
M*0F[Z6JV'#:5?>P7T+&#EPUA3ADI+\Q^LU<:>%[SO* RO T%:0&/L?FHS5[,
MK$6+I\P.]_OH<$UEG7]MS_YBJQ-6JEL7;U6G=>O!!=;;NN%L]SX=Y!%OSJ%3
MPP0C!5#O5LZGT:G?3DY9'E6Q*[=G%T@$38I'PF\X!J$[UG50:8C<"$@+MQ!Z
M(29]-;80*I"#;9=B[Y0,>A7UCGQ#JR05#UC'A'@M!*$_;ENE-$W)HH8B!/W7
MI)?OHW,&$B6[\@7ZZ[L3^G1%>.G'G\V=\)!\2FV"B9LZB_)HA\;XJS!ZYG88
M<<OW2-<KZOB*?Q82O9^@J!.:K3T?IT[W=ODY0W#CA$L'#^B^F@M7JS;_]8\:
M,Y(UG/EDSU4Y[[ZI\L89'GR#D_I)>2JV^Y'W.K.T11Z*AR$LY=0&?11LJOO7
MV*?D9P<2#%EN-!(K-&R[,-9F\=WO XJ[;F#TT&,2[)YXH,4/5#<HZJ.,,-=U
M-4+=+QQ>8[E1/Y )^6BN>%&@+?6H,6>+R Y>\_:IRA<T)&I'@MADS,IQ[(6"
M9?G@'+L/O07]R40&>:TL3O?[/!1C$U+1,&'L/ K:# M-#GEZMRR^!2>KX.,G
M@?+=W[L.ISK*\!17^JJ!Y%.>;\UQ*7WR6?,%J4S[FELJ(RJF=94VXO%^37#,
M;!>$<7PU>; [O$[WR3LIS\=':O?2UMZ/M2V\F XN):>7=K>;$_4%",/$;T2%
M?8:+-9 NX0$F)1M4,)=Y\QBL5: *CH$4MA4[)'_+EVEE_Y8A4&5Y;OGH[0.M
M0-IDF<@\UKLFK_?VTP 5?KM404R >TYNZRGKOF(?4)ZG@[:2JN_YY/F%@".;
MO;)Y&T6EKRLS[[;++[4!?F'.3)H6PSO35,LL7L4EOM"W]A4N2<7B&W-TZO0T
MA5]& ./&BM23&$(18_3CF?CJ.)OG?K&_S5&FU<_5ON9E5LOY/F2X1MV%,R1%
MD7Y73O&^&K68B;?H#H?90L*,(:=DOM+H\K4G=SG"*=RZZJ^/'=VJKK'':G.M
M2*737QL7H"-^U4]^:8X0HA28(+1("XA"20(<BK4L'+=3X*2)[?)^K!7%-B(<
M\%2/W]^B(P@/V,."IF3Z> =VP)SV[&]>U+QI"/^H*JM5_Z:BA<C"QK*;@IRM
MA.NX$,>]"J$#6]>+7$*!0W8Q4/;9*PG#U^J,TFZ6A2N^>G4PY5AMSZ>?(+ZF
M;1#W1.8;5N\X5L91Q]'WNI-W*^0TUA0)X\ X6,+,3!#OD[D4OCVJS3+79V_E
MTWPL*=']S;4QG;9TG\J6;"O+D]!2P65Q/#[G,076,^L&38\;N-'KN A'9 Q#
M% 5.[#INP5P'<G9B.;W06%^I<TNZ22#UY@?$OLC]DI) %6EX*RAP['@J:E87
M>C- "S4A=^B7)3-8G_THM\N;=V+<(E.=-^ZKL$4K\AH5_?>!7*3*H !1\G2*
M%%.>B^O?=K 2P0.!%4*)AD-IA@/\IO=ZRZF5X;-M3*EKS1EJ5_3O5!H;<)#)
M?RJIM@,RP\_]+S<1T,;*VDXJ9)=^<NQ"))5^F1?MYX1P0#=+F00@ZKG9^Y_?
MP/AYGXIVG8I*?\Q8=N,$"?'[+.*^']+19-P#MSG10X07"S[NJ/YF&$-95=DT
MBZ>C-EHY\.:IK(K!M:SJ*$XW&QH:V@?A[B4M,12CCH=^U5!$_5EJZ^L?<%]+
MX>&?99+'AOD/Z*K8M [ PC./'+-_MO2$F^%$))&..G"6A)5P-*ELZ<PQ2ZOQ
MH>Y>?H[I"DNR;E-M_V)UH.+8EUNY26Q*!4[\]Q[+O&<Y0=#G&L4%@IRKE23&
M"0$)A8VFH>(Q'M?00+]XPMX7!Z-\^<K7;K'$Q,'<Y7U$_CKJ/SL,PIVBX>J?
M9D& A/P6=W-4^MYWDYW8OI':C9'=(:SC =Q8L^QV?OPO][-G/Y^3$2#Y#N.I
M,B\*V1C5G^MR,L.!<S]O^PX+[]X@OO22YRIG[!IDT-TQ?I*C&+/IMFW'/:\W
M;XK#"D8Q9<N']U^>Z7^03;+^9<3&V"-VN//A4?B^?*7WT36LAO&PV5"+>AP9
MNGSZF=N+RGYG<6=>;ZB"MG..^ILK;5DA#HW!4K7\#?+IM$4/%69\[>5W5B$2
MRZ R4"N46=3,J3PQN$ZPT#[9.>/=RK"?H'96677XV'K1<-<I(=G/392=?=)1
MT&K#V$]?[PNVUWLTJ["C*T/3D]P+WDA.MYOE)%M9Z0C44IIW@7G%68F91[6,
MV@W]-HC/\X#,7!K; )ITBH-)%6%,ARZZ'!Z"-4FVW!U,*'&4[$8,5OO;5*3I
M#9RE8TW6D-0J<KAU[Z7OY\<%1)'NQQEU]KD^ROT^:H4.4Z25-6C=EU$;_F]'
M-9^X>]-5N1]WCV8);)KP44FRJLG??GQN E!)FT'']"7:<07Y5*)L9\%A#6>Q
MQJ@77@/PNPE#M$S+'D,)$0+E]0,5QEX.FHKC93'S5::O'XC/4\I3?_75^>&<
M\U*OJ?H(OF6D>4IQ.7WK$CA(X?E..C%1M,M75K9E*S74^]6]-#8_01-'*_Z:
MX4S#?N>BV[',YT3CU*N/!RX4/SP?D<!?*JNM#.P>$OC?8R#P[.*LYYRZVT/#
ME\%JQ$VD!.J>LTMF?H,H$AZ_UE?H5#:I,'2!D3DA5M3E2D#FNSR :$EXKW?I
M1R!*O:8@YP[H2ZBKW'M5,9R#X4.NOB%NK?1CJGW?+UZ2NJ\7I=O"?T,+9^$\
MNA5QNOKYB49;YU-4@+):I#7GS3EV%&W8V)Q7=UCYJQ*LC0>"EA+CV/+0PN$P
M.,WMKHO 9'-%H_&"*95L='C7=LF8O]ZK(O>TTJ_1M4Z(*(=5HP#C]_WNU%;F
M];2ZPQMSU?#2_B\NPOQ?SX@7]HE^#!U-RC(U/$5R-8\L?YU [=_H?MM6?B'A
M9SJ1TH$H8$TK&P8:1,WMK5C09*$RM!RZ[F\GQ8IRL._M4[GZK5^PS5=?4;$(
M=C<=O*EN^_PE!9.U+223<>X&<=Z?PD*W)<V!Z*O/_I%QRBL?B>_O^J!5,D!A
MTA*T$PX7[!XK[.]Y5@3*+@Q\L2.VD/;3-XS6V$I9,'@V6O((U5Y+2,LT]EYM
M\74)7D&%Q@_K8E^-9L42YPL_,0CFY'YSCOAZ^+GT$^$BH+:I<^]1QD&[OC##
M5^;+-9;9E962:8AH:=&.U:=VQ! E9$(#)<IV76HV)CB5$3TY5&U3HET"L:.<
M%5.8;D]@D4U 6:;X<ZT'DG2*02F^VMTZVR-WL</"JZ(</8Y4B9I5A %E4_3Q
MK?&><5W:"IT5K\T$ZH=2O#USUZ8>XX&+[)W%TU(TQ;ESGQK)^@>,/U$?&6&6
MEH>]WBTK\"U/L?>ZUQM#M,ZDFD+3KC=4E0K=DXL1NW\^C%CE.$ D^!NBU/=(
MS7.QT6S;?DH(0NV0L+=G9AL*+5=F/C5;4=Y7+#XV-.ORA&,A\$62#;](&V=K
MYDLVX- K7@:]4'UDX8E;0<J@-D/6<DVEO4N8S)W?)R"<RZ;+OU*_>-"E0.DJ
M^O!)T:/QER?SE!I8A]61X AN>;1QN)MCBGF4B"JJJ#*JK(C"2>5BML+KXEYU
MI=H<S:W14R\$X\LVHJZE?+O<0S9PZR;-LW @=%(-#R@;X(X8?=^!#E9!QWLB
ML=  /U+@ RHU=D5OE 4KTN$C@8;NW4;GAHE*4].:HZ[G%DY_$5LO=&HN^]CI
M)1SI7K#O\TT'Z:VY"9OS/;.7!ULLA.V/9*W?P /=)GA@\X/%4XS<C,8R0I<'
M#XQG#AE5SD""<!S5?6*[RK2J'U.,ZYB9Z;X^>.?L3 7EB9*?K]!8CU&7-E.Y
MXZ-G=[R)C;ER= N\/00^6M/_?>\2>53:,Q5FS&++D-E&0,:2PMM8KU2;^OGZ
MCV6/BK4ZY9>?:R*,"G$<6.D!Z.9:D32(=F+*?N.#E2K5A=KQ6AYW4\9'V04B
MP),FLHS,WFW*WU3W@#N$X+PZ\(!ON,H@+78W!G?$U EK3D&)@^<,^L H.EAS
M#,; B@0/9.AIX8%&]5^B[GC@G[(+R=V!#0P86*L934#>L@IWZ9#,4))TEU!1
MC\[CNWJ2^NRS;_*W0:KF63/=_H3]8O^QZ?2_Z(,'FI-0<L<47IJX$V(@U%L?
M:CQP.346#SR-4,]:8&G=BYG" YVK#3\%_N14PG0I-0,]9-R)P9XT R.N83AP
M0<I\>("(.4+SBT38.JB>H,/P[^N%J"? VX-@@N\2L4)IQ+">W&S8#&\O'J"P
M;9S>$5H&8<C+O!M^>BBZS43A62[? +NO05]9A#*M7G![\Y"(HCS+@QN7:_7)
M+  %]X*79#?KR_F>S*H%NQLLF5! QS+P0&K^=^.:AQNX,+9M+,A]HYY"&8[W
MS\ *"R2/QZ3\X\?C#X8\_G3\H'?]]2<*^_LW*POP %_Q/VA1K(EC[/:'+_WP
MEMU?#'X<DR3WWX*S'67=FE:Z'X*U%@PJOU@G>*=$TY4K973B2MY->R93/E&-
MGB]L6B>WJ[QZ[0Z"T,I9^_ MY>%?;-?\8=H'/#!]MYH(Y=B8#>O\H3WAC/N8
M% 1A)@*1V;%'5Q;9*3"G9"^C9+X.SK=]+'S8GB7ZQ:6'0@QTOD&PS&\?IYE^
M_%._<[];:AR-58$\ S/Q-\0T)TRQ#2U\&-W+<TJ'2)X^&#$EIR)J:FJGH<UY
M;#LS[>\2B_BG=_^Y(7$Z5AYCCXSBG;[55P?.F%[>IS#C>"46&W?IU,F Z"<G
M_9@R?O@<_M/G?T1E=.V_6PS"&*B0_A$B67]V2)E/,R:U]VCZ@,OCET!,^??\
M8XT'&MH>@?_"9\T_$^\/I!4V?PF _@B0.;VFM!/^:9@K/QSXJ:?N% K>6NJ
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MZP>4P.DCH\VUV575P?*SJJ_OE=XFZES]4Z;>4/G79"0SHX\')-_^'@<E)_!
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M#7'S^8N7*\:\I[PXI36G;7.:V?2NI\4](2,2O:Y. ,1IGT:KY.L"FSGEXX2
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MV"T]/;Y]7=>[>4QW/WC374@F;7TYN[9'K+B8-UCLXISENQ**LK@+D1N T[6
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MR'@+T7V8'-7$'C*2L65-?X6?KH")0N[=')%_$V^]Z]^U *&>6L%ZYK_CX43
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M @<XQG0=WYW0"*L>V/&])I@6.M#Z5?$@"<!K"<<SD  7[;:$L9,4L-9A<Q*
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MUNFG\_%B[8PW#8CM$P"-H.>V9:=5J9BVVA06LNXJD0!S2PF[T)KS*?1JS21
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M\.2T=]5,TT!JZ*7^S-I>^V7QDY%K*TU/XQ_+KMOG\TS<9WG&2!4MO_+5N<5
M:?(L"6"S4CM'M)S$&? <V[^$M[]_]F<2H!G^YP?D[$)QDSO)K^S6)( O$WY_
MTT /#7)W;HD@X+0PZ>/K#%N1BRNP68L?'A_9]_C^3JV_^5\7B>>M!!,H14F
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M/#)C9UL1H;-J-(A>@'SHX#FQJ#.K/5E) O NK'G.PFYEM@L_',JH0JY2QY,
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MQ45O5>983&$'8=2*8!A*#*2[)Q'BZ"XFW]V(OA(W75WH+0TYW_32N8&_,2;
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MY&#@JN#H4P^P8Q?VI-R-ZJ-\:>Q6Y2\K2^RT"'13W_\P1O-1+\ \L?0%8_/
MK6D0!H@'V-QY7430+ZU_- X<C8,AKL"^/YO^<3_-[GX(%A-]7!YAE/'[(DUC
MW& *SGOLEZ?/=X?.CX,\'7\\>YY]A=U8QP,".(]?C!_[VT8\X%!YO.XN'L =
MW2)ZR% $V_;M<64M3FE=YD&5M"2RBD@'02SO=7#1*S0V!S9'*2XVKJR8+KST
M9<;M,T[-T[3XVGGF[>' HGK+I0ZJ#]\QO'!"VX/WO>?Q@"IQ":N,>: *'M"@
MPGE_&WPX:Y"VBH)OH0EV#CIZOWID(8X'9'H1_B%PO58V/:!NQ7 \ !HFW[((
MW_N8]14)6Y@A, @[O'?03ICWJP2ZIHRCS.Z^9-CW[AF\0WIAD]S1UD&$H43C
M 81<8"UPA37CB+B#H"6PW9!BFU3H)4+B %T^3APX;9,54EV@TJC!MARJ/>FI
M)SPGD=/MS#(<WAWF.\ O%KAM^!YJ:$806?^V7JW,#[%GL!=1NJIJO0J^R EB
MP /F9G#>,*<,":O,0P;81"(.)PE\$'W83Y!R>['H[WF(UEYAS3TB)F0/IT"X
MJW\@N/\+P1\'9TL8'"'@-Q'HG_/WL#*2_F &G?<K'2>"X&5!0!PQ'C!&.BRN
M?7 J&D<!PSY9!9$2C.JI=*L::(N&X&/[7 UT:\<-J%&YURKK4%$-")'1%_ R
M@)H[-_'+^66BIJ7A&FV,J@,>L%"T@3M%,-LV@]'[KY27!XND*S?WX>);PI;0
MEI7RC6L@YBT\P ,T+BGM$T9,;=Q%Z,0*@7L\09BKA_#CQ1,1HS"$R226,A$/
M""N.N@'\C-O \$M7=H,(6 T%PO7N9#RY#FNVE"[_)66*61::UP[DI'@W*&\@
M<5L[[VV*@6RX;A+UA#FR8.S8__/_ _2Y[U7+VQ9RS\7O^(*F,F+1C#=-NGGG
M-/@M=TL&L/Q_UR6,5!)\ G72?S+"_[O@\=^!=O^[O>7_6\9GF@JFV,ZSU&#:
M,!R/8#DU5*S^47:6>=9']T;?^AUK\)J2+P%P4Q7A-BH?8]<QW@1>,C319T>E
M6QU)EP\Z.O(5S_4X-TRT6^17VV\.)]*..S%U0B*N8Y%2!11N)7WG95A+Z%$&
M:T]0&>T-U(-8(V"XVS=1Y7=#EGW)>WHU42>]X]Z,5WYS(A=]&S'#R*^[J4V(
MK+:BSUJF1</F^N2U"U/("J&6I_M%141:DZ$54F*:#Y=.7#>FGU>52K)T%5AX
M$*B+R9UV[!"EPLH/U6DRMYIYK!^T-"J>1;\V4HRQNVUR6#TJN';KW+?9DS=?
M !4-.5I80&XKL+-^'%YVARIE@UC[3$,S^_?9!PZ>;$_51_)F+\A[@V0>7"5Q
M7S/DV7V)XDP\W]!P?J0,0::6L^+)1J?Q=EE_N?)V"\7M:JUB#Z05..;=3+[.
M:5[BN4DZ[ TT["G6HOAKVH.51K_3@SBA98^:A;"R>CE:A4*A;*-..[C$Q:(%
MK1=BI>_W3ZPOF>OE8$W0DRT;7[.:#@Q"L,K%&%<S.5A8^6R,P[WRJ(,Y29_H
MB]+T*CQE(;Q'"1)Z(>.F)V<V(%=V4S'0 Y'/6268$'54?8V=YP&4],[@FG^U
ME$NAR\<@TX@3'SU2Q=;9_27[S+$0C/=]Z>"L&G1Z$$DZ]]U$53IP*^7!^S-%
MU" 9/G\2]_&3 .C]$L)M31=S9C;HQS 9>N45J+G)@(>EO:\&7DDE*NM6EA^Z
MR-IT!Q'%7CM1=4&C<XK(L1E.OU,2B)-Y;Q]^6$3?=)#1"@XE>TMO9RR;LZ7Y
M)<"#B:1A+<6Y"HVX<;C-U<&2V5HT:)VZM7(5F%2 SIIYDX_RQ-'=13>4YRXG
M\[=H NDT')+-:GUK]>3*5X5+@\//W;S\NO3\0//9"(Z)\!GJ,#R !LN4?AGU
M.6O&]['Z2+NQ:H;U-#W$VIZ7QLQ6TU-,?H,VC.5I3CRX*Z:*+,#$Z;"RBZ7]
ME.(+EO@J+MK4J3  -KT"DS6]9F&$(HV&6LQ +)HYN<'!!W/9Z=SO^X>RJVH"
M#=-$[GM-T&5^XKJFVB:L>JI_Z, $I0E&DX8U4&.$C-!F+P>PFK L8]-E_=?B
MP'@GM)!Z+;70%GW34G^MZC/#>_ZJKOVI,IDG?]E%\8=/">-1;G%[N 5JQ;PJ
M3#E[<4+L7>W@(UURD9SJ**^;B*C0H@N6-0 7)S'[T7Q690K.%T2HCM L;79<
M7Y]7BS)L3902[(5H/G!O*+ B;^.M&'U4:"TP=3]><8AF0JSV&>M'[FH%\6N.
M;%Y4VB>7I0V,=\.]D4#*KV M]S,:3K'PT FAT.2[*@[M5?MD^\YQG>?AUV\S
M7K][]TQ!+Y&_ .V37B*,#FE3XH3H8 ZZL@7,Z54QNN?9HMF%H)IX']29L$X)
MU(G%(0% L:XYHPOO6/A"24;8IT6DIT5;)@DQFJY(WA(IW4_:ZGAJV9-9K\DK
M<=)F)(:OFO<U1;OYA%J$(#]WOR1+!RA[C&A%Z>:1#7$+'F -9_GF%=C6(/;N
M ]IR)$J>WQ;R!F%9:*;,(NA^H6<WQ3)6\NZ]US+ 1]+G7N;S^RM\>AGSE$4'
MT"G#F5ND^-L.8AE$A+E,(K*C1936*VQT6//P4$A52C_FG$=5]0.ZTR@BD$1A
MF/8]#?DS&/;V46"X(@.4!5WI+W\7F50VIN4WJ3;R^L7$Q5<<0T<-.0^2R[H_
M40T(V.0*N/9;]!HL3H8Z.DJL<<XO: ^DZ-='*JM8Q6:KZCV_Q/I1=S!=VPY]
MA7KT]3GD IJJ&BGTC51)FR::4F&G;:>@T/,:]JMZ-YUR:-_0E_?+!3&#9P";
M&6$5-0;/=B:9$*A'G?,58-+QMFF-.D':,*'Q;R82-*U]$(/:0[G)(*$M 2<Q
ML?(5&/D._"E;8JO9.<6SB[NN=I<7780K<1R5-,9&1AO170$KCX:VR*F_M2^;
M>7QTRJSP&<N(G*1>K1-WG&:M V>IO![7XBLS*/(*D$Y0:+]."O(^<?G^($2V
M7= =& FD+N/0L1UIN-2[NI'>5R[*K;DXU/,NNEL\)J/ZG37LIF<FU7(8,G$F
MVM]$Q<P$1[?&9;OFYG"]?0T@322/X"^&]F1(350ML.0[XB2\F#7+^HJ+L299
M39!"KD3M^ T+<I>4>,]7"*'J7NLWAE1O_*_<$$I)F08%B\Q4>4NN*>A/ZN ^
MO4@)VA>5(MVD!JU(/??8:2H6:@26P0,;N##F(ZW#(^]M&S@SU'"CAU8YS@SG
M!:![3_=#35R06?(Q$:G6L@Q$*Q(&9-(=VB&[!Y#@5Z(1$C:K)3FQY-[IZ!.U
M[<NQ%UV;#-SUTH/\%50\K\[[,_U2O>U$\C<0[:UL^3, + :%BR[J>(,1U8?W
MER&H%D<FY&O!&$./Y*#6FJ /:H7:<RW.3(UO$]FU\H37 [MUKO(YUQ9B_= ;
MX5B>&8.&VO>5 ^5:P#9]1,ZS(F2*%I/'GA"Y4JF%TR8QW3/YC[W$Y^_X9TH/
MB6-54,Q8H<FUSD<.*<TN=LHWA8>SFT>T8+M:P0KU6GUCJ1:>LAV2 RI($+5:
M_K)TW^*HG9UTW\N21_K](#GDZ<-2*;$9CA1N?\5[0X2DA9IN$<RXK27681 %
M81.E7>)D26^V5^>);!@@456:EV_VY@?+/J0\ZV=H*LB[SI/82PBADZ'\38_-
M2YC#Y*^4++/A <$[6JKJH^,FQHO,3 ,J9T\9C*L;402+S]_S]J>Y-M]0%MS2
M5!,2X;AK6W.G@;LT8'1Z?O:KVD*VPV>N\]>J&VV 9]$?*AF#ID2),?1(4R9.
MDOZUHIZYSTG"V>,F6=H^]O2OK]Q<]M<H&^=&UH)NE1%M??#K5Y2ND1-].C6X
MSC4X-U1^1?/(>+Z]72C<D7MBPHOK9+%?IY!Z)>7Y[;B7,^UMD#8G17$L!.T8
MU4#M%;&L*-@'%8- 1;(GRH-3KV>,T9O?;)JKK)ILA=6, 1,,UT6J8BI!9C:C
M('^LTFL[8\HW3W*DPG.6J>T5TRZ^B!G-:0[R$&+GTC]<]LSCBO6>&IR0CVXR
MYDA(*_#*NC7 QG(1LKUR):66]V4+7VLGB>ZKT1O!,7U>C0NI.J1"Z%K]=(A/
MLYQ(5FF=F!DF;,'^R6&* %D$[6"@JV0E1_.[$I)!15GLG3ZW2<JQ24Q DZ@C
ME"M=+$Y/RL.C(E;S(JBW8_0B_1[-/58.3?7KZ(Q$?[_/"?W]&MB] .:7[0^V
MC(@>/)TM?CSUG$K.V6@T,1@**E:YSXB+?S/9\;!94Z*Z(DJ76)0HBX*J__*@
M!0,1>JH6W0Q],"SJ5D([NCC!C78,<^LA6W]4MM/ 9EG@Y5TR(>#G3D$2D\=!
M)%0U^[Z @"/+0\++X*%]"D'CYES]HL50-0O&P*\J$,XUN4_S#R\]$3)]OP6A
MN(5@RV+FD_E:N^)(LZP(1,V]&RJ7K'AR<JT.9FNC?*DJOG^4YSG9^,VW_KN4
M4?%\E4'0*Q;Y6H4FBP>6Y=B->4T88Z&]<'1 ;?)5L5MDK/RO,JECY370I*W)
M\008ZA7=YD,)6U,4Z1,5353Y8'A"S=G^,<'OQP3&VZ1-*;%5(M)-/+ONINPF
MH[<Y3WQ GVR 9R\_S@B%"L&*.K-RP@*1X2\I%$U=IK4^/YF[)./$WFU^9C-K
M90Q\"F-]J\R>W9?Z1D5%PI299)V^,[?\U#H=(WG E+^G^\=<9:0CE;%FGIE*
MMNWSSOQWTG$YA78C:@H/N: +1ZN]I(%VD[1^7!A@QZACBX*R2<7P#AY JY&+
MR%JYO/3ZF]_GV.JA<%76Q,LJ=(R=9\?;Q=0EMTMGH^SC\( @9PO1UGAT3L_:
MVAI62O2^I:W31TAAS%<*!-U3"D[MBY>Z#5%5+"0+1;\Z'-)!O?RB7E\5P&_U
MG$O^NIZS_A_J.?,RZ*H\</^^C.5XAVCV]Z+.1!L-/[_\6_KY28/DUG[TX> 1
M3'G%!;S/W+\-2R$$R[J!L=_>Y?D<US4"_U;72"[NI_\#[-B[.!8"HP)=PL<)
M\ED\8+N:P(@IZ=M?=\$^'FG" _;ICX^>NT\..F)6<)?L@@()G%UI!>_^R)M'
M],#.P824-V?IX,-FM^/A+@\6?.AP+4R@./#Y-O@)>%.6D .;$Q+T5R(^.U[4
M/[TAA"MWPL9'"D"<T^!]EJX^O^-*FC70=[]N4/^K3X08B WS! ]X0,UAV)'3
ME;LR*I"AA/:H++;M:W-UMKD(<1?X9F;E%AGATFYX<I3U1@(K:TEE*M)W90[(
MX=?W."H-I>I(JS7-AVK/FMY@&K=AXQM\SD-Y?E2HFLM[%UD9'SQL^WE*=8GQ
M%NE5*G[SHT"H'HDYK3:97;)HR(9$)+UV_^2=L-W5TC+QLM*LL4^Q'>X JF8^
MWXAJ5H<SJYE'4>4MZ)!;:,N)W*SQ)0^"\DF"635LN:]<,?EFBS+N8#H#V6)$
M"OM8L,A.%V%$I]<_H#=N8%3=X,SF&.=R$PY3>Q>;OL;/>Q6JIY/4TNB#M-9X
MHE_0%99K*V%R9S)HO,:T,2;287X]SK;3D7J:M>@[.M<2*X<3/*02;?)959]9
M.E8*/T(ZD5!]RJQ@.+'P!/Z00YN Q^CJ^*<Y]/=4!]V^L;?Z"0]/]+:O&[D;
M* -TNBK=[%BDO/8;;MMW9^#(]J<Q91S$&G(-@?G&L&:>-QBP?IA/01XA/U:I
M2=#C?2#1'=8EV)P0$7)7M@1\_,*;K"2@@0QZ?7#5[\($HA!S2ZAV13/\BCVH
MS-N*(99%5/>UI7"(,\43:1Y!'OF1UVTS"D+(^HFTJ31P1^RRHN@P3\*,5IQ9
ME#@/RCD^B.=VV)U4)VWY7M(\KM'+Z2^J2V*S,3$SDU3V#3RHF[@+#9#;:KTB
M:^61YLW?>+G7L:/?)KX66G397-)1+7UD^1S;F,_:/^QW#GJ]$F.&CAI105.0
MWD&=+W>UJ\$5V,5JBR1_47I<:Q&I+_62_0G-@Q-(3QIM$N)E^?Z1E&6<> -J
MKT.;RNOQ]*)&ME>T6EWLQ%C7?F9-F5?2RTM ]YFJ6?JF9\Z#(UE1+P!EO]\N
M_C<^YTI.:G]=T%<$E*.PE;MTA!Q6"AWXGLK"WJ*0D*_'1<)7Y"O(!QXA1\Z.
MU/==!8J <5U^ A_0;7O/RE:^R<UKU"D7V3F/4EZ;T;Y_<EO_ @AVUD&YX"M'
M5UFP$75/3*"%ZE&"Y"2Y%["U1C_<Y[61'5M(\#;EF7XE\JZSW!W=6R]8$ZZ]
MG; X_>79F;.72?(8M]<8B#:-H:SHR@"L+?+HEI"6J,F@)#5S\;MWDY/CWSH>
MO;=Q'0-*+4V/ UV*.T_<8R)_,CA0?Q15IU-*P/L^V6#3E1K&X;BWAKXUZY\^
M?5MHJ*WEYGM&ECSN6Z'>K347RW/[S+K,P:%CO0 + ]%6F!_"[^)[M'=4_X9*
M7//&3(HC2Z>S\ ?RMCME8?0.[U>%TM"/J,#Q#A;R(])(QZ]";7YG4?KA.159
MF1,3-LF*B6_&1#[&KZU/=.A+YUFRBQ5P0_3\Q]A3+YT]LE8!0)O0_+LP3-!,
MXT':!XS%531E6SV6S#7;=-R$75R\5><3](WF-C?7PRC#1.?&VW(C_:-NXF-?
M3%3<96JJU8<L4\\W\0#$QGP>SLY4V/7\P\/<EM9NO4V8"0:M0VE,-I8YP-5W
MNE/2>2:OG!]58-KN$)2'EJD2G?/VJ0B']NP=';WEQ4#0=#YC5?(*65YQ:N@#
ME9+BZNDKM<.:"C>U&#^^I_F(>(\'>.VNL>A0$)V&5)UK&&MC.4X"/^=,5;ZK
M'-PH@YW$I#1/G*X;+#M=KD6L7^.UOA.J PX/]R+NJ<J0,K&RI)!?B[6 )6U9
M+^'.H*.CR@QWM$G&[-[9'-R=?#93W?](E'7=<4U/[[WC:GP-'3WQC7<WWRIS
MO)*O*Q%67!BN [WQBM/VH32Y53:X^O " N)]0HN>QH5,G^0LS>E\B33.%J4!
MY+L!AZ+M0Q8EPZ*B^X99$=8R=W4 L^D!_HHJJ#U",*#UVI@.%PV7,+,#DXQ[
M99@W,"4FTJN<+DMHT391<3-@T5J1,400Q4>)B9LIY 9BW=_B/L(I)-+L.G0;
MT&D$R!!L/?BJ5M'RTU&&7D6LU?.X3L,9JP<:O((K8.U[CW7NT$8-$J'VGF$Y
M9DJ8;/$ >NSE5Q-V!L/I%+9N:U0+VO4>Z=-:UW;)VXGVZ.>-Q_QFZ93(^6_9
M.QICV#VG"DJ8[1_KQ[\U.I\X[0DY;P%S0ILLB=FJ/[HAI'XULIC-ZI&LG\]%
MQ>K^,I$KUP+4)<;(S119^6S3KQCJ\]FRS*4& 9CX\Y?M!G?1WY1YQ55+V[CC
MW=Q/&M(&G%908B!"\;=L!$_P8IY,B7!J 570%U.0D6HM#>Q:CQ1N3.LJYN<7
MY]R73XR1=3&!E-XR?SC*(O<DMLI\HS7C] :6;YIE]:*\Y+2()Y(OH3S_,FH]
M16)/['+R@+94[ 4RXC(RL<G(Z@O17#)3C <'GS^3DQM"BEY%34PP&,Z$\9X)
MS;PG0.P/8 '<R28>U"%M2?9<Q0-F'&F^V.MA*KI:Z>WUDT'!#_HOZMU]J>TP
MO;ZP=O^AQJ6!#@<T;^RF"6DL60^8#<N'=D]_/PTF'\4H&U:A_(?=R23(#-:D
M>\>"RP:Z-<Z2.[.8#1P5#4\;"+&3 DX,[3TBS3G6S%8L92"X'",TQ0(UV(W&
MW.#N%:;7EX;4.%:0N]%O*(QY.:0O2([U_=^2&7^K9$;(:^P9 G;Z##[8AAV1
MV4\6-/J=A'U<$#UZ#,(]+=\8.N#4Q,W7&V'VZ B=M)N';Q)@7/W 7,"OR>U?
M?"B&T50)JJ R"&QC$P^(]$[TQ[%X630E3XZ9Z)161]\:E+Q23ZE_#WX_6B?&
MJN9:YIK%@G<*F/7TG$_J3A'*I[&Z$^7W#%'T%(PT-T'B 4"_'IP@.@F5GN0^
ME5)">_16\]R;0IUGR6Z\\O?5YX*'IUR;BA00XL&8XK[#R7V.\_4H$^1$;9'I
M\O3NPHW!8M&<P8?5_>[YD+,]PI=:!+L?7>* 3(]G!1AXWM9(V)H::;D2?=K$
MZS%)M'9%64T";GBS2R]6:,4GWW,_D=P%V+/%W@WI-EPG)>4)FZF31E_9M48[
M/N/NE4C! X@G[,4^]:H\C+G&FZ#R69<(* [-?8)@[!L=QU+6H=*?3-LX8 7/
MAY28J^0N)8;;,W75)O%>SM;%5EM?++P\,J?XPICS/A2\V;$!F[5;RCCCQVF;
M056><7(_W#-[Q99[N73"3D1RZ/#C$TZ-7*N+G^_>L98_";@'$*H:+)$'%=IZ
M&D-VVB*_!0V*.BK4]?/POB^-?WA/FRM B7-G 43+C>%!)0Q_FFF72J=!C3.7
MOH1,Z@:<?EIX2MTTRDF6/Y/#7ODV:J19@<>\5\*DGKT995>S'^]6*U4>TEVW
M.2WVT<(4VJ3#Q/]&H$R^&=-P+%B69/#J$:I6LV_'[ JT,F:R[60IPJ=04V+W
MN1)7PBB[M]'>M1AUXC<#SQOI;IUTJQ'UEZ=^A2'604$-A)QS['2[DY\F/GZ2
M/+^38U;:*=P]EO3%778&0 $ S)=!U*:D0Z'>GE/U4B!2<TQQO\:##/5@%N-I
MZ>BC!Z467"6P&^L=38@3!)2>]@H/F"*!(=6JYYG;=J,G"+J)2%$=(&0HQEX5
M&R:E"917-.)N#:P&%C^(M;V[?MX*<?M=8QCI5:#LMPX+ C)D^K[-#'R(A<^8
M[F$%?]\F5@N(RI4GF. UCQ \P)\6#T!+^*3?AQK8'&U@HT)P="*BN  I^-X^
MK#T:HUX&/S@]B@=,$M('M@4X\I87,^[I&L$> 018.GU<S$!V"GQ 7P;"'M<1
M?98UOD4^?:A&F&@W$"K&%K9-2_ >\*[C[6,JQS4)5$=P>( H9H0 O<ZX-L*W
M^6U@&")":D.O]C./G LOP8RC(!\\@(=PZ6GX\?:MR)(C'!B=]7L.JS<P>NDG
M"9[D"B'/:CR-!V"2P<=7@%O\B[\V73U_]LL/DW%@IC6[7MK"W<7N4AS"A9/D
MT^O?3E%@:F;G4.QG%Y)1_;*VULO-M7WW+-7.HP]7[JX5SVD6F;=_ E^<7C_-
MV^[1R:47_4J2&<MK?+QM[X?16Z_ J:&7IWV0W@48V,W!]>;3V,/:.S&[$<_%
M5)W$8'*??Q71]K&(L$(JG<,+O.G\29MY8T,$M]1+R.=_+YF^_\[</9S\[TFJ
M9[@!B!5';2>[/8X.QBK8'$2.?ADE<WC Z;9:V,6&K8NEC9ZRV2/8Q0_I9?QA
MX,#?SZ_DO$$%Z)3;!GT&U?B2'W.(,3-3Q9O.-6XZ[THRH<:78T/#$P\4H!7;
M;T=GL#2HB6CW@F5]<\;R_B*'5X/G&WS4ZUY4)N@QN#B.13"??-RW[AV$]LW:
M@V\JF/R%-FZM&;2 R22T:3 PY88^J#BDP,N_6Z)6K2R<8-EQW7%=+ MV+KYO
MP\>PC-$WT?J9;@2=.XIN[I>7&WP]+&PHQ^5)A]Y$JG_7??"Q[D=K_Y7X!C&@
M*0T&1I1?L!(>D$N07W,BCF'A"6SQ%F$.42= N//1KMVBX6O ^O_4M/['3)+*
MX5\W-%.GC-I E@1)<*@9#]6)(P\Y1+4K?0H*DAPLR!C4<Y*>C?4"M%S]2$$D
M.%YSA"7RFW2+7.0V+=ELF0G+L&7T%<]52])'7M\BK'XGA67X7_D .45J# 4>
MT/WJ%6R*!(P\7I7CV9BQ_=UNF7_8[:^N;Q&&Y#[>DLA#0!ZPQ.,:*K^?IV)/
M',.>/SH#<UU"^/%1@"BJ4,NZ.8,,"W)6J-\-0N9=O!<F] S2DZIZ)TH#FC>>
MR3K:#\V<827M_8>B79G\HS1 ?^C//HT@5(4I,6<\X'1P4,8!*APKJ-8T>8(S
MG?K[W(O^.W-OKF!9B#TU* _F#T)6H/)'Z-#;&Z7UJ7;&<V249V*KK$^:S)'*
M V^L;(N&9%#6:>:TY"U-,/<^<I@7SK^PA/:_\5YUN3Y)'?N/>,61^!=VB8 U
MIZ)$C\@.@#B &A[0VO>KX_WN'3&ZQQ(P.Y: G,S.D93!'<U#*P^9,WRW-;#+
M1R[Z!"$R6[@S]L"?;MM</.?,Z])AP59Z29:$1H9KK_B=6[['HMMM=_?=?"@\
MFV0Z#TBS=.^Y.[F.VI$4&%W0+3Y<34JP&6LK*U1PJ-$SWI33^_RH5RX[C 9W
M3;[R;3EBDWIA?RDH*(X=H\3\3"T$K(4*6VD](=$>-F[**8XKV7#;+4I!!(&I
MW58TUHOKA)"'/C8\MI;)F@+QNH#.!^I3 /'D$M?N7^6C]A?RZ?P*%<,XYY5_
M&L58MU120KB"[S.F"EOXOCTT(0XL?S&U>\]G"([1:R"9P0D<4:=G+-+"T/_P
M&']I4?/S&)4I(:]D#7F>S/8P<G')B*L N;BV.P,-9Z&20RTIHI08EU7NK,O!
M_<R-[E1/IV!TS]7R9+/&UW_E&_87?'_."&P@8<$#PD#*"[A4 @Z>MH4A;V'H
M90BF 5)&Y'[A/BXG@KC4(%3FMX=34_ZC:/\H$5<X*K>.+ "&I.Y]!UIJ%D7E
M $GE3ZNJ!1Z'K/#_=%1W?5#[OQ<?@'[VF'N_61+U'^1RCH#NG2-51TJPNP0G
M _OA[;5_>'M4)I8#)="!U3T @O<)_D#@MS )C,Q@F?'VN^B%[&/M*Q_;9%55
M MKXJ;@ K1-QWJ"C3?L/F')?U_MHO7:/X4JZL3&EHHDVALNR=R*9/,^\);T*
M )R9 U644^_CJ@F2*<))[FM9!N_&UB9LO,8#Q/>ZA3^ [M_J#>Y:TZS$W, #
M?FG4YE >OM6)!VS$Z7\GQ@-^4$O ('; +3S E>#'3+#V0O=KN];!\^ZN5K!.
M:NP9,/89>)4P4@0_'M"@]2N#=AV[PP21@O9 >SOP]NBU(F4<;!VVL0*+9&KQ
M3!R'=\M^ ,WFX@%/""*/$3I*!^_/X@%[G:\@<^,@CR-8S1_IX]V+E)WP@%O5
MA.Q30>N?M*#0T<;O^13'1M0))ALMH%9>&$?9)X_Z4L^9\3^[HXQT#+G=_EKV
MHKPH1'X]ZY01Q1Z@EG/UVI,XQ(GJ23GM_<7)-"_6ITYPXPSQ^(VOL*0=6?DM
M<%[_7- 5^]V<;WB VZ.61=@%*:#ROE[=/F@AR\_->Q/F"Y?;VG=*F]L3W5(H
MAL[@?(_K7!#4[R/E%T*_JL<4GAG\V&W'S]&*W[LX6W5K\S!Q/T21$ $4EP@:
M>!L/F#VUJABRF66[G4MH$:&*7=R:Q1WZN;D@KQR+^.+OF^7\\%H]'-75<L9(
MF3Q-62A=#<&H-I^[%[*@D;6T6PJ50<VUC%T?H3.=#'F1*8PT%\E,SV65V>[,
M:PNJQ!ZJX '0,W4/FN7>;B;T+<+CO9,L!WJ.PN>"0&$P.S!"=#UV/_\(N=_W
MO4'=HX QG"]!4QI. N]5X $9-O"-)Z:F5:#Y8[%O[V]%S^;\(G?>+;W#EJVL
M'NT-ZL]9AR=_[4FQZ;C>1A]L\D24*7!+DS"4L_L=F[=_&4FL]^_Z\OVMKU/-
MA%_3Q[\N_D:$^(V(LQH5MGZZ#CA-LZ7Z=)GIZ:E[9*VN!EI'KPC1%40+FWQ0
M-1GD=[;?G?J,??_XDH<G78>O7=YF8^$=EGG>$VJ *;]K-=J8ZVZB!\2&L"DY
M6)!O,>O]AJ(;GTT\S":3]A/$O'-'["<8-GJP_3A#PHS7_Z/AZ#5R\#XF''?(
MJ(:CY2#'^0\#,53'51*XY9B/B I!* Y0<V4%L*YA#F<M*F6-?4&P;4'8)G\>
ME'JH,!/]%,$W?AK^T,_X*ND$^/'>3_Y]OXN04^,!%'8-PLGL"*HE3UW?^+&'
M%:$M5Q)3:<V__NS!P+YQ;\%W3(O6\8 B1&=5F.%D25?ZY?J$GMUM.>!?HH_T
M/T&ZGX!G/=RU>S]E^C_F5YG_<WZU^)_XU7^.4$9_1B@V?\[?_J?M,+=Y_!T\
MZ?,SL/_36(\CJ^C?B*R3?X+U/W/Y#P#V/U0" @*5??^?;HD/?>IE-X,=4W:<
M/TD78D7EG@HJI(GF1JP:DH-)EC90J.CIO7Q2KL"HS#Z-S>UJ9Z_HLN]D(TN8
M,(S)KO?1<WFE:?:D<C"'W<&;N"Q;$*TD-9VAE]'VQWMBGQ)O*]0W57<DZU:N
MC\IP/3;X=M.I'%DSN7;2*X/2'4&_^-CWS2O)]@;<651;5K?:;M"G\:,7'V+V
M##Y'(:.(N&4T?4[+(>)PK'X(("WV<C:49DC^;NZ*\<93!WFP:]Z$UXW)6V'D
MWZ@6S<?+X]$/M:5LB%S6"UM.J,@_"=OPXX "T)^3#F_U(.W3N#5A3R<H1R2U
MV;T>XQZ>'[;O6HRY5ZY+B%F;6EY3$3&I9YW-J_/\AGC-H:QU[_H?)%Y%YZ9*
M&N4\+ZPQ*6AZQ/Q(5LC=*49&IH.__ [\Z.V.>@./UUY+,BSXU:"!9EU_6=K)
MAJ&YM&N;\]YK\UMDI%UA@B)SXXV76[7];YT$>$UVE(1,LH2$NL%HO69:$N"T
MN2G-.!Y4OS&&1SO!4&2N-HS6H;]#</Q)6$U9AMM)T^G:%=&ORUO-<'JXY9HG
MCG:A&GWJV<-1ZV?N+SUO<JF["4+ZC#:OJ5H].'6)]25]7-@N'A",$T+G3#Z3
M%"%MVTTF*6T"5(?KHH[0,<3,H[V:%/[J$43Z%$3Z)$?]EYRQ=]','>9 #!P9
M33YFFPX<=)#LRC>[>S'7I!:BR'C*)XDT_AU$E(VH=M[V#O&@/S4-AF\J@]%+
M;3?N#FH]>J9>O"51+J$V#U.%:6#W>)>L\;*\KD*<>^YK]A>GPB_15]ZI^&:3
M,L[X46)P[B7LT%L#Y6M4CF2+$Q1EI77,R2_"^*J"+:M%Q;GCYDH.9$?)QM5X
M*9X8U<#6&/-*_!VQ]PL7!5\MU3@^2[Q97U'[HG!WETY"@[$EX-17TM%SGA%'
M??4NZIG4'FTLF6?#C $W=<..CS-6%;3))&ECR7GM3Y?PXWGRK]>\F=?8W]AM
M+DV0#KNEG5\QUJ;&O.VZ6U_V7IFOX^LU+8;HLQ9)K-"I,8-8HD:9ML<[YU@S
MJ2,E2P!>X1TP#F[TMXP0=Z\R=@2+E]])DRY9D7FF86._-W%F8I>H8ICKKU,T
MG@UX3*.M@"QYVL!?@\I69,IH\3M'<#1F==+(0_)ZL7W^R^S9:.+RW:$7S[6_
M[KZ_W]Z8[732]VO9;0@#$9H9RPVB<4MS;4H7&9+G*U@QSFCI&DL[T2[#):8!
MLX?DV+'4W<J%#)8:J:5N]NTN&:9+8,C0("0>T *FM<VWD3?@CZBCS5MB*S.F
MS X&KSF5?FMSO3CMR<II7U4)J*M3SGA!W2!UQBRSES3$#_'8?2<W7-Y")"WQ
M6=G&R4[[-R)!\# VV)6UMW&^13'6YZ_6:I6^!PFZN]1W[IW5.25H\WNQRF_M
MAO:)8C50P&FJ^.PQ3>_\B46#BMUW5U-F8_6# H+,%WCO&41 +3',,ZY3:]:M
M3A@$& V*Y.SO4"7@HP\0B_<)_?UFMSZ;-*=K=QO%TF@R[=]E)XX#WXF)"3L3
M>!7([975-'&AM\ZLP':4(S=\LM4#Q],/0K(TF*3DE^65N1W*5AME6UW.2%QK
M5I(R2YH9P[)TH=4"%"\1TG"A&0B_5IS9,WD@W1*;R*=Q3=Z:GOCV5XP]K8O*
M(<F&93N:EK);\@-2PQ3VJVNO$VTRJ:.@'*C#-AP7VO/IJN0I]/6&,XYTD]HN
MI&/;BPF3A^<\\K>LI$\0NW^DHSWL&5,=-SCY&BJ!2;++,JWMP^H10H'"9&"9
MF8AC?#%EDSV8YJ9UE"IEBV_D*X=*X1P$;P/L:D685!@ LW"W3][]_ </MUI1
MMHYIQ!J07NJ#NW < <XC<B7KI]Z9N&B_T'B^A-,)]0XOU?JRO[4,(ZIC+/;B
M-Z^(6ER)MO9&4EZP7QC:.%]-^?;42U/@Q.6OYTYZOIURJJ,PJ($PI*@ H'J@
MIW7F.+YHK:B!MKT@/T&-PHOASJ^#^OPZCO(&V!-KON3:M1J[MX:(7: LI!(2
M&VN!T\R@U.*F[:E#I1\_0_5@_8"X[O29[A!#N;05H5LZ<X:M#C<D]D-5H^0>
MD:ZG94D0M%3MJN9@GP/S[0NC_I41IJ4SI\P"O0DYJ;TDC('HEQ.<!0LOU0L.
MZI!V<@)J4<%!2'9J4DQ)TY[Q7FL.6C9VO=NV6_2B8R0ZWITO=<J;6R'.N\%J
M*/*ZK^JGK33MUN.U$UJYF,E;@QL;C]S)Z_G;$D8_!\V9WJ1C#$ Z-"OONFOZ
M72=BN8&SB:GBQ<)]5UFS[F521]2IS5 SV-14E+SYUE-DFZR%B$@^7?S:XWV%
MILTV._/U6.2YV*M%5]3I[6+7<S0!5;(P*H+'[C)&)3ZUQ@1-B[+8R/6AAE*6
MGML^MO=.#LZ6),][0Z=JH>B0;JI_KWWLJH89YMN+PQ K-;W]OG<^.#>BK<2U
MRV^7NZ93*"_B ?K#6(6IL1)J.VW*^2>TL?:1X,N%-#*GQ^!N_6*J3KP.@6E5
M)8*50W46!%L-.3#+W0TB?*\B4UJ&-[U1/=:T_C;JEF&:H:\]*SF=#N<,O4/?
MI[TJ6!?+//C1%\KJ _K*=$+FJ$.)=[&7AS9&S2VI#L2X]W*/N=+*P"2.5\>X
MYENMF.H9>B8>)Z2!LU"?-IJG@QK]B6' <0=Y-IUOV&ULA2SP,VJ4+V?DZ[AQ
MX0E>;2D68WYQYD0GQ.0YO[XO!(@H)T6TLM]+VL1FT H/S6J&6U0.NINLB4B*
MG%TQYY/^<)1T+Y;]B8":/5AQ:-2KJ/6C!4S0DD0LF,\O^RAY1\'3 &-Y]F!M
M-3F.?*6LM#;IX19?&?VEIPFQ,J,W13_Q?JD=NEO]63M_E1,/2!-@R21F>) 0
M]D=OS>-Q,/!_\.JNWYU:=^?OO<^\K"KPNHKZSO&7/X7N\8''QA@0H6O/4/CJ
M.6L\X/5"\9MJQT \8)/?*QS7S 0[N/AXV7[]TN3Z8#U(W\\H$@_P:X6%XP&0
M4%T5QEX7SG"4$$Y-%KY" +G;?"6^;5[,_V*)U[4'$;?[S)<VFX^_KY*%7=94
M 9P7:!-A +S,8BC3.?'/+Q\7'R)F"9#A&6[P066LSG'L[>I'3L>)C(1@^8OM
MV8+3+"]]8WKM:&E;M,[Z(D*"W-F9:MS]RH=&Q&M@D%S($0,U0_2A+2&?;+?-
M1Y4>Z-R *J.5 4[J"5^V" .ROT7(UBZWK17 $+E[)5LR1(=<-KT<5I\'C!,&
MKM9$ZVM2"HH$7DS91=NL6SS KE:5B^<ULN?PO-Z2QHH%97[@@^KY,KU-MHJG
M8,O6X4I6N/9I<WEKK8,W6*S'6] +<=(HV._1%3CF+EOT$0.0@0"%NQQQXC=A
M02-]-070Z^BK5DBEA!%^/("KKPLX3PTQP?F"&D#SEACJJ;2%D 8!,\R6V8BP
MN]DCR.6R<C-QU6CMB"QY;=[8M/7-CSTG[B4T1S92N9I)9:#6KVB'LXU$\3<<
MFN[5J+R)@=CU7CB*DLE)-SK3F5J9W/^**TH^?B5=C _C[$R1;H)51U\ [1G;
MZ\"VM=05F2>2*"RF^</(G\0V0(JO$C(9"9>._:"UE6.9=& _L<%7]Y ;#%ZY
M'<F)H9Q:)EIH2$6\HW-.L!>):EN.UQ<-]F!96Z4.EB]R ?9A:-@JPM9ZBIK.
M"W1-+F@M-Q*J9.^<AW#W%7[3/F0NR ?IKXWU:/QT>B[Y+FG0QVUU'+-Y5ZUU
MJS:#U$#@,\@MZJ/];!!%\1!Y1N@$_VFJ_G9[4^(!X++-7/06:641'J"8,0G<
M4F!4Y_RV-!92Y-T%%:U74W$,31>@("3=K! 7OXSJ?!#RCAUH6P=*"(4P$3BF
MY^Q[W+W=(?C"P.$,SOK5CYU4"W#46TG@@8"B(&&X"9-8J^B?)DE-&/92H=QQ
M?QNW\V\2U1\38?" I$63[WN]O#>P%R+5<&'48;"-N4H\@#4+QZA*L%,5TC;0
MWN88'A#QA\E_S*244WA$?],7J%GY(?9@X78LW^BCXD])#V<WQZZR'A#UEPQ;
M/X 4E+'_V$CFQX^2G PM/^=)&K93STIBEV$U,$'+J0221K"?33W8923$\S-9
MA#SB=>!TQN'^L1G8#1JX)M^URY?(KZ@WV$\/^K$!CI"0-><-PA8S,;DXG D,
MG?RS%!6/#85SM!)[ (/"NK=%ON]>K]O[>2P#)DBS PO/5A #12I%%Z3S%VT*
M'!O& S*T-Z+WTY_]Z# U(YCY[2%UJS9]\$>6+8@K0GO?8M46B(R<O1Z""9]V
MYSKA*I+7N(0'R/\T^<#O>[%+Y!R#*C]]RIT&AA&#OITR,<W !JK[,4\$>1 R
MRV?3D?E[T2GV'2-[QYV'_&K>"NP_:.6!9]SI\0#)W[CN_WGTLA;8YA\Z,_+W
M1?1=T7;^.XKV)YT9PPK!580G:>INOY7E[81TX)1R87_BL.5?:G7RY)F-@0WH
M-?15Q-G.X\D_EB7YF/[WN0#//S[_?1.CN0?\S ZI3A>:O$V8^AIO!1XP(['Q
M7]K#[]G\@C'P,\TC ):TQA-J29 8/."Y[>1//$01%.>2S^/)K:4C-!X@WONC
M@,'6Y,\=_&PE":!NSHE_I6Y]?U+OG[2%W EA;#RUZL<*-IIH<IJ00XM\:N.N
M#K 5^:1.]'FXE6MJ6X:[]GUCOJU(4M\MUV0H>NX0?I6?@2#/"/%)QH4-5(F.
MIQ4G"'TM0&.4MZ*1D,GJ7=-8;]-W#:H^U[,%SE^\\D,2"]@+:<K S7\H@^A/
MXWE+X(OESV) 8.X>!RG17\6@^4\'1/W+E$7_F\KX-S1X^2>B^SYV_VNFJA_6
MG/]?*_#Z/U?@.!SCK;_PE9P_]-?GST(C> '=/#R@3PFM?83]KM'?8]JOCH#<
M:2?;BO3L7HGBGV\,0=[*!,UG8@J^\QE&X+/IUUB(Z$!$=. N_A[XL2>OXX3
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M&J>^"_X)YKN:^Z)J6[;,,7IF,9)IJKU\.V]?3MGL-EB\F)TC^]C!LB-YO*!
MR!D/4#HRP!T2DH#0DK*6VSD[=N Z$X_C4Z$3Q%DCO$8WEDNF<38P8>CG0 D#
M0G)QNJCCB'0'?+@NBN..QJ@4@Q;O#<$V\N"8L,5?-?DL_'>:;%T*)9=!OYC<
M6<0##NA&X 27L EOVB V6S872.9%6]4^G+3TV!*9H.F8-Y<-19OW_,GP[3=*
M;93NT]UN*,D"G9\65N4VW)?5L?WJ'NVH]W?=68DCP9]!$16_BR'?48/"GUW%
MGV-R\W\/:?XW0:/C;Z#QWW.$OX-C_^EX\A^"WO\!@:@XT4"%!\^ER[)W3/"_
MX D6V#2!.)R=FN8,R6%(-NOAT2^82 %+XJRA1Z2#,+E]TEUN3,YK(\R5]H/S
MKZ9-1#'JL^CAAHH:]V^+TA<5>V]<R)*:EI$!&(S,6E6;P)Y.G"X;'C *;!HE
MD:NY^8@)IW#Q9)61!F_5\_-37WD79&<'.=2>^'V&EP<MM&O30H7ZC?$ U=K:
MX3I*SQ), #G <Q2LII!]P]]1T7C>Q/]NJ4M@NBR:>DQ\.C=,$A1=*9<;N#U)
M;_<<RU56#M=];:BID%KS-$Y-8=S@-O_I@'8QN+2WR1NAC33Z1D56U-#,MR5.
MSOZRVEPQYO1/[0)F$4$WGY;F\3M?YQ^Q6\@LV!VE2GDH&M2080]HB'E32]M8
ML/N,]=J'SB=;[P$G;FD =$@7YM.0&C ;[=&!:>HP-R#9HJ(D:B01&;Y84E[T
M8+EO=6UA8.:%9)TSMO@&ME5*5N=*<@L*&&9==52RXWOCL$WZ\:.D?*_$-N.;
M6^??K+Q5<J0,ESMZ\ZTS3$C]C#KJ(\/S,7( R\*VM3+J33CRJ7O?=CBEH!E/
M9$+[UW,4H5*OTS(?"DQ1M>3HQS6:LR4:U0]-MHSJ+5?VLIL4S+\/13B3L5SN
M//^M.]NY+/;R56 &C,R/5Q-Y1#[-'ZY(G@8VZ]\H<G#38K]V>+.F/5=^VEH#
MJ^()2?"J/.'T4N]\VT>SYBK8*:^1YAB_3SI*,R9X *-=S30&83:P;<9S!^Y[
MR=ZS%-2I,!9[*>$P0>U!DT4<5X"3T/9"2P855FAJ):E8 DAI<\#7NLB38";5
M+.09H_117R S)MW)KB$+]:$IN:U.?P]'VUMR+TS#*DHH4HR,D5/U&P] Q]_4
MWW"']^&\OR(I)NR Y'%N,S5I]+-$-CR@+:1OV]J126N:GBHQV[A)+&E]ND4@
MV3ZU3LG$1SV;WE_V"&@>_[$3Y=JHI^4HG$Z&FNEZE/>\UE9J[C79WHFTU).-
M[7(>Q7"6?UZ)X'LU J:C-Y)>V]28NP?Q@VNVN6->HXW?3)F$SNJ625\.Y'$C
MK^]]B(Y5*!BU>U.4;;@RZK;+%I_6\.J^4[!LT:/71@_BM>]:WE/B;-4A;?43
M&^(=@=D9#+FE71]?W,1T-"<_]/082.(ZO&[\Z-V66E/3A?-/DF"CIH>NVGD3
M4 V,C^C3'8B^R(T%/51T\'05FJ-6@V.S;(+;Q^-9ZHV6/2_$U;'PA[M KZ7T
MTZCU\/NV%KF+<I9!\=EX@&U%1<6'*)FIQ(P)[K?^15O2W;*S!P,.4#)D_25U
M82PH9Y3,Q&>?2??\[A9%M8RY]DL"5J[?<B=(6+0!4^ \31TZ258'F=9<<EL1
M)3+]MEBSO!_$@QO0XL9!-)U(*=]#()]F4[TGRCN\HMO,15'1S1EA'K@+_3MI
M9[1#TRD&=W92])X+.]O3%L9JD+";Q@,?QM*0?G*V:CVA:;'-MM)T0+DMIN+Z
M>FF/5E-\7$[3EEWHT[+N>("LU>T[E;?)2,-2#% 3<=.G+4+N# CO"&0)W[Y2
MZQ9_I_3% V+BB *Q#"N>5YG4(AB^F4A/(W1N>)UX@?VH=5C1=KB"U"XE6+-B
MD]F]_[/Y*9WU:MTS<L^_CHG-NO%_%9*^AAJ.0?H8B91!+G9I5,0JB[=8/'J>
M)0M@.G>5))7J,4KHQF_5$N1K=U\G$8*6-3ATLS"2_GR@1]-06'RK=6I4AG$/
MNJ.#7 MX!^.13%62#;9-S@V-TQA:)^FZ,-:\*WW[U7C14ZL$ED'ZU%E_,97'
M$Z]R1Y>'Q;^:CRE[6SL%"Q8M1,B[G&.Y\$F)A':0;4&D@=Z+&W&S=J (RY&I
ME#LA)MF3_=B4G&&.2J>&I(51/B+JB@YI5Z]?/Y@&:^N8UQ"9OYCLQ@8+@:I-
M\U5KGJIB!G\]:.O)J5/>RR3Q>G"MFXQW\Q(U,U8-;6^&7G@F\:9F1**>JGVD
MXS%G$G6P96AXU\LD2/'U%0%H[+SJO5JIE\]GYQMRRE%^@9:T49,J YD1C;NU
MW&61:K&K1C.-0.>7L0:O>&/%;\)(O#S,C#ETMSDN[\C0<H?M%,Z(JX:ZA)54
M.IVYRD7<80? %+1,EJF%-]!B:?IW**_H]F,)"(?A38XO9R*$B&XIUEB+P;D.
M,4^W=#AL),:\H!1PROFK#1BHR 7NEI>%Y2^-2E2:<Y?V\XSLD/MX)(P*KCXJ
MOH6Y7Q5[:15U/2;!Z?3+AW2G-O+*$,085Y7D30A(:4"8KUZ)L3NAPEEU('-*
M*%ZW"J!-RI,<-HF<#()(D)4)R$MFM;R^.:WA]F65V\26A4990LDC+MY<?55!
M@'A.@7J&LS['K_=YK5VR5<YK>S:_H/MO,17#4O8DSNX%:G1J3'A 3#&G9'BW
ML*X)L6BU_6K;K/Y5E$> "&7)[L6T70L*_7E@J=J[-MKSO&,1D&L:NGT:,XS%
MIP2(;'Y?D[QH ,VP?$V<X&D-X SR!ME8*DSD5!N:,W.">Z3]5:%-37:BPR,1
M88UZ'X1(URE.I7<O+E)W[8:J.0E-X#B@7O6.I#;#E;1CX^;*18OFG%;)R&0C
M_16MTFIO$_G$GA;T^$6-V9$2+51*TQYM<ZR7ZRWWX,_K343^T(J]ZY+=RD=)
MI[NH=FZ)!G 2![9*U:SZ,0[HZ5?0G'Z4<%:,A897^,JCZW>O?AEG@'R6R:2.
MJQ-'@]L2:IJ-E^6R#XJ?II.B=@Z^*HR_O_&H6/(K9,)"+.UK,T#5Z>[=QTP(
MGVG'4=*V@2]VW/.3-P)5AR6UZ3#F'8=2T\J^MB)/I5<3;TM?93&2NG/OE=OL
M[,S$+.;*5+[UAZ0ZR5Q6B,C)IZ*S4SE52=:&]8,WPJ8X(\3DDA>P](>R7D)-
ME<9M&[M:#3EO[2H?QP_U' U>_=B\ZYGP<!L00IL 8+JCHY%)S1ZX^QJM'SEM
MK\4YUE+)5A&3C7B]9%#*E]9=.BXY5%[0"1IUGFW76[MP39:O69HKGK0&LX/N
M:(6?P9KE*MOF&BDC;5:U=K.*S#HD6YW>O2A)%/ 7'WO3]H#_X4.1372 ??]%
M10HO[I76!#EL \L V."#H3Y['#5/Y^UWL7+BJF2GN\G,6^],B&*TD=0<R_K)
MP7#D(<?MS2'YO/FJ:&&+"6"7 VV]M  D,AY!$"OG",Q6F\YHN8$'-1<2XL"/
M5O5WMRWAJJK?O,?4FPVYS^7!<FKJFTG$90#D)?'F\,G<->)I7ZN%YH%.F"U$
M,:W$M*5HR5J[NK3&WCE;RY/AMI+TY8]-9XM9X\->4>Z]\+D5AP)K$(2_8C("
MC:8U]7K_X$--\'(?B:8%74V;@T':E'<ID\5>.-4I0$$"D 1*_<9V5\H#QUZJ
M+EPNL.,#+1#G&[=_?WY"X\$GN$ G2)2#P'&26\:87@=S^JD4,T6:0'=<=*[=
MJ.?H5/6' *8:>%DYC7@-#GNREHHO J)H0N%"MAU- ;5%H]!!.5&UD$R--VHS
M9/+G7'8YG1(,#EFK-9]2-A-MGE-.Q;9*7_45:YD"MO1<%NT?:6:[(PCM2WIQ
M]=)UUV<S=TG7N3^1/&$^PT(<MJCV1(+(Q1K76;X5E754 K<&.6QBX:"CHXR+
MO@+$+2 ""A_5-,)HY]NM(#%N:UIN'&*3MP>%C2?F;9V%8R\\XXWP]OBD?_["
M)IUAP(DIJ])5G"A6J1Q3P/_485W"9WZXSCK?=G=@DLSYOC7$@K%3JV#O9>"3
MCZR\"RR,ZXHB&,FI#(YE2)Y78(NQ7Y$;BMS(?%ZDV?#)@WSN!2J&#XSC5/T:
M+))6(TCPT]4Z _YGF;T.,R/9&6LB?OF' Z(QL\R?_=#AI[5O WH T#7?0T-,
MK3J*PD^JJG^;/$W(H+>\WD)K(+/.L<PXA<7<IM]C]I+[M>([U"*A0&GCD X@
MD^*Y":]<-52X9K;*]!51&B^_-=&RSC<F@I"2V*.;8L6>T@D0H]#/9UD0GS2(
MO]:9'4IA@*WI'.CT#.NLT47/!H&!XNV5^AN?:!>X38GG7Y#.F75[7@*<XF+J
M<?1RG!H)P K94K"!0X1%;K-_W"&Q#!>^R*-\UN5AK$O>C1(9W48">HVP@Y5M
MA&(YL@I61O53)+?1*W):+TMCKR8F?TM;B#E9&CPKTGS)2?;>;:7/1* ;M@2D
M<4@)'Y//\IPK29M=L,)"QUP_BZ=:ESNE\V)$LS%QK>E,=<_;3L6]LAOP>N)6
MM=;./_A2HP*9_5E)3SC27_8!F0R+8O I4@9 V?]XW^-)!EW#-*7C(S9NP+U\
M;;]O?@3X;(3!9W4QEGC @_@27'1UL56-XT\EXJ$X"]P."-Q[,)Z(4]EN^#^V
M H36_Y(*$$1!> #92,B'Z+4""CQ@I!D6"42E8GQP@?I #%W&#)@+-"$QNF'X
M\""#;6NI9-^C86L5B+D%)23P2@746#)M=!:./H,:UFO7@@><T,/:SRP+'MWU
M9-X]TM[?_=?W"AR\70>.[8 61@\1[V!(6=3>T:E"$(H/U![]!\*2Z+RLY8(J
MF./@<279#46".)\NM$QNL[W# QI??%\3]SO:!L77T6^+D4=P/9QO2=TAZ1]Z
MM?F9%',0IOBV-N2_Y+CD[W-<]P>.%7Y_;_GJQKU!D9FJBGC^ *47L5(4A0JA
M^1_:7$!DL-DTFXR=#CS 2G*$*KZ)SZIOI\QZ3;#=\>W-[D&H=O:2] GR;ZK#
MPY!7==5O[CIPAI <LA&@*1DB!+XH>1\/>"*(DT2"RIBQT?D$#=&%+6J;VYH]
M;\E7N9(A_>RS];6R_#Q^Z_&_(07XV^(%Z?\/3=S_Y?@_SK$ZU#9S_&:,2L%7
M#9YW=U6J;ANF^U,,?Y1E1(\$X@&S#GWPE4W@$87!EZP<EZ'<U5$#A7$XN["#
MI:#J\ EG0^L.14Z2P"+#$U2G#Z_!(B$*4#UO/ !8"=P9(OA,GEOQHK:^-[>$
MH>\N4%VN1Y2 _G+(Q1D$=8W\_XO@_R<<U_U-CH^/[52>B:8^2TV(!0LX/WI"
MRP>ZP[]C&F,]?517"6*"0H1UY=]K%(/E:@0O-([+DG!.5P/?C>,!B#KX7E-)
M7]NBH'&#*E3\EHO+;@F89YO-G/>![4 $$YN<Z#QLUL_9-W@!YTL(7PV4P/O5
M!$Z\81N!X"RW.[ "!CQ@8>40/I4,:]5L)<0V"1B*'Z>VP/_E$6QA GPXU;?+
MGK&_EXC#2!Y(JP"7VT#[![C_9^]_*/YG$-07AAQC?&#^3_DY\^'&>FTSMV[_
M9;.W?D?VEZPII8O_1BS_SV ??_<_ XO](]5']2^D['\ =2H_G2\B\$_X1\ZJ
M<I,ZD:WN@2?#A.\(\2]\4O@^YMKE%_5:O[5_S'[M\#*N3+EY9?AJK;[-X9_^
M,S156^B+?HSPL<G048G=O^?W+WFIMY!-)/93:Z>Z%M>O%*E__OOW])]S[W^4
M,*S_PB[_AQ-8ZW]<!S+1;+[SS_";(8'_E@0"W?K^7?PS>6(4Z?_HD=C_B[G_
M'\M_AA,?_DH]4_V1^7#&+1<AW7,+(LV+C#XF*]^;^:UC__-%]?>=]I[X^_F+
M2/O:T#K.Q6$UYW;?U)WN,KW(X)Y^TH</!1$>>U/^J5_=?OO,A_=;@$T36^%_
MOT1J%^G_?#'_^X7UA8N :2(0F"[/?_^N_]GJ/\,CH\?V+_@@H75XWT7Q/U_\
M?[\(A-MTK,O^2I3]Y[]_3_\Y_$]9S_A?PV-@W63_R<;ZK6#]>1?0;;;R&=W_
MJM3_?M&^D['XK^MB8#S<O[/_C#VRP=P/]9:GYS_D%]#97G#L;'V&TYX&(9;B
ME/XSX;Y_-P,K._MM_QF^?ZT_MFI[Z)_ZI69[=\7H^LW5N/QMO6ONGMOOG]6L
MK1<V--6^LOIKQN]S_QF$WTS/5WK^[6S[GW^@X\BO@K+DMAS[Y]_N__NW_L=5
M*^WXKTGS__P%G7K._Z,S8C[H8&M0L'[9WS1/^=*:/=$FDU^%352_*9-7.87G
M77S5=WMH;MH-R4T3_+WRE];R<>OV"74M65K\Y+.>UNK^(U:?EDR]]*JV$;6.
M-JD_5/SP_2_>B/H'7O6]-;6NY<!VDLW\M[_F?WY;^_R&/7*KR_V/NIW<?X8%
M5]O_L2S_<?WXE<"OH7?LM[^J/[_U^_R$_PS()J$VU^0#W:^&%_R[OQ)TNO*]
MVF8";I /C3W\NV[YG]_QE=_X42R]B-;"^/A5I#:TG'^(.M?S<2V3>TALVM&Y
M':&!!3-5OLAFK)]4DO^3)Z+^^IGX7U(7(T\U]0=OYY]];E/N0>7_-P%02P,$
M%     @ *5L*5;@2 WY+!P  _@<  !L   !G;6%B+3(P,C(P-C,P>&5X.3ED
M,3 P."YJ<&>=D6L\%&@;QI\YCYEQ&,8T,[T1E>30[H@B%&$<*P9E%4GDK(:5
MHL1(.2LR<HZ<">68>BUAG.(E,E'6.(ZQL:QJ4C$[>D_[X?VP^U[/?7UY[OM^
M?M?_]PA?"[E RH)F3@,0*  0T0'"-\ (P*#0S1()+BH$&H& PQ$8% J)QF%P
M."P&BQ67D)82E\!+8+%21"F\#$%65A8GN85$))"D";*$S4<@,-$.'"&&0(@1
MQ+'BA+\L80O H\$A<!4&4010/ 2&APC;@;PH)P+R3>!?@D!%&9$HM!@&*QJH
MDP)0" P&A<,V4XNZUT1] ,<CI!6HAD@9F[,H109!(^).'GK'D4>MLO3!Y9W[
M7 .88ACB%A*9LDMIM_(>%4VM_0>T=0X:&9O03,W,+6SM[$^<=/C!\9R;^WD/
M3R_OP!^#+@5?OA(2>2/JYJWHF-CDE+NIK+1[Z1GY#PH*BXI+2LL>U]36U3<T
M/FEZWM;>P>[LZNYY.33\:H3S>G1L<FIZ9G:.-\]?6/EM]?V'CX)/:Y\WN2
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M#<A3CY]I><_U+G*P&^FA,;-=LX9DA\^P*!1)_[?0 >3>].5>2Q_LY;IRSZ!
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M:09C326$D&U&(4LS99EB9JZ^]_[N_>?^<7_W]3[GKW/>[\=YGO?CO7 _<V<
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MC%>%S.C'Z5W;T251-@SC5-I[7J<# ^N1]LVD+,?\ \J36I4@WA8L1U"@,L!
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MG#PZOU*2K&%[/4/ZQ<JI7O[,LW[/=34P$8S#=O./[6)XV56<(_Z<P\RD._3
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M:=R()_T-7Y37"]E1&#5V%%4P]!M02P,$%     @ *5L*59 @BUN!!P  +0@
M !L   !G;6%B+3(P,C(P-C,P>&5X.3ED,3 Q,2YJ<&>=E'<TW&L:QW_335&&
M&3WN*A-<&2)$BRX([F"4$"V+-"T$4:\2-DI&2/00!$&0B-ZOJPPBH@01+61F
M8B01CD&4RYH[[MER=L_^L;O?]WG^>LKY?LY[SL.>87\$^,Q-S$P $!@ 0)P'
ML.<!(P "!A\'1U!.P+A@,"@4AD(@X%P8% :#1J'1W#S\?-P\6!XTFD^0#RN
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M#0&' !@4NAU\P?F!0",0<#@"@T(AT5@,%BN($104$A;!"0GCA04%<20<7I1
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M4:L^I':_(U2CU>1KFK'IVJFJH3S:Z<H'/3:W?^B,Z&J\VFSP>I@4E3T_]"G
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M+Q>FE=2HISU">GIL!?"5+\9]NIH14]S_.'#__H+ =4KX$X.2N#4/-NVP_JG
M)\X^&:R?V]G&)6,#_,3#OFO[8N]_)D6G^UH##5Y]9E3WWL4T9B=GI:-L@&I
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M?S7AW1_2R7MF(QRKA)6&*G[SGW?WO+HLP$XF>\-'MP*<]C7*\G97)-SU(71
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M(/UQ16D+\R;P9G*W]7J<TX:ETX\&,[6Q;]:DQI$*X<MYKI*<'CT\H ;.!IB
M.P_@F/G#/.CP6K K17*DN?+*7'9P77^@:;W+PZ@_\-\G JL^O.Z3LJBU'2#M
MYO[<*M3UR6Q<P/6H6XJ;K#=$[?-*>>V6;=$!-C/PRT@?83OYT4*UWJ"/&+S/
M7)S=;+S4K/:][<MD+2,J1_O6N&9+^%4ZH)WZKK&/"55E[-YNL0U%65AWBN$I
MVT^8=J*&_IA=TVZAYC\^[!LZL2*;SV0V:4\::XBF9L<=?DO^/F[Y)+2N?]#
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MS#).4M6-%2L;!,>*Y?Z[V>@?_@Y02P,$%     @ *5L*5=+-R09]#0  3@X
M !L   !G;6%B+3(P,C(P-C,P>&5X.3ED,3 Q."YJ<&>=EF=4D]NVAK\0>@LE
M=$)'V2)12A $0['01(H@$A"V%$$BO44,O1H%#-*[% 5%FA0I@A0)B")5$!!"
M!RDF(#'!  ?W./N6<<X=X][[KCG'^C'G6N-]UOHS#R<.B0"/\26C2P"( 0!
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M*<;*DCL)G*H_I9A@Z%5(7#Y01PV<PP1,8)N\IFGC&1:$:C-EL#_3:G$$0Q(
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M5F0_3&C^N%Q>:NHFF'5'[.<+:;RN"JQ4O_Q<R/A@7;=3=Y01N$8->*2;/DB
M.K.)QIA?P8 92HK^U</_E(=?_@%02P,$%     @ *5L*5<>8^HT,"P  S@L
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MKWCV">V<O^=4_Q#G]Z.$OFV7B+,U.&A_F%FY5.IN1 H\D3H;]J+/YW3?.VT
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MB I($3!T@O224",B>?%=MWRY'^Z]SYYO,WO6\YN]UQK&&&,&X#8U-#$$0$P
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M&L]'<NDV-L2W)N0OBA[R6:62Y"[II4'XMM;EB1D1UW>W_:<[2=E%%%_AZMJ
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M>X8CD_%-XO=,LL_?_9Z7YBZ%Z9'.RS>1WO+R\#>0TT2#-<,UR\KJ#]K&QAF
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M4$L! A0#%     @ *5L*5;6!%\PU7@  $?$% !4              ( !%4@
M &=M86(M,C R,C V,S!?;&%B+GAM;%!+ 0(4 Q0    ( "E;"E49^?DA23,
M (^A P 5              "  7VF  !G;6%B+3(P,C(P-C,P7W!R92YX;6Q0
M2P$"% ,4    "  I6PI5S/@PG]<?  "A5@$ %               @ 'YV0
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M.3ED,3 P-2YJ<&=02P$"% ,4    "  I6PI5&08:777Y  !R)0$ &P
M        @ ';FP, 9VUA8BTR,#(R,#8S,'AE>#DY9#$P,#8N:G!G4$L! A0#
M%     @ *5L*51@ _8YHS0  VO\  !L              ( !B94$ &=M86(M
M,C R,C V,S!X97@Y.60Q,# W+FIP9U!+ 0(4 Q0    ( "E;"E6X$@-^2P<
M /X'   ;              "  2IC!0!G;6%B+3(P,C(P-C,P>&5X.3ED,3 P
M."YJ<&=02P$"% ,4    "  I6PI5T<8I,1$/  #8#P  &P
M@ &N:@4 9VUA8BTR,#(R,#8S,'AE>#DY9#$P,#DN:G!G4$L! A0#%     @
M*5L*5:KHN4VX!0  808  !L              ( !^'D% &=M86(M,C R,C V
M,S!X97@Y.60Q,#$P+FIP9U!+ 0(4 Q0    ( "E;"E60((M;@0<  "T(   ;
M              "  >E_!0!G;6%B+3(P,C(P-C,P>&5X.3ED,3 Q,2YJ<&=0
M2P$"% ,4    "  I6PI5;R\\[_4(  "D"0  &P              @ &CAP4
M9VUA8BTR,#(R,#8S,'AE>#DY9#$P,3(N:G!G4$L! A0#%     @ *5L*5=V6
MYP%5!@  \P8  !L              ( !T9 % &=M86(M,C R,C V,S!X97@Y
M.60Q,#$S+FIP9U!+ 0(4 Q0    ( "E;"E7(U96=;P<   X(   ;
M      "  5^7!0!G;6%B+3(P,C(P-C,P>&5X.3ED,3 Q-"YJ<&=02P$"% ,4
M    "  I6PI5?2OCO\D*  !J"P  &P              @ $'GP4 9VUA8BTR
M,#(R,#8S,'AE>#DY9#$P,34N:G!G4$L! A0#%     @ *5L*5;N-=0S4"0
MB0H  !L              ( !":H% &=M86(M,C R,C V,S!X97@Y.60Q,#$V
M+FIP9U!+ 0(4 Q0    ( "E;"E5)^X[J+@H  -,*   ;              "
M 1:T!0!G;6%B+3(P,C(P-C,P>&5X.3ED,3 Q-RYJ<&=02P$"% ,4    "  I
M6PI5TLW)!GT-  !.#@  &P              @ %]O@4 9VUA8BTR,#(R,#8S
M,'AE>#DY9#$P,3@N:G!G4$L! A0#%     @ *5L*5<>8^HT,"P  S@L  !L
M             ( !,\P% &=M86(M,C R,C V,S!X97@Y.60Q,#$Y+FIP9U!+
M 0(4 Q0    ( "E;"E7(&"Z 30X  .4.   ;              "  7C7!0!G
M;6%B+3(P,C(P-C,P>&5X.3ED,3 R,"YJ<&=02P$"% ,4    "  I6PI5*?#H
M9(P#  !:!   &P              @ '^Y04 9VUA8BTR,#(R,#8S,'AE>#DY
?9#$P,C$N:G!G4$L%!@     9 !D ]08  ,/I!0    $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
